<SEC-DOCUMENT>0001682852-21-000022.txt : 20210805
<SEC-HEADER>0001682852-21-000022.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805161419
ACCESSION NUMBER:		0001682852-21-000022
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moderna, Inc.
		CENTRAL INDEX KEY:			0001682852
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				813467528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38753
		FILM NUMBER:		211148350

	BUSINESS ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6177146500

	MAIL ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Moderna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrna-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:1f43850e-4c17-48f6-8a24-63bc21a94b8b,g:a986bd34-a907-438b-9a06-ed4dd6fbe7f6,d:6f181a2054234caea38df80c330fc729--><html xmlns:country="http://xbrl.sec.gov/country/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:mrna="http://www.modernatx.com/20210630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrna-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18wLTEtMS0xLTA_996ec8f9-3b81-4a93-86cc-70519357f348">false</ix:nonNumeric><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18xLTEtMS0xLTA_523a8aa8-4b07-43c0-a34a-356d10f05473">2021</ix:nonNumeric><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18yLTEtMS0xLTA_f119d0b2-18f6-4ac2-bdce-6df232a0c126">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18zLTEtMS0xLTA_2011cfd2-2622-4563-a40e-67555ed786a8">0001682852</ix:nonNumeric><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY180LTEtMS0xLTA_53499593-f3a9-4aed-aeb1-d49b1a623eba">December 31</ix:nonNumeric><ix:nonNumeric contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrna-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i179b2e7c238549528ec055756ce46033_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iec99c2535a8b42dbac6e8d323141db5c_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i23d47f973c914379ad830c261ec3d4eb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i62917e20a8fb457d8e66c38f2ad33f7a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65439feeef443e58684902e2ca1fe70_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if266088069f84cf6945085f6b87d5db0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42b22b2df23458abe04d022388eae80_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97462bb9e06e4d0b8038908806010639_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i277a54dbb61f41e99601f903825b48d2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30b0955908be463b8c5776e5549bb45f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ceec1ef6dce41439e7509d5b3180cde_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa63e0b90e04379b97da2756114c4c1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b59c2ca6da04931aec1d8e534792b47_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied43d05ce83c48a9b037a38e01ad51ae_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07f544975bf44f01aaf6cd6152d44f8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id896a91ec74c4c49abdf78c300d13ca0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb94c429e024fb093ce6d4d944055ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i467f5e1c5b0a40dfb2090010d28b95ad_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da83908729448ee8a41870859147a93_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517010db08264600b828770102838edd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e7d1bca5614fa89de0a1a5b33cbe8c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e8320dc990645e7b4e723cd26fb61f1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9332a7030408410190b1a94c2e713ebe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d1c7922a0f42a1a5569a02e65e170a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81e9a8c1ff44ada911a7e8db3a243c4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9860610904e425f9bd0ba4654cee9f2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91bd58e1ce80434ba54c3ba11fd4e041_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b07a5c1b08c47c18dde953f4df74a85_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb708f43d5464f4e98cee5a3f7031313_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b175b3a826401ba7e904fd9486fa43_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3283b392eff2465faad3fdbe829de638_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653c8891e96b4e798b795df5d797ffda_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if21af94b32274ca2bc5f281d8b91964d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b68d04a23384807b92fd3080ce4ad8d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69519acdcd484f7baf0aee01a833d455_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc0ffd1101054ceaa3de2c3ffbcef1e4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae9686943f64febad60646379a0b1cb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488b334a3ef64d4caa66debe5db19d8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c08244b023c40ca9fc941a3e60c2c56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ef651667664c27bc69872dd1d33b05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ade9ccbd9704bd7b8ea5b560ac9b3d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d9d0afe13d46efb8ad43cfe9cc5715_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d47127223a64d2fb9cd36c959441e94_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife42851a7eda4b4f941a44f0037477f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b4459de21243118082e0ace346a32f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc39f92f55eb4e0a806e6264b2267ee7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b7a4b2f73947ee99915fb30be8e619_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae5f72aaadd64959816335e7e8bf64f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd50a086b08a418189feb030cb4bdb1b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54592b591bd49c48e564d5634910480_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9715f2b13dc4d9a9876fb015b5eb0d2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dbeca61b931429a9ecce401a75b9228_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>mrna:program</xbrli:measure></xbrli:unit><xbrli:unit id="clinic"><xbrli:measure>mrna:clinic</xbrli:measure></xbrli:unit><xbrli:context id="i60ed33a973974be78cf5fb2ffa1a2b11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd1d9442a7b4754a406bff7a39e5fd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157887d3dcbd422db9ab258078ee14a9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec75ac0ff6b94c738a5f8719561f6104_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96c0176d8aa4d39a5da077d3b371b0d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122512b403f742038c2c1468c00fb915_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fdf15d391e54159b27e230febc1be1f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05aff14929149cab57fd79aefeeeb56_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12aafa2a5b1746a4984dfb62d34e42da_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib627f3fa58de490c92d72c00c79d72c4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6c5bf45d0d43ac9807ba42e62b7367_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e5362a76064a92b61e459fcd0ce315_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98fd324dcb2a418298c8cc16153570f3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1537b27f156c48ffba4b540f307af8f9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd2776323b3943b9ad57f0cfb5a2e92e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90e522303a6d4db88a6e75f6bf51b675_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925c8f5cb9cd46f6a1ae86a03be5fc3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197583d029334a8a81529a09b6d9abab_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6503cc026fe46aebeebe1584e563292_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8c05f658d243b7a83bfd8f5c1c6f4c_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317ef19f70e3444197530823e5c919f1_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>mrna:option</xbrli:measure></xbrli:unit><xbrli:context id="i1ebdc9e4059d4f3e8af844afeb9fa830_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51ac7bdfcca483bb11c2dd61678484a_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfd3eaf51514a388430a090a9c38bf7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e91224fb8d4da7a4999fd677df954b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f7b3f76a0254c61a7d0c966cb15f054_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3a7ff346784334ad9e7b0a9a13d895_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5b1bfb294a14e0a9af5a1f7d2fe3c3d_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d59c82137047499203288390a8fb25_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3736c014f39246fab97d6e843cb4749d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia364f96dfa314c94ab36b5e61edb53d8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2020bda539b4500be4ec167f8f9dd69_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c916a0b4ca4f3aaaf4cdcb3d605a58_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib842bb3c0b504e23ad5bea99b14f72cf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84be31041f544b97a41d04069c6d8bf4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea751eab6f240dba31a0a82fdceab7e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f686c80a94472683e32b196c79f61c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162ebf7a6485464c849cf2578c7dab6b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c0e4a432e844f8b79c47cfa66d0c9a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7e7990e9d440e893ed1142076218aa_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7644505741a1400d86377f349317c0fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddeea55cf45455cb5d1c9673b0324ce_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e00f59aecfe46eba16e2160aad94c2e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d9addacdd64f378a73828f0159e567_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic00107eb57614d2783a2c32384445ff8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9334dd2e954444a97f8e4487361fbd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e7c7882cf1442f9e76d9e7fa5fb939_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0ecb7e5c464559a1438e2425eadc54_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b82d07ccaad4e878d47278bb6324ea1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie360ccfe76ce4f12acb76df75ae0cd29_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac3dd43b3bf4cbba83cd10d23c2765d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8812f9dae82547b18386cb8d2b5e9345_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d810941907046baa10069ee651b0e1f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4765f3aff24398975e633a19635d2d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4150668b3b4c44aa607c9d34eb7166_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52338e34ec645a58c3c88e7c09ae121_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic759b04977c945af9a1565724750bef0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e9a9ef8cc640939f59b6dbf739b2f2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4dcbd5648047cc838ad06ddef0f031_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b065b0be3c464e8433f98080bb78c2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01fb537f002a4b8c925b113ba3d2017d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cf2066964f4552b9838011a69044d2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e40b9256244a589946a1e85bf6cc70_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e02e1f5ba8748bd95d12afcf7465939_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b130a946c83453fb4a2d9207835ffe6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423fce28b3db46918d8d1d5c8d38b86c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea33fd392c424f96b2db18376181aebb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027a8da8a838499cac9ccfbdc2f7a524_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3dd508a23a494cb5ea06605d67c4ce_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd695349782d4fabb5331046948b8614_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e44fa9dff64d7aa736f647933beb2f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992dfe7000ea4086b948a45ff7846ebe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4821d306d1d84e8c92f59601e79d952a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6972a4b3a6464fa76fdb392c3e5aeb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2bd954162504b8b865d6ee4ff792361_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd7c27968a4482bb56525e657054318_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32cb4879eecb497aa9402f0d74f44387_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2262642e3b47c28ff6867f6509b071_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769d59bacc4a4a21bb4c83f4a46ff03f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib392451a0a484b5dbc71a9445c495423_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09bbf998b6c041a6901c1dc8996237b7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0489f9f56e42fe85ab3ecf9d6d2dad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c840483704458faf3161e93a3e01e8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5adcc5729bae40c6afb7af8e72c59291_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774f6d34510445e0ba7f5b0b00875252_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0466c7cd491448979678f3b868c44e9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if135f26414c04231aa2ea55c9a2c83a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25503043380a4bc7998a597473d1786d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e114d012176429c97c1208417394403_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55f81c1ceb8498fb37e9398c3b61120_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12cd6744128743138d2497b1a6aeab5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed771e34dc34a429c0397e23c4ef046_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519420c4ce3f4e889babc67663290d67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa12a4a1d724b97bb9fb7cdd250ec0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6954dbaff3c452da6a96be861950389_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i493f6838a0a64aaea82e5743f2952be8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f3e4a401171474a9007e9abf988d8d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic540ca4685794ebb951a1f68ef0b6cbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a16e85d6b1c4d0b82c2b3e4a95dd15b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846f0646bd6d49ea8fe231170844146e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194e3a1c43ff42a5b8386c49d1daa843_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230f554c3a46462b96c3244553fa4901_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d36108a148c4a0fbcdf9c7d9b7be3b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c96e2e95a944ce8baab70f57149619b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41cbbe97585b49f7816d2b3bc62ef46a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a7e6285a6f9420a8a1c73a6d999a977_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db80e5245884f98abb49e31eb422938_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b7d5d68b044d1a9277098a16618625_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1932c05e81914004be5dc08eaecfac86_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db557e9b08d465ab8c20a75ef2e9031_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864ecf97b4424e6094f85e6a8a246f8e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516ea12e44884479b0a6bcb19ac9af08_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ebc7385e514efdadb03d14e93eafbb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3181a82c5bb246f2ae1a34c07476b8df_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72d63351ccf43468dfcbe077e57e343_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775e0b2685f849e2bc13548cc7443839_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i353364e17b0948c69aab8712c81c2ae0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf448fa99154f69805bc0000070e21d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f00f671da6e4c1f98a8eaee2667cd74_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b8d474daa3437dbb2cd804326443ae_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91999e41635347b4902e1ad73f8105c3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d07569609954f7ba5c83a5cdacc1022_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414d3d35d2414d4cbfcac8697786c538_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25825286c884fff843aea0e9c363a1e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8429272a2a4b0998190fc4ddf309c0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ee58f9c9904729a24edfb35821ac46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if206a7fe2c0b4f61b8a9c7db48c74717_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3d345b623d43e5a20fa855453bc2d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18a60989d0ea4094b7de163b29974100_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73893cab9b854b6b8ba02c2e4b889f2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a24374f72e7438a9fbdca268f38643b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd72a3537a1453a82dc119e321ac20f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i174fd5ae68bf4b5da07bbc030ddd36e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002448bbfd364b528c594c150a64fdfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03cae867119545acb97a33eb075f4934_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8999a018dcb4fc1ae7ae79fda50084a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd279b33ffd34a2398ca36d866add3ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b2270f25574b2389448da3126d9486_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id873b1c04a36458dab4d7141b07cc3e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9969e6d3b7504aeeb9fcb51894156a6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f7fd21cde041c28f93122294043d54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e4394219d147b9aa8a86441e91f2d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f213588a2543558ea014b5a5ea5e8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idceb063e3fb1410babe61be92b0909bb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105c28fecd3545bfb3d35697e79fe0be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b9df3a23274885ab33d029964f7f40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fecea31d594dd0ab5690daae65344a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41d37e05a294447b61d26d700536c4f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7bc9694442496cb11758c11c2558be_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425177f7064948f1ac420fbb3fef0e74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782e7b05996e46d48e09abb10bd0b888_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f885124f6b8428f81517844f40eabfa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic255a6d51e9f4cf2a218bc9650ff2949_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06704fd367eb404db0554bb5e563f35e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de8c1fd48ac4d1aa4faaacb3fe97224_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a370046fc945508f2069a2bb7980ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00cdc03e1254d03b96024e1c1f004e0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084d5de85aad4c568986c67f724f5fc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8946ec3ac3654c46b29f79ecd814b660_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade5f7abc6404fd4b696f1bebae23486_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321e4ae9922946c7b2dc52c2fcf14229_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4bff8b1053446d87c6e24ff337360c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323f3434ce0f462a835692c193f97e98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieffb4ead51104e6aa5757fa06624c672_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b8c503b84d412cb2d8c21018da6a3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a01b9748ef64174a3c700db54d82b9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="campus"><xbrli:measure>mrna:campus</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i6ca4970aeb944ce094587b8e9e52cee5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01e27faf121473685c9340ddfba9ede_I20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extension_period"><xbrli:measure>mrna:extension_period</xbrli:measure></xbrli:unit><xbrli:context id="iad991ea73528435fa5b841a1edd13f95_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4919b4b841a4432188fe3621950e1631_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic93eda10a84048869aafc24b02582937_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCEastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b49c23c04b441dbe3849a5361236d8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b90abfb0dbe4272a84180b8ea7942bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf2947c07b840e4a74467063deb1ae6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i04fa63042c64408fbd832e6524b4b23f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie095a587c0d84c63a7d5403131e4b7e3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6207c51d5c4d1da7a394ed937340ff_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCEastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61568f63bbbf460192175495b73fb1e2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453114f3b5a7454382060dc9a3cc7f07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e4997c888f446e9fe81c8bdd3f1e5d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598d0bc0445a41abbc9bdcd1258b0d3c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8caec99e729443a0aee89f8db26aa392_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67185c627d644febad389a0c535248b1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c3513fce714f9e9e6c45c936e12fe2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c7f1943108a4146a37ed6c8267654a2_I20170626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e58c0fb75144621874b106da58aa126_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806cd5c4c8db4bbb96da09f4192d4f77_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic32a9001570747069665c11f135527dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib676efd3333c4e95baf151a431bb5025_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie402888bb2fc4ea880b40f2a9d7c22f0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied36f68f5ff84b10a3d60914c0b61586_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7005ad8225459bbf949983a16fb039_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a9e69e7d27416e8d304a0b72359725_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1bbe23395c4aa6988514c29e2ee39e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5940ab735af34e5e946ede601d642a53_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0202da86f1409fafc721c18c4b375b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940058d521aa4563a84e76e20cd336d6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67410869f8c478eb669bc8351987988_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc29bdcf87245dab06fb8bb8f5635ff_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0beaf98f2bec4a78acd4d80ffe785bbc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a56c15404a4b8eb579be1a6a78e357_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8310dab123334253aa6827d712250361_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0463634352040069acfeb178a893295_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45447fcebe4141ea9d78a8504cdc1c19_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b9ec1f5cce442791bacd86253cbd96_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db1b0e2148b492bb939ebb0463eb2d3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f6e9c4e55144bb8df23054a288a2e2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0ada455afe4e75bfe9e71f54e33319_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1fcb8aedfe9420c8551dec0ade1347b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3435c602db343908bad969f4cfa4f42_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7303c622b8134633b87246e130589360_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i230bf3fb1f8e419181b3f634ef694994_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e5a124b9bb45f6b74b3d193e94adbb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e219eb6c9048bbb915840c4add36fd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea21debe3524bff9d6e588cd4b5716b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29b4d951999485cba6731af4351eddc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i283d9247556a4278afc37abb5ac02feb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19460b8e62a442f88dd3c9900970530a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff02256a11834a66b8c527254b62d147_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i292b707793574fa196af16232e6fad08_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>mrna:dose</xbrli:measure></xbrli:unit><xbrli:context id="icbdd283932184bea9f7f771d39f918d6_D20210701-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdd0a3a2ce304bb5a423153da5ba16fc_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6f181a2054234caea38df80c330fc729_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:0.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:0.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-bottom:1pt;margin-top:0.35pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.111%"><tr><td style="width:1.0%"></td><td style="width:56.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ODc2MWZjNDQwMTcyNGQ3MmIwNWQwMTNlODE1YTgzMGIvdGFibGVyYW5nZTo4NzYxZmM0NDAxNzI0ZDcyYjA1ZDAxM2U4MTVhODMwYl8wLTEtMS0xLTA_5e600a29-6f3f-4d02-9664-e5eb7a68cec8">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3.5pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI2_d602facf-0061-4be3-8624-d36173809bcc">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:0.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl80Mzk4MDQ2NTEzMzY0_b0110775-a683-4dc1-bcaf-165a1fb3a83e">June 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTIx_150f5d98-c6cf-4a86-85d6-c700d3ff453e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from _ to _ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTIy_c1804b4d-e304-462e-87e4-0bf0a0c58ea3">001-38753</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="mrna-20210630_g1.jpg" alt="mrna-20210630_g1.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:212px"/></div><div style="margin-top:1.35pt;text-align:center"><span><br/></span></div><div style="margin-top:1.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI3_46ab1e23-75a2-4a94-95a3-fa59043b864f">Moderna, Inc.</ix:nonNumeric> </span></div><div style="margin-top:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:1pt;margin-top:0.5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.572%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV8wLTAtMS0xLTA_70286a7c-8e12-47b4-838b-a3efefe00097">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV8wLTMtMS0xLTA_baa33f40-f6f7-4dff-8327-3dbf300fa15e">81-3467528</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV8zLTAtMS0xLTA_8e4f297b-cfdd-44db-90c7-342dcca54dc4">200 Technology Square</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV80LTAtMS0xLTA_c43ddcdc-5a52-46d1-8fed-79df09c5f688">Cambridge,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV80LTEtMS0xLTA_17a2b846-ee24-46ac-97dc-5c9aeae1e186">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV80LTMtMS0xLTA_4dc74123-fcfd-46ee-aab5-4b99e96dad78">02139</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI4_36729990-df08-406f-b9ae-187406bcc277">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI5_647575e6-6ab8-448a-aece-adcb86bf605c">714-6500</ix:nonNumeric> </span></div><div style="margin-top:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:0.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZWE0YzRmNWRmNDZmNDRmZTk5YTYwOTNhMjY3NWFmYmMvdGFibGVyYW5nZTplYTRjNGY1ZGY0NmY0NGZlOTlhNjA5M2EyNjc1YWZiY18xLTAtMS0xLTA_2293f809-aafb-4636-9dea-0596a99bd528">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZWE0YzRmNWRmNDZmNDRmZTk5YTYwOTNhMjY3NWFmYmMvdGFibGVyYW5nZTplYTRjNGY1ZGY0NmY0NGZlOTlhNjA5M2EyNjc1YWZiY18xLTEtMS0xLTA_d3394fb3-d1e2-4d16-976e-a8c2f4099df4">MRNA</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZWE0YzRmNWRmNDZmNDRmZTk5YTYwOTNhMjY3NWFmYmMvdGFibGVyYW5nZTplYTRjNGY1ZGY0NmY0NGZlOTlhNjA5M2EyNjc1YWZiY18xLTItMS0xLTA_72303514-22ac-4734-9bda-4d1c52544784">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTIz_2b8a3f2d-4585-424e-b419-bcf08e3f4197">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI0_08861a5e-e6ac-4f7b-8f9b-e91eb7b9a43c">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.737%"><tr><td style="width:1.0%"></td><td style="width:19.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZGE2M2M5MDIwMDU2NDM2MTk1ZjdkZDdjOWRlMjFjNzAvdGFibGVyYW5nZTpkYTYzYzkwMjAwNTY0MzYxOTVmN2RkN2M5ZGUyMWM3MF8wLTAtMS0xLTA_b996a923-eab9-46b0-be88-47165d687ca4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZGE2M2M5MDIwMDU2NDM2MTk1ZjdkZDdjOWRlMjFjNzAvdGFibGVyYW5nZTpkYTYzYzkwMjAwNTY0MzYxOTVmN2RkN2M5ZGUyMWM3MF8wLTgtMS0xLTA_78854083-cedd-481d-b24b-aead0eb8959e">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZGE2M2M5MDIwMDU2NDM2MTk1ZjdkZDdjOWRlMjFjNzAvdGFibGVyYW5nZTpkYTYzYzkwMjAwNTY0MzYxOTVmN2RkN2M5ZGUyMWM3MF8xLTgtMS0xLTA_cf07a254-5595-4f1b-96e0-51b880e4084b">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.5pt;padding-left:9pt;padding-right:33.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI1_649f3689-49d8-4cf9-ae18-771467a5a63e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of July&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="iec99c2535a8b42dbac6e8d323141db5c_I20210730" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMDM3_4c243ea1-824c-43ff-9c8d-eb922056d9dd">403,646,312</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (&#8220;Form 10-Q&#8221;), including the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our activities with respect to our COVID-19 vaccine, and our plans and expectations regarding future generations of our COVID-19 vaccine, including boosters, that we may develop in response to variants of the SARS-CoV-2 virus, ongoing clinical development, manufacturing and supply, pricing, commercialization, if approved, regulatory matters (including dosage for vaccines and authorization or approval for boosters) and third-party and governmental arrangements and potential arrangements;</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately, particularly with respect to the timely production and delivery of our COVID-19 vaccine, including any variant booster vaccine candidate, if authorized;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the ability of third parties with whom we contract to successfully manufacture our commercial products at scale, as well as drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical and clinical use;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our commercial products, investigational medicines and technology;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ultimate impact of the current coronavirus pandemic, or the COVID-19 pandemic, or any other health epidemic, on our business, manufacturing, clinical trials, research programs, supply chain, regulatory review, healthcare systems or the global economy as a whole;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the direct or indirect impact of the COVID-19 pandemic or any future large-scale adverse health event, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to mitigate the impact of the pandemic, and our ability to execute business continuity plans to address disruptions caused by the COVID-19 pandemic or future large-scale adverse health event;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated next steps for our development candidates and investigational medicines that may be slowed down due to the impact of the COVID-19 pandemic, including our resources being significantly diverted towards our COVID-19 vaccine efforts, particularly if the federal government seeks to require us to divert such resources;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop development candidates and investigational medicines, including by applying learnings from one program to our other programs and from one modality to our other modalities;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and investigational medicines;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our investigational medicines;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize any future products, if approved;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our investigational medicines, if approved;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, and strategic plans for our business, investigational medicines, and technology;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory, and commercialization expertise;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our investigational medicines, if approved;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our investigational medicines, and our ability to serve those markets;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our investigational medicines;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to produce our products or investigational medicines with advantages in turnaround times or manufacturing cost;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of laws and regulations;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry; and</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties discussed in this Form 10-Q. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a promise or a guarantee of future performance. </span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, the terms &#8220;Moderna,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this Form 10-Q refer to Moderna, Inc. and its consolidated subsidiaries. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">ADDITIONAL INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website, www.modernatx.com including the Investor Relations section, www.investors.modernatx.com; and corporate blog www.modernatx.com/moderna-blog; as well as our social media channels: Facebook, www.facebook.com/modernatx; Twitter, www.twitter.com/modernatx; and LinkedIn, www.linkedin.com/company/modernatx; contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.15pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_13">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_16">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_16">, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_19">Condensed Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_19">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_19">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_19">June 30,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_19"> 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_22">Condensed Consolidated Statements of Comprehensive Income (Loss) for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_22"> and six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_22"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_22">June 30,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_22"> 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_25">Condensed Consolidated Statements of Stockholders' Equity for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_25">three and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_25">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_25">, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_28">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_28">June 30,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_28"> 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_28">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_31">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_88">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_94">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_94">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_97">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_103">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_106">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_109">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i6f181a2054234caea38df80c330fc729_112">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_112">47</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions, except per share data)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNC0xLTEtMS0w_86006b5e-91ac-44ac-8477-fe95ec8aa750">5,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNC0zLTEtMS0w_13d19462-91d5-4fed-a1f7-008019709eca">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNS0xLTEtMS0w_26b71a01-ab49-4aa9-9a59-68e81ebdaef4">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNS0zLTEtMS0w_867c17f7-3099-4891-92e6-79bf7ad87c81">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNi0xLTEtMS0w_de37f95a-461e-4c9a-8622-ae674319733c">2,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNi0zLTEtMS0w_d13b9465-2d13-4732-9e56-bda177ae3a8d">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNy0xLTEtMS0w_831f0eaa-e2bf-4b7c-a8b0-84b8d8d4f408">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNy0zLTEtMS0w_ae108b74-e7c7-476d-a056-d75f0a83efb5">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOC0xLTEtMS0w_3aefa160-6936-4329-9d95-d1da94be882c">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOC0zLTEtMS0w_f9feaad3-d72c-44fb-9126-e28620740be7">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOS0xLTEtMS0w_e5f58752-bdac-4b30-8177-c65ae4127802">10,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOS0zLTEtMS0w_0395a192-c548-437a-b072-07c68ecd7406">6,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTAtMS0xLTEtMA_1040046d-955f-4a50-bd83-1dde1d85c1eb">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTAtMy0xLTEtMA_41c6f697-b3f2-4ceb-ba85-1a7b07b90b81">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTEtMS0xLTEtMA_a5d8d765-cbea-467f-a606-5a73d4366bc1">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTEtMy0xLTEtMA_e4cb1ec7-da8e-4e13-a8f3-e1f8912e00e8">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTItMS0xLTEtMA_4c2c7324-5129-42c6-ae44-167eee61f192">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTItMy0xLTEtMA_3f2b3951-7209-4694-9349-800a8f552a6f">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTMtMS0xLTEtMA_5ad7c5f4-4165-43db-8855-3acd0282bbe5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTMtMy0xLTEtMA_b34b283f-c3a2-4fb1-a6b7-96e93d5c7d2c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTQtMS0xLTEtMA_1d5ffebb-5021-4e87-9385-a04a305a61a3">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTQtMy0xLTEtMA_1e6a756c-6063-4d13-845a-f4feb1fafac1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTUtMS0xLTEtMA_ed6dc656-15a5-43f1-bc81-e834a240d2b3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTUtMy0xLTEtMA_f1674fcc-156a-4fc9-84ea-c4e7f7c690c4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTYtMS0xLTEtMA_1582f529-48f3-4d3f-ae9d-3cbd0aab979c">16,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTYtMy0xLTEtMA_e3ef1d6b-35fd-4c9f-88c9-fe70413d46cf">7,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTktMS0xLTEtMA_108ca462-22cb-4edc-b4f5-dae6b51b8ec3">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTktMy0xLTEtMA_876d9989-e4a6-43d4-9cb6-713174cc1588">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjAtMS0xLTEtMA_ba08e85a-d58c-40c7-84c3-cc38831dea51">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjAtMy0xLTEtMA_5f028d64-8849-409d-ab85-50cc3353f936">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjEtMS0xLTEtMA_f771e1bf-6371-4cb5-91ee-65f0f3e06355">7,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjEtMy0xLTEtMA_692fd62e-dff8-45a9-9e48-460d4c3fde06">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjItMS0xLTEtMA_15f38ba0-a53d-4b7b-98ec-a458f127fd82">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjItMy0xLTEtMA_2b2c0b77-63d4-492e-8c2f-55e8d80cfa07">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjMtMS0xLTEtMA_4eb8e2aa-98ef-4b5d-ac07-10b3917da040">8,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjMtMy0xLTEtMA_d2f61c0b-c9db-42a9-8baa-aa1c50ca5125">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjQtMS0xLTEtMA_14f04f00-9a7d-4dad-9c98-15c85750d630">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjQtMy0xLTEtMA_07d3f94b-80c6-46ad-8f76-5eb6f00a9785">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjUtMS0xLTEtMA_b7d18e5a-d0e7-4a4b-a140-84a9f5e96704">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjUtMy0xLTEtMA_d6af8289-42ca-4890-8c20-05c0d5e531ba">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjYtMS0xLTEtMA_58c00049-fbbe-4552-9a41-b2c72be03e2f">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjYtMy0xLTEtMA_240e2ac7-301d-479e-ac0f-a4668216d6e6">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjctMS0xLTEtMA_2cf81fa4-d5b3-4150-af2a-631e7fd9cf21">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjctMy0xLTEtMA_672bad51-e5c9-45bb-8c4a-820805c07541">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjgtMS0xLTEtMA_99b290c8-721f-4180-8fc3-b9b55031bdcf">9,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjgtMy0xLTEtMA_fb6f764a-a79b-438d-8e44-1572d957c672">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjktMS0xLTEtMA_3f616319-5e06-494e-8493-cdb487f450cc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjktMy0xLTEtMA_5b3079fa-fed7-4fdb-a9ce-a9993c43c7eb"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM0OTY_9bdf3d67-ee73-4ec9-ac9b-257991163b00"><ix:nonFraction unitRef="usdPerShare" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM0OTY_9e44a717-5c6f-4ae0-9597-302129bab741">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDA_616afeda-3972-4168-878e-7ca1e53148b6"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDA_a3a348c7-019c-4ff6-92cd-eac5fd43ffcd">162</ix:nonFraction></ix:nonFraction>&#160;shares authorized as of June 30, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_2fdd8781-df15-42d6-80d4-66c219e14430"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_5844d2ae-a60b-481d-93aa-b4815392d366"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_5c5e8546-256e-4236-9513-f67631b26439"><ix:nonFraction unitRef="shares" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_b09555a3-456b-4bbe-aae2-762d9884abf5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at June 30, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMS0xLTEtMA_2fb9c95d-4844-4c7b-97d1-f98e5f09525c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMy0xLTEtMA_c85869f3-0fde-476c-832c-689249f90de9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM0OTg_30336f93-49ce-4ca5-81ff-6adaea782269"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM0OTg_874cb95c-9ef6-4ce9-bf26-ca7ad15d285b">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDI_805caf49-0ac2-4a6f-b377-5629e15e8570"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDI_abc8cc11-d5f9-478a-851b-2c13c93d0c23">1,600</ix:nonFraction></ix:nonFraction> shares authorized as of June 30, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDY_6befc6aa-5861-4e73-895b-8e81c6991ffe"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDY_e90311b3-8043-4d59-b57f-8735e5ef0eeb">403</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MTA_21ee4507-9d67-4d5b-94db-ffb69fae6925"><ix:nonFraction unitRef="shares" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MTA_88f8f995-bb8c-4d5c-8871-7933902a1747">399</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMS0xLTEtMA_c3ad253f-f663-47a2-9270-4c2c5cf6c96f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMy0xLTEtMA_a46b7640-9df4-417a-8b7f-e278b351f80e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzMtMS0xLTEtMA_63c0a93c-8ae1-445c-84d0-16276a3909c7">4,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzMtMy0xLTEtMA_1586f769-a2d1-4eb2-bf4d-ef4b5ca1995b">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzQtMS0xLTEtMA_6e39bd2a-b6d4-4787-9b87-2d1a640ac562">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzQtMy0xLTEtMA_00fa1b6a-0e8b-4251-a145-37398b069806">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzUtMS0xLTEtMA_973a2a70-4ded-45d4-a56a-beac1aa00adf">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzUtMy0xLTEtMA_15d71760-bc49-483c-8d84-9a2a034cc2a6">2,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzYtMS0xLTEtMA_4cf8167b-aad0-4ac8-8aec-6270d5ec2425">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzYtMy0xLTEtMA_1b64c772-4fbd-4be7-8caf-11113ba56fcb">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzctMS0xLTEtMA_5eb7ffe4-7ec6-4018-83fc-26d47fb1d319">16,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzctMy0xLTEtMA_41f80800-1d24-4e23-9785-23560401e5d3">7,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions, except per share data)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62917e20a8fb457d8e66c38f2ad33f7a_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy0yLTEtMS0yOTI_9a989915-9db2-4bd4-8bb5-a4438009db85">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65439feeef443e58684902e2ca1fe70_D20200401-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy00LTEtMS0w_c1e11010-3bc2-4823-890a-a5b713d2b71f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy02LTEtMS0w_0bea2202-0610-4ab4-b7a0-4630d605607d">5,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42b22b2df23458abe04d022388eae80_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy04LTEtMS0w_c68fc26c-b30c-4609-9681-252bffd3b60b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97462bb9e06e4d0b8038908806010639_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC0yLTEtMS0yOTI_d8cfac4c-b45b-453e-855d-4f1d63c36004">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277a54dbb61f41e99601f903825b48d2_D20200401-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC00LTEtMS0yOTI_3fbdc0d1-d60a-4f13-a54b-84fd7ec38f6b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC02LTEtMS0w_40cd2e82-de27-4e86-86d5-286ea297caef">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b0955908be463b8c5776e5549bb45f_D20200101-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC04LTEtMS0w_f72316c8-7cc2-421e-af3e-d327425ba9ad">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ceec1ef6dce41439e7509d5b3180cde_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS0yLTEtMS0yOTI_bc368c89-8adb-4034-8022-b59d6669616c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fa63e0b90e04379b97da2756114c4c1_D20200401-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS00LTEtMS0w_a1483734-00ee-4cc2-9501-fa2b7708a67d">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS02LTEtMS0w_9d0256b5-66e7-4c03-998d-660b44ab1247">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b59c2ca6da04931aec1d8e534792b47_D20200101-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS04LTEtMS0w_916b3d93-36d6-4eb2-a7ad-30ed7c163edc">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi0yLTEtMS0w_ff226d55-91ff-4137-8317-4e473ad24400">4,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi00LTEtMS0w_502cf42b-ac86-4b1a-b266-33fc226b1026">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi02LTEtMS0w_266db346-07e0-4505-bec0-da94a3bb73a1">6,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi04LTEtMS0w_f0576b2f-4526-4308-a558-b47012a882b1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC0yLTEtMS0yOTI_78b49c2b-906b-4327-8cda-c6213296446f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC00LTEtMS0yOTI_279a478f-52c3-4e88-b920-a46233082ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC02LTEtMS0w_930b9888-3abb-4986-8152-84783bf3f0a7">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC04LTEtMS0w_0f14397a-c458-4297-9f5d-f9efd54b69c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS0yLTEtMS0w_9933d0aa-9db1-4ebb-8c6c-45deb81adef9">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS00LTEtMS0w_a9f55195-b20b-4789-b56c-7bbdf12ca5b8">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS02LTEtMS0w_f4990841-f9d4-44c9-8507-e8e95ec2b4d6">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS04LTEtMS0w_b0a96185-4514-48f8-8eeb-2f1ae6619ee0">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtMi0xLTEtMA_7a3ee0cf-b38b-4390-89d7-5e6dfd43e378">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtNC0xLTEtMA_ae2a0458-8736-4e16-aa3c-c1d9c2e0b43a">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtNi0xLTEtMA_6c2a74dc-c5e9-449c-993b-b54dbdb22846">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtOC0xLTEtMA_1760bd58-eca2-46c3-bd12-a324689149d8">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtMi0xLTEtMA_f3112cbb-7c32-4557-9b57-d833abb57f59">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtNC0xLTEtMA_2a4380d4-98b4-47c4-ad74-a332bf1be96d">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtNi0xLTEtMA_37cc6bc6-3334-4ca5-9b8f-dcee386ae63c">1,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtOC0xLTEtMA_a65cbd7b-3e54-4106-92e1-fdc6d6f18eaf">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItMi0xLTEtMA_dd0705e3-02fe-452b-b229-8fd59a7005bc">3,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItNC0xLTEtMA_ddc240c2-6bec-4ef0-a92c-69d09f02ce68">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItNi0xLTEtMA_19947d1d-48af-458f-9b59-41896a900855">4,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItOC0xLTEtMA_71824254-a8f6-47d3-be5d-4f254de14f7f">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtMi0xLTEtMA_0998827c-bb0f-4002-8e85-3ed3f85e8a3b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtNC0xLTEtMA_a1fe42cc-f5e8-4148-b4e4-8a853deb301d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtNi0xLTEtMA_686f84cd-7852-44bb-a274-f7329372f18b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtOC0xLTEtMA_800a2cf1-c66d-4452-972f-055970cfa889">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtMi0xLTEtMA_4fc3df20-53f1-44d1-a0a0-26a2af4c341d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtNC0xLTEtMA_5bf3fe17-2819-4257-9004-e692c7f23193">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtNi0xLTEtMA_f0eed281-7e87-4328-99db-4b8d33660c15">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtOC0xLTEtMA_383b4b96-cc39-4683-bea8-08d08188f341">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtMi0xLTEtMA_aa9ef49e-e0ca-44f5-afe2-67d4302104c9">3,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtNC0xLTEtMA_bbd28b0b-ccd0-4f4c-940b-1fa2e0b3a12d">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtNi0xLTEtMA_6976605d-e5c6-4448-a716-744dd6d5ef71">4,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtOC0xLTEtMA_b7bb88cc-fcf3-4f31-aa83-342306db7f78">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtMi0xLTEtMA_f6bfe2ea-3128-4952-8652-8aa321d3fd14">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtNC0xLTEtMA_0acfb741-39c9-4156-9a80-7632f6c1ce5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtNi0xLTEtMA_25a6e04c-1ccc-4c28-b18e-0ed5c0a9fe2e">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtOC0xLTEtMA_92a903dc-74f3-4b0c-8599-2d8579cd8e6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctMi0xLTEtMA_27efacf0-90e9-4bb9-b3a4-20a9debe7867">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctNC0xLTEtMA_dcd84a1b-b945-49a7-a85a-9d595845c217">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctNi0xLTEtMA_fc5f0ad1-c855-49f3-b31a-330aa3c28591">4,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctOC0xLTEtMA_af7dbb7f-a161-4180-b0aa-e22f2a49df47">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtMi0xLTEtMjk4_f7c77a25-cf92-42c4-b0b9-5a6610f66aa6">6.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtNC0xLTEtMjk4_c5178212-278c-40dc-8184-0c80249b3d33">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtNi0xLTEtMA_c8eea9bf-7361-4d85-a139-32ffcadeacbb">9.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtOC0xLTEtMA_d0ec2b6b-e4b6-4372-9ee2-33773d698bc6">0.66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtMi0xLTEtMjk4_1b75f083-45be-4867-96d2-9313805f0c3c">6.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtNC0xLTEtMjk4_b46398f1-c675-44ce-8768-516474a9bdb5">0.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtNi0xLTEtMA_3cec61c5-11b5-428f-9fd1-6682fe8716f2">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtOC0xLTEtMA_642e9a54-7f29-40ae-979d-b8455b71b8a7">0.66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of earnings (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtMi0xLTEtMA_99d549c4-7277-4590-891e-68d071bc23ec">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtNC0xLTEtMA_065bf546-2c38-4e38-b6a5-7537fd21fa9c">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtNi0xLTEtMA_554f6f9e-c3b4-415a-a741-197fa8e70660">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtOC0xLTEtMA_0ca7fb71-d418-4b1c-9330-435b8bcc8661">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtMi0xLTEtMA_cce09205-2f69-4415-b3ec-ad8d2c82ce92">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtNC0xLTEtMA_f945db6b-a3f5-4d40-991b-bbc082483783">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtNi0xLTEtMA_d7f9d6b6-a4a8-430d-a56c-d5ddc0bd1130">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtOC0xLTEtMA_32b33e31-3a17-4a4d-a39b-3ae311bb66f9">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi0yLTEtMS0zNzQ_8688f8ee-709b-421f-b8ad-2d2b71b3481d">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi00LTEtMS0zNzQ_68d4d602-12fa-4ce6-b699-2d2471523ab8">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi0xLTEtMS0w_b51b98fd-45fc-408e-9f14-406c53b5cc02">4,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi0zLTEtMS0w_5a1b4be2-56cd-4a43-9fdc-2a6318247b2b">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sales securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains on available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC0yLTEtMS0zNzc_6b2eae84-b5bb-4b03-a4a7-1d0b9795c09b">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC00LTEtMS0zNzc_4aa60390-512e-4c81-87a6-b6cb6bee46d2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC0xLTEtMS0w_62a2e42c-df88-41ca-ad6c-619c82ac58a2">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC0zLTEtMS0w_8edbcef9-6cec-4c6d-867d-7f0adf58c297">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net realized (gains) losses on available-for-sale securities reclassified in net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0yLTEtMS0zMjgz_d8ba97da-83b2-4dc0-a7e8-4cb0237c0b3d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS00LTEtMS0zMjgz_23ca80cb-1f3e-4bb7-90a1-e2eedd834467">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS02LTEtMS0zMjg3_67ff2acf-382d-4633-b19c-5fa8477d5c29">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS04LTEtMS0zMjg3_5e139161-8d36-4208-b9ab-808e49ff7686">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase from available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy0yLTEtMS01NTg1_3628a6fb-837c-4fef-aa82-40b8361c726e">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy00LTEtMS01NTg3_be8ac990-75ee-4886-8c27-40873e20cca9">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy02LTEtMS01NTg5_eed2b67c-5bb0-4cb2-8360-361d536bb27e">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy04LTEtMS01NTkx_951b2e53-e01f-45c7-bbd0-c52a9425505f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC0yLTEtMS01MDUw_cbbdf2f4-1a66-4f4d-a9a4-1ecdd06f053a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC00LTEtMS01MDUy_812f72eb-a4c2-4f1e-b949-58ed884940c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC02LTEtMS01MDU0_24fb6caf-115d-4398-b072-3962d7fc32a2">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC04LTEtMS01MDU2_5db50faa-2385-4c06-9e6d-c7ca752b1a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi0yLTEtMS0zMjgz_d4289b70-dda1-4070-b971-da5e76b5dd7b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi00LTEtMS0zMjgz_2724ccf9-de09-4c59-b9ba-e9b893e50c46">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi02LTEtMS0zMjg3_6702f6fc-3a16-4d23-b01e-8140bcae47cf">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi04LTEtMS0zMjg3_b47b0a7e-84ab-45a7-8b5e-7948e6fc0117">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0yLTEtMS0zODE_15eaa164-7d84-4e4b-af99-3764cc381077">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS00LTEtMS0zODE_bc819166-6d60-4fdf-92cb-9db5a3b66b54">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0xLTEtMS0w_1571899c-4bae-41bc-9a03-d7ee349571d3">4,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0zLTEtMS0w_8f40b43b-a5ef-40ea-b9ad-2bf2fc105067">235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions)</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.345%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied43d05ce83c48a9b037a38e01ad51ae_I20210331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi0xLTEtMS0w_52fe441b-b838-43da-b289-d01b5aa569df">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied43d05ce83c48a9b037a38e01ad51ae_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi0zLTEtMS0w_fe2ce9fe-5bfc-4352-9ac9-8999da2c84a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f544975bf44f01aaf6cd6152d44f8a_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi01LTEtMS0w_220eb139-8c7a-470e-acc1-47ae666700b2">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id896a91ec74c4c49abdf78c300d13ca0_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi03LTEtMS0w_ee75950c-db77-49a9-bc77-f71304192e12">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb94c429e024fb093ce6d4d944055ef_I20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi05LTEtMS0w_5d8a1c88-404c-4e0f-be9c-f7385a9cba13">1,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467f5e1c5b0a40dfb2090010d28b95ad_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi0xMS0xLTEtMA_e2594549-b7e1-4594-a476-2b0a2a535d1f">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5da83908729448ee8a41870859147a93_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNC0xLTEtMS0w_84cdc574-4aab-4cc9-af31-27ae97779884">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517010db08264600b828770102838edd_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNC01LTEtMS0w_a31a80b3-500f-46f8-835d-00c8f22e9259">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNC0xMS0xLTEtMA_9562cd19-7f85-4968-bea1-00e58f002c62">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517010db08264600b828770102838edd_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS01LTEtMS01MDY1_d16ebb62-392e-46ae-9143-eebac16c1df0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS0xMS0xLTEtNTA3MQ_bdba4b8b-63ee-4f81-834f-730ccedc6510">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517010db08264600b828770102838edd_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS01LTEtMS0w_6a7abf43-8009-4c85-8f74-0a9c08360f86">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS0xMS0xLTEtMA_0c73b95e-76a7-47e6-a7e4-03f4bd8b5b78">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e7d1bca5614fa89de0a1a5b33cbe8c_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNi03LTEtMS0w_5a5bb92f-94a5-40a4-860a-826f35b65ab4">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNi0xMS0xLTEtMA_667ae553-4d5d-40a6-aad1-22200dd7470a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e8320dc990645e7b4e723cd26fb61f1_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNy05LTEtMS0w_f55cea93-d9bb-4254-b149-98e3463fa60c">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNy0xMS0xLTEtMA_dd69bbe5-86af-4d83-89b3-2d1134069039">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC0xLTEtMS0w_dbe7393b-fae7-485a-bb12-1e60d8acc8c6">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC0zLTEtMS0w_a69cb78d-1e84-494b-a114-fc39d2b40250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9332a7030408410190b1a94c2e713ebe_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC01LTEtMS0w_cc660768-339c-437c-8d8f-5b93eb0f3b76">4,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC03LTEtMS0w_91708dd2-ac80-46ea-adf3-735c423e4136">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d1c7922a0f42a1a5569a02e65e170a_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC05LTEtMS0w_bb45df16-62c4-43fe-9019-1fa4ae4b8e83">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC0xMS0xLTEtMA_24bb2ffc-f1f5-416c-82af-1c40176cdc07">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.345%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia81e9a8c1ff44ada911a7e8db3a243c4_I20200331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi0xLTEtMS0w_bd65e2c1-13ea-4f7d-8811-2646ddf6b328">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81e9a8c1ff44ada911a7e8db3a243c4_I20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi0zLTEtMS0w_96c8c7f4-6dc7-4520-bdb1-445a05ba3369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9860610904e425f9bd0ba4654cee9f2_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi01LTEtMS0w_b4453692-235a-40a4-835d-33bab2bcd3cc">3,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91bd58e1ce80434ba54c3ba11fd4e041_I20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi03LTEtMS0w_f402480f-3a04-4f8e-a28d-38d5ee9a2668">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b07a5c1b08c47c18dde953f4df74a85_I20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi05LTEtMS0w_e11199c6-9057-4b99-8036-1718ecea3a35">1,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb708f43d5464f4e98cee5a3f7031313_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi0xMS0xLTEtMA_464f563b-010e-446d-bd8c-3d452c0048a9">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy0wLTEtMS0wL3RleHRyZWdpb246MDZiOTM1N2M5ZWUxNDYzMmIyODJjNzg4OGNhYWRlNmNfMzI5ODUzNDg4MzQwNw_19b5eaff-6ba5-43b5-b9c0-fb0f73e96715">1</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54b175b3a826401ba7e904fd9486fa43_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy0xLTEtMS0w_c6d9e726-ffa9-4aa1-b136-cf3a6971056b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy01LTEtMS0w_ea4490cb-d6e2-45e1-8120-246f0175b2d0">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy0xMS0xLTEtMA_17610344-063d-4539-b02d-ca2ce33494b8">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54b175b3a826401ba7e904fd9486fa43_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNS0xLTEtMS0w_a2456fbc-5d73-4a96-a2e4-f30f84eab10d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNS01LTEtMS0w_a0c84763-ae3b-4ac0-bbdd-dc7263a88a8e">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNS0xMS0xLTEtMA_75427a13-954a-4e18-9104-11e3abfd7147">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi01LTEtMS00OTY_8fb25eeb-f395-4eb8-a577-0aad5feeea4f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi0xMS0xLTEtNDk2_e9e64730-5032-4e86-8d29-64a4be252fc1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi01LTEtMS0w_40151ee3-eeb8-4314-957c-3f4b116141f4">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi0xMS0xLTEtMA_f655ec1d-a822-4a46-a937-78b6d168d57d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3283b392eff2465faad3fdbe829de638_D20200401-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNy03LTEtMS0w_0f9fde6a-0e77-4a3e-b5e1-4d13cc782d8c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNy0xMS0xLTEtMA_8735f562-60ce-4304-a232-8bc1657c21ef">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i653c8891e96b4e798b795df5d797ffda_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOC05LTEtMS0w_9f326034-5ec4-46c9-8d83-d78b77002634">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOC0xMS0xLTEtMA_7c8b064d-5b36-4440-acf4-bec4a90a1920">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS0xLTEtMS0w_e5e74a4c-7976-4a7e-9ca9-7e58bdd28fa4">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS0zLTEtMS0w_d3c657c9-fe2b-460e-9d95-22ae517c318f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b68d04a23384807b92fd3080ce4ad8d_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS01LTEtMS0w_ed2f43e2-d6ca-4f00-9aaf-a91c8df429e2">4,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69519acdcd484f7baf0aee01a833d455_I20200630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS03LTEtMS0w_5f8476f6-89d6-4f0a-9e7a-c3ca15c46e4f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc0ffd1101054ceaa3de2c3ffbcef1e4_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS05LTEtMS0w_6d1ee37b-4684-4bf0-9a3a-a5021f185f77">1,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae9686943f64febad60646379a0b1cb_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS0xMS0xLTEtMA_dadbbc86-9b7c-4bcd-844b-ebdd3711cacc">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.345%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i488b334a3ef64d4caa66debe5db19d8b_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi0xLTEtMS01MDc_40da2eda-80a0-4ca9-a3c4-f28e5bf3b02e">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488b334a3ef64d4caa66debe5db19d8b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi0zLTEtMS01MDc_f08b0073-866d-46a1-a772-3e630faea50f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c08244b023c40ca9fc941a3e60c2c56_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi01LTEtMS01MDc_0624d997-0ce0-46f8-83cd-1ad05d30a4f6">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ef651667664c27bc69872dd1d33b05_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi03LTEtMS01MDc_8997375b-3721-4b19-8230-2dbd4a7e8f26">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ade9ccbd9704bd7b8ea5b560ac9b3d0_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi05LTEtMS01MDc_42628d9b-7643-4aea-a423-35143c14e294">2,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi0xMS0xLTEtNTA3_5bcad91f-03b5-4bc5-987f-da2cdedc85fe">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8d9d0afe13d46efb8ad43cfe9cc5715_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNC0xLTEtMS01MTE_0056358f-988a-4615-b60b-ca0addf79f4f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNC01LTEtMS01MTE_83edd3f0-b2a2-4bec-bf3c-7611d728767c">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNC0xMS0xLTEtNTEx_5a54ebbf-bacf-41df-aff7-3324fcb27f6a">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS01LTEtMS01MDc3_b00485ee-1a20-4af0-b1c5-691529a1f13a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS0xMS0xLTEtNTA4Mw_051345a0-701c-4c47-b7e7-04e14e303126">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS01LTEtMS01MTQ_142c7dd9-6ef6-4479-ac51-447eeb7805bf">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS0xMS0xLTEtNTE0_a27d584b-60c4-4699-a0eb-bcdd6b790df1">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d47127223a64d2fb9cd36c959441e94_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNi03LTEtMS01MTQ_5fa8f284-2485-4306-bfad-a6bd990dac54">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNi0xMS0xLTEtNTE0_79534314-458f-4cd5-b287-a1edb40a6cc1">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife42851a7eda4b4f941a44f0037477f0_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNy05LTEtMS01MTQ_6faeddc4-1638-43df-8cc9-00cc62716dad">4,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNy0xMS0xLTEtNTE0_2554e4ac-2421-46c6-a003-5862ec83467f">4,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC0xLTEtMS01MTQ_c0d5cf88-a4b6-41e7-ba3d-00981fdf0154">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC0zLTEtMS01MTQ_d3cbffed-69e5-43d0-981b-e9edc5d1f69b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9332a7030408410190b1a94c2e713ebe_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC01LTEtMS01MTQ_39d0619d-f6b4-4b5c-8f5f-e3c485aa9132">4,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC03LTEtMS01MTQ_43ababd5-6b2d-4d76-8e93-807e714f1af6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d1c7922a0f42a1a5569a02e65e170a_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC05LTEtMS01MTQ_42d1692c-4ae2-4605-91c7-0465e9753741">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC0xMS0xLTEtNTE0_0721906f-5179-462b-b98d-9b0918a2933c">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.345%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi0xLTEtMS01MTg_c0b72622-2c4f-4469-a59d-b2a61d675ac6">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi0zLTEtMS01MTg_e148bbb5-8f2c-4d57-b390-397ab083b612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b4459de21243118082e0ace346a32f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi01LTEtMS01MTg_1304f07b-33de-41bf-9952-8d099e08d5df">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc39f92f55eb4e0a806e6264b2267ee7_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi03LTEtMS01MTg_8f7a5100-bf81-4288-be67-0e8795b80d80">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b7a4b2f73947ee99915fb30be8e619_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi05LTEtMS01MTg_c248ec37-5725-43ee-9f03-43d5db1e9a24">1,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5f72aaadd64959816335e7e8bf64f0_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi0xMS0xLTEtNTE4_747bafbb-fe8e-4f3b-89fd-d088ded872e9">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy0wLTEtMS00NDAvdGV4dHJlZ2lvbjo5MTFjOWIzOTQ4ODI0MTg5ODMwM2NjYmY5YjA1MTgxM18zMjk4NTM0ODgzNDA3_f361b7c0-c870-4aea-a211-de1ad872b3df">2</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd50a086b08a418189feb030cb4bdb1b_D20200101-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy0xLTEtMS01MTg_bba1efbb-16ca-43a5-87ea-c45783096a3b">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy01LTEtMS01MTg_5834c929-791a-4d84-a07c-8a1b7973f907">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy0xMS0xLTEtNTE4_61711b4c-c791-42d9-8bbc-3f72fa1b0c71">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd50a086b08a418189feb030cb4bdb1b_D20200101-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNS0xLTEtMS01MTg_c32dd1b7-7b6a-4bcd-ac0d-120da26fc401">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNS01LTEtMS01MTg_452a2760-885e-41cb-b046-d72942abc517">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNS0xMS0xLTEtNTE4_b8806568-4096-4b45-9ff1-15b2c0aaa7f8">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNi01LTEtMS01MjM_0afed116-bba8-48a2-bcf1-7867c449a558">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNi0xMS0xLTEtNTIz_2f8aba3e-1dcf-4cb1-be91-18bf8942a824">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNy01LTEtMS01MjM_9ce2b11b-5246-4194-a327-ffe4343b38eb">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNy0xMS0xLTEtNTIz_08f140fa-0be4-4b8f-b40e-707646a76605">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9715f2b13dc4d9a9876fb015b5eb0d2_D20200101-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOC03LTEtMS01MjM_c2c47b14-9c61-45d5-8118-503e29fcc4a7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOC0xMS0xLTEtNTIz_8f556165-8205-4a50-86b4-fec59b17dfb1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbeca61b931429a9ecce401a75b9228_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOS05LTEtMS01MjM_837a3566-aa4f-4b43-8819-b19119a6df06">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOS0xMS0xLTEtNTIz_ea82f8e7-6df0-4961-8ac6-68fe850de469">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtMS0xLTEtNTIz_50b77336-6ce1-4f42-b766-21a65c264b63">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtMy0xLTEtNTIz_40e9c5eb-fa95-4f3b-aee8-fabe33f6fb77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b68d04a23384807b92fd3080ce4ad8d_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtNS0xLTEtNTIz_8f7d0313-6358-40c5-8fb3-b765b288471a">4,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69519acdcd484f7baf0aee01a833d455_I20200630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtNy0xLTEtNTIz_7dde1c52-ebb2-4434-9c0a-ca08fa202d68">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc0ffd1101054ceaa3de2c3ffbcef1e4_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtOS0xLTEtNTIz_ab230a08-f957-4dd1-9337-88cd85c2f353">1,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae9686943f64febad60646379a0b1cb_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtMTEtMS0xLTUyMw_7bc5643c-67a6-43da-9f53-63b94dd98da8">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMy0xLTEtMS0w_1af6e503-61f3-4f70-b3bf-4c7104956a62">4,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMy0zLTEtMS0w_00f986fd-a154-4e5d-ae0a-ecd7e0270dfb">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNS0xLTEtMS0w_c4220ba0-1dcf-4e88-b387-40fa77cf957f">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNS0zLTEtMS0w_eb4c437d-4055-4b2b-a9f4-9d68591dd149">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNi0xLTEtMS0w_d0f8c245-9550-483f-b8a3-52c0eba196bd">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNi0zLTEtMS0w_28146763-ac55-4485-bdca-777e102540d8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization/accretion of investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNy0xLTEtMS0w_03bcac82-1cbe-45d6-b367-5558183b60a2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNy0zLTEtMS0w_39401852-c1e0-4dbf-acca-12e7cd79beca">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfOS0xLTEtMS0w_d38ad934-bb74-48d7-bdad-695a73fb2b1b">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfOS0zLTEtMS0w_8a5664ea-13a0-48bd-98eb-c1bd00689224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTEtMS0xLTEtMA_aa190a58-d4e5-475c-bcad-d9c14d5c5d8f">629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTEtMy0xLTEtMA_a857149f-7bbb-4a77-91f4-8ac36fa25519">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTItMS0xLTEtMA_d3279857-1f4e-4021-aa51-e5e2541d1dad">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTItMy0xLTEtMA_9cb42928-f3db-4764-a439-b4eec60e6fac">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-27pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTMtMS0xLTEtMA_6bc63e1c-2d36-4599-81b8-9e2a54a0b23e">596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTMtMy0xLTEtMA_0adeffa0-0e72-4455-959c-e93a42dfb452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTQtMS0xLTEtMA_b40e1d12-c321-48d1-b0e6-ca61e47a694c">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTQtMy0xLTEtMA_ced72495-8a1b-4116-ace7-3b1a6fc60286">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTUtMS0xLTEtMA_a63c302f-3d92-41f5-b948-106e52bea283">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTUtMy0xLTEtMA_6935dd24-15e7-4a3a-9b6f-05f7f4a15027">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTYtMS0xLTEtMA_ef4c5fab-ac6e-4410-9775-9f646758c757">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTYtMy0xLTEtMA_26350cd1-2438-4766-a927-e0b03e3e51de">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTctMS0xLTEtMA_a17b1fad-7745-4233-9e0e-65d4de1272f4">3,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTctMy0xLTEtMA_e0dd970f-d3ff-4115-883d-19361395f7b3">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="mrna:OperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTgtMS0xLTEtMA_376e7498-5523-4802-8752-d9ad46275342">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="mrna:OperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTgtMy0xLTEtMA_48f0f868-4d73-48ea-ac84-9d9e18d68a8f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTktMS0xLTEtMA_c3313f00-c1d2-455a-8402-597c4cd6dbdf">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTktMy0xLTEtMA_de297d50-3ba9-402c-aa8c-782609d6217c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjAtMS0xLTEtMA_fc0f28b9-f870-427e-b93b-03d94d7e5405">7,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjAtMy0xLTEtMA_cbcaad8c-3d02-4d03-b712-dc388ee464ab">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjItMS0xLTEtMA_37d22eca-73c4-4be9-b296-606e1bdb9cc6">6,559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjItMy0xLTEtMA_bd7363fc-ee52-48f1-b2d4-40e41980159e">903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjMtMS0xLTEtMA_3b45d70c-fcd1-4dfd-9963-dc0acbde8729">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjMtMy0xLTEtMA_fdabeb2d-6059-4275-b0a4-140d4558a1c9">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjQtMS0xLTEtMA_19a271b6-2408-4876-b54f-c7e6abd6f2d7">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjQtMy0xLTEtMA_c887aa3b-1df2-427a-b7cf-1ea9da5bab38">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjUtMS0xLTEtMA_4ac1371a-34f9-4b20-9bb0-81472764eac1">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjUtMy0xLTEtMA_e6936ebe-108b-4009-9672-75f94c322b9f">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjYtMS0xLTEtMA_3a9b63b5-8b17-48b6-a4cb-f408ebc1dc7d">4,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjYtMy0xLTEtMA_3313b765-a586-42de-a953-d039c3f2ab86">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from public offerings of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjgtMS0xLTEtMA_59ba160d-62c0-41a9-936f-032e7dfcb5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjgtMy0xLTEtMA_67ac509f-2418-4b9c-83b1-bb5f2a6c5449">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock through equity plans, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjktMS0xLTEtMA_4f764a1f-2aa8-4ab3-9a3f-f0996a3142ce">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjktMy0xLTEtMA_87d7f341-b925-4e48-b410-53cf6d00e2c5">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" name="mrna:ChargesToFinancingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzEtMS0xLTEtMA_e4d535c5-de93-4061-b20a-da0b0ff5f856">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="mrna:ChargesToFinancingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzEtMy0xLTEtMA_9a936d08-c239-4ff3-b177-ae3439f5c615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzItMS0xLTEtMA_4954874d-6dab-4128-bad1-0259b45dabae">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzItMy0xLTEtMA_048b25f5-9799-4564-9a6d-f783dc54bb20">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzMtMS0xLTEtMA_a0af078b-b3e1-4152-8b90-e44fa023a6c2">2,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzMtMy0xLTEtMA_2dda383d-eccd-4bc9-9a13-2d2172194f5f">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzQtMS0xLTEtMA_779cd44e-2e89-4272-aead-01f07d4cfebd">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5f72aaadd64959816335e7e8bf64f0_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzQtMy0xLTEtMA_2461df94-7dc2-49ec-8e66-f62a8a703935">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzUtMS0xLTEtMA_bcde6739-5e8d-4a13-bf99-470c3301a4df">5,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae9686943f64febad60646379a0b1cb_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzUtMy0xLTEtMA_479bcc41-0cdd-4056-a423-a180f09a7e7d">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzctMS0xLTEtMA_5b1a541e-f7b4-4062-8913-528129c15e33">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzctMy0xLTEtMA_c2e6de98-9a0a-4f71-bb21-ec2ef9a0fa15">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained through finance lease modifications and reassessments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzgtMS0xLTEtMA_5f8a777a-734d-480e-a8fe-74acdbc7593d">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzgtMy0xLTEtMA_98b51117-9f4a-4f64-821d-4749bcc0fe8d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzktMS0xLTEtNzIwNw_8486a060-547a-4b0e-b27a-e5bb9dc66eab">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzktMy0xLTEtNzIyOA_ee08b805-7e3d-443c-ab59-948610efcbef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_34"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8zNC9mcmFnOjRhMGQzMjY3OTJhODQyMTQ4ZGM4YWVhOTFhNDM2MTQyL3RleHRyZWdpb246NGEwZDMyNjc5MmE4NDIxNDhkYzhhZWE5MWE0MzYxNDJfMzcyMw_6696612d-aac9-454a-997e-6e94a4d630ad" continuedAt="iefce6d5627a54ae3adb266556af62d2c" escape="true">Description of the Business</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iefce6d5627a54ae3adb266556af62d2c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in more than 50 countries and from the World Health Organization. Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the European Union and Japan and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. On June 1, 2021, we initiated the rolling submission process with the U.S. FDA for a Biologics License Application for our COVID-19 vaccine, and we currently anticipate completing our submission in August 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2021, we had <ix:nonFraction unitRef="program" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="INF" name="mrna:NumberOfDevelopmentProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8zNC9mcmFnOjRhMGQzMjY3OTJhODQyMTQ4ZGM4YWVhOTFhNDM2MTQyL3RleHRyZWdpb246NGEwZDMyNjc5MmE4NDIxNDhkYzhhZWE5MWE0MzYxNDJfMTg0NA_ceffccd4-9e16-47ab-83cc-b958bf261890">24</ix:nonFraction> mRNA development programs in our portfolio with <ix:nonFraction unitRef="clinic" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="INF" name="mrna:NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8zNC9mcmFnOjRhMGQzMjY3OTJhODQyMTQ4ZGM4YWVhOTFhNDM2MTQyL3RleHRyZWdpb246NGEwZDMyNjc5MmE4NDIxNDhkYzhhZWE5MWE0MzYxNDJfNDM5ODA0NjUxODA4Nw_f61e1dbf-09e3-490c-8efc-1eece58a3a05">14</ix:nonFraction> having entered the clinic. We have incurred significant expenses in connection with the discovery, development and commercialization of our products, and we expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with the ongoing development and commercialization of our COVID-19 vaccine and ongoing activities to support our platform research, drug discovery and clinical development, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, infrastructure and Research Engine and Early Development Engine (which includes our Moderna Technology Center), digital infrastructure, creation of a portfolio of intellectual property, and administrative support. We may finance our future cash needs that exceed our operating costs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of&#160;June 30, 2021&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of these financial statements. We are subject to numerous risks and uncertainties associated with pharmaceutical development and commercialization, and we are unable to predict the timing or amount of expenses or if we will be able to maintain profitability. If we are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg2Ng_137fa1b7-98f8-402c-befd-b7f37db9606b" continuedAt="ic1e4f4bbc07846b8b3c309218c2a7d88" escape="true">Summary of Basis of Presentation and Recent Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic1e4f4bbc07846b8b3c309218c2a7d88" continuedAt="i7b309edfc73945148b18b737e825736e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg3OA_507da3f6-9533-4f97-a80d-ac6924d0073d" escape="true">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="i7b309edfc73945148b18b737e825736e" continuedAt="i65c1b00553784ff4851703caa5fa7cc4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg3Mg_4ab56b16-8d1d-4f24-8f23-5c32e92be0a4" escape="true">The condensed consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2021 are consistent with those described in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1OQ_931b62f3-fa08-42ae-bd37-f7477609606e" escape="true">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg3NQ_94ced9cb-6080-4220-b9a4-f0e72e178149" escape="true">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains/losses and gains/losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg2MQ_5e54bd78-4985-494e-a3f0-90d30ba35dba" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income for the three and six months ended June 30, 2021 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ed33a973974be78cf5fb2ffa1a2b11_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMS0xLTEtMS0w_92593f84-ad25-41fd-9e25-ad58c09fe97a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd1d9442a7b4754a406bff7a39e5fd3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMS0zLTEtMS02MTgz_765cca95-af7f-44db-b290-3f3b52907da1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ef651667664c27bc69872dd1d33b05_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMS01LTEtMS03NzI5_58f1b0cb-408d-4966-95bd-b4bf33cd5e71">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157887d3dcbd422db9ab258078ee14a9_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMi0xLTEtMS0w_3fc3aa7f-4f44-4ec2-817f-21402c5cf9df">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec75ac0ff6b94c738a5f8719561f6104_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMi0zLTEtMS02MTgz_8c23a697-cbc0-4c00-862a-a663e107850b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia96c0176d8aa4d39a5da077d3b371b0d_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMi01LTEtMS03NzI5_c245e6c4-6c69-4eca-8c00-629c2d99c700">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122512b403f742038c2c1468c00fb915_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMy0xLTEtMS0w_9127360a-9927-443c-96d9-cda7507b031f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fdf15d391e54159b27e230febc1be1f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMy0zLTEtMS02MTgz_53ae6a97-b222-4996-bf25-5354d76f1e7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id896a91ec74c4c49abdf78c300d13ca0_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMy01LTEtMS03NzI5_39860487-c1e5-48f3-b08c-1518f26da064">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05aff14929149cab57fd79aefeeeb56_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNC0yLTEtMS02MDc_e4f7b211-f10e-486c-8095-f63fb64fe5b5">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12aafa2a5b1746a4984dfb62d34e42da_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNC0zLTEtMS02MTgz_f0e4102f-c6bd-4666-8f86-47a1adeb5fdd">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNC01LTEtMS03NzI5_2a421e43-9f31-4aad-baa8-2ccada744c83">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib627f3fa58de490c92d72c00c79d72c4_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNS0yLTEtMS02MDc_b27e04e9-a09a-4977-8259-971f5485bac7">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6c5bf45d0d43ac9807ba42e62b7367_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNS0zLTEtMS02MTgz_ab6194da-fc83-4103-91e0-544cbdcd71fb">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNS01LTEtMS03NzI5_1506763f-2bf4-491d-a9e1-823fa4a4d926">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1Mg_63488fb4-2ab4-4635-9082-2967cf3b7566" escape="true">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.</ix:nonNumeric>&#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1OA_a1690b51-e64a-4a60-9f47-100655549ba9" escape="true"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg2Nw_fea42f0c-6396-4428-a702-4ca8c26804f3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:69.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMi0yLTEtMS0w_6309d699-b470-4c16-8798-d07ef5372c17">5,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae9686943f64febad60646379a0b1cb_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMi00LTEtMS0w_b9268708-890b-4479-a935-480cada72e29">1,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMy0yLTEtMS0w_9afd3e36-6104-4559-8bbb-525f9eea245e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae9686943f64febad60646379a0b1cb_I20200630" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMy00LTEtMS0w_1388ad5f-027e-4c57-8e34-8d75dc54c228">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNC0yLTEtMS0w_73189ae8-c729-43b7-b3c8-1d29d876dcae">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae9686943f64febad60646379a0b1cb_I20200630" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNC00LTEtMS0w_e6c9821c-e761-46d0-ac7c-cafe6da7c803">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNS0yLTEtMS0w_d3ea4811-ee6f-4818-a6ef-31070900535f">5,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae9686943f64febad60646379a0b1cb_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNS00LTEtMS0w_8de06991-9ef2-4d87-87f0-fb6aa6f2873a">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="i65c1b00553784ff4851703caa5fa7cc4"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1NQ_b9b49c76-4af7-4970-b98b-09b7b3c43bbf" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfMTA2NA_cd31e7b1-1d85-45a2-afbd-9d2aef79d3c3" continuedAt="i00c21264ebb64e90b79e8b0f56ff7cfe" escape="true">Product Sales</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i00c21264ebb64e90b79e8b0f56ff7cfe" continuedAt="ie67b877671c647edad41b0fc896c0543"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfMTA2NQ_cc3e4df9-d303-48ff-87b7-bde2cb7889bc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.929%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e5362a76064a92b61e459fcd0ce315_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMS02LTEtMS03MDI_6247efdf-9532-49cf-a0d6-a765fe9cf1d2">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fd324dcb2a418298c8cc16153570f3_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMS0yLTEtMS0w_465d0265-2e3b-4962-8079-e9457d0d32ca">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1537b27f156c48ffba4b540f307af8f9_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMi02LTEtMS03MDI_1f42919c-3846-4f9b-90a9-29c35392e43f">2,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2776323b3943b9ad57f0cfb5a2e92e_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMi0yLTEtMS0w_00d2db8a-2176-416e-9e5a-9cf8b959cf91">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62917e20a8fb457d8e66c38f2ad33f7a_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMy02LTEtMS03MDI_add038c8-5d67-4d99-b7a4-537ffe0cea41">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMy0yLTEtMS0w_7d46e4c3-3f12-4659-8678-af81e3181979">5,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="id65439feeef443e58684902e2ca1fe70_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjM1NA_75a803d6-7e9d-4518-99a9-157bdba7e0c0"><ix:nonFraction unitRef="usd" contextRef="ie42b22b2df23458abe04d022388eae80_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjM1NA_c1310ea8-ecae-4336-be1d-340757976dc8">no</ix:nonFraction></ix:nonFraction> product sales for the three and six months ended June 30, 2020. As of June 30, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, we had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i90e522303a6d4db88a6e75f6bf51b675_I20210630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjY0NQ_1e571661-aa20-4d9d-bdf1-a4fc6546da78">7.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i925c8f5cb9cd46f6a1ae86a03be5fc3f_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjY3NA_3d07fe83-d60e-433d-8ccc-86fc1b0e790b">3.8</ix:nonFraction> billion, respectively, related to customer deposits, classified as current deferred revenue in our condensed consolidated balance sheets. Timing of product manufacturing, delivery, and receipt of marketing approval will determine the period in which revenue is recognized.</span></div></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:continuation id="ie67b877671c647edad41b0fc896c0543" continuedAt="ie4b584058f4448649b0c0a68bbd7fe4f">Grant Revenue</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="ie4b584058f4448649b0c0a68bbd7fe4f" continuedAt="i8c5304608b504743aaba6983998e159a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $<ix:nonFraction unitRef="usd" contextRef="i197583d029334a8a81529a09b6d9abab_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTUy_502ef6ac-480f-4717-823f-446fef5bffb2">56</ix:nonFraction>&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of June 30, 2021, we have earned the committed funding of $<ix:nonFraction unitRef="usd" contextRef="id6503cc026fe46aebeebe1584e563292_I20200630" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsCurrentFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMzgz_ac94bf93-f17e-4685-abca-14549533f7ea">5</ix:nonFraction>&#160;million. An additional $<ix:nonFraction unitRef="usd" contextRef="id6503cc026fe46aebeebe1584e563292_I20200630" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsRemainingFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfNDA2_82db2cc7-4cd5-404c-9b00-3e025ca961af">51</ix:nonFraction>&#160;million funding would be available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $<ix:nonFraction unitRef="usd" contextRef="i9d8c05f658d243b7a83bfd8f5c1c6f4c_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfNzU5_c3665231-9fec-4f8a-833e-949bff187ca2">483</ix:nonFraction>&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $<ix:nonFraction unitRef="usd" contextRef="i317ef19f70e3444197530823e5c919f1_I20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfOTU0_8fb68f57-9387-42b7-96cb-2519cf6a998a">472</ix:nonFraction>&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a <ix:nonFraction unitRef="option" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="mrna:NumberOfParticipant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfNjA0NzMxMzk1OTUzMQ_766e6735-cc47-4f62-a4aa-ba4ec9676bdc">30,000</ix:nonFraction> participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $<ix:nonFraction unitRef="usd" contextRef="i1ebdc9e4059d4f3e8af844afeb9fa830_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTE3OA_d74ea212-400c-4d4a-ba19-15a5f8e569b9">63</ix:nonFraction>&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $<ix:nonFraction unitRef="usd" contextRef="ie51ac7bdfcca483bb11c2dd61678484a_D20210401-20210430" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsPotentialReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjc0ODc3OTA3NDM3OA_86855f65-6500-4a02-b5b5-c205fc451cd6">236</ix:nonFraction>&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. The maximum award from BARDA, inclusive of the March 2021 and April 2021 amendments, was approximately $<ix:nonFraction unitRef="usd" contextRef="i8dfd3eaf51514a388430a090a9c38bf7_D20210101-20210331" decimals="-8" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTM3OQ_fb395885-79a5-4941-869b-efec53b20687">1.3</ix:nonFraction>&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $<ix:nonFraction unitRef="usd" contextRef="ie6e91224fb8d4da7a4999fd677df954b_I20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsCurrentFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTU5MA_6996cdfe-9462-4f3e-ad9c-2090c1f734d1">421</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received from BARDA an award of up to $<ix:nonFraction unitRef="usd" contextRef="i3f7b3f76a0254c61a7d0c966cb15f054_D20160901-20160930" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTkzMg_013566ef-51df-4d14-bf85-4c3045f8b9d0">126</ix:nonFraction>&#160;million, subsequently adjusted to $<ix:nonFraction unitRef="usd" contextRef="idc3a7ff346784334ad9e7b0a9a13d895_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTY0OTI2NzQ0NzYzNQ_25cb19a9-e0ae-43cb-9b06-db797e98e4b9">117</ix:nonFraction>&#160;million in 2021, to help fund our Zika vaccine program. <ix:nonFraction unitRef="option" contextRef="ia5b1bfb294a14e0a9af5a1f7d2fe3c3d_I20160930" decimals="INF" format="ixt-sec:numwordsen" name="mrna:RevenueFromGrantsNumberOfContractOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTk4Ng_d59b288a-7dde-4610-b1e9-b52ecf488a8a">Three</ix:nonFraction> of the <ix:nonFraction unitRef="option" contextRef="ia5b1bfb294a14e0a9af5a1f7d2fe3c3d_I20160930" decimals="INF" format="ixt-sec:numwordsen" name="mrna:RevenueFromGrantsNumberOfContractOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTk5Ng_5a3e4c9f-5ec6-4610-a054-541f6130e752">four</ix:nonFraction> contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $<ix:nonFraction unitRef="usd" contextRef="i23d59c82137047499203288390a8fb25_I20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsCurrentFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjEwNQ_575ef3ac-78bb-4a90-9d71-6e11decbaee0">59</ix:nonFraction>&#160;million, with an additional $<ix:nonFraction unitRef="usd" contextRef="i23d59c82137047499203288390a8fb25_I20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsRemainingFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjEyOA_d8631e53-6eb7-4866-a83d-20114e0ceb51">8</ix:nonFraction>&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of June 30, 2021, the available funding, net of revenue earned, was $<ix:nonFraction unitRef="usd" contextRef="i3736c014f39246fab97d6e843cb4749d_I20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsRemainingFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjQ5OQ_b6467c9b-5fde-4311-9453-6d9c02dcdb12">10</ix:nonFraction>&#160;million, with up to an additional $<ix:nonFraction unitRef="usd" contextRef="i3736c014f39246fab97d6e843cb4749d_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjUyOA_7485ef8e-7fcc-402b-af00-9bc52cece349">80</ix:nonFraction>&#160;million available, if additional follow-on projects are approved. </span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="i8c5304608b504743aaba6983998e159a"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjY5Mw_41cab9a4-75c5-4ccc-9419-d3b3a964c901" continuedAt="i0f93fc2619334c0ba5edaff20f3ad183" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue as of and for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia364f96dfa314c94ab36b5e61edb53d8_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi0xLTEtMS0w_50547eeb-f65b-45ad-89f7-8d166399ec91">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2020bda539b4500be4ec167f8f9dd69_D20200401-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi0zLTEtMS0w_16e43d52-180b-474a-ac69-49ec64edc009">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c916a0b4ca4f3aaaf4cdcb3d605a58_D20210101-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi01LTEtMS0w_e041e262-c29a-4a97-a238-1e49555e0c7e">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib842bb3c0b504e23ad5bea99b14f72cf_D20200101-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi03LTEtMS0w_49c78e91-68c4-48c4-8b3a-b9f819997355">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84be31041f544b97a41d04069c6d8bf4_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy0xLTEtMS0w_9a235543-f889-473b-aa6d-9413b8fc4178">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea751eab6f240dba31a0a82fdceab7e_D20200401-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy0zLTEtMS0w_55240b54-bfb2-4ab3-80c4-885fbd71d512">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f686c80a94472683e32b196c79f61c_D20210101-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy01LTEtMS0w_ba2feaee-ad20-4e29-9585-426f64cb267d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162ebf7a6485464c849cf2578c7dab6b_D20200101-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy03LTEtMS0w_1cbd33ac-210a-4392-9c8b-ecf2402a4546">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97462bb9e06e4d0b8038908806010639_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC0xLTEtMS0w_7e1dd2eb-1ecd-4726-aaef-bf2cb59745a6">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277a54dbb61f41e99601f903825b48d2_D20200401-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC0zLTEtMS0w_5e2382b5-f9e7-4324-b038-c49eba9e5822">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC01LTEtMS0w_a627b9e7-ec92-4e91-a2de-edb3e4b4fc4c">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b0955908be463b8c5776e5549bb45f_D20200101-20200630" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC03LTEtMS0w_1551190b-98e8-4529-a695-40c5606cc711">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RleHRyZWdpb246YjFjOWZhYWM1MzcxNDZlMThkYWMyM2M1N2RhNzQ3NjVfMTE3Mg_47dba873-22eb-43f7-ac07-d979ed2d1217" continuedAt="i0ab5d7e83b0c4c819c84067e30f41b2c" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0ab5d7e83b0c4c819c84067e30f41b2c" continuedAt="idf68684204e04799bae23184568d0f36"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of June 30, 2021 and December 31, 2020, we had collaboration agreements with AstraZeneca plc (AstraZeneca), Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and Chiesi Farmaceutici S.P.A. (Chiesi). Please refer to our 2020 Form 10-K under the heading &#8220;Third-Party Strategic Alliances&#8221; and Note 5 to our consolidated financial statements for further description of each of the collaboration agreements. </span></div><div><span><br/></span></div><ix:continuation id="i0f93fc2619334c0ba5edaff20f3ad183"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.500%"><tr><td style="width:1.0%"></td><td style="width:44.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c0e4a432e844f8b79c47cfa66d0c9a_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi0xLTEtMS0w_8f06d8b9-b6ac-4c92-be56-5d01573b5359">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7e7990e9d440e893ed1142076218aa_D20200401-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi0zLTEtMS0w_03483ef2-07c1-413f-a364-dc992559d355">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7644505741a1400d86377f349317c0fd_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi01LTEtMS0w_abe139be-1721-4911-8d4f-239ae5c8f7a2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaddeea55cf45455cb5d1c9673b0324ce_D20200101-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi03LTEtMS0w_22f0940c-72a6-455e-a473-0f4f140e51bd">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e00f59aecfe46eba16e2160aad94c2e_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy0xLTEtMS0w_6d91d054-0ddc-4b30-b51f-ea79cd764edd">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d9addacdd64f378a73828f0159e567_D20200401-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy0zLTEtMS0w_c7ad8c3f-87f6-4c0f-bb25-79b2f0aa92fb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00107eb57614d2783a2c32384445ff8_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy01LTEtMS0w_44712d71-8f1d-45d1-8aac-1e1441b33088">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9334dd2e954444a97f8e4487361fbd_D20200101-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy03LTEtMS0w_afb232f1-2e51-482a-b178-3c1bb394facf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e7c7882cf1442f9e76d9e7fa5fb939_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC0xLTEtMS0w_7a2a2845-54f8-47f8-99e0-26a16394cd2f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0ecb7e5c464559a1438e2425eadc54_D20200401-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC0zLTEtMS0w_d98d91ab-4617-401e-81e9-c1880cde7c32">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b82d07ccaad4e878d47278bb6324ea1_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC01LTEtMS0w_a5e52090-519e-4631-82ed-58626bbc8d6d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie360ccfe76ce4f12acb76df75ae0cd29_D20200101-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC03LTEtMS0w_cbae5fe2-01d7-4c2d-b502-95c099cf6e11">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac3dd43b3bf4cbba83cd10d23c2765d_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS0xLTEtMS0w_ea2317f8-aa50-40bd-84b7-3cb174053efb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8812f9dae82547b18386cb8d2b5e9345_D20200401-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS0zLTEtMS0w_e61f42c2-81b7-44b7-abca-d445401c0771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d810941907046baa10069ee651b0e1f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS01LTEtMS0w_225eade6-7142-4085-a633-c9d3e897b6b1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4765f3aff24398975e633a19635d2d_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS03LTEtMS0w_1d6a8d24-248b-4a78-bf88-5db1273d2dc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4150668b3b4c44aa607c9d34eb7166_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi0xLTEtMS0w_d2f49e2e-5b66-4497-aa7d-a6b541d171d1">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52338e34ec645a58c3c88e7c09ae121_D20200401-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi0zLTEtMS0w_05d82a47-8b9e-4ee6-9849-de77bac02880">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi01LTEtMS0w_88dc0db0-76b0-4946-b3cd-9a1a9432392f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e9a9ef8cc640939f59b6dbf739b2f2_D20200101-20200630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi03LTEtMS0w_fe71c615-c73b-496a-af00-4845bead1471">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RleHRyZWdpb246YjFjOWZhYWM1MzcxNDZlMThkYWMyM2M1N2RhNzQ3NjVfMTE3MA_83712127-043c-407f-8dfd-ed456a751933" continuedAt="iea52bd7bd35e4ae2a36ef0daf446ca41" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the six months ended June 30, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:38.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4dcbd5648047cc838ad06ddef0f031_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi0yLTEtMS0w_27e2fc2f-096c-45ee-84d7-7cbd810b8904">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630" decimals="-6" name="us-gaap:ContractWithCustomerAssetPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi00LTEtMS0w_b63d6520-3d8e-4898-a91c-70e6c31b412f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630" decimals="-6" name="mrna:ContractWithCustomerAssetDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi02LTEtMS0w_53eb26ed-ec6a-4aaf-b894-8af5e694488f">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b065b0be3c464e8433f98080bb78c2_I20210630" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi04LTEtMS0w_65e56954-1fec-4f68-97f8-87f3f071c836">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4dcbd5648047cc838ad06ddef0f031_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC0yLTEtMS0w_5c47a400-d812-4ef8-8eed-ef344c881b69">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC00LTEtMS0w_420b7a21-ef12-4a82-9a97-62aff5ab37cf">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC02LTEtMS0w_03d70c01-de0a-4005-9be7-c0dd07b018d0">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b065b0be3c464e8433f98080bb78c2_I20210630" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC04LTEtMS0w_6907cad3-5dec-429b-9fa9-be6d97347c58">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf68684204e04799bae23184568d0f36">As of June 30, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="i44b065b0be3c464e8433f98080bb78c2_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RleHRyZWdpb246YjFjOWZhYWM1MzcxNDZlMThkYWMyM2M1N2RhNzQ3NjVfMTE2Ng_cdac63cc-c243-48b2-ba4a-a753ce946b80">321</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2Ng_e618b934-2b1e-4bfb-a02d-e70f0dc740c8" continuedAt="i93c090c4811a437989afca719560c266" escape="true">Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i93c090c4811a437989afca719560c266" continuedAt="id5cbb8ed4eb147d7a5702306aba82e27"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2OA_11c2f8e7-23bd-49ea-bf45-2e7c4b1dac3f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at June 30, 2021 and December 31, 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0yLTEtMS0w_b8d49254-7c4f-40a8-b7ba-532b77072cb6">5,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi00LTEtMS0w_445b3de1-88db-44a9-befa-c1592eb0ecb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi02LTEtMS0w_7c491774-d1b3-4012-bc47-4c74b9016a8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi04LTEtMS0w_e4d4c56a-efee-429a-b4d0-21e6fc8e8a55">5,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fb537f002a4b8c925b113ba3d2017d_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0xMC0xLTEtMA_85e0ecc7-b6c0-4732-8b6b-d047cd15af20">5,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cf2066964f4552b9838011a69044d2_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0xMi0xLTEtMA_039000cb-a626-4114-aa7b-34049ca2d3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e40b9256244a589946a1e85bf6cc70_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0xNC0xLTEtMA_182510d9-0ab5-486f-9704-8ef471c26771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0yLTEtMS0w_8442cf19-f64b-448c-b751-1f37860b5eae">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC00LTEtMS0w_a2a1a27a-90b3-42b2-8fed-4aac9096d961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC02LTEtMS0w_70f00616-ba4d-4671-8d98-686f80f197a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC04LTEtMS0w_4102820c-11e5-4229-b41d-d92134249a6d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b130a946c83453fb4a2d9207835ffe6_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0xMC0xLTEtMA_fac2e90f-3dff-4d12-878f-88e7731e4dc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423fce28b3db46918d8d1d5c8d38b86c_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0xMi0xLTEtMA_a96244e0-09a7-4e7c-9c98-4a783c357384">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea33fd392c424f96b2db18376181aebb_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0xNC0xLTEtMA_fa913ad2-3dd2-47ee-ab5e-fde052039428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0yLTEtMS0w_43e46967-f205-4131-a50b-54d9f16a296b">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS00LTEtMS0w_808b27e2-fcd1-4cfc-989c-5c3c5685f4af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS02LTEtMS0w_a6c98ea0-51c8-4352-85d4-ac01f417c745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS04LTEtMS0w_1472f5d8-f7d7-4dcf-a931-0603a88c2071">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3dd508a23a494cb5ea06605d67c4ce_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0xMC0xLTEtMA_68d8b6c0-3d57-4b0e-804b-e27009c241e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd695349782d4fabb5331046948b8614_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0xMi0xLTEtMA_156aea4f-7c00-4530-9f9a-0341ad578204">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e44fa9dff64d7aa736f647933beb2f_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0xNC0xLTEtMA_7d7ba604-ad8e-49d2-8e9c-d8c237064bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0yLTEtMS0xMDE2OA_49d78bf4-8fb0-4fa9-ab56-6c3489711146">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi00LTEtMS0xMDE2OA_ab84965f-f4a3-4881-9357-15f0936ae6bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi02LTEtMS0xMDE2OA_86965eaa-c311-41d6-91b9-b640159f6720">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi04LTEtMS0xMDE2OA_e69fcb35-afd7-44df-8883-2605ee965857">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4821d306d1d84e8c92f59601e79d952a_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMC0xLTEtMTAxNjg_10eed521-5526-448d-9495-78f1073356bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6972a4b3a6464fa76fdb392c3e5aeb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMi0xLTEtMTAxNjg_cda564e6-1a5f-4c3f-a422-87ad58b242f2">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bd954162504b8b865d6ee4ff792361_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xNC0xLTEtMTAxNjg_49e6047a-772c-4f08-8491-cd3a52254960">2,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd7c27968a4482bb56525e657054318_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0yLTEtMS0w_b883d02a-5cfe-42d4-9d81-9f71fb9d095c">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd7c27968a4482bb56525e657054318_I20210630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi00LTEtMS0w_c8170b58-752e-4d73-8381-e83a8ca72938">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dd7c27968a4482bb56525e657054318_I20210630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi02LTEtMS0w_135a710e-945b-4cc4-b709-8e7aa41bd350">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd7c27968a4482bb56525e657054318_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi04LTEtMS0w_8a40fee4-bdfa-4d4d-addc-87e0b135731d">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cb4879eecb497aa9402f0d74f44387_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMC0xLTEtMA_4025cb7a-8228-481a-a591-5bfc945be7e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2262642e3b47c28ff6867f6509b071_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMi0xLTEtMA_a0417141-c112-447e-be9a-7bef5629f3b0">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769d59bacc4a4a21bb4c83f4a46ff03f_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xNC0xLTEtMA_90292869-da82-4946-b61b-fe8d20aeb46b">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0yLTEtMS0w_58803086-a5cb-4a58-8b72-48d3c784d94e">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy00LTEtMS0w_f7f53a30-780f-490b-9453-367751b71ba3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy02LTEtMS0w_be052cb4-b5cc-4b38-af39-ab78a2431e27">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy04LTEtMS0w_97685a41-2ea4-4a14-b617-97b5ad059bd9">12,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bbf998b6c041a6901c1dc8996237b7_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0xMC0xLTEtMA_14007ed5-95d3-4c2c-b73b-c51d964edafb">5,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0489f9f56e42fe85ab3ecf9d6d2dad_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0xMi0xLTEtMA_c4426832-68a1-452e-973c-36c5ac45b753">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c840483704458faf3161e93a3e01e8_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0xNC0xLTEtMA_260cdf92-4b8b-4561-818d-35ec5b920423">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMi0xLTEtMA_68e320c9-a4d7-481f-ab6c-f1060f0c916e">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtNC0xLTEtMA_2787367f-44e8-47e5-ae3a-2f7eb7999553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtNi0xLTEtMA_7108f792-258c-4a96-8cb4-440e87d8e003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtOC0xLTEtMA_5d71c7be-abd7-4374-b082-10bd84107002">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774f6d34510445e0ba7f5b0b00875252_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMTAtMS0xLTA_e641cf0c-693f-4768-95f7-7d4a2a1a3372">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0466c7cd491448979678f3b868c44e9d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMTItMS0xLTA_2ea0b6e6-5fef-48d1-94f8-c6e398ccdb9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if135f26414c04231aa2ea55c9a2c83a6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMTQtMS0xLTA_e011dcbd-0857-49fd-98bc-eec79ed4496c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25503043380a4bc7998a597473d1786d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMi0xLTEtMA_36fc9d89-f09e-4110-80a3-88b899f99ef4">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25503043380a4bc7998a597473d1786d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtNC0xLTEtMA_48d2c3dc-a976-4288-b517-f7e4500798c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25503043380a4bc7998a597473d1786d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtNi0xLTEtMA_c6faa08b-2943-4372-a239-2e24bb72fbde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25503043380a4bc7998a597473d1786d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtOC0xLTEtMA_00adb9c1-36de-4322-9fdf-ae242663c093">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e114d012176429c97c1208417394403_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMTAtMS0xLTA_eef8e570-652a-44b3-ae26-f38e5f5fe394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55f81c1ceb8498fb37e9398c3b61120_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMTItMS0xLTA_010f43ab-c677-4c90-aa91-4e3d3cf96d1f">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12cd6744128743138d2497b1a6aeab5f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMTQtMS0xLTA_4a587319-782a-4088-a5d5-d3c445b2d1db">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMi0xLTEtMA_af81aab3-acb4-4c1a-b081-2949025f06c0">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtNC0xLTEtMA_9f773a47-96de-4a01-90f3-46d6c475864c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtNi0xLTEtMA_404ce486-0d01-41dc-81ff-b6a5c23a7af7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtOC0xLTEtMA_aa7d936e-30c7-4b07-9ba7-5fc29c332b82">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519420c4ce3f4e889babc67663290d67_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMTAtMS0xLTA_5f50e76d-1d2e-44e1-92d4-3915d4d25e05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa12a4a1d724b97bb9fb7cdd250ec0e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMTItMS0xLTA_9c73f5a6-d333-4dad-b89d-adeaf9955175">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6954dbaff3c452da6a96be861950389_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMTQtMS0xLTA_365e4af1-e244-4ac6-b78a-89cc5e405200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMi0xLTEtMTAxNzM_92e03d25-1b72-44de-b037-3b168ed6bd37">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNC0xLTEtMTAxNzM_2ab41dc7-7e94-45af-ba31-80c2e7c26851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNi0xLTEtMTAxNzM_7aabe5d4-7680-47a5-a909-b1503264c409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtOC0xLTEtMTAxNzM_cf4b27c1-3b36-4f55-bd1d-61e1c18e93be">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3e4a401171474a9007e9abf988d8d1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTAtMS0xLTEwMTcz_b98101fb-d6b7-4703-b60e-b2ea33bf0b70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic540ca4685794ebb951a1f68ef0b6cbe_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTItMS0xLTEwMTcz_2b5fc64d-a669-4f7f-9e1d-f9afd395aa10">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a16e85d6b1c4d0b82c2b3e4a95dd15b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTQtMS0xLTEwMTcz_429d1404-ca52-4ba9-b74f-8374b81b31c9">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMi0xLTEtMA_bbca579c-ca0b-42e0-9f8a-9c208e8f9d6c">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtNC0xLTEtMA_00e34dc2-8536-4252-83f6-5d88f9338c97">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtNi0xLTEtMA_897584e0-2205-4a1e-9a29-69250c02c91d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtOC0xLTEtMA_9a7f8a2d-d528-4768-910d-15262d1bab45">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i194e3a1c43ff42a5b8386c49d1daa843_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMTAtMS0xLTA_cde5fc96-5785-4191-aa46-ff59a1b96fe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f554c3a46462b96c3244553fa4901_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMTItMS0xLTA_57e57788-a517-456c-a0a6-83e6497350c7">1,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d36108a148c4a0fbcdf9c7d9b7be3b0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMTQtMS0xLTA_8dfe5f43-923b-45d8-870e-feb43d029257">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMi0xLTEtMA_f31c8362-e3c6-4bca-8969-4f1e6005fadd">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNC0xLTEtMA_dc7e7298-6e67-4262-81db-4730b1fba635">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNi0xLTEtMA_0029e74b-e86c-401d-9d51-ac7ab6f70dc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtOC0xLTEtMA_e634abc1-19b0-4214-8630-383bb558b2a9">5,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cbbe97585b49f7816d2b3bc62ef46a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTAtMS0xLTA_d0ccac62-3a5d-4ca4-862c-32ee92f9c945">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7e6285a6f9420a8a1c73a6d999a977_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTItMS0xLTA_7f4da591-6227-4fec-9a86-91677ce8a8ca">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db80e5245884f98abb49e31eb422938_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTQtMS0xLTA_1a31fc8c-ce49-4c4e-b1ba-afced10d6acc">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2OQ_ef2d0742-40d0-478f-a969-41300c6440cb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities by contractual maturity at June 30, 2021 and December 31, 2020 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMi0yLTEtMS0w_341f8325-3752-423b-ab38-521f2558dad3">2,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMi00LTEtMS0w_ad143173-089f-4ccd-98aa-998758079138">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMy0yLTEtMS0w_2124c6d8-d1fb-41c3-b041-56e0e0b29fd0">4,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMy00LTEtMS0w_4965d9db-30a0-45e9-a739-0c1342321ae7">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfNC0yLTEtMS0w_65d82252-d137-40a1-b6dd-1b9af24c4fcb">6,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfNC00LTEtMS0w_f4d40ff9-f4eb-4ff2-a24c-9aba945e5a64">6,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMi0yLTEtMS0w_5a44a26b-b4fe-45ec-bcbb-8ce6cd3b0af8">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMi00LTEtMS0w_863576de-5bb3-48ae-874b-97951c552517">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMy0yLTEtMS0w_d69be412-5403-4e5a-8521-d54fc6a029c8">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMy00LTEtMS0w_0cf59c0a-0504-485a-819a-b18a8a08e3b6">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfNC0yLTEtMS0w_2dabf71e-e528-4058-826d-34fe73be3e52">2,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfNC00LTEtMS0w_4e967201-b89d-40f1-a50f-5adddec55c4f">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive loss, net of </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="id5cbb8ed4eb147d7a5702306aba82e27" continuedAt="i4c31db0e80c04ee6a3034e33a566c07a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did <ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_3be97475-88fd-4f84-bc2a-e50de86ec844"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_4f91f0df-40cf-434d-8b48-35f409deae7f"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_8c8323bb-65ba-4480-bc11-bbc49d0faacd"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_d985799a-beaf-44a3-b066-b3729be22efa">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any impairment charges related to available-for-sale securities for the three and six months ended June 30, 2021 and 2020. We did <ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfNDM5ODA0NjUxNDkwNw_45ce62e7-ee23-42f8-bb70-17e5ec94a76a"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfNDM5ODA0NjUxNDkwNw_c9b42616-6b8f-42e1-ab10-6cdc658a2ce8">no</ix:nonFraction></ix:nonFraction>t recognize any credit-related allowance to available-for-sale securities as of June 30, 2021 and December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2NQ_3e591292-a1f6-4fe2-b493-b6d537a6b82c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0b7d5d68b044d1a9277098a16618625_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMy0yLTEtMS0w_93435466-f201-4801-976b-28a39b53dad4">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1932c05e81914004be5dc08eaecfac86_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMy00LTEtMS0w_3b68ca40-d905-4f5f-83da-84be4a0afa58">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db557e9b08d465ab8c20a75ef2e9031_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMy02LTEtMS0w_c0d4cdac-aad6-4d43-88d0-1f64509b5f86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864ecf97b4424e6094f85e6a8a246f8e_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNC0yLTEtMS0w_568bebd3-2622-4cde-a199-a6e97332a969">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516ea12e44884479b0a6bcb19ac9af08_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNC00LTEtMS0w_98806bb8-a192-4c52-b8bf-17ca13ca628a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ebc7385e514efdadb03d14e93eafbb_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNC02LTEtMS0w_80692d8f-d24e-4893-bd95-cd106aaf4ae7">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3181a82c5bb246f2ae1a34c07476b8df_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNS0yLTEtMS0w_a1a0c51c-686a-4281-8a34-ba3da7306f22">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72d63351ccf43468dfcbe077e57e343_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNS00LTEtMS0w_5f5ce36f-dd99-4401-82fd-6d29de18eb3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775e0b2685f849e2bc13548cc7443839_I20210630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNS02LTEtMS0w_5e5b19ae-d3cd-40c1-b5ff-47881034f9df">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353364e17b0948c69aab8712c81c2ae0_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNi0yLTEtMS0w_6240292d-69c3-4322-84a5-6bd056c1a0dd">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf448fa99154f69805bc0000070e21d_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNi00LTEtMS0w_48b91d90-956b-4310-80a9-4214220b5b8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f00f671da6e4c1f98a8eaee2667cd74_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNi02LTEtMS0w_f0b55daa-57af-42bc-964b-6804b28ac956">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b8d474daa3437dbb2cd804326443ae_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy0yLTEtMS0xMDE4OA_82e9f11a-3269-416f-bb51-ad9cb935f928">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91999e41635347b4902e1ad73f8105c3_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy00LTEtMS0xMDE4OA_eac1e875-a385-4b58-ad3f-3ff738003c57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d07569609954f7ba5c83a5cdacc1022_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy02LTEtMS0xMDE4OA_870bcb1b-6060-46bc-9409-2ec8b0edd546">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414d3d35d2414d4cbfcac8697786c538_I20210630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy0yLTEtMS0w_ca442848-237c-445f-bc53-1cc8f68f9d74">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25825286c884fff843aea0e9c363a1e_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy00LTEtMS0w_2c5795f7-a7fd-439d-b362-5b516f1bdde8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8429272a2a4b0998190fc4ddf309c0_I20210630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy02LTEtMS0w_c16f8e96-8b9a-417f-9972-d2bb1b6939af">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414d3d35d2414d4cbfcac8697786c538_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfOC0yLTEtMS0w_cf8e75e5-9184-4870-ae73-ad27e2cce232">10,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25825286c884fff843aea0e9c363a1e_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfOC00LTEtMS0w_ac2f6380-f94c-44a7-9e4d-c3e2800d9f40">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8429272a2a4b0998190fc4ddf309c0_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfOC02LTEtMS0w_918fc28c-3c64-4e95-9873-3320859bc883">6,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414d3d35d2414d4cbfcac8697786c538_I20210630" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMTAtMi0xLTEtMA_d5b149cb-5339-47fe-8fc1-971a7cdb4775">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25825286c884fff843aea0e9c363a1e_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMTAtNC0xLTEtMA_67f086c6-4021-4cb0-bcec-8e89507701c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8429272a2a4b0998190fc4ddf309c0_I20210630" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMTAtNi0xLTEtMA_fa3dd629-630d-4924-b7fb-df426697492d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ee58f9c9904729a24edfb35821ac46_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfMy0yLTEtMS0w_a25ff787-8d68-4f5e-8116-282b1d3ae32c">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if206a7fe2c0b4f61b8a9c7db48c74717_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfMy00LTEtMS0w_1958ac97-cd8f-4e1a-a559-9d0209fb9a9c">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3d345b623d43e5a20fa855453bc2d1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfMy02LTEtMS0w_e7f6b304-7132-4b35-80e6-a3092bcff6e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a60989d0ea4094b7de163b29974100_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNC0yLTEtMS0w_8124543b-7ff0-4288-8035-cf290c157f97">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73893cab9b854b6b8ba02c2e4b889f2f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNC00LTEtMS0w_9ea06c3b-aa56-475d-aa22-459cda893bd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a24374f72e7438a9fbdca268f38643b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNC02LTEtMS0w_b4af8097-1ab0-40aa-81e5-c720d9b0f35b">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd72a3537a1453a82dc119e321ac20f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNS0yLTEtMS0w_b6bdf68e-a3fe-43f1-a964-e66a88f95604">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i174fd5ae68bf4b5da07bbc030ddd36e1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNS00LTEtMS0w_e616486c-80c9-4a43-9ced-7b6897c25376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002448bbfd364b528c594c150a64fdfb_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNS02LTEtMS0w_989a9da3-9df8-4d8a-87ee-7f01099c3348">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03cae867119545acb97a33eb075f4934_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNi0yLTEtMS0w_9f01860f-c3c2-4b23-b982-1eba9542502d">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8999a018dcb4fc1ae7ae79fda50084a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNi00LTEtMS0w_c966db06-0b65-492f-9bd8-f9b1dfaa4a31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd279b33ffd34a2398ca36d866add3ec_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNi02LTEtMS0w_f9c42204-8da3-444d-ace3-d6720b470152">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b2270f25574b2389448da3126d9486_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy0yLTEtMS0xMDE5Mw_be81706b-2958-4a8d-961b-7e9e1f0cf7db">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id873b1c04a36458dab4d7141b07cc3e9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy00LTEtMS0xMDE5Mw_9f27186a-a796-4ee0-8436-4e3aba1b82a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9969e6d3b7504aeeb9fcb51894156a6d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy02LTEtMS0xMDE5Mw_91579642-6bcb-4836-9ea5-41a323d37aa3">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f7fd21cde041c28f93122294043d54_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy0yLTEtMS0w_7df29a5f-67d6-4ecc-bf48-9617d1981758">3,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e4394219d147b9aa8a86441e91f2d0_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy00LTEtMS0w_e227bc2a-5483-47a2-ba1a-cb8f3ef25096">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f213588a2543558ea014b5a5ea5e8c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy02LTEtMS0w_3a23dbb1-e281-4f56-94db-98ab79806f17">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c31db0e80c04ee6a3034e33a566c07a">As of June 30, 2021 and December 31, 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis and did not have any Level 3 financial assets or financial liabilities.</ix:continuation> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RleHRyZWdpb246NDdlNjM1MjQzNzMyNDQ5OTljOGU4MDg1MDk1NGU0YTBfMjM2OA_93d0f766-23d3-4fab-bc12-b4ab1fe04cfb" continuedAt="i82c28cfca840436a901f06ffa4fc73b5" escape="true">Derivative Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i82c28cfca840436a901f06ffa4fc73b5" continuedAt="i59b1a42fbc0e42c992a0afbd3e42e7b9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge: (1) forecasted product sales that are denominated in foreign currencies and (2) foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our condensed consolidated statements of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flow Hedges</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate the foreign exchange risk arising from the fluctuations in foreign currency denominated product sales in Euro through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that do not exceed 15 months in duration. We hedge these cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative assets or liabilities associated with our hedging activities are recorded at fair value in other current assets or other current liabilities, respectively, in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated balance sheets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The gains or losses resulting from changes in the fair value of these hedges are initially recorded as a component of accumulated other comprehensive income (AOCI) in stockholders&#8217; equity and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently reclassified to product sales in the period during which the hedged transaction affects earnings.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We evaluate hedge effectiveness at the inception of the hedge prospectively, and on an on-going basis both retrospectively and prospectively. If we do not elect hedge accounting, or the contract does not qualify for hedge accounting treatment, the changes in fair value from period to period are recorded in the same income statement line item as the hedged item. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had net deferred gains of $<ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RleHRyZWdpb246NDdlNjM1MjQzNzMyNDQ5OTljOGU4MDg1MDk1NGU0YTBfNjA0NzMxMzk3NDgwNQ_a678ba7b-4c0e-4b6f-8daa-92497339ec6d">27</ix:nonFraction>&#160;million on our foreign currency forward contracts included in AOCI that are expected to be recognized into product sales within the next 12 months.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily accounts receivable in Euro and lease liabilities in Swiss Franc, that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities in our condensed consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our condensed consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our condensed consolidated statements of operations. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RleHRyZWdpb246NDdlNjM1MjQzNzMyNDQ5OTljOGU4MDg1MDk1NGU0YTBfMjM2OQ_b2ab8b17-3aa4-458d-a95f-7ec1fbb3e0a5" continuedAt="i90df9f0d2ce54ba98d9680c7ed91eab8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value of our foreign currency derivatives were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC0yLTEtMS01MjY2_7593b828-2ce5-4f9f-b023-73c71413c0da">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC00LTEtMS01MjY5_6b1ebc63-684d-41d7-8f0f-57f5ccd67ccd">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC02LTEtMS01MjY4_108a7755-6d47-4e92-9459-074e6b6d26f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC0yLTEtMS0w_09af1d5f-82d9-4e52-95b4-527836f838ca">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC00LTEtMS0w_8dd7e411-f83b-49d0-9287-62cbb03deb41">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC02LTEtMS0w_fc26762d-ab64-4ace-8b40-6fac4d1508bf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idceb063e3fb1410babe61be92b0909bb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS0yLTEtMS0w_11916799-fef7-46a0-842f-4d7fc6ae4efc"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS0yLTEtMS0w_bb737d9f-2821-4aef-97ad-e4e0e8e3422f">1,289</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS00LTEtMS0w_89f69c29-394c-46e0-adf8-0b28aa189070"><ix:nonFraction unitRef="usd" contextRef="idceb063e3fb1410babe61be92b0909bb_I20210630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS00LTEtMS0w_c0c9eb89-c336-4733-86ec-74f2c99a18f0">30</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idceb063e3fb1410babe61be92b0909bb_I20210630" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS02LTEtMS0w_2b4296ac-fdbc-41d5-8603-a064c87404fa"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS02LTEtMS0w_8f47bb39-2c2f-4eed-a1e3-a833224fd9bd">2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="i59b1a42fbc0e42c992a0afbd3e42e7b9"><ix:continuation id="i90df9f0d2ce54ba98d9680c7ed91eab8"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105c28fecd3545bfb3d35697e79fe0be_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNC0yLTEtMS0w_4ab5fde3-b2a0-4852-bb51-3adbd6cee979">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105c28fecd3545bfb3d35697e79fe0be_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNC00LTEtMS0w_e5f83e85-519f-4362-8503-ea0d8a1eecf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105c28fecd3545bfb3d35697e79fe0be_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNC02LTEtMS0w_a2727ad0-b146-4c3f-b98a-741a61dbd878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b9df3a23274885ab33d029964f7f40_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNS0yLTEtMS0w_1df08bdf-c543-459c-979d-90ac533a4831">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b9df3a23274885ab33d029964f7f40_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNS00LTEtMS0w_209f04be-af1d-4f23-b66e-1254376e4775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b9df3a23274885ab33d029964f7f40_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNS02LTEtMS0w_ed84f486-af95-4ade-9bc1-479488bb522b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheets within other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheets within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains (losses) on our foreign currency derivatives, net of tax, recognized in our condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmUyYWFlNWFmYzA2MjQ3MTVhMjlkMDNkODZlYWM4YTc2L3RhYmxlcmFuZ2U6ZTJhYWU1YWZjMDYyNDcxNWEyOWQwM2Q4NmVhYzhhNzZfMi00LTEtMS00NzUw_cbbdf2f4-1a66-4f4d-a9a4-1ecdd06f053a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmUyYWFlNWFmYzA2MjQ3MTVhMjlkMDNkODZlYWM4YTc2L3RhYmxlcmFuZ2U6ZTJhYWU1YWZjMDYyNDcxNWEyOWQwM2Q4NmVhYzhhNzZfMi02LTEtMS00NzUw_24fb6caf-115d-4398-b072-3962d7fc32a2">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of our foreign currency derivatives in our condensed consolidated statements of operations for the three and six months ended June 30, 2021 was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5fecea31d594dd0ab5690daae65344a_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmRkNWViNGMwNjY0NzQ1NGQ5NzIzNTAyNjgyOThmY2QxL3RhYmxlcmFuZ2U6ZGQ1ZWI0YzA2NjQ3NDU0ZDk3MjM1MDI2ODI5OGZjZDFfNy00LTEtMS01MDA3_640feb45-7262-478c-9a1b-2f3ce4f482af">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic41d37e05a294447b61d26d700536c4f_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmRkNWViNGMwNjY0NzQ1NGQ5NzIzNTAyNjgyOThmY2QxL3RhYmxlcmFuZ2U6ZGQ1ZWI0YzA2NjQ3NDU0ZDk3MjM1MDI2ODI5OGZjZDFfNy02LTEtMS01MDA3_e9180988-bf43-4d8e-b065-1c4dcf94283c">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had immaterial gains reclassified from AOCI to product sales during the three and six months ended June 30, 2021. There were no hedging activities for the three and six months ended June 30, 2020.</span></div></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RleHRyZWdpb246YzEzMmJmOGI1MzY2NGQ5OTg3NTFhZGUyODM3ODNiOTlfOTA_9bf54ea1-a22c-4345-9136-7f2ee3ba3582" continuedAt="i6839bd757ead41c58f0beb3011b668f0" escape="true">Inventory</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6839bd757ead41c58f0beb3011b668f0"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RleHRyZWdpb246YzEzMmJmOGI1MzY2NGQ5OTg3NTFhZGUyODM3ODNiOTlfODk_64c78901-4ca0-4745-b204-254ce29405ac" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of June 30, 2021 and December 31, 2020 consists of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMi0yLTEtMS0w_dfd4b1b4-a8e1-4c2e-9aca-39424750f36a">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMi00LTEtMS0w_235515c7-adea-4868-bd67-cd1ef4aeb70e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMy0yLTEtMS0w_5d163a74-0aff-434d-b00a-ace4ccdbf100">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMy00LTEtMS0w_1956e891-79a7-402d-89dd-fc9540f85a34">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNC0yLTEtMS0w_cb1c169a-2f61-4522-ad1c-cca75f80f174">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNC00LTEtMS0w_9fde226b-2969-42ff-8b64-41f34fdd04e9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNS0yLTEtMS0w_8a107484-195f-4bbb-bb2b-2ae74f8623d8">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNS00LTEtMS0w_f5f3c853-1999-49e3-8545-79deb1e9e781">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMjEz_efb8318c-e82d-4060-9e46-0990504d8efd" continuedAt="i4201801253ca4c85b8801d5bc94fc12f" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4201801253ca4c85b8801d5bc94fc12f" continuedAt="i63eba431017f415f8e5ec6404e86d88d"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMjE0_7ebe70a5-6264-4308-b603-5ad13ffef4eb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7bc9694442496cb11758c11c2558be_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMi0yLTEtMS0w_a16f1bb3-df38-436a-abcf-9d789f9861b0">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425177f7064948f1ac420fbb3fef0e74_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMi00LTEtMS0w_f6dc309d-5c4d-4b7e-b9cf-2eece2762720">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782e7b05996e46d48e09abb10bd0b888_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMy0yLTEtMS0w_b5387c1a-8e3e-4cef-b8a8-40c85bbdc038">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f885124f6b8428f81517844f40eabfa_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMy00LTEtMS0w_fbf966b7-ea50-4c02-9a52-268b64854a9d">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic255a6d51e9f4cf2a218bc9650ff2949_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNC0yLTEtMS0w_aa4d2777-c094-4979-b1b2-61f5468f9cbe">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06704fd367eb404db0554bb5e563f35e_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNC00LTEtMS0w_67341982-531a-49f6-9bb6-0a129699195a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de8c1fd48ac4d1aa4faaacb3fe97224_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNS0yLTEtMS0w_acc41e68-2cb7-4e41-9b89-5583da6d8176">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a370046fc945508f2069a2bb7980ce_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNS00LTEtMS0w_8791bcdf-0418-47da-8598-d4bb75a4f450">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if00cdc03e1254d03b96024e1c1f004e0_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNi0yLTEtMS0w_6096f9cc-fdc1-4495-ba81-c6c7f660ead9">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d5de85aad4c568986c67f724f5fc6_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNi00LTEtMS0w_0a84118e-bee6-42e8-8109-c9b88d8774c3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946ec3ac3654c46b29f79ecd814b660_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNy0yLTEtMS0w_7ef31cff-6eba-4c05-8977-c31c48877e5e">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade5f7abc6404fd4b696f1bebae23486_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNy00LTEtMS0w_f2cacc65-547b-44f6-a84d-b30b3e286d19">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i321e4ae9922946c7b2dc52c2fcf14229_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOC0yLTEtMS0w_f0298a9f-4585-4214-a978-c90058fa1c8a">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4bff8b1053446d87c6e24ff337360c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOC00LTEtMS0w_149f4bf5-5357-4e34-a3c6-c788d4b09a1a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOS0yLTEtMS0w_bac99fdb-0481-4e63-954d-9b9e6a508a1a">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOS00LTEtMS0w_056394b2-08a2-42d8-ba4d-64123cd79bf0">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTAtMi0xLTEtMA_a14e1997-e16b-41bb-abc9-e8ed302236c4">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTAtNC0xLTEtMA_0ee6f76b-587f-4914-a770-1e01594e35ec">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTEtMi0xLTEtMA_2437ed22-f01b-4c3f-a0e8-37765442f08d">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTEtNC0xLTEtMA_87a2aa59-2600-4cc4-acb9-b49329ade590">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i63eba431017f415f8e5ec6404e86d88d">Depreciation and amortization expense for the three months ended June 30, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMTY0OTI2NzQ0MjUyMQ_5bb2d088-7696-4824-90a7-b21b6e7c970a">69</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMTY0OTI2NzQ0MjUwOQ_4c3487ea-9eb0-4154-b72d-3198f3c75d6a">8</ix:nonFraction>&#160;million, respectively. Depreciation and amortization expense for the six months ended June 30, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMzI5ODUzNDg4NDAxNg_d0f8c245-9550-483f-b8a3-52c0eba196bd">84</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMzI5ODUzNDg4NDAyMA_28146763-ac55-4485-bdca-777e102540d8">15</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNDEx_1796a9e9-49b6-4532-9d7a-1258411c21f9" continuedAt="i992001bddf6d44fd9175d9b2e250e3a6" escape="true">Other Balance Sheet Components</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i992001bddf6d44fd9175d9b2e250e3a6" continuedAt="ia41f3c9978d144efa4f037952df112d8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNDEz_41cadde5-27c9-484b-bdb1-63684522f655" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:OtherPrepaidExpenseManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMi0yLTEtMS0w_a75c937f-d1ab-45d9-ad85-72bc06872a19">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:OtherPrepaidExpenseManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMi00LTEtMS0w_3983b468-0734-4890-9509-55b024e36900">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMy0yLTEtMS0w_02fc8f27-7cb0-4f22-8c15-d64d4535dfe4">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMy00LTEtMS0w_fa2802d5-4ea2-40db-951f-b0153510dd41">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNC0yLTEtMS0w_b48813a1-1e92-422a-9c03-c2e8dafec9b9">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNC00LTEtMS0w_2ad24010-0f9e-42f6-bf03-6246ae2f2a13">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNS0yLTEtMS0w_0289283b-4a41-4c9b-97f1-0d8f737fa44a">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNS00LTEtMS0w_c22fe90b-a6bd-49a1-8c08-01571775f2f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi0yLTEtMS0xMDYxMA_aad2badc-12b4-48ea-96d7-9a8d09a11eb4">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi00LTEtMS0xMDYxMA_46184c2c-934a-4eff-992a-71b755a8f1e8">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi0yLTEtMS0w_beb284cf-95ef-4e1a-a205-4f61ec97d5c4">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi00LTEtMS0w_91713c94-341a-4d81-ac73-e5f48fa22e98">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNDE2_c21119fa-c917-4d24-be4b-96f3cde1c546" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMi0yLTEtMS0w_59bcfbb8-3511-4b19-ba20-15152c100bda">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMi00LTEtMS0w_9fbefeee-7257-45ae-99e5-83c4a5826c1c">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMy0yLTEtMS0w_137059ab-cf63-4e6f-9923-185cf3d8e202">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMy00LTEtMS0w_5f91375b-c7da-424c-a052-7db9fdc0a38d">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNC0yLTEtMS0w_ad9db5bb-6f16-4d3b-a061-cf036b3b3c84">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNC00LTEtMS0w_760bad18-d1ec-46d7-aa2c-21a1553f92e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNS0yLTEtMS0w_08ebd2b2-874c-425c-b10f-cb1f9df8010a">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNS00LTEtMS0w_58769059-9772-44f9-bff7-05bd4e341cb9">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNi0yLTEtMS0w_4e641d29-7186-4047-af00-9932c8dfd818">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNi00LTEtMS0w_f6b67291-bb43-44a6-8da3-8d5148ade498">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNy0yLTEtMS0w_a4c55dc3-e6d5-4471-ac2a-d6b126913b96">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNy00LTEtMS0w_b555b54a-03a4-49d8-9345-853dd565685f">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOC0yLTEtMS0w_27eeba3b-02ff-40e1-9f67-233601b847d9">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOC00LTEtMS0w_2bfa977e-7934-4f80-b9e8-c168030bcf50">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOS0yLTEtMS05NzI0_6e1da8bf-57d4-4948-8c90-ab43573b3a74">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOS00LTEtMS05NzI0_e9b8efb0-1157-4533-a73c-cd7423f7b659">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMTEtMi0xLTEtMA_1329d4f4-327a-4ecb-8922-da8cf1058166">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMTEtNC0xLTEtMA_69e8cf51-f669-4e5d-b3d3-703d00461499">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="ia41f3c9978d144efa4f037952df112d8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNjA0NzMxMzk1MzQ2Mw_7d325d8b-ecce-4a23-ab47-c8c9984a60a1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMi0yLTEtMS04MzQ4_cf5e03b1-3f29-432e-91e9-203104f1fbf6">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMi00LTEtMS04MzQ4_ea2a92c5-4ea0-4ab3-bf75-df5db5cb6b3c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMy0yLTEtMS04MzQ4_e5513ea6-0ab4-4f23-a8e1-eb9cd25bfb8e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMy00LTEtMS04MzQ4_b81c1542-f31f-4167-8248-a737421a502a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNC0yLTEtMS04MzQ4_65ff28b7-3925-4b06-8439-9de702c649db">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNC00LTEtMS04MzQ4_4d2925a0-19c6-4015-bb51-2f1c96787047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNS0yLTEtMS04MzQ4_3c198c46-3023-4f4f-ab5e-a233086e5ad6">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNS00LTEtMS04MzQ4_3e60a57d-1d0f-4745-8a61-f5058c3b092e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNi0yLTEtMS04MzQ4_d0a966c3-8644-4f6d-bd75-d5c3b8121e74">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNi00LTEtMS04MzQ4_ed8a5b4b-d1c0-4bdd-8caa-de7a638d84a1">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue </span></div><div><span><br/></span></div><ix:continuation id="iea52bd7bd35e4ae2a36ef0daf446ca41"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 30, 2021 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925c8f5cb9cd46f6a1ae86a03be5fc3f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS0yLTEtMS0w_1b5d22ae-0acf-4b23-b0a6-c85917e8fe62">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS00LTEtMS0w_544def02-e180-41dc-a422-648ad4e6ba3a">6,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS02LTEtMS0w_a3b6dbd1-0539-4be5-b061-15d2c13949de">2,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e522303a6d4db88a6e75f6bf51b675_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS04LTEtMS0w_06763770-46ec-4959-942e-d43c5cb4dbcf">7,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323f3434ce0f462a835692c193f97e98_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi0yLTEtMS0w_60868f3a-c6ca-470d-aff0-b6e2c098a95e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi00LTEtMS0w_e40708a2-1e4c-457b-b562-4c6f7bcaebef">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi02LTEtMS0w_b9c25837-cb51-40fd-a17a-70b030c05957">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieffb4ead51104e6aa5757fa06624c672_I20210630" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi04LTEtMS0w_7457de9d-f53f-4650-a062-a97aafbcc6b4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b8c503b84d412cb2d8c21018da6a3a_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy0yLTEtMS0w_5b8d94a0-5316-48b4-bd56-4d8329494377">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy00LTEtMS0w_2fcaccdb-5088-4e71-8d91-8af9f826bc89">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy02LTEtMS0w_1ea61b1d-dabd-4466-8c42-78ec228fbf44">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a01b9748ef64174a3c700db54d82b9b_I20210630" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy04LTEtMS0w_ace91aac-be65-4733-abbc-35bf6ff2ce22">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC0yLTEtMS0w_eb6103af-cedb-4147-bfa8-5950273c542d">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC00LTEtMS0w_a6d235eb-1453-4e8c-87c7-b17b0691f931">6,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC02LTEtMS0w_8e3a68dd-278c-43d5-a8bc-7e6269361af5">2,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC04LTEtMS0w_c967219d-6235-454d-a566-9ab5aedc0401">7,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0NA_d69f7f26-e336-4c2f-85b2-6580ad4b65b8" continuedAt="i24bb57652c1e47e6bc672179118981ca" escape="true"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0NQ_5a9726c1-3360-4e52-8421-5c4cd0c4973e" continuedAt="i6adb540dd31f4b77a26029cda3ac5ea3" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i24bb57652c1e47e6bc672179118981ca" continuedAt="i3b08ba19f5d24d7aab5590ae12770f40"><ix:continuation id="i6adb540dd31f4b77a26029cda3ac5ea3" continuedAt="i3e2e25e645794d80857d6b05ee0fefbd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2035. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have <ix:nonFraction unitRef="campus" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="mrna:OperatingLeaseNumberOfProperties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzY2_0d0b00b4-526e-4d20-9a98-c5d578632f2a">two</ix:nonFraction> campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, located in Norwood. We also leased other office spaces globally for our business operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately <ix:nonFraction unitRef="sqft" contextRef="i6ca4970aeb944ce094587b8e9e52cee5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNjc3_33842325-4450-4583-97cc-9e0f8c70b999">261,000</ix:nonFraction>&#160;square feet. Our Cambridge facility leases have expiry ranges from 2022 to 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;<ix:nonFraction unitRef="sqft" contextRef="ia01e27faf121473685c9340ddfba9ede_I20160831" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfOTA5_d227bc21-a219-4873-8746-30e7b843f3b7">200,000</ix:nonFraction>&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease will expire in September&#160;2032. We have the option to extend the term for&#160;<ix:nonFraction unitRef="extension_period" contextRef="ia01e27faf121473685c9340ddfba9ede_I20160831" decimals="INF" format="ixt-sec:numwordsen" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTA5OQ_e34e112e-3965-4360-b933-3cb66ef9a80e">two</ix:nonFraction>&#160;extension periods of&#160;<ix:nonNumeric contextRef="ia01e27faf121473685c9340ddfba9ede_I20160831" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTEyMw_c731c6e4-ab7c-4877-9c60-2ac3651a72d4">ten years</ix:nonNumeric>&#160;each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately <ix:nonFraction unitRef="sqft" contextRef="iad991ea73528435fa5b841a1edd13f95_I20190228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTM2OA_631ce388-323a-4df1-9f15-b92b8b20ba61">200,000</ix:nonFraction> square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to <ix:nonFraction unitRef="extension_period" contextRef="i4919b4b841a4432188fe3621950e1631_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTU3Mw_83d10d86-ca76-4154-9daf-d8aa4c9f57a4">four</ix:nonFraction> additional <ix:nonNumeric contextRef="i4919b4b841a4432188fe3621950e1631_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0Ng_34164971-5c1f-437b-a634-21e367cc5a8d">five-year</ix:nonNumeric> terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $<ix:nonFraction unitRef="usd" contextRef="ic93eda10a84048869aafc24b02582937_I20200531" decimals="-6" format="ixt:numdotdecimal" name="mrna:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTc3OQ_bb791269-1612-4fe6-8eeb-f947e97c6455">22</ix:nonFraction> million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. </span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="i3b08ba19f5d24d7aab5590ae12770f40" continuedAt="i0aca0cbde9954e3d8806e8806946dc76"><ix:continuation id="i3e2e25e645794d80857d6b05ee0fefbd" continuedAt="i20b84a6d1dff41139489753e366c5fe0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a lease agreement for a <ix:nonFraction unitRef="sqft" contextRef="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNjA0NzMxMzk1Nzk1Mw_ffdcb914-10c7-4789-ae25-f391068a353c">240,000</ix:nonFraction> square foot building located on the same campus for expansion of our commercial and clinical activities (MTC East). The lease will expire in February 2034. We have the option to extend the term for <ix:nonFraction unitRef="extension_period" contextRef="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430" decimals="INF" format="ixt-sec:numwordsen" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNDM5ODA0NjUxNjMxNQ_e265b281-877c-43de-b4e5-bb18602594e4">two</ix:nonFraction> extension periods of <ix:nonNumeric contextRef="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNDM5ODA0NjUxNjMyMw_1c5da253-0c04-4de2-af98-1e00d7c539f1">five years</ix:nonNumeric> each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of June 30, 2021 and December 31, 2020, we had lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="if3b49c23c04b441dbe3849a5361236d8_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjA5NQ_236a8820-8983-4208-9791-8620acf685cb">251</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9b90abfb0dbe4272a84180b8ea7942bb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjEwMg_eda76c3d-1ccf-43b4-91cd-b033f11aaf32">24</ix:nonFraction>&#160;million, respectively, related to the embedded leases. As of June 30, 2021 and December 31, 2020, we had right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="if3b49c23c04b441dbe3849a5361236d8_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjE5OQ_2dbf5600-b095-464a-b9ad-844c69cc2bb9">296</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i9b90abfb0dbe4272a84180b8ea7942bb_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjIwNg_6e09e074-d88f-4a0c-af9c-6534c6c92095">zero</ix:nonFraction>, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="mrna:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0Nw_c830d7ad-064f-4314-b6a5-65193abbec2f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of June 30, 2021 and December 31, 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMy0yLTEtMS0w_76d96f5d-b0af-42da-bfca-de2ec1aa6881">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMy00LTEtMS0w_08e44755-c415-4015-aaab-a87164f2740b">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0yLTEtMS0w_fa4475ed-70cc-4f7b-b3fb-3f03d97fdb4c">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC00LTEtMS0w_908afbf8-11a8-4c75-a842-632c955005bb">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNS0yLTEtMS0w_7c2fe523-8069-425b-ab48-5937e8baa031">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNS00LTEtMS0w_545aed19-2f1c-4244-8d94-c6f6443f2396">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0yLTEtMS0w_ed176aa7-3932-4690-a333-bdab493134f9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS00LTEtMS0w_284f10c2-23fe-49a1-bfdc-2974de08a8f7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMi0xLTEtMA_042d4dc6-eaba-4407-9c3b-d8ca6c9d9ade">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtNC0xLTEtMA_639ad71d-bb6f-406c-9251-b761d3c10c62">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTEtMi0xLTEtMA_bd60f4e6-7fe2-4087-913e-0c1a79bd4294">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTEtNC0xLTEtMA_89552fb6-c030-4517-98e7-517da7934d1e">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTMtMi0xLTEtMA_b16418bc-3c09-47d3-ae36-f6e69ad55030">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTMtNC0xLTEtMA_3d59bb99-2a44-4170-9824-29b7976b298f">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTQtMi0xLTEtMA_acea8712-3e4e-4cc9-9d8b-3ac86b8fd2ef">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTQtNC0xLTEtMA_970063f4-18b2-4d24-a27e-9135554825f3">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTUtMi0xLTEtMA_bd00bbcc-3df7-4871-82f6-a308934968e8">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTUtNC0xLTEtMA_a0bbfb7d-0eb7-4153-8581-7ef65b1ce6ae">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTYtMi0xLTEtMA_d6904dfd-4ff6-4861-bd87-012df0b414d1">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTYtNC0xLTEtMA_2bbfaebd-a2fc-4921-bdb2-051350fd4b34">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC South, MTC North, and MTC East leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><ix:continuation id="i0aca0cbde9954e3d8806e8806946dc76" continuedAt="ifd58cd1afbcc4115aa4739f3c78bde7d"><ix:continuation id="i20b84a6d1dff41139489753e366c5fe0" continuedAt="ifd9e2246bf454fea96cf90a2aa8e9778"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0MQ_935fd56c-0976-46b1-8a33-812bbdea3428" continuedAt="iff42dda25c9a4dd68e7b6f7d9c25c208" escape="true"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0Mg_6673a82a-2959-4d05-8a83-bee0a7555f31" continuedAt="ie550c7787dbe43a4b39f86efa65aa87c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMS0yLTEtMS0w_9fff3f21-3787-4808-b3cb-f90fd9b12164">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMS00LTEtMS0w_3320057f-1737-464a-98a7-7320216d107c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMi0yLTEtMS0w_c1679a06-8127-48c0-9b80-e70ee45bdf48">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMi00LTEtMS0w_9319c298-15f2-47cf-91fd-1df6ee82e3f5">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMy0yLTEtMS0w_6ef9583b-1942-4636-8184-f33c7f5d7965">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMy00LTEtMS0w_d07298e2-71f5-49b5-ab7a-c56410bd0e19">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNC0yLTEtMS0w_4606f1e6-dc62-4be5-aa15-6f4a22998daa">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNC00LTEtMS0w_91a9a2c2-537f-483d-a441-f9987c96a58e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNS0yLTEtMS0w_88d80d76-a1e6-4ec9-92f4-278dcee9b828">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNS00LTEtMS0w_c34305bf-2931-43ef-869c-0580cea1fc07">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNi0yLTEtMS0w_d29c1c5e-5332-4cb5-bf20-b70e797bb93d">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="mrna:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNi00LTEtMS0w_c1ef7b73-e507-4371-ada4-8aa6a0c490e2">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNy0yLTEtMS0w_3b1940f3-01a8-488c-a890-e986a1181e13">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNy00LTEtMS0w_eaaaf6b6-d714-48ce-af72-af307cd5b5a7">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOC0yLTEtMS0w_ee5ab2ec-543c-4944-8f7a-4c83f82a4f34">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOC00LTEtMS0w_d17bfaf5-5bdd-4a5b-93f8-54236842a4cf">444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOS0yLTEtMS0w_1ff571e7-6f4a-49e8-a4ba-f5d99d9b9089">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOS00LTEtMS0w_b7d19c6a-cdaf-4fa1-a534-ec31a4633d9c">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $<ix:nonFraction unitRef="usd" contextRef="iebf2947c07b840e4a74467063deb1ae6_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzIyMw_2f149b59-c20e-4b27-8aee-089029e5a6fb">445</ix:nonFraction> million undiscounted future lease payments.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ifd58cd1afbcc4115aa4739f3c78bde7d" continuedAt="i68bb86adda01439eaff8eae24a5abbd2"><ix:continuation id="ifd9e2246bf454fea96cf90a2aa8e9778" continuedAt="iaa00bba994ec4d8ba7ee2d845b8bab03"><ix:continuation id="iff42dda25c9a4dd68e7b6f7d9c25c208" continuedAt="i352b05328e664794b06665c151b02dca"><ix:continuation id="ie550c7787dbe43a4b39f86efa65aa87c" continuedAt="i119d06b17e524b4bbb91ec834ee145cc">(2) </ix:continuation></ix:continuation></ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68bb86adda01439eaff8eae24a5abbd2"><ix:continuation id="iaa00bba994ec4d8ba7ee2d845b8bab03"><ix:continuation id="i352b05328e664794b06665c151b02dca"><ix:continuation id="i119d06b17e524b4bbb91ec834ee145cc">MTC South interest is based on an imputed interest rate of <ix:nonFraction unitRef="number" contextRef="i04fa63042c64408fbd832e6524b4b23f_D20210101-20210630" decimals="3" name="mrna:LeasesImputedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzMyNg_73eca801-16a1-4b04-a613-7f2913642e98">17.2</ix:nonFraction>%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of <ix:nonFraction unitRef="number" contextRef="ie095a587c0d84c63a7d5403131e4b7e3_D20210101-20210630" decimals="3" name="mrna:LeasesIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQxNw_6bb33004-bc85-4020-9601-7642751232c9">8.2</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ied6207c51d5c4d1da7a394ed937340ff_D20200101-20200630" decimals="3" name="mrna:LeasesIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNjA0NzMxMzk1Nzk2MQ_edfe51e6-53c9-4ba8-90e7-0108ce73da03">3.7</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i61568f63bbbf460192175495b73fb1e2_D20210101-20210630" decimals="3" name="mrna:LeasesIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQyNA_614f4fc0-71e4-4493-bb7f-f5a8298244c3">0.6</ix:nonFraction>%, respectively.</ix:continuation></ix:continuation></ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfNTgzOA_e0b09b83-6238-4a54-92b7-99bcddb14101" continuedAt="i37bcd64218044156b03e09bffa47838e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i37bcd64218044156b03e09bffa47838e" continuedAt="ifb47f8d423eb40c19c610963b497a0a8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Collaborations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our Personalized Cancer Vaccine (PCV) Agreement and PCV/SAV Agreement (which also relates to shared neoantigen mRNA cancer vaccine) with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $<ix:nonFraction unitRef="usd" contextRef="i453114f3b5a7454382060dc9a3cc7f07_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMTY0OTI2NzQ0NzgyNQ_45dafcff-a8de-4545-817a-6423df79e051"><ix:nonFraction unitRef="usd" contextRef="if3e4997c888f446e9fe81c8bdd3f1e5d_I20210630" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMTY0OTI2NzQ0NzgyNQ_586ef3a8-4232-4703-a555-d95fbfcf1ade">243</ix:nonFraction></ix:nonFraction>&#160;million for both periods as of June 30, 2021 and December 31, 2020. Please refer to our 2020 Form 10-K Note 5 to our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the three and six months ended June 30, 2021 and the year ended December 31, 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="ifb47f8d423eb40c19c610963b497a0a8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of June 30, 2021, we h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> $<ix:nonFraction unitRef="usd" contextRef="i598d0bc0445a41abbc9bdcd1258b0d3c_I20210630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjYxNw_5bb72f3d-f857-4c51-bf33-3a55fc0175e7">1.5</ix:nonFraction> billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2022. As of June 30, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i8caec99e729443a0aee89f8db26aa392_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjgwNg_83f428aa-b0a2-4dfa-8fb3-663bf51b23bc">49</ix:nonFraction> million o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f non-c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2024. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At June 30, 2021 and December 31, 2020, we had cancelable open purchase orders of $<ix:nonFraction unitRef="usd" contextRef="i67185c627d644febad389a0c535248b1_I20210630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMTY0OTI2NzQ0Nzc5Nw_4910c761-ae38-4fff-8b4d-94fd6b0a3232">1.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ic3c3513fce714f9e9e6c45c936e12fe2_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMzY5NQ_7251ffa9-d454-4527-a876-3874bc37e4f2">897</ix:nonFraction> million, respectively, in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at June 30, 2021 and December 31, 2020, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments, up to $<ix:nonFraction unitRef="usd" contextRef="i7c7f1943108a4146a37ed6c8267654a2_I20170626" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfNTAwOA_df30d242-c4dc-4ee2-b7e5-bc925b751a32">24</ix:nonFraction>&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. For the three and six months ended June 30, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjE5OTAyMzI2MTk5NA_8c1009d9-dbad-4e43-8fec-3c166b7c18a2">148</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjE5OTAyMzI2MjAwNw_a1ab59ff-2153-48c3-8c61-d41dba268ea4">232</ix:nonFraction>&#160;million, respectively, of royalty expenses associated with our product sales, which was recorded to cost of sales in our condensed consolidated statements of operations. We did not recognize any such royalties in the first half of 2020 as we did not have product sales during the period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of June 30, 2021.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjIwMg_4b8562f0-72d5-4551-bf5e-0e9e3145049f" continuedAt="i14b245bc23304087a7f739d3b532e7fc" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i14b245bc23304087a7f739d3b532e7fc" continuedAt="i97f936be5e614ff7b61bc62f994f6acf"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had a total of&#160;<ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfNjM_b4fbd6ef-1b2f-4e39-90a6-b13bddf03f81">60</ix:nonFraction> million&#160;shares reserved for future issuance under our Equity Plans, of which <ix:nonFraction unitRef="shares" contextRef="i0e58c0fb75144621874b106da58aa126_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTM1_9fe7c57e-9e59-4b14-b4b0-cd23780b830c">33</ix:nonFraction> million shares were reserved for equity awards previously granted, and&#160;<ix:nonFraction unitRef="shares" contextRef="i806cd5c4c8db4bbb96da09f4192d4f77_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjAx_954cd76c-7967-4976-8f0b-ad312b48a465">27</ix:nonFraction> million&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were available for future grants under the 2018 Equity Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjE5Mw_7d25977f-6c83-4f0f-b3be-150ae0477ce1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our option activity during the six months ended June 30, 2021:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair<br/>Value per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS0yLTEtMS0w_8918e03a-4d27-4f80-912b-76d13b8e2323">34.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS00LTEtMS0w_a9a2e50d-923b-4e84-bfb4-0af6a2c6e80a">17.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS02LTEtMS0w_654ccb5e-7679-4d8d-86e7-f5055ec367a2">9.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic32a9001570747069665c11f135527dc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS04LTEtMS0w_1fe136e3-bbb2-49be-8243-2a094a24d2d9">6.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS0xMC0xLTEtMA_9f3dae82-1dac-47b9-834d-0f1feb2d515c">2,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMi0yLTEtMS0w_01bc452e-4e4f-45c7-8e34-226c6f06aff0">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMi00LTEtMS0w_50cc27c7-2007-4162-97d3-36ad46693d1e">173.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMi02LTEtMS0w_d5e19509-d5e2-405d-af2e-86313db368da">76.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMy0yLTEtMS0w_5ebbc33b-5472-4e0c-bd5a-5078b3ca8ab2">3.86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMy00LTEtMS0w_c0f8bc33-7b46-4a28-930e-750f31c80fdd">15.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMy02LTEtMS0w_badac5e6-9af4-40ef-82e3-1c7ded373ca8">8.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNC0yLTEtMS0w_1963bf15-23ac-433d-8782-2695847259b5">0.45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNC00LTEtMS0w_85c5b3d4-51a6-4b08-92e5-8548e3d32ae8">27.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNC02LTEtMS0w_182186ca-cef5-42e6-a77e-35768b1ced4b">14.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS0yLTEtMS0w_d03be3ac-3294-47fb-a084-fac40cf236dd">30.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS00LTEtMS0w_09cfd54d-c342-4e8e-8f09-faea38c21fe8">22.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS02LTEtMS0w_3c8a915d-4c9b-4d9e-a21f-62beca67b529">11.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS04LTEtMS0w_bcdc4ac5-a357-4a82-b0ba-c2d800b3a64d">6.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS0xMC0xLTEtMA_219bef9e-6a2a-4e22-95dd-8c7d57560e15">6,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi0yLTEtMS0w_ada31f78-c586-4c12-b17b-7d4d67caa6c6">17.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi00LTEtMS0w_1d586c0b-24d0-4bc8-9e34-de1a8085f313">12.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi02LTEtMS0w_50d4c8ca-0512-4abb-94cc-dffdb4ccc31b">6.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi04LTEtMS0w_d2fbf2d7-a0dc-43bf-b87f-2a88d8aacaff">5.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi0xMC0xLTEtMA_1986f618-3703-4f1b-8ff5-deb6c6c32522">3,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy0yLTEtMS0w_69a40164-21ed-46b4-bd2e-00fc9e1872ac">13.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy00LTEtMS0w_f9985818-9635-4239-b954-5fed99c9eb1d">36.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy02LTEtMS0w_9d9b08a8-4406-4c20-8d31-619350b4db10">18.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy04LTEtMS0w_f9e56572-e76c-42fc-b34f-301e3c7964cf">7.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy0xMC0xLTEtMA_4b9e5d2c-9321-4a15-a935-231805a47f01">2,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of June 30, 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTMyMw_8b699010-40b0-4d2b-8c70-499e521db9e3">575</ix:nonFraction>&#160;million for the six months ended June 30, 2021. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately $<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTMzNw_1f2711ab-fba9-40f1-82ec-5cd6ac048b82">59</ix:nonFraction>&#160;million for the six months ended June 30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjE5OA_4099d58e-47c7-41de-ad17-7c5da5db61b0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity during the six months ended June 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average Fair Value per Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib676efd3333c4e95baf151a431bb5025_I20201231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMS0xLTEtMS0w_15e673c0-aa7e-4317-be74-a57092b555d2">2.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib676efd3333c4e95baf151a431bb5025_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMS0zLTEtMS0w_dc10e821-3a14-468a-b3f8-88413b36b93d">30.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMi0xLTEtMS0w_e589d3e6-4811-4a4d-8183-42c9bb9e3e2f">0.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMi0zLTEtMS0w_17caa3c6-a511-49e5-9c83-2bd0dccfc538">170.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMy0xLTEtMS0w_1cf2c53b-ed2e-499e-8a2d-4e6a5dba03e7">0.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMy0zLTEtMS0w_66dc3cb1-5204-4705-be2f-9078c226f3c6">25.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNC0xLTEtMS0w_1d6f11d1-b6b7-437a-8af7-2caebf26afaa">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNC0zLTEtMS0w_e2d1b14c-04bd-4499-8f11-ab47f02a6185">37.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie402888bb2fc4ea880b40f2a9d7c22f0_I20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNS0xLTEtMS0w_50d413e9-afdc-4f00-afe8-ffb136d0adf7">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie402888bb2fc4ea880b40f2a9d7c22f0_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNS0zLTEtMS0w_e6cb6fe2-9265-443e-9b60-d44212621c08">64.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock units vested during the six months ended June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedStockExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTEyMw_21c196c0-0bd5-4030-ab08-3c35d4ea369b">9</ix:nonFraction>&#160;million. The total intrinsic value of restricted stock units vested during the six months ended June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTIwMw_c212bc29-b0bc-4b2d-b479-89c5cd916cdb">54</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we granted PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally <ix:nonNumeric contextRef="ied36f68f5ff84b10a3d60914c0b61586_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTQxMw_0e320220-dc9c-47c7-8f55-a9c2e90c053a">three years</ix:nonNumeric>. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from <ix:nonFraction unitRef="number" contextRef="ife7005ad8225459bbf949983a16fb039_I20210331" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTU1NA_d6b17543-6720-4f51-9593-aab3afaf43d6">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i27a9e69e7d27416e8d304a0b72359725_I20210331" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTU2MA_15accfc6-e828-433c-bd80-373f1173529c">200</ix:nonFraction>%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan (ESPP)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sold an immaterial number of shares under the ESPP during the six months ended June 30, 2021. As of June 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i6b1bbe23395c4aa6988514c29e2ee39e_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTc0NA_a7e9f0bf-477f-45b3-9e6c-077265c165ea">4</ix:nonFraction>&#160;million shares were available for future issuance under the ESPP.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i97f936be5e614ff7b61bc62f994f6acf"><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjE5OQ_154d1243-3622-4612-93a4-f74729918d24" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5940ab735af34e5e946ede601d642a53_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi01LTEtMS0w_c35fc61c-d074-496e-972e-c575057b3f82">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a0202da86f1409fafc721c18c4b375b_D20200401-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi03LTEtMS0w_7c277e21-38a1-4b59-bc0d-e5beecd2abf0">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940058d521aa4563a84e76e20cd336d6_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi05LTEtMS0w_1dc9e5a7-2073-422c-b3d4-78e4e13704e7">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67410869f8c478eb669bc8351987988_D20200101-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi0xMS0xLTEtMA_754c00ec-e9e2-4204-953e-a5d41da52102">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc29bdcf87245dab06fb8bb8f5635ff_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy01LTEtMS0w_2d58f74b-b145-495d-a54c-498491d17183">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0beaf98f2bec4a78acd4d80ffe785bbc_D20200401-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy03LTEtMS0w_c75f3b1f-5e76-43ed-9e67-ff24b64b7167">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a56c15404a4b8eb579be1a6a78e357_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy05LTEtMS0w_bf11ec50-4d20-4c78-a3b8-e5f90f2df957">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310dab123334253aa6827d712250361_D20200101-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy0xMS0xLTEtMA_f933852a-3e96-4df3-8595-106ca8d50f48">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0463634352040069acfeb178a893295_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC01LTEtMS0w_ee19a741-76e7-4a61-963b-bc0d6b537ea3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45447fcebe4141ea9d78a8504cdc1c19_D20200401-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC03LTEtMS0w_c7d2e8d3-6d53-4e63-9a80-ebb87be5632c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b9ec1f5cce442791bacd86253cbd96_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC05LTEtMS0w_66b3dace-ad50-44ef-9488-ed5dcb1239d3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db1b0e2148b492bb939ebb0463eb2d3_D20200101-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC0xMS0xLTEtMA_bce70600-3771-4fbb-8346-6a0503509bfe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS01LTEtMS0w_d293d99c-28eb-4f48-8cb7-8df5eb37119a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS03LTEtMS0w_28fd8da0-4a56-4df4-addd-dac1f3b01fe5">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS05LTEtMS0w_8d341b7b-fa50-49ed-b75d-a6f0dd9e41fd">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS0xMS0xLTEtMA_b13e6eb6-9ae4-4c7a-a752-57c6636b2600">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f6e9c4e55144bb8df23054a288a2e2_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy0yLTEtMS0xMjYx_a9da8f35-c428-4493-b8c6-232d5d0e04ef">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0ada455afe4e75bfe9e71f54e33319_D20200401-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy00LTEtMS0xMjYx_62e6dc68-a007-4bc6-b937-98568faf0771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fcb8aedfe9420c8551dec0ade1347b_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy05LTEtMS0w_4080b860-3aef-4d8a-a4a6-74e11e25cd54">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3435c602db343908bad969f4cfa4f42_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy0xMS0xLTEtMA_1e01653a-7bde-4853-927a-c24bba8d3a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7303c622b8134633b87246e130589360_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC01LTEtMS0w_8d22578b-47db-42fd-a232-466229d35f41">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230bf3fb1f8e419181b3f634ef694994_D20200401-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC03LTEtMS0w_41e923f1-3558-4101-b992-54f8cfab4583">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e5a124b9bb45f6b74b3d193e94adbb_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC05LTEtMS0w_f85d32a7-2298-45a2-b1ae-7921a4378113">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e219eb6c9048bbb915840c4add36fd_D20200101-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC0xMS0xLTEtMA_19ee7eb7-73f1-42d2-b631-c336b2f3b5d9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea21debe3524bff9d6e588cd4b5716b_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS01LTEtMS0w_6465606e-9fcf-47ba-8925-ff27599daff8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib29b4d951999485cba6731af4351eddc_D20200401-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS03LTEtMS0w_6d50b0c4-119f-440b-9cc3-d6494ccee0d2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283d9247556a4278afc37abb5ac02feb_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS05LTEtMS0w_9e31feda-7a8e-4cda-8033-a7d8a6e2acd0">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19460b8e62a442f88dd3c9900970530a_D20200101-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS0xMS0xLTEtMA_48bf75e3-4fb9-430e-a40c-f4f369c0a5d3">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtNS0xLTEtMA_fba372f5-5978-4179-af66-62153478aa19">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtNy0xLTEtMA_40333873-42f6-4964-a186-a0ecf53b0659">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtOS0xLTEtMA_fb33c38c-9959-4c4f-a23b-8eb02abc2789">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtMTEtMS0xLTA_f56e8606-abed-4306-855f-8aefd0e5aec7">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTQxMA_2d6334b6-4998-4caf-8368-21cf89377e13">336</ix:nonFraction>&#160;million of total unrecognized compensation cost related to unvested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTQzNA_740ae8ad-ac4a-4094-9869-a2048cdae4fc">3.0</ix:nonNumeric> years at June 30, 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMzU1NQ_35e29035-da49-45a2-a3b4-d4a340915e23" continuedAt="i181b8e86f2a8410f868b98c48e93a44a" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i181b8e86f2a8410f868b98c48e93a44a" continuedAt="ia69a21941b134878b4be603b9131b26c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. For the three and six months ended June 30, 2021, we recorded provisions for income taxes of $<ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMzI5ODUzNDg4NzIxNA_0dbd9d5f-6785-4c3c-8947-076d404ba022">283</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTY0OTI2NzQ0NTkzMQ_b7f8edff-153d-4494-b1db-701a81399f4b">322</ix:nonFraction> million, respectively, compared to an insignificant amount for the same periods in 2020. Our effective tax rate for the three and six months ended June 30, 2021 was <ix:nonFraction unitRef="number" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTY0OTI2NzQ0NzI3OA_cb85caa5-76cb-4b28-8652-300ae0452c99">9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTY0OTI2NzQ0NzI4Mg_87111dde-8704-4176-981e-89b853b5942f">7</ix:nonFraction>%, respectively, and was lower than the U.S. statutory rate primarily due to the benefit related to the release of the valuation allowance on the majority of our tax attributes, the benefit of the foreign derived intangible income deduction and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three and six months ended June 30, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. On a periodic basis, we reassess any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, we determined we should reverse the majority of our valuation allowance through the annual effective tax rate (AETR) with respect to amounts we expect to realize through current year income. In addition, for the three and six months ended June 30, 2021, we have recorded a discrete benefit of $<ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTkzOA_104e1661-c6ba-4de6-acae-a9d45cef8f80"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTkzOA_dbe04f34-862f-4ef7-b7ea-ab395c6f0198">49</ix:nonFraction></ix:nonFraction>&#160;million related to the release of the valuation allowance on deferred tax assets that we expect to utilize in future years. We maintain a valuation allowance on certain state tax attributes that we expect will expire prior to the utilization. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. We do not currently expect the CARES Act to have a significant impact on our provision for income taxes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of June 30, 2021 and December 31, 2020, we had an immaterial amount of gross unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially increase within the next twelve months. We accrue interest and penalties related to unrecognized tax benefits as a component of our provision for income taxes. We did not recognize any material interest or penalties related to uncertain tax positions during the three and six months ended June 30, 2021 and 2020.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia69a21941b134878b4be603b9131b26c">We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We are not currently subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction since inception.</ix:continuation></span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RleHRyZWdpb246MmNjOGNiMjUwYTMxNGE1Mjk3NTUwODg4YTY2NWMwNmVfNzgz_7813ba1f-c77a-4a49-9112-ef173b627921" continuedAt="ie4933449ec5f4948be95964caadbfd0f" escape="true">Earnings (Loss) per Share </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie4933449ec5f4948be95964caadbfd0f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RleHRyZWdpb246MmNjOGNiMjUwYTMxNGE1Mjk3NTUwODg4YTY2NWMwNmVfNzc5_0489572f-fd46-488b-9f5e-9aa81ec17b8e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the three and six months ended June 30, 2021 and 2020 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy0yLTEtMS0xMjg4_25f2c9be-3b8b-4871-a310-9f7a3eb61423">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy00LTEtMS0xMjg4_6e43b98c-9e93-446e-8e58-afd62c187602">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy05LTEtMS0w_2d369218-5f8f-4e02-8dd2-604b6270da26">4,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy0xMS0xLTEtMA_f1eb1703-34ae-411f-b2eb-c892434cf854">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS0yLTEtMS0xMjg4_1e6a43c8-40d2-4850-99c3-dafc8b7f627f">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS00LTEtMS0xMjg4_91bbe852-7109-413d-8d3a-97cf5b7f7a38">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS05LTEtMS0w_b9dad254-d2f0-402c-ac4c-4fd2a182e8dd">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS0xMS0xLTEtMA_2d820cc7-7ef2-45eb-bec5-062c6d78b806">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi0yLTEtMS0xMjg4_4e6affc1-4dd2-40cc-928c-dcb7031fb7ba">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi00LTEtMS0xMjg4_36d67482-e265-4ff6-8194-f87bdb1a53f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi05LTEtMS0w_df3711ec-93e1-41da-9cfa-c1de8ee40148">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi0xMS0xLTEtMA_cde1952c-91ef-485a-bd1e-9d3658f73d77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy0yLTEtMS0xMjg4_7422777d-e37c-4303-a3d8-baaa32552921">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy00LTEtMS0xMjg4_d6492c7e-f062-486e-ba91-c1a7075586f8">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy05LTEtMS0w_6225f91d-b546-4f82-85f1-cf54f49af199">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy0xMS0xLTEtMA_c567ec70-6244-4d6d-934e-a7002b9104e3">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS01LTEtMS0w_9bdb900f-316d-445e-be6c-2133ddc57b95">6.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS03LTEtMS0w_126666bc-6fee-47d1-a02c-2e00835f4b52">0.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS05LTEtMS0w_94453d79-eec3-4ca6-9fe9-73a959621be1">9.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS0xMS0xLTEtMA_14bee66a-30a8-4632-ba28-9c7099439672">0.66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtMi0xLTEtMTI4OA_b73bb955-2bdc-44d1-a25e-5b75135abb2e">6.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtNC0xLTEtMTI4OA_9ab1cabf-ff26-43aa-a2a2-e0e6f1cb891e">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtOS0xLTEtMA_e8515786-3517-49ea-bc5b-080462f7e0a6">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtMTEtMS0xLTA_449b6e69-db71-42d3-90e9-1b16656c1a4f">0.66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RleHRyZWdpb246MmNjOGNiMjUwYTMxNGE1Mjk3NTUwODg4YTY2NWMwNmVfNzc0_ab967b8a-683f-4b41-b21d-0516064e4fa2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of June 30, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff02256a11834a66b8c527254b62d147_D20200101-20200630" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOmQ3Zjg5ZWUzYjA0YjRmMDBiNDY0MmJkMzAwODRkZGJlL3RhYmxlcmFuZ2U6ZDdmODllZTNiMDRiNGYwMGI0NjQyYmQzMDA4NGRkYmVfMi0xLTEtMS0w_ba3c8410-78cf-4eb1-8d9d-919e96d76a4a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292b707793574fa196af16232e6fad08_D20200101-20200630" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOmQ3Zjg5ZWUzYjA0YjRmMDBiNDY0MmJkMzAwODRkZGJlL3RhYmxlcmFuZ2U6ZDdmODllZTNiMDRiNGYwMGI0NjQyYmQzMDA4NGRkYmVfMy0xLTEtMS0w_7a6f17b8-d854-48dc-8ce9-4f11387a8265">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOmQ3Zjg5ZWUzYjA0YjRmMDBiNDY0MmJkMzAwODRkZGJlL3RhYmxlcmFuZ2U6ZDdmODllZTNiMDRiNGYwMGI0NjQyYmQzMDA4NGRkYmVfNC0xLTEtMS0w_7993f5ff-bfea-4b3a-803c-1cad8147834e">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84NS9mcmFnOmY1YzJkZWNlM2RjYzQ5NmZhNTFkZGE2YTI1YmYwYmE0L3RleHRyZWdpb246ZjVjMmRlY2UzZGNjNDk2ZmE1MWRkYTZhMjViZjBiYTRfMTA5Ng_5645685a-5f99-4ee6-be3a-6487112a89d9" continuedAt="i36a1bdae8a4d485d82531401ed3526fe" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i36a1bdae8a4d485d82531401ed3526fe"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2021, we have entered into additional supply agreements with customers to provide up to <ix:nonFraction unitRef="dose" contextRef="icbdd283932184bea9f7f771d39f918d6_D20210701-20210805" decimals="INF" format="ixt:numdotdecimal" name="mrna:NumberOfDosesOfVaccineCandidate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84NS9mcmFnOmY1YzJkZWNlM2RjYzQ5NmZhNTFkZGE2YTI1YmYwYmE0L3RleHRyZWdpb246ZjVjMmRlY2UzZGNjNDk2ZmE1MWRkYTZhMjViZjBiYTRfMTI4_66892580-564c-4a9c-9257-806959610b47">262</ix:nonFraction>&#160;million doses of our COVID-19 vaccine and our updated variant booster vaccine candidate based on the initial confirmed volume, subject to modifications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a Share Repurchase Program of our common stock, which expires on August 2, 2023. Pursuant to the Share Repurchase Program, we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ibdd0a3a2ce304bb5a423153da5ba16fc_I20210802" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84NS9mcmFnOmY1YzJkZWNlM2RjYzQ5NmZhNTFkZGE2YTI1YmYwYmE0L3RleHRyZWdpb246ZjVjMmRlY2UzZGNjNDk2ZmE1MWRkYTZhMjViZjBiYTRfNjA0NzMxMzk1NjU4Nw_718b1a15-5036-4bac-82b8-d6f4fe2f2f79">1.0</ix:nonFraction>&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act.</span></div></ix:continuation><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited financial information and related notes included in this Form 10-Q and our consolidated financial statements and related notes and other financial information in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on February 26, 2021 (the &#8220;2020 Form 10-K&#8221;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part II, Item 1A - Risk Factors in this Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases, independently and with our strategic collaborators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our platform, we develop technologies that enable the development of mRNA medicines for diverse applications. When we identify technologies that we believe could enable a new group of potential mRNA medicines with shared product features, we call that group a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">modality.&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the programs within a modality may target diverse diseases, they share similar mRNA technologies, delivery technologies, and manufacturing processes to achieve shared product features. The programs within a modality will also generally share similar pharmacology profiles, including the desired dose response, the expected dosing regimen, the target tissue for protein expression, safety and tolerability goals, and pharmaceutical properties. Programs within a modality often have correlated technology risk, but because they pursue diverse diseases they often have uncorrelated biology risk. We have created six modalities to date:</span></div><div><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">prophylactic vaccines;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">systemic secreted and cell surface therapeutics;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cancer vaccines;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">intratumoral immuno-oncology;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">localized regenerative therapeutics; and</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">systemic intracellular therapeutics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designated our prophylactic vaccines and systemic secreted and cell surface therapeutics modalities as our &#8220;core modalities&#8221;. In these core modalities, our strategy is to invest in additional development candidates using our accumulated innovations in technology, our process insights and our preclinical and clinical experience. Our exploratory modalities continue to be a critical part of advancing our strategy to maximize the application of our potential mRNA medicines.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moderna COVID-19 Vaccine</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, the U.S. Food and Drug Administration (FDA) authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in more than 50 countries and from the World Health Organization. Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the European Union and Japan and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. On June 1, 2021, we initiated the rolling submission process with the U.S. FDA for a Biologics License Application for our COVID-19 vaccine and we currently anticipate completing our submission in August 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into supply agreements with the U.S. Government, several other governments outside the United States and with UNICEF (on behalf of the COVAX Facility) for the supply of our COVID-19 vaccine. The agreements are generally subject to receipt of authorization or approval for the use and distribution of the vaccine from the relevant regulatory authority in each jurisdiction. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. As of June 30, 2021, we had approximately $7.2&#160;billion in deferred revenue in connection with the supply agreements with the U.S. Government and other customers, which will be recognized as revenue when revenue recognition criteria have been met. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the second quarter of 2021, we delivered approximately 126&#160;million doses of our COVID-19 vaccine to the U.S. government and approximately 73&#160;million doses to other governments, and recognized $4.2 billion in product sales. For the first quarter of 2021, we delivered approximately 88 million doses of our COVID-19 vaccine to the U.S. government and approximately 14 million doses to other governments, and recognized $1.7 billion in product sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we announced additional investments to facilitate the increased supply of our COVID-19 vaccine from our own and partnered manufacturing facilities, and an expansion of the Moderna Technology Center (MTC) in Norwood, Massachusetts, to more than double our facility space to help transform it from a production and lab space to an industrial technology center. As a result of these investments, we expect that we will supply between 800 million and 1 billion doses of our COVID-19 vaccine in 2021, at the 100 &#181;g dose. We anticipate these investments will also increase our global 2022 capacity for the vaccine to up to 3 billion doses, in the event that our 2022 production is dedicated to 50 &#956;g booster doses. If our 2022 production is dedicated to 100 &#956;g doses, we expect our total potential capacity to be approximately 2 billion doses. The ultimate dosage for our 2022 supply is subject to ongoing internal review, and is also subject to further regulatory approval and authorization, among other factors. These investments are expected to facilitate a doubling of drug substance manufacturing from Lonza&#8217;s Switzerland-based facility, a more than doubling of formulation, fill and finish and drug substance manufacturing at Rovi&#8217;s Spain-based facility, as well as a 50% increase of drug substance at Moderna&#8217;s facilities in the U.S. When completed, the investments are expected to also result in an increase in safety stock of raw materials and finished product used to deliver committed volumes. These forecasted increases to our supply are subject in part to performance by our manufacturing partners, which will require ramping-up capabilities at their own facilities and the hiring of qualified manufacturing personnel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moderna COVID-19 Vaccine Clinical Studies </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final analysis of adjudicated cases from the Phase 3 clinical trial for mRNA-1273, which we refer to as the COVE Study, demonstrated efficacy of 93% through six months after the second dose of the vaccine. The final analysis also demonstrated greater than 98% efficacy against severe cases of COVID-19 and 100% efficacy against death caused by COVID-19 in the per protocol cohort. The final analysis also demonstrated consistency in our subgroup analysis, including analyses by gender, by race and by preexisting medical conditions. The safety profile for mRNA-1273 continues to be consistent with the Phase 3 data over the longer period of safety follow up and across population subgroups.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2/3 TeenCOVE study of mRNA-1273 in adolescents ages 12-17 years has completed enrollment in the U.S. An initial analysis of 3,732 participants randomized 2:1 in the TeenCOVE study showed a vaccine efficacy rate of 93% in seronegative participants who received at least one injection (modified intent-to-treat cohort) in a secondary analysis. The median duration for follow-up in this analysis was 53 days following the second dose. mRNA-1273 was generally well tolerated. The majority of adverse events were mild or moderate in severity. No serious safety concerns have been identified to date. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events after the second dose of mRNA-1273 were headache, fatigue, myalgia and chills. The Conditional Marketing Authorization (CMA) for our COVID-19 vaccine in the European Union has been expanded to include adolescents 12 years of age and older. In addition, the Japanese Ministry of Health, Labor and Welfare also approved our COVID-19 vaccine for ages 12 to 17. We have filed for an EUA for adolescents with the U.S. FDA as well as with additional regulatory agencies around the world.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2/3 KidCOVE study of mRNA-1273 in the pediatric population ages 6 months-11 years is currently enrolling. We expect to enroll 12,000 healthy pediatric participants in the U.S. and Canada into this two-part, dose escalation study. In Part 1, each participant ages 2 years to less than 12 years may receive one of two dose levels (50 &#181;g or 100 &#181;g). Also in Part 1, each participant ages six months to less than 2 years may receive one of three dose levels (25 &#181;g, 50 &#181;g and 100 &#181;g). An interim analysis will be conducted to determine which dose will be used in Part 2, the placebo-controlled expansion portion of the study.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variant-Specific Booster Candidates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, we announced that we had completed manufacturing of clinical trial material for our variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as the Beta variant (or B.1.351, first identified in the Republic of South Africa) and that this vaccine had been shipped to the National Institutes of Health (NIH) for a Phase 1 clinical trial to be led and funded by the NIH&#8217;s National Institute of Allergy and Infectious Diseases. We are also developing a multivalent booster candidate, mRNA-1273.211, which combines mRNA-1273 (Moderna&#8217;s authorized vaccine against ancestral strains) and the Beta variant in a single vaccine.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from our Phase 2 study showed that a single 50 &#181;g dose of mRNA-1273, mRNA-1273.351 or mRNA-1273.211 given as a booster to previously vaccinated individuals (n=20 per group) increased neutralizing antibody titer responses against SARS-CoV-2 and important variants of concern, including the Gamma variant (or P.1, first identified in Brazil), the Beta variant, and the Delta variant (B.1.617.2). Neutralizing antibody levels following the boost approached those observed after primary vaccination with two doses of 100 &#181;g of mRNA-1273. These data have been submitted to a peer-reviewed journal for publication. Safety and tolerability profiles following third dose booster injections of 50 &#181;g of mRNA-1273, mRNA-1273.351 or mRNA-1273.211 were generally comparable to those observed after the second dose of mRNA-1273 in the previously reported Phase 2 and Phase 3 studies. Our Phase 2 study to evaluate three approaches to boosting is ongoing. We are also in the process of developing a booster tailored to the Delta variant (mRNA-1273.617), and anticipate developing a multivalent booster&#8212;referred to as mRNA-1273.213&#8212;that combines mRNA-1273.617 with another COVID-19 candidate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy on the dosing for boosters will be informed by ongoing clinical trials that assess mRNA-1273 at the 100 &#181;g dose against the results seen at the 50 &#181;g dose, before pursuing an approach with regulatory authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Updates for our Other Development Candidates </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">CMV vaccine (mRNA-1647): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine against cytomegalovirus, or CMV (mRNA-1647) is a vaccine combining six mRNAs in a single vial, which encode for two antigens located on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB). Both the pentamer and gB are essential for CMV to infect barrier epithelial surfaces and gain access to the body. mRNA-1647 is designed to produce an immune response against both the pentamer and gB for the prevention of CMV infection. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the interim analysis of the Phase 2 study, which we announced in April 2021, the 100 &#956;g dose has been chosen for the Phase 3 pivotal study for mRNA-1647, which will evaluate the prevention of primary CMV infection in seronegative women ages 16-40 years. We plan to enroll approximately 8,000 participants from approximately 150 sites across the U.S., Europe and Asia-Pacific into the Phase 3 study, which has begun site initiation and is expected to start in the near-term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna owns worldwide commercial rights for mRNA-1647.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Respiratory syncytial virus (RSV) vaccine (mRNA-1345):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA-1345 is a vaccine against RSV encoding for a prefusion F glycoprotein, which elicits a superior neutralizing antibody response compared to the postfusion state. The Phase 1 study of mRNA-1345 to evaluate the tolerability, reactogenicity and immunogenicity of mRNA-1345 in younger adults, older adults, women of child bearing age and children is ongoing. All younger adult (ages 18-49 years) and older adult (ages 65-79 years) cohorts are fully enrolled. Dosing in the older adult cohort (ages 65-79 years) is ongoing. The age range of toddlers in this de-escalation Phase 1 study is 12-59 months and the pediatric cohort is ongoing, as are the cohorts of women of child-bearing potential. The U.S. FDA has granted Fast Track designation for mRNA-1345 in adults older than 60 years of age.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also intend to evaluate the potential of combinations of mRNA-1345 with our vaccines against other respiratory pathogens in children and separately in older adults. There is no approved vaccine for RSV. Moderna owns worldwide commercial rights to mRNA-1345.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Seasonal influenza (flu) (mRNA-1010, mRNA-10202 and mRNA-1030):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2021, we announced three development candidates for a seasonal influenza vaccine (mRNA-1010, mRNA-1020 and mRNA-1030). In July 2021, the first participants were dosed in the Phase 1/2 study of mRNA-1010, our first generation flu program. mRNA-1010 is a </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages. Our vision is to develop a respiratory vaccine for the adult and elderly populations combining seasonal flu, COVID-19 variant booster and RSV. Moderna owns worldwide commercial rights to mRNA-1010. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Zika vaccine (mRNA-1893):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA-1893 is a vaccine against ZIKV. After administration of the vaccine, the mRNA is translated as a polyprotein and processed inside the cell to make a virus-like particle, or VLP. This process mimics the response of the cell after natural infection. This program is funded by BARDA. In 2020, we announced positive Phase 1 data showing that mRNA-1893 was well-tolerated at all dose levels, and safety and tolerability did not appear to be influenced by the serostatus of the participants at baseline. All dose levels of mRNA-1893 induced a strong neutralizing ZIKV-specific antibody response in baseline flavivirus seronegative participants. GMTs post-dose two were comparable to those in a small panel of Zika convalescent sera collected during the epidemic. In participants with pre-existing flavivirus antibodies, neutralizing antibody titers were boosted with a single dose of the vaccine as shown by the GMTs and the seroconversion rates. We have started a Phase 2 study that is expected to enroll approximately 800 participants in the United States and Puerto Rico. There is no approved vaccine for Zika.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Human immunodeficiency virus (HIV) (mRNA-1644 and mRNA-1574): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced two vaccine programs against HIV. mRNA-1644 is a novel approach to HIV vaccine strategy in humans designed to elicit broadly neutralizing HIV-1 antibodies (bNAbs) and is being developed in collaboration with the International AIDS Vaccine Initiative (IAVI) and the Gates Foundation. A Phase 1 study for mRNA-1644 will use iterative human testing to validate the approach and antigens and multiple novel antigens will be used for germline-targeting and immuno-focusing. A second approach, mRNA-1574, is being evaluated in collaboration with the National Institutes of Health (NIH) and includes multiple native-like trimer antigens. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Propionic acidemia (PA) (mRNA-3927):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Enrollment for the Phase 1/2 clinical trial for mRNA-3927, our therapy for the treatment of propionic acidemia, or PA, is ongoing. The Phase 1/2 study is designed to evaluate the safety and tolerability of mRNA-3927 in patients with PA. PA, is a rare, life-threatening, inherited metabolic disorder due to a defect in the mitochondrial enzyme propionyl-CoA carboxylase, or PCC. It primarily affects the pediatric population. There is no approved therapy for PA, including no approved enzyme replacement therapy. We have received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA and Orphan Drug Designation from the European Commission for the PA program. The FDA has also granted Fast Track designation to mRNA-3927. This is the first development candidate to enter the clinic in our intracellular therapeutics modality. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Methylmalonic acidemia (MMA) (mRNA-3705):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Site start-up activities ongoing for the Phase 1/2 study. The Phase 1/2 study is designed to evaluate the safety and tolerability of mRNA-3705 in patients with MMA. MMA is a rare, life-threatening, inherited metabolic disorder that is primarily caused by a defect in the mitochondrial enzyme methylmalonyl-coenzyme A mutase, or MUT. It primarily affects the pediatric population. There is no approved therapy that addresses the underlying disorder, including no approved enzyme replacement therapy, due to the complexity of the protein and its mitochondrial localization. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">IL-2 Mutein (mRNA-6231): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-6231 is an mRNA-encoded IL-2 modified for the expansion of regulatory T cells. A Phase 1 study in healthy volunteers has dosed its first participants. It is also our first subcutaneously administered therapeutic program. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Intratumoral Immuno-Oncology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have decided to discontinue the development of our OX40L program (mRNA-2416), which was in a Phase 2 study in ovarian patients. We are continuing development of Triplet (mRNA-2752) which includes OX40L and two proinflammatory cytokines, IL-23, and IL-36&#947;, encapsulated in our proprietary LNP. The Phase 1 is ongoing and new expansion cohorts are currently enrolling and dosing patients.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Pipeline</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows our current pipeline of 23 development programs, grouped into modalities&#8212;first our two core modalities where we believe we have reduced the technology risk, followed by our four exploratory modalities in which we are continuing to investigate the clinical use of mRNA medicines.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="mrna-20210630_g2.jpg" alt="mrna-20210630_g2.jpg" style="height:302px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Abbreviations: EBV, Epstein-Barr virus; PD-L1, programmed death-ligand-1; PKU, phenylketonuria; GSD1a, Glycogen storage disease type 1a; H7N9, H7N9 influenza vaccine; hMPV/PIV3, human metapneumovirus (hMPV)/parainfluenza virus type 3 (PIV3) vaccine; IL-2, Interleukin 2: IL-12, interleukin 12; IL-23, interleukin 23; IL-36&#947;, interleu; OX40L, wildtype OX40 ligand; VEGF-A, vascular endothelial growth factor&#160;A. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breadth of biology addressable using mRNA technology is reflected in our current development pipeline of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> programs. The diversity of proteins made from mRNA within our development pipeline is shown in the figure below.</span></div><div style="text-align:center"><img src="mrna-20210630_g3.jpg" alt="mrna-20210630_g3.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"/></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed six modalities, which are summarized as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Prophylactic vaccines: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our prophylactic vaccines modality currently includes ten programs, six of which have entered into clinical trials and demonstrated desired pharmacology, in the form of immunogenicity, in positive Phase 1 clinical trials: H7N9 vaccine (mRNA-1851), RSV vaccine (mRNA-1777), human metapneumovirus (hMPV)/parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653), Zika vaccine (mRNA-1893), CMV vaccine (mRNA-1647), COVID-19 vaccine (mRNA-1273)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We have ongoing Phase 1 trials for our RSV vaccine (mRNA-1345), flu vaccine (mRNA-1010) and hMPV/PIV3 vaccine (mRNA-1653). We have an ongoing Phase 2 study for our Zika vaccine (mRNA-1893) and CMV vaccine </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(mRNA-1647). Our CMV vaccine is also expected to start a Phase 3 trial in the near-term. Our COVID-19 vaccine (mRNA-1273) is described in detail above. Our three preclinical programs within our prophylactic vaccines modality are for Epstein-Barr virus (mRNA-1189), Nipah virus (mRNA-1215) and HIV (mRNA-1644 and mRNA-1574). Two other vaccines being developed as part of public health programs&#8213;H10N8 vaccine (mRNA-1440) and Chikungunya vaccine (mRNA-1388)&#8213;also produced positive Phase 1 clinical trial results, but are not being further developed without government or other funding. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Systemic secreted and cell surface therapeutics: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have four systemic secreted and cell surface therapeutics development candidates in our pipeline. Our secreted programs include our antibody against Chikungunya virus (mRNA-1944), Relaxin (mRNA-0184) for cardiac disorders, PD-L1 (mRNA-6981) for autoimmune hepatitis and IL-2 (mRNA-6231) for autoimmune disorders. Our antibody against Chikungunya virus (mRNA-1944) has had positive Phase 1 readouts to date. Our IL-2 program (mRNA-6231) is currently in a Phase 1 study, and is our first first autoimmune therapeutic candidate to enter the clinic. The remaining programs for Relaxin (mRNA-0184) and PD-L1 (mRNA-6981) are currently in preclinical development.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cancer vaccines:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are currently developing two programs within our cancer vaccines modality. Our personalized cancer vaccine program mRNA-4157 is being developed in collaboration with Merck and is in a multiple-arm Phase 1 trial and a randomized Phase 2 trial. Our second program within this modality, mRNA-5671, is a KRAS vaccine. Our strategic collaborator Merck has a Phase 1 clinical trial ongoing for mRNA-5671.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Intratumoral immuno-oncology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two programs in this modality. Our first program, OX40L/IL-23/IL-36&#947; (Triplet) (mRNA-2752), is currently in a Phase 1 study that is designed as an open-label, multicenter study of intratumoral injections of Triplet (mRNA-2752) alone or in combination with durvalumab (anti-PD-L1) with sites in the United States and Israel. Our second program, IL-12 (MEDI1191), is being developed in collaboration with AstraZeneca. AstraZeneca is currently enrolling an open-label multicenter Phase 1 clinical trial of intratumoral injections of MEDI1191 alone and in combination with the checkpoint inhibitor, durvalumab.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Localized regenerative therapeutics:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our localized VEGF-A program, AZD8601, which is being developed by AstraZeneca, has completed a Phase 1a/b trial to describe its safety, tolerability, protein production, and activity in diabetic patients. The study has met its primary objectives of describing safety and tolerability and secondary objectives of demonstrating protein production and changes in blood flow post AZD8601 administration. We believe these data provide clinical proof of mechanism for our mRNA technology outside of the vaccine setting. AstraZeneca has initiated a Phase 2a study of AZD8601 for VEGF-A for ischemic heart disease in patients undergoing coronary artery bypass grafting (CABG) surgery with moderately impaired systolic function, and the trial is ongoing. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Systemic intracellular therapeutics: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have four systemic intracellular therapeutics development candidates in our pipeline. Our intracellular programs address propionic acidemia, or PA (mRNA-3927), methylmalonic acidemia, or MMA (mRNA-3705), phenylketonuria, or PKU (mRNA-3283), and glycogen storage disorder type 1a, or GSD1a (mRNA-3745). We have an ongoing Phase 1 clinical trial for PA (mRNA-3927). MMA (mRNA-3705), PKU (mRNA-3283) and GSD1a (mRNA-3745) are currently in preclinical development. </span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue for each period presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began to record product sales for our COVID-19 vaccine subsequent to its authorization for emergency use by the FDA and Health Canada in December 2020. For the three months ended June 30, 2021, we recognized $4.2 billion of product sales from our COVID-19 vaccine, of which $2.1 billion was generated in the United States and $2.1&#160;billion was generated from the rest of the world. For the six months ended June 30, 2021, we recognized $5.9 billion of product sales from our COVID-19 vaccine, of which $3.4 billion was generated in the United States and $2.5&#160;billion was generated from the rest of the world.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than product sales, our revenue has been primarily derived from government-sponsored and private organizations including BARDA, DARPA and the Gates Foundation and from strategic alliances with AstraZeneca, Merck and Vertex to discover, develop, and commercialize potential mRNA medicines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was comprised as follows for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended June 30, 2021, $132 million of BARDA grant revenue was related to our mRNA-1273 program and $2 million was related to our Zika vaccine program. For the six months ended June 30, 2021, $322 million of BARDA grant revenue was related to our mRNA-1273 program and $4 million was related to our Zika vaccine program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborative revenue from our strategic alliances was comprised as follows for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect our product sales to significantly increase in 2021 compared to 2020. As of June 30, 2021, we had signed supply agreements of approximately $19.2 billion for the future supply of our COVID-19 vaccine through 2022 and had deferred revenue of $7.2&#160;billion associated with customer deposits received or billable under these agreements. Additional supply agreements have been agreed upon since June 30, 2021, and others are under discussion for 2021 and 2022 deliveries. In addition, we expect to continue to receive funding from our contract with BARDA. As of June 30, 2021, the remaining available funding, net of revenue, earned under our agreement with BARDA for the development of our mRNA-1273 vaccine was $421&#160;million. To the extent that existing or potential future products generate revenue, our revenue may vary due to many uncertainties in the independent development of our mRNA medicines and pursuant to our strategic alliances and other factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial product. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and final formulation and packaging costs. Cost of sales also includes shipping costs and royalties payable to third parties based on sales of our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business and primary focus of our activities generate a significant amount of research and development costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses represent costs incurred by us for the following:</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost to develop our platform;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discovery efforts leading to development candidates;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical, nonclinical, and clinical development costs for our programs;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost to develop our manufacturing technology and infrastructure; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">digital infrastructure costs.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs above comprise the following categories:</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, and stock-based compensation expense;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third parties, such as consultants, investigative sites, contract research organizations (CROs) that conduct our preclinical studies and clinical trials, and in-licensing arrangements;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities and acquiring materials for preclinical studies and clinical trials, including both internal manufacturing and third-party contract manufacturing organizations (CMOs);</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred for the procurement of materials, laboratory supplies, and non-capital equipment used in the research and development process; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation, and amortization, and other direct and allocated expenses incurred as a result of research and development activities.</span></div><div style="padding-left:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are generally not recorded or maintained on a program- or modality-specific basis. The following table reflects our research and development expenses, including direct program-specific expenses summarized by modality and indirect or shared operating costs summarized under other research and development expenses during the three and six months ended June 30, 2021 and 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program expenses by modality:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prophylactic vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intratumoral immuno-oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic secreted and cell surface therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic intracellular therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total program-specific expenses by modality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discovery programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform research</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical development and unallocated manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shared discovery and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes a total of 30 and 23 development candidates at June 30, 2021 and 2020, respectively. Program-specific expenses include external costs and allocated manufacturing costs of pre-launch inventory, mRNA supply and consumables, and are reflected as of the beginning of the period in which the program was internally advanced to development or removed if development was ceased. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;modality&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> refers to a group of programs with common product features and the associated combination of enabling mRNA technologies, delivery technologies, and manufacturing processes. The program-specific expenses by modality summarized in the table above include expenses we directly attribute to our programs, which consist primarily of external costs, such as fees paid to outside consultants, central laboratories, investigative sites, and CROs in connection with our preclinical studies and clinical trials, CMOs, and allocated manufacturing costs of inventory, mRNA supply and consumables. Costs to acquire and manufacture inventory, mRNA supply for preclinical studies and clinical trials are recognized and included in unallocated manufacturing expenses when incurred, and subsequently allocated to program-specific manufacturing costs after completion of the program-specific production. The timing of allocating manufacturing costs to the specific program varies depending on the program development and production schedule. We generally do not allocate personnel-related costs, including stock-based compensation, costs associated with our general platform research, technical development, and other shared costs on a program-specific basis. These costs were therefore excluded from the summary of program-specific expenses by modality.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery program expenses are costs associated with research activities for our programs in the preclinical discovery stage, and primarily consist of external costs for CROs and lab services, and allocated manufacturing cost of preclinical mRNA supply and consumables.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform research expenses are mainly costs to develop technical advances in mRNA science, delivery science, and manufacturing process design. These costs include personnel-related costs, computer equipment, facilities, preclinical mRNA supply and consumables, and other administrative costs to support our platform research. Technology development and unallocated manufacturing expenses are primarily related to non-program-specific manufacturing process development and manufacturing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shared discovery and development expenses are research and development costs such as personnel-related costs and other costs, which are not otherwise included in development programs, discovery programs, platform research, technical development and unallocated manufacturing expenses, stock-based compensation, and other expenses.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest component of our total operating expenses has historically been our investment in research and development activities, including preclinical and clinical development of our product candidates, development of our platform, mRNA technologies, and manufacturing technologies. We expense research and development costs as incurred and cannot reasonably estimate the nature, timing, and estimated costs required to complete the development of the development candidates and investigational medicines we are currently developing or may develop in the future. There are numerous risks and uncertainties associated with the research and development of such development candidates and investigational medicines, including, but not limited to:</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scope, progress, and expense of developing ongoing and future development candidates and investigational medicines;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry in and completion of related preclinical studies;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enrollment in and completion of subsequent clinical trials;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy of investigational medicines resulting from these clinical trials;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations relevant to the investigational medicines in development;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of the required regulatory approvals; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialization, including establishing manufacturing and marketing capabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to progress mRNA-1273 through the development process toward a Biologics License Application approval, indication expansion of mRNA-1273 and variant-specific vaccine candidates during the current pandemic, we expect to continue to incur significant additional expenses. At this time, the magnitude of these potential expenditures is not known. In connection with the BARDA agreement to accelerate development of mRNA-1273, significant grant revenue and expenses are expected in 2021. BARDA's funding is expected to offset those expenses that are covered under the BARDA agreement, subject to our obtaining reimbursement from BARDA. As of June 30, 2021, the remaining available funding, net of revenue, earned was $421&#160;million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. Continued research and development is central to the ongoing activities of our business. Investigational medicines in later stages of clinical development, such as our CMV vaccine (mRNA-1647) and our COVID-19 vaccine, generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development costs to continue to increase in the foreseeable future as our investigational medicines progress through the development phases and identify and develop additional programs. There are numerous factors associated with the successful commercialization of any of our investigational medicines, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time due to the early stage of development of our investigational medicines. Moreover, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We started to incur sales and marketing expenses in the fourth quarter of 2020 to prepare for commercial operations in connection with the sale of our COVID-19 vaccine. Selling, general and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for executives, finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and legal services, sales and marketing, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property, or IP. These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate selling, general and administrative expenses will increase as we continue to expand the number of programs in development and to establish our commercial activities both within and outside the United States. We have already incurred additional expenses related to building out a regulatory, sales and marketing team to support the sale, marketing and distribution of our COVID-19 vaccine. If we obtain regulatory approval for any of our other investigational medicines, and do not enter into one or more third-party commercialization collaboration and manufacturing arrangements, we will incur significant additional expenses related to building out these functions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a broad IP portfolio covering our development and commercialization of mRNA vaccine and therapeutic programs, including those related to mRNA design, formulation, and manufacturing platform technologies. We regularly file patent applications to protect </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">innovations arising from our research and development. We also hold trademarks and trademark applications in the United States and foreign jurisdictions. Costs to secure and defend our IP are expensed as incurred and are classified as selling, general and administrative expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest generated from our investments in cash and cash equivalents, money market funds, and high-quality fixed income securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of interest expense, gains (losses) from the sale of investments in marketable securities, foreign currency transaction and remeasurement gains (losses), gains (losses) on foreign currency balance sheet hedges, and other income and expense unrelated to our core operations. Interest expense is primarily derived from our finance leases related to our Moderna Technology Center, and certain contract manufacturing service agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses as we continue our research and development and commercialization efforts. We expect our programs to mature and advance to later stage clinical development, and we expect expenses to increase as we seek regulatory approvals for our investigational medicines and commercialize any approved mRNA medicines. If we fail to sustain profitability on a continuing basis, we may incur losses in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates in the preparation of our condensed consolidated financial statements during&#160;the three months ended June 30, 2021&#160;compared to those disclosed in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our condensed consolidated statements of operations for each period presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,399%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,288%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,001&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $4.3 billion for the three months ended June 30, 2021, compared to the same period in 2020, due to increases in product sales and grant revenue. Product revenue was $4.2 billion for the three months ended June 30, 2021 from sales of our COVID-19 vaccine. For the three months ended June 30, 2021, we delivered approximately 126&#160;million doses to the U.S. government and approximately 73&#160;million doses to other governments of our COVID-19 vaccine. We did not have product sales until December 2020. Grant revenue increased by $101 million for the three months ended June 30, 2021, compared to the same period in 2020, mainly driven by an increase in revenue from BARDA related to our mRNA-1273 vaccine development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $6.2 billion, for the six months ended June 30, 2021, compared to the same period in 2020, due to increases in product sales and grant revenue. Product revenue was $5.9 billion for the six months ended June 30, 2021 from sales of </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our COVID-19 vaccine. For the six months ended June 30, 2021, we delivered approximately 215 million doses to the U.S. government and approximately 87 million doses to other governments. We did not have product sales until December 2020. Grant revenue increased by $291 million for the six months ended June 30, 2021, compared to the same period in 2020, primarily driven by an increase in revenue from BARDA related to our mRNA-1273 vaccine development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing our COVID-19 vaccine inventory costs in December 2020, in connection with an EUA from the FDA, and based upon our expectation that these costs would be recoverable through commercialization of our COVID-19 vaccine. Prior to the capitalization of our COVID-19 vaccine inventory costs, such costs were recorded as research and development expenses in the period incurred. We expensed $242 million of pre-launch inventory costs in 2020. Our cost of sales was $750&#160;million, or 18%, of our product sales, for the three months ended June 30, 2021, including third-party royalties of $148&#160;million. Our cost of sales was $943&#160;million, or 16%, of our product sales, for the six months ended June 30, 2021, including third-party royalties of $232&#160;million. A portion of the inventory costs associated with our product sales for the six months ended June 30, 2021 was expensed previously. At the end of the first quarter of 2021, we had substantially utilized our zero-cost COVID-19 vaccine inventory. If inventory sold for the six months ended June 30, 2021 was valued at cost, our cost of sales for the period would have been $1.1&#160;billion, or 19%, of our product sales. We expect that our cost of sales as a percentage of product sales will remain at a similar level for the second half of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $269 million, or 177%, for the three months ended June 30, 2021, compared to the same period in 2020. The increase was primarily attributable to an increase in clinical trial expenses of $217 million, and an increase in personnel, technology and facility-related costs of $24 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $555 million, or 208%, for the six months ended June 30, 2021, compared to the same period in 2020. The increase was primarily attributable to an increase in clinical trial expenses of $436 million, an increase in personnel-related costs of $37 million, an increase in manufacturing expenses related to our clinical trials of $30 million, and an increase in consulting and outside services of $29 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases for both the three and six month periods in 2021 were largely driven by increased mRNA-1273 clinical development and headcount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $84 million, or 227%, for the three months ended June 30, 2021, compared to the same period in 2020. The increase was mainly due to an increase in consulting and outside services of $33 million, an increase in personnel-related costs of $20 million, and an increase in marketing expenses of $15 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $137 million, or 225%, for the six months ended June 30, 2021, compared to the same period in 2020. The increase was mainly due to an increase in consulting and outside services of $50 million, an increase in marketing, legal and licensing expenses of $32 million, and an increase in personnel-related costs of $31 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases for both the three and six month periods in 2021 were primarily driven by our COVID-19 vaccine commercialization-related activities and increased headcount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $4 million, or 57%, for the three months ended June 30, 2021, compared to the same period in 2020. Interest income decreased by $8 million, or 53%, for the six months ended June 30, 2021, compared to the same period in 2020. The decreases in interest income from our investments in marketable securities for both the three and six month periods in 2021 were mainly driven by an overall lower interest rate environment, partially offset by increased investment balances. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other expense, net for each period presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net remained flat for the three months ended June 30, 2021, compared to the same period in 2020. Total other expense, net increased by $9 million, or 300%, for the six months ended June 30, 2021, compared to the same period in 2020. The increase in other expense, net for the six-month period in 2021 was primarily due to losses on foreign currency transactions and remeasurements, partially offset by our balance sheet hedge activities. Our interest expense is primarily related to our finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes for the three and six months ended June 30, 2021 was $283 million and $322 million, respectively, as compared to an insignificant amount for the same periods in 2020. Our effective tax rate for the three and six months ended June 30, 2021 was lower than the U.S. statutory rate primarily due to the benefit related to the release of the valuation allowance on the majority of our tax attributes, the benefit of the foreign derived intangible income deduction and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three and six months ended months ended June 30, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a periodic basis, we reassess any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, in the first quarter of 2021, we released our valuation allowance on the majority of our federal and state net operating losses and other deferred tax assets through the annual effective tax rate (AETR) as income is earned, resulting in a reduction in the AETR. In addition, we have recorded a discrete benefit of $49 million related to the deferred tax assets that we expect to utilize in future years. As of June 30, 2021, we continue to maintain a valuation allowance on certain state tax attributes. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had cash, cash equivalents and investments of $12.2 billion. Cash, cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting primarily of government and corporate debt securities, are stated at fair value. As of June 30, 2021, we had current and non-current investments of approximately $2.4 billion and $4.2&#160;billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically funded our operations primarily from the sale of equity instruments and from proceeds from certain strategic alliance arrangements and grant agreements. Starting in August 2020, we have entered into supply agreements with the U.S. Government and several governments outside the United States for the supply of our COVID-19 vaccine and receive upfront deposits. As of June 30, 2021, we had $7.2&#160;billion in deferred revenue related to customer deposits received or billable. In addition, as of June 30, 2021, BARDA has committed to fund up to $1.3&#160;billion for the clinical development and advancement of mRNA-1273 to FDA licensure and the scale-up of manufacturing processes of our COVID-19 vaccine. As of June 30, 2021, the remaining available funding from BARDA, net of revenue earned was $421&#160;million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work toward the large-scale technical development, manufacturing scale-up in several countries and larger scale deployment of our COVID-19 vaccine. To support the scale-up, we have expended and will need to continue to expend significant resources and capital. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flow</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for each period presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from cash collected from customer deposits and accounts receivable related to our COVID-19 vaccine supply agreements as well as certain government-sponsored and private organizations and strategic alliances. Our cash flows from operating activities are significantly affected by our use of cash for operating expenses and working capital to support the business. Prior to 2020, we historically experienced negative cash flows from operating activities as we have invested in mRNA technologies, development pipeline, digital infrastructure, manufacturing technology and infrastructure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the six months ended June 30, 2021 was $7.0 billion and consisted of net income of $4.0 billion and non-cash adjustments of $90 million, plus a net change in assets and liabilities of $2.9 billion. Non-cash items included depreciation and amortization of $84 million, deferred income taxes of $72 million, stock-based compensation of $65 million, and amortization of investment premium and discount of $13 million. The net change in assets and liabilities was mainly due to an increase in deferred revenue of $3.4 billion, an increase in other liabilities of $440 million, an increase in accrued liabilities of $367 million and an increase in accounts payable of $44 million, partially offset by an increase in accounts receivable of $629 million, an increase in inventory of $596 million, and an increase in prepaid expenses and other assets of $110 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June 30, 2020 was $130 million and consisted of net loss of $241 million and non-cash adjustments of $62 million, plus a net change in assets and liabilities of $49 million. Non-cash items primarily included stock-based compensation of $45 million and depreciation and amortization of $15 million. The net change in assets and liabilities was due to an increase in deferred revenue of $51 million, an increase in accrued liabilities of $20 million, an increase in operating lease liabilities of $14 million, an increase in accounts payable of $12 million and an increase in other liabilities of $4 million, partially offset by an increase in accounts receivable of $28 million, an increase in right-of-use assets related to operating leases of $12 million, and an increase in prepaid expenses and other assets of $12 million.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary investing activities consist of purchases, sales, and maturities of our investments and capital expenditures for manufacturing, laboratory, computer equipment and software.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June 30, 2021 was $4.1 billion, which included purchases of marketable securities of $6.6 billion and purchases of property and equipment of $65 million, partially offset by proceeds from sales of marketable securities of $1.7 billion and proceeds from maturities of marketable securities of $860 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June 30, 2020 was $303 million, which included purchases of marketable securities of $903 million and purchases of property and equipment of $25 million, partially offset by proceeds from maturities of marketable securities of $517 million and proceeds from sales of marketable securities of $108 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated cash from financing activities of $2 million for the six months ended June 30, 2021, primarily from net proceeds from the issuance of common stock in connection with the exercise of stock options and employee stock purchases under our equity plans of $64 million, partially offset by changes in financing lease liabilities of $62 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated cash from financing activities of $2.0 billion for the six months ended June 30, 2020, primarily from net proceeds from equity offerings of $1.9 billion and net proceeds from the issuance of common stock in connection with the exercise of stock options under our equity plans of $106 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operation and funding requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception to the end of 2020, we incurred significant losses and negative cash flows from operations due to our significant research and development expenses. We generated net income in the first half of 2021 in connection with our product sales. We have retained earnings of $1.8 billion as of June 30, 2021. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. We also expect our expenses to increase associated with manufacturing costs, including our arrangements with our international supply and manufacturing partners. Our ongoing work on mRNA-1273, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, will require significant cash outflows during 2021, most of which may not be reimbursed or otherwise paid for by our partners or collaborators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of June 30, 2021, together with cash expected to be generated from operations, will be sufficient to enable us to fund our projected operations, capital expenditures and stock repurchases through at least the next 12&#160;months from the issuance of these financial statements. We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors including expenses related to the ongoing coronavirus pandemic, which may adversely affect our business. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to sustain profitability on a continuing basis, we may be required to finance future cash needs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, potential future strategic alliances from which we receive upfront fees, milestone payments, and other forms of consideration, and marketing, manufacturing, distribution and licensing arrangements. If we are required to finance future cash needs, additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of one or more of our investigational medicines, or slow down or cease work on one or more of our programs. If we raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders or increased fixed payment obligations, and any such securities may have rights senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise funds through strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or investigational medicines or grant licenses on terms that may not be favorable to us. Any of these events could significantly harm our business, financial condition, and prospects.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, other than disclosed at Note 11 and Note 12 to our condensed consolidated financial statements, there have been no material changes to our contractual obligations and commitments from those described under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off balance sheet arrangements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we did not have any off-balance sheet arrangements, as defined in Item&#160;303(a)(4)(ii) of Regulation S-K.</span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, we had cash, cash equivalents, and investments in marketable securities of $12.2 billion and $5.2 billion, respectively. Our investment portfolio is comprised of money market funds and marketable debt securities (including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities, and commercial paper), which are classified as available-for-sale securities. Our primary investment objectives are the preservation of capital and the maintenance of liquidity and our investment policy defines allowable investments based on quality of the institutions and financial instruments designed to minimize risk exposure. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates. Our available-for-sale securities are subject to interest rate risk and will fall in value if market interest rates increase. We generally hold investments in marketable debt securities to maturity to limit our exposure to interest rate risk. Due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. If market interest rates were to increase immediately and uniformly by one percentage point from levels at June 30, 2021, the net fair value of our marketable securities would decrease by approximately $98 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue generating activities and operations have been primarily denominated in U.S. dollars. As we expand internationally, our results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. To help manage the exposure to foreign currency exchange rate fluctuations, we have implemented cash flow hedging and balance sheet hedging programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge foreign currency product sales denominated in Euros, including the use of foreign exchange forward contracts or purchased options. We hedge our cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. These transactions are designated and qualify as cash flow hedges. Our foreign exchange contracts at June 30, 2021, carried at fair value, had maturities of up to six months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use foreign currency forward contracts to mitigate foreign currency exchange risk associated with foreign currency-denominated monetary assets and liabilities. These contracts reduce the impact of currency exchange rate movements on our assets and liabilities. As of June 30, 2021, our outstanding balance sheet hedging derivatives, carried at fair value, had maturities of less than three months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into these foreign exchange contracts to hedge forecasted revenue in the normal course of business and accordingly, they are not speculative in nature. We believe the counterparties to our foreign currency forward contracts are creditworthy multinational commercial banks. While we believe the risk of counterparty nonperformance is not material, a sustained decline in the financial stability of financial institutions as a result of disruption in the financial markets could affect our ability to secure creditworthy counterparties for our foreign currency hedging programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding our efforts to mitigate some foreign currency exchange risks, there can be no assurance that our hedging activities will adequately protect us against the risks associated with foreign currency fluctuations. As of June 30, 2021, a hypothetical adverse movement of 10 percent in foreign currency exchange rates compared to the U.S. dollars across all maturities would have resulted in potential declines in the fair value on our foreign currency forward contracts used in cash flow hedging of approximately $95 million. As of June 30, 2021, a hypothetical adverse movement of 10 percent in foreign currency exchange rates compared to the U.S. dollars across all maturities would have resulted in potential declines in the fair value on our foreign currency forward contracts used in balance sheet hedging of approximately $6 million. We expect that any increase or decrease in the fair value of the balance sheet hedging portfolio would be substantially offset by increases or decreases in the underlying exposures being hedged. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of&#160;June 30, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of&#160;June 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended June 30, 2021, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by a management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i6f181a2054234caea38df80c330fc729_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business.&#160;We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Information regarding risk and uncertainties related to our business appears in Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission, or the SEC, on February 26, 2021. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the condensed consolidated financial statements and the related notes. If any of the risks actually occur, it could harm our business, prospects, operating results and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i6f181a2054234caea38df80c330fc729_109"></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibits listed below are filed or incorporated by reference as part of this Form 10-Q.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Index</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendmentsnos4to.htm">Amendment </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendmentsnos4to.htm">Nos. P00004, P00005, P00006, P00007, P00008, P00009, P00010, P00011 and P00012</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendmentsnos4to.htm"> to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated June 15, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102amendmentnos8and.htm">Amendment No</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102amendmentnos8and.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102amendmentnos8and.htm">. 8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102amendmentnos8and.htm"> and 9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102amendmentnos8and.htm"> to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a4exhibit3116302021.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a5exhibit3126302021.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a6exhibit3216302021.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Link Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></td></tr><tr style="height:48pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i6f181a2054234caea38df80c330fc729_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6f181a2054234caea38df80c330fc729_10">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MODERNA, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David W. Meline</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Financial Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101amendmentsnos4to.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i36f8765b633b4ca08c44f4a402810b5d_1"></div><div style="min-height:81pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.1</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><br>CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;&#91;***&#93;&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED</font></div></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.090%"></td><td style="width:0.1%"></td></tr><tr style="height:10pt"><td colspan="30" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></div></td><td colspan="15" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></div></td></tr><tr style="height:10pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29</font></div></td></tr><tr><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">P00004</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11-Feb-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5. PROJECT NO.(If applicable)</font></td></tr><tr style="height:19pt"><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6. ISSUED BY</font></div><div style="margin-bottom:36pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W6QK ACC-APG NATICK DIVISION<br>BLDG 1 GENERAL GREENE AVENUE<br>NATICK MA 01760-5011</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W911QY</font></td><td colspan="18" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item 6)&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DEFENSE CONTRACT MANAGEMENT AGENCY<br>DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></div></td><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">S2206A</font></td></tr><tr style="height:60pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="24" rowspan="4" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:10pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:19pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W911QY20C0100</font></div></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">09-Aug-2020</font></div></td></tr><tr style="height:10pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:26.1pt;text-indent:-23.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8PTM0</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FACILITY CODE</font></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt 0 3.15pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended,&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; <br>(a) By completing Items 8 and 15, and returning&#160;&#160;&#160;&#160;copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59;<br>or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE<br>RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION<br>OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Schedule</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM&#160;10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:12.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor&#160;&#160;&#160;&#160; </font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not,&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is required to sign this document and return </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> copies to the issuing office.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)<br>Modification Control Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:36pt;padding-left:12.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.</font></div></td></tr><tr><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15A. NAME AND TITLE OF SIGNER (Type or print)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Stephane Bancel, CEO</font></div></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">TEL&#58; &#91;***&#93;&#160;&#160;&#160;&#160;EMAIL&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephane Bancel</font></div><div style="padding-left:17.1pt;text-indent:-14.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:5pt;padding-left:17.85pt;text-indent:-15.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">BY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11 Feb 2021</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $1,650,000,000</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00004) is to&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Exercise, fund Option 2 CLINs 2001AA, 2001AB, 2001AC for a total of $1,650,000,000 (Authority FAR 52.217-7)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Add clauses H. 16 &#38; H. 17, and revise the delivery schedule for the Base period, Option 1, and Option 2 LAW the table contained within H. 16 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Revise the table in Section G back to previous amounts, due to an administrative error on modification no. P00003, where the amounts were revised (Authority FAR 52.232-16)</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Update Contract Data Requirement List (CDRL) no.&#8217;s A003, A008, A009, A011, A014, A021, and the corresponding information to the CDRLs in Section C, Statement of Work. (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount has increased by $1,650,000,000 from $3,191,598,000 to $4,841,598,000.</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms and conditions remain unchanged.  Please see below for details.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION A -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">SOLICITATION&#47;CONTRACT FORM</font></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this contract was increased by $1,650,000,000.00 from $3,191,598,000.00 to $4,841,598,000.00.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION B -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.82pt">SUPPLIES OR SERVICES AND PRICES</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 0001</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), LAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 3 of 29</font></div></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 1001 </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 2001</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 2001AA</font></div><div style="margin-bottom:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 2001 AB</font></div><div style="margin-bottom:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 2001AC</font></div><div style="margin-bottom:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="margin-bottom:0.24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION C -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.82pt">DESCRIPTIONS AND SPECIFICATIONS</font></div><div><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 4 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF WORK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">SCOPE.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Background</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#8217;s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary of Health and Human Service declared a public health emergency on January 31,2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and&#47;or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Objective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The objective of this effort is to obtain the following&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Base Period&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 1&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 2&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 3&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 4&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Period is &#91;***&#93;, with overlapping options for a total of &#91;***&#93; if all options are exercised.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">APPLICABLE DOCUMENTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Federal Documents&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C.2.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:4.34pt">Title 21 Code of Federal Regulations (CFR), Food and Drugs&#58; Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs&#59; General&#59; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs&#59; General.<br>(https&#58;&#47;&#47;www.ecfr.gov&#47;cgi&#8209;bin&#47;text&#8209;idx&#63;SID&#61;a95cab20f443897a400bb7e44a27cf4c&#38;mc&#61;true&#38;tpl&#61;&#47;ecfrbrowse&#47;Title21&#47;21cfiv4_02.tpl#0)</font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">REQUIREMENTS.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, &#8220;Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)&#8221;), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 5 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">Contract Line Item Number (CLIN) 0001 - Base Period&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Coordinating with FDA to establish an approved commercial vial label, carton and packaging insert (printed or electronic).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including &#8220;Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&#38;C Act&#8221; (April 2020).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond &#91;***&#93; of product release, the contract will be subject to modification for acceptance purposes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer&#8217;s Representative (COR) within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 6 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 1001 - Option Period 1&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the produetto the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 7 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 2001 - Option Period 2&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 3001 - Option Period 3&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 8 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 4001 - Option Period 4&#59; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 9 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL AO 15.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002&#58; Data Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">Built tnRNA,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulated LNPs, and the fill, finish, and released product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor&#8217;s fill&#47;finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Key Personnel Listing (CDRL A007).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 10 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided &#8220;COVID-19 Dose Tracking Template&#8221; (CDRL Attachment 0003).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Incident Report.  The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and&#47;or cost and&#47;or performance in accordance with CDRL A016.  &#8220;Significant&#8221; is frequently defined as a &#91;***&#93; or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost&#47;schedule impact, such as breach of GCP during a clinical study, shall also be reported.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL A017.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL AOI 8.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug&#47;biologic product to ensure conformity with &#167;501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&#38;C Act, Title 21 United States Code (USC) &#167;351 (a)(2)(B)), regarding good manufacturing practices (GMP).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall host a Post Award Teleconference within &#91;***&#93; calendar days after contract award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide Meeting Minutes IAW CDRL A021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Kickoff Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contracting officer may request the contractor host a contract Kick-Off Meeting within &#91;***&#93; calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Bi-Weekly Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 11 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The contractor shall provide an Agenda, IAW CDRL A020&#59; Meeting Minutes in accordance with CDRL A021&#59; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Daily &#8220;Check-In&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in a daily &#8220;check-in&#8221; (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours&#8217; notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Access and General Protection&#47;Security Policy and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and&#47;or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor&#8217;s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Security Program and Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG&#8217;s requirement.  The contractor&#8217;s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL AO 19, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Operational Security (OPSEC)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)&#47;Plan IAW CDRL A024.  The contractor shall identify in the SOP&#47;Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002 Vendor Managed Inventory (VMI)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor shall provide the capability to store the vaccine for up to &#91;***&#93;, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to &#91;***&#93; prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations .  &#91;***&#93;.  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within &#91;***&#93; of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident..  BARDA&#47;JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective&#47;Preventive actions within &#91;***&#93; of detection of an incident with potential to impacts product quality.  BARDA&#47;JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations &#91;***&#93; in the United States.  The contractor shall be responsible for shipment of all vaccine product &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The vaccine product shall be shipped and tracked by the distribution vendor&#8217;s shipping tracking number, to the USG-designated sites within the continental United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 12 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION E -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.38pt">INSPECTION AND ACCEPTANCE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.4pt">Inspection&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine CLINs&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality inspection of Filled Drug Product (FDP) shall occur when the Contractor performs release testing to confirm that products complies with Contractor&#8217;s release specifications and criteria.  Contractor will submit the Certificate of Analysis for quality inspection of all drug product lots in BARDA Data Infrastructure (BDI) system.  Initial Inspection under this contract will be performed at the Contractor&#8217;s facility, or the subcontractor facility, by the BARDA Contracting Officer Technical Representative (COTR).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government shall inspect each shipment of product delivered to it hereunder for visible damage and quantity &#91;***&#93; of final delivery.  In the event Contractor supplies any product to the Government and it is established that such Product was damaged or does not include the required quantities at the time of final delivery, the Government shall promptly notify Contractor in writing &#91;***&#93;.  A BDI extract of the inspection documentation shall also be submitted in Wide Area Workflow (WAWF) as supporting documentation for invoice submittals.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Storage CLIN&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the USG requires storage of the FDP to a Vendor Managed Inventory (VMI) location, quantity inspection shall be conducted by submission of shipping or other documentation into WAWF confirming quantity to VMI location.  Physical inspection of the FDP shall be conducted upon receipt of product to USG CDC location.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data CLIN&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspection of all reports and Contract Data Requirement List (CDRL) under this contract will be performed at Destination by duly authorized representative of the Government.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.4pt">Acceptance</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Acceptance &#91;***&#93;.  Acceptance &#91;***&#93;.  Regardless of where acceptance occurs, the contractor is responsible for final delivery of Filled Drug Product (FDP) to a government designated CDC location.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Acceptance of vaccines under this agreement will be performed by the COTR in the BDI system, which constitutes government acceptance &#91;***&#93;.  Documentation of acceptance shall be submitted in accordance with WAWF instructions.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Acceptance of storage services under VMI CLIN No. 0002 shall occur upon &#91;***&#93;.  Acceptance of Data CLIN No. 0004 shall occur in WAWF by the KO.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The parties acknowledge that acceptance may depend on the compliance with the Contractor&#8217;s product specifications.  The KO and COR may prior to acceptance consult with FDA under its authority under Public Law 115-92 to determine whether the material to be delivered meets the Contractor&#8217;s product specifications.  To this end.  Contractor agrees to provide a letter to FDA authorizing the Government to engage in dialog with FDA about the ultimate compliance of this product with the Contractor&#8217;s product specifications prior to acceptance.  BARDA&#47;COR will accept product according to the approved Product Acceptance Procedure.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 13 of 29</font></div></div><div><font><br></font></div><div id="i36f8765b633b4ca08c44f4a402810b5d_7"></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION F -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.92pt">DELIVERIES OR PERFORMANCE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 1001 AB has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 1001 AC has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 2001AA has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 14 of 29</font></div></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 2001AB has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 2001AC has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.94pt">The contractor shall ship mRNA-1273 vaccines to the designated locations listed below.  The contractor shall be responsible for secure shipment of all vaccine product whether acceptance is conducted &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delivery Locations&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Location 1</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Location 2</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION G -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">CONTRACT ADMINISTRATION DATA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting and Appropriation</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 15 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary for the Payment Office</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this modification, the total funded amount for this document was increased by $ 1,650,000,000.00 from $3,191,598,000.00 to $4,841,598,000.00.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 2001AA&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AF&#58; &#91;***&#93; increased by $551,100,000.00 from $0.00 to $551,100,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AF has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 2001AB&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG&#58; &#91;***&#93; was increased by $551,100,000.00 from $0.00 to $551,100,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AG has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 2001AC&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AH&#58; &#91;***&#93; was increased by $547,800,000.00 from $0.00 to $547,800,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AH has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Procuring Contracting Officer&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Bldg. 1, General Greene Avenue<br>Natick, MA 01760-5011</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract Specialist&#58;<br>&#91;***&#93;<br>Bldg. 1, General Greene Avenue<br>Natick, MA 01760-5011</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT TECHNICAL POINT OF CONTACT</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Biologist&#47;Project Officer<br>200 C Street, SW<br>Washington, DC 20201</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 16 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">CONTRACTOR&#8217;S CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Moderna US, Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PLACES OF PERFORMANCE</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna US, Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">NOTIFICATION OF REVISIONS AND CHANGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO&#47;ACO or office of the PCO&#47;ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PERFORMANCE BASED PAYMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option IAW the following schedule&#58;<br><br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:24.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLIN</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERIOD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AA</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;90,210,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AB</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;132,308,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;180,420,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;198,462,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;601,400,000</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br><br>Delivery Invoicing&#58; PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items.  Attachment 0008, Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008 dated 4 December 2020.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252.232-&#160;&#160;&#160;&#160;7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Definitions.  As used in this clause&#8212;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 17 of 29</font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Department of Defense Activity Address Code (DoDAAC)&#8221; is a six position code that uniquely identifies a unit, activity, or organization.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Document type&#8221; means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Local processing office (LPO)&#8221; is the office responsible for payment certification when payment certification is done external to the entitlement system.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Payment request&#8221; and &#8220;receiving report&#8221; are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Electronic invoicing.  The WAWF system provides the method to electronically process vendor payment request and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">WAWF access.  To access WAWF, the Contractor shall&#8212;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Have a designated electronic business point of contact in the System for Award Management at </font><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.sam.gov</font><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Be registered to use WAWF at </font><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;wawf.eb.mil&#47;</font><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following the step-by-step procedures for self-registration available at this web site.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">WAWF training.  The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF.  Both can be accessed by selecting the &#8220;Web Based Training&#8221; link on the WAWF home page at </font><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;wawf.eb.mil&#47;</font><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">WAWF methods of document submission.  Document submissions may be via web entry, Electronic Data Interchange, or File Transfer Protocol.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">WAWF payment instructions.  The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Document type.  The Contractor shall submit payment requests using the following document type(s)&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMBO</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">For fixed price line items&#8212;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invoice and receiving report document type</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;For services that do not require shipment of a deliverable, submit either the Invoice 2-in-l, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 18 of 29</font></div></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">For customary progress payments based on costs incurred, submit a progress payment request.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">For performance based payments, submit a performance based payment request.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For commercial item financing, submit a commercial item financing request.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Document routing.  The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Routing Data Table</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"></td><td style="width:50.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Field Name in WAWF</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data to be entered in WA WF</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pay Official DoDAAC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HQ0337</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issue By DoDAAC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Admin DoDAAC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S2206A</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspect By DoDAAC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W56XNH</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceptor</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ship To</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TDB</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Payment request.  The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Receiving report.  The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">WAWF point of contact.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity&#8217;s WAWF point of contact.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; &#47; DCMA Boston-AFAW, Administrative Contracting Officer &#47; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Contact the WAWF helpdesk at &#91;***&#93;, if assistance is needed.</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of clause)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR REFERENCE&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEARS PGI 204.7108 Payment Instructions Table</font></div><div style="margin-bottom:24pt"><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.acq.osd.mi1&#47;dpap&#47;dars&#47;pgi&#47;pgi_htm&#47;current&#47;PGI204_71.htm#payment_instructions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 19 of 29</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION H -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.26pt">SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel&#58;</font></div><div style="margin-bottom:6pt;padding-left:0.24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Substitution of Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Disclosure of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 20 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractor&#8217;s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 21 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.  If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.  Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.  Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.  Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.  The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8220;Technology&#8221;).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(f), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; of award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Performance Based Payment Liquidated under Termination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna&#8217;s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Public Readiness and Emergency Preparedness (PREP) Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 22 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4,2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor CO VID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items and technology covered by this Contract are being developed for both civil and military applications.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Novation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 23 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Moderna TX, Inc.  This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, &#91;***&#93; above what was projected by Moderna and assumed within the price per dose for the doses of tnRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.  If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to &#91;***&#93; for &#91;***&#93; and &#91;***&#93; for &#91;***&#93;.  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.) Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.) Cancellation notice to the subcontractor,</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.) The basis of the cancellation, and</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.) Cancellation fees incurred.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.16</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Delivery Schedule, as revised 11 Feb 2021 via modification P00004</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna confirms that it will provide the USG with the first 300M doses manufactured within its US-based supply chain &#91;***&#93;, with the exception of doses required for clinical studies.  &#91;***&#93;.  Both parties acknowledge that resulting revisions to future accounting, invoicing, acceptance and delivery of doses subject to the revised label will be implemented via a subsequent modification.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.17</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Post-Termination Disposition of Undelivered Product</font></div><div style="margin-bottom:12pt"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 24 of 29</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION I -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.15pt">CONTRACT CLAUSES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252.232-&#160;&#160;&#160;&#160;7007 LIMITATION OF GOVERNMENT&#8217;S OBLIGATION (APR 2014)</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Contract line item </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">0003</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is incrementally funded.  For this item, the sum of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">$300,000,000.00</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the total price is presently available for payment and allotted to this contract.  An allotment schedule is set forth in paragraph (j) of this clause.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For items(s) identified in paragraph (a) of this clause, the Contractor agrees to perform up to the point at which the total amount payable by the Government, including reimbursement in the event of termination of those item(s) for the Government&#8217;s convenience, approximates the total amount currently allotted to the contract.  The Contractor is not authorized to continue work on those item(s) beyond that point.  The Government will not be obligated in any event to reimburse the Contractor in excess of the amount allotted to the contract for those item(s) regardless of anything to the contrary in the clause entitled &#8220;TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT.&#8221; As used in this clause, the total amount payable by the Government in the event of termination of applicable contract line item(s) for convenience includes costs, profit and estimated termination settlement costs for those item(s).</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Notwithstanding the dates specified in the allotment schedule in paragraph (j) of this clause, the Contractor will notify the Contracting Officer in writing at least ninety days prior to the date when, in the Contractor&#8217;s best judgment, the work will reach the point at which the total amount payable by the Government, including any cost for termination for convenience, will approximate 85 percent of the total amount then allotted to the contract for performance of the applicable item(s).  The notification will state (1) the estimated date when that point will be reached and (2) an estimate of additional funding, if any, needed to continue performance of applicable line items up to the next scheduled date for allotment of funds identified in paragraph (j) of this clause, or to a mutually agreed upon substitute date.  The notification will also advise the Contracting Officer of the estimated amount of additional funds that will be required for the timely performance of the item(s) funded pursuant to this clause, for subsequent period as may be specified in the allotment schedule in paragraph (j) of this clause, or otherwise agreed to by the parties.  If after such notification additional funds are not allotted by the date identified in the Contractor&#8217;s notification, or by an agreed substitute date, the Contracting Officer will terminate any item(s) for which additional funds have not been allotted, pursuant to the clause of this contract entitled &#8220;TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">When additional funds are allotted for continued performance of the contract line item(s) identified in paragraph (a) of this clause, the parties will agree as to the period of contract performance which will be covered by the funds.  The provisions of paragraph (b) through (d) of this clause will apply in like manner to the additional allotted funds and agreed substitute date, and the contract will be modified accordingly.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">If, solely by reason of failure of the Government to allot additional funds, by the dates indicated below, in amounts sufficient for timely performance of the contract line item(s) identified in paragraph (a) of this clause, the Contractor incurs additional costs or is delayed in the performance of the work under this contract and if additional funds are allotted, an equitable adjustment will be made in the price or prices (including appropriate target, billing, and ceiling prices where applicable) of the item(s), or in the time of delivery, or both.  Failure to agree to any such equitable adjustment hereunder will be a dispute concerning a question of fact within the meaning of the clause entitled &#8220;disputes.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">The Government may at any time prior to termination allot additional funds for the performance of the contract line item(s) identified in paragraph (a) of this clause.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 25 of 29</font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The termination provisions of this clause do not limit the rights of the Government under the clause entitled &#8220;DEFAULT.&#8221; The provisions of this clause are limited to work and allotment of funds for the contract line item(s) set forth in paragraph (a) of this clause.  This clause no longer applies once the contract if fully funded except with regard to the rights or obligations of the parties concerning equitable adjustments negotiated under paragraphs (d) or (e) of this clause.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Nothing in this clause affects the right of the Government to this contract pursuant to the clause of this contract entitled &#8220;TERMINATION FOR CONVENIENCE OF THE GOVERNMENT.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Nothing in this clause shall be construed as authorization of voluntary services whose acceptance is otherwise prohibited under 31 U.S.C. 1342.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">The parties contemplate that the Government will allot funds to this contract in accordance with the following schedule&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On execution of contract $0.00</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Modification P00003 dated 11 Dec 2020 - $300,000,000</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of clause)</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.59pt">LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page #</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#fa0101;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Plan</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx, Inc. Background Intellectual Property</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 December 2020</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_10"></div><hr style="page-break-after:always"><div style="min-height:59.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.090%"></td><td style="width:0.1%"></td></tr><tr style="height:10pt"><td colspan="30" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></div></td><td colspan="15" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></div></td></tr><tr style="height:10pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23</font></div></td></tr><tr><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">P00005</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">23-Apr-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5. PROJECT NO.(If applicable)</font></td></tr><tr style="height:19pt"><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6. ISSUED BY</font></div><div style="margin-bottom:36pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W6QK ACC-APG NATICK DIVISION<br>BLDG 1 GENERAL GREENE AVENUE<br>NATICK MA 01760-5011</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W911QY</font></td><td colspan="18" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item 6)&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DEFENSE CONTRACT MANAGEMENT AGENCY<br>DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></div></td><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">S2206A</font></td></tr><tr style="height:60pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="24" rowspan="4" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:10pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:19pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W911QY20C0100</font></div></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">09-Aug-2020</font></div></td></tr><tr style="height:10pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:26.1pt;text-indent:-23.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8PTM0</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FACILITY CODE</font></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt 0 3.15pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended,&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; <br>(a) By completing Items 8 and 15, and returning&#160;&#160;&#160;&#160;copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59;<br>or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE<br>RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION<br>OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Schedule</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM&#160;10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:12.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor&#160;&#160;&#160;&#160; </font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not,&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is required to sign this document and return </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> copies to the issuing office.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)<br>Modification Control Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:36pt;padding-left:12.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.</font></div></td></tr><tr><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15A. NAME AND TITLE OF SIGNER (Type or print) </font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stephen Hoge, President</font></div></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">TEL&#58; &#91;***&#93;&#160;&#160;&#160;&#160;EMAIL&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#47;s&#47; Stephen Hoge</font></div><div style="padding-left:17.1pt;text-indent:-14.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:5pt;padding-left:17.85pt;text-indent:-15.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">BY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">23 April 2021</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 2 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:30pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00005) is to&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Revise Section A and Section C to recognize 8.0mL fill volume (1600mcg) &#91;***&#93; along with the 6.3mL fill volume (1260mcg) &#91;***&#93; currently on contract (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Add H. &#91;***&#93; Invoicing, to Section H (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount remain unchanged.</font></div><div style="margin-bottom:30pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms and conditions remain unchanged.  Please see below for details.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION A -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">SOLICITATION&#47;CONTRACT FORM</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.28pt">The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division has a requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses (100 pg) in support of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND).  the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA).  All doses of mRNA-1273 Vaccine referenced herein are &#91;***&#93;.  All doses will be delivered in a multi-dose vial containing either 6.3mL fill volume (1260mcg) &#91;***&#93; (manufactured as described in Moderna&#8217;s FDA concurrence letter dated 01 April 2021 or 8.0mL fill volume (1600mcg) &#91;***&#93; (as described in Moderna&#8217;s FDA submission dated (01 April 2021).</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 3 of 23</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION C -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.82pt">DESCRIPTIONS AND SPECIFICATIONS</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF WORK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">SCOPE.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Background</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#8217;s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and&#47;or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Objective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The objective of this effort is to obtain the following&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Base Period&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 1&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 2&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 3&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 4&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Period is &#91;***&#93;, with overlapping options for a total of &#91;***&#93; if all options are exercised.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Consistent with the Updated EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) dated 01 April 2021, up to &#91;***&#93; may be extracted from Moderna&#8217;s newly authorized multidose vials with 8.0mL fdl volume (1600mcg).  The Government and Moderna agree that &#91;***&#93; per vial are only attainable using premium low dead volume (LDV) syringes, which are in short supply globally.  Utilizing initial ancillary equipment, vaccine administration personnel can reliably extract &#91;***&#93; from these vials&#59; however, the Government has identified needle&#47;syringe combinations that can be used to extract &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Given the two parties&#8217; shared interest in reducing vaccine waste and accelerating the availability of Moderna&#8217;s SARS-CoV-2 vaccine doses, the Government and Moderna intend that the Moderna vaccines doses be administered with needles and syringes compatible with extraction of &#91;***&#93; when possible.  Toward this end, the Government shall maintain a list of syringe and&#47;or needle combinations which will allow extraction of &#91;***&#93; per 8.0mL vial, which list shall be updated jointly by the Government and Moderna as any additional syringe and&#47;or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 4 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needle combinations compatible with extraction of &#91;***&#93;&#47;vial are identified.  Furthermore, the Government will, to the extent that appropriate needles and syringes are available, assemble and ship kits containing sufficient quantities of syringes and needles compatible with extraction of &#91;***&#93; per vial (Kit Moderna &#91;***&#93;) with Moderna&#8217;s SARS-CoV-2 vaccine.  The Government expects that these kits will be available beginning 01 May 2021 for a significant portion of Moderna&#8217;s remaining deliveries.  If, however, appropriate syringes and needles are not available, the Government will revert to shipping the Kit Moderna &#91;***&#93; with Moderna&#8217;s SARS-CoV-2 vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">APPLICABLE DOCUMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">Federal Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Title 21 Code of Federal Regulations (CFR), Food and Drugs&#58; Part 210.  Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs&#59; General&#59; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs&#59; General.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(https&#58;&#47;&#47;www.ecfr.gov&#47;cgi-bin&#47;text-idx&#63;SID&#61;a95cab20f443897a400bb7e44a27cf4c&#38;mc&#61;true&#38;tpl&#61;&#47;ecfrbrowse&#47;Title21&#47;21cfrv4_02.tpl#0)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">REQUIREMENTS.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, &#8220;Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)&#8221;), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">Contract Line Item Number (CLIN) 0001 - Base Period&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207.  Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including &#8220;Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&#38;C Act&#8221; (April 2020).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 5 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond &#91;***&#93; days of product release, the contract will be subject to modification for acceptance purposes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer&#8217;s Representative (COR) within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 1001 - Option Period 1&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27. 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 6 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drags and biologies for the following, but not limited to&#58; FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 2001 - Option Period 2&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207.  Registration of Producers of Drags and Listing of Drags in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that the product complies with the Drag Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 7 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 3001 - Option Period 3&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207.  Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 8 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 4001 - Option Period 4&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.3.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.28pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 9 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002&#58; Data Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 14230, provided at Appendix A.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">Bulk-mRNA,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulated LNPs, and the fill, finish, and released product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor&#8217;s fill&#47;finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Expiring Items Report (CDRL A006) for all FDP in the USG&#8217;s possession.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Key Personnel Listing (CDRL A007).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Mo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">nthl</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided &#8220;COVID-19 Dose Tracking Template&#8221; (CDRL Attachment 0003).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Product Acceptance Report (for each lot of Drug Product).  The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Incident Report.  The contractor shall communicate to BARD A and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and&#47;or cost and&#47;or performance in accordance with CDRL A016.  &#8220;Significant&#8221; is frequently defined as a &#91;***&#93; or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost&#47;schedule impact, such as breach of GCP during a clinical study, shall also be reported.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 10 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL AO 17.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL A018.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug&#47;biologic product to ensure conformity with &#167;501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&#38;C Act, Title 21 United States Code (USC) &#167;351 (a)(2)(B)), regarding good manufacturing practices (GMP).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide Meeting Minutes IAW CDRL A021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Kickoff Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Bi-Weekly Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The contractor shall provide an Agenda, IAW CDRL A020&#59; Meeting Minutes in accordance with CDRL A021&#59; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Daily &#8220;Check-In&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in a daily &#8220;check-in&#8221; (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours&#8217; notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Access and General Protection&#47;Security Policy and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and&#47;or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor&#8217;s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Security Program and Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 11 of 23</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement.  The contractor&#8217;s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL AO 19.  and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  Titis plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Operational Security (OPSEC)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)ZPlan IAW CDRL A024.  The contractor shall identify in the SOP&#47;Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002 Vendor Managed Inventory (VMI)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Contractor shall provide the capability to store the vaccine for up to &#91;***&#93;, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C. 3.1.1.6. ensure the product storage of FDP doses for up to &#91;***&#93; prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  &#91;***&#93;  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within &#91;***&#93; of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident.  BARDA&#47;JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective&#47;Preventive actions within &#91;***&#93; of detection of an incident with potential to impacts product quality.  BARDA&#47;JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations &#91;***&#93; in the United States.  The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted &#91;***&#93;.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The vaccine product shall be shipped and tracked by the distribution vendor&#8217;s shipping tracking number, to the USG-designated sites within the continental United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;.  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION G -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">CONTRACT ADMINISTRATION DATA</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Procuring Contracting Officer&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Bldg. 1, General Greene Avenue<br>Natick, MA 01760-5011</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract Specialist&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 12 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br>Bldg. 1, General Greene Avenue<br>Natick, MA 01760-5011</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT TECHNICAL POINT OF CONTACT</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Biologist&#47;Project Officer<br>200 C Street. SW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, DC 20201</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">CONTRACTOR&#8217;S</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Moderna US, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 Technology SQ.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PLACES</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> OF PERFORMANCE</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna US, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 Technology SQ.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">NOTIFICATION</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> OF REVISIONS AND CHANGE</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO&#47;ACO or office of the PCO&#47;ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PERFORMANCE</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> BASED PAYMENT</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option I AW the following schedule&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:24.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLIN</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERIOD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AA</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;90,210,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AB</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;132,308,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;180,420,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;198,462,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;601,400,000</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br><br></font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delivery Invoicing&#58; PBPs are a type of contract financing and are recouped by the Government through deductions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 13 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of payments otherwise due to the contractor for the partial or complete delivery of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items.  Attachment 0008, Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008 dated 4 December 2020.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252.232-&#160;&#160;&#160;&#160;7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Definitions.  As used in this clause&#8212;</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Department of Defense Activity Address Code (DoDAAC)&#8221; is a six position code that uniquely identifies a unit, activity, or organization.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Document type&#8221; means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Local processing office (LPO)&#8221; is the office responsible for payment certification when payment certification is done external to the entitlement system.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Payment request&#8221; and &#8220;receiving report&#8221; are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Electronic invoicing.  The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">WAWF access.  To access WAWF, the Contractor shall&#8212;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Have a designated electronic business point of contact in the System for Award Management at </font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.sam.gov</font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Be registered to use WAWF at </font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;wawf.eb.mil&#47;</font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following the step-by-step procedures for self-registration available at this web site.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">WAWF training.  The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF.  Both can be accessed by selecting the &#8220;Web Based Training&#8221; link on the WAWF home page at </font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;wawf.eb.miF</font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">WAWF methods of document submission.  Document submissions may be via web entry.  Electronic Data Interchange, or File Transfer Protocol.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">WAWF payment instructions.  The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Document type.  The Contractor shall submit payment requests using the following document type(s)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMBO</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">For fixed price line items&#8212;</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 14 of 23</font></div></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invoice and receiving report document type</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B) For services that do not require shipment of a deliverable, submit either the Invoice 2-in-1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">For customary progress payments based on costs incurred, submit a progress payment request.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">For performance based payments, submit a performance based payment request.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For commercial item financing, submit a commercial item financing request.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Document routing.  The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.</font></div><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Routing Data Table</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.371%"><tr><td style="width:1.0%"></td><td style="width:49.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Field Name in HA IFF</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data to be entered in WA WF</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pay Official DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HQ0337</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issue By DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Admin DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S2206A</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspect By DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W56XNH</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceptor</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ship To</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TDB</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Payment request.  The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Receiving report.  The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">WAWF point of contact.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity&#8217;s WAWF point of contact.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; &#47; DCMA Boston-AFAW, Administrative Contracting Officer &#47; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Contact the WAWF helpdesk at &#91;***&#93;, if assistance is needed.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of clause)</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR REFERENCE&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DFARS PGI 204.7108 Payment Instructions Table</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 15 of 23</font></div></div><div style="margin-bottom:0.12pt"><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.acq.osd.mi1&#47;dpap&#47;dars&#47;pgi&#47;pgihtm&#47;current&#47;PGI204_71.htm#payment_instructions</font></div><div id="i36f8765b633b4ca08c44f4a402810b5d_492"></div><div style="margin-bottom:0.24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION H -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.1</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable.  Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.2</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Substitution of Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.3</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Disclosure of Information&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 16 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractors employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.4</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services.  Office of the Assistant Secretary&#8217; for Preparedness and Response.  Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.5</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 17 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.6</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8220;Technology&#8221;).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; of award.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.7</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Performance Based Payment Liquidated under Termination</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna&#8217;s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2.  Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.8</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Public Readiness and Emergency Preparedness (PREP) Act&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 18 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19. 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4. 2020), and amended on April 15. 2020. 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the CO VID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor CO VID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items and technology covered by tins Contract are being developed for both civil and military applications.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.9</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">&#91;***&#93; .</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.10</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.11</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.12</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of performance under this contract, the Government may require storage of the filled drag product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.13</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.14</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Novation</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 19 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Moderna TX, Inc.  This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.15</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, &#91;***&#93; above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  Moderna will reduce the cost of Option 2 by &#91;***&#93; for each successfully accelerated drag product fill under the Base Period &#91;***&#93; and &#91;***&#93; for each successfully accelerated drag product fill under Option 1 &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.  If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government &#91;***&#93; for &#91;***&#93; and &#91;***&#93; for &#91;***&#93;.  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fdl reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.) Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.)Cancellation notice to the subcontractor,<br>ii.) The basis of the cancellation, and<br>iii.) Cancellation fees incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause.  IAW agreed cancellation costs incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.16</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Delivery Schedule, as revised H Feb 2021 via modification P00004</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna confirms that it will provide the USG with the first 300M doses manufactured within its US-based supply chain &#91;***&#93;, with the exception of doses required for clinical studies.  The delivery schedule assumes that Moderna will work to further maximize fill&#47;finish capacity by working with the FDA to increase fill volumes, &#91;***&#93;.  Both parties acknowledge that resulting revisions to future accounting, invoicing, acceptance and delivery of doses subject to the revised label will be implemented via a subsequent modification.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.17</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Post-Termination Disposition of Undelivered Product</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 20 of 23</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.18</font><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;. </font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to facilitate projections and invoicing, the Government shall provide or direct a third party (e.g., McKesson) to provide to Moderna (1) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; (2) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; and (3) the number of &#91;***&#93; remaining in inventory and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with a &#91;***&#93;.</font></div><div style="margin-bottom:30pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both parties acknowledge that the delivery schedule is based on &#91;***&#93; 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna&#8217;s delivery requirement, &#91;***&#93;.  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period.  Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>&#91;***&#93;<br>Page 21 of 23</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.59pt">LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page #</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Plan</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx. Inc. Background Intellectual Property</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 December 2020</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_16"></div><hr style="page-break-after:always"><div style="min-height:59.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:0.24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.860%"></td><td style="width:0.1%"></td></tr><tr style="height:19pt"><td colspan="30" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></div></td><td colspan="15" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></div></td></tr><tr style="height:10pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">24</font></div></td></tr><tr><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">P00006</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4-Jun-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5. PROJECT NO.(If applicable)</font></td></tr><tr style="height:10pt"><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6. ISSUED BY</font></div><div style="margin-bottom:36pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W6QK ACC-APG NATICK DIVISION<br>BLDG 1 GENERAL GREENE AVENUE<br>NATICK MA 01760-5011</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W911QY</font></td><td colspan="18" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item 6)&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DEFENSE CONTRACT MANAGEMENT AGENCY<br>DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></div></td><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">S2206A</font></td></tr><tr style="height:68pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="24" rowspan="4" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:10pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:19pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W911QY20C0100</font></div></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">09-Aug-2020</font></div></td></tr><tr style="height:10pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:26.1pt;text-indent:-23.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8PTM0</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FACILITY CODE</font></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt 0 3.15pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended,&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; <br>(a) By completing Items 8 and 15, and returning&#160;&#160;&#160;&#160;copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59;<br>or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE<br>RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION<br>OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Schedule</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM&#160;10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:12.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor&#160;&#160;&#160;&#160; </font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not,&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is required to sign this document and return </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> copies to the issuing office.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)<br>Modification Control Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:36pt;padding-left:12.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.</font></div></td></tr><tr><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15A. NAME AND TITLE OF SIGNER (Type or print) </font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Stephane Bancel, CEO</font></div></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">TEL&#58; &#91;***&#93;&#160;&#160;&#160;&#160;EMAIL&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephane Bancel</font></div><div style="padding-left:17.1pt;text-indent:-14.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:5pt;padding-left:17.85pt;text-indent:-15.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">BY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4 Jun 2021</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 2 of 24</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $3,993,662.60</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00006) is to&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Change the Purchasing Office from W911QY (NCD) to W58P05 (JCRD)&#59; the new Contracting Officer is &#91;***&#93; and Contract Specialist remains unchanged (Authority FAR 52.243-1)</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Update CLIN 0002 pricing for VMI Storage and obligate funding of $1,355,232.80&#59; revise CLIN structure for 0002 to add 0002AA, 0002AB, 00002AC&#59; void out CLINs 1002, 2002, 3002, 4002 (Authority FAR 52.243-1).</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Add Accelerated Distribution CLINs 0005, 0005AA, 0005AB, 0005AC, and fund in the amount of $2,638,429.80 (Authority FAR 43.103(a)).</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Revise Section E, Inspect and Acceptance (Authority FAR 52.243-1).</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Revise the Acceptor DODAAC from W911QY to W58P05 in FAR Clause 252.232-7006 (Authority FAR 52.243-1)</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total value of the contract has increased by $3,993,662.60 from $8,141,598,000 to $8,145,591,662.60.  The total funded amount has increased by $3,993,662.60 from $4,841,598,000 to $4,845,591,662.60.</font></div><div style="margin-bottom:48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms and conditions remain unchanged.  Please see below for details.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $1,650,000,000</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00004) is to&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Exercise, fund Option 2 CLINs 2001AA, 2001AB, 2001AC for a total of $1,650,000,000 (Authority FAR 52.217- 7)</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Add clauses H. 16 &#38; H. 17, and revise the delivery schedule for the Base period, Option 1, and Option 2 IAW the table contained within H. 16 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 3 of 24</font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Revise the table in Section G back to previous amounts, due to an administrative error on modification no. P00003, where the amounts were revised (Authority FAR 52.232-16)</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Update Contract Data Requirement List (CDRL) no.&#8217;s A003, A008, A009, A011, A014, A021, and the corresponding information to the CDRLs in Section C, Statement of Work, (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount has increased by $ 1.650.000.000 from $3.191.598.000 to $4,841,598,000.</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms and conditions remain unchanged.  Please see below for details.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION A -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">SOLICITATION&#47;CONTRACT FORM</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this contract was increased by $3,993,662.60 from $4,841,598,000.00 to $4,845,591,662.60.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8216;administered by&#8217; organization has changed from</font></div><div style="margin-bottom:30pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DEFENSE CONTRACT MANAGEMENT AGENCY<br>DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138<br>to<br>DEFENSE CONTRACT MANAGEMENT AGENCY<br>DCMA BOSTON<br>37 GRENIER STREET, BLDG. 1108<br>HANSCOM AIR FORCE BASE MA 01731 -1600</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION B - SUPPLIES OR SERVICES AND PRICES</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 0002</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has increased by 11.00 from 1.00 to 12.00.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unit price amount has increased by $112,936.07 from $0.00 to $112,936.067.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unit of issue has changed from Job to Months.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost constraint TBN has been deleted.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this line item has increased by $1,355,232.80 from $0.00 to $1,355,232.80.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 1002</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. </font></div><div style="margin-bottom:24pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 4 of 24</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.</font></div><div style="margin-bottom:30pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.<br>The unit of issue Job has been deleted.<br>The option status has changed from Option to No Status.<br>The cost constraint TBN has been deleted.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 2002<br>The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.<br>The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. </font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.</font></div><div style="margin-bottom:30pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.<br>The unit of issue Job has been deleted.<br>The option status has changed from Option to No Status.<br>The cost constraint TBN has been deleted.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 3001<br>The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 3002</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 5 of 24</font></div></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.</font></div><div style="margin-bottom:30pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.<br>The unit of issue Job has been deleted.<br>The option status has changed from Option to No Status.<br>The cost constraint TBN has been deleted.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 4001</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), I AW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 4002</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. </font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.<br>The unit of issue Job has been deleted.<br>The option status has changed from Option to No Status.<br>The cost constraint TBN has been deleted.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 6 of 24</font></div></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 0005 is added as follows&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ITEM NO</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0005</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated Distribution<br>FFP<br>&#91;***&#93; associated with Base, Option 1, and Option 2 periods (300M doses total) to meet fluctuating CDC allocation requirements &#91;***&#93;.</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NET AMT</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 005AA is added as follows&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ITEM NO</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">00055AA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Job</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base Period<br>FFP<br>&#91;***&#93;<br>FOB&#58; Destination<br>PURCHASE REQUEST NUMBER&#58; &#91;***&#93;<br>PSC CD&#58; 6505</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NET AMT</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN AJ<br>CIN&#58; GFEBS001165492700002</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 0005AB is added as follows&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ITEM NO</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0005AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Job</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option 1 Period<br>FFP<br>&#91;***&#93;<br>FOB&#58; Destination<br>PURCHASE REQUEST NUMBER&#58; &#91;***&#93;<br>PSC CD&#58; 6505</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NET AMT</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN AJ<br>CIN&#58; GFEBS001165492700003</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 0005AC is added as follows&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ITEM NO</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0005AC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Job</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;.  </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58;  Destination PURCHASE REQUEST NUMBER&#58; &#91;***&#93; </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSC CD&#58;  6505</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NET AMT</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN AJ<br>CIN&#58; GFEBS001165492700004</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$879,476.60</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION C -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.82pt">DESCRIPTIONS AND SPECIFICATIONS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 7 of 24</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF WORK<br>LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">SCOPE.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Background</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#8217;s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary&#8217; of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to CO VID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and&#47;or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Objective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The objective of this effort is to obtain the following&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Base Period&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 1&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 2&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 3&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 4&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Period is &#91;***&#93;, with overlapping options for a total of &#91;***&#93; if all options are exercised.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Consistent with the Updated EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) dated 01 April 2021, up to &#91;***&#93; may be extracted from Moderna&#8217;s newly authorized multidose vials with 8.0mL fill volume (1600mcg).  The Government and Moderna agree that &#91;***&#93; per vial are only attainable using premium low dead volume (LDV) syringes, which are in short supply globally.  Utilizing initial ancillary equipment, vaccine administration personnel can reliably extract &#91;***&#93; from these vials&#58; however, the Government has identified needle&#47;syringe combinations that can be used to extract &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Given the two parties&#8217; shared interest in reducing vaccine waste and accelerating the availability of Moderna&#8217;s SARS-CoV-2 vaccine doses, the Government and Moderna intend that the Moderna vaccines doses be administered with needles and syringes compatible with extraction of &#91;***&#93; when possible.  Toward this end, the Government shall maintain a list of syringe and&#47;or needle combinations which will allow extraction of &#91;***&#93; per 8.0mL vial, which list shall be updated jointly by the Government and Moderna as any additional syringe and&#47;or needle combinations compatible with extraction of &#91;***&#93;&#47;vial are identified.  Furthermore, the Government will, to the extent that appropriate needles and syringes are available, assemble and ship kits containing sufficient quantities of syringes and needles compatible with extraction of &#91;***&#93; per vial (Kit Moderna &#91;***&#93;) with Moderna&#8217;s SARS-CoV-2 vaccine.  The Government expects that these kits will be available beginning 01 May 2021 for a significant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 8 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">portion of Moderna&#8217;s remaining deliveries.  If, however, appropriate syringes and needles are not available, the Government will revert to shipping the Kit Moderna &#91;***&#93; with Moderna&#8217;s SARS-CoV-2 vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">APPLICABLE DOCUMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">Federal Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Title 21 Code of Federal Regulations (CFR), Food and Drugs&#58; Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs&#59; General&#59; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs&#59; General.  (https&#58;&#47;&#47;www.ecfr.gov&#47;cgi-bin&#47;text- idx&#63;SID&#61;a95cab20f443897a400bb7e44a27cf4c&#38;mc&#61;tme&#38;tpl&#61;&#47;ecfrbrowse&#47;Title21&#47;21cfrv4_02.tpl#0)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">REQUIREMENTS.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, &#8220;Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)&#8221;), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">Contract Line Item Number (CLIN) 0001 - Base Period&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002.  FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including &#8220;Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&#38;C Act&#8221; (April 2020).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG.  Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 9 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond &#91;***&#93; days of product release, the contract will be subject to modification for acceptance purposes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARD A and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer&#8217;s Representative (COR) within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 1001 - Option Period 1&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 10 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 2001 - Option Period 2&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA).  Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability&#8217; and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery&#8217; location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL AOOL</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 11 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third part) in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if am are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 3001 - Option Period 3&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA).  Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory&#8217; (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 12 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 4001 - Option Period 4&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 13 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002&#58; Data Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, formulated LNPs, and the fill, finish, and released product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor&#8217;s fill&#47;finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Expiring Items Report (CDRL A006) for all FDP in the USG&#8217;s possession.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Key Personnel Listing (CDRL A007).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided &#8220;COVID-19 Dose Tracking Template&#8221; (CDRL Attachment 0003).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Product Acceptance Report (for each lot of Drug Product).  The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Incident Report.  The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and&#47;or cost and&#47;or performance in accordance with CDRL A016.  &#8220;Significant&#8221; is frequently defined as a &#91;***&#93; or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost&#47;schedule impact, such as breach of GCP during a clinical study, shall also be reported.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL AO 17.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 14 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL AO 18.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug&#47;biologic product to ensure conformity&#8217; with &#167;501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&#38;C Act, Title 21 United States Code (USC) &#167;351 (a)(2)(B)), regarding good manufacturing practices (GMP).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide Meeting Minutes IAW CDRL A021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Kickoff Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Bi-Weekly Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The contractor shall provide an Agenda.  IAW CDRL A020&#59; Meeting Minutes in accordance with CDRL A02L and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Daily &#8220;Check-In&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in a daily &#8220;check-in&#8221; (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours&#8217; notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Access and General Protection&#47;Security Policy and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall provide all information required for background checks necessary&#8217; to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and&#47;or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor&#8217;s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Security Program and Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG&#8217;s requirement.  The contractor&#8217;s security&#8217; practices and procedures shall be detailed in a Security Plan, in accordance with CDRL A019, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  This plan shall be delivered to the USG within 45 days of award, and the USG </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 15 of 24</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Operational Security (OPSEC)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)ZPlan IAW CDRL A024.  The contractor shall identify in the SOP&#47;Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002 Vendor Managed Inventory (VMI)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor shall provide the capability to store the vaccine for up to &#91;***&#93;, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to &#91;***&#93; prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  &#91;***&#93;.  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within &#91;***&#93; of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident.  B ARDA&#47;JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective&#47;Preventive actions within &#91;***&#93; of detection of an incident with potential to impacts product qualify, BARDA&#47;JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations &#91;***&#93; in the United States.  The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The vaccine product shall be shipped and tracked by the distribution vendor&#8217;s shipping tracking number, to the USG-designated sites within the continental United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;.  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION E -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.38pt">INSPECTION AND ACCEPTANCE</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Acceptance&#47;Inspection Schedule was added for CLIN 0005&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT BY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT BY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Acceptance&#47;Inspection Schedule was added for SUBCLIN 0005AA&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT BY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT BY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Acceptance&#47;Inspection Schedule was added for SUBCLIN 0005AB&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT BY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT BY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 16 of 24</font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Acceptance&#47;Inspection Schedule was added for SUBCLIN 0005AC&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT BY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT BY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.4pt">Inspection&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine CLINs&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality inspection of Filled Drug Product (FDP) shall occur when the Contractor performs release testing to confirm that products complies with Contractor&#8217;s release specifications and criteria.  Contractor will submit the Certificate of Analysis for quality inspection of all drug product lots in BARDA Data Infrastructure (BDI) system.  Initial Inspection under this contract will be performed at the Contractor&#8217;s facility, or the subcontractor facility, by the BARDA Contracting Officer Technical Representative (COTR).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government shall inspect each shipment of product delivered to it hereunder for visible damage and quantity &#91;***&#93; of final delivery.  In the event Contractor supplies any product to the Government and it is established that such Product was damaged or does not include the required quantities at the time of final delivery, the Government shall promptly notify Contractor in writing &#91;***&#93;.  A BDI extract of the inspection documentation shall also be submitted in Wide Area Workflow (WAWF) as supporting documentation for invoice submittals.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Storage CLIN&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspection of storage under this contract will be performed at destination by a duly authorized representative of the Government.  Contractor shall submit an invoice into WAWF at the end of each month during the period of performance specified.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated Distribution CLIN&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspection of Accelerated Distribution shall occur at origin when the Contractor completes deliveries for each ordering period&#58; a).  Base Period, b).  Option 1 Period, and c).  Option 2 Period.  Contractor shall submit an invoice against the appropriate subCLIN under CLIN 0005 in WAWF, accordingly.  Inspection will be conducted by the BARDA Contracting Officer&#8217;s Technical Representative (COTR) to ensure all vaccines doses have been delivered.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data CLIN&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspection of all reports and Contract Data Requirement List (CDRL) under this contract will be performed at Destination by a duly authorized representative of the Government.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.4pt">Acceptance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  Acceptance &#91;***&#93;.  Acceptance &#91;***&#93;.  Regardless of where acceptance occurs, the contractor is responsible for final delivery of Filled Drug Product (FDP) to a government designated CDC location.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  Acceptance of vaccines under this agreement will be performed by the COTR in the BDI system, which constitutes government acceptance at origin.  Documentation of acceptance shall be submitted in accordance with WAWF instructions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.  Acceptance of storage &#38; accelerated distribution shall occur in WAWF by the KO.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 17 of 24</font></div></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.  The parties acknowledge that acceptance may depend on the compliance with the Contractor&#8217;s product specifications.  The KO and COR may prior to acceptance consult with FDA under its authority under Public Law 115-92 to determine whether the material to be delivered meets the Contractor&#8217;s product specifications.  To this end, Contractor agrees to provide a letter to FDA authorizing the Government to engage in dialog with FDA about the ultimate compliance of this product with the Contractor&#8217;s product specifications prior to acceptance.  BARDA&#47;COR will accept product according to the approved Product Acceptance Procedure.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION F -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.92pt">DELIVERIES OR PERFORMANCE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule Item has been deleted from CLIN 0002&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A<br>FOB&#58; Destination</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item has been added to CLIN 0002&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery&#8217; Schedule for SUBCLIN 0005AA has been added&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule for SUBCLIN 0005AB has been added&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule for SUBCLIN 0005AC has been added&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 18 of 24</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery&#8217; Schedule for CLIN 1002 has been deleted&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A<br>FOB&#58; Destination </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule for CLIN 2002 has been deleted&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A<br>FOB&#58; Destination </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule for CLIN 3002 has been deleted&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A<br>FOB&#58; Destination</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule for CLIN 4002 has been deleted&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A<br>FOB&#58; Destination</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION G -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">CONTRACT ADMINISTRATION DATA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting and Appropriation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary for the Payment Office</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this modification, the total funded amount for this document was increased by $3,993,662.60 from $4,841,598,000.00 to $4,845,591,662.60.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 0002&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AJ&#58; &#91;***&#93; was increased by $1,355,232.80 from $0.00 to $1,355,232.80</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AJ has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 0005AA&#58;<br>Funding on SUBCLIN 0005AA is initiated as follows&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">ACRN&#58; AJ</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 19 of 24</font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIN&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acctng Data&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase&#58; $879,476.60</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total&#58; $879,476.60</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 0005AB&#58;<br>Funding on SUBCLIN 0005AB is initiated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN&#58; AJ</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIN&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acctng Data&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase&#58; $879,476.60</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total&#58; $879,476.60</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 0005AC&#58;<br>Funding on SUBCLIN 0005AC is initiated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN&#58; AJ</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIN&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acctng Data&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase&#58; $879,476.60</font></div><div style="margin-bottom:24pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total&#58; $879,476.60</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Procuring Contracting Officer&#58;<br>&#91;***&#93;<br>Joint COVID-19 Response Division<br>US Army Contracting Command<br>6472 Integrity Court (Building 4401)<br>Aberdeen Proving Ground, MD 21005-3013</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract Specialist&#58;<br>&#91;***&#93;<br>Joint COVID-19 Response Division</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 20 of 24</font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br>US Army Contracting Command<br>6472 Integrity Court (Building 4401)<br>Aberdeen Proving Ground, MD 21005-3013</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT TECHNICAL POINT OF CONTACT</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Biologist&#47;Project Officer<br>200 C Street, SW<br>Washington, DC 20201</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">CONTRACTOR&#8217;S CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Moderna US, Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PLACES OF PERFORMANCE</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna US. Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">NOTIFICATION OF REVISIONS AND CHANGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO&#47;ACO or office of the PCO&#47;ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PERFORMANCE BASED PAYMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table dated 4 May 2021.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option I AW the following schedule&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:24.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLIN</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERIOD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AA</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;90,210,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AB</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;132,308,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;180,420,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;198,462,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;601,400,000</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 21 of 24</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delivery Invoicing&#58; PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items. Attachment 0008.  Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252.232-&#160;&#160;&#160;&#160;7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Definitions.  As used in this clause&#8212;</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Department of Defense Activity Address Code (DoDAAC)&#8221; is a six position code that uniquely identifies a unit, activity, or organization.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Document type&#8221; means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Local processing office (LPO)&#8221; is the office responsible for payment certification when payment certification is done external to the entitlement system.</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Payment request&#8221; and &#8220;receiving report&#8221; are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Electronic invoicing.  The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">WAWF access.  To access WAWF.  the Contractor shall&#8212;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Have a designated electronic business point of contact in the System for Award Management at </font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.sam.gov</font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Be registered to use WAWF at </font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;wawf.eb.mil&#47;</font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following the step-by-step procedures for self-registration available at this web site.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">WAWF training.  The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF.  Both can be accessed by selecting the &#8220;Web Based Training&#8221; link on the WAWF home page at </font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;wawf.eb.miF</font><font style="color:#3a51a2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">WAWF methods of document submission.  Document submissions may be via web entry.  Electronic Data Interchange, or File Transfer Protocol.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">WAWF payment instructions.  The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Document type.  The Contractor shall submit payment requests using the following document type(s)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMBO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 22 of 24</font></div></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">For fixed price line items&#8212;</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invoice and receiving report document type</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B) For services that do not require shipment of a deliverable, submit either the Invoice 2-in-1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N&#47;A</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">For customary progress payments based on costs incurred, submit a progress payment request.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">For performance based payments, submit a performance based payment request.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For commercial item financing, submit a commercial item financing request.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Document routing.  The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.</font></div><div style="padding-left:3.6pt;padding-right:3.6pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Routing Data Table</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.371%"><tr><td style="width:1.0%"></td><td style="width:49.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Field Name in HA IFF</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data to be entered in WA WF</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pay Official DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HQ0337</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issue By DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Admin DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S2206A</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspect By DoDAAC</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W56XNH</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceptor</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ship To</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;padding-right:3.6pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TDB</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Payment request.  The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Receiving report.  The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">WAWF point of contact.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity&#8217;s WAWF point of contact.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; &#47; DCMA Boston-AFAW.  Administrative Contracting Officer &#47; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Contact the WAWF helpdesk at &#91;***&#93;, if assistance is needed.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of clause)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 23 of 24</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR REFERENCE&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DFARS PGI 204.7108 Payment Instructions Table<br></font><font style="color:#0100f7;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.acq.osd.mi1&#47;dpap&#47;dars&#47;pgi&#47;pgi_htm&#47;current&#47;PGI204_71.htm#payment_instructions</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00006)<br>Page 24 of 24</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.59pt">LIST OF DOCUMENTS&#59; EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page #</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 December 2020</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_22"></div><hr style="page-break-after:always"><div style="min-height:59.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.090%"></td><td style="width:0.1%"></td></tr><tr style="height:10pt"><td colspan="30" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></div></td><td colspan="15" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></div></td></tr><tr style="height:10pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29</font></div></td></tr><tr><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">P00007</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15-Jun-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5. PROJECT NO.(If applicable)</font></td></tr><tr style="height:19pt"><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6. ISSUED BY</font></div><div style="margin-bottom:36pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W6QK ACC-APG NATICK DIVISION<br>BLDG 1 GENERAL GREENE AVENUE<br>NATICK MA 01760-5011</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W58Po5</font></td><td colspan="18" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item 6)&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DEFENSE CONTRACT MANAGEMENT AGENCY<br>DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></div></td><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">S2206A</font></td></tr><tr style="height:60pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="24" rowspan="4" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:10pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:19pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">W911QY20C0100</font></div></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">09-Aug-2020</font></div></td></tr><tr style="height:10pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:26.1pt;text-indent:-23.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8PTM0</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FACILITY CODE</font></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt 0 3.15pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended,&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; <br>(a) By completing Items 8 and 15, and returning&#160;&#160;&#160;&#160;copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59;<br>or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE<br>RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION<br>OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Schedule</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM&#160;10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:12.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor&#160;&#160;&#160;&#160; </font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not,&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is required to sign this document and return </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> copies to the issuing office.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)<br>Modification Control Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:36pt;padding-left:12.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.</font></div></td></tr><tr><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15A. NAME AND TITLE OF SIGNER (Type or print) </font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Stephane Bancel, CEO</font></div></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">TEL&#58; &#91;***&#93;&#160;&#160;&#160;&#160;EMAIL&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Stephane Bancel</font></div><div style="padding-left:17.1pt;text-indent:-14.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6&#47;15&#47;2021</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:5pt;padding-left:17.85pt;text-indent:-15.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">BY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15 June 2021</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">P00007</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $3,300,000,000.00</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of this modification (P00007) is to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Revise Section A (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Exercise, revise delivery schedule for, and fund Option 3 and 4 CLINs 3001, 3001AA, 3001AB, 3001AC, 3001AD, 4001, 4001AA, 4001AB, 4001AC for a total of $3,300,000,00 (Authority FAR 52.217-7)</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Update Contracting Officer (Authority FAR 43.103(b))</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Add Performance Based Payments for Options 3 and 4&#59; and revise the table in Section G, accordingly (Authority FAR 52.232-16)</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Add clause H.19 Product Variations (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Revise Attachment 0007, Performance Based Payment (PBP) Milestone Schedule, and Attachment 0008, PBP Milestone Billing Plan (Authority FAR 52.243-1).</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total funded amount has increased by $3,300,000,000 from $4,845,591,662.60 to $8,145,591,662.60.  The total contract value amount remains unchanged.</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms and conditions remain unchanged.  Please see below for details.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION A -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">SOLICITATION&#47;CONTRACT FORM</font></div><div style="margin-bottom:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this contract was increased by $3,300,000,000.00 from $4,845,591,662.60 to $8,145,591,662.60.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.28pt">The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division has a requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses (&#91;***&#93;) in support of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO- CBRND), the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 2 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All doses of mRNA-1273 Vaccine to satisfy the delivery requirements of CLINs 0001, 1001, and 2001 are 100 pg doses which will be delivered in a multi-dose vial containing either 6.3mL fill volume (1260mcg) &#91;***&#93; or 8.0mL fill volume (1600mcg) &#91;***&#93; (as described in Moderna&#8217;s COVID-19 Vaccine Authorized Fact Sheet and label).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifications of doses of mRNA-1273 Vaccine to satisfy the delivery requirements of CLINs 3001 and 4001 are described in Section H.19.</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery schedule for CLINs 3001 and 4001 may be concurrent with Moderna&#8217;s Biologics License Application and FDA approval of the SARS-CoV-2 vaccine.  Moderna agrees to continue to perform all regulatory efforts required to ensure that product delivered while the SARS-CoV-2 vaccine was under Emergency Use Authorization will remain available for use in the US.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION B -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.82pt">SUPPLIES OR SERVICES AND PRICES</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 3001</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), Clause no. H-19, and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUB CLIN 3001AA</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from 33.4M Doses to 25M Doses.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 8,400,000.00 from 33,400,000.00 to 25,000,000.00.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this line item has decreased by $138,600,000.00 from $551,100,000.00 to $412,500,000.00.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 3001AB</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from 33.4M Doses to 25M Doses.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 8,400,000.00 from 33,400,000.00 to 25,000,000.00.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this line item has decreased by $138,600,000.00 from $551,100,000.00 to $412,500,000.00.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUB CLIN 3001 AC</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from 33.2M Doses to 30M Doses.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 3,200,000.00 from 33.200.000.00 to 30,000,000.00.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of tins line item has decreased by $52,800,000.00 from $547,800,000.00 to $495,000,000.00.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN 4001</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN extended description has changed from&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 3 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), Clause no. 19, and CDRLs (Exhibit A) on this contract.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AA</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from 33.4M Doses to 10M Doses.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 23,400.000.00 from 33.400,000.00 to 10,000,000.00.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this line item has decreased by $386,100,000.00 from $551,100,000.00 to $165,000,000.00.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AB</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from 33.4M Doses to 28M Doses.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 5.400.000.00 from 33.400.000.00 to 28,000,000.00.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this line item has decreased by $89,100,000.00 from $551,100,000.00 to $462,000,000.00.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AC</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CLIN description has changed from 33.2M Doses to 28M Doses.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing detail quantity has decreased by 5,200,000.00 from 33.200.000.00 to 28,000,000.00.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option status has changed from Option to Option Exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of this line item has decreased by $85,800,000.00 from $547,800,000.00 to $462,000,000.00.</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 3001AD is added as follows&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ITEM NO</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3001AD EXERCISED OPTION</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20M Doses<br>FFP</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000,000</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.50</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$330,000,000.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a.  If executed, the option shall be awarded upon EUA or no later than &#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b.  The government shall provide &#91;***&#93; notification to exercise the option.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">FOB&#58; Destination</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PURCHASE REQUEST NUMBER&#58; &#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PROJECT&#58; Operation Warp Speed</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PSC CD&#58; 6505</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NET AMT</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$330,000,000.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN AM</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$330,000,000.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIN&#58; GFEBS001166190500004</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AD is added as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 4 of 29</font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ITEM NO</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4001AD EXERCISED OPTION</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34M Doses<br>FFP</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,000,000</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.50</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$561,000,000.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a.  If executed, the option shall be awarded upon EUA or no later than &#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b.  The government shall provide &#91;***&#93; notification to exercise the option.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">FOB&#58; Destination</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PURCHASE REQUEST NUMBER&#58; &#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PROJECT&#58; Operation Warp Speed</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PSC CD&#58; 6505</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NET AMT</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$561,000,000.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN AM</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$561,000,000.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIN&#58; GFEBS001166190500008</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION C -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.82pt">DESCRIPTIONS AND SPECIFICATIONS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF WORK<br>LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">SCOPE.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Background</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In December 2019, a novel coronavirus now known as SARS-Co V-2 was first detected in Wuhan, Hubei Province, People&#8217;s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to CO VID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and&#47;or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Objective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The objective of this effort is to obtain the following&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Base Period&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 5 of 29</font></div></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 1&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 2&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Option Period 3&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Option Period 4&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Period is &#91;***&#93;, with overlapping options for a total of &#91;***&#93; if all options are exercised.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Consistent with the Updated EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) dated 01 April 2021, up to &#91;***&#93; may be extracted from Moderna&#8217;s newly authorized multidose vials with 8.0mL fill volume (1600mcg).  The Government and Moderna agree that &#91;***&#93; per vial are only attainable using premium low dead volume (LDV) syringes, which are in short supply globally.  Utilizing initial ancillary equipment, vaccine administration personnel can reliably extract &#91;***&#93; from these vials&#59; however, the Government has identified needle&#47;syringe combinations that can be used to extract &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Given the two parties&#8217; shared interest in reducing vaccine waste and accelerating the availability of Moderna&#8217;s SARS-CoV-2 vaccine doses, the Government and Moderna intend that the Moderna vaccines doses be administered with needles and syringes compatible with extraction of &#91;***&#93; when possible.  Toward this end, the Government shall maintain a list of syringe and&#47;or needle combinations which will allow extraction of &#91;***&#93; per 8.0mL vial, which list shall be updated jointly by the Government and Moderna as any additional syringe and&#47;or needle combinations compatible with extraction of &#91;***&#93;&#47;vial are identified.  Furthermore, the Government will, to the extent that appropriate needles and syringes are available, assemble and ship kits containing sufficient quantities of syringes and needles compatible with extraction of &#91;***&#93; per vial (Kit Moderna &#91;***&#93;) with Moderna&#8217;s SARS-CoV-2 vaccine.  The Government expects that these kits will be available beginning 01 May 2021 for a significant portion of Moderna&#8217;s remaining deliveries.  If, however, appropriate syringes and needles are not available, the Government will revert to shipping the Kit Moderna &#91;***&#93; with Moderna&#8217;s SARS-CoV-2 vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">APPLICABLE DOCUMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">Federal Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Title 21 Code of Federal Regulations (CFR), Food and Drugs&#58; Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs&#59; General&#59; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs&#59; General.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(https&#58;&#47;&#47;www.ecfr.gov&#47;cgi-bin&#47;text-idx&#63;SID&#61;a95cab20f443897a400bb7e44a27cf4c&#38;mc&#61;tme&#38;tpl&#61;&#47;ecfrbrowse&#47;Title21&#47;21cfrv4_02.tpl#0)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">REQUIREMENTS.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, &#8220;Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)&#8221;), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">Contract Line Item Number (CLIN) 0001 - Base Period&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 6 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including &#8220;Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&#38;C Act&#8221; (April 2020).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond &#91;***&#93; of product release, the contract will be subject to modification for acceptance purposes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer&#8217;s Representative (COR) within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 1001 - Option Period 1&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 7 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 2001 - Option Period 2&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 8 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability&#8217; and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery&#8217; location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL AOOL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if am are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 3001 - Option Period 3&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 9 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA).  Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory&#8217; (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.4.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to&#58; FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.34pt;text-decoration:underline">CLIN 4001 - Option Period 4&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of &#91;***&#93;.  (Based on FDP stability data that supports a &#91;***&#93; shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 10 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Audits.  The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.3.5.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.34pt">FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002&#58; Data Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, formulated LNPs, and the fill, finish, and released product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor&#8217;s fill&#47;finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Expiring Items Report (CDRL A006) for all FDP in the USG&#8217;s possession.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Key Personnel Listing (CDRL A007).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 11 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided &#8220;COVID-19 Dose Tracking Template&#8221; (CDRL Attachment 0003).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Product Acceptance Report (for each lot of Drug Product).  The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Incident Report.  The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and&#47;or cost and&#47;or performance in accordance with CDRL A016.  &#8220;Significant&#8221; is frequently defined as a &#91;***&#93; or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost&#47;schedule impact, such as breach of GCP during a clinical study, shall also be reported.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL AO 17.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL AO 18.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.34pt">Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug&#47;biologic product to ensure conformity&#8217; with &#167;501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&#38;C Act, Title 21 United States Code (USC) &#167;351 (a)(2)(B)), regarding good manufacturing practices (GMP).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.84pt">The contractor shall provide Meeting Minutes IAW CDRL A021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Post Award Kickoff Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Bi-Weekly Teleconference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The contractor shall provide an Agenda.  IAW CDRL A020&#59; Meeting Minutes in accordance with CDRL A02L and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 12 of 29</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Daily &#8220;Check-In&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall participate in a daily &#8220;check-in&#8221; (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours&#8217; notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt">Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Access and General Protection&#47;Security Policy and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall provide all information required for background checks necessary&#8217; to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and&#47;or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor&#8217;s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Security Program and Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG&#8217;s requirement.  The contractor&#8217;s security&#8217; practices and procedures shall be detailed in a Security Plan, in accordance with CDRL AO 19, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt;text-decoration:underline">Operational Security (OPSEC)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)Plan IAW CDRL A024.  The contractor shall identify in the SOP&#47;Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.84pt;text-decoration:underline">CLIN 0002 Vendor Managed Inventory (VMI)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Contractor shall provide the capability to store the vaccine for up to &#91;***&#93;, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to &#91;***&#93; prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  &#91;***&#93;  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within &#91;***&#93; of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident.  BARDA&#47;JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective&#47;Preventive actions within &#91;***&#93; of detection of an incident with potential to impacts product qualify.  BARDA&#47;JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations &#91;***&#93; in the United States.  The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">The vaccine product shall be shipped and tracked by the distribution vendor&#8217;s shipping tracking number, to the USG-designated sites within the continental United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.34pt">&#91;***&#93;.  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 13 of 29</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION E -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.38pt">INSPECTION AND ACCEPTANCE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Acceptance&#47;Inspection Schedule was added for SUBCLIN 3001AD&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT BY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT BY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Acceptance&#47;Inspection Schedule was added for SUBCLIN 4001AD&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INSPECT BY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT AT</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCEPT BY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Origin</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION F -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.92pt">DELIVERIES OR PERFORMANCE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 3001AA has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 3001AB has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 3001AC has been changed from&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 14 of 29</font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule for SUBCLIN 3001 AD has been added&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 4001AA has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery&#8217; Schedule item for SUBCLIN 4001AB has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 15 of 29</font></div></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule item for SUBCLIN 4001AC has been changed from&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Delivery Schedule for SUBCLIN 4001AD has been added&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DODAAC &#47;<br>CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOB&#58; Destination </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION G -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">CONTRACT ADMINISTRATION DATA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting and Appropriation Summary for the Payment Office</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this modification, the total funded amount for this document was increased by $3,300,000,000.00 from $4,845,591,662.60 to $8,145,591,662.60.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 3001AA&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AK&#58; &#91;***&#93; was increased by $412,500,000.00 from $0.00 to $412,500,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AK has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 3001AB&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AK&#58; &#91;***&#93; was increased by $412,500,000.00 from $0.00 to $412,500,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AK has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 3001 AC&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AL&#58; &#91;***&#93; was increased by $495,000,000.00 from $0.00 to $495,000,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AL has been added.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 16 of 29</font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 3001 AD&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funding on SUBCLIN 3001AD is initiated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN&#58; AM</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIN&#58; GFEBS001166190500004</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acctng Data&#58; 0212021202220400000665654255&#160;&#160;&#160;&#160;S.0074658.5.58.1&#160;&#160;&#160;&#160;6100.9000021001</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase&#58; $330,000,000.00</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total&#58; $330,000,000.00</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost Code&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AA&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AK&#58; &#91;***&#93; was increased by $165,000,000.00 from $0.00 to $165,000,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AK has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AB&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AN&#58; &#91;***&#93; was increased by $462,000,000.00 from $0.00 to $462,000,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AN has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AC&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AN&#58; &#91;***&#93; was increased by $462,000,000.00 from $0.00 to $462,000,000.00</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract ACRN AN has been added.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIN &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost Code &#91;***&#93; has been added.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBCLIN 4001AD&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funding on SUBCLIN 4001AD is initiated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACRN&#58; AM</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIN&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AcctngData&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase&#58; $561,000,000.00</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total&#58; $561,000,000.00</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 17 of 29</font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost Code&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Procuring Contracting Officer&#58;<br>&#91;***&#93;<br>Joint COVID-19 Response Division<br>US Army Contracting Command<br>6472 Integrity Court (Building 4401)<br>Aberdeen Proving Ground, MD 21005-3013</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract Specialist&#58;<br>&#91;***&#93;<br>Joint COVID-19 Response Division<br>US Army Contracting Command<br>6472 Integrity Court (Building 4401)<br>Aberdeen Proving Ground, MD 21005-3013</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">GOVERNMENT TECHNICAL POINT OF CONTACT</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Biologist&#47;Project Officer<br>200 C Street, SW<br>Washington, DC 20201</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">CONTRACTOR&#8217;S CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;<br>Moderna US, Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PLACES OF PERFORMANCE</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna US, Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">NOTIFICATION OF REVISIONS AND CHANGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO&#47;ACO or office of the PCO&#47;ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">PERFORMANCE BASED PAYMENT</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 18 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table dated 4 May 2021.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option I AW the following schedule&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.352%"><tr><td style="width:1.0%"></td><td style="width:33.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLIN</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERIOD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AA</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$90,210,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AB</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$132,308,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$180,420,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001AD</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$198,462,000</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$601,400,000</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2e2a2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delivery Invoicing&#58; PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery&#8217; of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items.  Attachment 0008, Performance- based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION H -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.26pt">SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 19 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the contract (including, when applicable.  Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Substitution of Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Disclosure of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractor&#8217;s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 20 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Unless authorized in writing by the CO. the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1. in any maimer which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially&#8217; as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary&#8217; information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.  If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.  Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.  Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 21 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.  Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.  The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273.  Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8220;Technology&#8221;).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  DoD Medical Product Priority, PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; of award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Performance Based Payment Liquidated under Termination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna&#8217;s mRNA-1273 CO VID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">Public Readiness and Emergency Preparedness (PREP) Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;). Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against CO VID-19. 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the CO VID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 22 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the CO VID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items and technology covered by this Contract are being developed for both civil and military&#8217; applications.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.28pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Novation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US. Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US. Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, &#91;***&#93; funded above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, &#91;***&#93;, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 23 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  Moderna will reduce the cost of Option 2 by &#91;***&#93; for each successfully accelerated drug product fill under the Base Period &#91;***&#93; and &#91;***&#93; for each successfully accelerated drag product fill under Option 1 &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.  If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.  In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period.  Moderna agrees to credit the Government &#91;***&#93; for &#91;***&#93; and &#91;***&#93; for &#91;***&#93;.  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drag product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.  In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.) Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.) Cancellation notice to the subcontractor,</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.) The basis of the cancellation, and</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.) Cancellation fees incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause.  IAW agreed cancellation costs incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Delivery Schedule, as revised 11 Feb 2021 via modification P00004</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna confirms that it will provide the USG with the first 300M doses manufactured within its US-based supply chain &#91;***&#93;, with the exception of doses required for clinical studies.  The delivery schedule assumes that Moderna will work to further maximize fill&#47;finish capacity by working with the FDA to increase fill volumes, &#91;***&#93;.  Both parties acknowledge that resulting revisions to future accounting, invoicing, acceptance and delivery of doses subject to the revised label will be implemented via a subsequent modification.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Post-Termination Disposition of Undelivered Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#91;***&#93;. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to facilitate projections and invoicing, the Government shall provide or direct a third party &#91;***&#93; to provide to Moderna (1) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; (2) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; and (3) the number of &#91;***&#93; remaining in inventory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W911QY20C0100<br>(P00007)<br>Page 24 of 29</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both parties acknowledge that the delivery schedule is based &#91;***&#93; 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna&#8217;s delivery requirement, &#91;***&#93;.  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">Product &#91;***&#93; (as added via P00007)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specific to CLINs 3001 and 4001, Moderna will deliver to the Government &#91;***&#93;&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">mRNA-1273 Primary Series (0.2mg&#47;mL, 100pg, 2-dose)</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#91;***&#93;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All doses delivered in calendar year 2021 will be delivered in multi-dose vials &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government and Moderna agree that total monthly delivery quantities for each of CLIN 3001 and 4001 will follow the schedule in the table below.  The Government and Moderna also agree on the following points specific to product ordering&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.59pt">LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page #</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security&#8217; Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Performance Based Payment (PBP) Milestone Billing Plan<br>14 June 2021</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Pages 16</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_31"></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attachment 0007</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Based Payment (PBP) Milestone Schedule</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14 June 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIN</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severable &#47; Cumulative</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Completion Verification Method</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0001</font></td><td colspan="3" rowspan="5" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capacity and Raw Material Severable Reservation</font></td><td colspan="3" rowspan="5" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severable</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$601,400,000</font></td><td colspan="3" rowspan="5" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna shall provide&#58;<br>1) Written confirmation from the CMO network that sufficient capacity has been reserved&#59; and, 2) Written confirmation of reservation of sufficient raw materials along with a manufacturing schedule.</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4001</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_37"></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.154%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.917%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="18" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P00008</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16-Jun-2021</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4. REQUESTION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5. PROJECT NO. (If applicable)</font></td></tr><tr><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W58P05</font></td><td colspan="15" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACC-APG-COVID RESPONSE-W58P05<br>6472 INTEGRITY COURT (BUILDING 4401)<br>ABERDEEN PROVING GROUND MD 21005-3012</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DEFENSE CONTRACT MANAGEMENT AGENCY<br>DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="18" rowspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MODERNA US, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200 TECHNOLOGY SQ</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W911QY20C0100</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8PTM0</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FACILITY CODE</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09-Aug-2020</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.65pt;padding-right:2.75pt;text-indent:-16.9pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; (a) By completing Items 8 and 15, and returning _____ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="33" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></td></tr><tr><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">is required to sign this document and return ___</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___ copies to the issuing office.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.) Modification Control Number&#58;  &#91;***&#93;</font></div><div style="margin-bottom:36pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15 A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Stephen Hoge, President</font></div></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">tel&#58; &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">email&#58;  &#91;***&#93;</font></div></td></tr><tr style="height:33pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephen Hoge</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 16, 2021</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BY</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 16, 2021</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature person authorized to sign)</font></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of Contracting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">P00008<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00008) is to&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Add H.20 Donation of Excess Product and Exhibit B (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount remain unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms and conditions remain unchanged.  Please see below for details.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION H - SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.1&#160;&#160;&#160;&#160;Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify&#8217; the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.2&#160;&#160;&#160;&#160;Substitution of Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.3&#160;&#160;&#160;&#160;Disclosure of Information&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractors employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.4&#160;&#160;&#160;&#160;Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Unless otherwise specified in tins contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.5&#160;&#160;&#160;&#160;Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.6&#160;&#160;&#160;&#160;Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8216;&#8216;Technology&#8221;).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; of award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.7&#160;&#160;&#160;&#160;Performance Based Payment Liquidated under Termination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna&#8217;s mRNA-1273 CO VID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2.  Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.8&#160;&#160;&#160;&#160;Public Readiness and Emergency Preparedness (PREP) Act&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;), Pub. L. No. 109-148. Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against CO VID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the CO VID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the CO VID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#58; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items and technology covered by this Contract are being developed for both civil and military applications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.9&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.10&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.11&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.12&#160;&#160;&#160;&#160;Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of performance under this contract, the Government may require storage of the filled drag product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.13&#160;&#160;&#160;&#160;Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.14&#160;&#160;&#160;&#160;Novation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.15&#160;&#160;&#160;&#160;Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, &#91;***&#93; funded above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Moderna will reduce the cost of Option 2 by &#91;***&#93; for each successfully accelerated drug product fill under the Base Period &#91;***&#93; and &#91;***&#93; for each successfully accelerated drug product fill under Option 1 &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government &#91;***&#93; for &#91;***&#93; and &#91;***&#93; for &#91;***&#93;.  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drag product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fdl reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.)&#160;&#160;&#160;&#160;Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.)&#160;&#160;&#160;&#160;Cancellation notice to the subcontractor,</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.)&#160;&#160;&#160;&#160;The basis of the cancellation, and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.)&#160;&#160;&#160;&#160;Cancellation fees incurred.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.)&#160;&#160;&#160;&#160;Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.)&#160;&#160;&#160;&#160;Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.16&#160;&#160;&#160;&#160;Delivery Schedule, as revised 11 Feb 2021 via modification P00004</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.17&#160;&#160;&#160;&#160;Post-Termination Disposition of Undelivered Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.18&#160;&#160;&#160;&#160;&#91;***&#93; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to facilitate projections and invoicing, the Government shall provide or direct a third party &#91;***&#93; to provide to Moderna (1) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; (2) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; and (3) the number of &#91;***&#93; remaining in inventory and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both parties acknowledge that the delivery schedule is based on &#91;***&#93; 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna&#8217;s delivery requirement, &#91;***&#93;.  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.19&#160;&#160;&#160;&#160;Product &#91;***&#93; (as added via P00007)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specific to CLINs 3001 and 4001, Moderna will deliver to the Government &#91;***&#93;&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-1273 Primary Series (0.2mg&#47;mL, l00pg, 2-dose)</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All doses delivered in calendar year 2021 will be delivered in multi-dose vials &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government and Moderna agree that total monthly delivery quantities for each of CLIN 3001 and 4001 will follow the schedule in the table below.  The Government and Moderna also agree on the following points specific to product ordering&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.20&#160;&#160;&#160;&#160;Donation of Excess Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;If the Government determines that a quantity of doses of mRNA-1273 supplied to the Government under this contract is no longer needed by the Government, the Government may donate such doses to a foreign nation or non-governmental organization (NGO) facilitating donation to a foreign nation, subject to the remainder of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clause H.20.  The Government shall notify Contractor in writing prior to any proposed donation to a foreign nation or NGO, which notice will include &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Contractor must verify in writing that all of the required conditions below are met before any such donation is made, &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The Government&#8217;s donations will be from supplies of vaccine delivered to and accepted by the Government.  To the extent the Government commits to deliver doses that have not yet been physically delivered to the Government, such donation will not occur until such doses have been delivered to the Government.  The Government will be responsible for delivery of the donated doses to, and coordination of delivery with, the receiving foreign nation or NGO, as applicable.  The Government or the receiving foreign nation or NGO, as applicable, will (i) satisfy all customs shipping requirements for import and export of the product&#59; and (ii) as the exporter, file any required FDA export notifications.  To the extent not already provided to the Government, the Contractor will provide all information necessary to complete any requirements identified in this paragraph in advance of shipment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;When the conditions above are met for any donation, the Parties will &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e. &#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;Shipment of any donated doses under this Article does not constitute a violation of the Defense Production Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page #</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit B</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Donation of Excess Product</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_43"></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.044%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="21" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P00009</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16-Jun-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4. REQUESTION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5. PROJECT NO. (If applicable)</font></td></tr><tr><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W58P05</font></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item 6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACC-APG-COVID RESPONSE-W58P05</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6472 INTEGRITY COURT (BUILDING 4401)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND MD 21005-3013</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DCMA BOSTON</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">495 SUMMER STREET</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BOSTON MA 02210-2138</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="18" rowspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MODERNA US, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200 TECHNOLOGY SQ</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CAMBRIDGE MA 02139-3578</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:21pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W911QY20C0100</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE      8PTM0</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FACILITY CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09-Aug-2020</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.65pt;padding-right:2.75pt;text-indent:-16.9pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; (a) By completing Items 8 and 15, and returning _____ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">is required to sign this document and return __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___ copies to the issuing office.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.) Modification Control Number&#58;      &#91;***&#93;</font></div><div style="margin-bottom:66pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15 A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Stephen Hoge, President</font></div></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">tel&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">email&#58;  &#91;***&#93;</font></div></td></tr><tr style="height:33pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephen Hoge</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 16, 2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BY</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 16, 2021</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature person authorized to sign)</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of Contracting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_46"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">P00009<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00009) is to&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Update Exhibit B as outlined in clause H.20 with donation information for donation to Canada (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount remains unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page #</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit B</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Donation of Excess Product</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B - Donation of Excess</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product As of 16 June 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.884%"><tr><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Country</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mod No</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batch</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exp Date</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID Vaccine Type</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS Source</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fill Finish Site</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Total</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273<br>&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_52"></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.044%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="21" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P00010</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17-Jun-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4. REQUESTION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5. PROJECT NO. (If applicable)</font></td></tr><tr><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W58P05</font></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item 6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACC-APG-COVID RESPONSE-W58P05</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6472 INTEGRITY COURT (BUILDING 4401)</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND MD 21005-3013</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DCMA BOSTON</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">495 SUMMER STREET</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BOSTON MA 02210-2138</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="18" rowspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MODERNA US, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200 TECHNOLOGY SQ</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CAMBRIDGE MA 02139-3578</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:21pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W911QY20C0100</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FACILITY CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09-Aug-2020</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.65pt;padding-right:2.75pt;text-indent:-16.9pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; (a) By completing Items 8 and 15, and returning _____ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">is required to sign this document and return ___</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__ copies to the issuing office.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.) Modification Control Number&#58;         &#91;***&#93;</font></div><div style="margin-bottom:48pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15 A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Stephen Hoge, President</font></div></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">tel&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">email&#58;  &#91;***&#93;</font></div></td></tr><tr style="height:33pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephen Hoge</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 17, 2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BY</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 17, 2021</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature person authorized to sign)</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of Contracting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_55"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">P00010</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00010) is to&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Update Exhibit B as outlined in clause H.20 with donation information for donation to Taiwan (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount remains unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page#</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit B</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Donation of Excess Product</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_58"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B - Donation of Excess Product</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of 17 June 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recipient</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mod No</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batch</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exp Date</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID Vaccine Type</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS Source</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fill Finish Site</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Total</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_61"></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.044%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="21" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P00011</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01-Jul-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4. REQUESTION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5. PROJECT NO. (If applicable)</font></td></tr><tr><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W58P05</font></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACC-APG-COVID RESPONSE-W58P05</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6472 INTEGRITY COURT (BUILDING 4401)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND MA 21005-3013</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DCMA BOSTON</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">495 SUMMER STREET</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BOSTON MA 02210-2138</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="18" rowspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MODERNA US, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200 TECHNOLOGY SQ</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CAMBRIDGE MA 02139-3578</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:27pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W911QY20C0100</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE     8PTM0</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FACILITY CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09-Aug-2020</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.65pt;padding-right:2.75pt;text-indent:-16.9pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; (a) By completing Items 8 and 15, and returning _____ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">is required to sign this document and return ___1__ copies to the issuing office.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.) Modification Control Number&#58;      &#91;***&#93;</font></div><div style="margin-bottom:36pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15 A. NAME AND TITLE OF SIGNER (Type or print) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Stephen Hoge, President</font></div></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">tel&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">email&#58; &#91;***&#93;</font></div></td></tr><tr style="height:33pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephen Hoge</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BY</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">07-20-21</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature person authorized to sign)</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of Contracting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">P00011<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00011) is to&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Update language in H.16 to remove the requirement to deliver 300M doses prior to sale or export (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Update Exhibit B as outlined in clause H.20 with donation information for multiple recipients identified within the past 10 business days (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Update language in H.20(d) to reflect current operating procedures (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount remains unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION H - SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.1&#160;&#160;&#160;&#160;Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.2&#160;&#160;&#160;&#160;Substitution of Key Personnel</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.3&#160;&#160;&#160;&#160;Disclosure of Information&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractor&#8217;s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.4&#160;&#160;&#160;&#160;Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.5&#160;&#160;&#160;&#160;Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.6&#160;&#160;&#160;&#160;Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8220;Technology&#8221;).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; of award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.7&#160;&#160;&#160;&#160;Performance Based Payment Liquidated under Termination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna&#8217;s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.8&#160;&#160;&#160;&#160;Public Readiness and Emergency Preparedness (PREP) Act&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against CO VID-19, 85 Fed. Reg. 15198 (Mar. 17,2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor CO VID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items and technology covered by this Contract are being developed for both civil and military applications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.9&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.10&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.11&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.12&#160;&#160;&#160;&#160;Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of performance under this contract, the Government may require storage of the filled drag product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.13&#160;&#160;&#160;&#160;Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.14&#160;&#160;&#160;&#160;Novation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US, Inc.  as a counterparty instead of Moderna TX, Inc.  This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.15&#160;&#160;&#160;&#160;Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, &#91;***&#93; above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Moderna will reduce the cost of Option 2 by &#91;***&#93; for each successfully accelerated drug product fill under the Base Period &#91;***&#93;) and &#91;***&#93; for each successfully accelerated drug product fill under Option 1 &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government &#91;***&#93; for &#91;***&#93; and &#91;***&#93; for &#91;***&#93;.  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e.  within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;In the event that Moderna is unable to fill those reserved slots (i.e.  due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.)&#160;&#160;&#160;&#160;Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.)&#160;&#160;&#160;&#160;Cancellation notice to the subcontractor,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.)&#160;&#160;&#160;&#160;The basis of the cancellation, and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.)&#160;&#160;&#160;&#160;Cancellation fees incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.)&#160;&#160;&#160;&#160;Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.)&#160;&#160;&#160;&#160;Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.16&#160;&#160;&#160;&#160;Delivery Schedule, as revised </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> via modification P00004</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.17&#160;&#160;&#160;&#160;Post-Termination Disposition of Undelivered Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.18&#160;&#160;&#160;&#160;&#91;***&#93; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to facilitate projections and invoicing, the Government shall provide or direct a third party (e.g., McKesson) to provide to Moderna (1) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; (2) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; and (3) the number of &#91;***&#93; remaining in inventory and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both parties acknowledge that the delivery schedule is based on &#91;***&#93; 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna&#8217;s delivery requirement, &#91;***&#93;.  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.19&#160;&#160;&#160;&#160;Product &#91;***&#93; (as added via P00007)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specific to CLINs 3001 and 4001, Moderna will deliver to the Government &#91;***&#93;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-1273 Primary Series (0.2mg&#47;mL, 100pg, 2-dose)</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All doses delivered in calendar year 2021 will be delivered in multi-dose vials &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government and Moderna agree that total monthly delivery quantities for each of CLIN 3001 and 4001 will follow the schedule in the table below.  The Government and Moderna also agree on the following points specific to product ordering&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.20&#160;&#160;&#160;&#160;Donation of Excess Product</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;If the Government determines that a quantity of doses of mRNA-1273 supplied to the Government under this contract is no longer needed by the Government, the Government may donate such doses to a foreign nation or non-governmental organization (NGO) facilitating donation to a foreign nation, subject to the remainder of this Clause H.20.  The Government shall notify Contractor in writing prior to any proposed donation to a foreign nation or NGO, which notice will include &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Contractor must verify in writing that all of the required conditions below are met before any such donation is made, &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The Government&#8217;s donations will be from supplies of vaccine delivered to and accepted by the Government.  To the extent the Government commits to deliver doses that have not yet been physically delivered to the Government such donation will not occur until such doses have been delivered to the Government.  The Government will be responsible for delivery of the donated doses to, and coordination of delivery with, the receiving foreign nation or NGO, as applicable.  The Government or the receiving foreign nation or NGO, as applicable, will (i) satisfy all customs shipping requirements for import and export of the product&#59; and (ii) as the exporter, file any required FDA export notifications.  To the extent not already provided to the Government, the Contractor will provide all information necessary to complete any requirements identified in this paragraph in advance of shipment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;When the conditions above are met for any donation, the Parties will &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;Shipment of any donated doses under this Article does not constitute a violation of the Defense Production Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_67"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B - Donation of Excess Product</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of 1 July 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.768%"><tr><td style="width:1.0%"></td><td style="width:11.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Country</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mod No</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batch</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exp Date</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID Vaccine Type</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS Source</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NGO Facilitator (if applicable)</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fill Finish Site</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Total</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.768%"><tr><td style="width:1.0%"></td><td style="width:11.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_70"></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.044%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="21" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P00012</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20-Jul-2021</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4. REQUESTION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SEE SCHEDULE</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5. PROJECT NO. (If applicable)</font></td></tr><tr><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W58P05</font></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACC-APG-COVID RESPONSE-W58P05</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6472 INTEGRITY COURT (BUILDING 4401)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND MA 21005-3013</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DCMA BOSTON</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">495 SUMMER STREET</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BOSTON MA 02210-2138</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="18" rowspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MODERNA US, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200 TECHNOLOGY SQ</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CAMBRIDGE MA 02139-3578</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:27pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W911QY20C0100</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE     8PTM0</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FACILITY CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09-Aug-2020</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.65pt;padding-right:2.75pt;text-indent:-16.9pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; (a) By completing Items 8 and 15, and returning _____ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">is required to sign this document and return ___1__ copies to the issuing office.</font></div></td></tr><tr><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.) Modification Control Number&#58;      &#91;***&#93;</font></div><div style="margin-bottom:36pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 14 Continuation Page</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15 A. NAME AND TITLE OF SIGNER (Type or print) </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Stephane Bancel, CEO</font></div></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">tel&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">email&#58; &#91;***&#93;</font></div></td></tr><tr style="height:33pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephane Bancel</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BY</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">07-20-21</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature person authorized to sign)</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of Contracting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_73"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been added by full text&#58;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">P00012<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00012) it to&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Update Exhibit B as outlined in clause H.20 with donation information for multiple recipients identified with the past 7 business days (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The modification was required by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount remains unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following have been modified&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Type</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page#</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDRLs</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 Feb 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit B</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Donation of Excess Product</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 July 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0001</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0002</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0003</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excel</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0004</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data Rights</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0006</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0007</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0008</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 July 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(End of Summary of Changes)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i36f8765b633b4ca08c44f4a402810b5d_76"></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B - Donation of Excess Product</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of 13 July 2021</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Country</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mod No</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batch</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exp Date</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID Vaccine Type</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DS Source</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fill Finish Site</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose Total</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273<br>&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1273 </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1.5pt double #000000;border-left:1.5pt double #000000;border-right:1.5pt double #000000;border-top:1.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_6.jpg" src="image_6.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102amendmentnos8and.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i05813f904142428c8aa2478490201f7f_1"></div><div style="min-height:75.57pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.2</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;&#91;***&#93;&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED</font></div></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.090%"></td><td style="width:0.1%"></td></tr><tr style="height:10pt"><td colspan="30" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></div></td><td colspan="15" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></div></td></tr><tr style="height:10pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">P00008</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See Block 16C</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">OS273940</font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5. PROJECT NO.(If applicable)</font></td></tr><tr style="height:19pt"><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6. ISSUED BY</font></div><div style="margin-bottom:36pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA<br>200 Independence Ave., S.W.<br>Room 640-G<br>Washington DC 20201</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA</font></td><td colspan="18" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7. ADMINISTERED BY (If other than item 6)&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">US DEPT OF HEALTH &#38; HUMAN SERVICES<br>ASST SEC OF PREPAREDNESS &#38; RESPONSE<br>ACQ MANAGEMENT, CONTRACTS, &#38; GRANTS<br>O'NEILL HOUSE OFFICE BUILDING<br>Washington DC 20515</font></div></td><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA02</font></td></tr><tr style="height:51pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="24" rowspan="4" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">MODERNAUS, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:10pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:19pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10A. MOD. OF CONTRACT&#47;ORDER NO.<br>75A50120C00034</font></div></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="24" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:5.1pt;text-indent:-2.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10B. DATED (SEE ITEM 13)<br>04&#47;03&#47;2020</font></div></td></tr><tr style="height:10pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:26.1pt;text-indent:-23.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE&#160;&#160;&#160;&#160;1492235</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FACILITY CODE</font></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt 0 3.15pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended,&#160;&#160;&#160;&#160;</font><font style="font-family:'Webdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.<br>Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58; <br>(a) By completing Items 8 and 15, and returning ___________ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59;<br>or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE<br>RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION<br>OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></div><div style="margin-bottom:6pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See Schedule&#160;&#160;&#160;&#160;Net Increase&#58;&#160;&#160;&#160;&#160;$236, 364, 615.00</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS. IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM&#160;10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:12.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FAR 52.243- 2 Alternate 1 (APR 1984) Changes - Cost-Reimbursement</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="48" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">D. OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">E. IMPORTANT&#58; Contractor&#160;&#160;&#160;&#160; </font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not,&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings 2',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is required to sign this document and return </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> copies to the issuing office.</font></div></td></tr><tr><td colspan="51" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.5pt;text-indent:-10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-bottom:6pt;padding-left:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Tax ID Number&#58; 27-0226313<br>DUNS Number&#58; 069723520<br>This contract (75A50120C00034 - Moderna COVID-19 Vaccine)was awarded under<br>BAA-18-100-SOL-00003 - Development of an mRNA Vaccine for SARS-CoV-2.</font></div><div style="margin-bottom:6pt;padding-left:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The purpose of this modification is to support the additional scope of the Clinical<br>Development Plan (CLIN 0002)which includes increases the P301(Efficacy)(WBS 1.4.3.1)&#59;<br>Clinical(FTEs and digital clinical system)(WBS 1.4)&#59;Biologics License Application BLA (WBS<br>1.5.2) and Pharmacovigilance (supporting EUA) (WBS 1.5.3.1).</font></div><div style="margin-bottom:6pt;padding-left:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The obligated amount of CLIN 0002 is increased from $961,387,795 by $236,364,615 to Continued ...</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.</font></div></td></tr><tr><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15A. NAME AND TITLE OF SIGNER (Type or print)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Stephane Bancel, CEO</font></div></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR</font></div><div style="padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Stephane Bancel</font></div><div style="padding-left:17.1pt;text-indent:-14.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:5pt;padding-left:17.85pt;text-indent:-15.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">BY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04&#47;18&#47;2021</font></div></td></tr></table></div><div style="height:47.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><div id="i05813f904142428c8aa2478490201f7f_4"></div><hr style="page-break-after:always"><div style="min-height:49.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Reference No. of Document Being Continued</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">75A50120C00034&#47;P00008</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">OF</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="36" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NAME OF OFFEROR OR CONTRACTOR</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MODERNATX, INC. 1492235</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Item No.<br>(A)</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Supplies&#47;Services<br>(B)</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Quantity<br>(C)</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Unit<br>(D)</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Unit Price<br>(E)</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amount<br>(F)</font></td></tr><tr style="height:25pt"><td colspan="3" rowspan="20" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2</font></td><td colspan="33" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$1,197,752,410.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CLIN 0002 is the only CLIN changed by the issuance of this modification. CLIN 0002 remains cost plus fixed fee (CPFF). Fee was not applied to the additional scope.</font></div></td></tr><tr style="height:10pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prior Contract Value</font></td><td colspan="12" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Additional Funding</font></td><td colspan="9" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revised Contract Value</font></td></tr><tr style="height:10pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CLIN 0001</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;3,212,541</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;-</font></td><td colspan="9" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;3,212,541</font></td></tr><tr style="height:10pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CLIN 0002</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;961,387,795</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;236,364,615</font></td><td colspan="9" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;1,197,752,410</font></td></tr><tr style="height:10pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CLIN 0003</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;53,000,000</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;-</font></td><td colspan="9" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;53,000,000</font></td></tr><tr style="height:10pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;1,017,600,336</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;236,364,615</font></td><td colspan="9" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$&#160;&#160;&#160;&#160;1,253,964,951</font></td></tr><tr style="height:33pt"><td colspan="33" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">All other contract terms and conditions remain unchanged.<br>Period of Performance&#58; 04&#47;03&#47;2020 to 08&#47;31&#47;2023</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change Item 2 to read as follows(amount shown is the obligated amount)&#58;</font></div></td></tr><tr style="height:10pt"><td colspan="24" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Base CLIN 0002 - Development of mRNA vaccine to BLA</font></td><td colspan="9" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">236,364,615.00</font></td></tr><tr style="height:10pt"><td colspan="12" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></td><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020.199COV1.25103 Appr. Yr.&#58; 2020 CAN&#58; 199COV1 Object Class&#58;</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25103</font></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Funded&#58;&#160;&#160;&#160;&#160;$0.00</font></td><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></td><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020.199C014.25103 Appr. Yr.&#58; 2020 CAN&#58; 199C014 Object Class&#58;</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25103</font></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Funded&#58;&#160;&#160;&#160;&#160;$0.00</font></td><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></td><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021.199C035.25103 Appr. Yr.&#58; 2021 CAN&#58; 199C035 Object Class&#58;</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25103</font></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Funded&#58;&#160;&#160;&#160;&#160;$0.00</font></td><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></td><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021.199C035.25103 Appr. Yr.&#58; 2021 CAN&#58; 199C035 Object Class&#58;</font></td><td colspan="12" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25103</font></td></tr><tr style="height:10pt"><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Funded&#58; $236,364,615.00</font></td><td colspan="12" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><div id="i05813f904142428c8aa2478490201f7f_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00008</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">C.  Statement of Work<br>Updated with Modification P00008</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Independently, and not as an agent of the United States Government, the contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mRNA-1273 Vaccine Development (WBS 1.0)<br>The Contractor, Moderna, Inc. (&#8220;Moderna&#8221;) shall execute the preclinical, clinical, and chemistry, manufacturing and controls (CMC) activities required to license a vaccine against the SARS-CoV-2 virus (hereafter referred to as &#8220;mRNA-1273&#8221;).  Building upon early clinical development already underway, this proposal will support the late stage development, including the demonstration of clinical efficacy and generation of a dataset supportive of licensure.  Moderna will additionally evaluate the platform manufacturing capabilities relative to the needs for supply in response to a pandemic.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">* Program Management (WBS 1.1) - Updated with Mod P00007</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"><br>mRNA-1273 Program Management (WBS 1.1.1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna&#8217;s mRNA-1273 program team is composed of a multidisciplinary, highly matrixed, group of functional leads with experience in, and responsibility for, integrating plans and operationalizing strategies across Research, Toxicology, CMC, Regulatory Affairs, Clinical Development, Medical Affairs, Market Access and Launch Readiness in support of vaccine deployment under Emergency Use Authorization and Quality.  Collectively, the team has advanced ten programs to first-in-human studies within five years.  The group will be led by a program lead (PL) who will oversee and coordinate the activities necessary to meet the program objective of licensure.  The PL will be the point of accountability for the development and deployment of mRNA-1273.  &#91;***&#93;.  The Sub Principal Investigator will be responsible for ensure sufficient manufacturing capacity and production of mRNA-1273.  A program management office (PMO) will be responsible for managing the cost and schedule constraints of the contract via an integrated master schedule and corresponding budget, identifying and managing program risk, and ensuring contract compliance.  With the input from the mRNA-1273 project team, the PMO will be responsible for coordinating the drafting of and management to an integrated development plan.  Upon execution of the contract, weekly meetings with BARDA will be held to monitor program performance and monthly and annual reports will be will delivered to BARDA for the record.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Moderna will contribute a portion of the subcontractor program management effort to support the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonclinical Toxicology (WBS 1.2)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Development and Reproductive Toxicology of mRNA-1273 (WBS 1.2.2.1)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To assess the risk of administering the vaccine to pregnant women, a complete GLP rat developmental and reproductive toxicology (DART) study is planned.  Female Sprague Dawley rats will be dosed at the highest anticipated clinical dose level and include a control arm of phosphate-buffered saline (PBS).  As is typical for DART evaluations for vaccines, the animals will be immunized three times prior to mating and two times during gestation.  Each group will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">have two cohorts (one group will undergo Cesarean section with examination of the uteri and embryos&#59; the other group will have natural delivery and will be terminated at weaning).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonclinical (WBS 1.3)<br>For the purposes of this proposal it is assumed that the VRC continues to support nonclinical activities to develop murine and non-human primate efficacy studies, and animal models to assess the potential of vaccine- enhanced disease.  The scope of work below will execute additional robustness experiments in these developed models.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Assess Disease Enhancement (WBS 1.3.3.1)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The CoV spike protein expressed by the mRNA-1273 vaccine is stabilized in the prefusion conformation which should be optimal for inducing high quality antibody responses with low binding antibody to neutralizing antibody ratios.  mRNA delivery and induction of CD8 T cells and Th1 CD4 T cells will avoid Th2-biased responses.  The SARS-CoV-2 S protein expressed by the mRNA-1273 vaccine is stabilized in the pre-fusion conformation which should be optimal for inducing high functional antibody responses with low binding antibody to neutralizing antibody ratios, as it has been seen in RSV DS-Cav1 clinical trials and 2P-stabilized CoV S animal studies.  In addition, mRNA vaccines induce Th1 skewed response as has been evident in several pre-clinical and clinical vaccine programs at Moderna, including pandemic flu and CMV (PMID 28457665, 29456015).  By expressing pre-fusion SARS-CoV-2 S delivered with mRNA we should induce CD8 T cells and Th1-biased CD4 T cell responses as shown in both human, NHP, and murine studies, thus avoiding a Th2- biased response.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We plan to perform studies in mouse and NHPs to assess the theoretical risk of vaccine induced disease enhancement triggered by CoV infection following vaccination with imRNA-1273.  &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;<br><br>Ralph Baric is also developing a human ACE-2 transgenic mouse model, resulting in viremia and lung pathology upon wild-type SARS-CoV-2 infection.  This model should facilitate evaluation of wild-type SARS- CoV-2 virus and will also be used to evaluation protection from mRNA-1273 vaccination.  This model is however still under development and data are unlikely to become available before June&#47;July 2020.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, Vincent Munster (NIH&#47;NIAID) has developed a Rhesus macaque model of SARS-CoV infection.  After challenge animals get sick but infection is not lethal.  Decreased respiration and irregular breathing, weight loss, fever spike at day 1 and evidence of pneumonia are all observed.  In addition, hematological evidence of disease is seen, as well as viremia and shedding in nose, throat, and rectum up to day 10.  Unlike what is observed clinically a high challenge dose of virus is required, and animals recover without intervention.  Animals will be immunized with limiting doses of mRNA-1273 to allow breakthrough infection and endpoints relevant for disease enhancement will be collected.  Results from these challenge studies may become available by end of June 2020.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2 of 8</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Establish a Surrogate of Protection (WBS 1.3.3.2)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The primary endpoint for accelerated approval of a SARS-CoV-2 vaccine would be a neutralization assay.  This endpoint must be supported with a body of pre-clinical work that demonstrates a correlation between neutralizing titers and efficacy and that quantifies a protective serologic threshold titer using the same neutralization assay.  Murine and NHP efficacy models are being developed in parallel to the Phase 1 clinical study.  Building on data from these preliminary models and studies, Moderna will conduct NHP efficacy and murine passive transfer studies to confirm and refine the surrogate of protection.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">** Clinical (WBS 1.4) -- Updated with Mod P00008<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Phase 1 study of mRNA-1273 in 120 healthy subjects 18-55 years of age will evaluate the safety and immunogenicity of two injections (28 days apart) at four dose levels (25, 50, 100 and 250 &#94;g).  The proposed Phase 2 study will enroll n&#61;600 healthy subjects (&#62;18 years) to receive two injections, 28 days apart, of placebo or 50 or 100 &#94;g mRNA-1273, at 1&#58;1&#58;1, age stratified (18-55 yrs&#59; &#62;55 yrs).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The total safety database from the mRNA-1273 Phase 1 and Phase 2 studies will be approximately 445 adult participants exposed and approximately 245 adult participants at the highest dose level.  The proposed Phase 2 study (synopsis included below) is intended to support entry to subsequent Phase 3 study(ies).  &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">** Phase 2 Safety and Immunogenicity Study (WBS 1.4.2.1) - Updated with Mod P00007<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Immediately following dose selection in the initial Phase 1 study the program will initiate a Phase 2 clinical study.  The P201 study will confirm the safety and immunogenicity results from the open-label Phase 1, again testing a two-dose administration series 28d apart.  Its assumed that 600 participants, randomized 1&#58;1&#58;1 active&#58; placebo, testing a two dose levels of mRNA-1273.  Enrollment will be age-stratified participants 18 year of age and above into two age cohorts.  Primary objectives will include standard clinical safety evaluation with conventional safety and SARS-CoV-2-specific IgG endpoints though a neutralizing antibody assay would be preferred if available.  Secondary objectives will evaluate of the specific humoral response against SARS-CoV-2 by binding and neutralizing antibody (nAb) response.  Safety will be followed through 6 months post-last vaccination and primary immunogenicity endpoint will be measured at D57.  The study will enroll in the US under IND.  The study will assess COVID-19 as exploratory endpoint which may extend the duration of follow-up accordingly.  Clinical trial assessments will include measurement of SARS-CoV-2 S-specific binding antibody and neutralizing activity in sera.  This will provide an indication of vaccine-induced antibody quality and relative potency.  Historically, immune-complex mediated lung pathology has been associated with a high ratio of binding to functional antibody activity.  In addition, vaccine-induced T cell responses will be evaluated by peptide pool stimulation to define the pattern of cytokine production.  &#91;***&#93;.  To support the EUA, an interim clinical study synopsis will be drafted based on D57 safety and immunogenicity data.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">** Pediatrics (WBS 1.4.2.3 Updated with Mod P00007 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and WBS 1.4.2.4)<br>Moderna will conduct an initial pediatric study plan (PSP) under Pediatric Research Equity Act requirements during the IND phase.  A deferral will be requested for children less than 6 months </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3 of 8</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of age at the time of initial BLA approval.  Having demonstrated the mRNA-1273 is safe, tolerated, and effective in adults, Moderna will test the safety and immunogenicity of mRNA-1273 in a pediatric population with an aged-based step-down design.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The P203 study is a Phase 2&#47;3, randomized, observer-blind, placebo controlled, study to evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in 3000 healthy adolescents 12 to &#60; 18 years of age.  Participants will be randomly assigned to receive injections of either 100 &#94;g of mRNA-1273 vaccine or a placebo control in a 2&#58;1 randomization ratio.  The goal of the study is to seek an indication for use of mRNA 1273 (100 &#94;g IM, given as 2 injections, 28 days apart) in the 12 to &#60; 18 year age group.  The basis for demonstrating vaccine effectiveness is proposed to be met by serum antibody (Ab) response measured in this adolescent age group.  The approach to inferring vaccine effectiveness will depend on whether or not an accepted serum Ab threshold conferring protection against COVID-19 has been established.  If an Ab threshold of protection has been established, effectiveness will be inferred based on the proportion of adolescent study participants with serum Ab levels (on study Day 57) meeting or exceeding the Ab threshold.  If an Ab threshold of protection has not been established, effectiveness will be inferred based on demonstrating non-inferiority of the geometric mean value of serum nAb from adolescent participants compared to the geometric mean value of serum nAb from adults enrolled in the ongoing clinical endpoint efficacy trial (Study P301).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This adolescent study will monitor all participants for a total of 12 months following the second dose of vaccine or placebo.  Safety assessments will include solicited ARs (7 days post each injection), unsolicited AEs (28 days post each injection), medically attended adverse events (MAAEs), serious adverse events (SAEs), and adverse event of special interest (AESI) (pediatric MIS C) throughout the study period.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The 204 study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is a Phase 2&#47;3, randomized, observer-blind, placebo controlled, study to evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in approximately 6,000 healthy children 6 months to &#60; 12 years of age.  Approximately 6,000 participants will be enrolled in a dose-escalation, age de-escalation design testing 50 and 100 ug dose levels across three age groups&#58; 6 to &#60;12 years of age, 2 to &#60;6 years of age and 6 month to &#60;2 years of age.  Safety and Immunogenicity endpoints will follow the P203.  The study will enroll in the US and up to two ex-US countries (e.g. Canada and&#47;or Australia).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">** Phase 3 Pivotal Study (WBS 1.4.3.1) - &#8212; Updated with Mod P00008<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase 3 Pivotal Study (WBS 1.4.3.1).  The Phase 3 mRNA-1273-P301 study will confirm the trends observed during the Phase 1 and 2 trials, evaluating safety and efficacy in a larger number of subjects aged 18 and above.  Approximately 30,000 subjects will be enrolled according to 1&#58;1 randomization (active&#58; placebo).  Primary objectives will be 1) to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 and 2) to evaluate the safety and reactogenicity of 2 injections of the mRNA-1273 vaccine given 28 days apart.  Secondary objectives will evaluate&#58; the efficacy of mRNA-1273 to prevent severe COVID-19&#59; the efficacy of mRNA-1273 to prevent virologically confirmed SARS-CoV-2 infection or COVID-19 regardless of symptomatology or severity&#59; VE against a broad definition of COVID-19 disease&#59; VE to prevent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4 of 8</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">death due to COVID-19 disease&#59; VE against all-cause mortality&#59; the efficacy of mRNA-1273 to prevent COVID-19 after the first dose of investigational product (IP)&#59; the efficacy of mRNA-1273 to prevent COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection&#59; the efficacy of mRNA-1273 to prevent asymptomatic SARS-CoV-2 infection.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The sample size of this Phase 3 is driven by the total number of cases to demonstrate VE (mRNA-1273 vs.  placebo) to prevent COVID-19.  &#91;***&#93;.<br><br>&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On issuance of the EUA, in agreement with the FDA and OWS, the P301 study will offer vaccine to participants that were randomized to receive placebo and the study will transition to an open label study.  All 30K participants will return for a Participant Decision Visit.  Participants will complete an updated ICF, a sera and NP swab sample will be collected to test for asymptomatic infection, and participants randomized to the placebo arm will be offered vaccine.  After unblinding the sponsor will continue to leverage the clinical trial infrastructure.  Doubling the exposed population will reduce the incidence of rare events potentially detectable with high confidence in the trial to approximately 1&#47;10,000 or 0.01%.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Lot to Lot Consistency (WBS 1.4.3.2)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Based on FDA feedback received on 27 Aug this study is no longer required for licensure.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Post-Authorization Safety and Effectiveness Studies (WBS 1.4.4.1, 1.4.4.2, 1.4.4.3 and 1.4.4.4)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During EUA, Moderna will conduct signal refinement analyses using tokenized real-world data within the United States.  The population complements but does not duplicate the populations under observation in the CDC&#8217;s Vaccine Safety DataLink and the FDA&#8217;s CMS programs.  This real-world data infrastructure will significantly decrease the time between safety signal identification and evaluation.  Using the tokenized data the sponsor will be able to conduct an early post-authorization general safety study at a point in time approximately 8-12 months after the initiation of the study to provide further reassurance that prespecified adverse events of interest are being addressed during the EUA period.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further, Moderna is planning to establish an observational pregnancy cohort study, (e.g., with the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) Mother to Baby cohort).  Unlike a traditional passive pregnancy registry this approach will enable the calculation of incidence rates for adverse pregnancy and birth outcomes.  It will also enable the identification of key confounders and non-medically attended outcomes (e.g., spontaneous abortions) that are incompletely recorded in secondary healthcare records.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to continued evaluation of effectiveness after crossover, early in the EUA period, tokenized real- world data will provide COVID-19 incidence rates within geographic zones surrounding the clinical trial sites as a proxy for rates among unvaccinated individuals.  The Moderna envisions conducting one descriptive analysis involving both trial and geographic incidence rates 3-6 months after EUA and before broad product distribution removes the utility of this early approach.  Simultaneously, a prospective cohort study within a large integrated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5 of 8</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">healthcare delivery system (e.g., a Kaiser Permanente region) will be initiated to formally evaluate the vaccine effectiveness (VE) and long-term effectiveness of mRNA-1273 at the patient level with a concurrent comparator group.  Effectiveness outcomes to be evaluated include effectiveness against severe COVID-19, Follow-up time will be two years after the last dose, and interim analyses will be performed based on the number of events of the primary effectiveness outcome to assess durability of protection.  A final analysis including 1-dose VE and 2-dose VE will be evaluated.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Moderna will contribute by funding these EUA studies.  The USG will obtain access to the data.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Medical Affairs (WBS 1.4.6.1) &#8212; Updated with Mod P00007<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Medical Affairs group will provide scientific and clinical support for mRNA-1273 through the EUA period.  This will include developing patient and healthcare provider materials to support vaccine deployment under EUA and establishing a non-promotional call center to support vaccine distribution and administration.  Given the importance of vaccine confidence during EUA, special consideration will be given to scientific communication on the mRNA platform, vaccine development in a pandemic, and the safety, immunogenicity and effectiveness data of mRNA-1273</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.  Moderna will contribute by funding these activities.  The USG will obtain access to the data.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory (WBS 1.5)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">IND Preparation and Filing (WBS 1.5.1.1)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna&#8217;s Regulatory Affairs group, in close collaboration with BARDA, will work to draft a comprehensive regulatory master plan to guide the preclinical, CMC and clinical development of mRNA-1273 within the first 90 days of the contract.  An original investigational new drug application (IND) will be filed with the United States Food and Drug Administration (FDA) to support the clinical development of the Moderna product from Phase 2 onwards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">IND Maintenance (WBS 1.5.1.2)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Moderna-owned IND will be maintained to support the desired clinical development plan.  As needed, meetings will be conducted to receive feedback and gain concurrence on the specifics of the development activities with the FDA.  Moderna will file for Emergency Use Authorization, following the FDA guidance of EUA for COVID-19 vaccines.  A product-specific VRBPAC will be held.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">***BLA Submission (WBS 1.5.2.1) - Updated with ModP00008<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna will submit a Biologics License Application (BLA) and seek approval for the mRNA-1273 vaccine.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">*** The Pharmacovigilance (WBS 1.5.3.1) Updated with Mod P00008<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna will conduct standard pharmacovigilance for all active mRNA-1273 clinical studies.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CMC (WBS 1.6)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">CTM Manufacture for Phase 2 (WBS 1.6.3.2)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Clinical trial materials for the P201 study will be supplied using the AMP process.  The target yield of each lot is approximately &#91;***&#93; vials&#59; consequently, manufacture of up to five drug product (DP) lots is expected to deliver &#91;***&#93; total vials.  The DP will be a frozen liquid stored at </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6 of 8</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;.  The DP vials will be labeled and packaged by Moderna to support clinical testing in the US.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Process Development for Late Stage Clinical Supply (WBS 1.6.3.3)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mRNA Process Development<br>Technical Development will confirm and optimize the process parameters for mRNA manufacture.  &#91;***&#93;<br><br>&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">BLA Readiness (WBS 1.6.3.8)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In support of the Biologics License Application (BLA) due to the nature of the proposed timeline, it is likely that Moderna will need to complete some of process validation activities, primarily process characterization, after the completion of process performance qualification and before BLA filing.  Moderna intends to rapidly develop a robust process for clinical manufacturing and PPQ, and then fully describe the acceptable design space for the process prior to BLA filing.  Other activities to support this BLA filing, such as completing raw material qualification activities&#59; if not included in the BLA submission, will require a supplement to the initial BLA.  In the initial BLA filing Moderna will describe its control strategy to cover the gap between initial BLA filing and the BLA supplement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Process Development for Full Commercial Scale (WBS1.6.4.1)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following section outlines the process development activities &#91;***&#93;.  The goal of this work is to demonstrate the capability to produce mRNA-1273 at a scale that can support clinical demand.<br><br>&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Controls (Analytical and Validation) (WBS 1.6.5)<br>Potency Assay Development and Implementation (WBS 1.6.5.1)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Analytical Method Development and Validation (WBS 1.6.5.2)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna has established a set of analytical methods that are applied to the release and stability testing of intermediates and DP.  These methods are sufficient to assure the identity, strength, quality, purity and potency of the final product, and will have been qualified for use for mRNA-1273 as part of the Phase 2 CTM campaign.  Robustness of product release and stability methods, structural characterization and identification of impurities to further support product specifications, product comparability assessment will continue to support Phase 3 development and licensure.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Characterization Assay Development and Implementation (WBS 1.6.5.3)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A heightened characterization panel of analytical techniques will be used to assess any process modifications and to confirm process reproducibility for both drug substance and drug product during process development and scale up.  As the applicability of the methods used in the heightened panel to elucidate quality attributes of drug substance and drug product is determined, these methods may be elevated to the respective release panel.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7 of 8</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Stability Studies (WBS 1.6.5.4)<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Throughout the program, many studies will be undertaken &#91;***&#93;.  This includes studies using development bench scale material, engineering lot material, and GMP material.  This body of data will be used to apply interim and long-term shelf life to the drug product and process intermediates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8 of 8</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i05813f904142428c8aa2478490201f7f_10"></div><hr style="page-break-after:always"><div style="min-height:49.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.552%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.347%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="24" rowspan="2" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></div></td><td colspan="6" rowspan="2" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. CONTRACT ID CODE</font></td><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></td></tr><tr style="height:12pt"><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P00009</font></div></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Block 16C</font></div></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OS277805</font></div></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5. PROJECT NO. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(if applicable)</font></div></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6. ISSUED BY&#160;&#160;&#160;&#160;CODE</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ASPR-BARDA</font></td><td colspan="21" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7. ADMINISTERED BY </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(if other than Item 6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ASPR-BARDA02</font></td></tr><tr><td colspan="12" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ASPR-BARDA<br>200 Independence Ave., S.W.<br>Room 640-G<br>Washington DC 20201</font></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">US DEPT OF HEALTH &#38; HUMAN SERVICES<br>ASST SEC OF PREPAREDNESS &#38; RESPONSE<br>ACQ MANAGEMENT, CONTRACTS, &#38; GRANTS<br>O&#8217;NEILL HOUSE OFFICE BUILDING<br>Washington DC 20515</font></td></tr><tr style="height:21pt"><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(No., street, county, State and ZIP Code)</font></div></td><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(X)</font></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:27pt"><td colspan="12" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MODERNATX, INC 1492235<br>Attn&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br>MODERNATX, INC.&#160;&#160;&#160;&#160;200 TECHNOLOGY<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 021393578</font></div></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9B. DATED </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(SEE ITEM 11)</font></div></td></tr><tr style="height:28pt"><td colspan="9" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10A. MODIFICATION OF CONTACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75A50120C00034</font></div></td></tr><tr style="height:28pt"><td colspan="9" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CODE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1492235</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FACILITY CODE</font></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10B. DATED </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">04&#47;03&#47;2020</font></div></td></tr><tr><td colspan="42" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="42" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended.&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods&#58; (a) By completing Items 8 and 15, and returning ___________ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted &#59; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="42" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(if required)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Schedule&#160;&#160;&#160;&#160;Net Increase&#58;&#160;&#160;&#160;&#160;$144,140,941.00</font></div></td></tr><tr><td colspan="42" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS&#47;ORDERS. IT MODIFIES THE CONTRACT&#47;ORDER No. AS DESCRIBED IN ITEM 14.</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CHECK ONE</font></td><td colspan="39" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Specify authority)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B. THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(such as changes in paying office, appropriation data, etc.)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</font></td><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">FAR 52.243- 2 Alternate 1 (APR 1984) Changes - Cost-Reimbursement</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="39" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D. OTHER </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Specify type of modification and authority)</font></div></td></tr><tr><td colspan="42" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">E. IMPORTANT&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Contractor&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is not&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is required to sign this document and return ________________ copies to the issuing office.</font></div></td></tr><tr><td colspan="42" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax ID Number&#58; 27-0226313</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DUNS Number&#58; 069723520</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This contract (75A50120C00034 - Moderna COVID-19 Vaccine)was awarded under</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BAA-18-100-SOL-00003 - Development of an mRNA Vaccine for SARS-CoV-2.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The purpose of this modification is to support the additional scope of the Clinical Development Plan (CLIN 0002)for the P204 Pediatrics study (0-&#60;12) WBS 1.4.2.4 in the amount of $144,140,941.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The P204 study is a Phase 2&#47;3 study to evaluate the safety of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to &#60; 12 years of age.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Continued ...</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="18" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15A. NAME AND TITLE OF SIGNER </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;Stephane Bancel, CEO</font></div></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Stephane Bancel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><hr style="page-break-after:always"><div style="min-height:49.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.391%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="6" rowspan="2" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="12" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">REFERENCE NO. OF DOCUMENT BEING CONTINUED</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75A50120C00034&#47;P00009</font></div></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF</font></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font></td></tr><tr><td colspan="27" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NAME OF OFFEROR OR CONTRACTOR<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MODERNATX, INC 1492235</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ITEM NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(A)</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(B)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">QUANTITY</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(C)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">UNIT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(D)</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">UNIT PRICE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(E)</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AMOUNT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(F)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The obligated amount of CLIN 0002 is increased from $1,197,752,410 by $144,140,941 to $1,341,893,351.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CLIN 0002 is the only CLIN changed by the issuance of this modification. CLIN 0002 remains cost plus fixed fee (CPFF). Fee was not applied to the additional scope.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Prior Contract Value&#160;&#160;&#160;&#160;Additional Funding&#160;&#160;&#160;&#160;Revised Contract Value</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CLIN 0001&#160;&#160;&#160;&#160;$3,212,541&#160;&#160;&#160;&#160;$-&#160;&#160;&#160;&#160;$3,212,541</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CLIN 0002&#160;&#160;&#160;&#160;$1,197,752,410&#160;&#160;&#160;&#160;$144,140,941&#160;&#160;&#160;&#160;$1,341,893,351</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CLIN 0003&#160;&#160;&#160;&#160;$53,000,000&#160;&#160;&#160;&#160;$-&#160;&#160;&#160;&#160;$53,000,000</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total&#160;&#160;&#160;&#160;$1,253,964,951&#160;&#160;&#160;&#160;$144,140,941&#160;&#160;&#160;&#160;$1,398,105,892</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All other contract terms and conditions remain unchanged.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Period of Performance&#58; 04&#47;03&#47;2020 to 08&#47;31&#47;2023</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change Item 2 to read as follows (amount shown is the obligated amount)&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Base CLIN 0002 &#8211; Development of mRNA vaccine to BLA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2020.199cov1.25103 Appr. Yr.&#58; 2020 CAN&#58; 199cov1 Object Class&#58; 25103</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded&#58; $0.00</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2020.199co014.25103 Appr. Yr.&#58; 2020 CAN&#58; 199co14 Object Class&#58; 25103</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded&#58; $0.00</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2021.199co35.25103 Appr. Yr.&#58; 2021 CAN&#58; 199co035 Object Class&#58; 25103</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded&#58; $0.00</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2021.199co35.25103 Appr. Yr.&#58; 2021 CAN&#58; 199co035 Object Class&#58; 25103</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded&#58; $0.00</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2021.199co35.25103 Appr. Yr.&#58; 2021 CAN&#58; 199co035 Object Class&#58; 25103</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Funded&#58; $144,140,941.00</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144,140,941.00</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div></div><div id="i05813f904142428c8aa2478490201f7f_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#2f5496;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Statement of Work (SOW) P204 - Modification P00009</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#2d74b5;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P204 Pediatrics (WBS 1.4.2.4)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">mRNA-1273-P204 is a Phase 2&#47;3, 2-part, open-label, dose-escalation, age de-escalation, randomized, observer-blind, placebo-controlled, expansion study intended to infer the effectiveness of mRNA-1273 in children aged 6 months to &#60; 12 years. The study population will be divided into 3 age groups (6 to &#60; 12 years, 2 to &#60; 6 years, and 6 months to &#60; 2 years) and up to 3 dose levels (25, 50, and 100 &#94;g) of mRNA- 1273 will be evaluated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The study will be conducted in 2 parts. Part 1 of the study will be open label and consist of dose-escalation, age de-escalation in 750 participants (see Table below for the number of participants in each age group) to select the dose for each age group. Part 2 of the study will be placebo-controlled, observer-blind evaluation of the selected dose in 6,000 participants (2,000 participants in each age group). No participants in Part 1 will participate in Part 2 of the study. The total participants in mRNA-1273-P204 study is 6,750 participants.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The study will begin with the oldest age group (6 to &#60; 12 year) and age de-escalate. Each age group will begin with Part 1 and advance to Part 2. The mRNA-1273 investigational vaccine or placebo will be administered as 2 intramuscular (IM) injections, approximately 28 days apart.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The mRNA-1273 dose levels that will be evaluated in each age group in Part 1 and Part 2 of the study are given in the Table below. Only the 6-month to &#60; 2-year age group will receive the 25 &#94;g dose level.</font></div><div style="margin-bottom:6pt;padding-left:0.24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.239%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Age Group</font></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Part 1</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Part 2</font></td></tr><tr style="height:40pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">mRNA-1273</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">25 gg</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">mRNA-1273<br>50 gg</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">mRNA-1273</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100 gg</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Selected Dose Level of<br>mRNA-1273<br>From Part 1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Placebo</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 to &#60; 12 years</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 1<br>(n&#61;75)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 2<br>(n&#61;75)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 8 (n&#61;1500)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 9 (n&#61;500)</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2 to &#60; 6 years</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 3<br>(n&#61;75)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 4<br>(n&#61;75)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 10 (n&#61;1500)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 11 (n&#61;500)</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 months to &#60; 2 years</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 5 (n&#61;150)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 6 (n&#61;150)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 7 (n&#61;150)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 12 (n&#61;1500)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Study arm 13 (n&#61;500)</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The study will enroll in the US and Canada. The result of mRNA-1273-P204 study is to expand the label indication to 6 months to &#60; 12 years old.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a4exhibit3116302021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id175d68ad2834759bb8f6394a604a082_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, St&#233;phane Bancel, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a5exhibit3126302021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i30351d5edabf472b9c577d8463dbca86_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David W. Meline, certify that&#58;</font></div><div style="margin-bottom:9pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#47;s&#47; David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a6exhibit3216302021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic43c66aa691d4fd997664fb53f713150_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">18 U.S.C. SECTION&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">In connection with the Quarterly Report on Form 10-Q of Moderna, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, St&#233;phane Bancel, Chief Executive Officer of the Company, and David W. Meline, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge&#58; </font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="margin-bottom:11pt;padding-left:31.5pt;padding-right:31.5pt;text-align:center;text-indent:-11.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mrna-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1f43850e-4c17-48f6-8a24-63bc21a94b8b,g:a986bd34-a907-438b-9a06-ed4dd6fbe7f6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrna="http://www.modernatx.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.modernatx.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.modernatx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness">
        <link:definition>2101101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessAdditionalInformationDetails" roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandards" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards">
        <link:definition>2103102 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies">
        <link:definition>2204201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsTables" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables">
        <link:definition>2305301 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails">
        <link:definition>2406402 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2407403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSales" roleURI="http://www.modernatx.com/role/ProductSales">
        <link:definition>2108103 - Disclosure - Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesTables" roleURI="http://www.modernatx.com/role/ProductSalesTables">
        <link:definition>2309302 - Disclosure - Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesDetails" roleURI="http://www.modernatx.com/role/ProductSalesDetails">
        <link:definition>2410404 - Disclosure - Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenue" roleURI="http://www.modernatx.com/role/GrantRevenue">
        <link:definition>2111104 - Disclosure - Grant Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenueTables" roleURI="http://www.modernatx.com/role/GrantRevenueTables">
        <link:definition>2312303 - Disclosure - Grant Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenueDetails" roleURI="http://www.modernatx.com/role/GrantRevenueDetails">
        <link:definition>2413405 - Disclosure - Grant Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenue" roleURI="http://www.modernatx.com/role/CollaborationRevenue">
        <link:definition>2114105 - Disclosure - Collaboration Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenueTables" roleURI="http://www.modernatx.com/role/CollaborationRevenueTables">
        <link:definition>2315304 - Disclosure - Collaboration Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" roleURI="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails">
        <link:definition>2416406 - Disclosure - Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" roleURI="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails">
        <link:definition>2417407 - Disclosure - Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.modernatx.com/role/FinancialInstruments">
        <link:definition>2118106 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables">
        <link:definition>2319305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
        <link:definition>2420408 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails">
        <link:definition>2421409 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2422410 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails">
        <link:definition>2423411 - Disclosure - Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments">
        <link:definition>2124107 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2325306 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsCashFlowHedgesDetails" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashFlowHedgesDetails">
        <link:definition>2426412 - Disclosure - Derivative Financial Instruments - Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails">
        <link:definition>2427413 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.modernatx.com/role/Inventory">
        <link:definition>2128108 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.modernatx.com/role/InventoryTables">
        <link:definition>2329307 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.modernatx.com/role/InventoryDetails">
        <link:definition>2430414 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.modernatx.com/role/PropertyandEquipmentNet">
        <link:definition>2131109 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetTables">
        <link:definition>2332308 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails">
        <link:definition>2433415 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponents" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents">
        <link:definition>2134110 - Disclosure - Other Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsTables" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables">
        <link:definition>2335309 - Disclosure - Other Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2436416 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2437417 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails">
        <link:definition>2438418 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsDeferredRevenueDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails">
        <link:definition>2439419 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.modernatx.com/role/Leases">
        <link:definition>2140111 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.modernatx.com/role/LeasesTables">
        <link:definition>2341310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails">
        <link:definition>2442420 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetInformationDetails" roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails">
        <link:definition>2443421 - Disclosure - Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails">
        <link:definition>2444422 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails_1" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1">
        <link:definition>2444422 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.modernatx.com/role/CommitmentsandContingencies">
        <link:definition>2145112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesStrategicCollaborationsDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails">
        <link:definition>2446423 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails">
        <link:definition>2447424 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails">
        <link:definition>2448425 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.modernatx.com/role/StockBasedCompensation">
        <link:definition>2149113 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.modernatx.com/role/StockBasedCompensationTables">
        <link:definition>2350311 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2451426 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails">
        <link:definition>2452427 - Disclosure - Stock-Based Compensation - Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails">
        <link:definition>2453428 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2454429 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.modernatx.com/role/IncomeTaxes">
        <link:definition>2155114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesDetails">
        <link:definition>2456430 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShare" roleURI="http://www.modernatx.com/role/EarningsLossperShare">
        <link:definition>2157115 - Disclosure - Earnings (Loss) per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareTables" roleURI="http://www.modernatx.com/role/EarningsLossperShareTables">
        <link:definition>2358312 - Disclosure - Earnings (Loss) per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" roleURI="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails">
        <link:definition>2459431 - Disclosure - Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>2460432 - Disclosure - Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.modernatx.com/role/SubsequentEvents">
        <link:definition>2161116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.modernatx.com/role/SubsequentEventsDetails">
        <link:definition>2462433 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrna_SupplyAndManufacturingAgreementsMember" abstract="true" name="SupplyAndManufacturingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AccruedDevelopmentOperation" abstract="false" name="AccruedDevelopmentOperation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ProductSalesMember" abstract="true" name="ProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiability" abstract="false" name="OperatingAndFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_NumberOfParticipant" abstract="false" name="NumberOfParticipant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_OperatingLeaseLiabilities" abstract="false" name="OperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RevenueFromGrantsCurrentFundingCapacity" abstract="false" name="RevenueFromGrantsCurrentFundingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" abstract="true" name="PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" abstract="true" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ChargesToFinancingLeaseLiabilities" abstract="false" name="ChargesToFinancingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CollaborationArrangementMember" abstract="true" name="CollaborationArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DefenseAdvancedResearchProjectsAgencyMember" abstract="true" name="DefenseAdvancedResearchProjectsAgencyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseRightOfUseAsset" abstract="false" name="OperatingAndFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" abstract="true" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_RevenueFromGrantsMaximumAward" abstract="false" name="RevenueFromGrantsMaximumAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractwithCustomerAssetRollForward" abstract="true" name="ChangeInContractwithCustomerAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_FinancingRightOfUseAssetMember" abstract="true" name="FinancingRightOfUseAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_PersonalizedMRNACancerVaccinesProductsMember" abstract="true" name="PersonalizedMRNACancerVaccinesProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_NoncurrentMarketableSecuritiesMember" abstract="true" name="NoncurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MTCSouthMember" abstract="true" name="MTCSouthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrna_RevenueFromGrantsPotentialReimbursement" abstract="false" name="RevenueFromGrantsPotentialReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_LeasesIncrementalBorrowingRate" abstract="false" name="LeasesIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" abstract="false" name="ContractWithCustomerLiabilityDeductionsDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityLineItems" abstract="true" name="ChangeInContractWithCustomerLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_OtherCollaborativePartiesMember" abstract="true" name="OtherCollaborativePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" abstract="false" name="LesseeOperatingLeaseNumberOfExtensionPeriods" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_RevenueFromGrantsNumberOfContractOptions" abstract="false" name="RevenueFromGrantsNumberOfContractOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ContractOptionsMember" abstract="true" name="ContractOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ChangeInContractwithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractwithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_RevenueFromGrantsRemainingFundingCapacity" abstract="false" name="RevenueFromGrantsRemainingFundingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MTCNorthMember" abstract="true" name="MTCNorthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RawMaterialsAccountsPayable" abstract="false" name="RawMaterialsAccountsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_LeasesImputedInterestRate" abstract="false" name="LeasesImputedInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_AccruedOtherExternalGoodsAndServicesCurrent" abstract="false" name="AccruedOtherExternalGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_NumberOfDevelopmentProgram" abstract="false" name="NumberOfDevelopmentProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" abstract="true" name="CollaborationArrangementIncludingArrangementsWithAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_InitialProjectMember" abstract="true" name="InitialProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OtherGrantRevenueMember" abstract="true" name="OtherGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityTable" abstract="true" name="ChangeInContractWithCustomerLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrna_OperatingLeaseNumberOfProperties" abstract="false" name="OperatingLeaseNumberOfProperties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_CurrentMarketableSecuritiesMember" abstract="true" name="CurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" abstract="false" name="NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_OtherPrepaidExpenseManufacturing" abstract="false" name="OtherPrepaidExpenseManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MTCSouthMTCNorthAndMTCEastMember" abstract="true" name="MTCSouthMTCNorthAndMTCEastMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_EmbeddedLeasesMember" abstract="true" name="EmbeddedLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" abstract="true" name="RestrictedStockAndRestrictedStockUnitsRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" abstract="false" name="RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MTCEastMember" abstract="true" name="MTCEastMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" abstract="false" name="IncreaseDecreaseInRightOfUseAssetOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedClinicalTrials" abstract="false" name="AccruedClinicalTrials" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_TheBillAndMelindaGatesFoundationMember" abstract="true" name="TheBillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_VertexMember" abstract="true" name="VertexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrna_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrna_NorwoodMassachusettsMember" abstract="true" name="NorwoodMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrna_AllowanceForTenantImprovements" abstract="false" name="AllowanceForTenantImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ClinicalOperationsAndSupportCommitmentMember" abstract="true" name="ClinicalOperationsAndSupportCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_NumberOfDosesOfVaccineCandidate" abstract="false" name="NumberOfDosesOfVaccineCandidate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_AccruedManufacturing" abstract="false" name="AccruedManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CambridgeMassachusettsMember" abstract="true" name="CambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ContractWithCustomerAssetDeductionsDuringPeriod" abstract="false" name="ContractWithCustomerAssetDeductionsDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_StockOptionAndIncentivePlan2018Member" abstract="true" name="StockOptionAndIncentivePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RevenueFromGrantsNumberOfContractOptionsExercised" abstract="false" name="RevenueFromGrantsNumberOfContractOptionsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mrna-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1f43850e-4c17-48f6-8a24-63bc21a94b8b,g:a986bd34-a907-438b-9a06-ed4dd6fbe7f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_980083c8-195d-4a57-81b3-e9fa58486176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4fd6da14-adcf-49c1-a7d7-b2090fa5b107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_980083c8-195d-4a57-81b3-e9fa58486176" xlink:to="loc_us-gaap_PreferredStockValue_4fd6da14-adcf-49c1-a7d7-b2090fa5b107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1c64b0d1-ba94-4f04-a8d8-8241ceb0ac51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_980083c8-195d-4a57-81b3-e9fa58486176" xlink:to="loc_us-gaap_CommonStockValue_1c64b0d1-ba94-4f04-a8d8-8241ceb0ac51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_df60f38d-e98f-4a54-b357-d33262fdef66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_980083c8-195d-4a57-81b3-e9fa58486176" xlink:to="loc_us-gaap_AdditionalPaidInCapital_df60f38d-e98f-4a54-b357-d33262fdef66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b183365-0390-4a7f-a46b-fe48a2de1d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_980083c8-195d-4a57-81b3-e9fa58486176" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b183365-0390-4a7f-a46b-fe48a2de1d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21fc6590-39ba-49bb-949d-72db652c8795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_980083c8-195d-4a57-81b3-e9fa58486176" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21fc6590-39ba-49bb-949d-72db652c8795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_93181b5f-61f8-40f5-842f-421698666163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_93181b5f-61f8-40f5-842f-421698666163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cc85f295-f10c-4b46-ad47-5d5b0bb15a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cc85f295-f10c-4b46-ad47-5d5b0bb15a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_79b07efb-c847-43bc-939d-7c330622d984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_79b07efb-c847-43bc-939d-7c330622d984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_18964d7e-351a-43a5-9a41-c48c046bde9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:to="loc_us-gaap_AssetsCurrent_18964d7e-351a-43a5-9a41-c48c046bde9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_47169fc8-b96d-407c-b263-0711f31a9e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_47169fc8-b96d-407c-b263-0711f31a9e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a24b9df2-1cda-42db-85db-b179c595c2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a24b9df2-1cda-42db-85db-b179c595c2b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8e44c630-6667-472a-b06c-cf698fb57d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a71980f2-8ca5-400b-9b7a-9f5834a46694" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8e44c630-6667-472a-b06c-cf698fb57d41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4e36001b-29fa-4319-b3ed-b6c6e54b675e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_afa2f400-2cf5-417a-a088-f5f83fd3e247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e36001b-29fa-4319-b3ed-b6c6e54b675e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_afa2f400-2cf5-417a-a088-f5f83fd3e247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fd1bf559-9dda-4d0f-b63f-b6f6f159081f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e36001b-29fa-4319-b3ed-b6c6e54b675e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fd1bf559-9dda-4d0f-b63f-b6f6f159081f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e2bec3aa-43bc-4582-ba8d-8806a4d313ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e36001b-29fa-4319-b3ed-b6c6e54b675e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e2bec3aa-43bc-4582-ba8d-8806a4d313ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3bc024d1-5b5c-436f-8e3b-b311f6c81adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e36001b-29fa-4319-b3ed-b6c6e54b675e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3bc024d1-5b5c-436f-8e3b-b311f6c81adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8a29d07a-2d17-44d2-93c8-9537a59cad49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e36001b-29fa-4319-b3ed-b6c6e54b675e" xlink:to="loc_us-gaap_LiabilitiesCurrent_8a29d07a-2d17-44d2-93c8-9537a59cad49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1e5793cd-9ed6-4f40-ad3e-2dda013bfc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_327650d4-896c-4c61-8639-fe352be1af74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1e5793cd-9ed6-4f40-ad3e-2dda013bfc43" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_327650d4-896c-4c61-8639-fe352be1af74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1d1cfbe1-c19c-4d20-8231-12cbcd5c7975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1e5793cd-9ed6-4f40-ad3e-2dda013bfc43" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1d1cfbe1-c19c-4d20-8231-12cbcd5c7975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1bef7ca-64f5-4ee6-9ec6-81ae0244e667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1e5793cd-9ed6-4f40-ad3e-2dda013bfc43" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1bef7ca-64f5-4ee6-9ec6-81ae0244e667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f41a59bc-5498-4c9d-bde9-e5cde08a3f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1e5793cd-9ed6-4f40-ad3e-2dda013bfc43" xlink:to="loc_us-gaap_InventoryNet_f41a59bc-5498-4c9d-bde9-e5cde08a3f7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fefadf20-132d-4f63-a944-be752b9236e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1e5793cd-9ed6-4f40-ad3e-2dda013bfc43" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fefadf20-132d-4f63-a944-be752b9236e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_899bc5dd-c0c5-491e-a471-92ea07117e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_774a9fff-9b25-4720-9fe4-117666319956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_899bc5dd-c0c5-491e-a471-92ea07117e7a" xlink:to="loc_us-gaap_Liabilities_774a9fff-9b25-4720-9fe4-117666319956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_161708d1-bb74-4c9c-b904-0b577d82304f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_899bc5dd-c0c5-491e-a471-92ea07117e7a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_161708d1-bb74-4c9c-b904-0b577d82304f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2361efe1-85f4-4c99-8e73-ece3797ceacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_899bc5dd-c0c5-491e-a471-92ea07117e7a" xlink:to="loc_us-gaap_StockholdersEquity_2361efe1-85f4-4c99-8e73-ece3797ceacd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_07fed79d-c9b7-4b34-8b07-8a20b4b16c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1d76aab1-525a-42aa-99f2-1dd74b6036ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fed79d-c9b7-4b34-8b07-8a20b4b16c52" xlink:to="loc_us-gaap_AccountsPayableCurrent_1d76aab1-525a-42aa-99f2-1dd74b6036ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c0682b3d-e95d-4a34-9ddc-df65caf3f043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fed79d-c9b7-4b34-8b07-8a20b4b16c52" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c0682b3d-e95d-4a34-9ddc-df65caf3f043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5701df32-cda4-41c8-b843-b16883d1eb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fed79d-c9b7-4b34-8b07-8a20b4b16c52" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5701df32-cda4-41c8-b843-b16883d1eb0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9b02a45f-76b9-491b-b112-9ef2a4c13172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fed79d-c9b7-4b34-8b07-8a20b4b16c52" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9b02a45f-76b9-491b-b112-9ef2a4c13172" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_571cb12d-7044-48fd-a9b5-17a0375930f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_72456e06-1b41-4d31-a51a-c434881c514f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_571cb12d-7044-48fd-a9b5-17a0375930f7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_72456e06-1b41-4d31-a51a-c434881c514f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1cc28a5c-bb6f-4c85-b414-0334c8877b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_571cb12d-7044-48fd-a9b5-17a0375930f7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1cc28a5c-bb6f-4c85-b414-0334c8877b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bf139cd1-d0b0-484e-ac96-1299e2752403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_571cb12d-7044-48fd-a9b5-17a0375930f7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bf139cd1-d0b0-484e-ac96-1299e2752403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6932752-252e-4a49-8f72-c1b09f368543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3d56e6ec-3a6f-48f3-ba62-685350a55b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b6932752-252e-4a49-8f72-c1b09f368543" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3d56e6ec-3a6f-48f3-ba62-685350a55b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_215fc890-57dc-48f1-adf3-1967e62cad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b6932752-252e-4a49-8f72-c1b09f368543" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_215fc890-57dc-48f1-adf3-1967e62cad0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_585c8ae9-c107-4467-a422-a365bbb5ed98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_10377250-205e-4969-b26d-8c397af01ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_585c8ae9-c107-4467-a422-a365bbb5ed98" xlink:to="loc_us-gaap_OperatingIncomeLoss_10377250-205e-4969-b26d-8c397af01ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9081cfba-eb87-404d-8e2c-8c8074d78872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_585c8ae9-c107-4467-a422-a365bbb5ed98" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9081cfba-eb87-404d-8e2c-8c8074d78872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_86fedc4a-113f-4964-a409-6596171190d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_585c8ae9-c107-4467-a422-a365bbb5ed98" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_86fedc4a-113f-4964-a409-6596171190d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7195adbd-0168-4e5d-83bd-090c8b7e0f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ecc23671-41cf-4684-8e00-40c6db037452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7195adbd-0168-4e5d-83bd-090c8b7e0f57" xlink:to="loc_us-gaap_Revenues_ecc23671-41cf-4684-8e00-40c6db037452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d5c2fe2-ff0a-4a9b-819d-04905c3d82c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7195adbd-0168-4e5d-83bd-090c8b7e0f57" xlink:to="loc_us-gaap_CostsAndExpenses_6d5c2fe2-ff0a-4a9b-819d-04905c3d82c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9ab49044-6dcb-4339-b360-01dce0f1c2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_dc9838c4-d13e-4bad-8167-2c93e1a22f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9ab49044-6dcb-4339-b360-01dce0f1c2fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_dc9838c4-d13e-4bad-8167-2c93e1a22f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_99f2d4e9-40fa-4193-a943-f98d4adf014a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9ab49044-6dcb-4339-b360-01dce0f1c2fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_99f2d4e9-40fa-4193-a943-f98d4adf014a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8f1fad3c-fd7a-46fa-8b3c-87a802465f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_7f7f55e2-9048-434d-aefa-fac4b791d74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8f1fad3c-fd7a-46fa-8b3c-87a802465f98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_7f7f55e2-9048-434d-aefa-fac4b791d74b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7e7ff600-58a1-454c-a7d3-0f9be6dd4da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8f1fad3c-fd7a-46fa-8b3c-87a802465f98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7e7ff600-58a1-454c-a7d3-0f9be6dd4da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b38bb911-4c87-4ada-baca-15f2942b9deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fcec56d0-2506-4983-acc6-b54b09f01235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b38bb911-4c87-4ada-baca-15f2942b9deb" xlink:to="loc_us-gaap_NetIncomeLoss_fcec56d0-2506-4983-acc6-b54b09f01235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9f5df338-b61b-4d1d-8722-3b9a9459b9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b38bb911-4c87-4ada-baca-15f2942b9deb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9f5df338-b61b-4d1d-8722-3b9a9459b9a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2155503e-89f3-4e87-ac30-5b3a6ce0f3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b38bb911-4c87-4ada-baca-15f2942b9deb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2155503e-89f3-4e87-ac30-5b3a6ce0f3bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b89fadd8-9910-400e-b9e8-91100363e7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b89fadd8-9910-400e-b9e8-91100363e7eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc577f75-6b0d-43a8-b72c-43a8ea79dc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc577f75-6b0d-43a8-b72c-43a8ea79dc0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_eff91804-d593-4731-a52f-0ebbdf8e8adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_eff91804-d593-4731-a52f-0ebbdf8e8adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseLiabilities_8ff1dd3e-8295-4ec8-9f4c-cf8d24ad3946" xlink:href="mrna-20210630.xsd#mrna_OperatingLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_mrna_OperatingLeaseLiabilities_8ff1dd3e-8295-4ec8-9f4c-cf8d24ad3946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_97b03b7e-ec39-4617-b64f-47a0e1b53111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_97b03b7e-ec39-4617-b64f-47a0e1b53111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_0bf5cd5b-6877-4d66-90ae-64523b4060c7" xlink:href="mrna-20210630.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_0bf5cd5b-6877-4d66-90ae-64523b4060c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e1652b0a-268a-4fdc-9580-dd13c6605fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e1652b0a-268a-4fdc-9580-dd13c6605fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_85cc4f05-db7e-4f9b-a72c-98b637e46df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_85cc4f05-db7e-4f9b-a72c-98b637e46df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5cca9ee4-72e6-4262-9846-8a0d13bc7797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5cca9ee4-72e6-4262-9846-8a0d13bc7797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f5d77286-c3eb-4fec-8c93-caf452808b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f5d77286-c3eb-4fec-8c93-caf452808b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_478a7695-7467-4e5e-b59b-c1fb95601ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_478a7695-7467-4e5e-b59b-c1fb95601ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_899d4c46-8e29-48f9-9d58-8de730f559a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_899d4c46-8e29-48f9-9d58-8de730f559a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84dc6ba4-72e1-4c70-a38f-c5322402f805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_NetIncomeLoss_84dc6ba4-72e1-4c70-a38f-c5322402f805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_92e35242-3679-419f-988e-1d12cc4b83f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae78a839-8fee-4e09-a2ed-6930e1d2991b" xlink:to="loc_us-gaap_ShareBasedCompensation_92e35242-3679-419f-988e-1d12cc4b83f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44131c0f-6bc4-4a53-93d9-82ee2cc84bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_56b3dde9-a3b7-4480-a185-0ac1735a9a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44131c0f-6bc4-4a53-93d9-82ee2cc84bf4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_56b3dde9-a3b7-4480-a185-0ac1735a9a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a429e290-098b-49db-87fb-4c55a342f043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44131c0f-6bc4-4a53-93d9-82ee2cc84bf4" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a429e290-098b-49db-87fb-4c55a342f043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_1a439dac-63c5-445c-ae51-c77ccc16464b" xlink:href="mrna-20210630.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44131c0f-6bc4-4a53-93d9-82ee2cc84bf4" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_1a439dac-63c5-445c-ae51-c77ccc16464b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_854b5be6-e021-4371-a0c0-1f82d89976d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cad3043f-c49d-4191-9356-406e60a0fc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_854b5be6-e021-4371-a0c0-1f82d89976d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cad3043f-c49d-4191-9356-406e60a0fc35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d47e99-2070-47d1-b707-f0b65394a009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_854b5be6-e021-4371-a0c0-1f82d89976d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d47e99-2070-47d1-b707-f0b65394a009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7daf6645-c177-4eaf-be1d-7bc00f6709c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_854b5be6-e021-4371-a0c0-1f82d89976d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7daf6645-c177-4eaf-be1d-7bc00f6709c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29b4855c-096a-46a3-9ea1-09977560fb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6ed69062-37e2-46b8-bd28-5a015760a1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29b4855c-096a-46a3-9ea1-09977560fb0e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6ed69062-37e2-46b8-bd28-5a015760a1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b57fd71c-6cff-432f-8596-fa39ef0364c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29b4855c-096a-46a3-9ea1-09977560fb0e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b57fd71c-6cff-432f-8596-fa39ef0364c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86fb7115-0c7e-4645-8969-9f9f7a8f8fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29b4855c-096a-46a3-9ea1-09977560fb0e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86fb7115-0c7e-4645-8969-9f9f7a8f8fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bcfa1865-2fb6-4d35-b2cc-2e385b23f3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29b4855c-096a-46a3-9ea1-09977560fb0e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bcfa1865-2fb6-4d35-b2cc-2e385b23f3cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5993cb0b-ec50-4c4a-8c2b-7c84835209a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9064cb0f-7bbd-46c1-959c-55305729f027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5993cb0b-ec50-4c4a-8c2b-7c84835209a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9064cb0f-7bbd-46c1-959c-55305729f027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4ad3ed9b-725f-462b-b9b9-257e2d5022d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5993cb0b-ec50-4c4a-8c2b-7c84835209a5" xlink:to="loc_us-gaap_RestrictedCashCurrent_4ad3ed9b-725f-462b-b9b9-257e2d5022d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e3eb63b2-7b19-48be-bc78-22bb945e2458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5993cb0b-ec50-4c4a-8c2b-7c84835209a5" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e3eb63b2-7b19-48be-bc78-22bb945e2458" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e83f34d-ede7-4a46-b123-e56e5bebb7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e596427d-7bed-4371-9b00-b5174874421d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e83f34d-ede7-4a46-b123-e56e5bebb7c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e596427d-7bed-4371-9b00-b5174874421d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2d3c6f5b-cdb7-4fe6-9d20-ba24a118dd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e83f34d-ede7-4a46-b123-e56e5bebb7c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2d3c6f5b-cdb7-4fe6-9d20-ba24a118dd1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_858aacff-05ad-42dc-9099-7448dced7d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e83f34d-ede7-4a46-b123-e56e5bebb7c2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_858aacff-05ad-42dc-9099-7448dced7d69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e267590f-37c3-4d9b-97fa-882c960ce9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7def40a2-c9d1-4f82-a872-fbb7afb0471d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e267590f-37c3-4d9b-97fa-882c960ce9a8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7def40a2-c9d1-4f82-a872-fbb7afb0471d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e992fbd9-da65-43b1-89e9-4b4314470bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e267590f-37c3-4d9b-97fa-882c960ce9a8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e992fbd9-da65-43b1-89e9-4b4314470bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fddf61b4-1795-463a-85de-437e8835a386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_372a6256-bddb-48cb-ba5e-aea750a8a44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fddf61b4-1795-463a-85de-437e8835a386" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_372a6256-bddb-48cb-ba5e-aea750a8a44e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5c88ece3-5efc-4b7b-a79e-aa5bba117840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fddf61b4-1795-463a-85de-437e8835a386" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5c88ece3-5efc-4b7b-a79e-aa5bba117840" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5fe3a358-33a6-4a65-9c41-d561daefa6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3a3b4737-6af3-4961-b44f-150bae623685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5fe3a358-33a6-4a65-9c41-d561daefa6de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3a3b4737-6af3-4961-b44f-150bae623685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_b7e2f15c-1527-4705-9011-b8fa1ebd9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5fe3a358-33a6-4a65-9c41-d561daefa6de" xlink:to="loc_us-gaap_DerivativeAssets_b7e2f15c-1527-4705-9011-b8fa1ebd9e17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d48634d2-71ce-4ce7-95fb-012d0c00c7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d70fb13b-1030-40f1-b406-4b2931c55494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d48634d2-71ce-4ce7-95fb-012d0c00c7c8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d70fb13b-1030-40f1-b406-4b2931c55494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_829b6baa-319d-4c1e-b44b-e7f2af914bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d48634d2-71ce-4ce7-95fb-012d0c00c7c8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_829b6baa-319d-4c1e-b44b-e7f2af914bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a69d05c6-9919-4b99-bd95-3cc2e32605f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d48634d2-71ce-4ce7-95fb-012d0c00c7c8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a69d05c6-9919-4b99-bd95-3cc2e32605f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2f92c23d-1a36-4850-8c5a-c3574eec7e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9caefa48-36c7-4630-a49f-2db556494091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2f92c23d-1a36-4850-8c5a-c3574eec7e56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9caefa48-36c7-4630-a49f-2db556494091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_33ad64e7-9c9a-43d2-ae5d-46b353efb018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2f92c23d-1a36-4850-8c5a-c3574eec7e56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_33ad64e7-9c9a-43d2-ae5d-46b353efb018" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c125edd1-3dbc-47c0-a837-44eb2e91f1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_50b394a8-d493-4155-855f-427bbe8a3721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c125edd1-3dbc-47c0-a837-44eb2e91f1ce" xlink:to="loc_us-gaap_OtherAssetsCurrent_50b394a8-d493-4155-855f-427bbe8a3721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_56eb0149-0eaa-4e4b-9e08-a9709c34c6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c125edd1-3dbc-47c0-a837-44eb2e91f1ce" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_56eb0149-0eaa-4e4b-9e08-a9709c34c6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing_2322d80a-5766-40c4-b4c4-bfa7489caf1c" xlink:href="mrna-20210630.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c125edd1-3dbc-47c0-a837-44eb2e91f1ce" xlink:to="loc_mrna_OtherPrepaidExpenseManufacturing_2322d80a-5766-40c4-b4c4-bfa7489caf1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4102f8fb-20ee-4761-a56c-19f37c35af9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c125edd1-3dbc-47c0-a837-44eb2e91f1ce" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4102f8fb-20ee-4761-a56c-19f37c35af9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_34c6c6e9-8eb8-43c7-9979-edc873266c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c125edd1-3dbc-47c0-a837-44eb2e91f1ce" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_34c6c6e9-8eb8-43c7-9979-edc873266c36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_3b2ccb15-510e-4c66-8ab4-53378eae17a3" xlink:href="mrna-20210630.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_3b2ccb15-510e-4c66-8ab4-53378eae17a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_e78ccc8b-d838-4bb1-a680-21c5c7ee47fd" xlink:href="mrna-20210630.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_mrna_AccruedDevelopmentOperation_e78ccc8b-d838-4bb1-a680-21c5c7ee47fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_020c7c72-6d0d-4ba4-b219-538ddbbb4af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_020c7c72-6d0d-4ba4-b219-538ddbbb4af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_65dd31cc-64a9-4bdd-aa82-047bb3040ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_65dd31cc-64a9-4bdd-aa82-047bb3040ee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_8b41903d-e676-4d97-a33f-24b12aa185ed" xlink:href="mrna-20210630.xsd#mrna_AccruedClinicalTrials"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_mrna_AccruedClinicalTrials_8b41903d-e676-4d97-a33f-24b12aa185ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_febdf7b2-4e47-470b-bf12-c24d914ecc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_febdf7b2-4e47-470b-bf12-c24d914ecc2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_0ad427e8-5d19-4d05-8d76-2731d7c82e06" xlink:href="mrna-20210630.xsd#mrna_AccruedManufacturing"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_mrna_AccruedManufacturing_0ad427e8-5d19-4d05-8d76-2731d7c82e06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_d6732f4e-7eb1-4383-b7f6-6dc3e31e530e" xlink:href="mrna-20210630.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ae1a5f7f-59bf-4d34-8126-41be9ebda30e" xlink:to="loc_mrna_RawMaterialsAccountsPayable_d6732f4e-7eb1-4383-b7f6-6dc3e31e530e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b2a76250-f3a0-4339-a72d-5046322a8f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_abfbc221-0a68-471b-8dfc-e8c5496ddf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b2a76250-f3a0-4339-a72d-5046322a8f52" xlink:to="loc_us-gaap_TaxesPayableCurrent_abfbc221-0a68-471b-8dfc-e8c5496ddf21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_051ce4a6-2ce3-428a-9a45-5e4e9a430901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b2a76250-f3a0-4339-a72d-5046322a8f52" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_051ce4a6-2ce3-428a-9a45-5e4e9a430901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_e50afca2-91ff-40d4-abc3-6d24e8c52c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b2a76250-f3a0-4339-a72d-5046322a8f52" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_e50afca2-91ff-40d4-abc3-6d24e8c52c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7f4974b6-5930-4599-a3c4-3a99344c28f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b2a76250-f3a0-4339-a72d-5046322a8f52" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7f4974b6-5930-4599-a3c4-3a99344c28f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_972cad57-d87d-424f-9f0c-324d6d1967aa" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9cab387-4af0-4429-890e-fbfa5330253f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_972cad57-d87d-424f-9f0c-324d6d1967aa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9cab387-4af0-4429-890e-fbfa5330253f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ca0ff9c8-c414-45ec-a5bd-f879a5c3ad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_972cad57-d87d-424f-9f0c-324d6d1967aa" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ca0ff9c8-c414-45ec-a5bd-f879a5c3ad8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_a6d361d0-b037-41f4-9517-3245a0cdced0" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b34fd18c-e208-4728-b2b1-919dbab25f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_a6d361d0-b037-41f4-9517-3245a0cdced0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b34fd18c-e208-4728-b2b1-919dbab25f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_bf7f0eab-0bd7-4214-85aa-3aa905aee93d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_a6d361d0-b037-41f4-9517-3245a0cdced0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_bf7f0eab-0bd7-4214-85aa-3aa905aee93d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_2187455d-e396-4dbf-b52a-8491b2776814" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_12b3c49b-b6b0-4f06-a3e2-63dd5748180f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_2187455d-e396-4dbf-b52a-8491b2776814" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_12b3c49b-b6b0-4f06-a3e2-63dd5748180f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_286aca5b-cf6c-437b-90e7-ffa00903a3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_2187455d-e396-4dbf-b52a-8491b2776814" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_286aca5b-cf6c-437b-90e7-ffa00903a3f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_e3e3ecca-b9c2-4e47-9158-f178f1296e10" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_e76e029d-46ef-45c5-9223-49a0fce9011a" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_e3e3ecca-b9c2-4e47-9158-f178f1296e10" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_e76e029d-46ef-45c5-9223-49a0fce9011a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_48f82191-4b7b-4cd5-8aa1-19c73c6bfa2e" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_e3e3ecca-b9c2-4e47-9158-f178f1296e10" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_48f82191-4b7b-4cd5-8aa1-19c73c6bfa2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5ee15de-1008-4b6b-9caa-a78c63aedc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d060bba0-e4f5-456e-8677-6d6ff4ec2c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5ee15de-1008-4b6b-9caa-a78c63aedc78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d060bba0-e4f5-456e-8677-6d6ff4ec2c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5b0106a9-f37e-47e8-b0a2-9e9f99b3ddbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5ee15de-1008-4b6b-9caa-a78c63aedc78" xlink:to="loc_us-gaap_OperatingLeaseLiability_5b0106a9-f37e-47e8-b0a2-9e9f99b3ddbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2814a430-aa4b-4ae2-830b-0948a93f2f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a9cea9f5-38e0-45bf-83b2-d221ca637962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2814a430-aa4b-4ae2-830b-0948a93f2f21" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a9cea9f5-38e0-45bf-83b2-d221ca637962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f72758ad-e464-43f4-911e-6a1ca6515ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2814a430-aa4b-4ae2-830b-0948a93f2f21" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f72758ad-e464-43f4-911e-6a1ca6515ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_86032dc6-6c1a-40ff-a47d-62797f2e4392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2814a430-aa4b-4ae2-830b-0948a93f2f21" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_86032dc6-6c1a-40ff-a47d-62797f2e4392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f35c6c1b-1c6e-4c46-99e6-30c118129e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2814a430-aa4b-4ae2-830b-0948a93f2f21" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f35c6c1b-1c6e-4c46-99e6-30c118129e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_7cea9619-1b29-4766-b8df-c14e09099278" xlink:href="mrna-20210630.xsd#mrna_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2814a430-aa4b-4ae2-830b-0948a93f2f21" xlink:to="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_7cea9619-1b29-4766-b8df-c14e09099278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_9f43e8be-4bcf-4130-bc58-980dac33cb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2814a430-aa4b-4ae2-830b-0948a93f2f21" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_9f43e8be-4bcf-4130-bc58-980dac33cb91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c8b971c-3e32-4238-8055-14b7884dfaad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2d51f23f-ab74-4262-a10c-4b1dffefe633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c8b971c-3e32-4238-8055-14b7884dfaad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2d51f23f-ab74-4262-a10c-4b1dffefe633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7ce9290f-6743-47b5-b475-727bee7aba8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c8b971c-3e32-4238-8055-14b7884dfaad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7ce9290f-6743-47b5-b475-727bee7aba8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35ef8cd3-0ddf-43b6-b745-26cff39fcd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c8b971c-3e32-4238-8055-14b7884dfaad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35ef8cd3-0ddf-43b6-b745-26cff39fcd3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc16cddb-af0a-4f0e-b640-d6ff76a11e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c8b971c-3e32-4238-8055-14b7884dfaad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc16cddb-af0a-4f0e-b640-d6ff76a11e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1508774e-8075-48f5-b1f6-c5658384b94e" xlink:href="mrna-20210630.xsd#mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c8b971c-3e32-4238-8055-14b7884dfaad" xlink:to="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1508774e-8075-48f5-b1f6-c5658384b94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8b0200e1-0c80-4a40-8420-df2e83f34593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c8b971c-3e32-4238-8055-14b7884dfaad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8b0200e1-0c80-4a40-8420-df2e83f34593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a120fac5-ab11-437d-bd5c-e32664fbb299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d98ba3ef-bb26-45e1-853f-c06e3429d30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a120fac5-ab11-437d-bd5c-e32664fbb299" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d98ba3ef-bb26-45e1-853f-c06e3429d30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_01e97814-4945-4956-a3d4-ccf03fbd8468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a120fac5-ab11-437d-bd5c-e32664fbb299" xlink:to="loc_us-gaap_FinanceLeaseLiability_01e97814-4945-4956-a3d4-ccf03fbd8468" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fda76c06-41e0-4b0d-b488-93eda132725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f32af491-fb11-428b-9031-65cf538a4825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fda76c06-41e0-4b0d-b488-93eda132725f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f32af491-fb11-428b-9031-65cf538a4825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_88e40aab-387e-420c-9d92-8d09eb5b8795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fda76c06-41e0-4b0d-b488-93eda132725f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_88e40aab-387e-420c-9d92-8d09eb5b8795" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mrna-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1f43850e-4c17-48f6-8a24-63bc21a94b8b,g:a986bd34-a907-438b-9a06-ed4dd6fbe7f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i0cb53ca17f8c452bad01e00541c38aa6_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_859f8012-f336-47c2-932a-bbc303882779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_RevenuesAbstract_859f8012-f336-47c2-932a-bbc303882779" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cf2148c9-d7d2-46f6-a6c0-c25a8e3adc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_859f8012-f336-47c2-932a-bbc303882779" xlink:to="loc_us-gaap_Revenues_cf2148c9-d7d2-46f6-a6c0-c25a8e3adc93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7a38d302-6c3d-4e96-b226-6bd2acb8bd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7a38d302-6c3d-4e96-b226-6bd2acb8bd14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4fd73101-d994-47b6-bb06-6be2978cdb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4fd73101-d994-47b6-bb06-6be2978cdb08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1c2f809c-cf85-4f96-a821-8d3d10c6d90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1c2f809c-cf85-4f96-a821-8d3d10c6d90b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_30eb8097-8186-41ef-b5b9-f67ae1b9dd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_CostsAndExpenses_30eb8097-8186-41ef-b5b9-f67ae1b9dd90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9fbeb607-9c18-41b5-a8b3-dd462ee7e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_OperatingIncomeLoss_9fbeb607-9c18-41b5-a8b3-dd462ee7e2d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c5b4f338-14ed-4a38-9396-4ca8e5f7ee76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c5b4f338-14ed-4a38-9396-4ca8e5f7ee76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a5e75511-310e-48e5-bce3-841f1125c4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a5e75511-310e-48e5-bce3-841f1125c4ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bd3885eb-e645-4f89-9ae4-ded31d736cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bd3885eb-e645-4f89-9ae4-ded31d736cd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_069e60eb-2ca8-45c7-9f34-924ecffbc946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_069e60eb-2ca8-45c7-9f34-924ecffbc946" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2f95bfe-eba7-4338-b253-4dfe1cd1bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_NetIncomeLoss_a2f95bfe-eba7-4338-b253-4dfe1cd1bd76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5eb0b0ae-804b-4220-8818-f45a66aa92b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:to="loc_us-gaap_EarningsPerShareBasic_5eb0b0ae-804b-4220-8818-f45a66aa92b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b823f18-6f4b-494c-b292-9f25d9c7d601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b823f18-6f4b-494c-b292-9f25d9c7d601" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c53ee6d-06a7-44cb-b281-01be22904557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c53ee6d-06a7-44cb-b281-01be22904557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2bd2337b-9ba7-44f0-8c49-4aea56932281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2bd2337b-9ba7-44f0-8c49-4aea56932281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d86014fc-a5f0-4711-851c-febda67a624f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_StatementTable_d86014fc-a5f0-4711-851c-febda67a624f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c224213-9391-4a32-81d3-3d9127af72ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d86014fc-a5f0-4711-851c-febda67a624f" xlink:to="loc_srt_ProductOrServiceAxis_1c224213-9391-4a32-81d3-3d9127af72ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c224213-9391-4a32-81d3-3d9127af72ee_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1c224213-9391-4a32-81d3-3d9127af72ee" xlink:to="loc_srt_ProductsAndServicesDomain_1c224213-9391-4a32-81d3-3d9127af72ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1c224213-9391-4a32-81d3-3d9127af72ee" xlink:to="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_f053b9dc-b0be-47f9-93f8-ebfa0ceeaf30" xlink:href="mrna-20210630.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:to="loc_mrna_ProductSalesMember_f053b9dc-b0be-47f9-93f8-ebfa0ceeaf30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_3e84e3bd-0344-4a41-a3b5-319efddd5938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:to="loc_us-gaap_GrantMember_3e84e3bd-0344-4a41-a3b5-319efddd5938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_5b26d92a-7dee-4303-bd48-c0097de04f65" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:to="loc_mrna_CollaborationArrangementMember_5b26d92a-7dee-4303-bd48-c0097de04f65" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i008e7a3748624ec0ba39e5443a95b2b0_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7afae51-0963-4dbf-9243-3a47016b3f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7afae51-0963-4dbf-9243-3a47016b3f8a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_986bc395-ff1d-4d04-91d0-40c8a9b045a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_SharesOutstanding_986bc395-ff1d-4d04-91d0-40c8a9b045a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_06d71b9c-de49-4d6d-bed4-6abb759ed65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockholdersEquity_06d71b9c-de49-4d6d-bed4-6abb759ed65e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_018a94fa-6caf-44b0-870d-5667941ad86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_018a94fa-6caf-44b0-870d-5667941ad86c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b07930c6-5b1e-44d9-814b-f4068a9babcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b07930c6-5b1e-44d9-814b-f4068a9babcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6b56c69-b5de-4d9d-9814-5688f5b886db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6b56c69-b5de-4d9d-9814-5688f5b886db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f0f4481e-73ba-40a1-800d-3596017a93d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f0f4481e-73ba-40a1-800d-3596017a93d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_27afa377-addf-47fb-8aa4-bba93f56b374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_27afa377-addf-47fb-8aa4-bba93f56b374" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ff47401-be3b-49d5-bdcc-55cd3df9ea40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ff47401-be3b-49d5-bdcc-55cd3df9ea40" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3997d1e2-201c-49b1-9ed0-19cca1653a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3997d1e2-201c-49b1-9ed0-19cca1653a42" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b942c622-5061-41a4-8ac5-95c1057afe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_NetIncomeLoss_b942c622-5061-41a4-8ac5-95c1057afe0f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d8061ccc-e669-4bc3-bad6-12a3a18a4a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_86f6fd18-91d0-471c-bbec-ce5e5a7ce7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_468415ac-9853-4437-819a-df93c354717f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e7afae51-0963-4dbf-9243-3a47016b3f8a" xlink:to="loc_us-gaap_StatementTable_468415ac-9853-4437-819a-df93c354717f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2e59e8a-c801-4dac-a1ba-b6628b657ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468415ac-9853-4437-819a-df93c354717f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2e59e8a-c801-4dac-a1ba-b6628b657ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2e59e8a-c801-4dac-a1ba-b6628b657ca8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2e59e8a-c801-4dac-a1ba-b6628b657ca8" xlink:to="loc_us-gaap_EquityComponentDomain_e2e59e8a-c801-4dac-a1ba-b6628b657ca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2e59e8a-c801-4dac-a1ba-b6628b657ca8" xlink:to="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dbe54072-02fe-4391-b2ba-1681fa46c155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_CommonStockMember_dbe54072-02fe-4391-b2ba-1681fa46c155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3ccb1cfe-1f11-4589-9d7e-7f88d3e8dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3ccb1cfe-1f11-4589-9d7e-7f88d3e8dd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0cdcb020-96e6-43f7-a732-dfa28825832f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0cdcb020-96e6-43f7-a732-dfa28825832f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b285d42e-99ab-4806-8147-6a4c4970c66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_RetainedEarningsMember_b285d42e-99ab-4806-8147-6a4c4970c66d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="extended" id="iad23fbd81fdf487a903a78f9015eecbf_SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_85d8e762-b730-41cc-b9d8-a25b70f1daef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_85d8e762-b730-41cc-b9d8-a25b70f1daef" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_226693ab-5490-405f-bd7a-fd6f09212807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:to="loc_us-gaap_StockholdersEquity_226693ab-5490-405f-bd7a-fd6f09212807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0804c5de-a91c-439a-a88c-cce6708b0ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0804c5de-a91c-439a-a88c-cce6708b0ad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fba658b-2876-4756-8917-b81135f9cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2ada3785-d419-41f0-a098-4b3c5ea3c243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_85d8e762-b730-41cc-b9d8-a25b70f1daef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2ada3785-d419-41f0-a098-4b3c5ea3c243" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b5856ebd-fb38-41a4-96fb-f9e8c486e731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2ada3785-d419-41f0-a098-4b3c5ea3c243" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b5856ebd-fb38-41a4-96fb-f9e8c486e731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b5856ebd-fb38-41a4-96fb-f9e8c486e731_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5856ebd-fb38-41a4-96fb-f9e8c486e731" xlink:to="loc_us-gaap_EquityComponentDomain_b5856ebd-fb38-41a4-96fb-f9e8c486e731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5856ebd-fb38-41a4-96fb-f9e8c486e731" xlink:to="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e17c9878-90bd-432f-9c9b-0b5df6968e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e17c9878-90bd-432f-9c9b-0b5df6968e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_08d5deb9-5844-4ba6-8280-4d56dbd432af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_08d5deb9-5844-4ba6-8280-4d56dbd432af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04a52c3c-5af6-4f9f-9f9f-12235af04f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04a52c3c-5af6-4f9f-9f9f-12235af04f6a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#ProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="extended" id="i8b2b949122914df3ba5c19e9c9e691fb_ProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_db5201bf-4c61-426b-9a0e-b87f853653c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:to="loc_us-gaap_Revenues_db5201bf-4c61-426b-9a0e-b87f853653c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8583d763-ebf5-47db-b488-89cfee43e6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8583d763-ebf5-47db-b488-89cfee43e6d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b930e61f-e71a-417f-9bff-552fc225c7d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:to="loc_srt_StatementGeographicalAxis_b930e61f-e71a-417f-9bff-552fc225c7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b930e61f-e71a-417f-9bff-552fc225c7d1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b930e61f-e71a-417f-9bff-552fc225c7d1" xlink:to="loc_srt_SegmentGeographicalDomain_b930e61f-e71a-417f-9bff-552fc225c7d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b930e61f-e71a-417f-9bff-552fc225c7d1" xlink:to="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c4e6bba9-3458-4ff5-bbc8-44d2875f4817" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:to="loc_country_US_c4e6bba9-3458-4ff5-bbc8-44d2875f4817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_044ba90e-dd1d-4fb5-be57-d69f3dae98d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:to="loc_us-gaap_NonUsMember_044ba90e-dd1d-4fb5-be57-d69f3dae98d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_924d75fb-224c-4395-920d-6b599662deb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:to="loc_srt_ProductOrServiceAxis_924d75fb-224c-4395-920d-6b599662deb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_924d75fb-224c-4395-920d-6b599662deb2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_924d75fb-224c-4395-920d-6b599662deb2" xlink:to="loc_srt_ProductsAndServicesDomain_924d75fb-224c-4395-920d-6b599662deb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e3a7b09-0512-4a12-9f21-ced91c7a5b13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_924d75fb-224c-4395-920d-6b599662deb2" xlink:to="loc_srt_ProductsAndServicesDomain_9e3a7b09-0512-4a12-9f21-ced91c7a5b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_ac94afee-74f5-46ea-8714-62240f3dd5a8" xlink:href="mrna-20210630.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e3a7b09-0512-4a12-9f21-ced91c7a5b13" xlink:to="loc_mrna_ProductSalesMember_ac94afee-74f5-46ea-8714-62240f3dd5a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#GrantRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="extended" id="ibc4cd6007cd24aee8345975a9ea24c82_GrantRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_bfdcfa51-4192-4795-876f-f7c20fe7989f" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_bfdcfa51-4192-4795-876f-f7c20fe7989f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_53afb1e0-96bf-40aa-a6d1-8ebbd9504fa4" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_53afb1e0-96bf-40aa-a6d1-8ebbd9504fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_01301703-d056-43ac-b963-f3b557ffc2d0" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_01301703-d056-43ac-b963-f3b557ffc2d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_b3c1710e-41d7-49cd-ad4c-a0b39725096b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_us-gaap_OtherCommitment_b3c1710e-41d7-49cd-ad4c-a0b39725096b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipant_93ab8771-5d19-4af3-92ff-bf090d6b1c75" xlink:href="mrna-20210630.xsd#mrna_NumberOfParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_NumberOfParticipant_93ab8771-5d19-4af3-92ff-bf090d6b1c75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_323e3407-cf83-40e7-b3c7-c0e2b6979dcf" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_323e3407-cf83-40e7-b3c7-c0e2b6979dcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_995722b0-1101-49b4-b4b0-a648313ead53" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_995722b0-1101-49b4-b4b0-a648313ead53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_4f67ad6a-b6a0-4eeb-bf28-7ace26747365" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_4f67ad6a-b6a0-4eeb-bf28-7ace26747365" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5eb87b6c-417c-4f56-8cef-097023c7bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5eb87b6c-417c-4f56-8cef-097023c7bb28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b05c95dd-3853-4303-a4bd-4427b57993d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_us-gaap_Revenues_b05c95dd-3853-4303-a4bd-4427b57993d6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0c7739bb-e2c9-499b-8415-8bd5412bdefe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:to="loc_srt_MajorCustomersAxis_0c7739bb-e2c9-499b-8415-8bd5412bdefe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0c7739bb-e2c9-499b-8415-8bd5412bdefe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0c7739bb-e2c9-499b-8415-8bd5412bdefe" xlink:to="loc_srt_NameOfMajorCustomerDomain_0c7739bb-e2c9-499b-8415-8bd5412bdefe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0c7739bb-e2c9-499b-8415-8bd5412bdefe" xlink:to="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_f7fe6ebd-b99f-4a24-9f4b-c3a8a5aa92bb" xlink:href="mrna-20210630.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_f7fe6ebd-b99f-4a24-9f4b-c3a8a5aa92bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_f2fa8214-5f3f-4fad-b477-9fff38d14f6e" xlink:href="mrna-20210630.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_f2fa8214-5f3f-4fad-b477-9fff38d14f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_b2049737-3c5c-4478-9666-012a047f207e" xlink:href="mrna-20210630.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_b2049737-3c5c-4478-9666-012a047f207e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_65e38cee-ac85-4afa-b2ba-d68861b94d2e" xlink:href="mrna-20210630.xsd#mrna_OtherGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_OtherGrantRevenueMember_65e38cee-ac85-4afa-b2ba-d68861b94d2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade" xlink:to="loc_us-gaap_ProjectMember_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade" xlink:to="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember_7db6cc7f-a224-4ed0-a590-f532e772d83e" xlink:href="mrna-20210630.xsd#mrna_ContractOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:to="loc_mrna_ContractOptionsMember_7db6cc7f-a224-4ed0-a590-f532e772d83e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember_5479e329-1116-4682-b589-7af75efa6c3b" xlink:href="mrna-20210630.xsd#mrna_InitialProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:to="loc_mrna_InitialProjectMember_5479e329-1116-4682-b589-7af75efa6c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8f92a912-0a19-4930-a477-1208fa909cac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:to="loc_srt_ProductOrServiceAxis_8f92a912-0a19-4930-a477-1208fa909cac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f92a912-0a19-4930-a477-1208fa909cac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8f92a912-0a19-4930-a477-1208fa909cac" xlink:to="loc_srt_ProductsAndServicesDomain_8f92a912-0a19-4930-a477-1208fa909cac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ccd4c1fa-4a1c-4e3b-bd69-fc606ca630ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8f92a912-0a19-4930-a477-1208fa909cac" xlink:to="loc_srt_ProductsAndServicesDomain_ccd4c1fa-4a1c-4e3b-bd69-fc606ca630ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e91bc47c-a982-431b-8dda-f265dcde00ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ccd4c1fa-4a1c-4e3b-bd69-fc606ca630ad" xlink:to="loc_us-gaap_GrantMember_e91bc47c-a982-431b-8dda-f265dcde00ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="extended" id="i91aecf33630746979ed4dead03e270f4_CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_33f16d3a-62bd-4d84-b6ea-a966f5436a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add5ff44-cb9a-4c39-a091-6de9746f4444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_33f16d3a-62bd-4d84-b6ea-a966f5436a0f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add5ff44-cb9a-4c39-a091-6de9746f4444" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_33f16d3a-62bd-4d84-b6ea-a966f5436a0f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5b5f047e-f316-4525-95db-6a7b5938dd4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:to="loc_srt_ProductOrServiceAxis_5b5f047e-f316-4525-95db-6a7b5938dd4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b5f047e-f316-4525-95db-6a7b5938dd4b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5b5f047e-f316-4525-95db-6a7b5938dd4b" xlink:to="loc_srt_ProductsAndServicesDomain_5b5f047e-f316-4525-95db-6a7b5938dd4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4481ca06-107b-45e9-9fcd-14ee6eea3471" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5b5f047e-f316-4525-95db-6a7b5938dd4b" xlink:to="loc_srt_ProductsAndServicesDomain_4481ca06-107b-45e9-9fcd-14ee6eea3471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_6db6706a-f337-4f59-b284-37bf3f83a2da" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4481ca06-107b-45e9-9fcd-14ee6eea3471" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_6db6706a-f337-4f59-b284-37bf3f83a2da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e907a3a-d086-4c43-a915-79bfaac441c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:to="loc_srt_CounterpartyNameAxis_0e907a3a-d086-4c43-a915-79bfaac441c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e907a3a-d086-4c43-a915-79bfaac441c4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0e907a3a-d086-4c43-a915-79bfaac441c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e907a3a-d086-4c43-a915-79bfaac441c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0e907a3a-d086-4c43-a915-79bfaac441c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember_aebe5d2b-ae55-4843-853d-39298f555c68" xlink:href="mrna-20210630.xsd#mrna_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_AstraZenecaMember_aebe5d2b-ae55-4843-853d-39298f555c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_89ae0fb8-23a6-44cf-8351-30317dfa61e9" xlink:href="mrna-20210630.xsd#mrna_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_MerckMember_89ae0fb8-23a6-44cf-8351-30317dfa61e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_6dc390b9-9848-4a2e-9881-d1a9530b9514" xlink:href="mrna-20210630.xsd#mrna_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_VertexMember_6dc390b9-9848-4a2e-9881-d1a9530b9514" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember_af8c780d-8c44-4457-b682-de44ce9c7bf2" xlink:href="mrna-20210630.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_OtherCollaborativePartiesMember_af8c780d-8c44-4457-b682-de44ce9c7bf2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="extended" id="ia6e29719190048278e3a2b0e7421c88f_CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:to="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_d530ecea-8bd5-4f85-b143-3502473fc596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_d530ecea-8bd5-4f85-b143-3502473fc596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetPurchase_a26f4d88-7a23-4348-8a64-6a384f6cf647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetPurchase_a26f4d88-7a23-4348-8a64-6a384f6cf647" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_9324a66d-81f0-4b38-a055-0de3b0769dec" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:to="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_9324a66d-81f0-4b38-a055-0de3b0769dec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_a1ed5c43-0161-4660-8925-37b2233127a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_de551570-87b6-409d-8438-f1e29c834a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:to="loc_us-gaap_ContractWithCustomerLiability_de551570-87b6-409d-8438-f1e29c834a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a682fec6-1940-46c3-9d40-ad59d015e91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a682fec6-1940-46c3-9d40-ad59d015e91f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_d1fea0bc-244d-4f09-9b1b-859db0ef0981" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_d1fea0bc-244d-4f09-9b1b-859db0ef0981" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_75453087-3955-40eb-9689-1c841f596cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_bb44feb3-14d1-4afc-8bc9-af9082387ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_bb44feb3-14d1-4afc-8bc9-af9082387ef3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd3fd6cc-1bc0-44e5-8ebf-411f7914242a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd3fd6cc-1bc0-44e5-8ebf-411f7914242a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8729ac78-d0fe-4741-a6d1-ec42f3015c0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd3fd6cc-1bc0-44e5-8ebf-411f7914242a" xlink:to="loc_srt_ProductOrServiceAxis_8729ac78-d0fe-4741-a6d1-ec42f3015c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8729ac78-d0fe-4741-a6d1-ec42f3015c0d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8729ac78-d0fe-4741-a6d1-ec42f3015c0d" xlink:to="loc_srt_ProductsAndServicesDomain_8729ac78-d0fe-4741-a6d1-ec42f3015c0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ded3b2b8-4f46-4184-8401-f6d5729e6700" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8729ac78-d0fe-4741-a6d1-ec42f3015c0d" xlink:to="loc_srt_ProductsAndServicesDomain_ded3b2b8-4f46-4184-8401-f6d5729e6700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_21d73d83-bf98-46d6-b45f-836d139a12c2" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ded3b2b8-4f46-4184-8401-f6d5729e6700" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_21d73d83-bf98-46d6-b45f-836d139a12c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended" id="ie945c78579544a0a991561ff2f55d565_FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bf8d4bd0-521e-49b1-9800-6f6b0434641c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bf8d4bd0-521e-49b1-9800-6f6b0434641c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ce3f55de-6a79-4eaa-bdb2-276dc58b4b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ce3f55de-6a79-4eaa-bdb2-276dc58b4b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637680f5-058e-4c4a-a3d7-31c4840bd7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637680f5-058e-4c4a-a3d7-31c4840bd7b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f248a99-c5c8-4cfa-a321-2561c0ef8eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f248a99-c5c8-4cfa-a321-2561c0ef8eb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9258c93e-aa0e-4e5f-8845-1c318090b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9258c93e-aa0e-4e5f-8845-1c318090b18b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9258c93e-aa0e-4e5f-8845-1c318090b18b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9258c93e-aa0e-4e5f-8845-1c318090b18b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9258c93e-aa0e-4e5f-8845-1c318090b18b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9258c93e-aa0e-4e5f-8845-1c318090b18b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_2fb2e147-e094-4ff0-a7f0-2768079e2069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_2fb2e147-e094-4ff0-a7f0-2768079e2069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e3040bde-a457-4d55-b2e0-f751c7d12927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e3040bde-a457-4d55-b2e0-f751c7d12927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5e036df3-c93d-4825-bc56-a1fe50062eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5e036df3-c93d-4825-bc56-a1fe50062eac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ca08cc17-01cc-42e9-a9bd-8a36e9b85bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ca08cc17-01cc-42e9-a9bd-8a36e9b85bc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ecf801e1-770e-4b99-ad89-ed85d261f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ecf801e1-770e-4b99-ad89-ed85d261f26d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf6a74be-1ee3-4041-b31a-9829799ce5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf6a74be-1ee3-4041-b31a-9829799ce5f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bf6a74be-1ee3-4041-b31a-9829799ce5f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf6a74be-1ee3-4041-b31a-9829799ce5f1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bf6a74be-1ee3-4041-b31a-9829799ce5f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf6a74be-1ee3-4041-b31a-9829799ce5f1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_54dc87cb-61fc-428b-b2bc-61d4bed806ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_54dc87cb-61fc-428b-b2bc-61d4bed806ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_ce2478ec-a0f6-439d-97f7-518d4276400c" xlink:href="mrna-20210630.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_ce2478ec-a0f6-439d-97f7-518d4276400c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_700e257f-492c-4161-a766-5c97fdf0fcb5" xlink:href="mrna-20210630.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_700e257f-492c-4161-a766-5c97fdf0fcb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_60493d01-ea82-48a6-af7b-fee1f85ef755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_60493d01-ea82-48a6-af7b-fee1f85ef755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3a4c358b-d6e5-4672-9847-05ac1fe80bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3a4c358b-d6e5-4672-9847-05ac1fe80bcb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended" id="ia70ff7ffc4414441ad68b9a4452ed8f8_FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0035a510-5eec-49f2-a05e-f3b98b8c1f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0035a510-5eec-49f2-a05e-f3b98b8c1f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_02f4c55f-91e0-4bfb-ac50-8d1f77e4b9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_DerivativeAssets_02f4c55f-91e0-4bfb-ac50-8d1f77e4b9c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d33a1e6f-95d7-4ccf-bce9-646856058160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d33a1e6f-95d7-4ccf-bce9-646856058160" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b264c09d-e0ce-42bd-8c1d-e160fe8e1299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_DerivativeLiabilities_b264c09d-e0ce-42bd-8c1d-e160fe8e1299" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e34aa72f-c921-46f4-82a3-821449568fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e34aa72f-c921-46f4-82a3-821449568fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e34aa72f-c921-46f4-82a3-821449568fe6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e34aa72f-c921-46f4-82a3-821449568fe6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e34aa72f-c921-46f4-82a3-821449568fe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f50960b7-8e0f-4a7e-b8b5-359b09cd128a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e34aa72f-c921-46f4-82a3-821449568fe6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f50960b7-8e0f-4a7e-b8b5-359b09cd128a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b97bf247-68cf-4ae0-839f-cfeef025d819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f50960b7-8e0f-4a7e-b8b5-359b09cd128a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b97bf247-68cf-4ae0-839f-cfeef025d819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d7bb4843-41b5-4d93-a4e4-e61828fa04d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d7bb4843-41b5-4d93-a4e4-e61828fa04d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4239f974-409a-4b9a-a355-a1c5a2140ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4239f974-409a-4b9a-a355-a1c5a2140ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_91b7c6c0-92b4-40ad-87cc-3865e33ec5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_91b7c6c0-92b4-40ad-87cc-3865e33ec5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae7fbef1-c765-47d9-ae13-cd01721ad294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae7fbef1-c765-47d9-ae13-cd01721ad294" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fd04a364-1004-46ed-9412-5a80d2cd64b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fd04a364-1004-46ed-9412-5a80d2cd64b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b659f728-c517-452e-8bb5-c7d0558a2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b659f728-c517-452e-8bb5-c7d0558a2fe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b659f728-c517-452e-8bb5-c7d0558a2fe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b659f728-c517-452e-8bb5-c7d0558a2fe5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b659f728-c517-452e-8bb5-c7d0558a2fe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b659f728-c517-452e-8bb5-c7d0558a2fe5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8183300-7110-4fd9-bec6-1722040755a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8183300-7110-4fd9-bec6-1722040755a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25657013-7dff-4832-883f-f90a51920930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25657013-7dff-4832-883f-f90a51920930" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="extended" id="iee1319f6a2124abd90d54e1b91d3c175_DerivativeFinancialInstrumentsBalanceSheetHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_636319dd-0937-4f4f-bfb0-523d6e7a4afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_636319dd-0937-4f4f-bfb0-523d6e7a4afb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_fe78bfe0-50cd-4d1a-9c39-70a09817998b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeAssets_fe78bfe0-50cd-4d1a-9c39-70a09817998b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8e08302d-10e3-4f38-9a55-a10a8f59ddf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeLiabilities_8e08302d-10e3-4f38-9a55-a10a8f59ddf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d7258c9a-4de7-47b9-94e2-fd4af6fe8e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d7258c9a-4de7-47b9-94e2-fd4af6fe8e40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d96a6b29-74c7-4dad-94db-1e8bc8fd4375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d96a6b29-74c7-4dad-94db-1e8bc8fd4375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d96a6b29-74c7-4dad-94db-1e8bc8fd4375_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d96a6b29-74c7-4dad-94db-1e8bc8fd4375" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d96a6b29-74c7-4dad-94db-1e8bc8fd4375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9336260c-1002-444d-8c64-f7d4e4374d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d96a6b29-74c7-4dad-94db-1e8bc8fd4375" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9336260c-1002-444d-8c64-f7d4e4374d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fa497cc0-cbce-4855-af19-c323722ae7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9336260c-1002-444d-8c64-f7d4e4374d90" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fa497cc0-cbce-4855-af19-c323722ae7b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8a66252-83fe-4975-90c5-59e063ae58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8a66252-83fe-4975-90c5-59e063ae58ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8a66252-83fe-4975-90c5-59e063ae58ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8a66252-83fe-4975-90c5-59e063ae58ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8a66252-83fe-4975-90c5-59e063ae58ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f682ed3-f490-4a9b-9405-5f0784f398c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8a66252-83fe-4975-90c5-59e063ae58ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f682ed3-f490-4a9b-9405-5f0784f398c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_43b30bf8-0073-451f-b2f9-7a3f32b18e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f682ed3-f490-4a9b-9405-5f0784f398c0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_43b30bf8-0073-451f-b2f9-7a3f32b18e2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_74aef084-d0b1-4fcb-aa44-d96017778699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_HedgingDesignationAxis_74aef084-d0b1-4fcb-aa44-d96017778699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_74aef084-d0b1-4fcb-aa44-d96017778699_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_74aef084-d0b1-4fcb-aa44-d96017778699" xlink:to="loc_us-gaap_HedgingDesignationDomain_74aef084-d0b1-4fcb-aa44-d96017778699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_74aef084-d0b1-4fcb-aa44-d96017778699" xlink:to="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18b10de2-5c77-464c-ab19-68339c503b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18b10de2-5c77-464c-ab19-68339c503b5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_184ed802-c3a0-4891-95e0-498b907949dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:to="loc_us-gaap_NondesignatedMember_184ed802-c3a0-4891-95e0-498b907949dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_56c2a499-4ecc-41d9-bade-80f8c0023aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_56c2a499-4ecc-41d9-bade-80f8c0023aff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_56c2a499-4ecc-41d9-bade-80f8c0023aff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_56c2a499-4ecc-41d9-bade-80f8c0023aff" xlink:to="loc_us-gaap_HedgingRelationshipDomain_56c2a499-4ecc-41d9-bade-80f8c0023aff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_231ce5ec-7a7d-494e-b313-e85b9eb3f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_56c2a499-4ecc-41d9-bade-80f8c0023aff" xlink:to="loc_us-gaap_HedgingRelationshipDomain_231ce5ec-7a7d-494e-b313-e85b9eb3f6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_24af5402-6a34-475a-a09b-b75af30e3d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_231ce5ec-7a7d-494e-b313-e85b9eb3f6f7" xlink:to="loc_us-gaap_CashFlowHedgingMember_24af5402-6a34-475a-a09b-b75af30e3d5c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="if7974d36aa734a8e894a467b6610184c_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_85164b32-7e27-40f0-94cb-ddf5c70224f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_85164b32-7e27-40f0-94cb-ddf5c70224f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9145da6a-0088-4f47-889c-d3bfd9c8c510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9145da6a-0088-4f47-889c-d3bfd9c8c510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e1f77932-1d2a-46ed-aec0-7ac5d40004c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e1f77932-1d2a-46ed-aec0-7ac5d40004c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2e873e91-d0a1-407e-96a5-8dde5717001e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2e873e91-d0a1-407e-96a5-8dde5717001e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_823a7a08-f69c-40c9-94ee-eca3c929c647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_823a7a08-f69c-40c9-94ee-eca3c929c647" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12da8554-1ef8-4068-8911-9fdd6e300e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_823a7a08-f69c-40c9-94ee-eca3c929c647" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12da8554-1ef8-4068-8911-9fdd6e300e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12da8554-1ef8-4068-8911-9fdd6e300e75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12da8554-1ef8-4068-8911-9fdd6e300e75" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12da8554-1ef8-4068-8911-9fdd6e300e75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12da8554-1ef8-4068-8911-9fdd6e300e75" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_4f9df959-6f73-49e9-a2f1-7b644cf8fed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_EquipmentMember_4f9df959-6f73-49e9-a2f1-7b644cf8fed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bbf4648c-8eaf-4504-901c-72cf0e8431f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bbf4648c-8eaf-4504-901c-72cf0e8431f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9f18e7b0-2cfd-4d21-9459-b72eff1f2c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9f18e7b0-2cfd-4d21-9459-b72eff1f2c52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3a2b9836-4f43-4327-97c8-02dd6c74813d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_ComputerEquipmentMember_3a2b9836-4f43-4327-97c8-02dd6c74813d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_96f9cbda-f922-4393-981d-5054c7862724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_96f9cbda-f922-4393-981d-5054c7862724" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_3ec0a258-fe16-4f43-be42-cb03e7ba05a6" xlink:href="mrna-20210630.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_3ec0a258-fe16-4f43-be42-cb03e7ba05a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_75f3759e-a996-4214-acde-36407060f957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_ConstructionInProgressMember_75f3759e-a996-4214-acde-36407060f957" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended" id="ib7386eff60c34ffa9e6a7bbf71229ec8_OtherBalanceSheetComponentsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_e360fec2-f54e-4ad3-a781-66988ed5a0ef" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_e360fec2-f54e-4ad3-a781-66988ed5a0ef" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4bfb3c4c-1a65-4193-a3e5-b5f8344b5f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4bfb3c4c-1a65-4193-a3e5-b5f8344b5f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_61ad14dc-f604-417f-831c-968d0a8e4ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_61ad14dc-f604-417f-831c-968d0a8e4ef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_ead4a315-bf5b-41e8-8885-fac061f016c4" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_ead4a315-bf5b-41e8-8885-fac061f016c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6eecd279-7418-4293-8a63-410304f86a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_08194543-a4f5-4ef8-8938-6be11d5c05da" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_e360fec2-f54e-4ad3-a781-66988ed5a0ef" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_08194543-a4f5-4ef8-8938-6be11d5c05da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_107cdc4b-cb38-4e15-9545-20c2335ad7af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_08194543-a4f5-4ef8-8938-6be11d5c05da" xlink:to="loc_srt_ProductOrServiceAxis_107cdc4b-cb38-4e15-9545-20c2335ad7af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_107cdc4b-cb38-4e15-9545-20c2335ad7af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_107cdc4b-cb38-4e15-9545-20c2335ad7af" xlink:to="loc_srt_ProductsAndServicesDomain_107cdc4b-cb38-4e15-9545-20c2335ad7af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_107cdc4b-cb38-4e15-9545-20c2335ad7af" xlink:to="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_323aafb6-0f5c-4a28-980d-747b73cc895c" xlink:href="mrna-20210630.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:to="loc_mrna_ProductSalesMember_323aafb6-0f5c-4a28-980d-747b73cc895c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_85dbccdd-8497-4a95-ba35-4e7190ac2311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:to="loc_us-gaap_GrantMember_85dbccdd-8497-4a95-ba35-4e7190ac2311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_2952b54b-2731-4bc7-a425-6bba37bbc5b7" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:to="loc_mrna_CollaborationArrangementMember_2952b54b-2731-4bc7-a425-6bba37bbc5b7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i4181538d35fa4deb99660d3d0f6eac82_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_2f8a0df0-7f8b-4e56-b6a6-7728590d34d2" xlink:href="mrna-20210630.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_2f8a0df0-7f8b-4e56-b6a6-7728590d34d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5f72e8fc-2233-4b08-bf48-223a454d6221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5f72e8fc-2233-4b08-bf48-223a454d6221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_afb07a19-23b0-4fde-8273-313dcafb6d0c" xlink:href="mrna-20210630.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_afb07a19-23b0-4fde-8273-313dcafb6d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a540c88-12ac-4f2f-aff4-54b370f1061f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a540c88-12ac-4f2f-aff4-54b370f1061f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements_37b42350-c5d8-4356-bc10-171cb72668da" xlink:href="mrna-20210630.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_AllowanceForTenantImprovements_37b42350-c5d8-4356-bc10-171cb72668da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_431fdb8b-3e3f-40a5-bc5f-78e220a6621a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_OperatingLeaseLiability_431fdb8b-3e3f-40a5-bc5f-78e220a6621a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d15f5474-7b1c-466f-863c-59705e3e695c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d15f5474-7b1c-466f-863c-59705e3e695c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef99fd56-a83d-47e9-aaa3-f8bd82dba91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef99fd56-a83d-47e9-aaa3-f8bd82dba91b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesImputedInterestRate_358c0421-23f7-4afb-9eb4-4c84362da668" xlink:href="mrna-20210630.xsd#mrna_LeasesImputedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_LeasesImputedInterestRate_358c0421-23f7-4afb-9eb4-4c84362da668" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesIncrementalBorrowingRate_0930eb20-2adf-4d81-b1c6-e3256d6d50b8" xlink:href="mrna-20210630.xsd#mrna_LeasesIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_LeasesIncrementalBorrowingRate_0930eb20-2adf-4d81-b1c6-e3256d6d50b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7ce12268-e9f6-4bf7-ba61-eeb660b0f614" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:to="loc_srt_StatementGeographicalAxis_7ce12268-e9f6-4bf7-ba61-eeb660b0f614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7ce12268-e9f6-4bf7-ba61-eeb660b0f614_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7ce12268-e9f6-4bf7-ba61-eeb660b0f614" xlink:to="loc_srt_SegmentGeographicalDomain_7ce12268-e9f6-4bf7-ba61-eeb660b0f614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7ce12268-e9f6-4bf7-ba61-eeb660b0f614" xlink:to="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_35db24ac-db24-489f-90e8-55f94db59245" xlink:href="mrna-20210630.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:to="loc_mrna_CambridgeMassachusettsMember_35db24ac-db24-489f-90e8-55f94db59245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_c66fd157-6492-44d0-a50b-ff8f189926c9" xlink:href="mrna-20210630.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:to="loc_mrna_NorwoodMassachusettsMember_c66fd157-6492-44d0-a50b-ff8f189926c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4ddc9dd8-efcb-499c-892d-b880e4006d43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4ddc9dd8-efcb-499c-892d-b880e4006d43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4ddc9dd8-efcb-499c-892d-b880e4006d43_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4ddc9dd8-efcb-499c-892d-b880e4006d43" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4ddc9dd8-efcb-499c-892d-b880e4006d43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4ddc9dd8-efcb-499c-892d-b880e4006d43" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_f4bd4c6e-298d-4892-b5cf-91db50d1bb9c" xlink:href="mrna-20210630.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_f4bd4c6e-298d-4892-b5cf-91db50d1bb9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMember_e6155aa7-794c-47f9-8013-d23a502a489c" xlink:href="mrna-20210630.xsd#mrna_MTCSouthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCSouthMember_e6155aa7-794c-47f9-8013-d23a502a489c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember_06813402-eed5-437e-85c8-996fffecef3a" xlink:href="mrna-20210630.xsd#mrna_MTCNorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCNorthMember_06813402-eed5-437e-85c8-996fffecef3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCEastMember_bb81d20e-7b34-4e5f-a8ba-a2a80fb67268" xlink:href="mrna-20210630.xsd#mrna_MTCEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCEastMember_bb81d20e-7b34-4e5f-a8ba-a2a80fb67268" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9b93a467-5da3-4480-81bf-5947738e8ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9b93a467-5da3-4480-81bf-5947738e8ec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9b93a467-5da3-4480-81bf-5947738e8ec5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9b93a467-5da3-4480-81bf-5947738e8ec5" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9b93a467-5da3-4480-81bf-5947738e8ec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_b3ed1572-bdb6-4893-a1b9-64bd799c2468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9b93a467-5da3-4480-81bf-5947738e8ec5" xlink:to="loc_us-gaap_LeaseContractualTermDomain_b3ed1572-bdb6-4893-a1b9-64bd799c2468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember_64486e35-14c5-4fb9-8e53-4b71e921d429" xlink:href="mrna-20210630.xsd#mrna_EmbeddedLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_b3ed1572-bdb6-4893-a1b9-64bd799c2468" xlink:to="loc_mrna_EmbeddedLeasesMember_64486e35-14c5-4fb9-8e53-4b71e921d429" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CommitmentsandContingenciesStrategicCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="extended" id="i9953582f03ec45858fc6207b38ffba65_CommitmentsandContingenciesStrategicCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_380f5bb5-898e-4fba-a019-59b6785ec322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_e5c9dd73-327b-4ac3-8ce1-393f12a8609c" xlink:href="mrna-20210630.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_380f5bb5-898e-4fba-a019-59b6785ec322" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_e5c9dd73-327b-4ac3-8ce1-393f12a8609c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_380f5bb5-898e-4fba-a019-59b6785ec322" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1de06d3-4a9c-48b1-9d87-3a7f6329f850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1de06d3-4a9c-48b1-9d87-3a7f6329f850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f1de06d3-4a9c-48b1-9d87-3a7f6329f850_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1de06d3-4a9c-48b1-9d87-3a7f6329f850" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f1de06d3-4a9c-48b1-9d87-3a7f6329f850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bf3ca81-12c9-435a-87c8-dbadafa86f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1de06d3-4a9c-48b1-9d87-3a7f6329f850" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bf3ca81-12c9-435a-87c8-dbadafa86f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_e8341152-5814-4798-aff9-269771ef8288" xlink:href="mrna-20210630.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bf3ca81-12c9-435a-87c8-dbadafa86f76" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_e8341152-5814-4798-aff9-269771ef8288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed6292fb-08d6-4a81-bf13-00abfc2ddee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed6292fb-08d6-4a81-bf13-00abfc2ddee9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ed6292fb-08d6-4a81-bf13-00abfc2ddee9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed6292fb-08d6-4a81-bf13-00abfc2ddee9" xlink:to="loc_us-gaap_ProjectMember_ed6292fb-08d6-4a81-bf13-00abfc2ddee9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_bcbe49fc-6bbc-4f89-a318-d6b3c1381701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed6292fb-08d6-4a81-bf13-00abfc2ddee9" xlink:to="loc_us-gaap_ProjectMember_bcbe49fc-6bbc-4f89-a318-d6b3c1381701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_1e785ed2-403e-40df-aebf-d01d752a060c" xlink:href="mrna-20210630.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_bcbe49fc-6bbc-4f89-a318-d6b3c1381701" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_1e785ed2-403e-40df-aebf-d01d752a060c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended" id="i9421a2794e4e46ddba2db6a24476c0f4_CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_1eb8d5b1-a718-40f7-af11-39e8050f1008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_69a7cc41-6431-48da-9347-562a4fcb000b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_1eb8d5b1-a718-40f7-af11-39e8050f1008" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_69a7cc41-6431-48da-9347-562a4fcb000b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_f5cfd2dc-95f2-4e29-abc8-a9be97a39b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_1eb8d5b1-a718-40f7-af11-39e8050f1008" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_f5cfd2dc-95f2-4e29-abc8-a9be97a39b6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_09e85028-05de-4299-b46c-42b33cb894e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_f5cfd2dc-95f2-4e29-abc8-a9be97a39b6c" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_09e85028-05de-4299-b46c-42b33cb894e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_09e85028-05de-4299-b46c-42b33cb894e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_09e85028-05de-4299-b46c-42b33cb894e7" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_09e85028-05de-4299-b46c-42b33cb894e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_09e85028-05de-4299-b46c-42b33cb894e7" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_3f1fe1ff-33ab-4522-b6aa-b1edb99331ad" xlink:href="mrna-20210630.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_3f1fe1ff-33ab-4522-b6aa-b1edb99331ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_bcb87373-a4ae-464f-80df-a5f23ee81207" xlink:href="mrna-20210630.xsd#mrna_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:to="loc_mrna_ClinicalServicesMember_bcb87373-a4ae-464f-80df-a5f23ee81207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_f5e9f76e-b66b-45fb-9ae2-fe948f93d795" xlink:href="mrna-20210630.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_f5e9f76e-b66b-45fb-9ae2-fe948f93d795" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ie13b3a42ceca4aed84ff098dfea6d272_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3055606-edf0-42c5-afd1-08f190d0cbce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3055606-edf0-42c5-afd1-08f190d0cbce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2757e18d-b8ae-433e-a9f8-acf8d0d1a70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2757e18d-b8ae-433e-a9f8-acf8d0d1a70c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c530f3b-b3a1-45d6-b75c-2e1e53caacaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c530f3b-b3a1-45d6-b75c-2e1e53caacaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d33d62ec-86a1-4ea5-9fdf-c3cf9b6f32f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d33d62ec-86a1-4ea5-9fdf-c3cf9b6f32f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4911919e-4c6b-4e51-9d75-4b9b55d4310f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4911919e-4c6b-4e51-9d75-4b9b55d4310f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_63ae8110-207d-491e-a91a-145e856c4144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_RestrictedStockExpense_63ae8110-207d-491e-a91a-145e856c4144" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_340dcf35-7634-445c-a283-bef6ab83a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_340dcf35-7634-445c-a283-bef6ab83a3ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3f1fb828-4aac-4304-9635-1c7a9e7f4613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3f1fb828-4aac-4304-9635-1c7a9e7f4613" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_3a77dddc-2f97-48ca-9808-1a42ef3fe2f3" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_3a77dddc-2f97-48ca-9808-1a42ef3fe2f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b234af5a-d767-4c43-94b9-b5982690c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b234af5a-d767-4c43-94b9-b5982690c3d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21842050-3c7c-4222-be64-1ba1091b2228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21842050-3c7c-4222-be64-1ba1091b2228" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5cebcc29-700a-4aa6-ada5-7fa55eeeaa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5cebcc29-700a-4aa6-ada5-7fa55eeeaa60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_21838655-faaa-41b9-83b3-c367d9fcf606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:to="loc_us-gaap_PlanNameAxis_21838655-faaa-41b9-83b3-c367d9fcf606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_21838655-faaa-41b9-83b3-c367d9fcf606_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_21838655-faaa-41b9-83b3-c367d9fcf606" xlink:to="loc_us-gaap_PlanNameDomain_21838655-faaa-41b9-83b3-c367d9fcf606_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83683c15-575a-4013-bfbb-2a33a6b7bbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_21838655-faaa-41b9-83b3-c367d9fcf606" xlink:to="loc_us-gaap_PlanNameDomain_83683c15-575a-4013-bfbb-2a33a6b7bbf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_7a9dbaa6-8be8-4052-a6a9-8dfb56c0eaad" xlink:href="mrna-20210630.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_83683c15-575a-4013-bfbb-2a33a6b7bbf8" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_7a9dbaa6-8be8-4052-a6a9-8dfb56c0eaad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9da3f1af-440a-4cc3-a7f5-3da15b0703df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:to="loc_us-gaap_AwardTypeAxis_9da3f1af-440a-4cc3-a7f5-3da15b0703df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9da3f1af-440a-4cc3-a7f5-3da15b0703df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9da3f1af-440a-4cc3-a7f5-3da15b0703df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9da3f1af-440a-4cc3-a7f5-3da15b0703df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9da3f1af-440a-4cc3-a7f5-3da15b0703df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f76941e9-5d08-49f3-9f96-46c0b27087fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f76941e9-5d08-49f3-9f96-46c0b27087fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a83d5e2a-1880-40d2-9494-4638782acba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_EmployeeStockMember_a83d5e2a-1880-40d2-9494-4638782acba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_87a28216-b539-4e72-8c7c-74a74b4eb8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_87a28216-b539-4e72-8c7c-74a74b4eb8b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a9b792b0-be57-4ecd-82b9-c71de54b4e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_PerformanceSharesMember_a9b792b0-be57-4ecd-82b9-c71de54b4e5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ffadd773-cdba-4324-9012-b2698991b2d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:to="loc_srt_RangeAxis_ffadd773-cdba-4324-9012-b2698991b2d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ffadd773-cdba-4324-9012-b2698991b2d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ffadd773-cdba-4324-9012-b2698991b2d7" xlink:to="loc_srt_RangeMember_ffadd773-cdba-4324-9012-b2698991b2d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ffadd773-cdba-4324-9012-b2698991b2d7" xlink:to="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05186ba1-da99-4575-b7ee-bfea89dcef19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:to="loc_srt_MinimumMember_05186ba1-da99-4575-b7ee-bfea89dcef19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20fe0ba2-ad2d-4c72-aba0-a5096fe76fa1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:to="loc_srt_MaximumMember_20fe0ba2-ad2d-4c72-aba0-a5096fe76fa1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended" id="i3673bef0ebe14c678df3cdd188a269c2_StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c57befa4-384f-4907-b253-8ee5c82c3b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c57befa4-384f-4907-b253-8ee5c82c3b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12235a42-88e0-40ee-a30f-7dd175cb6797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12235a42-88e0-40ee-a30f-7dd175cb6797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ad7063e8-f573-4e44-a49e-898c1e6da702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ad7063e8-f573-4e44-a49e-898c1e6da702" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_467b7624-91a3-421b-a578-eefa69b4c6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_467b7624-91a3-421b-a578-eefa69b4c6ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc45ced-82f1-4378-bda2-05a794e0e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa1857fa-b02a-4cc9-8e6c-41f341f127cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa1857fa-b02a-4cc9-8e6c-41f341f127cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b526955-0535-42f2-a5ba-4a81fdbff2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b526955-0535-42f2-a5ba-4a81fdbff2a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29773420-b3bb-4431-a31c-21dfabe14e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29773420-b3bb-4431-a31c-21dfabe14e8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4f2c5107-7f68-43c5-b7e9-d65fabccc9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4f2c5107-7f68-43c5-b7e9-d65fabccc9c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5b51baae-5661-4cd4-ae3b-25f8950b3b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f818430-0a97-4165-8157-2f2b3a5e7375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f818430-0a97-4165-8157-2f2b3a5e7375" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f818430-0a97-4165-8157-2f2b3a5e7375" xlink:to="loc_us-gaap_AwardTypeAxis_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aa76d75-11c4-4d27-9fe9-e1020aafac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aa76d75-11c4-4d27-9fe9-e1020aafac2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2d802328-8b71-4f59-b99f-72f7b22174fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aa76d75-11c4-4d27-9fe9-e1020aafac2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2d802328-8b71-4f59-b99f-72f7b22174fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i6c5b50bf3e2c481ab25ac473ba8397d3_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5e82db86-b70d-48e6-bb31-25350e8ef644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b938d0a1-cef3-4b59-b20d-e231f9452760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5e82db86-b70d-48e6-bb31-25350e8ef644" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b938d0a1-cef3-4b59-b20d-e231f9452760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5e82db86-b70d-48e6-bb31-25350e8ef644" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:to="loc_us-gaap_AwardTypeAxis_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_700bfbe9-d9f3-4922-b9b7-315a29c90a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_700bfbe9-d9f3-4922-b9b7-315a29c90a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_24aa2ae3-833d-4275-a631-53d95a1cdae6" xlink:href="mrna-20210630.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:to="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_24aa2ae3-833d-4275-a631-53d95a1cdae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f247023f-50b9-46a1-94d7-ca2d570fca33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:to="loc_us-gaap_EmployeeStockMember_f247023f-50b9-46a1-94d7-ca2d570fca33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5940d485-6d2f-4011-9663-1807764a5953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5940d485-6d2f-4011-9663-1807764a5953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5940d485-6d2f-4011-9663-1807764a5953_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5940d485-6d2f-4011-9663-1807764a5953" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5940d485-6d2f-4011-9663-1807764a5953_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5940d485-6d2f-4011-9663-1807764a5953" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_35e736f5-3d19-44f2-9f90-58968ff0e76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:to="loc_us-gaap_CostOfSalesMember_35e736f5-3d19-44f2-9f90-58968ff0e76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c597d9a-2760-4485-a79a-5faeb13e405b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c597d9a-2760-4485-a79a-5faeb13e405b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_93b9e1cd-65c1-47eb-a3a7-bc7c73b461c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_93b9e1cd-65c1-47eb-a3a7-bc7c73b461c5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i1f83be9df342481a9fe959b470b13638_EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_001bad19-9ea3-4a93-b420-ac12391945f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01a0561b-aa3e-4084-9235-06e6cb42cb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_001bad19-9ea3-4a93-b420-ac12391945f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01a0561b-aa3e-4084-9235-06e6cb42cb91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b455060-d5cd-4b04-92d8-8ed76e9374e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_001bad19-9ea3-4a93-b420-ac12391945f4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b455060-d5cd-4b04-92d8-8ed76e9374e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_69f5e374-24f5-41b5-8511-bf15ee3a258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b455060-d5cd-4b04-92d8-8ed76e9374e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_69f5e374-24f5-41b5-8511-bf15ee3a258d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_69f5e374-24f5-41b5-8511-bf15ee3a258d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_69f5e374-24f5-41b5-8511-bf15ee3a258d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_69f5e374-24f5-41b5-8511-bf15ee3a258d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_69f5e374-24f5-41b5-8511-bf15ee3a258d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4cf2216e-a85c-4265-84e4-69a8982e637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4cf2216e-a85c-4265-84e4-69a8982e637b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e57ab7b1-50c1-4176-92ea-ac52668b2af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e57ab7b1-50c1-4176-92ea-ac52668b2af3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended" id="id838945a4e62498da0737f306906f857_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate_8ea94344-05bb-47e1-bc64-11dd0ce7ba09" xlink:href="mrna-20210630.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:to="loc_mrna_NumberOfDosesOfVaccineCandidate_8ea94344-05bb-47e1-bc64-11dd0ce7ba09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_558aca0a-6713-4ae8-a710-5a76659a0768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_558aca0a-6713-4ae8-a710-5a76659a0768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_06813e2c-3583-4e96-af46-233102d35b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:to="loc_us-gaap_SubsequentEventTable_06813e2c-3583-4e96-af46-233102d35b8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2d775dc6-de76-4f1b-846b-d8b7113e1450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_06813e2c-3583-4e96-af46-233102d35b8e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2d775dc6-de76-4f1b-846b-d8b7113e1450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2d775dc6-de76-4f1b-846b-d8b7113e1450_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2d775dc6-de76-4f1b-846b-d8b7113e1450" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2d775dc6-de76-4f1b-846b-d8b7113e1450_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcd7135f-9ffe-4077-a7a3-f6ed7e94f04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2d775dc6-de76-4f1b-846b-d8b7113e1450" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcd7135f-9ffe-4077-a7a3-f6ed7e94f04d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7c28eae0-4fd4-4d81-b139-20a3f6b9de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fcd7135f-9ffe-4077-a7a3-f6ed7e94f04d" xlink:to="loc_us-gaap_SubsequentEventMember_7c28eae0-4fd4-4d81-b139-20a3f6b9de7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mrna-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1f43850e-4c17-48f6-8a24-63bc21a94b8b,g:a986bd34-a907-438b-9a06-ed4dd6fbe7f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mrna_ClinicalServicesMember_ed6626a8-35e1-4757-9e6e-7d316307b658_terseLabel_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_label_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_documentation_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember" xlink:href="mrna-20210630.xsd#mrna_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalServicesMember" xlink:to="lab_mrna_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_61029fba-54e7-4751-bdc2-dbb43065df10_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount for share repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_d1ce2f35-cf0f-4ec2-a894-66e9fae86bbd_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_57fa9c03-078d-40e4-818b-4081b070e8c0_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9b35f66e-838f-468e-a761-8d5f165a0900_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_VertexMember_5ad9e63b-cb85-47bd-be20-f61f7f8cebe4_terseLabel_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_mrna_VertexMember_label_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_mrna_VertexMember_documentation_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember" xlink:href="mrna-20210630.xsd#mrna_VertexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VertexMember" xlink:to="lab_mrna_VertexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_936d7d24-da02-4591-8249-407ec79f091f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_e7f2dbc4-8364-4073-a91e-28043eeb5077_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCV products</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:href="mrna-20210630.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8690421b-810f-4f70-84e4-089957f4b237_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_1e9c5e79-b2a2-427d-aa11-13cf1f558c68_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e3d43a9-fd87-4628-885a-454279de7f06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c2708dd-b1ff-4bd1-be6a-9473d0c257a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f089b496-827e-4ea5-a48f-88666cac381f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4e234bc1-6a95-4e20-b196-ede42400378e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_62f265e3-5faa-4451-8467-1c200406eea9_terseLabel_en-US" xlink:label="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="mrna-20210630.xsd#mrna_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_dbfcf249-e3f7-4cc1-9d9e-a0703975a7b8_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract options exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_c7a6c22f-8097-4d7f-950c-4558b9e0299e_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Plan</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_label_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_documentation_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:href="mrna-20210630.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:to="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_589de157-09d0-4b80-bbb1-0db7da1c3ab4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b1911edb-2ea8-437a-be65-04948d1ddd32_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_adf946a0-d6d8-4e52-8f75-198ad80247fb_terseLabel_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember" xlink:href="mrna-20210630.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CurrentMarketableSecuritiesMember" xlink:to="lab_mrna_CurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8cd2e8c0-5ec1-438c-8f78-1c91d3a50f03_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_32764a48-2332-4232-bd85-1440c98e1659_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5d17049b-3599-477a-a236-633bd87f1935_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation-related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4fb09026-b4a8-4e2f-8efc-199d88d0715b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetPurchase_d3809500-1818-44bd-9436-d0886a6c0722_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetPurchase_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetPurchase" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetPurchase" xlink:to="lab_us-gaap_ContractWithCustomerAssetPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_86b80135-d453-4d13-97c5-ae5195e577d6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dcb107a2-1866-49d2-91ea-8715abb12a3d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a4446204-69c9-49cc-8f6b-bbf12b65b439_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_2ab272e2-5f70-4401-b5e6-a8b7010abf57_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_3f3927a5-13b6-483a-b95c-e9a0268b8444_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f80a86d1-3913-4da3-9fad-02beb9a2e216_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_18faa45f-3972-4d93-91e4-fb2672b43924_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6e523d35-eb76-4168-b9f0-a45a6b6c0486_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Balances of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5fff328f-99c9-4f59-9ee6-dad57d668077_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_51c87ea0-0201-47cc-8529-f926a5f1eb38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_cc932a96-b913-4c87-8d5a-f3b4555b86c1_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value added tax receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1c8c57ce-2a0c-4d08-bad8-6d7b70d49eb9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138f5865-b694-4fa5-92a2-02654142e5ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_05b6b0de-bbda-418b-a5fa-e930f8ed533f_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3d19a1d7-4c1f-4023-a79d-2aa5543e1cdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ea73a46-7c8b-4230-981b-c2fd7ef7d8a8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9144e766-94bb-4da5-8335-f5e2898deb50_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_a1777d02-bf51-4ea0-8695-691232d871a8_terseLabel_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_label_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_documentation_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements" xlink:href="mrna-20210630.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AllowanceForTenantImprovements" xlink:to="lab_mrna_AllowanceForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7bfa9dc0-cae6-4f69-80d7-4a81291ef2a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_7da1fbff-3487-4dfc-9903-3f3884f4d6bd_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4447921b-f053-4890-a91c-b8d9f9b897e0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_db52d342-4e51-4975-bc55-ab61896c4d74_terseLabel_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Current Marketable Securities</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:href="mrna-20210630.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:to="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_22834509-3c2f-4732-b185-4d50dd8c8d67_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_466bbe85-7f4f-4460-a99c-560c2bfaf0f6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ce2c388-5935-4c8d-8dbe-fbdf00c2a243_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8873d8f8-6854-48ae-a93b-003101d6dfd4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d0e307d6-aa11-44bd-a507-5607c70f6ff2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_18e3b905-b7b3-4587-9957-9fa695fbe448_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_603238eb-076c-4954-a6cd-81362d9b583c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2841cfcd-8b84-4263-a224-9a281ed2e6c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b86651a-4979-4f1d-833b-c6a307adaaae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_904524c9-9f3f-4fb4-8631-5bb20b6c4244_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_1abd586d-264e-4c33-857d-bdf1dd9815d6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bae1b7f9-43a0-40d4-92ed-c1477f8caf32_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ba229979-4801-4c4b-8c62-71c2640eca50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains on available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_bca508ee-9956-4744-b922-6c2a358b18fd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized and unrealized loss</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdafd167-1c43-43e3-8df1-0b2e878f544a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_301a12e8-4075-4ddc-b39b-83d6f4c2434a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_d46528f1-70e5-4f7b-a30f-7ae5c5306ab5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b5fa54e5-06aa-40f8-afd1-1f202c89e82c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aaa074d6-316d-48d2-94d2-b4898f5efe99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0300fabf-7303-445f-8e10-4a5fb5a5315a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AstraZenecaMember_c6439113-9c1a-4b09-8e91-8efe75376482_terseLabel_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_label_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember" xlink:href="mrna-20210630.xsd#mrna_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AstraZenecaMember" xlink:to="lab_mrna_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_60df276a-1ed5-401c-96d7-96f3e561746d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_30241d5f-6aa4-4dcd-8aa9-6349b0b69a72_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_93bffa97-5764-45a0-b3ef-cbe34ce4ffb7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_cb415db1-8517-4aba-9d27-bfd4d60343fd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d469e62e-5020-4a7c-8e93-c71aaf393248_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_55e9eb08-fa04-4532-b475-e1ee4b8b0ef3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_111a0f3b-4cbd-4d79-8a35-eb374d493652_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.0001; 162&#160;shares authorized as of June 30, 2021 and December 31, 2020; no shares issued or outstanding at June 30, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c191db0c-3be9-478f-acb4-a64212e7cbb7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_InitialProjectMember_68db7f23-78c5-408c-b67c-772a059125a6_terseLabel_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial project</link:label>
    <link:label id="lab_mrna_InitialProjectMember_label_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:label id="lab_mrna_InitialProjectMember_documentation_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember" xlink:href="mrna-20210630.xsd#mrna_InitialProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_InitialProjectMember" xlink:to="lab_mrna_InitialProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d0e2fdf-5b63-4c92-af73-bb10ecb70ddc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2a8ae4c-4de9-4569-bf49-cab11c1ca253_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2b4705b5-7b96-4882-956d-23f18cdf1ea0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCSouthMember_783072a3-85a0-4f33-9d39-591c1f07c8fe_terseLabel_en-US" xlink:label="lab_mrna_MTCSouthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South</link:label>
    <link:label id="lab_mrna_MTCSouthMember_label_en-US" xlink:label="lab_mrna_MTCSouthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South [Member]</link:label>
    <link:label id="lab_mrna_MTCSouthMember_documentation_en-US" xlink:label="lab_mrna_MTCSouthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMember" xlink:href="mrna-20210630.xsd#mrna_MTCSouthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCSouthMember" xlink:to="lab_mrna_MTCSouthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a10e3c0e-7934-413b-8b6b-4a9b9110dc94_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24d99182-a901-474a-b230-36e0845cec7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_8f70dc9d-534c-44c3-9768-2f8c54869acd_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_18143414-b3a5-4755-9b0d-2784318fa2bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_4c1cdddf-6c26-487b-aad6-51d620a4e9f9_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_a1a3cd5d-773f-409b-ae11-a61c63db9267_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5fa6b3ff-158b-4b73-9255-06783d2029a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_e2718ca1-cefe-4f2e-b22f-29fd978eb81d_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1c8b542f-11bf-4395-ad13-18ebb77d1ead_periodStartLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_35f9c211-cc80-48d4-959f-3dff3b9bab53_periodEndLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1eee1624-817a-4e82-ae83-644ceb95d63f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2e12f8aa-4c09-48af-8f86-e94c90963853_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5a54ec85-eb34-4db9-bd5d-e9b1c56644ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_999169b7-b8d2-4d6d-aa1c-8525a4e68cff_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_ed738b92-8113-4dba-8341-4e08ef67a9bf_terseLabel_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge leases</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_label_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember" xlink:href="mrna-20210630.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CambridgeMassachusettsMember" xlink:to="lab_mrna_CambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_fca1c15b-bf49-4ece-80c5-c93f55e2afca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_65442eb5-6958-41f0-9ff1-deffa1f4e89a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationArrangementMember_202f54f9-a018-4497-94eb-0b92e29dae43_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_label_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementMember" xlink:to="lab_mrna_CollaborationArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c41ad59d-d266-4884-a98f-6787731c63d7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_280c4280-b158-4edb-bb94-f45d24d7ce83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d46ee82f-3006-4720-ba3b-8fe1987482dc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8e3043e8-85c9-4669-9ed8-02fc2053cc9b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3a1df1ca-c365-4913-bfd3-ffe42327720f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5236decb-915d-467c-9196-b790435602ad_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ef94afd7-b514-430f-990b-3617ba22ba8c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7751897f-272b-46f8-9065-c48a8f3c2372_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_370762cf-075c-41d3-8899-d0856eb36ecb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9a972281-aab9-43b2-86d7-775620752e5c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_df590124-a73f-41b7-8b34-b6d4e9ccf03f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_3ecd3569-a80e-44dc-b654-3316425e5bde_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_6d973406-741b-480d-9c91-88029fb70fc5_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_63a74d32-2d9e-4619-aff1-1a01a81db984_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_29215d5d-bfb1-425a-91d4-8db7ffa00a36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5d90c777-beae-4ad7-b06d-680cc4e5bab0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ccd93d2c-5d42-439b-b908-6a41e999db92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5ab478da-93b5-44ec-8105-e2f165ff9343_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_53f2f06a-d14c-4cb9-94f9-20c053a00e90_terseLabel_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;&amp; Melinda Gates Foundation</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember" xlink:href="mrna-20210630.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TheBillAndMelindaGatesFoundationMember" xlink:to="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_35615c79-ceea-4882-8f0d-9fc7f91b605e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_0673db92-9f42-402e-a0d6-c4452c467bd7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, financing, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5cbb8d4b-5e35-41a7-9c6a-d58f852db1ea_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9623ee64-876c-4cf8-a0df-91df3edc5e6e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f13704b-ff32-4975-9c0a-8f07a17d50d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a4761494-5096-479c-88c2-e2a13a25116d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9a66d776-292b-4707-909f-e22751a186a1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_88cd6f26-4074-42a2-8265-7995fa79da03_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_1960be12-fc30-4656-8cf1-7ef7b983bea7_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2c43d343-984f-4300-ba22-8c3d25cb16a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_ac04ee53-6541-415e-9d59-8ed0de0b9db5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_adbe66ab-e996-4c51-8775-1c95c4575fca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_5659fb5e-7190-4625-95cd-fbd7990c95ea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e53c5002-7267-4372-aefc-18d16e982025_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9797b63a-b16e-4aec-92bf-4a98f7e0960d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on derivative instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8ebdac02-eccc-4de0-8fe0-89e3754f33b5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_713085d3-a42a-491e-a385-21ba4f1bfec0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f8346997-3755-4c5a-9ae5-025b53e15697_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_779ac516-79d7-4cfe-ad61-55d4a111142a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_690078cd-6e48-4257-9ad2-2904b0cfebcd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42841485-9495-459c-8db6-9d62452501eb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9958b085-0480-4dd3-8d90-1a9c4654edc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a81a1d77-cce8-4ede-a5e7-0a9021ea8a05_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ac949ca8-8fe3-45f2-a81a-3395c2fac19c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2575c985-300c-44af-bbac-0e3985fbb2eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_67410548-36da-4510-a047-6a33a17035ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a3d8306a-7050-4660-a1f3-86fff62ae269_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_64f8c6c8-6594-4d0e-aac4-f5ecdb2b2903_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_032e7354-c137-4e41-be7e-7350e438db7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f5add49d-1b4e-4cef-b743-e8afb24c4c70_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9d718297-7676-468e-95d3-710915f5b0b2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3369de7c-9e9a-48a7-b155-b43b7459bd72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fa92dfae-99dc-4983-b5b6-94db783891bc_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f582e905-f531-47cd-b7ea-eaec7a258de0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_c807bce4-bf99-490e-9429-032a91ca3207_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_f993a8b6-2c89-4ccb-b364-8fc5139b4b41_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency hedges expected to be recognized within the next 12 months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_e3ab7d9c-351b-4f86-b57d-0452d722ee6d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_94e831c0-24c8-4cad-914f-2410f040c0a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_291f1184-26d6-486a-97b9-5d56fcbb57e7_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4555c329-9284-424a-a168-f76fa4bb7ca4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_09027dd5-09f8-4a69-9896-8b6229b72431_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_label_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Deductions During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Deductions During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:to="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LeasesImputedInterestRate_e75d4896-33e8-4804-9ac9-cad44df5a074_terseLabel_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest rate</link:label>
    <link:label id="lab_mrna_LeasesImputedInterestRate_label_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Imputed Interest Rate</link:label>
    <link:label id="lab_mrna_LeasesImputedInterestRate_documentation_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Imputed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesImputedInterestRate" xlink:href="mrna-20210630.xsd#mrna_LeasesImputedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LeasesImputedInterestRate" xlink:to="lab_mrna_LeasesImputedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_832f12e2-7ae0-480c-94b2-020aaccf738c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1ee3ad32-ac26-4600-8a96-75a25ce1f7fe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_671f06f1-9301-47c8-b09b-b93cf56716d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ee138f55-720f-42c3-97a5-cfff1d91104e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs of $1</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b2aee85f-d20b-4c39-9a94-188d9dfa5a14_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_55ad95eb-c0a6-4577-b4a9-8fea0da244f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_b79c51db-6e25-434c-b046-b49fff4e8e0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a72a4407-73bf-47be-8182-69747aa14d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fac3e8d8-f09e-4969-80f8-d6753eba63df_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_55e97307-a5c8-47ad-999e-0b653bfa40cf_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Assets:</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:to="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_83dd9542-f018-4068-af13-866ffd9040a3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_cc15541f-3f34-4f4d-8201-b28946c63526_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_90c4378f-f545-4a92-beba-698e1ae1cc5d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eb08342f-f683-493b-94db-2704ba7f3e72_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_907abee6-dc22-4951-9fb9-adb445f49f00_terseLabel_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical operations and support commitment</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_label_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_documentation_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:href="mrna-20210630.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:to="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_ef51d3c6-95ad-4a53-b14b-d6b3b949d225_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6cece3ca-7f03-4c6f-8d88-a7af20598a7d_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d9b9aa7d-df04-4f21-99e0-7cfcceff05cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_1adbd5fa-514a-4e9b-a306-0ff992d32c8f_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue by Strategic Collaborator:</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_label_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Including Arrangements With Affiliate [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:to="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9515630d-8b85-4785-bd54-b60de0088ce4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ec0eb452-ff2b-417d-9b81-21b7993a272c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2d0da034-82fd-4bf0-90e8-d7f4ff55838a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2021 and December 31, 2020; 403 and 399 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_032c11dc-40e6-4470-8916-15a496b66f72_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c71ea66-b01a-4c63-bfe0-efef97133d4a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of cost expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_eaed0a4b-379a-4e41-ac69-f8447b6c7b1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5cd6fa04-6aab-41fc-aed0-ca90b19c2865_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_fa00d60d-1f66-47be-a4dd-3116b2aa5534_terseLabel_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, financing (Note 11)</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_label_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_documentation_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember" xlink:href="mrna-20210630.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinancingRightOfUseAssetMember" xlink:to="lab_mrna_FinancingRightOfUseAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_586ca11a-faf5-4d6f-be2b-1d929abe6ce4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_487199b0-7f94-444e-8440-30bcb7606a6c_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f14563af-5834-4a23-b2fb-6cdc27be5698_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_861d05a6-28f6-4043-b678-a8b13293f51f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6e53b294-4d42-4e3d-b185-c2441c1e3cca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08aaeb9c-7385-454e-a0ce-a1d82c1f49b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e17542e2-1265-4dd5-88bf-46987f758b77_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remainder of the year)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_fa93b4ab-2f86-426b-8391-90ea3ec0adb5_terseLabel_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_label_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborative Parties [Member]</link:label>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_documentation_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborative Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember" xlink:href="mrna-20210630.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherCollaborativePartiesMember" xlink:to="lab_mrna_OtherCollaborativePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e5c5551a-dcef-414f-a668-d22d3127fd82_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_31016a97-b95e-46f3-9f55-17befaf1478d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_66c2ab0a-1690-4ce3-8898-5e52f752552b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_910d8658-b64a-41bd-aede-a93f57440fa8_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_4e556b47-a808-4bcc-bdf0-8f96972c7af8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0458b252-4e3e-4976-bfb8-7ddc5e2dce79_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0cffe5ab-86aa-410b-ba7a-57cb58ca7027_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_8a56fbe6-7db8-43b5-9544-9b912d23b0d3_terseLabel_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood leases</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_label_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_documentation_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember" xlink:href="mrna-20210630.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NorwoodMassachusettsMember" xlink:to="lab_mrna_NorwoodMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_57274ddc-9f4e-406e-8940-9c98dd4318d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1177e364-3d06-4ec7-a9e5-eeb10b8b0e12_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts representing interest or imputed interest, operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2863483d-ca57-429c-8b96-48e106974556_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest or imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_d514b350-4a50-4959-9742-bb4aa82cc2f3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c1df74d-ef74-4bdf-8a00-5864c760c23b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ac2e9ebc-5a93-4c7a-9b29-4e79e44eaeb5_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_570cf7e1-871b-4cb4-b7ee-6c2d1a9dc089_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e729c919-852e-4b56-99a7-5928e09f33bd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3d64895a-6881-411f-a9a8-3f2ae80103f6_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d146395-ac7b-4be3-92cc-df23b23ee51b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0b3f721b-a74c-4640-8f5d-7fd8ca22109d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest or imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_d558e00f-1d26-49d3-b043-41ef3b764440_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_9ddf347a-5771-47bb-8189-c6a89f86e899_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0447fb60-3ed7-4a12-8354-b90806858785_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0fbce1ef-6363-4c34-8a12-bd03eb290513_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_96d3f4cf-367a-4043-b2db-2f5fcaca9359_terseLabel_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Down payments to manufacturing vendors</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_label_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Manufacturing</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_documentation_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing" xlink:href="mrna-20210630.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherPrepaidExpenseManufacturing" xlink:to="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a098305-9d8c-496d-bc84-885659fa4422_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_70e5dd28-388e-4cf4-a8c4-51bb20164b8e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4396b039-b566-4702-b506-f004aed3b1a7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_9d66904e-d6c0-4729-b73d-67c78ea87dc2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_931d52db-322c-4884-a466-296e4763e5b7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43009ebb-c1e5-4a80-a1fc-6dbae8e16fac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c987fcd1-56c3-41bd-bedf-c545719fc5d2_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_47359b35-7d9d-4666-9ac9-c97a1804677f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96b5abd6-aed6-42f0-80ba-731775caf850_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9cbcf02e-2a94-4946-ac4b-8116fef676c8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ed62455-324e-4e98-8c02-b96a354cacca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_6036c238-743f-47b2-a1f4-3627cb205eff_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_5fe895b2-4dc4-40a5-bdfa-2e0ad365ea07_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_98d7a8d2-0032-4781-9e81-32b00549c38a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1d92bac6-5621-4bce-bbd0-9e88202878e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_7f309f1a-3115-4d6a-a2c3-08bfbcda65b4_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7f8c7866-ac37-4a20-8df0-dac090da9ece_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef9d17ae-f748-401b-af34-4af83666dfee_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_220b4e90-117a-4bae-b642-ad1506bcf65a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4c9d133f-4963-40b3-b6fc-300974b3c8e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c45427f0-24db-490e-a493-58dc308d2762_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_974fca94-413a-4d56-afd3-a65f7b2f4855_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bb70fba4-68e7-4b11-ae6e-98f67da9e1a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a547259e-ef59-405f-9a1a-b5ad2daec8aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_338860d8-5732-46ad-a9b1-c8f70e04d978_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_bfaa97f5-52f5-487b-b59c-93d8bde2688c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_45ed6221-365a-43ad-a957-f63f0bbd0887_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8e593ecf-74f9-4b97-b0b5-96de08f498ea_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ded730b2-bb7c-4461-8fec-61b935dbca2f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfParticipant_a3b85014-76a0-4bfe-a1c2-4f121b067db0_terseLabel_en-US" xlink:label="lab_mrna_NumberOfParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of participant</link:label>
    <link:label id="lab_mrna_NumberOfParticipant_label_en-US" xlink:label="lab_mrna_NumberOfParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Participant</link:label>
    <link:label id="lab_mrna_NumberOfParticipant_documentation_en-US" xlink:label="lab_mrna_NumberOfParticipant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipant" xlink:href="mrna-20210630.xsd#mrna_NumberOfParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfParticipant" xlink:to="lab_mrna_NumberOfParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2165315f-cfc5-48ca-a36d-21502bec6d89_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_944302b0-a454-492b-9de1-ca04ab606f52_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1a62bfbe-6d1d-4527-9ae7-9e65d87ab6cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7fd88973-89b6-432c-bb78-2c3df8af3881_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1f34d9ac-5ac2-41c4-b362-1e461c334a78_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7972c2ea-9d66-493e-a202-1f9fa6d431ac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ea607cdf-dcdf-4dc5-a091-d95555932a4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_e8bb1161-4321-454e-9e4d-ec795c539d7c_terseLabel_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other external goods and services</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_label_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:href="mrna-20210630.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:to="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_675d11e0-6072-461e-a716-5599e7a07c97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ae7b13c7-6cfb-4f20-be65-9c89dc81bfb1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cca388a5-52dc-4eb9-9f7f-426467f06cfd_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e28e1a99-3267-4292-a3df-85f5be71ef31_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7d12860c-5020-4704-84d3-ccd30e36bfc7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fedaa6ce-3176-48bd-8c4d-89bc59957481_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_be479a7d-6e60-4342-ab31-ba0f8c8181aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_6c0375e5-9830-416b-8409-59773c7803b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_94e6661b-22a0-4084-abe2-f92cf55de53d_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_86ccbb41-06c9-466a-b80d-19c63b496626_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount committed for funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:to="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_a4b13ce3-3173-48cd-b174-92d11101b81e_terseLabel_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_label_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_documentation_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:href="mrna-20210630.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_91265578-29b2-46db-9ea7-b2772b229460_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential reimbursements</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Potential Reimbursement</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Potential Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsPotentialReimbursement" xlink:to="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f6242971-0739-4134-9f80-3a7df96d0b06_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b4b82854-fd6c-4bae-acfa-b05b02b3325a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_72375403-1f58-4518-979f-9533e9ae8d50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_aeecce6d-70b3-4440-8704-77eed2051809_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_703dfc70-2ac2-492a-8f80-a3f3c61e7482_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cf3e153b-9f25-41b5-acfe-8383f49b0be3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_119f0fb4-42b1-43f5-ae50-5b0846159cbc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_e84575ce-7561-4c91-ac70-3e528d341602_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_88ef60b4-289b-4e57-aa81-a72b18c2dda0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_9c06aa8d-ddde-464d-b6f3-7ca751bd9b47_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_deccaa1d-5830-4a01-8a2c-c63cf5811285_terseLabel_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units (RSU) [Member]</link:label>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_documentation_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:href="mrna-20210630.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:to="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_922da20b-05a7-47cf-8b11-74386c9a9463_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_afd85998-57d8-4b5d-97a1-4cc9558b350a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d9bac02c-bfaa-442f-86f4-415feafb7103_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0e72cb0c-707a-45aa-a729-c2389a069fb8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_0c8551c5-33a8-49b6-9a9e-9f09acf5625a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_65cbad85-ecec-49ad-8fd7-351ae412b740_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities:</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_3bfd402a-d964-4b85-b8b9-273898490264_verboseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:to="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_cb92ab13-1a3e-4612-9f77-90f4bd0dd63e_terseLabel_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARPA</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_label_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_documentation_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:href="mrna-20210630.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:to="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_f8c069b7-1ac7-4d55-a06e-8c6257f546a5_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_28d5e0c6-56f1-4c8e-aa0d-10911cd65baf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_73ff07f4-c5bf-4a89-bae3-1886d627948f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2d8b3545-71e9-49ce-86f8-dc10d958722c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_ca8bce49-6425-4b1c-a467-cf5f4f62e1c6_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:to="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_8b25fa3d-59ed-4eec-bd86-d683b14a7bea_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b4cf766b-415c-42b8-b03c-71e3db345ab1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_a6dafcc6-b804-4d80-9d71-f29ead4e06d5_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_bc7a22cb-5b66-41e9-a7b6-fe4a6b42688f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cd51b373-b715-454c-98e5-ea95ca6d7823_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c0cf2213-6f41-4af5-9fb5-0ff39dddbf1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b233490a-b99e-4e4e-b819-77516975fec8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_85449c1c-9890-4020-a220-4e69b1218895_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1656cd96-9265-4df7-9a54-24169c74ecb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_94a94307-f068-405d-a84e-9ec885422aeb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_9f1cd9e9-d745-4a79-9251-b5fb744c4c6e_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:to="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_e804f7fb-c305-4f9f-ace6-772df09962d4_terseLabel_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained through finance lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_label_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets Obtained Through Finance Lease Modifications And Reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_documentation_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets Obtained Through Finance Lease Modifications And Reassessments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:href="mrna-20210630.xsd#mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:to="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7116503b-2505-451b-8780-4884e58506f4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_92758b7f-dd82-41ec-ab43-cb13ba686f87_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_fd69064e-7cda-4a17-8ff8-639afd974fc3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7eba1f63-a9c6-4eee-a5a9-e675b5af94f3_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_29880f52-9988-4e3e-8261-410519e7478f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1cf56163-828f-4093-ae06-7cfe4b97c853_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e0aa33ec-7be3-4a07-b196-84b5d3c6800e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares used in calculation of earnings (loss) per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_46dd81a4-d4f2-4ad3-904d-c7c4a1046342_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6320cf69-8e20-47a5-8112-f89393ea9463_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_6825b3a2-9968-4485-81d8-8b37f32f7a9e_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_24c9464c-1ebc-4b09-a15b-3bc7b5e5f3ef_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_1c19f2f3-cded-408f-a572-0884cc59887e_terseLabel_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development operations</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_label_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_documentation_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation" xlink:href="mrna-20210630.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedDevelopmentOperation" xlink:to="lab_mrna_AccruedDevelopmentOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_9f006e97-9326-45bf-8808-6d2b69162d75_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_edd1a4ee-ddd5-4881-944c-2a03ed4e1ef9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fe4d3e29-15cc-4e8f-9f35-256b12f30f79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5b3af2ab-5fe3-42e4-9460-6c9934e33f88_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e9b81a59-a127-4507-b09d-e35545a84dee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8560d0e8-f96f-429b-9ca4-99119ff107ae_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_e1e997dd-d024-4a36-a6ba-123f3fad976b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b8b13d27-bc99-42b8-887d-2718be40b77b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31eec209-759f-40c7-8e79-a5ed8f1e70d3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCEastMember_f50a0e2d-c7ac-454e-8eb1-b69bd01afb46_terseLabel_en-US" xlink:label="lab_mrna_MTCEastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC East</link:label>
    <link:label id="lab_mrna_MTCEastMember_label_en-US" xlink:label="lab_mrna_MTCEastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC East [Member]</link:label>
    <link:label id="lab_mrna_MTCEastMember_documentation_en-US" xlink:label="lab_mrna_MTCEastMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC East</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCEastMember" xlink:href="mrna-20210630.xsd#mrna_MTCEastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCEastMember" xlink:to="lab_mrna_MTCEastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherGrantRevenueMember_0a4e564a-a61d-418a-a5c4-386f0315daa0_terseLabel_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_label_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue [Member]</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_documentation_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember" xlink:href="mrna-20210630.xsd#mrna_OtherGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherGrantRevenueMember" xlink:to="lab_mrna_OtherGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b613bff0-7f33-4301-b895-0b3dc9757025_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_89ae45c3-987e-4fdf-ad25-60e0846e8f89_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dc97bbde-8582-4a2e-be17-f7e02c20cb1f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f34c739a-99a2-4ab3-952d-10dbbef81b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_89bbafa8-1145-4f23-837a-acc399b41788_verboseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6162fdbd-2da1-4ba9-b98e-a4502ddd33d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics_fe27ba98-54a4-4b50-9e07-59c251746825_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinics</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics_label_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs That Have Entered Clinics, Number Of Clinics</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics_documentation_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs That Have Entered Clinics, Number Of Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" xlink:href="mrna-20210630.xsd#mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" xlink:to="lab_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0692b8af-dbdf-469e-a604-0358153970cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_efd01092-0467-4c8e-967c-c4684d444025_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0946f124-6e0f-4161-bb7e-783628f495b4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d7f25ad0-ae1e-4114-9a6c-da33b3ff0083_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_dc8adee7-6c46-47d9-8df3-ce29f1bbb7d9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77159c72-1106-4286-ad2b-bd91e0e5ceec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCNorthMember_8391b29f-6aa9-43a3-b55a-cadeac4ed2cf_terseLabel_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North</link:label>
    <link:label id="lab_mrna_MTCNorthMember_label_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North [Member]</link:label>
    <link:label id="lab_mrna_MTCNorthMember_documentation_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember" xlink:href="mrna-20210630.xsd#mrna_MTCNorthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCNorthMember" xlink:to="lab_mrna_MTCNorthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_fa265565-30a6-4f98-8b84-fd3250d17580_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_81c67ef1-8cec-4844-bd40-791d029cf6d4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_adeb9491-7d5f-42c8-b3db-0b1e4577dc4a_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_66c0adfa-4ae1-4ddb-9a15-fd60b5daa951_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55ecd283-e839-460c-b20e-6493c6e5ae98_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e7abf838-a300-45b7-b735-8f9ac12b115c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d0c70363-0b8d-4b78-b685-1ee16db8badd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_83fc7a50-f783-40aa-91a0-3427376f11c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_bc1e3abf-ddb6-413a-b833-437fa9c01732_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities - financing</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_c690acc4-3fb4-44a8-8233-811ce50f859d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_dd1fe3eb-e9d9-4fcb-ad36-6e3be8c4ab64_terseLabel_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_label_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_documentation_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable" xlink:href="mrna-20210630.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RawMaterialsAccountsPayable" xlink:to="lab_mrna_RawMaterialsAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5ebdd778-aa11-417c-a321-15c9f59d9046_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ae59ce7-8dcc-4c6e-9ac4-12d63074e45c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_b2b90be8-c00d-4883-be20-d7886a68ae4f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_366e3131-edce-4c80-9956-95bc6a4ea199_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_bddd633b-713d-4bdf-b093-883ff825a046_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_56e46a81-820a-4494-a7b6-53fbd301491d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_97e08b32-16b3-4e52-99d4-db9851791564_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70e9537e-3c8d-4ab7-a53b-75f8780cb8c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_17baaaae-81f2-4487-a4bc-29aed82d5ed8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_6fe2635d-4e7e-4a98-8904-e1bbc57500a6_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:href="mrna-20210630.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2ce748c3-c0e6-4913-bad3-425d68723c03_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_18367efe-d2a1-4aa5-9831-81f2dd3f0d9f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_db8ad4a4-2843-45db-bdf2-08d00c2b1d97_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5c0b5ebf-3935-40b8-b8d4-7f9bb9cffaeb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4ca6fdb9-1be4-42ad-90e5-f49166d5b927_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a8fcc81e-e62f-4a0c-b40a-71443c8a5e3e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_68382f06-c29a-43f6-9b06-82fc090f5826_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offerings of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0e2046e0-f167-4eb7-9fa3-ec5c142cc93c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b8b347d6-4f01-475d-ba75-d9b90500609c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d325872c-405a-49ab-ae34-126c6e4a981c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f0cb9663-6b6e-4772-b599-8769653df72f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_e227ea1e-2da3-41bc-b863-32047d5780bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_aa95382b-7d12-4c90-abae-49cf990baef5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_664677a4-65ab-4d0b-8e32-b58018af2cec_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fbef3ef8-d729-409e-b249-3bf62315bcdc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_256969a6-4025-4f0d-a814-30298b1485bb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8d530ec2-9897-4a6e-ae43-0849790a8fbd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5181c440-29b7-4cac-8e77-4ebb8d48f6a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_8836f6d6-3ccf-45cd-99b1-d90b5f58a8ea_terseLabel_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_label_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseLiabilities" xlink:href="mrna-20210630.xsd#mrna_OperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLeaseLiabilities" xlink:to="lab_mrna_OperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8a3f69d6-610a-466c-afb6-1c45409d7396_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Basis of Presentation and Recent Accounting Standards</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9a8523d8-c8b8-48ae-a9cd-a06108241d71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f2b6644-bc40-43bb-b9db-c44c17e422f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_f501793a-c36e-4b22-aabe-f23c191b749f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net realized (gains) losses on available-for-sale securities reclassified in net income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3a7246ef-e8b6-4421-a109-8da0ecd79b71_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_79ea7f2d-bee3-4b25-a1bc-138bca410087_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_aecd2fa5-119a-46de-978c-a7df64857b29_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_6e7aaa86-5fde-4046-8d10-15e23fb4b93d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e5d652c7-ec0c-433a-9807-5688b04115f2_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_82b48caa-c3cf-48b9-b550-761610a61b31_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22ae800b-c05a-459c-9a2d-0592204a0e15_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e2dfeb0f-a21e-4e98-930d-50466d712477_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_508b5125-61f1-442f-80f4-8a94e71f8215_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f409732d-5f0a-4f3d-b41c-4a4266e99c56_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDevelopmentProgram_691126ae-e466-41d7-b639-523c1b4d0080_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development programs</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentProgram_label_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Program</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentProgram_documentation_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentProgram" xlink:href="mrna-20210630.xsd#mrna_NumberOfDevelopmentProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDevelopmentProgram" xlink:to="lab_mrna_NumberOfDevelopmentProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b5c570ef-ef49-4451-88b6-e6ef1955bdd3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5e091f8a-d4e6-46f7-87a2-0166fa0057c0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_35eab9a3-a365-4474-b7d2-bf5c138e77bf_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e98d794b-763e-4d66-9101-a4c3779634a1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a752a26f-b360-48a0-a46e-0700b0c62b36_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b9062b65-37a5-456f-b00c-4a796038c060_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_88884103-e091-4e80-8bc9-050b59706a68_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d5afd3c8-424a-4027-90df-3672df8cd7f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_55bc3515-29bc-4cb9-ac8e-f52b58f831db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_47efd847-6cc3-4413-8900-4f3d35ca95dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d36b02e2-7542-4bf5-b0e7-8cfde98a4aa3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LeasesIncrementalBorrowingRate_faf716d0-e6fe-4529-b867-97baa6661056_terseLabel_en-US" xlink:label="lab_mrna_LeasesIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_mrna_LeasesIncrementalBorrowingRate_label_en-US" xlink:label="lab_mrna_LeasesIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Incremental Borrowing Rate</link:label>
    <link:label id="lab_mrna_LeasesIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_mrna_LeasesIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesIncrementalBorrowingRate" xlink:href="mrna-20210630.xsd#mrna_LeasesIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LeasesIncrementalBorrowingRate" xlink:to="lab_mrna_LeasesIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedManufacturing_d4d4c6e9-ea80-4ad8-8044-f0cee77c443c_terseLabel_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_label_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_documentation_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing" xlink:href="mrna-20210630.xsd#mrna_AccruedManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedManufacturing" xlink:to="lab_mrna_AccruedManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8b34e16e-59e3-466c-a8f0-008e68a67e54_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4b1d443e-365b-4954-99d0-bea4047def23_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_89c52cff-380c-49db-a529-7e2cb812a932_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9234d4ac-59c3-4315-95c4-22b9d324750c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f3f043f3-570c-45d6-b2a4-738993ac5118_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_724129fb-1c85-44f3-adb7-ba1305c7fd3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_99626793-dcf4-40ab-bda8-0b003c064ace_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:href="mrna-20210630.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:to="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract_686c44d2-1e0b-46ca-9b22-f0e8899d7227_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2ea5ad9f-7832-4604-9638-603ba3bae2e3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_577ead01-fb25-40c7-a8ad-88968b69b1f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_49d3e1e3-d37b-42a2-982d-826e5560b27b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_e69a0df8-34ef-48e0-9345-e571d6ddc5ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_576d7f56-a091-4e45-a476-42728d9086e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6b046604-5e2c-41fe-88d7-14d835e7cd0d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_db6054c0-d565-4364-91a2-483dc1d677e2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3c833967-4395-4129-b1c9-983935c0ba68_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_bc3ec710-ef0e-4f1f-ab5c-84c270066616_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses of vaccine candidate</link:label>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_label_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_documentation_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate" xlink:href="mrna-20210630.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDosesOfVaccineCandidate" xlink:to="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_e4fc8eda-319f-4433-919b-e792183c61c7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_14bbf701-7003-48a9-a397-dc15ef357fc1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5d9b8b9-a4a2-49a1-9b7d-1dd878058797_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_e50cbd15-7287-47ab-bbb6-274e1418c0d5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockExpense_136d4c08-2f2f-413d-87ed-74f263823a6e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockExpense_label_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense" xlink:to="lab_us-gaap_RestrictedStockExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_761e09a1-90a6-4291-a5e8-bcf391ba71b2_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e0799434-cd25-4f50-bb5e-20313a88516a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options (in millions)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_39fb041c-6bd7-4b68-8c08-ceb26da6bb58_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_131a8036-c7d1-4846-8bf2-c25a9976fbba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_98073a4b-2d2b-4911-b00f-1af722198a58_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_df9c99e3-ddd4-442b-9f05-e55fdcafa4ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2efb652b-f93e-419b-a2c9-cfc0623b8d22_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_83cde6e7-6563-4ec7-be1b-b7372466fa64_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_378975d5-53a9-443e-93d3-8470cf4a6df3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2ee15fa6-0cbc-46fd-ae68-37f5cb97cc34_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_67a80c57-4f8c-468c-9b6b-92431531d49d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_17929ceb-7fbc-4b1a-bedd-178ed34a0f78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1880802f-533f-4977-947b-4af39dd46f88_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_6c31ecb5-fa05-4112-8d6e-e2fb86302a84_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_39ae6592-2a64-46bd-94b9-2e695d9a08c1_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c23620b2-a9b0-4863-8702-180bb0f78b6d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_8949bd76-1cfc-4975-b839-39623fe2f1d2_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_c6b24bb7-09b9-439b-815d-340181a9f4e9_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total grant revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_be3ddcf3-1aad-4f92-bdcb-a45627db45f1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c01fb356-a5dd-47c8-9fc3-1105d1b7eac0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_e2b65f1e-24ba-4abc-bfd7-946ffef6da7f_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_7bdb364a-4ff4-4cba-96e2-2cdc86d02b9f_terseLabel_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="mrna-20210630.xsd#mrna_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_023b8cc0-89b6-465f-a16c-1b38d785170c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d1d40314-3299-4fcd-849f-5775351d2ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2cb596a7-e07d-4db6-a02b-01480eb9c491_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_361a5a47-10ea-4799-88f1-28059944d814_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5707e67a-6eaf-4e64-b81f-266c7429e3cc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_844a779a-58e1-4cf9-862c-a0bd222eedf3_verboseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Budgeted amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:href="mrna-20210630.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_01a7025c-3f9d-4566-9ca7-fdb8cb12ca65_terseLabel_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South, MTC North and MTC East</link:label>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_label_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South, MTC North and MTC East [Member]</link:label>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_documentation_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South, MTC North and MTC East</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:href="mrna-20210630.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:to="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_9fb0612e-ddb8-4598-b853-7120cb708330_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCV agreement</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:href="mrna-20210630.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2148a0c5-4786-4a51-aaa3-e870740d6c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e8ea5c8e-35cc-416c-9075-e3eb22b50940_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_63ead05b-a3a8-463f-9741-8b54779a90d2_negatedTerseLabel_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_label_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_documentation_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:href="mrna-20210630.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:to="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b8f9cc4-8673-4677-8325-d5ddf44cbe83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Fair Value per Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_dfbe643f-3b61-46c7-91bc-e2c38fc4dcf1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ProductSalesMember_5cd241fb-ed20-406a-890e-d5ee37978610_terseLabel_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_mrna_ProductSalesMember_label_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales [Member]</link:label>
    <link:label id="lab_mrna_ProductSalesMember_documentation_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember" xlink:href="mrna-20210630.xsd#mrna_ProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ProductSalesMember" xlink:to="lab_mrna_ProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_2a59d777-f1f7-4b5b-a796-2cb666be8e4c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c3e49988-1de0-4527-a267-135da6006b40_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_07312965-51df-4828-a86d-a88c6cee7b7f_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_adec2be5-e274-4f9a-b00c-fd06389d6e8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6965b61a-5f4d-472b-a18a-6b831f904d28_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_612b4bc1-d1e7-48d4-84cd-f62a0d3b2193_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MerckMember_5aabc523-ddf1-4ba1-881d-5fce2c6e503a_terseLabel_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_mrna_MerckMember_label_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_mrna_MerckMember_documentation_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember" xlink:href="mrna-20210630.xsd#mrna_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MerckMember" xlink:to="lab_mrna_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_53693ebd-9c81-4cde-8db7-b5beec628920_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f34326b2-1b35-4fb0-a19b-16120bb137e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d922c1dc-17b4-4af2-8c39-57069be00850_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses related allowance</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_5d1f0d73-ec43-4799-ad0f-4874ce9ec0f2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_eafe0a8d-1be8-4df9-9bed-3428232390d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a0d3529e-19d1-41bc-a405-0dabc6d4fc73_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_56cbb9df-98bc-4248-b400-ce41fc683d77_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aa639d95-4407-4e24-bd71-0bf3845d9075_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_2fccfcd4-be39-4d9d-b1a7-a7342bda1ebd_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3e2c432b-f7a2-4bb7-b87c-080b78406c58_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1dc77c32-21d0-4bb7-9017-2c828e8f12bf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33c9679f-ab50-430a-a069-9e6279a7a968_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_482dce86-9aab-4135-abb5-25cf77fb975f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options to purchase common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9d4eb23b-3aa0-479f-845c-bbbb5b785e7e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3d20752-d9c4-4a25-b434-7bfc3f4e9ad4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_59ec8f40-9ca7-46c5-aa95-2a72615f2a4d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of restricted stock units</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4ab26180-1b00-4c2e-aa5f-e62f0d918590_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea9bb625-d84b-4e12-a32e-81a700ea3db7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_cb21cf13-9596-4377-a6e8-1227704afb32_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_22888498-1a3b-44d4-9fa0-ed517f87cfd5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0bc7c416-4495-4ab5-951f-1693ed8d66bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4b6ac56e-9cf5-4481-9011-4e0ae2da9c14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_75bf3d99-dad2-4485-9cd7-a54505be39f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_adf1d810-ad03-42ec-9934-dd6104cce901_terseLabel_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of campuses</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_label_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_documentation_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties" xlink:href="mrna-20210630.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLeaseNumberOfProperties" xlink:to="lab_mrna_OperatingLeaseNumberOfProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3385a549-d7c2-4ddc-b45a-d8d6b1f30582_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_9da1034c-a2c3-4d50-a593-630212ee73a1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1f08af78-6cf3-49e1-978b-f412e9ab8175_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a954a8f0-331d-42f9-b657-b235e46e1dca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_009922f5-d2f6-4c7e-9a27-c9493c9c7fe3_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsMaximumAward" xlink:to="lab_mrna_RevenueFromGrantsMaximumAward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a3e636b4-b447-470c-a1a5-e49aa7d21f61_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_e7eb685d-39f1-4915-87bd-c48b1510de0d_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a2bd8be-54ac-4ee5-8650-d2336efcc58d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9261064-95b1-4eff-b6d6-0f6b63ddca7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c36f0f3f-3f86-4ed1-b682-49d00c5159b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_66e97fe7-7099-44fc-9b96-872fd730d39d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase from available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_60fd355b-ee94-4e31-b151-c2682a7165e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19978039-e0aa-4f3c-ad49-64fdf213f051_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae05ac45-e5de-4190-84bf-7ea06648186d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_98058511-9e3f-4724-b6ea-9535bcd6aa6d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4d91828d-df3f-4d36-875b-0bd923197635_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_285c980f-1dc5-4709-af67-2ddc1d2ee221_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1554f1ab-ca53-425f-b27f-16dfc79a48e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_89a9787b-6491-4b3d-b274-980933b1288b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_8c91752c-00b7-4fbd-ae15-0b8f4962257b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_cfeca508-85ad-4325-8a27-b3a75dea756e_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_56cf831c-13f9-43fe-a85e-140a1ee320c2_terseLabel_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in financing lease liabilities</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_label_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_documentation_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities" xlink:href="mrna-20210630.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChargesToFinancingLeaseLiabilities" xlink:to="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_29484a85-091b-47c5-a26e-b7229c529e39_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a1f1e4ef-ef7f-42b8-a71f-f401e4f209c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_627a0e52-e691-42c8-9063-62b139696b13_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_EmbeddedLeasesMember_e132f25b-0dce-4138-b403-a52f095ee53e_terseLabel_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases</link:label>
    <link:label id="lab_mrna_EmbeddedLeasesMember_label_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases [Member]</link:label>
    <link:label id="lab_mrna_EmbeddedLeasesMember_documentation_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember" xlink:href="mrna-20210630.xsd#mrna_EmbeddedLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EmbeddedLeasesMember" xlink:to="lab_mrna_EmbeddedLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_b00f23ca-b50a-428f-a295-53d3e117a0c7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remainder of the year)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_69bd18f1-26b2-40f3-ae6c-4f6fe4983b20_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedClinicalTrials_eea2f8ac-1518-4e9d-a5c1-9bb0556abe26_terseLabel_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_label_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_documentation_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials" xlink:href="mrna-20210630.xsd#mrna_AccruedClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedClinicalTrials" xlink:to="lab_mrna_AccruedClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_46b93370-ad96-41c4-a6b2-91c981a91df7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_bced975d-5840-4770-9d02-c84157d9dd05_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock through equity plans, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d07e267a-19a8-490d-9e0d-1821261a4e0f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_70b780f1-f3cd-4403-8dba-23099265d4cb_terseLabel_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply and manufacturing agreements</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_label_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Agreements [Member]</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_documentation_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:href="mrna-20210630.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:to="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8456635d-3410-4275-8bb6-563221527ebc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b60d4cce-8a67-4725-af35-13fe91fbf96a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_324c9a4f-d863-43a8-be98-bca1a41b4889_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to non-vested stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_5871adf6-96aa-4a5f-974d-9cd8dda45707_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_146402ad-d77c-4092-bee9-ec8c83361ea5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractOptionsMember_1bc19501-179a-4548-ae2e-702713195e7c_terseLabel_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract options</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_label_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Options [Member]</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_documentation_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember" xlink:href="mrna-20210630.xsd#mrna_ContractOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractOptionsMember" xlink:to="lab_mrna_ContractOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_5e63c945-9f74-4618-b254-0c628c53808e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_837b603f-88e5-4bd7-ab37-8450c888c44c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_ca73a524-487f-4629-a6a9-ea9c80f628c5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_c001e61e-2361-479d-838f-cbef402b45d4_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_fa216d36-f5cf-4046-a57e-21550a8962c6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c222d0ea-2763-44dc-9412-92106c844714_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6fe142a6-4285-4990-84c1-241120b3910d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_feab35c1-ba3d-498e-bb9b-73107cf0b6dc_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b511af2a-fc09-486b-8fea-f55695ac0534_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="mrna-20210630.xsd#mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_68fb0ed2-3178-4171-90c5-b1fdfef78e36_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1e52249b-88c3-40b9-bb67-7b9b862c2e64_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e89bc8af-907e-4fc9-8504-db777172c368_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_828fbbd0-aac9-4f81-8a3f-a312c3da0c13_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ea9892d-fd46-4fe4-8c0e-eb004804a397_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_94ac15cc-7df7-4d14-9330-8adea47feade_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b7776cc7-1c49-4e28-a9b7-c08a4a7e08f5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mrna-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1f43850e-4c17-48f6-8a24-63bc21a94b8b,g:a986bd34-a907-438b-9a06-ed4dd6fbe7f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:type="simple" xlink:href="mrna-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_699b7f88-46ad-44be-8685-cac6c4335baa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_DocumentType_699b7f88-46ad-44be-8685-cac6c4335baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d47bc57f-76fb-4219-b709-5871925c46c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_DocumentQuarterlyReport_d47bc57f-76fb-4219-b709-5871925c46c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e571965a-bde8-4885-a937-84dbbd499a9a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_DocumentPeriodEndDate_e571965a-bde8-4885-a937-84dbbd499a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_585d5c6e-e75e-448d-b059-4df0885b77c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_DocumentTransitionReport_585d5c6e-e75e-448d-b059-4df0885b77c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0d141046-4900-4f0a-ad50-600e2669db79" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityFileNumber_0d141046-4900-4f0a-ad50-600e2669db79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_88ee6d73-104c-47b3-b54e-3beb4915f4c0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityRegistrantName_88ee6d73-104c-47b3-b54e-3beb4915f4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_53908701-6bbb-4c4f-8f85-4f449850c552" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_53908701-6bbb-4c4f-8f85-4f449850c552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1e198a8a-7f02-4f28-acdc-5863735d34e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityTaxIdentificationNumber_1e198a8a-7f02-4f28-acdc-5863735d34e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8ad19fab-d23e-41a9-b226-8f0dc49680c2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityAddressAddressLine1_8ad19fab-d23e-41a9-b226-8f0dc49680c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_718a1866-d374-4819-aa2c-7d8f6dd64743" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityAddressCityOrTown_718a1866-d374-4819-aa2c-7d8f6dd64743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5d2315bf-736c-49ba-b953-85db4429b405" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityAddressStateOrProvince_5d2315bf-736c-49ba-b953-85db4429b405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_71d4b961-e180-402b-b873-17e8dd544e8d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityAddressPostalZipCode_71d4b961-e180-402b-b873-17e8dd544e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8be3c2d1-163b-43d4-9f8c-226eb23572ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_CityAreaCode_8be3c2d1-163b-43d4-9f8c-226eb23572ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b88da97b-caee-482a-97a1-7f0ef993e34f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_LocalPhoneNumber_b88da97b-caee-482a-97a1-7f0ef993e34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_afccd85d-cd7b-4072-b4ce-a1f17a1a469f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_Security12bTitle_afccd85d-cd7b-4072-b4ce-a1f17a1a469f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b7500b30-c227-47f1-bba9-9feb59b586ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_TradingSymbol_b7500b30-c227-47f1-bba9-9feb59b586ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_eb3632f0-54fb-420a-a7c3-6ceeb4248718" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_SecurityExchangeName_eb3632f0-54fb-420a-a7c3-6ceeb4248718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bbdf59f9-3499-4344-991e-93224a605f5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityCurrentReportingStatus_bbdf59f9-3499-4344-991e-93224a605f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0311f8fd-1774-43f1-aca8-f9acb267a38a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityInteractiveDataCurrent_0311f8fd-1774-43f1-aca8-f9acb267a38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_883853d4-6247-4b28-8aad-13c7c6377826" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityFilerCategory_883853d4-6247-4b28-8aad-13c7c6377826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cd082bc0-c4a9-488d-bd6e-04fb9ef5069f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntitySmallBusiness_cd082bc0-c4a9-488d-bd6e-04fb9ef5069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f9a4d0c7-cefd-40df-bf66-6bbccbcdc2ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityEmergingGrowthCompany_f9a4d0c7-cefd-40df-bf66-6bbccbcdc2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_12c855ce-5a26-4752-a32e-7ccd009c5cb4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityShellCompany_12c855ce-5a26-4752-a32e-7ccd009c5cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0f47c9b6-b691-4586-8fc1-ea106a167c85" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0f47c9b6-b691-4586-8fc1-ea106a167c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7d7fa83e-4728-4319-a51d-8ecf40f7cb15" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_AmendmentFlag_7d7fa83e-4728-4319-a51d-8ecf40f7cb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_49727e10-330c-4f8a-86c8-e12f5afc50f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_DocumentFiscalYearFocus_49727e10-330c-4f8a-86c8-e12f5afc50f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a7a9e0a7-a62e-46ad-836c-8b346b52a2c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a7a9e0a7-a62e-46ad-836c-8b346b52a2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f84e33e8-d77b-4099-a49b-8e5b37278494" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_EntityCentralIndexKey_f84e33e8-d77b-4099-a49b-8e5b37278494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_96bedf25-82c7-4d9b-bb7c-2d052faddab9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee344810-074c-4426-b499-3a5fdc3ee70f" xlink:to="loc_dei_CurrentFiscalYearEndDate_96bedf25-82c7-4d9b-bb7c-2d052faddab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49e28e34-b0b7-4587-bd3a-24e043ef47a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49e28e34-b0b7-4587-bd3a-24e043ef47a1" xlink:to="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eed125b6-c3a2-46c8-9b76-7b10a04a7fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eed125b6-c3a2-46c8-9b76-7b10a04a7fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6c229e87-d15b-481f-bdb9-bb58ca6cf219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6c229e87-d15b-481f-bdb9-bb58ca6cf219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eb902942-859a-408a-8b42-3bff37905de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eb902942-859a-408a-8b42-3bff37905de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_feb11cf7-e258-4573-86ae-bfa2c0daf68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:to="loc_us-gaap_InventoryNet_feb11cf7-e258-4573-86ae-bfa2c0daf68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb28c89a-bbaa-4505-abfa-fe6e65ab29a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb28c89a-bbaa-4505-abfa-fe6e65ab29a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_edd08669-dcc3-47fa-b651-c8787a0dbfac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a76522b8-cf16-46f7-9f2e-b561c2463842" xlink:to="loc_us-gaap_AssetsCurrent_edd08669-dcc3-47fa-b651-c8787a0dbfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d5c20e81-b92d-4455-b179-bc51113757d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d5c20e81-b92d-4455-b179-bc51113757d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_82825b40-9ced-4aac-889d-c3147dbeb5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_82825b40-9ced-4aac-889d-c3147dbeb5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d9494b7-a91d-4831-85bb-84e7d3fe4ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d9494b7-a91d-4831-85bb-84e7d3fe4ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e6197085-9c9a-4463-9ec3-3bf573471f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e6197085-9c9a-4463-9ec3-3bf573471f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_4f504526-da66-4c4f-918a-3e785e6b02cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_4f504526-da66-4c4f-918a-3e785e6b02cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1fef0ca8-7ccf-4022-85a9-86b6b527c707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1fef0ca8-7ccf-4022-85a9-86b6b527c707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ac2b84b0-de96-4184-8905-8832cc894d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfdf67bd-616f-4768-ab2c-fb8692056f80" xlink:to="loc_us-gaap_Assets_ac2b84b0-de96-4184-8905-8832cc894d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49e28e34-b0b7-4587-bd3a-24e043ef47a1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_dcb88350-86c7-43c4-b5e6-100f04615e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_dcb88350-86c7-43c4-b5e6-100f04615e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e841dace-4859-4191-8dea-539175e1c22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcb88350-86c7-43c4-b5e6-100f04615e8c" xlink:to="loc_us-gaap_AccountsPayableCurrent_e841dace-4859-4191-8dea-539175e1c22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2302862a-2427-41e9-9de6-2b4b303ae264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcb88350-86c7-43c4-b5e6-100f04615e8c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2302862a-2427-41e9-9de6-2b4b303ae264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_76b6625c-aac7-4c61-86e2-23b383597397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcb88350-86c7-43c4-b5e6-100f04615e8c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_76b6625c-aac7-4c61-86e2-23b383597397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ab67dfcd-da70-4ee6-ab61-5ded87024f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcb88350-86c7-43c4-b5e6-100f04615e8c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ab67dfcd-da70-4ee6-ab61-5ded87024f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a780459c-56e7-4751-a79f-34d47d35e121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dcb88350-86c7-43c4-b5e6-100f04615e8c" xlink:to="loc_us-gaap_LiabilitiesCurrent_a780459c-56e7-4751-a79f-34d47d35e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b753903c-3447-43a0-856b-3c4e6dad7109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b753903c-3447-43a0-856b-3c4e6dad7109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f1d8d44-920f-4688-a96b-26843af10908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f1d8d44-920f-4688-a96b-26843af10908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_28b02337-918e-49f4-b69c-0396ed46edb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_28b02337-918e-49f4-b69c-0396ed46edb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1df2bdde-c8ac-4147-b1c0-bf98bda808de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1df2bdde-c8ac-4147-b1c0-bf98bda808de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_996535a5-7be7-4a29-92e7-6415b8b29041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_Liabilities_996535a5-7be7-4a29-92e7-6415b8b29041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_182802b9-04c6-438f-ad6f-37ea4624f2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_182802b9-04c6-438f-ad6f-37ea4624f2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_331abaa0-77b6-463d-a4ef-36bca5aa91fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:to="loc_us-gaap_PreferredStockValue_331abaa0-77b6-463d-a4ef-36bca5aa91fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6af69e27-e3b7-45ca-8d88-6925e14f8f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:to="loc_us-gaap_CommonStockValue_6af69e27-e3b7-45ca-8d88-6925e14f8f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_11680ef2-a0ed-4440-8a4c-7c364c4390bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_11680ef2-a0ed-4440-8a4c-7c364c4390bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_57d56eec-a414-4699-b675-487dcdbfbebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_57d56eec-a414-4699-b675-487dcdbfbebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b34f2715-348a-4e0b-a404-441e1e18b33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b34f2715-348a-4e0b-a404-441e1e18b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f4ed13a-3f50-4780-9343-8f0f949923a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2b199de7-2cf9-4485-9b41-43e1b4cc77a9" xlink:to="loc_us-gaap_StockholdersEquity_2f4ed13a-3f50-4780-9343-8f0f949923a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_61175804-dde2-454d-af40-cab10e9cd6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7cdcf6ef-00d3-4555-8754-d31706a0705b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_61175804-dde2-454d-af40-cab10e9cd6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_846cb53d-6d6c-4c2f-9f99-2ba32767088e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_846cb53d-6d6c-4c2f-9f99-2ba32767088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d6b380da-cbd5-43b7-8ea8-757d254c8ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d6b380da-cbd5-43b7-8ea8-757d254c8ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7abd95b9-912a-4575-bbe1-2f4a6545e33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7abd95b9-912a-4575-bbe1-2f4a6545e33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_77b449a7-8229-4110-9748-5c00501d9a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_77b449a7-8229-4110-9748-5c00501d9a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bc76c8cc-3790-4d3f-837c-72428310e6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bc76c8cc-3790-4d3f-837c-72428310e6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c1ae7471-5021-43d6-956a-323ae916f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c1ae7471-5021-43d6-956a-323ae916f5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_991bdabc-d39b-4530-8d4a-14081561b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_CommonStockSharesIssued_991bdabc-d39b-4530-8d4a-14081561b5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1ad57eb-cd74-417e-a7ff-13b350b8dcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c594f52d-5487-4850-99ae-81ec7892ac56" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c1ad57eb-cd74-417e-a7ff-13b350b8dcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_21535a16-be0f-4a80-bacc-28dd8c4960c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d86014fc-a5f0-4711-851c-febda67a624f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_21535a16-be0f-4a80-bacc-28dd8c4960c3" xlink:to="loc_us-gaap_StatementTable_d86014fc-a5f0-4711-851c-febda67a624f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c224213-9391-4a32-81d3-3d9127af72ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d86014fc-a5f0-4711-851c-febda67a624f" xlink:to="loc_srt_ProductOrServiceAxis_1c224213-9391-4a32-81d3-3d9127af72ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1c224213-9391-4a32-81d3-3d9127af72ee" xlink:to="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_f053b9dc-b0be-47f9-93f8-ebfa0ceeaf30" xlink:href="mrna-20210630.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:to="loc_mrna_ProductSalesMember_f053b9dc-b0be-47f9-93f8-ebfa0ceeaf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_3e84e3bd-0344-4a41-a3b5-319efddd5938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:to="loc_us-gaap_GrantMember_3e84e3bd-0344-4a41-a3b5-319efddd5938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_5b26d92a-7dee-4303-bd48-c0097de04f65" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02f5e386-ef4b-484e-83da-582b419c9679" xlink:to="loc_mrna_CollaborationArrangementMember_5b26d92a-7dee-4303-bd48-c0097de04f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d86014fc-a5f0-4711-851c-febda67a624f" xlink:to="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_859f8012-f336-47c2-932a-bbc303882779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_RevenuesAbstract_859f8012-f336-47c2-932a-bbc303882779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cf2148c9-d7d2-46f6-a6c0-c25a8e3adc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_859f8012-f336-47c2-932a-bbc303882779" xlink:to="loc_us-gaap_Revenues_cf2148c9-d7d2-46f6-a6c0-c25a8e3adc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7a38d302-6c3d-4e96-b226-6bd2acb8bd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7a38d302-6c3d-4e96-b226-6bd2acb8bd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4fd73101-d994-47b6-bb06-6be2978cdb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4fd73101-d994-47b6-bb06-6be2978cdb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1c2f809c-cf85-4f96-a821-8d3d10c6d90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1c2f809c-cf85-4f96-a821-8d3d10c6d90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_30eb8097-8186-41ef-b5b9-f67ae1b9dd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_898b8043-d2d5-49b5-b93e-f3d20dba063f" xlink:to="loc_us-gaap_CostsAndExpenses_30eb8097-8186-41ef-b5b9-f67ae1b9dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9fbeb607-9c18-41b5-a8b3-dd462ee7e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_OperatingIncomeLoss_9fbeb607-9c18-41b5-a8b3-dd462ee7e2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c5b4f338-14ed-4a38-9396-4ca8e5f7ee76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c5b4f338-14ed-4a38-9396-4ca8e5f7ee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a5e75511-310e-48e5-bce3-841f1125c4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a5e75511-310e-48e5-bce3-841f1125c4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bd3885eb-e645-4f89-9ae4-ded31d736cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bd3885eb-e645-4f89-9ae4-ded31d736cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_069e60eb-2ca8-45c7-9f34-924ecffbc946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_069e60eb-2ca8-45c7-9f34-924ecffbc946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2f95bfe-eba7-4338-b253-4dfe1cd1bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_NetIncomeLoss_a2f95bfe-eba7-4338-b253-4dfe1cd1bd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5eb0b0ae-804b-4220-8818-f45a66aa92b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:to="loc_us-gaap_EarningsPerShareBasic_5eb0b0ae-804b-4220-8818-f45a66aa92b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b823f18-6f4b-494c-b292-9f25d9c7d601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_874f1d61-f71c-41d9-a2fd-7d1234b7f1ba" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b823f18-6f4b-494c-b292-9f25d9c7d601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2eb88cdf-ed99-4fd5-bb5d-646bf6910f9a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c53ee6d-06a7-44cb-b281-01be22904557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c53ee6d-06a7-44cb-b281-01be22904557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2bd2337b-9ba7-44f0-8c49-4aea56932281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_74847911-6ef7-4827-86f9-fab73987021d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2bd2337b-9ba7-44f0-8c49-4aea56932281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_04e3ad8d-ed70-4a2a-9c4b-eb35cb37b803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77ae240e-9aa4-4d5b-8621-b39cd9535242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_04e3ad8d-ed70-4a2a-9c4b-eb35cb37b803" xlink:to="loc_us-gaap_NetIncomeLoss_77ae240e-9aa4-4d5b-8621-b39cd9535242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_288f9062-701c-4e30-b31a-a57bbe1b5082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_04e3ad8d-ed70-4a2a-9c4b-eb35cb37b803" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_288f9062-701c-4e30-b31a-a57bbe1b5082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9f209a01-fb6b-4b62-83c4-41e6904b5dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_288f9062-701c-4e30-b31a-a57bbe1b5082" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9f209a01-fb6b-4b62-83c4-41e6904b5dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_6b035c6d-ca5d-4352-b670-f8ed9d0c1553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_288f9062-701c-4e30-b31a-a57bbe1b5082" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_6b035c6d-ca5d-4352-b670-f8ed9d0c1553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e859df11-779b-4228-a415-4a01c77a0c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_288f9062-701c-4e30-b31a-a57bbe1b5082" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e859df11-779b-4228-a415-4a01c77a0c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract_91c0fd70-2eaf-4b39-a22d-afb96cdd6a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_04e3ad8d-ed70-4a2a-9c4b-eb35cb37b803" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract_91c0fd70-2eaf-4b39-a22d-afb96cdd6a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1b554fc6-a60e-4d18-9c66-0ed80619fbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract_91c0fd70-2eaf-4b39-a22d-afb96cdd6a95" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1b554fc6-a60e-4d18-9c66-0ed80619fbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9c930adc-7fbd-489c-9d27-251aa28ec155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_04e3ad8d-ed70-4a2a-9c4b-eb35cb37b803" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9c930adc-7fbd-489c-9d27-251aa28ec155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_73cab88e-9b8e-402d-9387-c81e1fde8dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_04e3ad8d-ed70-4a2a-9c4b-eb35cb37b803" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_73cab88e-9b8e-402d-9387-c81e1fde8dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c01444a8-a137-4693-b35f-649026b14b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_468415ac-9853-4437-819a-df93c354717f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c01444a8-a137-4693-b35f-649026b14b73" xlink:to="loc_us-gaap_StatementTable_468415ac-9853-4437-819a-df93c354717f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2e59e8a-c801-4dac-a1ba-b6628b657ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468415ac-9853-4437-819a-df93c354717f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2e59e8a-c801-4dac-a1ba-b6628b657ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2e59e8a-c801-4dac-a1ba-b6628b657ca8" xlink:to="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dbe54072-02fe-4391-b2ba-1681fa46c155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_CommonStockMember_dbe54072-02fe-4391-b2ba-1681fa46c155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3ccb1cfe-1f11-4589-9d7e-7f88d3e8dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3ccb1cfe-1f11-4589-9d7e-7f88d3e8dd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0cdcb020-96e6-43f7-a732-dfa28825832f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0cdcb020-96e6-43f7-a732-dfa28825832f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b285d42e-99ab-4806-8147-6a4c4970c66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e8ea2b5-a230-4adb-b524-b1ed1b78624e" xlink:to="loc_us-gaap_RetainedEarningsMember_b285d42e-99ab-4806-8147-6a4c4970c66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7afae51-0963-4dbf-9243-3a47016b3f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468415ac-9853-4437-819a-df93c354717f" xlink:to="loc_us-gaap_StatementLineItems_e7afae51-0963-4dbf-9243-3a47016b3f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7afae51-0963-4dbf-9243-3a47016b3f8a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_986bc395-ff1d-4d04-91d0-40c8a9b045a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_SharesOutstanding_986bc395-ff1d-4d04-91d0-40c8a9b045a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_06d71b9c-de49-4d6d-bed4-6abb759ed65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockholdersEquity_06d71b9c-de49-4d6d-bed4-6abb759ed65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_018a94fa-6caf-44b0-870d-5667941ad86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_018a94fa-6caf-44b0-870d-5667941ad86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b07930c6-5b1e-44d9-814b-f4068a9babcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b07930c6-5b1e-44d9-814b-f4068a9babcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6b56c69-b5de-4d9d-9814-5688f5b886db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6b56c69-b5de-4d9d-9814-5688f5b886db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f0f4481e-73ba-40a1-800d-3596017a93d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f0f4481e-73ba-40a1-800d-3596017a93d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_27afa377-addf-47fb-8aa4-bba93f56b374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_27afa377-addf-47fb-8aa4-bba93f56b374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ff47401-be3b-49d5-bdcc-55cd3df9ea40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ff47401-be3b-49d5-bdcc-55cd3df9ea40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3997d1e2-201c-49b1-9ed0-19cca1653a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3997d1e2-201c-49b1-9ed0-19cca1653a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b942c622-5061-41a4-8ac5-95c1057afe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_NetIncomeLoss_b942c622-5061-41a4-8ac5-95c1057afe0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d8061ccc-e669-4bc3-bad6-12a3a18a4a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_SharesOutstanding_d8061ccc-e669-4bc3-bad6-12a3a18a4a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_86f6fd18-91d0-471c-bbec-ce5e5a7ce7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa6fe8e2-7490-43b1-ac94-1ef64f6d71b0" xlink:to="loc_us-gaap_StockholdersEquity_86f6fd18-91d0-471c-bbec-ce5e5a7ce7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_86e28010-6445-41cd-ad13-d28fbc9505b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_96400b1e-4cec-41a1-bb5e-f5ba63f32080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_86e28010-6445-41cd-ad13-d28fbc9505b1" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_96400b1e-4cec-41a1-bb5e-f5ba63f32080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b2e528d-231f-40b5-813f-c21add423f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_86e28010-6445-41cd-ad13-d28fbc9505b1" xlink:to="loc_us-gaap_NetIncomeLoss_3b2e528d-231f-40b5-813f-c21add423f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dbffe0ca-95a8-44d9-98ff-7250050e4cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_86e28010-6445-41cd-ad13-d28fbc9505b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dbffe0ca-95a8-44d9-98ff-7250050e4cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a38c2531-715d-46ad-9b1f-9761d3230272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a38c2531-715d-46ad-9b1f-9761d3230272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d18d3cf-cf07-4182-8319-0ad447d55cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a38c2531-715d-46ad-9b1f-9761d3230272" xlink:to="loc_us-gaap_NetIncomeLoss_9d18d3cf-cf07-4182-8319-0ad447d55cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c41ff03-16a9-4499-9b92-0481870469af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a38c2531-715d-46ad-9b1f-9761d3230272" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c41ff03-16a9-4499-9b92-0481870469af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0a428395-2f07-4e31-abbe-d006d011a0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c41ff03-16a9-4499-9b92-0481870469af" xlink:to="loc_us-gaap_ShareBasedCompensation_0a428395-2f07-4e31-abbe-d006d011a0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b2833a5f-257e-491d-83e1-ff1be8f19dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c41ff03-16a9-4499-9b92-0481870469af" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b2833a5f-257e-491d-83e1-ff1be8f19dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_1ab5928d-af7b-4822-891a-1ce2073c1953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c41ff03-16a9-4499-9b92-0481870469af" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_1ab5928d-af7b-4822-891a-1ce2073c1953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_15350604-0b3f-4a4d-a0d0-848e1a0f0298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c41ff03-16a9-4499-9b92-0481870469af" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_15350604-0b3f-4a4d-a0d0-848e1a0f0298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c41ff03-16a9-4499-9b92-0481870469af" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_30261851-70ab-448f-8397-a1e8c024288d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_30261851-70ab-448f-8397-a1e8c024288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eea5a6d1-0f78-4a83-877c-3a1098e49a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eea5a6d1-0f78-4a83-877c-3a1098e49a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bee79f2f-137a-4219-820e-53a5ce41970e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bee79f2f-137a-4219-820e-53a5ce41970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_06793453-e210-4d2a-8c7d-1533c40b434f" xlink:href="mrna-20210630.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_06793453-e210-4d2a-8c7d-1533c40b434f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c5a05acb-fe3d-49ce-88c8-0d5a3a370181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c5a05acb-fe3d-49ce-88c8-0d5a3a370181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_75e299f2-279e-4fc0-8f4f-337818f39335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_75e299f2-279e-4fc0-8f4f-337818f39335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_82f9659b-9340-470c-bfa3-66eb86f2225a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_82f9659b-9340-470c-bfa3-66eb86f2225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseLiabilities_83768648-8ed6-4544-b7a2-b3238796550e" xlink:href="mrna-20210630.xsd#mrna_OperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_mrna_OperatingLeaseLiabilities_83768648-8ed6-4544-b7a2-b3238796550e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_de6e6783-d3cb-4716-9bbd-98fcd834d9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69b43938-e973-4843-9284-c6b5602e340a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_de6e6783-d3cb-4716-9bbd-98fcd834d9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e11e8dfd-7f3f-4ff5-be8a-1089c4ece3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a38c2531-715d-46ad-9b1f-9761d3230272" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e11e8dfd-7f3f-4ff5-be8a-1089c4ece3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a35f4d2a-ae70-49bf-9376-e7ddda61c789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a35f4d2a-ae70-49bf-9376-e7ddda61c789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_911f564d-7149-4bcf-be73-0497f57f286a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a35f4d2a-ae70-49bf-9376-e7ddda61c789" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_911f564d-7149-4bcf-be73-0497f57f286a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c783acf6-20f1-4cb0-88db-b5d4728ab443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a35f4d2a-ae70-49bf-9376-e7ddda61c789" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c783acf6-20f1-4cb0-88db-b5d4728ab443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d84f5ac7-da9b-438d-bcae-018fe628948b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a35f4d2a-ae70-49bf-9376-e7ddda61c789" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d84f5ac7-da9b-438d-bcae-018fe628948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c747775e-e66d-4feb-b735-1cd75c70aee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a35f4d2a-ae70-49bf-9376-e7ddda61c789" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c747775e-e66d-4feb-b735-1cd75c70aee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70faaeb2-f84f-464c-b837-a28af788caf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a35f4d2a-ae70-49bf-9376-e7ddda61c789" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70faaeb2-f84f-464c-b837-a28af788caf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d84e0c4-4488-40c1-9dc6-3027a6f0e394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d84e0c4-4488-40c1-9dc6-3027a6f0e394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2ee5733d-b43c-4b2e-b0ef-a470a8df580a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d84e0c4-4488-40c1-9dc6-3027a6f0e394" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2ee5733d-b43c-4b2e-b0ef-a470a8df580a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_52d59fa1-0ca2-41d7-9ad1-3c630774beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d84e0c4-4488-40c1-9dc6-3027a6f0e394" xlink:to="loc_us-gaap_ProceedsFromStockPlans_52d59fa1-0ca2-41d7-9ad1-3c630774beb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_1684696c-c6ba-44e1-8d4a-09370e076075" xlink:href="mrna-20210630.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d84e0c4-4488-40c1-9dc6-3027a6f0e394" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_1684696c-c6ba-44e1-8d4a-09370e076075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5684c6e6-a9af-47f6-9187-027ebb3064fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d84e0c4-4488-40c1-9dc6-3027a6f0e394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5684c6e6-a9af-47f6-9187-027ebb3064fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6f96457-d107-43a5-977e-eb9a649b39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6f96457-d107-43a5-977e-eb9a649b39e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64a8c578-8686-4710-a6c4-8f94b9d78eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64a8c578-8686-4710-a6c4-8f94b9d78eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aba56bb5-dcff-407e-888c-5e7620083c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aba56bb5-dcff-407e-888c-5e7620083c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0e1ecd06-cf74-4aad-b578-b92b5ffe5cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_48880fc2-340a-4137-a819-2b39f67b2caf" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0e1ecd06-cf74-4aad-b578-b92b5ffe5cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d90baf4e-08c7-4b84-95f2-642564915627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0e1ecd06-cf74-4aad-b578-b92b5ffe5cfc" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d90baf4e-08c7-4b84-95f2-642564915627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_7ba20854-8c59-4a3b-b385-949e1ac0f340" xlink:href="mrna-20210630.xsd#mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0e1ecd06-cf74-4aad-b578-b92b5ffe5cfc" xlink:to="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_7ba20854-8c59-4a3b-b385-949e1ac0f340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1913cd0d-e76c-427a-80e3-e57d9bfb27bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0e1ecd06-cf74-4aad-b578-b92b5ffe5cfc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1913cd0d-e76c-427a-80e3-e57d9bfb27bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="mrna-20210630.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d060484b-6dd0-429a-aae1-ff962f6d951a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b6612592-4e20-434b-a05f-af14e011d4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d060484b-6dd0-429a-aae1-ff962f6d951a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b6612592-4e20-434b-a05f-af14e011d4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#DescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a72a4ea-cf0b-4d4d-9908-a08f052bcc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentProgram_e4e11c71-52d3-435e-822d-da9967460f98" xlink:href="mrna-20210630.xsd#mrna_NumberOfDevelopmentProgram"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a72a4ea-cf0b-4d4d-9908-a08f052bcc43" xlink:to="loc_mrna_NumberOfDevelopmentProgram_e4e11c71-52d3-435e-822d-da9967460f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics_53fb30d9-8ed4-4fef-a288-047533a9894f" xlink:href="mrna-20210630.xsd#mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a72a4ea-cf0b-4d4d-9908-a08f052bcc43" xlink:to="loc_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics_53fb30d9-8ed4-4fef-a288-047533a9894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="simple" xlink:href="mrna-20210630.xsd#SummaryofBasisofPresentationandRecentAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8b57b1ec-5814-4f0c-abd4-df4dc0cd7401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8b3ae92e-249d-420a-8fe6-4b6c2e3f1f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b57b1ec-5814-4f0c-abd4-df4dc0cd7401" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8b3ae92e-249d-420a-8fe6-4b6c2e3f1f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="simple" xlink:href="mrna-20210630.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8dac4905-3181-4b35-8c51-e545a9af4540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7d8d40fd-cec2-48a6-82ce-7572ebb3b844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8dac4905-3181-4b35-8c51-e545a9af4540" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7d8d40fd-cec2-48a6-82ce-7572ebb3b844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0d08ec9e-2fda-4b30-adfe-a99093c19fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8dac4905-3181-4b35-8c51-e545a9af4540" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0d08ec9e-2fda-4b30-adfe-a99093c19fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b68f7000-4a19-4d57-b31c-d096e782b201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8dac4905-3181-4b35-8c51-e545a9af4540" xlink:to="loc_us-gaap_UseOfEstimates_b68f7000-4a19-4d57-b31c-d096e782b201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_30454434-f4b6-47b0-98ab-debcc2339379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8dac4905-3181-4b35-8c51-e545a9af4540" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_30454434-f4b6-47b0-98ab-debcc2339379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2d584a96-0f29-4b68-8239-cc5b26425db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8dac4905-3181-4b35-8c51-e545a9af4540" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2d584a96-0f29-4b68-8239-cc5b26425db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_781c99f6-1cca-4b19-8005-66dd9dde98d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8dac4905-3181-4b35-8c51-e545a9af4540" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_781c99f6-1cca-4b19-8005-66dd9dde98d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_81238056-9ff7-41f1-8056-e3606c823599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74b8227c-7d8d-462f-aaf5-6f7b978697c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81238056-9ff7-41f1-8056-e3606c823599" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74b8227c-7d8d-462f-aaf5-6f7b978697c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fcd3ae40-c8ac-4030-b95a-fe2ea93680f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81238056-9ff7-41f1-8056-e3606c823599" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fcd3ae40-c8ac-4030-b95a-fe2ea93680f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0ae5a5b8-207a-4e7d-82ac-5e66c02db864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81238056-9ff7-41f1-8056-e3606c823599" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0ae5a5b8-207a-4e7d-82ac-5e66c02db864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bbe395d1-91ce-42bf-af90-425a9db9d0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2ada3785-d419-41f0-a098-4b3c5ea3c243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bbe395d1-91ce-42bf-af90-425a9db9d0b9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2ada3785-d419-41f0-a098-4b3c5ea3c243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b5856ebd-fb38-41a4-96fb-f9e8c486e731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2ada3785-d419-41f0-a098-4b3c5ea3c243" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b5856ebd-fb38-41a4-96fb-f9e8c486e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5856ebd-fb38-41a4-96fb-f9e8c486e731" xlink:to="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e17c9878-90bd-432f-9c9b-0b5df6968e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e17c9878-90bd-432f-9c9b-0b5df6968e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_08d5deb9-5844-4ba6-8280-4d56dbd432af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_08d5deb9-5844-4ba6-8280-4d56dbd432af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04a52c3c-5af6-4f9f-9f9f-12235af04f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85d82b64-5b8c-4fd6-8b18-98edf1fb870f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04a52c3c-5af6-4f9f-9f9f-12235af04f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_85d8e762-b730-41cc-b9d8-a25b70f1daef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2ada3785-d419-41f0-a098-4b3c5ea3c243" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_85d8e762-b730-41cc-b9d8-a25b70f1daef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_85d8e762-b730-41cc-b9d8-a25b70f1daef" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_226693ab-5490-405f-bd7a-fd6f09212807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:to="loc_us-gaap_StockholdersEquity_226693ab-5490-405f-bd7a-fd6f09212807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0804c5de-a91c-439a-a88c-cce6708b0ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0804c5de-a91c-439a-a88c-cce6708b0ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fba658b-2876-4756-8917-b81135f9cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c543a315-584a-4eb7-9cda-a8336475c770" xlink:to="loc_us-gaap_StockholdersEquity_9fba658b-2876-4756-8917-b81135f9cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b4c7b7ca-6acd-4ae5-88e1-f3623f894f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4fac87ec-7ee8-43d5-9123-90b91bf7cd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b4c7b7ca-6acd-4ae5-88e1-f3623f894f0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4fac87ec-7ee8-43d5-9123-90b91bf7cd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f05f93f3-cfe4-4b80-ab85-05a710174013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b4c7b7ca-6acd-4ae5-88e1-f3623f894f0b" xlink:to="loc_us-gaap_RestrictedCashCurrent_f05f93f3-cfe4-4b80-ab85-05a710174013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5ec9f3a1-2eea-45d9-8d71-e2a6ad04881a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b4c7b7ca-6acd-4ae5-88e1-f3623f894f0b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5ec9f3a1-2eea-45d9-8d71-e2a6ad04881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9f90d07-9031-404f-9f59-fb1137c016fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b4c7b7ca-6acd-4ae5-88e1-f3623f894f0b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9f90d07-9031-404f-9f59-fb1137c016fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSales" xlink:type="simple" xlink:href="mrna-20210630.xsd#ProductSales"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b73eeb3b-6cb0-401b-b397-e23e71bf92b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5784b634-7f8c-470c-be66-92e5cfa7e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b73eeb3b-6cb0-401b-b397-e23e71bf92b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5784b634-7f8c-470c-be66-92e5cfa7e9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#ProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fe9f967-5b52-44ca-bfe8-cf233dd2b1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_ad3ae47b-984c-4aea-b169-54ae5c8df1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fe9f967-5b52-44ca-bfe8-cf233dd2b1ff" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_ad3ae47b-984c-4aea-b169-54ae5c8df1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#ProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3fdd20f-1746-46ff-bfff-9145660501ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3fdd20f-1746-46ff-bfff-9145660501ca" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b930e61f-e71a-417f-9bff-552fc225c7d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:to="loc_srt_StatementGeographicalAxis_b930e61f-e71a-417f-9bff-552fc225c7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b930e61f-e71a-417f-9bff-552fc225c7d1" xlink:to="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c4e6bba9-3458-4ff5-bbc8-44d2875f4817" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:to="loc_country_US_c4e6bba9-3458-4ff5-bbc8-44d2875f4817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_044ba90e-dd1d-4fb5-be57-d69f3dae98d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e2b8e6d4-95ba-43d7-afb6-61c74e3daff3" xlink:to="loc_us-gaap_NonUsMember_044ba90e-dd1d-4fb5-be57-d69f3dae98d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_924d75fb-224c-4395-920d-6b599662deb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:to="loc_srt_ProductOrServiceAxis_924d75fb-224c-4395-920d-6b599662deb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e3a7b09-0512-4a12-9f21-ced91c7a5b13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_924d75fb-224c-4395-920d-6b599662deb2" xlink:to="loc_srt_ProductsAndServicesDomain_9e3a7b09-0512-4a12-9f21-ced91c7a5b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_ac94afee-74f5-46ea-8714-62240f3dd5a8" xlink:href="mrna-20210630.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e3a7b09-0512-4a12-9f21-ced91c7a5b13" xlink:to="loc_mrna_ProductSalesMember_ac94afee-74f5-46ea-8714-62240f3dd5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_89e5ffa8-2eb5-42d6-a354-13eb7d9a56ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_db5201bf-4c61-426b-9a0e-b87f853653c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:to="loc_us-gaap_Revenues_db5201bf-4c61-426b-9a0e-b87f853653c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8583d763-ebf5-47db-b488-89cfee43e6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7151cef7-2c04-4335-8f46-e186f9f5abae" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8583d763-ebf5-47db-b488-89cfee43e6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenue" xlink:type="simple" xlink:href="mrna-20210630.xsd#GrantRevenue"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_6e80aeab-59bc-40e2-9522-7c7f60df4b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a5723f08-cc6e-45a7-a2fa-94a62acc261f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_6e80aeab-59bc-40e2-9522-7c7f60df4b5c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a5723f08-cc6e-45a7-a2fa-94a62acc261f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#GrantRevenueTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_d15370ae-2979-475e-ac4f-12bcf6c47ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f59447ac-ebef-4897-9f05-29b89d6577f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_d15370ae-2979-475e-ac4f-12bcf6c47ef1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f59447ac-ebef-4897-9f05-29b89d6577f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#GrantRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_06834c6a-facc-4b1e-ac32-9bcbf4e6a407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_06834c6a-facc-4b1e-ac32-9bcbf4e6a407" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0c7739bb-e2c9-499b-8415-8bd5412bdefe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:to="loc_srt_MajorCustomersAxis_0c7739bb-e2c9-499b-8415-8bd5412bdefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0c7739bb-e2c9-499b-8415-8bd5412bdefe" xlink:to="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_f7fe6ebd-b99f-4a24-9f4b-c3a8a5aa92bb" xlink:href="mrna-20210630.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_f7fe6ebd-b99f-4a24-9f4b-c3a8a5aa92bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_f2fa8214-5f3f-4fad-b477-9fff38d14f6e" xlink:href="mrna-20210630.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_f2fa8214-5f3f-4fad-b477-9fff38d14f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_b2049737-3c5c-4478-9666-012a047f207e" xlink:href="mrna-20210630.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_b2049737-3c5c-4478-9666-012a047f207e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_65e38cee-ac85-4afa-b2ba-d68861b94d2e" xlink:href="mrna-20210630.xsd#mrna_OtherGrantRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0cdf6532-9beb-45a7-9d3f-d7a79b7c3850" xlink:to="loc_mrna_OtherGrantRevenueMember_65e38cee-ac85-4afa-b2ba-d68861b94d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c7d015e9-0ba6-4d18-9456-10e2ab0a4ade" xlink:to="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember_7db6cc7f-a224-4ed0-a590-f532e772d83e" xlink:href="mrna-20210630.xsd#mrna_ContractOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:to="loc_mrna_ContractOptionsMember_7db6cc7f-a224-4ed0-a590-f532e772d83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember_5479e329-1116-4682-b589-7af75efa6c3b" xlink:href="mrna-20210630.xsd#mrna_InitialProjectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_92619b9a-fa06-4d21-8aea-25a02a82f260" xlink:to="loc_mrna_InitialProjectMember_5479e329-1116-4682-b589-7af75efa6c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8f92a912-0a19-4930-a477-1208fa909cac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:to="loc_srt_ProductOrServiceAxis_8f92a912-0a19-4930-a477-1208fa909cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ccd4c1fa-4a1c-4e3b-bd69-fc606ca630ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8f92a912-0a19-4930-a477-1208fa909cac" xlink:to="loc_srt_ProductsAndServicesDomain_ccd4c1fa-4a1c-4e3b-bd69-fc606ca630ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e91bc47c-a982-431b-8dda-f265dcde00ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ccd4c1fa-4a1c-4e3b-bd69-fc606ca630ad" xlink:to="loc_us-gaap_GrantMember_e91bc47c-a982-431b-8dda-f265dcde00ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6060abcf-0b5f-483e-bc76-0a2e538b1ecf" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_bfdcfa51-4192-4795-876f-f7c20fe7989f" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_bfdcfa51-4192-4795-876f-f7c20fe7989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_53afb1e0-96bf-40aa-a6d1-8ebbd9504fa4" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_53afb1e0-96bf-40aa-a6d1-8ebbd9504fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_01301703-d056-43ac-b963-f3b557ffc2d0" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_01301703-d056-43ac-b963-f3b557ffc2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_b3c1710e-41d7-49cd-ad4c-a0b39725096b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_us-gaap_OtherCommitment_b3c1710e-41d7-49cd-ad4c-a0b39725096b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipant_93ab8771-5d19-4af3-92ff-bf090d6b1c75" xlink:href="mrna-20210630.xsd#mrna_NumberOfParticipant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_NumberOfParticipant_93ab8771-5d19-4af3-92ff-bf090d6b1c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_323e3407-cf83-40e7-b3c7-c0e2b6979dcf" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_323e3407-cf83-40e7-b3c7-c0e2b6979dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_995722b0-1101-49b4-b4b0-a648313ead53" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_995722b0-1101-49b4-b4b0-a648313ead53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_4f67ad6a-b6a0-4eeb-bf28-7ace26747365" xlink:href="mrna-20210630.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_4f67ad6a-b6a0-4eeb-bf28-7ace26747365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5eb87b6c-417c-4f56-8cef-097023c7bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5eb87b6c-417c-4f56-8cef-097023c7bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b05c95dd-3853-4303-a4bd-4427b57993d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9409d3ed-463c-4351-821e-6cb9441960f6" xlink:to="loc_us-gaap_Revenues_b05c95dd-3853-4303-a4bd-4427b57993d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="simple" xlink:href="mrna-20210630.xsd#CollaborationRevenue"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_d9b3da18-ffb9-4d0a-ad02-54d05b6d5351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2c281194-c13f-41d0-8ad0-8165f0433637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_d9b3da18-ffb9-4d0a-ad02-54d05b6d5351" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2c281194-c13f-41d0-8ad0-8165f0433637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#CollaborationRevenueTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_df6c45f0-e44a-49c3-ba9d-952e309f7662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8eef89c1-de4e-4843-bfdd-fcaa68862d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_df6c45f0-e44a-49c3-ba9d-952e309f7662" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8eef89c1-de4e-4843-bfdd-fcaa68862d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_10ceeaa1-fab8-44c5-925d-060e5aa88588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_df6c45f0-e44a-49c3-ba9d-952e309f7662" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_10ceeaa1-fab8-44c5-925d-060e5aa88588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_532369bb-bd6a-4915-9900-8d25934ffa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_532369bb-bd6a-4915-9900-8d25934ffa3b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5b5f047e-f316-4525-95db-6a7b5938dd4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:to="loc_srt_ProductOrServiceAxis_5b5f047e-f316-4525-95db-6a7b5938dd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4481ca06-107b-45e9-9fcd-14ee6eea3471" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5b5f047e-f316-4525-95db-6a7b5938dd4b" xlink:to="loc_srt_ProductsAndServicesDomain_4481ca06-107b-45e9-9fcd-14ee6eea3471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_6db6706a-f337-4f59-b284-37bf3f83a2da" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4481ca06-107b-45e9-9fcd-14ee6eea3471" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_6db6706a-f337-4f59-b284-37bf3f83a2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e907a3a-d086-4c43-a915-79bfaac441c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:to="loc_srt_CounterpartyNameAxis_0e907a3a-d086-4c43-a915-79bfaac441c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0e907a3a-d086-4c43-a915-79bfaac441c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember_aebe5d2b-ae55-4843-853d-39298f555c68" xlink:href="mrna-20210630.xsd#mrna_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_AstraZenecaMember_aebe5d2b-ae55-4843-853d-39298f555c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_89ae0fb8-23a6-44cf-8351-30317dfa61e9" xlink:href="mrna-20210630.xsd#mrna_MerckMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_MerckMember_89ae0fb8-23a6-44cf-8351-30317dfa61e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_6dc390b9-9848-4a2e-9881-d1a9530b9514" xlink:href="mrna-20210630.xsd#mrna_VertexMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_VertexMember_6dc390b9-9848-4a2e-9881-d1a9530b9514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember_af8c780d-8c44-4457-b682-de44ce9c7bf2" xlink:href="mrna-20210630.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adf0bdb-8caa-4585-8196-6cd92f99e1df" xlink:to="loc_mrna_OtherCollaborativePartiesMember_af8c780d-8c44-4457-b682-de44ce9c7bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_33f16d3a-62bd-4d84-b6ea-a966f5436a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_09b1b785-6b2c-476b-bdbd-9576e72fe55d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_33f16d3a-62bd-4d84-b6ea-a966f5436a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add5ff44-cb9a-4c39-a091-6de9746f4444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_33f16d3a-62bd-4d84-b6ea-a966f5436a0f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add5ff44-cb9a-4c39-a091-6de9746f4444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_76c8ff08-3b2c-4fe0-87db-b9a8f70b3bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd3fd6cc-1bc0-44e5-8ebf-411f7914242a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_76c8ff08-3b2c-4fe0-87db-b9a8f70b3bab" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd3fd6cc-1bc0-44e5-8ebf-411f7914242a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8729ac78-d0fe-4741-a6d1-ec42f3015c0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd3fd6cc-1bc0-44e5-8ebf-411f7914242a" xlink:to="loc_srt_ProductOrServiceAxis_8729ac78-d0fe-4741-a6d1-ec42f3015c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ded3b2b8-4f46-4184-8401-f6d5729e6700" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8729ac78-d0fe-4741-a6d1-ec42f3015c0d" xlink:to="loc_srt_ProductsAndServicesDomain_ded3b2b8-4f46-4184-8401-f6d5729e6700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_21d73d83-bf98-46d6-b45f-836d139a12c2" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ded3b2b8-4f46-4184-8401-f6d5729e6700" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_21d73d83-bf98-46d6-b45f-836d139a12c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd3fd6cc-1bc0-44e5-8ebf-411f7914242a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:to="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_d530ecea-8bd5-4f85-b143-3502473fc596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_d530ecea-8bd5-4f85-b143-3502473fc596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetPurchase_a26f4d88-7a23-4348-8a64-6a384f6cf647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetPurchase"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetPurchase_a26f4d88-7a23-4348-8a64-6a384f6cf647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_9324a66d-81f0-4b38-a055-0de3b0769dec" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:to="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_9324a66d-81f0-4b38-a055-0de3b0769dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_a1ed5c43-0161-4660-8925-37b2233127a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c3b8607b-aec1-48f2-9cb7-a65e537afb0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_a1ed5c43-0161-4660-8925-37b2233127a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_de551570-87b6-409d-8438-f1e29c834a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:to="loc_us-gaap_ContractWithCustomerLiability_de551570-87b6-409d-8438-f1e29c834a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a682fec6-1940-46c3-9d40-ad59d015e91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a682fec6-1940-46c3-9d40-ad59d015e91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_d1fea0bc-244d-4f09-9b1b-859db0ef0981" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_d1fea0bc-244d-4f09-9b1b-859db0ef0981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_75453087-3955-40eb-9689-1c841f596cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_ec3c3e04-a464-4374-8f91-de610e9d1b24" xlink:to="loc_us-gaap_ContractWithCustomerLiability_75453087-3955-40eb-9689-1c841f596cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_bb44feb3-14d1-4afc-8bc9-af9082387ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7eaae0a-9fe0-4ccc-a5bc-6f76468495d9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_bb44feb3-14d1-4afc-8bc9-af9082387ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e8240bbe-2f99-49e4-ac2f-bab95330f842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_68cf4f1d-3ee2-4986-82ee-27bf09ecebec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e8240bbe-2f99-49e4-ac2f-bab95330f842" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_68cf4f1d-3ee2-4986-82ee-27bf09ecebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f2e277d0-1b64-40b1-a9fc-2d54a70bf8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ad16b542-622c-4c5d-8700-504b44be9017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f2e277d0-1b64-40b1-a9fc-2d54a70bf8fd" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ad16b542-622c-4c5d-8700-504b44be9017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_38f580b4-19b3-49d3-a526-f44f5ac91f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f2e277d0-1b64-40b1-a9fc-2d54a70bf8fd" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_38f580b4-19b3-49d3-a526-f44f5ac91f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e00d443b-08c9-4b8a-a573-853d2c21db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f2e277d0-1b64-40b1-a9fc-2d54a70bf8fd" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e00d443b-08c9-4b8a-a573-853d2c21db3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ab9a183d-1d3c-4961-8f70-2c17d39aac29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ab9a183d-1d3c-4961-8f70-2c17d39aac29" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9258c93e-aa0e-4e5f-8845-1c318090b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9258c93e-aa0e-4e5f-8845-1c318090b18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9258c93e-aa0e-4e5f-8845-1c318090b18b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_2fb2e147-e094-4ff0-a7f0-2768079e2069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_2fb2e147-e094-4ff0-a7f0-2768079e2069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e3040bde-a457-4d55-b2e0-f751c7d12927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e3040bde-a457-4d55-b2e0-f751c7d12927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5e036df3-c93d-4825-bc56-a1fe50062eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5e036df3-c93d-4825-bc56-a1fe50062eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ca08cc17-01cc-42e9-a9bd-8a36e9b85bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ca08cc17-01cc-42e9-a9bd-8a36e9b85bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ecf801e1-770e-4b99-ad89-ed85d261f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8083bcdc-d30f-41dc-b059-d2d990228f5a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ecf801e1-770e-4b99-ad89-ed85d261f26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf6a74be-1ee3-4041-b31a-9829799ce5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf6a74be-1ee3-4041-b31a-9829799ce5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf6a74be-1ee3-4041-b31a-9829799ce5f1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_54dc87cb-61fc-428b-b2bc-61d4bed806ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_54dc87cb-61fc-428b-b2bc-61d4bed806ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_ce2478ec-a0f6-439d-97f7-518d4276400c" xlink:href="mrna-20210630.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_ce2478ec-a0f6-439d-97f7-518d4276400c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_700e257f-492c-4161-a766-5c97fdf0fcb5" xlink:href="mrna-20210630.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e083b84b-9e6f-492c-ab40-bb28cd2ee414" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_700e257f-492c-4161-a766-5c97fdf0fcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f2fd9231-cc80-45d8-8cf3-b1cbd8822f21" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_60493d01-ea82-48a6-af7b-fee1f85ef755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_60493d01-ea82-48a6-af7b-fee1f85ef755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3a4c358b-d6e5-4672-9847-05ac1fe80bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151e144f-edc3-4775-882e-2b4c992d30fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3a4c358b-d6e5-4672-9847-05ac1fe80bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b881095f-14a0-4f03-8d68-06b021449103" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bf8d4bd0-521e-49b1-9800-6f6b0434641c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bf8d4bd0-521e-49b1-9800-6f6b0434641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ce3f55de-6a79-4eaa-bdb2-276dc58b4b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ce3f55de-6a79-4eaa-bdb2-276dc58b4b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637680f5-058e-4c4a-a3d7-31c4840bd7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637680f5-058e-4c4a-a3d7-31c4840bd7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f248a99-c5c8-4cfa-a321-2561c0ef8eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230a5e73-37c7-4f44-9016-95f38b62d706" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f248a99-c5c8-4cfa-a321-2561c0ef8eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_efdbb272-2f89-4f10-98ee-2d9dd86e0dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6a344faa-dab2-42dc-a145-45c9b8570fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_efdbb272-2f89-4f10-98ee-2d9dd86e0dfe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6a344faa-dab2-42dc-a145-45c9b8570fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_51b0615b-dc79-464e-b7e3-0357b7741709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6a344faa-dab2-42dc-a145-45c9b8570fdb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_51b0615b-dc79-464e-b7e3-0357b7741709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_bdcc809c-3990-47e1-a8a1-a685a9b0c446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6a344faa-dab2-42dc-a145-45c9b8570fdb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_bdcc809c-3990-47e1-a8a1-a685a9b0c446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_deb36f07-7304-44b6-b077-a6076cbcfb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6a344faa-dab2-42dc-a145-45c9b8570fdb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_deb36f07-7304-44b6-b077-a6076cbcfb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_c020f892-27a8-45fa-b15b-14b4e31e830c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_efdbb272-2f89-4f10-98ee-2d9dd86e0dfe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_c020f892-27a8-45fa-b15b-14b4e31e830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_625530a7-22c5-4934-b471-1532a54c3d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_c020f892-27a8-45fa-b15b-14b4e31e830c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_625530a7-22c5-4934-b471-1532a54c3d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e56b9346-d6bf-477e-a0b2-427e43d6c321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_c020f892-27a8-45fa-b15b-14b4e31e830c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e56b9346-d6bf-477e-a0b2-427e43d6c321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_f18f75bb-548b-4da7-8d19-5c86fded83a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_c020f892-27a8-45fa-b15b-14b4e31e830c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_f18f75bb-548b-4da7-8d19-5c86fded83a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_39a45e65-7a23-4736-8c79-9027e401d32e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_566e30a6-29c0-4c0e-a338-ed02623226cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_39a45e65-7a23-4736-8c79-9027e401d32e" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_566e30a6-29c0-4c0e-a338-ed02623226cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3a2d9a49-94ac-48f5-9be7-d314bd84e823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_39a45e65-7a23-4736-8c79-9027e401d32e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3a2d9a49-94ac-48f5-9be7-d314bd84e823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ebdbb3fc-7ada-45d8-9961-da0238f4f725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ebdbb3fc-7ada-45d8-9961-da0238f4f725" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e34aa72f-c921-46f4-82a3-821449568fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e34aa72f-c921-46f4-82a3-821449568fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f50960b7-8e0f-4a7e-b8b5-359b09cd128a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e34aa72f-c921-46f4-82a3-821449568fe6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f50960b7-8e0f-4a7e-b8b5-359b09cd128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b97bf247-68cf-4ae0-839f-cfeef025d819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f50960b7-8e0f-4a7e-b8b5-359b09cd128a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b97bf247-68cf-4ae0-839f-cfeef025d819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac49cbe2-b02f-40ff-ac58-9cf5e1a13c15" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d7bb4843-41b5-4d93-a4e4-e61828fa04d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d7bb4843-41b5-4d93-a4e4-e61828fa04d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4239f974-409a-4b9a-a355-a1c5a2140ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4239f974-409a-4b9a-a355-a1c5a2140ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_91b7c6c0-92b4-40ad-87cc-3865e33ec5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_91b7c6c0-92b4-40ad-87cc-3865e33ec5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae7fbef1-c765-47d9-ae13-cd01721ad294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae7fbef1-c765-47d9-ae13-cd01721ad294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fd04a364-1004-46ed-9412-5a80d2cd64b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47024ba6-819f-471e-b791-10acaf96bb3a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fd04a364-1004-46ed-9412-5a80d2cd64b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b659f728-c517-452e-8bb5-c7d0558a2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b659f728-c517-452e-8bb5-c7d0558a2fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b659f728-c517-452e-8bb5-c7d0558a2fe5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8183300-7110-4fd9-bec6-1722040755a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8183300-7110-4fd9-bec6-1722040755a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25657013-7dff-4832-883f-f90a51920930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1a7a66d-8f17-4c50-acb5-9f424d09209e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25657013-7dff-4832-883f-f90a51920930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8cdb1846-64cc-4c47-986a-580b5a2a94f2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0035a510-5eec-49f2-a05e-f3b98b8c1f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0035a510-5eec-49f2-a05e-f3b98b8c1f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_02f4c55f-91e0-4bfb-ac50-8d1f77e4b9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_DerivativeAssets_02f4c55f-91e0-4bfb-ac50-8d1f77e4b9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d33a1e6f-95d7-4ccf-bce9-646856058160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d33a1e6f-95d7-4ccf-bce9-646856058160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b264c09d-e0ce-42bd-8c1d-e160fe8e1299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03d386c2-5939-45e2-9870-d922b70eb6a9" xlink:to="loc_us-gaap_DerivativeLiabilities_b264c09d-e0ce-42bd-8c1d-e160fe8e1299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="mrna-20210630.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bfbdca75-772d-4a23-afa1-d332eaf47c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cffd01cb-9997-45d0-aa2e-e839f56fca23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bfbdca75-772d-4a23-afa1-d332eaf47c71" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cffd01cb-9997-45d0-aa2e-e839f56fca23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_82a01cab-3dec-4914-be3e-eac77e2e4fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_87c8bced-b36f-4d7d-8027-ef79fa162591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_82a01cab-3dec-4914-be3e-eac77e2e4fe9" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_87c8bced-b36f-4d7d-8027-ef79fa162591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashFlowHedgesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#DerivativeFinancialInstrumentsCashFlowHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f5d0db16-850a-4bde-9066-e330b5ff9867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_612462f6-ce70-4b74-938d-d1f4cca8cf81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f5d0db16-850a-4bde-9066-e330b5ff9867" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_612462f6-ce70-4b74-938d-d1f4cca8cf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_68cb8b0a-07ee-453f-b22c-6bbacd67a8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_68cb8b0a-07ee-453f-b22c-6bbacd67a8ab" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d96a6b29-74c7-4dad-94db-1e8bc8fd4375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d96a6b29-74c7-4dad-94db-1e8bc8fd4375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9336260c-1002-444d-8c64-f7d4e4374d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d96a6b29-74c7-4dad-94db-1e8bc8fd4375" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9336260c-1002-444d-8c64-f7d4e4374d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fa497cc0-cbce-4855-af19-c323722ae7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9336260c-1002-444d-8c64-f7d4e4374d90" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fa497cc0-cbce-4855-af19-c323722ae7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8a66252-83fe-4975-90c5-59e063ae58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8a66252-83fe-4975-90c5-59e063ae58ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f682ed3-f490-4a9b-9405-5f0784f398c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8a66252-83fe-4975-90c5-59e063ae58ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f682ed3-f490-4a9b-9405-5f0784f398c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_43b30bf8-0073-451f-b2f9-7a3f32b18e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f682ed3-f490-4a9b-9405-5f0784f398c0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_43b30bf8-0073-451f-b2f9-7a3f32b18e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_74aef084-d0b1-4fcb-aa44-d96017778699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_HedgingDesignationAxis_74aef084-d0b1-4fcb-aa44-d96017778699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_74aef084-d0b1-4fcb-aa44-d96017778699" xlink:to="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18b10de2-5c77-464c-ab19-68339c503b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18b10de2-5c77-464c-ab19-68339c503b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_184ed802-c3a0-4891-95e0-498b907949dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_08cc0978-0164-4c75-a73e-f30ef092036c" xlink:to="loc_us-gaap_NondesignatedMember_184ed802-c3a0-4891-95e0-498b907949dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_56c2a499-4ecc-41d9-bade-80f8c0023aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_56c2a499-4ecc-41d9-bade-80f8c0023aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_231ce5ec-7a7d-494e-b313-e85b9eb3f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_56c2a499-4ecc-41d9-bade-80f8c0023aff" xlink:to="loc_us-gaap_HedgingRelationshipDomain_231ce5ec-7a7d-494e-b313-e85b9eb3f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_24af5402-6a34-475a-a09b-b75af30e3d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_231ce5ec-7a7d-494e-b313-e85b9eb3f6f7" xlink:to="loc_us-gaap_CashFlowHedgingMember_24af5402-6a34-475a-a09b-b75af30e3d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3a1bf6d1-abad-4197-bfb0-ef9c6d00f39c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_636319dd-0937-4f4f-bfb0-523d6e7a4afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_636319dd-0937-4f4f-bfb0-523d6e7a4afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_fe78bfe0-50cd-4d1a-9c39-70a09817998b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeAssets_fe78bfe0-50cd-4d1a-9c39-70a09817998b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8e08302d-10e3-4f38-9a55-a10a8f59ddf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeLiabilities_8e08302d-10e3-4f38-9a55-a10a8f59ddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d7258c9a-4de7-47b9-94e2-fd4af6fe8e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_685b67a6-6d69-4ddf-ac98-792f438ac81d" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d7258c9a-4de7-47b9-94e2-fd4af6fe8e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Inventory" xlink:type="simple" xlink:href="mrna-20210630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e9646338-f78a-4b14-96cd-4a551c57246d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_0375949b-8982-480b-a7b3-fa4cc5d0e832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e9646338-f78a-4b14-96cd-4a551c57246d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_0375949b-8982-480b-a7b3-fa4cc5d0e832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b2c4776e-3e38-4ad1-a813-a2f1fb46b365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_afbf554b-334c-441f-a03c-f689b9d3785e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b2c4776e-3e38-4ad1-a813-a2f1fb46b365" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_afbf554b-334c-441f-a03c-f689b9d3785e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_928ac8f3-b030-4a04-9748-1d03eaa5de85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22b2d9f7-f34e-42c5-ae3b-6cf3b62dad93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_928ac8f3-b030-4a04-9748-1d03eaa5de85" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22b2d9f7-f34e-42c5-ae3b-6cf3b62dad93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8840bc5c-05bb-40ee-b7cd-2ccd0c7d63b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_928ac8f3-b030-4a04-9748-1d03eaa5de85" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8840bc5c-05bb-40ee-b7cd-2ccd0c7d63b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b53ae829-bf2e-48c6-a7f6-a2e36b67d773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_928ac8f3-b030-4a04-9748-1d03eaa5de85" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b53ae829-bf2e-48c6-a7f6-a2e36b67d773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2da65513-47b1-45ba-a46a-61f88884f62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_928ac8f3-b030-4a04-9748-1d03eaa5de85" xlink:to="loc_us-gaap_InventoryNet_2da65513-47b1-45ba-a46a-61f88884f62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="mrna-20210630.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1a0412e1-f096-4269-b727-88dd88f564e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a2356288-0941-49a8-af82-230b198573f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1a0412e1-f096-4269-b727-88dd88f564e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a2356288-0941-49a8-af82-230b198573f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3c620da4-5aa1-4d19-9dfa-f1ba975442c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c3ec02cb-4cc6-435b-b991-ff882d3a9d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3c620da4-5aa1-4d19-9dfa-f1ba975442c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c3ec02cb-4cc6-435b-b991-ff882d3a9d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_41403319-8c4c-4b59-b248-550d4f7900f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_823a7a08-f69c-40c9-94ee-eca3c929c647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_41403319-8c4c-4b59-b248-550d4f7900f7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_823a7a08-f69c-40c9-94ee-eca3c929c647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12da8554-1ef8-4068-8911-9fdd6e300e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_823a7a08-f69c-40c9-94ee-eca3c929c647" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12da8554-1ef8-4068-8911-9fdd6e300e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12da8554-1ef8-4068-8911-9fdd6e300e75" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_4f9df959-6f73-49e9-a2f1-7b644cf8fed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_EquipmentMember_4f9df959-6f73-49e9-a2f1-7b644cf8fed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bbf4648c-8eaf-4504-901c-72cf0e8431f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bbf4648c-8eaf-4504-901c-72cf0e8431f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9f18e7b0-2cfd-4d21-9459-b72eff1f2c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9f18e7b0-2cfd-4d21-9459-b72eff1f2c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3a2b9836-4f43-4327-97c8-02dd6c74813d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_ComputerEquipmentMember_3a2b9836-4f43-4327-97c8-02dd6c74813d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_96f9cbda-f922-4393-981d-5054c7862724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_96f9cbda-f922-4393-981d-5054c7862724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_3ec0a258-fe16-4f43-be42-cb03e7ba05a6" xlink:href="mrna-20210630.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_3ec0a258-fe16-4f43-be42-cb03e7ba05a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_75f3759e-a996-4214-acde-36407060f957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c235a2b1-8b8f-4f23-9e06-adfe659b5818" xlink:to="loc_us-gaap_ConstructionInProgressMember_75f3759e-a996-4214-acde-36407060f957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_823a7a08-f69c-40c9-94ee-eca3c929c647" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_85164b32-7e27-40f0-94cb-ddf5c70224f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_85164b32-7e27-40f0-94cb-ddf5c70224f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9145da6a-0088-4f47-889c-d3bfd9c8c510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9145da6a-0088-4f47-889c-d3bfd9c8c510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e1f77932-1d2a-46ed-aec0-7ac5d40004c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e1f77932-1d2a-46ed-aec0-7ac5d40004c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2e873e91-d0a1-407e-96a5-8dde5717001e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9cc263bc-e6bd-45ef-a11a-e387179a154b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2e873e91-d0a1-407e-96a5-8dde5717001e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7826ff7d-b245-4cc0-8a72-20fefa2edc75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a8b87924-4220-4aca-aaf9-544f4a9600ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7826ff7d-b245-4cc0-8a72-20fefa2edc75" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a8b87924-4220-4aca-aaf9-544f4a9600ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_562f5e7a-0142-490e-9b0c-e86a1b0163de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_6995f9f1-18a8-4c4e-a755-d4da82f19b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_562f5e7a-0142-490e-9b0c-e86a1b0163de" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_6995f9f1-18a8-4c4e-a755-d4da82f19b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ec667810-a981-4c7f-9409-47f69899ad5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_562f5e7a-0142-490e-9b0c-e86a1b0163de" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ec667810-a981-4c7f-9409-47f69899ad5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_2d7e38c9-005c-4b82-b760-90ccbe60fc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_562f5e7a-0142-490e-9b0c-e86a1b0163de" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_2d7e38c9-005c-4b82-b760-90ccbe60fc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_99a8b047-a839-4f11-9b12-a797aa165457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_562f5e7a-0142-490e-9b0c-e86a1b0163de" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_99a8b047-a839-4f11-9b12-a797aa165457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0c441f1-4374-444c-8bba-cf2ec96a55cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing_86049de6-c0f7-4997-a99b-f11e706c253b" xlink:href="mrna-20210630.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0c441f1-4374-444c-8bba-cf2ec96a55cb" xlink:to="loc_mrna_OtherPrepaidExpenseManufacturing_86049de6-c0f7-4997-a99b-f11e706c253b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_ae8794d4-2e45-4e31-a8ee-2f5a8afb538a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0c441f1-4374-444c-8bba-cf2ec96a55cb" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_ae8794d4-2e45-4e31-a8ee-2f5a8afb538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_f6ca3671-aa46-4ad8-a525-50dd1e769cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0c441f1-4374-444c-8bba-cf2ec96a55cb" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_f6ca3671-aa46-4ad8-a525-50dd1e769cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_69752abc-1150-43a0-99d0-e53bbd2b00bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0c441f1-4374-444c-8bba-cf2ec96a55cb" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_69752abc-1150-43a0-99d0-e53bbd2b00bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_bbf4395c-3a9f-4042-89b1-de0835bc96be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0c441f1-4374-444c-8bba-cf2ec96a55cb" xlink:to="loc_us-gaap_OtherAssetsCurrent_bbf4395c-3a9f-4042-89b1-de0835bc96be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f69c9bed-283e-45da-913a-11240d33d85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0c441f1-4374-444c-8bba-cf2ec96a55cb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f69c9bed-283e-45da-913a-11240d33d85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_5d8a054e-e099-481a-8027-af81a82a4a09" xlink:href="mrna-20210630.xsd#mrna_AccruedClinicalTrials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_mrna_AccruedClinicalTrials_5d8a054e-e099-481a-8027-af81a82a4a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_30aaef1b-3b7e-4e06-a219-b23e813cdedf" xlink:href="mrna-20210630.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_mrna_RawMaterialsAccountsPayable_30aaef1b-3b7e-4e06-a219-b23e813cdedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_32ee5532-30c7-4667-8894-7bff53c71753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_32ee5532-30c7-4667-8894-7bff53c71753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_fe7540c3-986d-4748-b55b-73bc4da8c75e" xlink:href="mrna-20210630.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_mrna_AccruedDevelopmentOperation_fe7540c3-986d-4748-b55b-73bc4da8c75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_6fd4c328-fb73-4d4e-b7dd-bcf9b61871fa" xlink:href="mrna-20210630.xsd#mrna_AccruedManufacturing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_mrna_AccruedManufacturing_6fd4c328-fb73-4d4e-b7dd-bcf9b61871fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_64f631f9-2769-4c29-9b00-826283f536d4" xlink:href="mrna-20210630.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_64f631f9-2769-4c29-9b00-826283f536d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7f8dd9e8-5ea6-4c61-9a02-0ddabad3494c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7f8dd9e8-5ea6-4c61-9a02-0ddabad3494c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b8dbf7d4-3d3a-4777-9912-be20453c9a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b8dbf7d4-3d3a-4777-9912-be20453c9a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_adf01de2-3bca-4d92-9e35-68da182276e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f4b9254-ba07-43eb-803f-b01377eb6cc0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_adf01de2-3bca-4d92-9e35-68da182276e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60cfc003-4bce-4454-a039-f6cf021806f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_df781040-064b-40f6-8535-f8f8ec9ed264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60cfc003-4bce-4454-a039-f6cf021806f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_df781040-064b-40f6-8535-f8f8ec9ed264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_74779666-51ea-401e-8bad-7cba4f56f94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60cfc003-4bce-4454-a039-f6cf021806f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_74779666-51ea-401e-8bad-7cba4f56f94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_d67466ba-a071-47a5-9c57-65225782068b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60cfc003-4bce-4454-a039-f6cf021806f2" xlink:to="loc_us-gaap_TaxesPayableCurrent_d67466ba-a071-47a5-9c57-65225782068b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_75530b8a-26f9-4240-a492-a74b5578ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60cfc003-4bce-4454-a039-f6cf021806f2" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_75530b8a-26f9-4240-a492-a74b5578ca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_540411f1-cb48-43b5-b32e-8e72563e3091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60cfc003-4bce-4454-a039-f6cf021806f2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_540411f1-cb48-43b5-b32e-8e72563e3091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48151dea-3af1-423e-8168-83edd0f05295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_08194543-a4f5-4ef8-8938-6be11d5c05da" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48151dea-3af1-423e-8168-83edd0f05295" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_08194543-a4f5-4ef8-8938-6be11d5c05da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_107cdc4b-cb38-4e15-9545-20c2335ad7af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_08194543-a4f5-4ef8-8938-6be11d5c05da" xlink:to="loc_srt_ProductOrServiceAxis_107cdc4b-cb38-4e15-9545-20c2335ad7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_107cdc4b-cb38-4e15-9545-20c2335ad7af" xlink:to="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_323aafb6-0f5c-4a28-980d-747b73cc895c" xlink:href="mrna-20210630.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:to="loc_mrna_ProductSalesMember_323aafb6-0f5c-4a28-980d-747b73cc895c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_85dbccdd-8497-4a95-ba35-4e7190ac2311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:to="loc_us-gaap_GrantMember_85dbccdd-8497-4a95-ba35-4e7190ac2311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_2952b54b-2731-4bc7-a425-6bba37bbc5b7" xlink:href="mrna-20210630.xsd#mrna_CollaborationArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b0ed960-fdd7-4704-bf96-14aac9ff267b" xlink:to="loc_mrna_CollaborationArrangementMember_2952b54b-2731-4bc7-a425-6bba37bbc5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_e360fec2-f54e-4ad3-a781-66988ed5a0ef" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_08194543-a4f5-4ef8-8938-6be11d5c05da" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_e360fec2-f54e-4ad3-a781-66988ed5a0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:href="mrna-20210630.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_e360fec2-f54e-4ad3-a781-66988ed5a0ef" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4bfb3c4c-1a65-4193-a3e5-b5f8344b5f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4bfb3c4c-1a65-4193-a3e5-b5f8344b5f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_61ad14dc-f604-417f-831c-968d0a8e4ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_61ad14dc-f604-417f-831c-968d0a8e4ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_ead4a315-bf5b-41e8-8885-fac061f016c4" xlink:href="mrna-20210630.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_ead4a315-bf5b-41e8-8885-fac061f016c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6eecd279-7418-4293-8a63-410304f86a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_8d884ab0-8d11-44a4-a28f-5f3cc570de0a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6eecd279-7418-4293-8a63-410304f86a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:type="simple" xlink:href="mrna-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b0728185-08bf-473b-8ae9-2d2221f13694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ff02ce4e-ba91-4333-90cd-2be789ae2987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b0728185-08bf-473b-8ae9-2d2221f13694" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ff02ce4e-ba91-4333-90cd-2be789ae2987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_80d7c637-28a1-4c4a-9132-da24863fc6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b0728185-08bf-473b-8ae9-2d2221f13694" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_80d7c637-28a1-4c4a-9132-da24863fc6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8601957c-c23b-473e-a84f-a6ec14be47eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_bf602908-26ae-4bf6-b0fa-564162644e36" xlink:href="mrna-20210630.xsd#mrna_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8601957c-c23b-473e-a84f-a6ec14be47eb" xlink:to="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_bf602908-26ae-4bf6-b0fa-564162644e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_48beec24-be12-44e6-bade-d4438eab4d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8601957c-c23b-473e-a84f-a6ec14be47eb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_48beec24-be12-44e6-bade-d4438eab4d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_445af9e2-0bbc-431d-92fe-679f08e55414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8601957c-c23b-473e-a84f-a6ec14be47eb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_445af9e2-0bbc-431d-92fe-679f08e55414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bd6437e2-05eb-4546-b1e1-05971896f643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd6437e2-05eb-4546-b1e1-05971896f643" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7ce12268-e9f6-4bf7-ba61-eeb660b0f614" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:to="loc_srt_StatementGeographicalAxis_7ce12268-e9f6-4bf7-ba61-eeb660b0f614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7ce12268-e9f6-4bf7-ba61-eeb660b0f614" xlink:to="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_35db24ac-db24-489f-90e8-55f94db59245" xlink:href="mrna-20210630.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:to="loc_mrna_CambridgeMassachusettsMember_35db24ac-db24-489f-90e8-55f94db59245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_c66fd157-6492-44d0-a50b-ff8f189926c9" xlink:href="mrna-20210630.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1be5db53-775e-4a49-a6bb-774498299272" xlink:to="loc_mrna_NorwoodMassachusettsMember_c66fd157-6492-44d0-a50b-ff8f189926c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4ddc9dd8-efcb-499c-892d-b880e4006d43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4ddc9dd8-efcb-499c-892d-b880e4006d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4ddc9dd8-efcb-499c-892d-b880e4006d43" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_f4bd4c6e-298d-4892-b5cf-91db50d1bb9c" xlink:href="mrna-20210630.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_f4bd4c6e-298d-4892-b5cf-91db50d1bb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMember_e6155aa7-794c-47f9-8013-d23a502a489c" xlink:href="mrna-20210630.xsd#mrna_MTCSouthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCSouthMember_e6155aa7-794c-47f9-8013-d23a502a489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember_06813402-eed5-437e-85c8-996fffecef3a" xlink:href="mrna-20210630.xsd#mrna_MTCNorthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCNorthMember_06813402-eed5-437e-85c8-996fffecef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCEastMember_bb81d20e-7b34-4e5f-a8ba-a2a80fb67268" xlink:href="mrna-20210630.xsd#mrna_MTCEastMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6279c060-f171-4888-a240-cfde1ee100d3" xlink:to="loc_mrna_MTCEastMember_bb81d20e-7b34-4e5f-a8ba-a2a80fb67268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9b93a467-5da3-4480-81bf-5947738e8ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9b93a467-5da3-4480-81bf-5947738e8ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_b3ed1572-bdb6-4893-a1b9-64bd799c2468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9b93a467-5da3-4480-81bf-5947738e8ec5" xlink:to="loc_us-gaap_LeaseContractualTermDomain_b3ed1572-bdb6-4893-a1b9-64bd799c2468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember_64486e35-14c5-4fb9-8e53-4b71e921d429" xlink:href="mrna-20210630.xsd#mrna_EmbeddedLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_b3ed1572-bdb6-4893-a1b9-64bd799c2468" xlink:to="loc_mrna_EmbeddedLeasesMember_64486e35-14c5-4fb9-8e53-4b71e921d429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e6958d8-4f5f-4c7b-b0f1-95bd32fcd628" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_2f8a0df0-7f8b-4e56-b6a6-7728590d34d2" xlink:href="mrna-20210630.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_2f8a0df0-7f8b-4e56-b6a6-7728590d34d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5f72e8fc-2233-4b08-bf48-223a454d6221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5f72e8fc-2233-4b08-bf48-223a454d6221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_afb07a19-23b0-4fde-8273-313dcafb6d0c" xlink:href="mrna-20210630.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_afb07a19-23b0-4fde-8273-313dcafb6d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a540c88-12ac-4f2f-aff4-54b370f1061f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5a540c88-12ac-4f2f-aff4-54b370f1061f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements_37b42350-c5d8-4356-bc10-171cb72668da" xlink:href="mrna-20210630.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_AllowanceForTenantImprovements_37b42350-c5d8-4356-bc10-171cb72668da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_431fdb8b-3e3f-40a5-bc5f-78e220a6621a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_OperatingLeaseLiability_431fdb8b-3e3f-40a5-bc5f-78e220a6621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d15f5474-7b1c-466f-863c-59705e3e695c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d15f5474-7b1c-466f-863c-59705e3e695c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef99fd56-a83d-47e9-aaa3-f8bd82dba91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef99fd56-a83d-47e9-aaa3-f8bd82dba91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesImputedInterestRate_358c0421-23f7-4afb-9eb4-4c84362da668" xlink:href="mrna-20210630.xsd#mrna_LeasesImputedInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_LeasesImputedInterestRate_358c0421-23f7-4afb-9eb4-4c84362da668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesIncrementalBorrowingRate_0930eb20-2adf-4d81-b1c6-e3256d6d50b8" xlink:href="mrna-20210630.xsd#mrna_LeasesIncrementalBorrowingRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91a453e9-da85-4740-8b4a-047953a67e78" xlink:to="loc_mrna_LeasesIncrementalBorrowingRate_0930eb20-2adf-4d81-b1c6-e3256d6d50b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fcf1354f-4879-4ce6-a457-b47262c51155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fcf1354f-4879-4ce6-a457-b47262c51155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_dfd28f8d-593b-43ff-8e9c-f967686344d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_dfd28f8d-593b-43ff-8e9c-f967686344d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_3ac6cb39-4ee6-4a55-bd86-e0d51478e19b" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_3ac6cb39-4ee6-4a55-bd86-e0d51478e19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_af7855d3-cc79-4702-bcd7-358167c4d56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_af7855d3-cc79-4702-bcd7-358167c4d56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1c0773e7-8e5d-4636-8c76-ec89c1459393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1c0773e7-8e5d-4636-8c76-ec89c1459393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_2fcf52e4-420a-486e-bb16-cdf7bf530138" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_2fcf52e4-420a-486e-bb16-cdf7bf530138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b755b799-b6c0-4cc8-b97f-b73907ba98cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b755b799-b6c0-4cc8-b97f-b73907ba98cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4139fda1-6143-43f9-9b0b-5d7790ecd5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4139fda1-6143-43f9-9b0b-5d7790ecd5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_b27a8606-fb49-4476-ac30-2a42ee7180c3" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_b27a8606-fb49-4476-ac30-2a42ee7180c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_8402192f-f4c5-4063-b843-949e52b93143" xlink:href="mrna-20210630.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiability_8402192f-f4c5-4063-b843-949e52b93143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a20594a7-6964-4a32-ba60-7b5b21cd8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a20594a7-6964-4a32-ba60-7b5b21cd8b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_72838a5d-dfc0-42a2-b3fb-6e73da56cafb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_72838a5d-dfc0-42a2-b3fb-6e73da56cafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e78e2992-4b53-40e8-a897-5ae467fab483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4c3839-cf15-4f0f-b53e-3d5be217d0d9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e78e2992-4b53-40e8-a897-5ae467fab483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fec2ff99-3687-4fe7-85c8-f0d3c6949519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fec2ff99-3687-4fe7-85c8-f0d3c6949519" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a1b8326f-7429-411e-b356-8b0e93e79cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a1b8326f-7429-411e-b356-8b0e93e79cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e5bc8f7a-bd8d-48bd-b763-2ba20b8b4c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e5bc8f7a-bd8d-48bd-b763-2ba20b8b4c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9e26e30b-790d-441d-b929-a7d40cea0f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9e26e30b-790d-441d-b929-a7d40cea0f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_efb14ea3-8199-4afe-ba18-6ab3bc93bd45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_efb14ea3-8199-4afe-ba18-6ab3bc93bd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43abe602-767d-4d8a-ada1-77e80dfa7fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43abe602-767d-4d8a-ada1-77e80dfa7fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ee57fd5e-94f9-4ee2-8d01-6d6437cbb738" xlink:href="mrna-20210630.xsd#mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ee57fd5e-94f9-4ee2-8d01-6d6437cbb738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d51552f7-b1af-4519-ba1a-9463d3035c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d51552f7-b1af-4519-ba1a-9463d3035c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74d3c24a-0771-419b-ad5c-80fcd3f73c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74d3c24a-0771-419b-ad5c-80fcd3f73c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_90cd3a93-2ce4-4b36-9161-eea70e2a19e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_895be4da-3322-406c-b707-ac5460a2a9f1" xlink:to="loc_us-gaap_OperatingLeaseLiability_90cd3a93-2ce4-4b36-9161-eea70e2a19e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fec2ff99-3687-4fe7-85c8-f0d3c6949519" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2fda9783-dd44-4bf7-933c-b769207cb23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2fda9783-dd44-4bf7-933c-b769207cb23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_58fdded1-8e85-43ee-a9d1-046121ec11aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_58fdded1-8e85-43ee-a9d1-046121ec11aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_09a3542e-e5d7-4e35-9963-bc5eaa8b7855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_09a3542e-e5d7-4e35-9963-bc5eaa8b7855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0336a067-ccb1-4b47-b2dd-5128b253c817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0336a067-ccb1-4b47-b2dd-5128b253c817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c0225094-caa7-4874-95af-82ed8b2122c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c0225094-caa7-4874-95af-82ed8b2122c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_b48c8d06-12d9-4a46-a9e0-c55d7d6066a5" xlink:href="mrna-20210630.xsd#mrna_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_b48c8d06-12d9-4a46-a9e0-c55d7d6066a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5fe671f8-1b4d-4442-aa3e-68f6a5c9b057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5fe671f8-1b4d-4442-aa3e-68f6a5c9b057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a6a1383f-1583-45d7-ba03-98ae5e30ddca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a6a1383f-1583-45d7-ba03-98ae5e30ddca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f4747bc3-ec4c-4336-a725-3eaba22b6996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_de8c7d4b-ba77-46f6-ba23-e3c673bce9be" xlink:to="loc_us-gaap_FinanceLeaseLiability_f4747bc3-ec4c-4336-a725-3eaba22b6996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mrna-20210630.xsd#LeasesMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mrna-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f69551a3-4dab-4353-ac54-8d3eff6528ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7f317136-fc38-4d8e-b171-436bd1c40baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f69551a3-4dab-4353-ac54-8d3eff6528ea" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7f317136-fc38-4d8e-b171-436bd1c40baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CommitmentsandContingenciesStrategicCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5dbaa319-bc07-4b76-afb7-1425a4d2a6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5dbaa319-bc07-4b76-afb7-1425a4d2a6ae" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1de06d3-4a9c-48b1-9d87-3a7f6329f850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1de06d3-4a9c-48b1-9d87-3a7f6329f850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bf3ca81-12c9-435a-87c8-dbadafa86f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1de06d3-4a9c-48b1-9d87-3a7f6329f850" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bf3ca81-12c9-435a-87c8-dbadafa86f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_e8341152-5814-4798-aff9-269771ef8288" xlink:href="mrna-20210630.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bf3ca81-12c9-435a-87c8-dbadafa86f76" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_e8341152-5814-4798-aff9-269771ef8288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed6292fb-08d6-4a81-bf13-00abfc2ddee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed6292fb-08d6-4a81-bf13-00abfc2ddee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_bcbe49fc-6bbc-4f89-a318-d6b3c1381701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed6292fb-08d6-4a81-bf13-00abfc2ddee9" xlink:to="loc_us-gaap_ProjectMember_bcbe49fc-6bbc-4f89-a318-d6b3c1381701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_1e785ed2-403e-40df-aebf-d01d752a060c" xlink:href="mrna-20210630.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_bcbe49fc-6bbc-4f89-a318-d6b3c1381701" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_1e785ed2-403e-40df-aebf-d01d752a060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_380f5bb5-898e-4fba-a019-59b6785ec322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df069cfb-4633-47fc-ab09-6e4dbc4ae3ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_380f5bb5-898e-4fba-a019-59b6785ec322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_e5c9dd73-327b-4ac3-8ce1-393f12a8609c" xlink:href="mrna-20210630.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_380f5bb5-898e-4fba-a019-59b6785ec322" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_e5c9dd73-327b-4ac3-8ce1-393f12a8609c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c192db35-93bc-41b2-9db3-0da30db292f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_f5cfd2dc-95f2-4e29-abc8-a9be97a39b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c192db35-93bc-41b2-9db3-0da30db292f9" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_f5cfd2dc-95f2-4e29-abc8-a9be97a39b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_09e85028-05de-4299-b46c-42b33cb894e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_f5cfd2dc-95f2-4e29-abc8-a9be97a39b6c" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_09e85028-05de-4299-b46c-42b33cb894e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_09e85028-05de-4299-b46c-42b33cb894e7" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_3f1fe1ff-33ab-4522-b6aa-b1edb99331ad" xlink:href="mrna-20210630.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_3f1fe1ff-33ab-4522-b6aa-b1edb99331ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_bcb87373-a4ae-464f-80df-a5f23ee81207" xlink:href="mrna-20210630.xsd#mrna_ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:to="loc_mrna_ClinicalServicesMember_bcb87373-a4ae-464f-80df-a5f23ee81207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_f5e9f76e-b66b-45fb-9ae2-fe948f93d795" xlink:href="mrna-20210630.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1d155f5d-aa89-46c3-be4b-b49ab73143ff" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_f5e9f76e-b66b-45fb-9ae2-fe948f93d795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_1eb8d5b1-a718-40f7-af11-39e8050f1008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_f5cfd2dc-95f2-4e29-abc8-a9be97a39b6c" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_1eb8d5b1-a718-40f7-af11-39e8050f1008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_69a7cc41-6431-48da-9347-562a4fcb000b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_1eb8d5b1-a718-40f7-af11-39e8050f1008" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_69a7cc41-6431-48da-9347-562a4fcb000b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17f44a38-b8a1-4e64-914e-167ba722527e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_f88ae4a4-333c-4397-8586-db08b172c8f6" xlink:href="mrna-20210630.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17f44a38-b8a1-4e64-914e-167ba722527e" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_f88ae4a4-333c-4397-8586-db08b172c8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8906a261-3603-45c4-9dd3-42dfa83f517b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17f44a38-b8a1-4e64-914e-167ba722527e" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8906a261-3603-45c4-9dd3-42dfa83f517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33f3a41f-6a4a-410b-9030-bb369b4477ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4867a044-e4ca-49f7-9620-5e4344fd5e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33f3a41f-6a4a-410b-9030-bb369b4477ca" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4867a044-e4ca-49f7-9620-5e4344fd5e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5deb76e-4123-4c6f-a505-c7e8a500bfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3024a246-86f0-4a26-a5e6-982e85f8e41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5deb76e-4123-4c6f-a505-c7e8a500bfe4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3024a246-86f0-4a26-a5e6-982e85f8e41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_014d77ad-f68e-4df9-a17d-77732fdca28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5deb76e-4123-4c6f-a505-c7e8a500bfe4" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_014d77ad-f68e-4df9-a17d-77732fdca28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_efb8c7a1-c1c9-4f91-a142-781fe4903e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5deb76e-4123-4c6f-a505-c7e8a500bfe4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_efb8c7a1-c1c9-4f91-a142-781fe4903e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_123e4f83-16a6-4aa0-a84a-039203f9d199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_123e4f83-16a6-4aa0-a84a-039203f9d199" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_21838655-faaa-41b9-83b3-c367d9fcf606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:to="loc_us-gaap_PlanNameAxis_21838655-faaa-41b9-83b3-c367d9fcf606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83683c15-575a-4013-bfbb-2a33a6b7bbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_21838655-faaa-41b9-83b3-c367d9fcf606" xlink:to="loc_us-gaap_PlanNameDomain_83683c15-575a-4013-bfbb-2a33a6b7bbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_7a9dbaa6-8be8-4052-a6a9-8dfb56c0eaad" xlink:href="mrna-20210630.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_83683c15-575a-4013-bfbb-2a33a6b7bbf8" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_7a9dbaa6-8be8-4052-a6a9-8dfb56c0eaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9da3f1af-440a-4cc3-a7f5-3da15b0703df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:to="loc_us-gaap_AwardTypeAxis_9da3f1af-440a-4cc3-a7f5-3da15b0703df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9da3f1af-440a-4cc3-a7f5-3da15b0703df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f76941e9-5d08-49f3-9f96-46c0b27087fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f76941e9-5d08-49f3-9f96-46c0b27087fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a83d5e2a-1880-40d2-9494-4638782acba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_EmployeeStockMember_a83d5e2a-1880-40d2-9494-4638782acba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_87a28216-b539-4e72-8c7c-74a74b4eb8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_87a28216-b539-4e72-8c7c-74a74b4eb8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a9b792b0-be57-4ecd-82b9-c71de54b4e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_902b8ab2-7c59-405b-bcb6-0ad07f425272" xlink:to="loc_us-gaap_PerformanceSharesMember_a9b792b0-be57-4ecd-82b9-c71de54b4e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ffadd773-cdba-4324-9012-b2698991b2d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:to="loc_srt_RangeAxis_ffadd773-cdba-4324-9012-b2698991b2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ffadd773-cdba-4324-9012-b2698991b2d7" xlink:to="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05186ba1-da99-4575-b7ee-bfea89dcef19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:to="loc_srt_MinimumMember_05186ba1-da99-4575-b7ee-bfea89dcef19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20fe0ba2-ad2d-4c72-aba0-a5096fe76fa1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1bb30d7c-0e62-49c9-b00e-a029f307c220" xlink:to="loc_srt_MaximumMember_20fe0ba2-ad2d-4c72-aba0-a5096fe76fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eda616-6d7e-4a97-9c00-5e0d3d21ee5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3055606-edf0-42c5-afd1-08f190d0cbce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b3055606-edf0-42c5-afd1-08f190d0cbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2757e18d-b8ae-433e-a9f8-acf8d0d1a70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2757e18d-b8ae-433e-a9f8-acf8d0d1a70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c530f3b-b3a1-45d6-b75c-2e1e53caacaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c530f3b-b3a1-45d6-b75c-2e1e53caacaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d33d62ec-86a1-4ea5-9fdf-c3cf9b6f32f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d33d62ec-86a1-4ea5-9fdf-c3cf9b6f32f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4911919e-4c6b-4e51-9d75-4b9b55d4310f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4911919e-4c6b-4e51-9d75-4b9b55d4310f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_63ae8110-207d-491e-a91a-145e856c4144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_RestrictedStockExpense_63ae8110-207d-491e-a91a-145e856c4144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_340dcf35-7634-445c-a283-bef6ab83a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_340dcf35-7634-445c-a283-bef6ab83a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3f1fb828-4aac-4304-9635-1c7a9e7f4613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3f1fb828-4aac-4304-9635-1c7a9e7f4613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_3a77dddc-2f97-48ca-9808-1a42ef3fe2f3" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_3a77dddc-2f97-48ca-9808-1a42ef3fe2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b234af5a-d767-4c43-94b9-b5982690c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b234af5a-d767-4c43-94b9-b5982690c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21842050-3c7c-4222-be64-1ba1091b2228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_21842050-3c7c-4222-be64-1ba1091b2228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5cebcc29-700a-4aa6-ada5-7fa55eeeaa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db649d6b-e341-40f1-a08a-8bba44d9f873" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5cebcc29-700a-4aa6-ada5-7fa55eeeaa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc5b172-db6a-4d2a-8614-9d463747c4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d064e3fd-d63e-45b9-b366-e2e386c62b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc5b172-db6a-4d2a-8614-9d463747c4a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d064e3fd-d63e-45b9-b366-e2e386c62b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d4987a7-9f58-4dc1-a35d-d8b9216bf64e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d064e3fd-d63e-45b9-b366-e2e386c62b6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d4987a7-9f58-4dc1-a35d-d8b9216bf64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1409b423-0baa-4794-acdf-fa0b108a052c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d064e3fd-d63e-45b9-b366-e2e386c62b6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1409b423-0baa-4794-acdf-fa0b108a052c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97d00f55-65f2-4630-8107-1b24ef52bbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d064e3fd-d63e-45b9-b366-e2e386c62b6c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97d00f55-65f2-4630-8107-1b24ef52bbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_159a6604-f230-4d3c-a30d-20531f6339da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d064e3fd-d63e-45b9-b366-e2e386c62b6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_159a6604-f230-4d3c-a30d-20531f6339da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e023b7d6-8133-43da-92b9-fc4dda26922c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d064e3fd-d63e-45b9-b366-e2e386c62b6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e023b7d6-8133-43da-92b9-fc4dda26922c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9eb8ead-fb51-4466-b44e-d841a9689866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc5b172-db6a-4d2a-8614-9d463747c4a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9eb8ead-fb51-4466-b44e-d841a9689866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da286633-c91c-4bda-abfb-83efa90ef5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9eb8ead-fb51-4466-b44e-d841a9689866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da286633-c91c-4bda-abfb-83efa90ef5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_033b136b-334a-4b97-a185-a85bd14fe7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9eb8ead-fb51-4466-b44e-d841a9689866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_033b136b-334a-4b97-a185-a85bd14fe7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c243b422-d6d4-49b1-a642-51f1bd79971c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9eb8ead-fb51-4466-b44e-d841a9689866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c243b422-d6d4-49b1-a642-51f1bd79971c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_439fdc04-dcbc-4e52-907e-13a5fc2c4578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9eb8ead-fb51-4466-b44e-d841a9689866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_439fdc04-dcbc-4e52-907e-13a5fc2c4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c30a8507-4245-4070-a8e4-13fc6fac78e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9eb8ead-fb51-4466-b44e-d841a9689866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c30a8507-4245-4070-a8e4-13fc6fac78e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_b79a1a33-9eff-428c-8202-1aceed32f80e" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc5b172-db6a-4d2a-8614-9d463747c4a1" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_b79a1a33-9eff-428c-8202-1aceed32f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_a3e4968f-523e-40c3-9b01-41b429e51314" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_b79a1a33-9eff-428c-8202-1aceed32f80e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_a3e4968f-523e-40c3-9b01-41b429e51314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ec855fc-9b8f-492b-8aff-2ad380d69e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_b79a1a33-9eff-428c-8202-1aceed32f80e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ec855fc-9b8f-492b-8aff-2ad380d69e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_94b3bf91-779e-4d64-9b2f-3103b2dbfa52" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_b79a1a33-9eff-428c-8202-1aceed32f80e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_94b3bf91-779e-4d64-9b2f-3103b2dbfa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_b7d933d2-5ee1-49d3-964c-4db936e4587a" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_b79a1a33-9eff-428c-8202-1aceed32f80e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_b7d933d2-5ee1-49d3-964c-4db936e4587a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_473bf6b1-d30d-408a-821f-50de30429269" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_b79a1a33-9eff-428c-8202-1aceed32f80e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_473bf6b1-d30d-408a-821f-50de30429269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc5b172-db6a-4d2a-8614-9d463747c4a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b69b4b46-bd46-4f1b-ac06-8137d6d06cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b69b4b46-bd46-4f1b-ac06-8137d6d06cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e6a10ad3-447c-400f-9804-80536ca4b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e6a10ad3-447c-400f-9804-80536ca4b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_dd9447b4-6677-4142-bcd6-933f1202b830" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_dd9447b4-6677-4142-bcd6-933f1202b830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b1636b78-5231-43f2-b3d7-6922ef617cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b1636b78-5231-43f2-b3d7-6922ef617cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_357d81f1-4991-41c4-aa73-c681e83e48d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_357d81f1-4991-41c4-aa73-c681e83e48d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ee8ae78c-9807-48c1-bae9-cf03915d3d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ee8ae78c-9807-48c1-bae9-cf03915d3d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7810561c-7b3f-4e4f-98da-efa3d48678f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2aa7e670-dc01-45f1-bf51-ab65e7f847bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7810561c-7b3f-4e4f-98da-efa3d48678f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d4e3151a-ed38-448b-900b-27b5482cfef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccc5b172-db6a-4d2a-8614-9d463747c4a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d4e3151a-ed38-448b-900b-27b5482cfef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_23d2cc82-1e3f-4adb-a6f4-c5ed9f73e97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d4e3151a-ed38-448b-900b-27b5482cfef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_23d2cc82-1e3f-4adb-a6f4-c5ed9f73e97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d9f551ba-1e55-4308-a5df-10f347d2bf96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d4e3151a-ed38-448b-900b-27b5482cfef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d9f551ba-1e55-4308-a5df-10f347d2bf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_c2a57145-1229-408d-bde6-b06901850124" xlink:href="mrna-20210630.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d4e3151a-ed38-448b-900b-27b5482cfef2" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_c2a57145-1229-408d-bde6-b06901850124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_666bd2d6-7414-444d-a561-3b8827bab48c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d4e3151a-ed38-448b-900b-27b5482cfef2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_666bd2d6-7414-444d-a561-3b8827bab48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_26596f27-e948-40ec-97ac-bbe66c631841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d4e3151a-ed38-448b-900b-27b5482cfef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_26596f27-e948-40ec-97ac-bbe66c631841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73229653-bf64-4ee8-9bb7-55c1929ab2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f818430-0a97-4165-8157-2f2b3a5e7375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73229653-bf64-4ee8-9bb7-55c1929ab2ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f818430-0a97-4165-8157-2f2b3a5e7375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f818430-0a97-4165-8157-2f2b3a5e7375" xlink:to="loc_us-gaap_AwardTypeAxis_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aa76d75-11c4-4d27-9fe9-e1020aafac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1a0b018c-acda-42b1-9cae-f4aa7d3ff8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aa76d75-11c4-4d27-9fe9-e1020aafac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2d802328-8b71-4f59-b99f-72f7b22174fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8aa76d75-11c4-4d27-9fe9-e1020aafac2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2d802328-8b71-4f59-b99f-72f7b22174fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f818430-0a97-4165-8157-2f2b3a5e7375" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c57befa4-384f-4907-b253-8ee5c82c3b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c57befa4-384f-4907-b253-8ee5c82c3b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12235a42-88e0-40ee-a30f-7dd175cb6797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12235a42-88e0-40ee-a30f-7dd175cb6797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ad7063e8-f573-4e44-a49e-898c1e6da702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ad7063e8-f573-4e44-a49e-898c1e6da702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_467b7624-91a3-421b-a578-eefa69b4c6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_467b7624-91a3-421b-a578-eefa69b4c6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc45ced-82f1-4378-bda2-05a794e0e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bcfa4fde-5f87-4d93-a37f-4a7250a0350f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc45ced-82f1-4378-bda2-05a794e0e5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd319eb-6997-4cd4-8830-09fb18daa53c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa1857fa-b02a-4cc9-8e6c-41f341f127cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa1857fa-b02a-4cc9-8e6c-41f341f127cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b526955-0535-42f2-a5ba-4a81fdbff2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b526955-0535-42f2-a5ba-4a81fdbff2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29773420-b3bb-4431-a31c-21dfabe14e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29773420-b3bb-4431-a31c-21dfabe14e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4f2c5107-7f68-43c5-b7e9-d65fabccc9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4f2c5107-7f68-43c5-b7e9-d65fabccc9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5b51baae-5661-4cd4-ae3b-25f8950b3b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5de6403d-3344-41cf-93f5-175418b94b8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5b51baae-5661-4cd4-ae3b-25f8950b3b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e312975a-3574-4da8-8408-c5b514d689d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e312975a-3574-4da8-8408-c5b514d689d8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:to="loc_us-gaap_AwardTypeAxis_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fa1ee2fa-0060-4874-9e1e-3fce39eac3b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_700bfbe9-d9f3-4922-b9b7-315a29c90a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_700bfbe9-d9f3-4922-b9b7-315a29c90a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_24aa2ae3-833d-4275-a631-53d95a1cdae6" xlink:href="mrna-20210630.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:to="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_24aa2ae3-833d-4275-a631-53d95a1cdae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f247023f-50b9-46a1-94d7-ca2d570fca33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6b961bf-77f8-4a78-8c8e-e6d90ddcafc4" xlink:to="loc_us-gaap_EmployeeStockMember_f247023f-50b9-46a1-94d7-ca2d570fca33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5940d485-6d2f-4011-9663-1807764a5953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5940d485-6d2f-4011-9663-1807764a5953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5940d485-6d2f-4011-9663-1807764a5953" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_35e736f5-3d19-44f2-9f90-58968ff0e76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:to="loc_us-gaap_CostOfSalesMember_35e736f5-3d19-44f2-9f90-58968ff0e76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c597d9a-2760-4485-a79a-5faeb13e405b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4c597d9a-2760-4485-a79a-5faeb13e405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_93b9e1cd-65c1-47eb-a3a7-bc7c73b461c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f968cdf1-7cda-4eb3-805a-aa9cdc0a009b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_93b9e1cd-65c1-47eb-a3a7-bc7c73b461c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5e82db86-b70d-48e6-bb31-25350e8ef644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c00c414f-3130-461d-b03d-37c503743233" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5e82db86-b70d-48e6-bb31-25350e8ef644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b938d0a1-cef3-4b59-b20d-e231f9452760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5e82db86-b70d-48e6-bb31-25350e8ef644" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b938d0a1-cef3-4b59-b20d-e231f9452760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrna-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2fe07e31-d974-4ca4-adc1-f96f046d9b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4a851dec-2dd4-4f2c-85fc-3adc2ad9f2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2fe07e31-d974-4ca4-adc1-f96f046d9b9f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4a851dec-2dd4-4f2c-85fc-3adc2ad9f2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_52b80436-e3b8-44a5-9023-ced498e3a32e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_21aa3980-485f-4934-b798-45462b2f8bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52b80436-e3b8-44a5-9023-ced498e3a32e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_21aa3980-485f-4934-b798-45462b2f8bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f7cddce3-3a59-4020-bda6-17abbe85d289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52b80436-e3b8-44a5-9023-ced498e3a32e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f7cddce3-3a59-4020-bda6-17abbe85d289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_506ac57c-0cb3-4207-8e7f-ece2bf36dfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52b80436-e3b8-44a5-9023-ced498e3a32e" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_506ac57c-0cb3-4207-8e7f-ece2bf36dfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShare" xlink:type="simple" xlink:href="mrna-20210630.xsd#EarningsLossperShare"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e4589aaa-202e-4fb5-9ab2-8d70905517f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9545993e-4c00-45d7-ae83-2d3ece13af2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e4589aaa-202e-4fb5-9ab2-8d70905517f9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9545993e-4c00-45d7-ae83-2d3ece13af2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareTables" xlink:type="simple" xlink:href="mrna-20210630.xsd#EarningsLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1288aa80-b3e4-4090-b748-e13f8ea150d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c897a509-6473-4d5f-b284-29fc4836a432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1288aa80-b3e4-4090-b748-e13f8ea150d2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c897a509-6473-4d5f-b284-29fc4836a432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a9a56b41-38ce-45c4-b4ba-a0c6ed44a6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1288aa80-b3e4-4090-b748-e13f8ea150d2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a9a56b41-38ce-45c4-b4ba-a0c6ed44a6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_14735c07-aa4f-4bda-a720-02d8e2cbb89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_049785f0-8088-4944-b41e-3f9f49af2e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14735c07-aa4f-4bda-a720-02d8e2cbb89c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_049785f0-8088-4944-b41e-3f9f49af2e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22ae277b-7cf8-4fc6-aca2-396241374a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_049785f0-8088-4944-b41e-3f9f49af2e15" xlink:to="loc_us-gaap_NetIncomeLoss_22ae277b-7cf8-4fc6-aca2-396241374a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_37d8d027-0739-461f-a3a7-7fa6b351aa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14735c07-aa4f-4bda-a720-02d8e2cbb89c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_37d8d027-0739-461f-a3a7-7fa6b351aa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a1dea9b-98ea-4925-b082-fb17c7e49efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_37d8d027-0739-461f-a3a7-7fa6b351aa00" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a1dea9b-98ea-4925-b082-fb17c7e49efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_25506628-727c-4bdf-82c6-3119891a66e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_37d8d027-0739-461f-a3a7-7fa6b351aa00" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_25506628-727c-4bdf-82c6-3119891a66e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bee7d564-6016-46e3-a6a3-a87203c636e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_37d8d027-0739-461f-a3a7-7fa6b351aa00" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bee7d564-6016-46e3-a6a3-a87203c636e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_baa93f1d-96ce-455a-96d0-fe5f8dbb3241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14735c07-aa4f-4bda-a720-02d8e2cbb89c" xlink:to="loc_us-gaap_EarningsPerShareBasic_baa93f1d-96ce-455a-96d0-fe5f8dbb3241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f13def99-73fe-45e9-995b-fbd4052c6ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14735c07-aa4f-4bda-a720-02d8e2cbb89c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f13def99-73fe-45e9-995b-fbd4052c6ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0613d16b-ab7e-4d46-a521-72286ce974c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b455060-d5cd-4b04-92d8-8ed76e9374e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0613d16b-ab7e-4d46-a521-72286ce974c0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b455060-d5cd-4b04-92d8-8ed76e9374e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_69f5e374-24f5-41b5-8511-bf15ee3a258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b455060-d5cd-4b04-92d8-8ed76e9374e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_69f5e374-24f5-41b5-8511-bf15ee3a258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_69f5e374-24f5-41b5-8511-bf15ee3a258d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4cf2216e-a85c-4265-84e4-69a8982e637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4cf2216e-a85c-4265-84e4-69a8982e637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e57ab7b1-50c1-4176-92ea-ac52668b2af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cd03c28-aa80-4976-8d4d-550cd7895a71" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e57ab7b1-50c1-4176-92ea-ac52668b2af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_001bad19-9ea3-4a93-b420-ac12391945f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b455060-d5cd-4b04-92d8-8ed76e9374e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_001bad19-9ea3-4a93-b420-ac12391945f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01a0561b-aa3e-4084-9235-06e6cb42cb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_001bad19-9ea3-4a93-b420-ac12391945f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01a0561b-aa3e-4084-9235-06e6cb42cb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mrna-20210630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_33f38f3c-e0a8-4ce1-9908-3aa281b6edd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_d3323831-6180-44fc-b100-91f0678a82e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_33f38f3c-e0a8-4ce1-9908-3aa281b6edd6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_d3323831-6180-44fc-b100-91f0678a82e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrna-20210630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5f1083fa-46ba-4e8a-b129-806abb8ae207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_06813e2c-3583-4e96-af46-233102d35b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5f1083fa-46ba-4e8a-b129-806abb8ae207" xlink:to="loc_us-gaap_SubsequentEventTable_06813e2c-3583-4e96-af46-233102d35b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2d775dc6-de76-4f1b-846b-d8b7113e1450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_06813e2c-3583-4e96-af46-233102d35b8e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2d775dc6-de76-4f1b-846b-d8b7113e1450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcd7135f-9ffe-4077-a7a3-f6ed7e94f04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2d775dc6-de76-4f1b-846b-d8b7113e1450" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcd7135f-9ffe-4077-a7a3-f6ed7e94f04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7c28eae0-4fd4-4d81-b139-20a3f6b9de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fcd7135f-9ffe-4077-a7a3-f6ed7e94f04d" xlink:to="loc_us-gaap_SubsequentEventMember_7c28eae0-4fd4-4d81-b139-20a3f6b9de7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_06813e2c-3583-4e96-af46-233102d35b8e" xlink:to="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate_8ea94344-05bb-47e1-bc64-11dd0ce7ba09" xlink:href="mrna-20210630.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:to="loc_mrna_NumberOfDosesOfVaccineCandidate_8ea94344-05bb-47e1-bc64-11dd0ce7ba09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_558aca0a-6713-4ae8-a710-5a76659a0768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ca0e4c2e-59ab-4cba-8f36-1e4e83a8ce69" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_558aca0a-6713-4ae8-a710-5a76659a0768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   "0   !!" 8   "Y.09Q    "7!(67,  $SE
M  !,Y0%USO"5    5$E$051XG.W.H0$ ( S L/W_-'A,)!/-!9FSS/P.O I)
M(2DDA:20%))"4D@*22$I)(6DD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20
;%))"LBYT 2JF;8TOG%]@     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_6.jpg
<TEXT>
begin 644 image_6.jpg
MB5!.1PT*&@H    -24A$4@   "0   !!" 8   "Y.09Q    "7!(67,  $SE
M  !,Y0%USO"5    5$E$051XG.W.H0$ ( S L/W_-'A,)!/-!9FSS/P.O I)
M(2DDA:20%))"4D@*22$I)(6DD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20
;%))"LBYT 2JF;8TOG%]@     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mrna-20210630_g1.jpg
<TEXT>
begin 644 mrna-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2764&AO=&]S:&]P(#,N,  X0DE-! 0
M     %(< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' (   (  !P"!0 >36]D97)N82!,;V=O($9)3D%,(# Y,3,Q,B!#35E+.$))
M300E       0Z9NJ@=5(@;5'E,83D9_8?#A"24T$.@     !"P   !     !
M       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU
M;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +
M<')I;G1E<DYA;65415A4    % !% %  4P!/ $X ( !7 &\ <@!K $8 ;P!R
M &, 90 @ #@ -  U       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R
M &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT
M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-! H
M      $  #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              #E   #XP
M       !                          $              ^,   #E
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #E
M %)G:'1L;VYG   #XP    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    Y0    !29VAT;&]N9P   ^,
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!$       $! #A"24T$%       !     4X
M0DE-! P     &ND    !    H    "4   '@  !%8   &LT &  !_]C_X@Q8
M24-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D
M!@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0
M  #3+4A0("
M             !%C<')T   !4    #-D97-C   !A    &QW='!T   !\
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M0S8Q.38V+3(N,0
M                    6%E:(        /-1  $    !%LQ865H@
M             %A96B        !OH@  ./4   .06%E:(        &*9  "W
MA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:
M  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M     $P)5@!0    5Q_G;65A<P         !
M H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X
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M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "4
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M:M7+^J7U=RL8X[L&FH$0VRE@KL!_>%C!N_STN*<K,0*'?])1PX,?#'-.?N2
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M3X:@8G6.E9MGIXF91?9^Y78USM/Y#3N7'XN=T/K?4\CJ77\NH8]-AJZ=@6O
M:UC?^U%E7YSKOY?_ %'H^G=ZC5]0<VG;3DXF%D-UHR<<MJ<QX^@_]%LW[?Y:
M7NDZ@QKM(^HI/(Q@1#(,W'0XI8\?'BQF7Z/^LX?TWK;+*ZJW66N#*V N>]Q
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M)')$C#D$(@0UGA]@<&$QXOGX8?/^^OU'J6#TS&=DYMK::FCN=2?W:V_2>_\
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M_1;;)GTY+]FV=GTG?NJRC&)'%?4VMSY1D]NK]&..,W^]'B>:^J5;;:^N5/\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !#Z    $!  ,    ! X8   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HS," P-SHT,#HU,0     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   /CH , !     $
M  #E          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "      !    _^$!@$U- "H    (
M  P!   #     0^@   ! 0 #     0.&   ! @ #     P   )X!!@ #
M 0 "   !$@ #     0     !%0 #     0 #   !&@ %     0   *0!&P %
M     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*'
M:0 $     0   .@   $@  @ "  (   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,S @,#<Z-# Z-3$
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   #XZ #  0    !
M    Y0         & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M5R"-+M9\=/8&ZG0B%;+DQ@Q%0$PLSS&LJ,%TB8"]T46;EY8P3 !ZAZJ^"@%
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M'^LGB)HXQS\^(P/LU0B_XY?$?=O&Y%O#'XV+O[EQ]#;. ]A1>>?+ NT;MMT
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M?7)"O0,>F8X&.DDTBR*)%$"G76, J&GM;9."@0++#/;DX]Z6:S.A)X]2$K/
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M>53ZCT9H OQ'Q^(U:G$Q4=!149"0[)O'1$-'LXJ+CVB946K".CVR;1BR;(D
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M2N/9<32^BL7DY.9+5;'>:LD<41J5I8BSB4KI_']\,;0O\DVY'^3F,/\ :O\
MV]WOU/\ [_\ &?\ @.1_XM3_ *5]FL\_\S@ZS?[K^F/]D]U?]D-']\,;0O\
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M/+D)8Y["6-+I#SZF/+YP'2ZS;?1F[WM2J?*6]C[Y('), 6NTC ?$]K13(/\
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M ?X[B9EUU!_*910QA_?$=2#:@XV_COZ6P?Z]N<ZK3XJG9_$/U89CR1NB5/\
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M(J+9HT:H$30;-FZ)")(((D(DDD0J:92E* !-55454151% 554!550. JJ.
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M$B:(?PW8>*S]>L3<[,&TBLIT(-D%N^5,W?Z ,F?B9O!5\Y%7BL33PBO*TJ&
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M?<6'WE'CA]__ !0Y'_YWEKK+A]B'XYFP/_S,?_0M<%MP=41^+MVI_P CF/\
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M?%.LD*M7,=2#+8B0^?(9.^QYTR1>2L9B[IT=<)&W#<5H/=MVIX_B_4),^?\
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9-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mrna-20210630_g2.jpg
<TEXT>
begin 644 mrna-20210630_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (:!0 # 2(  A$! Q$!_\0
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MD@(#JDDBJQ4D$9P>,@U]/_$[]D?P/I/@OQY?Z#:^/= U#PMAQ>>+;:&/3]1
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M6=W?7PSS]PR1+#]"7#^VSO0!]E?\/+OA1_SY^(?_  #3_P".4?\ #R[X4?\
M/GXA_P# -/\ XY7Q3\2/V0/%GPQ\+:KKU[K/AW5H-(NX[34K32;\S7%H7;:A
MD78-H;((!YP1QUK3U;]D#7;SXE^*=!L+K2?#ND>'K>VFOM5US5LVD!FC5D4S
M^2A)8DX'EC'0GN0#[#_X>7?"C_GS\0_^ :?_ !RC_AY=\*/^?/Q#_P" :?\
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MQ;X48N@?L649)QUH _0[_AY=\*/^?/Q#_P" :?\ QRC_ (>7?"C_ )\_$/\
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M6IZ!H^I_9);./4$FU"TB=RL+W"*H52PV\9S\W0<X /LK_AY=\*/^?/Q#_P"
M:?\ QRC_ (>7?"C_ )\_$/\ X!I_\<KX:\1?LM^(=#^&\_C.S\0^%_$EA:F$
M7MKH6IBZGM#*P5!(%7;]X@<,:;\3_P!E_7OA/H2WFK^)/"T^J*8A-X?L]4#Z
ME"9 "H,)49^\,[2>N>G- 'W/_P /+OA1_P ^?B'_ , T_P#CE'_#R[X4?\^?
MB'_P#3_XY7Q5XB_8X\;^'/"=[JTU]H-SJ6GV8U"_\.6NH!]3M+?&3))%MP
M03ACUK%_9M^$'A_XP>.+?2_$GBF+P]9-/# EO&-UW>R2,0L<(P0.G+GA<C@Y
MH ^[_P#AY=\*/^?/Q#_X!I_\<H_X>7?"C_GS\0_^ :?_ !ROS4^(/A^W\*>/
M/$6BVCR26NG:C<6D33$%RB2,H+$ #.!V%<_0!^I?_#R[X4?\^?B'_P  T_\
MCE'_  \N^%'_ #Y^(?\ P#3_ ..5^6E% 'ZE_P##R[X4?\^?B'_P#3_XY1_P
M\N^%'_/GXA_\ T_^.5^6E% 'ZE_\/+OA1_SY^(?_  #3_P".4?\ #R[X4?\
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MH!&BNK!B0QP.YQS0!]R_\/+OA1_SY^(?_ -/_CE'_#R[X4?\^?B'_P  T_\
MCE> 3?L=^"M2\4_#7[$WC'0-)\3W=W97.D^)HH;?5(FBB9UD4!=H0E0.0>H]
M:\6^(W[+_B/X=Z5I&JS:OX?U+3-2U$Z6;BPU-)$LKG_GE</@*A SDY(&#DB@
M#[H_X>7?"C_GS\0_^ :?_'*/^'EWPH_Y\_$/_@&G_P <KXB\5_LE>*O#^G^'
M;[3=:\.>+K/6]3CTB"X\/ZC]HCCNG&5C=BH [\C.,51^(G[,NO?#_5M*TB/Q
M#X9\3ZUJ%Z-.&EZ#J0GN8)R<!)(V52O.1GH".<4 ?=?_  \N^%'_ #Y^(?\
MP#3_ ..4?\/+OA1_SY^(?_ -/_CE?#WQ*_91\5_#7PK>Z]+JN@:];Z;(D6JV
M^BW_ -HGTQW.%$Z[1M^;Y>,\UH? 'X3?#7QEH<5YXW\0ZH-5U+5XM&TS0?#I
MA:\W.!_I$BN"?*!..!V[T ?:/_#R[X4?\^?B'_P#3_XY1_P\N^%'_/GXA_\
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MY\_$/_@&G_QROA'5OV9]?M_'^A^$-$UWPWXPU+5MWER>']36XBAV<OYQ(!C
M'.2,8!QFH?BU^SEX@^$NAVFN3:KH?B70Y[@V;:EX?O?M,,-P 3Y,A*J5; )Z
M8H ^]/\ AY=\*/\ GS\0_P#@&G_QRC_AY=\*/^?/Q#_X!I_\<KY$^!'P-^&7
MQ2\&W2:CXDUZ/Q8EI<WMQ-96BC3='CC4E#=.ZY;?@XV'V[9/SC(H5V4-N .
MP[^] 'ZD_P##R[X4?\^?B'_P#3_XY1_P\N^%'_/GXA_\ T_^.5^6E% 'ZE_\
M/+OA1_SY^(?_  #3_P".4?\ #R[X4?\ /GXA_P# -/\ XY7Y:44 ?J7_ ,/+
MOA1_SY^(?_ -/_CE'_#R[X4?\^?B'_P#3_XY7Y:44 ?J7_P\N^%'_/GXA_\
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M:WTKXL:-JWC/PU:M=:IH;VKV\2[.)$CN7;;(RGC '7@XK@] _9=^*/BCP/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G_\
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MN[PMJ*7<":D\<VTK(LG*@@@@Q[0NWC-<+_PP_P#&_P#Z$*Y_\#;7_P".T?\
M##_QO_Z$*Y_\#;7_ ..T >H:Y^V?X5TWXF^ _$?A_1=6U=M$%Q'J.L:Y%;1:
ME>13+LV?N $.P<@MU/'J3R_[3W[4FG_%[PK:Z#H6L^+-0LFNA=7$7B"#3X8T
M*@A0@MX@Q/S'DMVZ'J.7_P"&'_C?_P!"%<_^!MK_ /':/^&'_C?_ -"%<_\
M@;:__': .D^"O[0/PR^'_A_PYJ6L>#K\^._"_P!I%E=:.8HK?4Q*I"_;"?F.
MW) P#Q]<5\X:E>G4M1NKMHTB:XE:4QQC"KN). .PYKVO_AA_XW_]"%<_^!MK
M_P#':/\ AA_XW_\ 0A7/_@;:_P#QV@#PNBO=/^&'_C?_ -"%<_\ @;:__':/
M^&'_ (W_ /0A7/\ X&VO_P =H \+HKW3_AA_XW_]"%<_^!MK_P#':/\ AA_X
MW_\ 0A7/_@;:_P#QV@#PNBO=/^&'_C?_ -"%<_\ @;:__':/^&'_ (W_ /0A
M7/\ X&VO_P =H \+HKW3_AA_XW_]"%<_^!MK_P#':BNOV*?C58VLUS<>!IX8
M(4:221KZU 50,DG][T H Y#]H3_DOOQ+_P"QFU/_ -*I*\_KZE^,W['GQA\4
M?&#QUK.F>"KBZTW4==OKNUG%W;*)(I+AW1L&0$94@X(!YKCO^&'_ (W_ /0A
M7/\ X&VO_P =H \+KJ/AAXT;X<_$3P[XG6'[3_95]%=&'^^JL"R_4C->F?\
M##_QO_Z$*Y_\#;7_ ..T?\,/_&__ *$*Y_\  VU_^.T =1XWM?V>9H_&?B^#
MQ3K'B#5=:BDGTSPRMC+;2:?=2MOW23GY'522,#L3]XXKO-!^.WPOU#4OA_\
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M"3A03P,\4 ?JS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_AL'Q+_ - 72ORE_P#BZ/\ AL'Q+_T!=*_*7_XNO!:*^B_U>RO_ )\+\?\
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ML#F-7#T5:*M;YI/]3^F.%<PKYKDU#%XEWG).[[VDXW^=CHJ***\(^K"BBB@
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M=V=N,XV\_2DLDR:2NJ4>^_\ P1RXHXEB[2KS6MMEOVVW/=O^&U_%/_0"T?\
M*7_XNC_AM?Q3_P! +1_RE_\ BZ\(OO#>K:9IUM?WFF7=K8W/^IN9H&6.3O\
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M8+"Q9<'E6 R>I! /3OW/QV^/%O\ !^VL[>"R&I:Q>*7CA=BL<<8."[$<G)R
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M=F[J[U>BNE?\;ZV6CU/HC^TO$?\ SVTO_P !Y/\ XY1_:7B/_GMI?_@/)_\
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MWT,.ZT>:Z5W9;:O^FNYY.*Q<<+-PY92LKNS>BU_R>[6VESZ%_M+Q'_SVTO\
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M?QID_?'J,A2<5\QBL'5PDK5%IT?1GW6!S+#YA"]%ZK==5_7<](U;_CW7_?\
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MR3N&_P"W_P#TN1T5%%%?+'WH4444 %%%% !1110 4444 %?%O[:?_)4M+_[
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M]5\)_P#DJ7@[_L,V?_H]*ZK]J+_DNGB;_MU_])8JY7X3@GXI>#L#/_$YL_\
MT>E=7^U&K+\=/$A((#"V(]Q]FB']#7ER_P"1Q#_KU+_TJ)[T/^2;J?\ 7^'_
M *;F>54445[Y\B%%%% 'NNH>,-(D^)G@'8=.$5K#IQGU9;ER4VH R/\ /Y8
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MBI2C2Q$%RV3;LEKJN6W1K1WZ6L/\(^ -!\#VD4.D:9;6TJP1V[W20HLTRH
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MX%_Z!*OWO_Y8=_\ \,/WW_0VV_\ X M_\71_PP_??]#;;_\ @"W_ ,77 ?\
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M]R_^0#Z]P+_T"5?O?_RP[_\ X8?OO^AMM_\ P!;_ .+H_P"&'[[_ *&VW_\
M %O_ (NN _X:N^)'_07M_P#P"A_^)H_X:N^)'_07M_\ P"A_^)H^K<3_ //^
M'W+_ .0#Z]P+_P! E7[W_P#+#O\ _AA^^_Z&VW_\ 6_^+H_X8?OO^AMM_P#P
M!;_XNN _X:N^)'_07M__  "A_P#B:/\ AJ[XD?\ 07M__ *'_P")H^K<3_\
M/^'W+_Y /KW O_0)5^]__+#O_P#AA^^_Z&VW_P# %O\ XNC_ (8?OO\ H;;?
M_P  6_\ BZX#_AJ[XD?]!>W_ / *'_XFC_AJ[XD?]!>W_P# *'_XFCZMQ/\
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MF^ ?%,U[.)KZYTZ=I1&[F*/$381 QQ@9(W +NX)&:[:L'Q]_R(OB/_L&W/\
MZ*:DY:62L-4];MW,KXJ?"S2OBSX<&EZD\EO)$_FV]U" 7A?&.AZ@@\CO[$ U
MX#)^P_=ASL\7PLN>"U@0?R\ROK&BO9P6=X_+Z?LL/4M'M9/\TSYK,^%\ISBM
M]8QE'FGM=.2^^S5SY,_X8?OO^AMM_P#P!;_XNC_AA^^_Z&VW_P# %O\ XNOK
M.BO0_P!:<V_Y^_\ DL?\CR/]0N'O^?#_ / Y_P#R1\F?\,/WW_0VV_\ X M_
M\71_PP_??]#;;_\ @"W_ ,77UG11_K3FW_/W_P EC_D'^H7#W_/A_P#@<_\
MY(^3/^&'[[_H;;?_ , 6_P#BZ/\ AA^^_P"AMM__  !;_P"+KZSHH_UIS;_G
M[_Y+'_(/]0N'O^?#_P# Y_\ R1\F?\,/WW_0VV__ ( M_P#%T?\ ##]]_P!#
M;;_^ +?_ !=?6=%'^M.;?\_?_)8_Y!_J%P]_SX?_ ('/_P"2/DS_ (8?OO\
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M0><LT7X/Z/H7B.PUJ"YO7NK*;4)XTD=2A:\D$DN0%Z J-O/ ZYKNJ* /,D^
MVE6-GIXTG6=7T74["YO+B#5;22(SA;F5I9H6#QLCQEB" RG&U2#D9J]>?">>
M73=/M[3QMXHL+FU25)KQ;N.9[L2$,YD26-X\Y'R[57:"0N!Q7?T4 9/A7PQ8
M>"_#NGZ)I<1AL+&(0Q*S%FP.Y/<DY)/J:UJ** "BBB@ HHHH **** "OC/\
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MU)_$R>;/?-<2"2W#RM&BQ;2%RF 3N4Y]JI>#;3X@)H^G0:%-;31M$UU;1SB
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MSX9?\B>K_P!?7_Z3 ****^!/UP**** "BBB@ HHHH **** "OE?]N3_F2O\
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M;E'XN^%K'PKXDM(K!(X8KNPM[QK>&;SHXG=<LJ/D[EST.3P>IKB*T->U^_\
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M ,,$_!W_ * VI?\ @XNO_BZ^AZ*KF?<CDCV/GC_A@GX._P#0&U+_ ,'%U_\
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M_?H?GA17U%<?L/W'G/Y'BZ,PY^7S+ AL>^)*B_X8?OO^AMM__ %O_BZ_:_\
M6;*?^?WX2_R/Y@? _$*=OJW_ )-#_P"2/F*BOIW_ (8?OO\ H;;?_P  6_\
MBZ/^&'[[_H;;?_P!;_XNG_K-E/\ S^_"7^0O]1^(?^@5_P#@4/\ Y(^8J*^G
M?^&'[[_H;;?_ , 6_P#BZ/\ AA^^_P"AMM__  !;_P"+H_UFRG_G]^$O\@_U
M'XA_Z!7_ .!0_P#DCYBHKZ=_X8?OO^AMM_\ P!;_ .+H_P"&'[[_ *&VW_\
M %O_ (NC_6;*?^?WX2_R#_4?B'_H%?\ X%#_ .2/F*BOIW_AA^^_Z&VW_P#
M%O\ XNC_ (8?OO\ H;;?_P  6_\ BZ/]9LI_Y_?A+_(/]1^(?^@5_P#@4/\
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M]JFU'XT:EK$E[]HTW3(/M</V4SPP,98(CG>J,6R=V2<,3STQ7K/_  P_??\
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M??\ 0VV__@"W_P 71_PP_??]#;;_ /@"W_Q='^LV4_\ /[\)?Y!_J/Q#_P!
MK_\  H?_ "1\Q45]._\ ##]]_P!#;;_^ +?_ !='_##]]_T-MO\ ^ +?_%T?
MZS93_P _OPE_D'^H_$/_ $"O_P "A_\ )'C/P;4GQTI SC3=2)_\ 9Z_1FO
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MWBZO&<*M)R4M[RA_\E\O0^8J*^G?^&'[[_H;;?\ \ 6_^+H_X8?OO^AMM_\
MP!;_ .+KT/\ 6;*?^?WX2_R/(_U'XA_Z!7_X%#_Y(^8E4LP &2> !7Z(^+HA
M-K>JJ8O- 316V^7YF,7\ISCRI.F,YVC&,[XL>8GF'@']CFP\.^(+74];UO\
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M_O\ XT?V4G_/>Z_[_O\ XU=HH I?V4G_ #WNO^_[_P"-']E)_P ][K_O^_\
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MU,FBBB@] ]'^!'_(W7G_ %XO_P"C(ZQ_BW_R4+5?^V7_ **2MCX$?\C=>?\
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M\R.-0R>4YR020<'.5S72:[X!\+>*[2SL-:T'2]8@L5 MX;ZUCF$(P!\H8''
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MQ.QZ_,<X'L/0=<5],?M>> 9/B%\ ?$]M:H3JFFQ#5[%E&66:W/F?+[E0Z_\
M J^5/#/Q7EFTO3+RU\,:QJL5U:QS^=8PJ\>YERR@[NJG(/N*F4E%79]QPSAX
M8F52,(IU%JFVMNMKZ?KJ>\>'[>&:9H5=&FC"EXPPW*#G!([9P?RKSO\ :X^*
MW@#X>?"_5O"GBKQP/!FL>)]-N+73YX+::YFCW*5\TI"I8)DX)XSR!R*XGQE\
M0KS363QAIGA'Q'X=UO3T"O?7%L@M;F'/^IN!OY4]C]X'&.U?*_[?6I6WQ#^(
MEQK^I:1+97O_  K2ROK>UNL[K60ZN$W+ZY5WQD?=?ID\90JJ<G$]7/\  8C
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M2/DNBOI__A _#O\ T!;+_ORM'_"!^'?^@+9?]^5H/;_UEH?\^W^!\P45]/\
M_"!^'?\ H"V7_?E:/^$#\._] 6R_[\K0'^LM#_GV_P #Y@HKZ?\ ^$#\._\
M0%LO^_*T?\('X=_Z ME_WY6@/]9:'_/M_@?,%%?3_P#P@?AW_H"V7_?E:/\
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M_%4?\-">%_\ GGJ'_?A?_BJ"_P"R\;_SZ?W'IM%>9?\ #0GA?_GGJ'_?A?\
MXJC_ (:$\+_\\]0_[\+_ /%4!_9>-_Y]/[CTVBO,O^&A/"__ #SU#_OPO_Q5
M'_#0GA?_ )YZA_WX7_XJ@/[+QO\ SZ?W'IM%>9?\-">%_P#GGJ'_ 'X7_P"*
MH_X:$\+_ ///4/\ OPO_ ,50']EXW_GT_N/3:\Y^/.CW&K> RUO&TAL[E+EU
M49.P*RD_ANS^%0K^T)X69@"E^HSU,"\?^/5W6@^(-/\ %&FI?:;<+<VSG;N
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MV9_^9D_[=O\ VK0>%GG_ "+ZGR_]*1[A1110?E(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 8/C[_D1?$?\ V#;G_P!%-6]6#X^_
MY$7Q'_V#;G_T4U;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_A$];_Z VH?^ K_ .%!^U4\31J14XS5GYF516K_ ,(GK?\ T!M0_P# 5_\
M"C_A$];_ .@-J'_@*_\ A07[:G_,OO*^GZS>:7#=Q6LOE1W4?E3#:#N7(..1
MQR.U7=8\8:EKRO\ ;FMY9'(+3+:Q)*<=/G"AOUJ+_A$];_Z VH?^ K_X4?\
M")ZW_P! ;4/_  %?_"@R?U=RYW:_?0FL_&6JV.CG2DEA>P+F0PS6\<@W$8W9
M92<XK$K5_P"$3UO_ * VH?\ @*_^%'_")ZW_ - ;4/\ P%?_  H*C*A!MQ:5
M]]C*HK5_X1/6_P#H#:A_X"O_ (4?\(GK?_0&U#_P%?\ PH+]M3_F7WF57N'[
M,_\ S,G_ &[?^U:\E7PCKK,%71=0))P +63G]*]\^!?@G4/">D7]SJ41MKB^
M9"+=OO*B!L%O0G<>/:@\'/*]+ZC.',KNUOO3/3J***#\P"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#!\??\B+XC_P"P;<_^BFK>
MK!\??\B+XC_[!MS_ .BFK>H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K!L_^1ZU?_L&V7_HVZK>K!L_^1ZU?_L&V7_HV
MZH WJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K!\??\B+XC_[!MS_Z*:MZL'Q]_P B+XC_ .P;<_\ HIJ -ZBBB@ HHHH
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M?_%4?VD__/C=?DG_ ,55VB@"E_:3_P#/C=?DG_Q5']I/_P ^-U^2?_%5=HH
MI?VD_P#SXW7Y)_\ %4?VD_\ SXW7Y)_\55VB@"E_:3_\^-U^2?\ Q5']I/\
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M?&Z_)/\ XJC^TG_Y\;K\D_\ BJNT4 4O[2?_ )\;K\D_^*H_M)_^?&Z_)/\
MXJKM% %+^TG_ .?&Z_)/_BJ/[2?_ )\;K\D_^*J[10!2_M)_^?&Z_)/_ (JC
M^TG_ .?&Z_)/_BJNT4 4O[2?_GQNOR3_ .*K#\=7[OX(\0J;*X4'3K@;F"X'
M[IN3\U=36#X^_P"1%\1_]@VY_P#134 :/]I/_P ^-U^2?_%4?VD__/C=?DG_
M ,55VB@"E_:3_P#/C=?DG_Q5']I/_P ^-U^2?_%5=HH I?VD_P#SXW7Y)_\
M%4?VD_\ SXW7Y)_\55VB@"E_:3_\^-U^2?\ Q5']I/\ \^-U^2?_ !57:* *
M7]I/_P ^-U^2?_%4?VD__/C=?DG_ ,55VB@"E_:3_P#/C=?DG_Q5']I/_P ^
M-U^2?_%5=HH I?VD_P#SXW7Y)_\ %4?VD_\ SXW7Y)_\55VB@"E_:3_\^-U^
M2?\ Q5']I/\ \^-U^2?_ !57:* *7]I/_P ^-U^2?_%4JZ@[,!]BN5R<9(7
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/C[_D1?$?\
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M?]?\?_I';4E+X3_Y"'B3_K_C_P#2.VH Z*BBB@ HHHH **** "BBB@ HHHH
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M110 4444 %%%% !1110!@^/O^1%\1_\ 8-N?_135O5@^/O\ D1?$?_8-N?\
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M<_\ Q=>\\TC+>'X_\ \%99*.T_P_X)\KS>+/E^_^M8&J>*-RGY_UK['_ .&
M?@Q_T =0_P#!M<__ !=)_P ._P#X+_\ 0 O_ /P;7/\ \71',X+_ )=_C_P!
MRRV3^W^'_!/F?]D3PP?B1^TIIUY,GFZ=X5LY-3<MRIN'_=PJ?<;BX_W*_22O
M//A#\ _!7P,M]3B\'Z4^GG4G1[J26XDG>38"$&78X W-P/[QKT.O(KUG7J.H
M^IZ]"DJ--4UT*6K?\>Z_[_\ 0UDUK:M_Q[K_ +_]#637.;A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+X3_Y"'B3_ *_X
M_P#TCMJ2E\)_\A#Q)_U_Q_\ I';4 =%1110 4444 %%%% !1110 4444 %%%
M% %1M(L78LUE;LQ.23$N3^E)_8VG_P#/C;?]^5_PJY13NQ613_L;3_\ GQMO
M^_*_X4?V-I__ #XVW_?E?\*N4478613_ +&T_P#Y\;;_ +\K_A1_8VG_ //C
M;?\ ?E?\*N4478613_L;3_\ GQMO^_*_X4?V-I__ #XVW_?E?\*N4478613_
M +&T_P#Y\;;_ +\K_A1_8VG_ //C;?\ ?E?\*N447861#;VD%HI$$,<(/)$:
M!<_E4U%%(84444 %%%% !1110 4444 %%%% &#X^_P"1%\1_]@VY_P#135O5
M@^/O^1%\1_\ 8-N?_135O4 %%%% !1110 4V2-)HV215=&&"K#(-.HH I_V-
MI_\ SXVW_?E?\*/[&T__ )\;;_ORO^%7**=V*R*?]C:?_P ^-M_WY7_"C^QM
M/_Y\;;_ORO\ A5RBB["R*?\ 8VG_ //C;?\ ?E?\*/[&T_\ Y\;;_ORO^%7*
M*+L+(I_V-I__ #XVW_?E?\*/[&T__GQMO^_*_P"%7**+L+(I_P!C:?\ \^-M
M_P!^5_PH_L;3_P#GQMO^_*_X5<HHNPLAD<:0QJD:*B+P%48 _"GT44AA1110
M 4444 %8-G_R/6K_ /8-LO\ T;=5O5@V?_(]:O\ ]@VR_P#1MU0!O4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#X^_P"1
M%\1_]@VY_P#135O5@^/O^1%\1_\ 8-N?_134 ;U%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !145Q;BY0*7D0 YS&Y4_F*K_V
M4G_/>Z_[_O\ XT 7:*I?V4G_ #WNO^_[_P"-']E)_P ][K_O^_\ C0!=HJE_
M92?\][K_ +_O_C1_92?\][K_ +_O_C0 :M_Q[K_O_P!#635K5-+1;=?W]R?F
M[SMZ'WK*_LU/^>UQ_P!_F_QH MT54_LU/^>UQ_W^;_&C^S4_Y[7'_?YO\: +
M=%5/[-3_ )[7'_?YO\:/[-3_ )[7'_?YO\: +=%5/[-3_GM<?]_F_P :/[-3
M_GM<?]_F_P : +=%5/[-3_GM<?\ ?YO\:/[-3_GM<?\ ?YO\: +=%5/[-3_G
MM<?]_F_QH_LU/^>UQ_W^;_&@"W153^S4_P">UQ_W^;_&C^S4_P">UQ_W^;_&
M@"W153^S4_Y[7'_?YO\ &C^S4_Y[7'_?YO\ &@"W153^S4_Y[7'_ '^;_&C^
MS4_Y[7'_ '^;_&@"W153^S4_Y[7'_?YO\:/[-3_GM<?]_F_QH MT54_LU/\
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M]_W_ ,: +M%4O[*3_GO=?]_W_P :/[*3_GO=?]_W_P : +M%4O[*3_GO=?\
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M_O\ XT?V4G_/>Z_[_O\ XT 7:*I?V4G_ #WNO^_[_P"-']E)_P ][K_O^_\
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M* "BBB@ K!L_^1ZU?_L&V7_HVZK>K!L_^1ZU?_L&V7_HVZH WJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\??\B+XC_[
M!MS_ .BFK>K!\??\B+XC_P"P;<_^BFH WJ*** "BBB@ HHHH **** "BBB@
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M6*_DV1><^W P#N;T7FB-3$SORR;MYL%*I+9L/^$]\1_]!N]_[_&C_A/?$?\
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M&!,9LFCN<GT.'&*SK1J02=.HW?S\E_F3-2BDXR;_ *1/_P )[XC_ .@W>_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_VP(=
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M]*U6&U/^C0WUK'*L1P!\@8''&.E?/7CYM!>^^(C>,8X8?B$WEGPU'O9[I?\
M1T\@:>Q 8XN/,R4 )/W@!6-XL\*P:AH'QNU_6[%;CQ5I,%C-;7C L]G<)8P.
M7@_N-O&25P3@ YQ0!]46/AG0]*NXI;/2["TN4,K1M# B.OF$&0C R-Q +>I
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M&K:I&VLW[,,,TUP?,^;W"%%/^[7FY324JLZW;3[SFPD;S<^QZQJW_'NO^_\
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MQ1 OB?Q7XAGT]X8IXO%&FQV;6KD,=JA57)(P2#T^7UKW:@ I&4-U /;D4M%
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M<5LQ_&Z=1SX!\=_^$_+_ (U\)3H8VF_X;/"C"M'[+/=_[42*%40*B* %5>
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M "BBB@ HHHH **** "E\)_\ (0\2?]?\?_I';4E+X3_Y"'B3_K_C_P#2.VH
MZ*BBB@ HHHH **** "BBB@ HHHH *P/$'@71/%$RS:A9+).HP)49D8CT)!Y_
M&M^BLZE.%6/+45UYDRBI*TE<XG_A3?A;_GRD_P# A_\ &C_A3?A;_GRD_P#
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M444 %%%% !1110 4444 %%%% !1110 5@V?_ "/6K_\ 8-LO_1MU6]6#9_\
M(]:O_P!@VR_]&W5 &]1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV+7UE_[\O_A0!=HJE_;%KZR_]^7_ ,*/[8M?67_OR_\ A0!=HJE_;%KZR_\
M?E_\*/[8M?67_OR_^% %VBJ7]L6OK+_WY?\ PH_MBU]9?^_+_P"% %VBJ7]L
M6OK+_P!^7_PH_MBU]9?^_+_X4 7:*I?VQ:^LO_?E_P#"C^V+7UE_[\O_ (4
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MW:?<77A+64OGMFQ<6DJ&*XAYP&:-L-M/9NA]<@@>@4 %%%% %+5O^/=?]_\
MH:R:UM6_X]U_W_Z&LF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "E\)_\A#Q)_P!?\?\ Z1VU)2^$_P#D(>)/^O\ C_\
M2.VH Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUBZC3-UI1F1Y8QZE0=RD9'/!&1TXJZU.EBO>3M(TQ%&AC/>BTI=^_J?5X(8
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M >]?2M>+_LUV.I:+I>K:;<:7X"TFPC=)88/ ]T\P+MG>TVX#DX7![X/I7M%
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MZHUNMQY MB\2[AN5"X.0Q&/X<<]:2+Q39S>&XM*O[*YG>*>2=9X+H1Y9P/O
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M_1MU0!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQCTO3[6SB9WBMXEB5I&W,0H !)[GB@"S1110 4444 %?#UUI0^&'[27Q!\+
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M_P >Z_[_ /0UDUK:M_Q[K_O_ -#637EGB!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %+X3_P"0AXD_Z_X__2.VI*7PG_R$
M/$G_ %_Q_P#I';4 =%1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/C[_D1?$?\
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M110 4444 %%%% !1110 5@^/O^1%\1_]@VY_]%-6]6#X^_Y$7Q'_ -@VY_\
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M 4444 %%%% !1110 4444 %%%% !1110 4OA/_D(>)/^O^/_ -([:DI?"?\
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MC[=N[V2/2P>7U\=?V2V[GI'V>Z_Y_/\ R$*/L]U_S^?^0A7F'_"R-:_OP_\
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M=-V+GV6\_P"?[_R"M'V6\_Y_O_(*U=HKZ8\,I?9;S_G^_P#(*T?9;S_G^_\
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M05J[10!2^RWG_/\ ?^05H^RWG_/]_P"05J[10!2^RWG_ #_?^05H^RWG_/\
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M/^VG_HQJP_'G_(&UK_L.0?\ IOAK<\ ?\BC8?]M/_1C5A^//^0-K7_8<@_\
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MHH **** "L&S_P"1ZU?_ +!ME_Z-NJWJP;/_ )'K5_\ L&V7_HVZH WJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\??\
MB+XC_P"P;<_^BFK>K!\??\B+XC_[!MS_ .BFH WJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4\:>$?#/C2
M\TVRUGC4XO,GL9+:[>UO$  $ABDC99 N&4-@X.1FNKKPW]H?Q!J>BZ@PT_4K
MJPQX3URX'V>4IB6-(/+DX_B7)P>V30!O^.OA;86OPPUCPSH]M96NEZMO&L:A
MJM[(TJ0LO[RX:1P[2R*H&-[#@#Y@!BMO4/A;X4\6Z7H;>7<)!868M[&ZTN_G
MLW%NRK\F^%U+(0JG:21P*\.\5:5/I=K<Z.^N:YJ%GKW@"^U*_6]U.:0O<Q>2
M5E3YOW6?-<%8]JD8&,5T?@G0X9O$7ARRFUK6H]"TGPA9:DEI!JDX5IO,<F1R
M'RX !&QB5(P"#@4 >LK\*O"T=]8W,>DQQ&ST]M*CACD=8&M2,&*2('9(O)^^
M#@G-95C\!?!6GV5]:+IMQ<V]W9-IS)>:A<7'E6S?>BAWR'RE/'";?NCT%>#Z
M;XRUC3_&W@'6=)FU:"Q\0M>-%'K?B1KNZU6/['),KM9+F&%?,";3&P(R 5&<
M5U>BZY>^'/@1J/C'2/%%_K/C'4/#(U22QO;TW$:SXR\Z0-DQ!6<@J@"C:!MR
M* /8]>\#^%?L.LW>JV\4-I=:2-,OYIIVC3[$@<[6;< H =_FX//7BLS_ (5K
MX&\16^I65O#',_VF"XN'LKZ1)[>=($2)ED1P\3>4%'RD94\YR<^(:G;>(M-\
M$^)&FU32_P"R=2\*7UQ-:GQ7<:O/>$1 K<1)-$OEJ-Q#;#M^<<<"KEIK%UH_
MCJ$V][+8V]QXRTRWNC'(462-M(7"/CJI;;P>,XH ^B-*LM%\#:7I>C6SPZ?;
M%OLUI#-,2\KX+$!F)9W.&8DDD\D]ZVJ^99O$SZCX]GFN=2DO;/3_ (B-%"3*
M95MXUTAF9$'. &+' [DUD^&?%.HP_$GX;:E976K6.D>)I[K_ )#?B1KJZU*$
MVKRB1K)<PP*'"[3&P(X!49Q0!]845Y;^SSI,G_"O].UV]U34]5U75(0]Q-?W
MTLR<,P4)&S%$P,#*@$XR<FO4J "BBB@ HHHH \X^/WQF@^!?P^D\1RZ7<:S/
M)<QV5K9P,$#SR9V>8YX1,CEL'J!CFOFO3_ 6O?%3Q+;^+/BM?1ZUJ,+;[#P_
M;Y_LS3,]E0G]X_ RS9_' (^EOVA_AW_PM3X*^+?#21^9=W5BTEH,<_:(\20X
M]/G11]":^4OAW^T5HT_@_0KG4+;5I[V6T0W#VMA)*GFCY7PP&#\RM7RN?U,7
M"$(T':,KIVW\M>VY]5P_@ECJTX1ASS2NEY=7;[CZ"LC;6T4KRS111VZ>9*S,
M (TP3N;T& >3Z&O';OX[>)/&UXB>![;3-%T.9V2SUG78)[FYU/;PSVEC"ID:
M,-@>8>.>QXK@_BWX]\*^(+>ZUS3+'6HM0:V^RZE975A/#::I9_Q0S,N"A SM
MD!!'3IT]+M]+.I>"=%\:Z'9R3:/K BMFTN349]*:!I9X;6R3-N,R00@D>7O1
M3N>0#+<<.6X:FDE):GO9YEN,P-"GBI)J$M'=6:EV]+:IK?R:L)9^+/BSHMO=
MZA;MHGQ,L;%P-0TJUL)])UB '/*0R]>C$!AEMN%[X](\(>,M&^)?A:VU[0YF
MELYLHT<B[)8)%X>*1?X74\$?B,@@U8M_!,_P7^S:G::RVL6NI7]I::K#>6L*
M.S32);QR0RHHD^2213MF>7Y"P!!Q7!Z+IT'@?]ISQ7HFG#RM,\2:)'XBEMU^
MY'=I/Y$KJ.V\,K'U(KLQV%IN#LM4?,82O/F5WH,^*7PIT?Q]'!+<B:PUBS;?
M8ZQ8.8KNT<'(9''.,\X/'X\UJ? OX]>+]/\ B%IGPM^(4":UJ5[#-+I7B:P"
MJ+F.)"["YB_@8!<;AP20,'ECTNK8^:N(_9CTC_A-?C_\0O&LB[[+0((O#.GN
M1\OF$^;<D>C*VU<^C5Y615L1]:=",OW:3;7;T[:GH9M3H_5U6:]^]O\ ASZ5
M\:J9/#.H*HRS0R #_@#5\ZU],:L UJH(R-W]#7FFI_#O2&N6=;QK+=SY19<#
MZ9[5U\1957QSIU:%M+IINQSY+F%+"*=.K?77N>945Z%_PKO2O^@Q^J?XT?\
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M?9_=_P $\EHKUK_A6^B_\\YO^_IJ2#X>:)#(',#RXYVR2$BFN%<>WJX_>_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'Q]_R(OB/_L&W/\
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MRPZQX<TRW6[B\.PW#12:O<*<^7,^TX10,J@SN;&<=K5U\<+#QSX+2'P_H/\
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M7W!'&D,:QQJJ(H"JJC  '0 5Z_#=+]Q/$O[;T]%_P;GGYW4_>QH+[*_%_P#
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M^P;9?^C;J@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L'Q]_R(OB/_L&W/\ Z*:MZL'Q]_R(OB/_ +!MS_Z*:@#>HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *:RJV-R@XY&13J* &[5X^4<=..E(L2*Y<(H8]6 Y-/HH :T:,NUD5E_
MND<5@>*/ ]AXLNM!GNVFC;1K]=0@6$J%>01O&%<$'*XD/ QT'-=#10 WRT\O
M9L79TVXXI/*3R]FQ=G]W''Y4^B@!GE)MV[%V^F.*&B1UPR*PSG!'>GT4 ,:)
M)&#,BL5Z$C.*?110 4444 %%%% !7EO[3WP[D^*'P,\5Z):QM)J:VOVRP$8^
M?[3"1+&%]V*;?^!&O4J* /S]T']H&W72;(ZEX?\ $L6H>2GVA(]&F*K)M&X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4#  0X'Z4OVJ+U/_ 'R?\*ZFBNTY3EOM47J?^^3_ (4?:HO4_P#?)_PKJ:*
M.6^U1>I_[Y/^%'VJ+U/_ 'R?\*ZFB@#EOM47J?\ OD_X4?:HO4_]\G_"NIHH
M Y;[5%ZG_OD_X4?:HO4_]\G_  KJ:* .6^U1>I_[Y/\ A1]JB]3_ -\G_"NI
MHH Y;[5%ZG_OD_X5'X7U2VBU#Q'NDQF_C(^4_P#/G;#T]0:ZVDP.>.M %/\
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MT4 4O[8L_P#GM_XZW^%']L6?_/;_ ,=;_"KM% %+^V+/_GM_XZW^%']L6?\
MSV_\=;_"KM% %+^V+/\ Y[?^.M_A1_;%G_SV_P#'6_PJ[10!RWCK5K63P1XA
M19<LVG7  VG_ )Y-[5N?VQ9_\]O_ !UO\*N$!@01D4M %+^V+/\ Y[?^.M_A
M1_;%G_SV_P#'6_PJ[10!2_MBS_Y[?^.M_A1_;%G_ ,]O_'6_PJ[10!2_MBS_
M .>W_CK?X4?VQ9_\]O\ QUO\*NT4 4O[8L_^>W_CK?X4?VQ9_P#/;_QUO\*N
MT4 4O[8L_P#GM_XZW^%']L6?_/;_ ,=;_"KM% %+^V+/_GM_XZW^%']L6?\
MSV_\=;_"KM% %+^V+/\ Y[?^.M_A1_;%G_SV_P#'6_PJ[10!2_MBS_Y[?^.M
M_A1_;%G_ ,]O_'6_PJ[10!2_MBS_ .>W_CK?X4?VQ9_\]O\ QUO\*NT4 4O[
M8L_^>W_CK?X4?VQ9_P#/;_QUO\*NT4 4O[8L_P#GM_XZW^%']L6?_/;_ ,=;
M_"KM% %+^V+/_GM_XZW^%8MKJ$"^,M4G+,(7L+1%DV-@LLER6 ..H#+^8KIZ
M* *7]L6?_/;_ ,=;_"C^V+/_ )[?^.M_A5VB@"E_;%G_ ,]O_'6_PH_MBS_Y
M[?\ CK?X5=HH I?VQ9_\]O\ QUO\*/[8L_\ GM_XZW^%7:* *7]L6?\ SV_\
M=;_"C^V+/_GM_P".M_A5VB@"E_;%G_SV_P#'6_PH_MBS_P">W_CK?X5=HH I
M?VQ9_P#/;_QUO\*/[8L_^>W_ (ZW^%7:* *7]L6?_/;_ ,=;_"C^V+/_ )[?
M^.M_A5VB@"E_;%G_ ,]O_'6_PH_MBS_Y[?\ CK?X5=HH I?VQ9_\]O\ QUO\
M*/[8L_\ GM_XZW^%7:* *7]L6?\ SV_\=;_"C^V+/_GM_P".M_A5VB@"E_;%
MG_SV_P#'6_PH_MBS_P">W_CK?X5=HH I?VQ9_P#/;_QUO\*P_'6K6LG@CQ"B
MRY9M.N !M/\ SR;VKJ:0@,"",B@"G_;%G_SV_P#'6_PH_MBS_P">W_CK?X5=
MHH I?VQ9_P#/;_QUO\*/[8L_^>W_ (ZW^%7:* *7]L6?_/;_ ,=;_"C^V+/_
M )[?^.M_A5VB@"E_;%G_ ,]O_'6_PH_MBS_Y[?\ CK?X5=HH I?VQ9_\]O\
MQUO\*/[8L_\ GM_XZW^%7:* *7]L6?\ SV_\=;_"C^V+/_GM_P".M_A5VB@"
ME_;%G_SV_P#'6_PH_MBS_P">W_CK?X5=HH I?VQ9_P#/;_QUO\*/[8L_^>W_
M (ZW^%7:* *7]L6?_/;_ ,=;_"G1ZM:R.J++EF. -I_PJW10 4444 %%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mrna-20210630_g3.jpg
<TEXT>
begin 644 mrna-20210630_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ) !0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (_.C_OK^='G1_WU_.LNBKY2.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNA?O"CE#F"BBBJ)"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "A?O"BA?O"@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3R/0"H-<^*5UKUXM[-H6@QW[72WES=BQ\U[N11C]X)&90IZE4"J2<D5]N_\
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M(W!4+\A.2>TA^&?AA_ACI>I:[H-[J<ND^ ]0U2'3=6U2[VV]S'J)C52JR+L
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M1"+<)FB=2906(&T,F "<GG$MGZ+D&4Y;BLOEB\<G=3Y59VZ1M^;_ "W/=?\
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M3YKW_NV7ZL****9\*%%%% !1110 4444 %"_>%%"_>% !1110 4444 %%%%
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MQV]HS\@K'PK^T%I>M7&L66C_ !*M-7N(E@FOX+74$GEC4 *C2 ;BH"J "<#
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M7Y7U^J%7$_*_$#_F%_[?_P#; HHHJC\A"BBB@ HHHH **** "A?O"BA?O"@
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M /8EUS^S? =CJD5V7M+_ ,076DZC;"0M&KN%>VE"YPIW?NR1C<)5SG:*^O\
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MQ)H_O;48C< P( ). &..G)]&T'XP>']<UV#10]Q::G.2L,,T1(D(4L0'7<O
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M>&R/:@#Y8\/_ !@^+%G>:#=:KXHL+_3;/QU_PAMY FEQ12:DK.<W#L/]60,
M(@7IDD]^'DUA?#6H_&+5KWX-Z5X\TF+Q5?1S^(;Z2$MI^YL8*>3)+L7(<LN
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M'!!%>*>,/CIXVF^'>JZ;;QP>&/&-O;:'<6VK6\L=]')'?7"Q;VC>%51_E?*
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M:/J.M",,[V^FB(.J*I9G+321H  .[ GH 33$8/\ PH'X8?\ 1./"/_@BM?\
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MJ2)I;643OF%MBJ0>C$/EOGZXP!H?\--?#?[.;D:_,ULOV??.NEWACC\^)98
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MU^G%4IYL9]:9-<=3G@<DY_6O'?'OQ=^W1RZ=X9NF$;/Y$^M0IYF'/'DVB_\
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M[VD9PIC.#MR>..<=ZY&'QSJ7BZ[TS31=1RSZC!;VKFXD";9P-BG.W(!RJXX
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M++LSC:0 PP/FKT'P?X7M?!/A/1O#UC)-+9:59Q64$EPP:1DC0(I8@ $X S@
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MLSVL/B*6*IJK1ES19Y[XC^+?_"/>(KO2_P"Q9[I;?:IFCF1<$JK[F5L80AB
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M=VQCO]*[OX8Z;!X@_9A@L_#Q^U7-RK?:XXE%M)))Y^;B(G<,G9NC#$C<H4Y
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MMDUJ:W<-#;C#2/$RD#*-\IW9&.>*XW5M8GU[_A&K>+7(["*\N(X+J($@2HS
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M4E2" ?QZ8QS7S;??LF^.;6 26?\ 9SQ1%XH].BNSA23GSE9E'WB6&"<@ >I
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MGAL=?3[1;*^!-$T,JN,=R%)P>@_$5C>%_'&B>++..]\/ZK9ZH-@F1(9U+#N
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MR'R=/*XQ^\8U:&F6JWQO! HN2,&0=3QC)]\<9ZXXJ+1VW6\GM(PJ_0 4444
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MUL?[>NDNK@_:[M8;,E1,RJ" 2P)  "Y(&<5RFOV_B+P/XXN=<\+VDNM6%_\
M)<06Z?99AD+DD D9!4G=SG><@=:^GQ"@Z+C\:&AC8Y* GU->=',)JI.I)<W/
MNGUUOTMU/;J9/3E1I4:<N3V=N5K=65NMT]&[W1YMIVK"]L;6XFN_$,$\L2N\
M)C7=$Q )0_/R1TJSYT3_ /+?Q(_OA?\ &N_^SQC_ )9K^5.\I/[B_E7#[7R/
M55!VU9X]XD^'WACQA'<+J^AZQ?F=!&\DR(7V@Y&&QD8)SQ7A.J?L^^%O"GB#
M['#I.N7*2VUH UQ*V_+W@C9@0.FTJNWU;-?:_EK_ '5_*H+.ZM=0A\ZW:.:,
M.\>]0"-R,58?@RD?A772QU:E'W6[>IYU?*\+B)+GBN;T7],^8/ /P+\(Z@L>
MMR>']:N&AOK@VVVXQ'M28JC %#SM0=Z]@^QVIX&CZP_LUR /_1=>C+&B+A45
M1Z "EV+Z#\JRK8NI6=ZC;]6S?#Y?1PL>6C%1]$D><?8;4==#U0?]O8_^-T?8
MK3_H":G_ .!@_P#C=>C[1Z4DC+&C.Y"HHR6;@ >M8^U?;\SK]BN_X(\,\5VL
M&I>)O#VDQ:/=J!,;Z>-KK<S1H/E_AXRW'2NM^PV__0OWO_@;_P#85;^':MXD
MUG6?%TJXBO&^R6 ;J+>,X+?\";G'J*[VO0QE1TW##_R+7U>K^[;Y'C9;1]LJ
MF,O_ !'=:+X5I'[[<W_;QYO]AM_^A?O?_ W_ .PH^PVW?0+\>ZWO/_H%>D45
MYWM7_5SV?8+O^"/-_L5I_P! 34__  ,'_P ;KDX[2#7/B$QCTG4'L]'M]K1B
MY!83R=]VSIM[8ZBO8/$VO0>&=!O=3N,;+>,L%)QO;^%?Q.!^-9/PYT&;2/#P
MGOOGU349&O;MB.=[\[?P&!CUS7HT*CI49UVM_=7SW^Y:?-'C8JC]8Q-+"IZ+
MWY:+9?"OG+7_ +=9A?8[;I_9&L+["Y4_^TZ?]BA'72M>3W68'_VG7H>T>@_*
MC:/0?E7G^U\CV?8^?X'GGV>%?^7'Q$GOYB\?^.4;8DZ)XC3WR./TKT/8O]U?
MRI/+0]57\J/:^0>P\SST7$:_\O/B./WP#_[-7'7%W#X@^(D"F_U=['1H3(9&
MC#.MP_ &-^.%YSG.17K/B_Q!:>$?#]UJ4T:N8UVQ18YED/"H/J?TR:H?#KPO
M)X?\.H;]5?5;V1KR\=@,^:YR1^ P/P->E0J>QHSKM:OW8_/=_):?-'B8NE]:
MQ-/!IZ1M.7HG[J^<E?TBS#-_;\9US5@/^FEJ#C_R)3EU2%?N^([M?]^Q_P#L
MC7H2PHN<*%^G%!A0]5S^->;[1=OZ^X]OV+[_ )_YG!IKK+]SQ3C_ '[!O\#4
MR^(KL8V>*[;_ (':R+_[)79-8P2?>B4_6H6T6Q?[UM&?PHYX]OR_R#V4^C_/
M_,Y.36KZXC:-_$>FSQMU282@'\"F*I^)5NO%WAF^T&^U71Y["[A,+(+EE*C'
M!7.,$=0?:NW;0M.;K90?]^E_PK@O"/C#PUX\\>>,/#NFV<$J>&Q;13W2*N))
MI#+O1<#HGE@$_P!XL.W-1M)-J.B):E%I.6_FSYRD_9QU/0]=T>QC\0Z3>-J#
MRC,<RKL"(6+$;NF=HY(Y8#FOH+X3>'=<^&.BS6L"V=]=7$F^>:.ZBPV!A5 W
M'  _4FNPNOAUH=UJ=I?O;$3VR21IM;"E7V[@1W^XOY58;P/H[?\ +J/^^V_Q
MK)>S73^OO-I.JUO_ %]Q8C\8^)5'.B-+_P!<Y4;^0IS>.O$"9+>'+H#VB9OY
M"LY_ &EM]U&3Z,?\::O@*T3E+FY0_P"Q)C^E5^[[?U]Y'[Y=?Q_X!YU^T)X2
MG^,VCZ8O]G7.F:MILS&*XDMGV&)P/,0]_P"%6'NN.^:^?]%^%/B.VU34[2)K
M63^SYTA=GD=-VY X.-G& RY&<\\9XS]D?\(C+%_J-7U"+T_T@_X5FZ'X#U/P
M^VI&W\1WO^G7CWC[B3\S*HP>>?N]34N-.Y:G67](L_#KQ/X?\!^$[#1(G=S;
MJ6EG=2#+*Q+.Y !QEB<#L,#M75K\4-";I,Q_ _U KG)-&UX<#6C,/^FT"-_/
M-5VT?7&^^VFS#_IK91_T2GR4_P"O^&)]I5_I?\$YK]H[Q?I6H>#],N+6[)NK
M>_!6%2"SAXI$88!SQN!SV&:^5=9\0!=Q+X R3STKZ$^*?P?\3^-KZQGLY-+M
MXK>-HS#'&8AN8@[^%Y.!C''UY->5ZW^R?XTOK:9(KZP)92-K$K^O_P!:OR[B
M#*<;C<<ZF'I7BDE>ZU_'Y?(\;%4ZM:IS<IX-:ZXX0D'",S,B^BEB1_.M#1=;
M,FN6WF,-BHS)_O8Q_+/YUZ!_PR7XXC>198K./:/E99RRL?3A<X_"LM/V:?B%
M:W,4O]C!!&^X,9>".>F!7RSR/,EJZ#_,X?8U%O$ZOP_XF^PS17&X_NV# #O[
M?CT_&OO#P3I]QI?@W0K*Z^:ZMK""&4C^^L:@_J*^ [/X7^,-.(2ZT=BA^5O+
MF0_7J17TQX1US4X?#>F+J'B1;?4Q;1BYCEM6;$@4;OF .>>]?:\*Y?B,/4K>
MWIRBVE:Z=NOXGIX"7L7+F1[9XBU2'0]#OKZY=HH8(F8LO#=. ,]R< >YKE?A
M'X3?P[H37L[.+K5 MQ+$V3L.6(&3S]UAG/.0:\WU36M0\4:LNDMK=C=6%NRW
M$[RNT<4C _+&<@?4CI7:1^+?$O CFTRX'_3&\C)/_?35]9"A]:Q/M^E.Z7K]
MI_+;UN>DJT9U.=K;;]3T^BO/X_&7B6-?FT*2?_:A=7'_ (Z*>OQ(O;?_ (_=
M#O(O7%NW]2*]3V4CJ]O#K^1W<DBPQL['"J"3QG@5Q/@'QK<>--=\0OY;6^GV
MC10VT3KANLFYF]R0..V,5A^*/C/%;Z3-#96SQ:E<?NK?S.-K'C<1STZ_E6AX
M-\4>&_#.AV>G03Y:.,+)-MP7;)8DY _B9OSKRYJM4Q<80^&&LO5K1?K]W<R=
M:,JB2EHM_P!#T2BL2+QIHTP&+Z/GMN!/Z&K\>K64R[EN4*^IR!7H<K6Z.I2B
M]F7*J:EJEMI,"2W4@B1Y4A7/5G=@J@?B:FCNH9?N31M]'%>:_$#3[KQ9\0-
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MR>!4,EW!%]^>-?JXKQVZUJ29=MUXI5_]FTM7<_F0O\ZK[K>\XW:_J?TQ&O\
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M2YR%B7NXXRYYR.Y&X]1\/_A?HGPYMI_[.CDN-1NCNO-4O'\VZNFZDNY]^<#
M_&NNK1U(P7+2^;ZO_)$*FYOFJ_=T_P""PHHHKF.D**Q/%OC70_ NEMJ.O:E!
MIMJ. TI^9SZ(HY8^P!->827WCCXW$QZ;]J\ ^"GX:^E4#4[Y/^F:_P#+%3_>
MZ]",C(K:%)R7,]%W_K<QG547RK5]OZV-CQY\9);?6G\)^"+%?$WC%AB2-3_H
MNGCION)!P,?W0<]N,C.A\+OA-'X(DN]:U>\.O>,M2^;4-8F&3V_=1#^",8
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MS;S2;E=QO- L[D#K+9.T#?7 ./\ QVG[.$MF>5[6K'?^ON/8HKB*?_5RH_\
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MM;L='CW7EU'!W"L<L?H!R:J-&AA_WCW[MW?WL.6,/>9>I&8*I). .237-_\
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MUE?^])\V?SXK8CA2)0$0* ,#BGT5NY-[G*HQCL@HHHI%!1110 4444 %%%%
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MHO\ -^;^21?K-U3Q!9Z6PC=FEN&^[;PC=(WX=OQJF5U?6NI_LFT/9?FF8?\
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MEB/6VT\;?P+GFE]:4_X,7+\%][T^ZX>TO\*N:>J>)--T7(N[N..3M$IW.?\
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MR>M:-GH=AIV#;6D4;#^(+EOS/-7EI<E>?Q34?17_ !?^06F]W8Y_[#K^H_\
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MB]M=#@/_ "SM4\Z7Z%CP/J*ZWIP.!13]K&/P02]=?^!^ ?684_X--+S?O/\
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MM]UW2RC_ .^F_P *A:ZEA7:&M[)/3.YOR%0-Y4_+_:;[Z_)'5V;U_P"#_P
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MFL/K$.C^Y&N_3]2"U\1>']/)CTNT:=QQML;4EC^.!G\ZL?V[K=YQ9Z$T2_\
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M)3.Q^H/R_I79T461,LQQ-N6F^1=HI1^^VK^;9';V\5I"L4$20Q*,+'&H51]
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MM4>54J3K3<ZC;;W;U845'YC;L8XJ2@S"@G S110!'YWM3E8.*:T7I3D7;]:
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M6M)<U1)"EI$K:A>+96=I9Q';!!"J*HZ<#']*Y^\U$\_,?SK)M]<N-O\ 9VI
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M_CV\,W3_ /7Q,D/\Z/MOBRX_U>FZ=:?]?%PS_P#H(I.M4>G,Q..*:M.HDO\
M$OR3_0Z2.)(5VQHJ+Z*,"G5S!T_Q9=?ZS5K"R_Z]K8R8_P"^S2?\(?J-Q_Q]
M^)M1?U^R[8/Y UE<P]A37QU5\N9_I;\3J*H76OZ98Y^T:C:P8[23*#_.L/\
MX5OH\W_'V;R__P"OJZ=OY$?Y%7[7P3H-GCR](M<CH9(PY_\ 'LT:ARX2.\Y/
MY)?K^A5N/B1X>@?8NH"XD[);QO(3^0Q4/_">27'%CX>U>Z]'> 1(?^!$UT]O
M:PVJ[8(8X5_NQJ%'Z5+1J'M,-'X:;?K+_)+\SDFU?Q=>_P"HT"TL0>C7EV'_
M #""D_LGQA??Z_7+'3@>HLK7S/R+FNNHHL/ZWR_PZ<5\K_\ I5SD?^%>M=\Z
MCX@U>]]8UN/*C/\ P%1_6K%G\-?#5FVY=*AE?J6N"TN?^^B:Z2DDF2%-\CK&
MHZLQP*+(3QV*E[JFTNRT_!6(K/3K33UVVMK#;+TVPQA!^@JQUK(NO%VB661-
MJUFA'5?/4M^0.:RY?B=X?#[(+J6\D_YYVT#N?Y8HNB8X7$UO>4)/Y,ZNBN2_
MX3J[NO\ CQ\,:M/Z-<1K I^A)I/[4\9WG^IT33]._P"OR[,N/^^!1<OZC57Q
MM1]9+\KW_ ZZBN0_L?QC>_Z_Q!9Z>.ZV=GYGZN:3_A7C77.H^(=8O?6-;CRH
MS_P%1_6@?U>C'XZR^2;_ $2_$Z>\U.STY=UW=P6R]<S2*@_4U@7GQ.\,63;6
MU:*9^@6W5I<_]\@T6?PR\,63;AI,4S]2UPS2Y_[Z)K?L]-L]/7;:6L%LO3$,
M80?H*-0_V*'\TONC_P#)'+'XB37G&E^&M7OO222$01G_ ($Q_I2?;/'6I9\K
M3]*T9#_S]3-.X^FSC-=G10/ZU2A_#HKYW;_-+\#B_P#A#?$&H<ZGXONU4]8]
M-A2WQ[!N3^-26_PH\/)();N"?59Q_P M;^X>4_EG'Z5ULF?PI8\\^E'*@>88
MFUH2Y5_=2C_Z2D5M/T>QTE-EC96]FO3$$2I_(5;ILAXIF<4['!*4I.\G=DM%
M%%!(445DZEXLT71\B]U6SMF'5))E#?\ ?.<TBX4YU'RP3;\C6HKB'^+VAS,4
MTR'4-;D'&W3[-WY^I IO_"3>,]7XTWPO#IL9^[/J]R/UC3YA1<[_ .S<2M:D
M>3_$U'\'9_<CN:KW5S;6,)FN9X[>%>LDKA5'XFN-_P"$1\6ZMSJGBUK.,];?
M2+<1X^DC?-4MK\(?#D<PGO8+C6;D?\MM2N'F8_49"_I1J/ZOA:?\2M?_  IO
M\9<OZBWWQ=\.6TQM[.>;6KOM;Z7"T['Z$?+^M5?^$E\;:[QI7AJWTB%NEQK,
M_P W_?M/F!^M=M8Z;::7 (;.UAM(1TC@C"+^0%6*6H_K&%I?PJ-WWDV_P7*O
MON<#_P *]US7.?$/BV\FB;K::6@M8_\ =+#EA]:W?#_P^\.^&2&T_2;>*8<^
M>Z^9+GUWMD_K70T4[&=3,,34CR<UH]E:*^Y6044UF/:E7..>M,\\6BLK6O%6
MC^'(]VIZE:V7&0LTH#'Z+U/X"N3;XK3:YE/"GAZ_US/ NY5^S6OUWOU^F!2N
M=U' XBO'GA#W>[TC][LOQ/0:R->\7:-X7A,FJZG;V0QD+(XWM]%')_ 5RG_"
M*^-/$W.M^(X]%MFZV>A(0^/>9OF!^G%:VA?"_P -^&Y/M%OIJ7-X3N:[O"9Y
M2W][+9P?IBEJ='U?"4?XU7F?:"_]N=E]RD9)^(6N>)_E\)^')I(6Z:IK&;>W
M]F5?O./IBA?A=>>(F$OC#7[K6%)S_9UJ3;6@]BJ\MCU)!KT%22.:6BW</[0=
M+3"05/SWE_X$]O\ MWE*&CZ#IWAZU%MIEC!8P?W((PH/N<=3[FK#YW'-3TA4
M'J*I'ERE*I)RF[MD<6=Q]*E.<''6@ #H**"1D9;G/2GTFX>M+0 4444 %%%%
M !1110 4444 -D;:/>HQ(1WS4K*&IGE>IH >IW &EHZ<44 %%%% !1110 4J
M??7ZBDI4^^OU% $<+;HP>E/HHH **,CUHH ***1EW4 +1110 4444 %%%% !
M1110 444C,%ZT +12*P;I2T %%%% !367=WQ3J* #I1110 45YGI_P 5M9FU
M"PDO?#^GVVA7^JW6DV]W#JSR7/F0F<!W@-NH"G[.V=LC$ @X(!Q-X.^.&B>*
M-2;3IF^QW;211P21I/);3;[6.X'[YHD5&*NVU'VNP3.WG 5QV9Z,>1BHI+<3
M1LC\J:X^U^,GA.\T^[O8=0N)(;?R3M&G7/F3+*Y2%X(_+WSH[ A6B#*V#@FG
M7GQ@\*:?I=EJ$^H7"V]T)F4+I]RTL2PMLF>:,1EX5C;Y7:0*$/#$4!9EC7?A
MGH'BJU^RZY8Q:O; Y$5T@8 ^HXR#]*F\&_#GP]\/K6:UT#3_ .S[69_,: 32
M2(&[E0[';GN%P#6?JGQD\)Z1JMQIL]]=27D+^4R6NF75P#)Y8E\M6CB97?RV
M#[%)8KDXP#BW8_$_PWJ6J65A:W\D\MXJ-#-':3&V)>/S$0S[/+60IAA&S!\$
M<<BC0-0\<VNG:;8R:_--=V%U9QE%N-/8+,X8@"/IALD@ 'N:\]\-P:G;^-FU
M+5;NXGGGL746T]RUQ]D4,,+O;JQR<[0!GH.]=W\7>/A[JC$<(87+?W0)D);\
M!D_A7$76H#=)*A7]Z.9%YRO;!].:][+:,)1E4:UV,*DGL9'CNWBU31[B3R@]
MY;H9;>51\Z,.>#[^E<*VLQ75M',LT95E#9##C(KL[J].3S7-7VFZ:TIE:PM6
MD)R6:%23^E>^<QS-UK=L,C[1&?93DG\!5"2_$BDC/XC%;FL:;:7T6WRHX)5Y
MCFA0*R'\/Y5S$VFWZY!:W;'\6YAG\,<4 0SW6<\UZ?\ LZ^';^_\2:AXEAM/
MM=EH\/ENBGYRTG4H.Y"KG'>O';J5X)C%,OER?F&^A[U]5_ C0;SX:^";'6YE
MDAEO)?M&I6S Y^SL0%)'9HUP_K@N.]>9F%7DH-+=FU**<M3U2UNHKZVBN('$
MD,BAD8="#4-]-)''\F .F2#2W%B-!\2W-E&,65ZAO;8#HK;@)D'MED;ZR-5J
MOE+MJZ.II)V9A/YDHR;C/L.*:EL."RN:VY+>.3[R _A5:2P1>57\CS4.=9?U
M8I4Z#Z% QQ#JK"ES$O'S?@U6X[<[L"4C_9<9IS6THZHC_P"[Q6?M)=4S14J7
M0I;8>R$CW>G*L0ZVXS]<U*\"#[\+)_P'(_.F?9X7^Z1_WT14>T@]&:>Q@ >-
M>D _*E\\+TB _ 4UK+T=Q]&I/L\G:1OQYJ[TQ>QAW)/M1_YYX_!:/MC]D;\
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M?Y&@/9X=;U'\H_YM&_-=0V_^MFCC_P!]@*HS>)](@^_JEFI]//7/\ZIQ> M
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MM6_Z[*9?_0B:-0]G@X[U)/TBOS<OT(KSXH>%K7Y6U>&5NRVZM*2?0;0:J_\
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MFY/S=PHHHIF 4444 %%%% !47S\YS4M% %>IH\[1FCRU]*=3 ****0!1110
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MRM1_;4R_?TR['^ZH;^M!7O=O_)BHNH:.N=NGX^EI_P#6H_M;1.]LJGT-J?\
M"K7_  D2+]^QOH_]Z#_Z](?%%BOWS-'_ +T3?X4!RR_DE]__  "LNN:#&>5C
MB/O;$?\ LM.77]!;C?#^,!'_ ++5A?%6E-TNP/JC#^E2_P!O:9*,&\A(_P!I
MO\:!.+ZTY??_ /:E5?$&AH<B:%3[1G_"I8_$FC]5NX5[="#_ "JPNH::WW;F
MU/T=:DQ93'.('/\ P$T&3]GUC+[_ /@%7_A*-*_Y_HOS-*OB;2VSB^A'U;'\
MZN?8;;_GWB_[X%-;3;1\;K6%OK&#_2@B]#L_O7^17_X2+2_^?^W_ ._@I/\
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M_P#D3F_^$^T[M#>D>HMFI/\ A.K9ON:9JDGIMM#\WTYKI:*-1^TP_P#S[?\
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MZY;1OY;S:;=1W"(V =I9"0#@@X]ZT;F\@LK::XN9H[>WA0R232L%1% R6)/
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M>*"5.#M\):J1^!%M@TT?&#0!TL/%7_A(ZM_\C47OJQ69U45\/#6O1:BY_P!
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M>A^G<&1G3CBK;VC;K_-VW^1I:UX+N](F,<-Q;:J\8E,RZ>7=[?RSA_,1E5D
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M^*HW\V5X-/M;7'DVT,7_ %SC"_RJQ113.=R<M6PHHHH$%%%% $>P],5)110
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M7 ( ZK7O@[X3\20O%?Z?.T4GVH2I!J%S )EN&#S+)Y<B[U9@#M;(!' %7?\
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MOV];'H1Q6(JTFO:/FCKN]5U^[?TN2?\ ")Z'_P! ;3__  %C_P */^$3T/\
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ML+.'+R?B^^CM:VWJPK$\7>*H/!^D_;9K:YOG:188;6S4-+,YR=JY('0,220
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M=RQLBAI)@NQ0&QG !Z$XYJ;Q)KFMZYJ4DVOW_P!HNA;I%Y6Q%940;5+%0,G
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ML0K;F!*_*P;D#J.*]+T#X/\ C#5-76WU#3I=(L5;,U\D\,NY<''E#<<DG'+
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M !130^6QBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*1CM&: %HJ/S3GIQ4E !1110 C+N&*%4+TI:* "BBB@ HHHH **** "BBB@
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M^-'.@]FSC:*[+_A'[#_GA_X^W^-(WAS3FZV^?^!M_C1SH/9LXZBNQ7P[IZC
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MSP_\?;_&C_A'[#_GA_X^W^-+G0O9LXVBNR_X1^P_YX?^/M_C1_PC]A_SP_\
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MR]+?_P ?;_&G?\(_8?\ /#_Q]O\ &CG0>S9QM%=E_P (_8?\\/\ Q]O\:/\
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M?;_&C_A'[#_GA_X^W^-'.@]FSC:5/OK]178_\(_8?\\/_'V_QH'A^P7D0?\
MC[?XT<Z#V;-&BBBL#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>mrna-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrna="http://www.modernatx.com/20210630"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrna-20210630.xsd" xlink:type="simple"/>
    <context id="i179b2e7c238549528ec055756ce46033_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iec99c2535a8b42dbac6e8d323141db5c_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i23d47f973c914379ad830c261ec3d4eb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62917e20a8fb457d8e66c38f2ad33f7a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id65439feeef443e58684902e2ca1fe70_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if266088069f84cf6945085f6b87d5db0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie42b22b2df23458abe04d022388eae80_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i97462bb9e06e4d0b8038908806010639_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i277a54dbb61f41e99601f903825b48d2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30b0955908be463b8c5776e5549bb45f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ceec1ef6dce41439e7509d5b3180cde_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4fa63e0b90e04379b97da2756114c4c1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b59c2ca6da04931aec1d8e534792b47_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5c212449977847f097fb6ce69dc98327_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ied43d05ce83c48a9b037a38e01ad51ae_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07f544975bf44f01aaf6cd6152d44f8a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id896a91ec74c4c49abdf78c300d13ca0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifeb94c429e024fb093ce6d4d944055ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i467f5e1c5b0a40dfb2090010d28b95ad_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5da83908729448ee8a41870859147a93_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i517010db08264600b828770102838edd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02e7d1bca5614fa89de0a1a5b33cbe8c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e8320dc990645e7b4e723cd26fb61f1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9332a7030408410190b1a94c2e713ebe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i45d1c7922a0f42a1a5569a02e65e170a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia81e9a8c1ff44ada911a7e8db3a243c4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if9860610904e425f9bd0ba4654cee9f2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i91bd58e1ce80434ba54c3ba11fd4e041_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0b07a5c1b08c47c18dde953f4df74a85_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibb708f43d5464f4e98cee5a3f7031313_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i54b175b3a826401ba7e904fd9486fa43_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3283b392eff2465faad3fdbe829de638_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i653c8891e96b4e798b795df5d797ffda_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if21af94b32274ca2bc5f281d8b91964d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7b68d04a23384807b92fd3080ce4ad8d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i69519acdcd484f7baf0aee01a833d455_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icc0ffd1101054ceaa3de2c3ffbcef1e4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifae9686943f64febad60646379a0b1cb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i488b334a3ef64d4caa66debe5db19d8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c08244b023c40ca9fc941a3e60c2c56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0ef651667664c27bc69872dd1d33b05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ade9ccbd9704bd7b8ea5b560ac9b3d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8d9d0afe13d46efb8ad43cfe9cc5715_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4d47127223a64d2fb9cd36c959441e94_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife42851a7eda4b4f941a44f0037477f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5b4459de21243118082e0ace346a32f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc39f92f55eb4e0a806e6264b2267ee7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0b7a4b2f73947ee99915fb30be8e619_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae5f72aaadd64959816335e7e8bf64f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd50a086b08a418189feb030cb4bdb1b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie54592b591bd49c48e564d5634910480_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie9715f2b13dc4d9a9876fb015b5eb0d2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7dbeca61b931429a9ecce401a75b9228_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i60ed33a973974be78cf5fb2ffa1a2b11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iecd1d9442a7b4754a406bff7a39e5fd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i157887d3dcbd422db9ab258078ee14a9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iec75ac0ff6b94c738a5f8719561f6104_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia96c0176d8aa4d39a5da077d3b371b0d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i122512b403f742038c2c1468c00fb915_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6fdf15d391e54159b27e230febc1be1f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if05aff14929149cab57fd79aefeeeb56_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12aafa2a5b1746a4984dfb62d34e42da_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib627f3fa58de490c92d72c00c79d72c4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5c6c5bf45d0d43ac9807ba42e62b7367_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib3e5362a76064a92b61e459fcd0ce315_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i98fd324dcb2a418298c8cc16153570f3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1537b27f156c48ffba4b540f307af8f9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifd2776323b3943b9ad57f0cfb5a2e92e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i90e522303a6d4db88a6e75f6bf51b675_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i925c8f5cb9cd46f6a1ae86a03be5fc3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i197583d029334a8a81529a09b6d9abab_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id6503cc026fe46aebeebe1584e563292_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9d8c05f658d243b7a83bfd8f5c1c6f4c_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i317ef19f70e3444197530823e5c919f1_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i1ebdc9e4059d4f3e8af844afeb9fa830_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie51ac7bdfcca483bb11c2dd61678484a_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i8dfd3eaf51514a388430a090a9c38bf7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie6e91224fb8d4da7a4999fd677df954b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3f7b3f76a0254c61a7d0c966cb15f054_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="idc3a7ff346784334ad9e7b0a9a13d895_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia5b1bfb294a14e0a9af5a1f7d2fe3c3d_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="i23d59c82137047499203288390a8fb25_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3736c014f39246fab97d6e843cb4749d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia364f96dfa314c94ab36b5e61edb53d8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2020bda539b4500be4ec167f8f9dd69_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82c916a0b4ca4f3aaaf4cdcb3d605a58_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib842bb3c0b504e23ad5bea99b14f72cf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i84be31041f544b97a41d04069c6d8bf4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4ea751eab6f240dba31a0a82fdceab7e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic2f686c80a94472683e32b196c79f61c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i162ebf7a6485464c849cf2578c7dab6b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i50c0e4a432e844f8b79c47cfa66d0c9a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a7e7990e9d440e893ed1142076218aa_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7644505741a1400d86377f349317c0fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaddeea55cf45455cb5d1c9673b0324ce_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e00f59aecfe46eba16e2160aad94c2e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie4d9addacdd64f378a73828f0159e567_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic00107eb57614d2783a2c32384445ff8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d9334dd2e954444a97f8e4487361fbd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i75e7c7882cf1442f9e76d9e7fa5fb939_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc0ecb7e5c464559a1438e2425eadc54_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7b82d07ccaad4e878d47278bb6324ea1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie360ccfe76ce4f12acb76df75ae0cd29_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0ac3dd43b3bf4cbba83cd10d23c2765d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8812f9dae82547b18386cb8d2b5e9345_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3d810941907046baa10069ee651b0e1f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc4765f3aff24398975e633a19635d2d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3d4150668b3b4c44aa607c9d34eb7166_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib52338e34ec645a58c3c88e7c09ae121_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic759b04977c945af9a1565724750bef0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i32e9a9ef8cc640939f59b6dbf739b2f2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide4dcbd5648047cc838ad06ddef0f031_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44b065b0be3c464e8433f98080bb78c2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i01fb537f002a4b8c925b113ba3d2017d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i81cf2066964f4552b9838011a69044d2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia3e40b9256244a589946a1e85bf6cc70_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e02e1f5ba8748bd95d12afcf7465939_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1b130a946c83453fb4a2d9207835ffe6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i423fce28b3db46918d8d1d5c8d38b86c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iea33fd392c424f96b2db18376181aebb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i027a8da8a838499cac9ccfbdc2f7a524_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1b3dd508a23a494cb5ea06605d67c4ce_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibd695349782d4fabb5331046948b8614_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i42e44fa9dff64d7aa736f647933beb2f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i992dfe7000ea4086b948a45ff7846ebe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4821d306d1d84e8c92f59601e79d952a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idf6972a4b3a6464fa76fdb392c3e5aeb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia2bd954162504b8b865d6ee4ff792361_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4dd7c27968a4482bb56525e657054318_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i32cb4879eecb497aa9402f0d74f44387_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icf2262642e3b47c28ff6867f6509b071_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i769d59bacc4a4a21bb4c83f4a46ff03f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib392451a0a484b5dbc71a9445c495423_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09bbf998b6c041a6901c1dc8996237b7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4e0489f9f56e42fe85ab3ecf9d6d2dad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i16c840483704458faf3161e93a3e01e8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5adcc5729bae40c6afb7af8e72c59291_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i774f6d34510445e0ba7f5b0b00875252_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0466c7cd491448979678f3b868c44e9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if135f26414c04231aa2ea55c9a2c83a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25503043380a4bc7998a597473d1786d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e114d012176429c97c1208417394403_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia55f81c1ceb8498fb37e9398c3b61120_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12cd6744128743138d2497b1a6aeab5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ed771e34dc34a429c0397e23c4ef046_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i519420c4ce3f4e889babc67663290d67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fa12a4a1d724b97bb9fb7cdd250ec0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6954dbaff3c452da6a96be861950389_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i493f6838a0a64aaea82e5743f2952be8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f3e4a401171474a9007e9abf988d8d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic540ca4685794ebb951a1f68ef0b6cbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a16e85d6b1c4d0b82c2b3e4a95dd15b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i846f0646bd6d49ea8fe231170844146e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i194e3a1c43ff42a5b8386c49d1daa843_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i230f554c3a46462b96c3244553fa4901_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d36108a148c4a0fbcdf9c7d9b7be3b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c96e2e95a944ce8baab70f57149619b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41cbbe97585b49f7816d2b3bc62ef46a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a7e6285a6f9420a8a1c73a6d999a977_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2db80e5245884f98abb49e31eb422938_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0b7d5d68b044d1a9277098a16618625_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1932c05e81914004be5dc08eaecfac86_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0db557e9b08d465ab8c20a75ef2e9031_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i864ecf97b4424e6094f85e6a8a246f8e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i516ea12e44884479b0a6bcb19ac9af08_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i14ebc7385e514efdadb03d14e93eafbb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3181a82c5bb246f2ae1a34c07476b8df_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id72d63351ccf43468dfcbe077e57e343_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i775e0b2685f849e2bc13548cc7443839_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i353364e17b0948c69aab8712c81c2ae0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2bf448fa99154f69805bc0000070e21d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1f00f671da6e4c1f98a8eaee2667cd74_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i70b8d474daa3437dbb2cd804326443ae_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i91999e41635347b4902e1ad73f8105c3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8d07569609954f7ba5c83a5cdacc1022_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i414d3d35d2414d4cbfcac8697786c538_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie25825286c884fff843aea0e9c363a1e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2e8429272a2a4b0998190fc4ddf309c0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i37ee58f9c9904729a24edfb35821ac46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if206a7fe2c0b4f61b8a9c7db48c74717_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b3d345b623d43e5a20fa855453bc2d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18a60989d0ea4094b7de163b29974100_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73893cab9b854b6b8ba02c2e4b889f2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a24374f72e7438a9fbdca268f38643b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabd72a3537a1453a82dc119e321ac20f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i174fd5ae68bf4b5da07bbc030ddd36e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i002448bbfd364b528c594c150a64fdfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03cae867119545acb97a33eb075f4934_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8999a018dcb4fc1ae7ae79fda50084a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd279b33ffd34a2398ca36d866add3ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3b2270f25574b2389448da3126d9486_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id873b1c04a36458dab4d7141b07cc3e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9969e6d3b7504aeeb9fcb51894156a6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3f7fd21cde041c28f93122294043d54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0e4394219d147b9aa8a86441e91f2d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1f213588a2543558ea014b5a5ea5e8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idceb063e3fb1410babe61be92b0909bb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i105c28fecd3545bfb3d35697e79fe0be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78b9df3a23274885ab33d029964f7f40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5fecea31d594dd0ab5690daae65344a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic41d37e05a294447b61d26d700536c4f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e7bc9694442496cb11758c11c2558be_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i425177f7064948f1ac420fbb3fef0e74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i782e7b05996e46d48e09abb10bd0b888_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5f885124f6b8428f81517844f40eabfa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic255a6d51e9f4cf2a218bc9650ff2949_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i06704fd367eb404db0554bb5e563f35e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5de8c1fd48ac4d1aa4faaacb3fe97224_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia6a370046fc945508f2069a2bb7980ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if00cdc03e1254d03b96024e1c1f004e0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i084d5de85aad4c568986c67f724f5fc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8946ec3ac3654c46b29f79ecd814b660_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iade5f7abc6404fd4b696f1bebae23486_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i321e4ae9922946c7b2dc52c2fcf14229_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1e4bff8b1053446d87c6e24ff337360c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i323f3434ce0f462a835692c193f97e98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieffb4ead51104e6aa5757fa06624c672_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie0b8c503b84d412cb2d8c21018da6a3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a01b9748ef64174a3c700db54d82b9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ca4970aeb944ce094587b8e9e52cee5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia01e27faf121473685c9340ddfba9ede_I20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-31</instant>
        </period>
    </context>
    <context id="iad991ea73528435fa5b841a1edd13f95_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i4919b4b841a4432188fe3621950e1631_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic93eda10a84048869aafc24b02582937_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="if3b49c23c04b441dbe3849a5361236d8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9b90abfb0dbe4272a84180b8ea7942bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebf2947c07b840e4a74467063deb1ae6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i04fa63042c64408fbd832e6524b4b23f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie095a587c0d84c63a7d5403131e4b7e3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ied6207c51d5c4d1da7a394ed937340ff_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61568f63bbbf460192175495b73fb1e2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i453114f3b5a7454382060dc9a3cc7f07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3e4997c888f446e9fe81c8bdd3f1e5d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i598d0bc0445a41abbc9bdcd1258b0d3c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8caec99e729443a0aee89f8db26aa392_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i67185c627d644febad389a0c535248b1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic3c3513fce714f9e9e6c45c936e12fe2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c7f1943108a4146a37ed6c8267654a2_I20170626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2017-06-26</instant>
        </period>
    </context>
    <context id="i0e58c0fb75144621874b106da58aa126_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i806cd5c4c8db4bbb96da09f4192d4f77_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic32a9001570747069665c11f135527dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib676efd3333c4e95baf151a431bb5025_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie402888bb2fc4ea880b40f2a9d7c22f0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ied36f68f5ff84b10a3d60914c0b61586_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ife7005ad8225459bbf949983a16fb039_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i27a9e69e7d27416e8d304a0b72359725_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b1bbe23395c4aa6988514c29e2ee39e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5940ab735af34e5e946ede601d642a53_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6a0202da86f1409fafc721c18c4b375b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i940058d521aa4563a84e76e20cd336d6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib67410869f8c478eb669bc8351987988_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifdc29bdcf87245dab06fb8bb8f5635ff_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0beaf98f2bec4a78acd4d80ffe785bbc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i85a56c15404a4b8eb579be1a6a78e357_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8310dab123334253aa6827d712250361_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id0463634352040069acfeb178a893295_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45447fcebe4141ea9d78a8504cdc1c19_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib6b9ec1f5cce442791bacd86253cbd96_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8db1b0e2148b492bb939ebb0463eb2d3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if9f6e9c4e55144bb8df23054a288a2e2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1d0ada455afe4e75bfe9e71f54e33319_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie1fcb8aedfe9420c8551dec0ade1347b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3435c602db343908bad969f4cfa4f42_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7303c622b8134633b87246e130589360_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i230bf3fb1f8e419181b3f634ef694994_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i36e5a124b9bb45f6b74b3d193e94adbb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80e219eb6c9048bbb915840c4add36fd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifea21debe3524bff9d6e588cd4b5716b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib29b4d951999485cba6731af4351eddc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i283d9247556a4278afc37abb5ac02feb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19460b8e62a442f88dd3c9900970530a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iff02256a11834a66b8c527254b62d147_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i292b707793574fa196af16232e6fad08_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icbdd283932184bea9f7f771d39f918d6_D20210701-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="ibdd0a3a2ce304bb5a423153da5ba16fc_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="program">
        <measure>mrna:program</measure>
    </unit>
    <unit id="clinic">
        <measure>mrna:clinic</measure>
    </unit>
    <unit id="option">
        <measure>mrna:option</measure>
    </unit>
    <unit id="campus">
        <measure>mrna:campus</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extension_period">
        <measure>mrna:extension_period</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="dose">
        <measure>mrna:dose</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18wLTEtMS0xLTA_996ec8f9-3b81-4a93-86cc-70519357f348">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18xLTEtMS0xLTA_523a8aa8-4b07-43c0-a34a-356d10f05473">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18yLTEtMS0xLTA_f119d0b2-18f6-4ac2-bdce-6df232a0c126">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY18zLTEtMS0xLTA_2011cfd2-2622-4563-a40e-67555ed786a8">0001682852</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80L2ZyYWc6MWQwOGEzNjJmMzA3NDg5OTk1NmFjMTZmNmQxMmQ4ZGUvdGFibGU6Mzc2N2Y1MmM5M2M3NDljM2ExYzYyMDgwZTY3ZDZhMGMvdGFibGVyYW5nZTozNzY3ZjUyYzkzYzc0OWMzYTFjNjIwODBlNjdkNmEwY180LTEtMS0xLTA_53499593-f3a9-4aed-aeb1-d49b1a623eba">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ODc2MWZjNDQwMTcyNGQ3MmIwNWQwMTNlODE1YTgzMGIvdGFibGVyYW5nZTo4NzYxZmM0NDAxNzI0ZDcyYjA1ZDAxM2U4MTVhODMwYl8wLTEtMS0xLTA_5e600a29-6f3f-4d02-9664-e5eb7a68cec8">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI2_d602facf-0061-4be3-8624-d36173809bcc">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl80Mzk4MDQ2NTEzMzY0_b0110775-a683-4dc1-bcaf-165a1fb3a83e">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTIx_150f5d98-c6cf-4a86-85d6-c700d3ff453e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTIy_c1804b4d-e304-462e-87e4-0bf0a0c58ea3">001-38753</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI3_46ab1e23-75a2-4a94-95a3-fa59043b864f">Moderna, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV8wLTAtMS0xLTA_70286a7c-8e12-47b4-838b-a3efefe00097">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV8wLTMtMS0xLTA_baa33f40-f6f7-4dff-8327-3dbf300fa15e">81-3467528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV8zLTAtMS0xLTA_8e4f297b-cfdd-44db-90c7-342dcca54dc4">200 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV80LTAtMS0xLTA_c43ddcdc-5a52-46d1-8fed-79df09c5f688">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV80LTEtMS0xLTA_17a2b846-ee24-46ac-97dc-5c9aeae1e186">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6NDdhOTI5NzgyZDYyNGU5MmE5NGM3Y2YwYmZiMmNmNDkvdGFibGVyYW5nZTo0N2E5Mjk3ODJkNjI0ZTkyYTk0YzdjZjBiZmIyY2Y0OV80LTMtMS0xLTA_4dc74123-fcfd-46ee-aab5-4b99e96dad78">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI4_36729990-df08-406f-b9ae-187406bcc277">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI5_647575e6-6ab8-448a-aece-adcb86bf605c">714-6500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZWE0YzRmNWRmNDZmNDRmZTk5YTYwOTNhMjY3NWFmYmMvdGFibGVyYW5nZTplYTRjNGY1ZGY0NmY0NGZlOTlhNjA5M2EyNjc1YWZiY18xLTAtMS0xLTA_2293f809-aafb-4636-9dea-0596a99bd528">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZWE0YzRmNWRmNDZmNDRmZTk5YTYwOTNhMjY3NWFmYmMvdGFibGVyYW5nZTplYTRjNGY1ZGY0NmY0NGZlOTlhNjA5M2EyNjc1YWZiY18xLTEtMS0xLTA_d3394fb3-d1e2-4d16-976e-a8c2f4099df4">MRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZWE0YzRmNWRmNDZmNDRmZTk5YTYwOTNhMjY3NWFmYmMvdGFibGVyYW5nZTplYTRjNGY1ZGY0NmY0NGZlOTlhNjA5M2EyNjc1YWZiY18xLTItMS0xLTA_72303514-22ac-4734-9bda-4d1c52544784">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTIz_2b8a3f2d-4585-424e-b419-bcf08e3f4197">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI0_08861a5e-e6ac-4f7b-8f9b-e91eb7b9a43c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZGE2M2M5MDIwMDU2NDM2MTk1ZjdkZDdjOWRlMjFjNzAvdGFibGVyYW5nZTpkYTYzYzkwMjAwNTY0MzYxOTVmN2RkN2M5ZGUyMWM3MF8wLTAtMS0xLTA_b996a923-eab9-46b0-be88-47165d687ca4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZGE2M2M5MDIwMDU2NDM2MTk1ZjdkZDdjOWRlMjFjNzAvdGFibGVyYW5nZTpkYTYzYzkwMjAwNTY0MzYxOTVmN2RkN2M5ZGUyMWM3MF8wLTgtMS0xLTA_78854083-cedd-481d-b24b-aead0eb8959e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGFibGU6ZGE2M2M5MDIwMDU2NDM2MTk1ZjdkZDdjOWRlMjFjNzAvdGFibGVyYW5nZTpkYTYzYzkwMjAwNTY0MzYxOTVmN2RkN2M5ZGUyMWM3MF8xLTgtMS0xLTA_cf07a254-5595-4f1b-96e0-51b880e4084b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMTI1_649f3689-49d8-4cf9-ae18-771467a5a63e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iec99c2535a8b42dbac6e8d323141db5c_I20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xL2ZyYWc6OTJjMjFiZGZkNTcyNDE5ZmIwYjJhM2ZlMmQ2OWYxYWIvdGV4dHJlZ2lvbjo5MmMyMWJkZmQ1NzI0MTlmYjBiMmEzZmUyZDY5ZjFhYl8yMDM3_4c243ea1-824c-43ff-9c8d-eb922056d9dd"
      unitRef="shares">403646312</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNC0xLTEtMS0w_86006b5e-91ac-44ac-8477-fe95ec8aa750"
      unitRef="usd">5603000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNC0zLTEtMS0w_13d19462-91d5-4fed-a1f7-008019709eca"
      unitRef="usd">2624000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNS0xLTEtMS0w_26b71a01-ab49-4aa9-9a59-68e81ebdaef4"
      unitRef="usd">2387000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNS0zLTEtMS0w_867c17f7-3099-4891-92e6-79bf7ad87c81"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNi0xLTEtMS0w_de37f95a-461e-4c9a-8622-ae674319733c"
      unitRef="usd">2020000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNi0zLTEtMS0w_d13b9465-2d13-4732-9e56-bda177ae3a8d"
      unitRef="usd">1391000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNy0xLTEtMS0w_831f0eaa-e2bf-4b7c-a8b0-84b8d8d4f408"
      unitRef="usd">643000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfNy0zLTEtMS0w_ae108b74-e7c7-476d-a056-d75f0a83efb5"
      unitRef="usd">47000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOC0xLTEtMS0w_3aefa160-6936-4329-9d95-d1da94be882c"
      unitRef="usd">316000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOC0zLTEtMS0w_f9feaad3-d72c-44fb-9126-e28620740be7"
      unitRef="usd">252000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOS0xLTEtMS0w_e5f58752-bdac-4b30-8177-c65ae4127802"
      unitRef="usd">10969000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfOS0zLTEtMS0w_0395a192-c548-437a-b072-07c68ecd7406"
      unitRef="usd">6298000000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTAtMS0xLTEtMA_1040046d-955f-4a50-bd83-1dde1d85c1eb"
      unitRef="usd">4207000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTAtMy0xLTEtMA_41c6f697-b3f2-4ceb-ba85-1a7b07b90b81"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTEtMS0xLTEtMA_a5d8d765-cbea-467f-a606-5a73d4366bc1"
      unitRef="usd">794000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTEtMy0xLTEtMA_e4cb1ec7-da8e-4e13-a8f3-e1f8912e00e8"
      unitRef="usd">297000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTItMS0xLTEtMA_4c2c7324-5129-42c6-ae44-167eee61f192"
      unitRef="usd">104000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTItMy0xLTEtMA_3f2b3951-7209-4694-9349-800a8f552a6f"
      unitRef="usd">90000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTMtMS0xLTEtMA_5ad7c5f4-4165-43db-8855-3acd0282bbe5"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTMtMy0xLTEtMA_b34b283f-c3a2-4fb1-a6b7-96e93d5c7d2c"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTQtMS0xLTEtMA_1d5ffebb-5021-4e87-9385-a04a305a61a3"
      unitRef="usd">66000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTQtMy0xLTEtMA_1e6a756c-6063-4d13-845a-f4feb1fafac1"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTUtMS0xLTEtMA_ed6dc656-15a5-43f1-bc81-e834a240d2b3"
      unitRef="usd">2000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTUtMy0xLTEtMA_f1674fcc-156a-4fc9-84ea-c4e7f7c690c4"
      unitRef="usd">2000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTYtMS0xLTEtMA_1582f529-48f3-4d3f-ae9d-3cbd0aab979c"
      unitRef="usd">16153000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTYtMy0xLTEtMA_e3ef1d6b-35fd-4c9f-88c9-fe70413d46cf"
      unitRef="usd">7337000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTktMS0xLTEtMA_108ca462-22cb-4edc-b4f5-dae6b51b8ec3"
      unitRef="usd">77000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMTktMy0xLTEtMA_876d9989-e4a6-43d4-9cb6-713174cc1588"
      unitRef="usd">18000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjAtMS0xLTEtMA_ba08e85a-d58c-40c7-84c3-cc38831dea51"
      unitRef="usd">848000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjAtMy0xLTEtMA_5f028d64-8849-409d-ab85-50cc3353f936"
      unitRef="usd">470000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjEtMS0xLTEtMA_f771e1bf-6371-4cb5-91ee-65f0f3e06355"
      unitRef="usd">7302000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjEtMy0xLTEtMA_692fd62e-dff8-45a9-9e48-460d4c3fde06"
      unitRef="usd">3867000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjItMS0xLTEtMA_15f38ba0-a53d-4b7b-98ec-a458f127fd82"
      unitRef="usd">613000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjItMy0xLTEtMA_2b2c0b77-63d4-492e-8c2f-55e8d80cfa07"
      unitRef="usd">34000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjMtMS0xLTEtMA_4eb8e2aa-98ef-4b5d-ac07-10b3917da040"
      unitRef="usd">8840000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjMtMy0xLTEtMA_d2f61c0b-c9db-42a9-8baa-aa1c50ca5125"
      unitRef="usd">4389000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjQtMS0xLTEtMA_14f04f00-9a7d-4dad-9c98-15c85750d630"
      unitRef="usd">175000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjQtMy0xLTEtMA_07d3f94b-80c6-46ad-8f76-5eb6f00a9785"
      unitRef="usd">177000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjUtMS0xLTEtMA_b7d18e5a-d0e7-4a4b-a140-84a9f5e96704"
      unitRef="usd">105000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjUtMy0xLTEtMA_d6af8289-42ca-4890-8c20-05c0d5e531ba"
      unitRef="usd">97000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjYtMS0xLTEtMA_58c00049-fbbe-4552-9a41-b2c72be03e2f"
      unitRef="usd">328000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjYtMy0xLTEtMA_240e2ac7-301d-479e-ac0f-a4668216d6e6"
      unitRef="usd">110000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjctMS0xLTEtMA_2cf81fa4-d5b3-4150-af2a-631e7fd9cf21"
      unitRef="usd">1000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjctMy0xLTEtMA_672bad51-e5c9-45bb-8c4a-820805c07541"
      unitRef="usd">3000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjgtMS0xLTEtMA_99b290c8-721f-4180-8fc3-b9b55031bdcf"
      unitRef="usd">9449000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjgtMy0xLTEtMA_fb6f764a-a79b-438d-8e44-1572d957c672"
      unitRef="usd">4776000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjktMS0xLTEtMA_3f616319-5e06-494e-8493-cdb487f450cc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMjktMy0xLTEtMA_5b3079fa-fed7-4fdb-a9ce-a9993c43c7eb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM0OTY_9bdf3d67-ee73-4ec9-ac9b-257991163b00"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM0OTY_9e44a717-5c6f-4ae0-9597-302129bab741"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDA_616afeda-3972-4168-878e-7ca1e53148b6"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDA_a3a348c7-019c-4ff6-92cd-eac5fd43ffcd"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_2fdd8781-df15-42d6-80d4-66c219e14430"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_5844d2ae-a60b-481d-93aa-b4815392d366"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_5c5e8546-256e-4236-9513-f67631b26439"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNhM2FlYzY3N2Q3YTRjNGE5NDI1YzAyNWMwOTRhZWU4XzMyOTg1MzQ4ODM1MDQ_b09555a3-456b-4bbe-aae2-762d9884abf5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMS0xLTEtMA_2fb9c95d-4844-4c7b-97d1-f98e5f09525c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzEtMy0xLTEtMA_c85869f3-0fde-476c-832c-689249f90de9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM0OTg_30336f93-49ce-4ca5-81ff-6adaea782269"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM0OTg_874cb95c-9ef6-4ce9-bf26-ca7ad15d285b"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDI_805caf49-0ac2-4a6f-b377-5629e15e8570"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDI_abc8cc11-d5f9-478a-851b-2c13c93d0c23"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDY_6befc6aa-5861-4e73-895b-8e81c6991ffe"
      unitRef="shares">403000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MDY_e90311b3-8043-4d59-b57f-8735e5ef0eeb"
      unitRef="shares">403000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MTA_21ee4507-9d67-4d5b-94db-ffb69fae6925"
      unitRef="shares">399000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2MWU5ZjM5ZGMzMzQ2OGNhMjQ0MjcyNzI5ZDc3YzQ2XzMyOTg1MzQ4ODM1MTA_88f8f995-bb8c-4d5c-8871-7933902a1747"
      unitRef="shares">399000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMS0xLTEtMA_c3ad253f-f663-47a2-9270-4c2c5cf6c96f"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzItMy0xLTEtMA_a46b7640-9df4-417a-8b7f-e278b351f80e"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzMtMS0xLTEtMA_63c0a93c-8ae1-445c-84d0-16276a3909c7"
      unitRef="usd">4931000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzMtMy0xLTEtMA_1586f769-a2d1-4eb2-bf4d-ef4b5ca1995b"
      unitRef="usd">4802000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzQtMS0xLTEtMA_6e39bd2a-b6d4-4787-9b87-2d1a640ac562"
      unitRef="usd">16000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzQtMy0xLTEtMA_00fa1b6a-0e8b-4251-a145-37398b069806"
      unitRef="usd">3000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzUtMS0xLTEtMA_973a2a70-4ded-45d4-a56a-beac1aa00adf"
      unitRef="usd">1757000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzUtMy0xLTEtMA_15d71760-bc49-483c-8d84-9a2a034cc2a6"
      unitRef="usd">-2244000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzYtMS0xLTEtMA_4cf8167b-aad0-4ac8-8aec-6270d5ec2425"
      unitRef="usd">6704000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzYtMy0xLTEtMA_1b64c772-4fbd-4be7-8caf-11113ba56fcb"
      unitRef="usd">2561000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzctMS0xLTEtMA_5eb7ffe4-7ec6-4018-83fc-26d47fb1d319"
      unitRef="usd">16153000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xNi9mcmFnOmIxMTRjNWZlZmY0ZjQzNmJhNzMzODJmYTI2NmZjMDc1L3RhYmxlOmQ5ODc3OGUzMDE0NjQ4YTQ4ZTU2YWM1OTBlY2MwNGQ0L3RhYmxlcmFuZ2U6ZDk4Nzc4ZTMwMTQ2NDhhNDhlNTZhYzU5MGVjYzA0ZDRfMzctMy0xLTEtMA_41f80800-1d24-4e23-9785-23560401e5d3"
      unitRef="usd">7337000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i62917e20a8fb457d8e66c38f2ad33f7a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy0yLTEtMS0yOTI_9a989915-9db2-4bd4-8bb5-a4438009db85"
      unitRef="usd">4197000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id65439feeef443e58684902e2ca1fe70_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy00LTEtMS0w_c1e11010-3bc2-4823-890a-a5b713d2b71f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy02LTEtMS0w_0bea2202-0610-4ab4-b7a0-4630d605607d"
      unitRef="usd">5930000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie42b22b2df23458abe04d022388eae80_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMy04LTEtMS0w_c68fc26c-b30c-4609-9681-252bffd3b60b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97462bb9e06e4d0b8038908806010639_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC0yLTEtMS0yOTI_d8cfac4c-b45b-453e-855d-4f1d63c36004"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i277a54dbb61f41e99601f903825b48d2_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC00LTEtMS0yOTI_3fbdc0d1-d60a-4f13-a54b-84fd7ec38f6b"
      unitRef="usd">38000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC02LTEtMS0w_40cd2e82-de27-4e86-86d5-286ea297caef"
      unitRef="usd">333000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30b0955908be463b8c5776e5549bb45f_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNC04LTEtMS0w_f72316c8-7cc2-421e-af3e-d327425ba9ad"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ceec1ef6dce41439e7509d5b3180cde_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS0yLTEtMS0yOTI_bc368c89-8adb-4034-8022-b59d6669616c"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fa63e0b90e04379b97da2756114c4c1_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS00LTEtMS0w_a1483734-00ee-4cc2-9501-fa2b7708a67d"
      unitRef="usd">29000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS02LTEtMS0w_9d0256b5-66e7-4c03-998d-660b44ab1247"
      unitRef="usd">28000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b59c2ca6da04931aec1d8e534792b47_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNS04LTEtMS0w_916b3d93-36d6-4eb2-a7ad-30ed7c163edc"
      unitRef="usd">33000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi0yLTEtMS0w_ff226d55-91ff-4137-8317-4e473ad24400"
      unitRef="usd">4354000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi00LTEtMS0w_502cf42b-ac86-4b1a-b266-33fc226b1026"
      unitRef="usd">67000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi02LTEtMS0w_266db346-07e0-4505-bec0-da94a3bb73a1"
      unitRef="usd">6291000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfNi04LTEtMS0w_f0576b2f-4526-4308-a558-b47012a882b1"
      unitRef="usd">75000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC0yLTEtMS0yOTI_78b49c2b-906b-4327-8cda-c6213296446f"
      unitRef="usd">750000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC00LTEtMS0yOTI_279a478f-52c3-4e88-b920-a46233082ff5"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC02LTEtMS0w_930b9888-3abb-4986-8152-84783bf3f0a7"
      unitRef="usd">943000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOC04LTEtMS0w_0f14397a-c458-4297-9f5d-f9efd54b69c7"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS0yLTEtMS0w_9933d0aa-9db1-4ebb-8c6c-45deb81adef9"
      unitRef="usd">421000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS00LTEtMS0w_a9f55195-b20b-4789-b56c-7bbdf12ca5b8"
      unitRef="usd">152000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS02LTEtMS0w_f4990841-f9d4-44c9-8507-e8e95ec2b4d6"
      unitRef="usd">822000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfOS04LTEtMS0w_b0a96185-4514-48f8-8eeb-2f1ae6619ee0"
      unitRef="usd">267000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtMi0xLTEtMA_7a3ee0cf-b38b-4390-89d7-5e6dfd43e378"
      unitRef="usd">121000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtNC0xLTEtMA_ae2a0458-8736-4e16-aa3c-c1d9c2e0b43a"
      unitRef="usd">37000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtNi0xLTEtMA_6c2a74dc-c5e9-449c-993b-b54dbdb22846"
      unitRef="usd">198000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTAtOC0xLTEtMA_1760bd58-eca2-46c3-bd12-a324689149d8"
      unitRef="usd">61000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtMi0xLTEtMA_f3112cbb-7c32-4557-9b57-d833abb57f59"
      unitRef="usd">1292000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtNC0xLTEtMA_2a4380d4-98b4-47c4-ad74-a332bf1be96d"
      unitRef="usd">189000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtNi0xLTEtMA_37cc6bc6-3334-4ca5-9b8f-dcee386ae63c"
      unitRef="usd">1963000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTEtOC0xLTEtMA_a65cbd7b-3e54-4106-92e1-fdc6d6f18eaf"
      unitRef="usd">328000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItMi0xLTEtMA_dd0705e3-02fe-452b-b229-8fd59a7005bc"
      unitRef="usd">3062000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItNC0xLTEtMA_ddc240c2-6bec-4ef0-a92c-69d09f02ce68"
      unitRef="usd">-122000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItNi0xLTEtMA_19947d1d-48af-458f-9b59-41896a900855"
      unitRef="usd">4328000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTItOC0xLTEtMA_71824254-a8f6-47d3-be5d-4f254de14f7f"
      unitRef="usd">-253000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtMi0xLTEtMA_0998827c-bb0f-4002-8e85-3ed3f85e8a3b"
      unitRef="usd">3000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtNC0xLTEtMA_a1fe42cc-f5e8-4148-b4e4-8a853deb301d"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtNi0xLTEtMA_686f84cd-7852-44bb-a274-f7329372f18b"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTMtOC0xLTEtMA_800a2cf1-c66d-4452-972f-055970cfa889"
      unitRef="usd">15000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtMi0xLTEtMA_4fc3df20-53f1-44d1-a0a0-26a2af4c341d"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtNC0xLTEtMA_5bf3fe17-2819-4257-9004-e692c7f23193"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtNi0xLTEtMA_f0eed281-7e87-4328-99db-4b8d33660c15"
      unitRef="usd">-12000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTQtOC0xLTEtMA_383b4b96-cc39-4683-bea8-08d08188f341"
      unitRef="usd">-3000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtMi0xLTEtMA_aa9ef49e-e0ca-44f5-afe2-67d4302104c9"
      unitRef="usd">3063000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtNC0xLTEtMA_bbd28b0b-ccd0-4f4c-940b-1fa2e0b3a12d"
      unitRef="usd">-117000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtNi0xLTEtMA_6976605d-e5c6-4448-a716-744dd6d5ef71"
      unitRef="usd">4323000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTUtOC0xLTEtMA_b7bb88cc-fcf3-4f31-aa83-342306db7f78"
      unitRef="usd">-241000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtMi0xLTEtMA_f6bfe2ea-3128-4952-8652-8aa321d3fd14"
      unitRef="usd">283000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtNC0xLTEtMA_0acfb741-39c9-4156-9a80-7632f6c1ce5e"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtNi0xLTEtMA_25a6e04c-1ccc-4c28-b18e-0ed5c0a9fe2e"
      unitRef="usd">322000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTYtOC0xLTEtMA_92a903dc-74f3-4b0c-8599-2d8579cd8e6a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctMi0xLTEtMA_27efacf0-90e9-4bb9-b3a4-20a9debe7867"
      unitRef="usd">2780000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctNC0xLTEtMA_dcd84a1b-b945-49a7-a85a-9d595845c217"
      unitRef="usd">-117000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctNi0xLTEtMA_fc5f0ad1-c855-49f3-b31a-330aa3c28591"
      unitRef="usd">4001000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMTctOC0xLTEtMA_af7dbb7f-a161-4180-b0aa-e22f2a49df47"
      unitRef="usd">-241000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtMi0xLTEtMjk4_f7c77a25-cf92-42c4-b0b9-5a6610f66aa6"
      unitRef="usdPerShare">6.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtNC0xLTEtMjk4_c5178212-278c-40dc-8184-0c80249b3d33"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtNi0xLTEtMA_c8eea9bf-7361-4d85-a139-32ffcadeacbb"
      unitRef="usdPerShare">9.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjAtOC0xLTEtMA_d0ec2b6b-e4b6-4372-9ee2-33773d698bc6"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtMi0xLTEtMjk4_1b75f083-45be-4867-96d2-9313805f0c3c"
      unitRef="usdPerShare">6.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtNC0xLTEtMjk4_b46398f1-c675-44ce-8768-516474a9bdb5"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtNi0xLTEtMA_3cec61c5-11b5-428f-9fd1-6682fe8716f2"
      unitRef="usdPerShare">9.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjEtOC0xLTEtMA_642e9a54-7f29-40ae-979d-b8455b71b8a7"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtMi0xLTEtMA_99d549c4-7277-4590-891e-68d071bc23ec"
      unitRef="shares">402000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtNC0xLTEtMA_065bf546-2c38-4e38-b6a5-7537fd21fa9c"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtNi0xLTEtMA_554f6f9e-c3b4-415a-a741-197fa8e70660"
      unitRef="shares">401000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjQtOC0xLTEtMA_0ca7fb71-d418-4b1c-9330-435b8bcc8661"
      unitRef="shares">367000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtMi0xLTEtMA_cce09205-2f69-4415-b3ec-ad8d2c82ce92"
      unitRef="shares">431000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtNC0xLTEtMA_f945db6b-a3f5-4d40-991b-bbc082483783"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtNi0xLTEtMA_d7f9d6b6-a4a8-430d-a56c-d5ddc0bd1130"
      unitRef="shares">430000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8xOS9mcmFnOjgxMDFmMTZmOTllMTQzOWNhM2IwYWFkMGRkMGU0NTJhL3RhYmxlOjFjMWVkZTIzMzc1YjRlYTc4NWQ5MGI2ZWQ3OGRkNzlmL3RhYmxlcmFuZ2U6MWMxZWRlMjMzNzViNGVhNzg1ZDkwYjZlZDc4ZGQ3OWZfMjUtOC0xLTEtMA_32b33e31-3a17-4a4d-a39b-3ae311bb66f9"
      unitRef="shares">367000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi0yLTEtMS0zNzQ_8688f8ee-709b-421f-b8ad-2d2b71b3481d"
      unitRef="usd">2780000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi00LTEtMS0zNzQ_68d4d602-12fa-4ce6-b699-2d2471523ab8"
      unitRef="usd">-117000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi0xLTEtMS0w_b51b98fd-45fc-408e-9f14-406c53b5cc02"
      unitRef="usd">4001000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfMi0zLTEtMS0w_5a1b4be2-56cd-4a43-9fdc-2a6318247b2b"
      unitRef="usd">-241000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC0yLTEtMS0zNzc_6b2eae84-b5bb-4b03-a4a7-1d0b9795c09b"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC00LTEtMS0zNzc_4aa60390-512e-4c81-87a6-b6cb6bee46d2"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC0xLTEtMS0w_62a2e42c-df88-41ca-ad6c-619c82ac58a2"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNC0zLTEtMS0w_8edbcef9-6cec-4c6d-867d-7f0adf58c297"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0yLTEtMS0zMjgz_d8ba97da-83b2-4dc0-a7e8-4cb0237c0b3d"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS00LTEtMS0zMjgz_23ca80cb-1f3e-4bb7-90a1-e2eedd834467"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS02LTEtMS0zMjg3_67ff2acf-382d-4633-b19c-5fa8477d5c29"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS04LTEtMS0zMjg3_5e139161-8d36-4208-b9ab-808e49ff7686"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy0yLTEtMS01NTg1_3628a6fb-837c-4fef-aa82-40b8361c726e"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy00LTEtMS01NTg3_be8ac990-75ee-4886-8c27-40873e20cca9"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy02LTEtMS01NTg5_eed2b67c-5bb0-4cb2-8360-361d536bb27e"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNy04LTEtMS01NTkx_951b2e53-e01f-45c7-bbd0-c52a9425505f"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC0yLTEtMS01MDUw_cbbdf2f4-1a66-4f4d-a9a4-1ecdd06f053a"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC00LTEtMS01MDUy_812f72eb-a4c2-4f1e-b949-58ed884940c9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC02LTEtMS01MDU0_24fb6caf-115d-4398-b072-3962d7fc32a2"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfOC04LTEtMS01MDU2_5db50faa-2385-4c06-9e6d-c7ca752b1a43"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi0yLTEtMS0zMjgz_d4289b70-dda1-4070-b971-da5e76b5dd7b"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi00LTEtMS0zMjgz_2724ccf9-de09-4c59-b9ba-e9b893e50c46"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi02LTEtMS0zMjg3_6702f6fc-3a16-4d23-b01e-8140bcae47cf"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNi04LTEtMS0zMjg3_b47b0a7e-84ab-45a7-8b5e-7948e6fc0117"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0yLTEtMS0zODE_15eaa164-7d84-4e4b-af99-3764cc381077"
      unitRef="usd">2795000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS00LTEtMS0zODE_bc819166-6d60-4fdf-92cb-9db5a3b66b54"
      unitRef="usd">-103000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0xLTEtMS0w_1571899c-4bae-41bc-9a03-d7ee349571d3"
      unitRef="usd">4014000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yMi9mcmFnOjVjZjQ4NWVlNDJlNTQwM2M4MmZlNDMzMTNjODk3YjBkL3RhYmxlOmNmOTI2ZDMxMDY3OTQyNGFhZjVlNDc1MDBkY2I3YjI0L3RhYmxlcmFuZ2U6Y2Y5MjZkMzEwNjc5NDI0YWFmNWU0NzUwMGRjYjdiMjRfNS0zLTEtMS0w_8f40b43b-a5ef-40ea-b9ad-2bf2fc105067"
      unitRef="usd">-235000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ied43d05ce83c48a9b037a38e01ad51ae_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi0xLTEtMS0w_52fe441b-b838-43da-b289-d01b5aa569df"
      unitRef="shares">401000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ied43d05ce83c48a9b037a38e01ad51ae_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi0zLTEtMS0w_fe2ce9fe-5bfc-4352-9ac9-8999da2c84a6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07f544975bf44f01aaf6cd6152d44f8a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi01LTEtMS0w_220eb139-8c7a-470e-acc1-47ae666700b2"
      unitRef="usd">4860000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id896a91ec74c4c49abdf78c300d13ca0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi03LTEtMS0w_ee75950c-db77-49a9-bc77-f71304192e12"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifeb94c429e024fb093ce6d4d944055ef_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi05LTEtMS0w_5d8a1c88-404c-4e0f-be9c-f7385a9cba13"
      unitRef="usd">-1023000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i467f5e1c5b0a40dfb2090010d28b95ad_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfMi0xMS0xLTEtMA_e2594549-b7e1-4594-a476-2b0a2a535d1f"
      unitRef="usd">3838000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5da83908729448ee8a41870859147a93_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNC0xLTEtMS0w_84cdc574-4aab-4cc9-af31-27ae97779884"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i517010db08264600b828770102838edd_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNC01LTEtMS0w_a31a80b3-500f-46f8-835d-00c8f22e9259"
      unitRef="usd">31000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNC0xMS0xLTEtMA_9562cd19-7f85-4968-bea1-00e58f002c62"
      unitRef="usd">31000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i517010db08264600b828770102838edd_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS01LTEtMS01MDY1_d16ebb62-392e-46ae-9143-eebac16c1df0"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS0xMS0xLTEtNTA3MQ_bdba4b8b-63ee-4f81-834f-730ccedc6510"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i517010db08264600b828770102838edd_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS01LTEtMS0w_6a7abf43-8009-4c85-8f74-0a9c08360f86"
      unitRef="usd">35000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNS0xMS0xLTEtMA_0c73b95e-76a7-47e6-a7e4-03f4bd8b5b78"
      unitRef="usd">35000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i02e7d1bca5614fa89de0a1a5b33cbe8c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNi03LTEtMS0w_5a5bb92f-94a5-40a4-860a-826f35b65ab4"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNi0xMS0xLTEtMA_667ae553-4d5d-40a6-aad1-22200dd7470a"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i4e8320dc990645e7b4e723cd26fb61f1_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNy05LTEtMS0w_f55cea93-d9bb-4254-b149-98e3463fa60c"
      unitRef="usd">2780000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfNy0xMS0xLTEtMA_dd69bbe5-86af-4d83-89b3-2d1134069039"
      unitRef="usd">2780000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC0xLTEtMS0w_dbe7393b-fae7-485a-bb12-1e60d8acc8c6"
      unitRef="shares">403000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC0zLTEtMS0w_a69cb78d-1e84-494b-a114-fc39d2b40250"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9332a7030408410190b1a94c2e713ebe_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC01LTEtMS0w_cc660768-339c-437c-8d8f-5b93eb0f3b76"
      unitRef="usd">4931000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC03LTEtMS0w_91708dd2-ac80-46ea-adf3-735c423e4136"
      unitRef="usd">16000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45d1c7922a0f42a1a5569a02e65e170a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC05LTEtMS0w_bb45df16-62c4-43fe-9019-1fa4ae4b8e83"
      unitRef="usd">1757000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjFhYzg2NGEzYzIyNzQ1ZDZhYTFiMjcwMjYyNGM1OTk0L3RhYmxlcmFuZ2U6MWFjODY0YTNjMjI3NDVkNmFhMWIyNzAyNjI0YzU5OTRfOC0xMS0xLTEtMA_24bb2ffc-f1f5-416c-82af-1c40176cdc07"
      unitRef="usd">6704000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ia81e9a8c1ff44ada911a7e8db3a243c4_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi0xLTEtMS0w_bd65e2c1-13ea-4f7d-8811-2646ddf6b328"
      unitRef="shares">370000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia81e9a8c1ff44ada911a7e8db3a243c4_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi0zLTEtMS0w_96c8c7f4-6dc7-4520-bdb1-445a05ba3369"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9860610904e425f9bd0ba4654cee9f2_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi01LTEtMS0w_b4453692-235a-40a4-835d-33bab2bcd3cc"
      unitRef="usd">3268000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91bd58e1ce80434ba54c3ba11fd4e041_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi03LTEtMS0w_f402480f-3a04-4f8e-a28d-38d5ee9a2668"
      unitRef="usd">-6000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b07a5c1b08c47c18dde953f4df74a85_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi05LTEtMS0w_e11199c6-9057-4b99-8036-1718ecea3a35"
      unitRef="usd">-1621000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb708f43d5464f4e98cee5a3f7031313_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMi0xMS0xLTEtMA_464f563b-010e-446d-bd8c-3d452c0048a9"
      unitRef="usd">1641000000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy0wLTEtMS0wL3RleHRyZWdpb246MDZiOTM1N2M5ZWUxNDYzMmIyODJjNzg4OGNhYWRlNmNfMzI5ODUzNDg4MzQwNw_19b5eaff-6ba5-43b5-b9c0-fb0f73e96715"
      unitRef="usd">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i54b175b3a826401ba7e904fd9486fa43_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy0xLTEtMS0w_c6d9e726-ffa9-4aa1-b136-cf3a6971056b"
      unitRef="shares">18000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy01LTEtMS0w_ea4490cb-d6e2-45e1-8120-246f0175b2d0"
      unitRef="usd">1303000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfMy0xMS0xLTEtMA_17610344-063d-4539-b02d-ca2ce33494b8"
      unitRef="usd">1303000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i54b175b3a826401ba7e904fd9486fa43_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNS0xLTEtMS0w_a2456fbc-5d73-4a96-a2e4-f30f84eab10d"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNS01LTEtMS0w_a0c84763-ae3b-4ac0-bbdd-dc7263a88a8e"
      unitRef="usd">78000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNS0xMS0xLTEtMA_75427a13-954a-4e18-9104-11e3abfd7147"
      unitRef="usd">78000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi01LTEtMS00OTY_8fb25eeb-f395-4eb8-a577-0aad5feeea4f"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi0xMS0xLTEtNDk2_e9e64730-5032-4e86-8d29-64a4be252fc1"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id454323ad0714cbf9e5f59f2d2fb2eca_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi01LTEtMS0w_40151ee3-eeb8-4314-957c-3f4b116141f4"
      unitRef="usd">25000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNi0xMS0xLTEtMA_f655ec1d-a822-4a46-a937-78b6d168d57d"
      unitRef="usd">25000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3283b392eff2465faad3fdbe829de638_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNy03LTEtMS0w_0f9fde6a-0e77-4a3e-b5e1-4d13cc782d8c"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfNy0xMS0xLTEtMA_8735f562-60ce-4304-a232-8bc1657c21ef"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i653c8891e96b4e798b795df5d797ffda_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOC05LTEtMS0w_9f326034-5ec4-46c9-8d83-d78b77002634"
      unitRef="usd">-117000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOC0xMS0xLTEtMA_7c8b064d-5b36-4440-acf4-bec4a90a1920"
      unitRef="usd">-117000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS0xLTEtMS0w_e5e74a4c-7976-4a7e-9ca9-7e58bdd28fa4"
      unitRef="shares">393000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS0zLTEtMS0w_d3c657c9-fe2b-460e-9d95-22ae517c318f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b68d04a23384807b92fd3080ce4ad8d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS01LTEtMS0w_ed2f43e2-d6ca-4f00-9aaf-a91c8df429e2"
      unitRef="usd">4677000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69519acdcd484f7baf0aee01a833d455_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS03LTEtMS0w_5f8476f6-89d6-4f0a-9e7a-c3ca15c46e4f"
      unitRef="usd">8000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icc0ffd1101054ceaa3de2c3ffbcef1e4_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS05LTEtMS0w_6d1ee37b-4684-4bf0-9a3a-a5021f185f77"
      unitRef="usd">-1738000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifae9686943f64febad60646379a0b1cb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjc0ODAwYzEwZDBhMDRkNjNiOWE4ZDZmZmEwMTY2MjA0L3RhYmxlcmFuZ2U6NzQ4MDBjMTBkMGEwNGQ2M2I5YThkNmZmYTAxNjYyMDRfOS0xMS0xLTEtMA_dadbbc86-9b7c-4bcd-844b-ebdd3711cacc"
      unitRef="usd">2947000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i488b334a3ef64d4caa66debe5db19d8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi0xLTEtMS01MDc_40da2eda-80a0-4ca9-a3c4-f28e5bf3b02e"
      unitRef="shares">399000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i488b334a3ef64d4caa66debe5db19d8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi0zLTEtMS01MDc_f08b0073-866d-46a1-a772-3e630faea50f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c08244b023c40ca9fc941a3e60c2c56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi01LTEtMS01MDc_0624d997-0ce0-46f8-83cd-1ad05d30a4f6"
      unitRef="usd">4802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0ef651667664c27bc69872dd1d33b05_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi03LTEtMS01MDc_8997375b-3721-4b19-8230-2dbd4a7e8f26"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ade9ccbd9704bd7b8ea5b560ac9b3d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi05LTEtMS01MDc_42628d9b-7643-4aea-a423-35143c14e294"
      unitRef="usd">-2244000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfMi0xMS0xLTEtNTA3_5bcad91f-03b5-4bc5-987f-da2cdedc85fe"
      unitRef="usd">2561000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie8d9d0afe13d46efb8ad43cfe9cc5715_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNC0xLTEtMS01MTE_0056358f-988a-4615-b60b-ca0addf79f4f"
      unitRef="shares">4000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNC01LTEtMS01MTE_83edd3f0-b2a2-4bec-bf3c-7611d728767c"
      unitRef="usd">59000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNC0xMS0xLTEtNTEx_5a54ebbf-bacf-41df-aff7-3324fcb27f6a"
      unitRef="usd">59000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS01LTEtMS01MDc3_b00485ee-1a20-4af0-b1c5-691529a1f13a"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS0xMS0xLTEtNTA4Mw_051345a0-701c-4c47-b7e7-04e14e303126"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1ddd59e22f5431fb185c13cfccfa438_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS01LTEtMS01MTQ_142c7dd9-6ef6-4479-ac51-447eeb7805bf"
      unitRef="usd">65000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNS0xMS0xLTEtNTE0_a27d584b-60c4-4699-a0eb-bcdd6b790df1"
      unitRef="usd">65000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4d47127223a64d2fb9cd36c959441e94_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNi03LTEtMS01MTQ_5fa8f284-2485-4306-bfad-a6bd990dac54"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNi0xMS0xLTEtNTE0_79534314-458f-4cd5-b287-a1edb40a6cc1"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ife42851a7eda4b4f941a44f0037477f0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNy05LTEtMS01MTQ_6faeddc4-1638-43df-8cc9-00cc62716dad"
      unitRef="usd">4001000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfNy0xMS0xLTEtNTE0_2554e4ac-2421-46c6-a003-5862ec83467f"
      unitRef="usd">4001000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC0xLTEtMS01MTQ_c0d5cf88-a4b6-41e7-ba3d-00981fdf0154"
      unitRef="shares">403000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7fbd8f78cd0e428ea2178ceddea1426a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC0zLTEtMS01MTQ_d3cbffed-69e5-43d0-981b-e9edc5d1f69b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9332a7030408410190b1a94c2e713ebe_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC01LTEtMS01MTQ_39d0619d-f6b4-4b5c-8f5f-e3c485aa9132"
      unitRef="usd">4931000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC03LTEtMS01MTQ_43ababd5-6b2d-4d76-8e93-807e714f1af6"
      unitRef="usd">16000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45d1c7922a0f42a1a5569a02e65e170a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC05LTEtMS01MTQ_42d1692c-4ae2-4605-91c7-0465e9753741"
      unitRef="usd">1757000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjUyOTcyMTdjOWMzYzRjMWNiYTkxNjQ0ZjEwZTdkMGNlL3RhYmxlcmFuZ2U6NTI5NzIxN2M5YzNjNGMxY2JhOTE2NDRmMTBlN2QwY2VfOC0xMS0xLTEtNTE0_0721906f-5179-462b-b98d-9b0918a2933c"
      unitRef="usd">6704000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi0xLTEtMS01MTg_c0b72622-2c4f-4469-a59d-b2a61d675ac6"
      unitRef="shares">337000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi0zLTEtMS01MTg_e148bbb5-8f2c-4d57-b390-397ab083b612"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5b4459de21243118082e0ace346a32f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi01LTEtMS01MTg_1304f07b-33de-41bf-9952-8d099e08d5df"
      unitRef="usd">2670000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc39f92f55eb4e0a806e6264b2267ee7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi03LTEtMS01MTg_8f7a5100-bf81-4288-be67-0e8795b80d80"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0b7a4b2f73947ee99915fb30be8e619_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi05LTEtMS01MTg_c248ec37-5725-43ee-9f03-43d5db1e9a24"
      unitRef="usd">-1497000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae5f72aaadd64959816335e7e8bf64f0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMi0xMS0xLTEtNTE4_747bafbb-fe8e-4f3b-89fd-d088ded872e9"
      unitRef="usd">1175000000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy0wLTEtMS00NDAvdGV4dHJlZ2lvbjo5MTFjOWIzOTQ4ODI0MTg5ODMwM2NjYmY5YjA1MTgxM18zMjk4NTM0ODgzNDA3_f361b7c0-c870-4aea-a211-de1ad872b3df"
      unitRef="usd">2000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifd50a086b08a418189feb030cb4bdb1b_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy0xLTEtMS01MTg_bba1efbb-16ca-43a5-87ea-c45783096a3b"
      unitRef="shares">48000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy01LTEtMS01MTg_5834c929-791a-4d84-a07c-8a1b7973f907"
      unitRef="usd">1853000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMy0xMS0xLTEtNTE4_61711b4c-c791-42d9-8bbc-3f72fa1b0c71"
      unitRef="usd">1853000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifd50a086b08a418189feb030cb4bdb1b_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNS0xLTEtMS01MTg_c32dd1b7-7b6a-4bcd-ac0d-120da26fc401"
      unitRef="shares">8000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNS01LTEtMS01MTg_452a2760-885e-41cb-b046-d72942abc517"
      unitRef="usd">106000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNS0xMS0xLTEtNTE4_b8806568-4096-4b45-9ff1-15b2c0aaa7f8"
      unitRef="usd">106000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNi01LTEtMS01MjM_0afed116-bba8-48a2-bcf1-7867c449a558"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNi0xMS0xLTEtNTIz_2f8aba3e-1dcf-4cb1-be91-18bf8942a824"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie54592b591bd49c48e564d5634910480_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNy01LTEtMS01MjM_9ce2b11b-5246-4194-a327-ffe4343b38eb"
      unitRef="usd">45000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfNy0xMS0xLTEtNTIz_08f140fa-0be4-4b8f-b40e-707646a76605"
      unitRef="usd">45000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie9715f2b13dc4d9a9876fb015b5eb0d2_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOC03LTEtMS01MjM_c2c47b14-9c61-45d5-8118-503e29fcc4a7"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOC0xMS0xLTEtNTIz_8f556165-8205-4a50-86b4-fec59b17dfb1"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i7dbeca61b931429a9ecce401a75b9228_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOS05LTEtMS01MjM_837a3566-aa4f-4b43-8819-b19119a6df06"
      unitRef="usd">-241000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfOS0xMS0xLTEtNTIz_ea82f8e7-6df0-4961-8ac6-68fe850de469"
      unitRef="usd">-241000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtMS0xLTEtNTIz_50b77336-6ce1-4f42-b766-21a65c264b63"
      unitRef="shares">393000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if21af94b32274ca2bc5f281d8b91964d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtMy0xLTEtNTIz_40e9c5eb-fa95-4f3b-aee8-fabe33f6fb77"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b68d04a23384807b92fd3080ce4ad8d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtNS0xLTEtNTIz_8f7d0313-6358-40c5-8fb3-b765b288471a"
      unitRef="usd">4677000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69519acdcd484f7baf0aee01a833d455_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtNy0xLTEtNTIz_7dde1c52-ebb2-4434-9c0a-ca08fa202d68"
      unitRef="usd">8000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icc0ffd1101054ceaa3de2c3ffbcef1e4_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtOS0xLTEtNTIz_ab230a08-f957-4dd1-9337-88cd85c2f353"
      unitRef="usd">-1738000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifae9686943f64febad60646379a0b1cb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yNS9mcmFnOmI0NzBjODBjZGVlZjRiYjA4Y2RlNjkwMzg1MTgyNjQ1L3RhYmxlOjY0ZmY0MmY3OGVmMDRmZWQ4MzYwYjQzZGVhNTU4YzNjL3RhYmxlcmFuZ2U6NjRmZjQyZjc4ZWYwNGZlZDgzNjBiNDNkZWE1NThjM2NfMTAtMTEtMS0xLTUyMw_7bc5643c-67a6-43da-9f53-63b94dd98da8"
      unitRef="usd">2947000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMy0xLTEtMS0w_1af6e503-61f3-4f70-b3bf-4c7104956a62"
      unitRef="usd">4001000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMy0zLTEtMS0w_00f986fd-a154-4e5d-ae0a-ecd7e0270dfb"
      unitRef="usd">-241000000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNS0xLTEtMS0w_c4220ba0-1dcf-4e88-b387-40fa77cf957f"
      unitRef="usd">65000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNS0zLTEtMS0w_eb4c437d-4055-4b2b-a9f4-9d68591dd149"
      unitRef="usd">45000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNi0xLTEtMS0w_d0f8c245-9550-483f-b8a3-52c0eba196bd"
      unitRef="usd">84000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNi0zLTEtMS0w_28146763-ac55-4485-bdca-777e102540d8"
      unitRef="usd">15000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNy0xLTEtMS0w_03bcac82-1cbe-45d6-b367-5558183b60a2"
      unitRef="usd">-13000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfNy0zLTEtMS0w_39401852-c1e0-4dbf-acca-12e7cd79beca"
      unitRef="usd">-2000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfOS0xLTEtMS0w_d38ad934-bb74-48d7-bdad-695a73fb2b1b"
      unitRef="usd">-72000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfOS0zLTEtMS0w_8a5664ea-13a0-48bd-98eb-c1bd00689224"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTEtMS0xLTEtMA_aa190a58-d4e5-475c-bcad-d9c14d5c5d8f"
      unitRef="usd">629000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTEtMy0xLTEtMA_a857149f-7bbb-4a77-91f4-8ac36fa25519"
      unitRef="usd">28000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTItMS0xLTEtMA_d3279857-1f4e-4021-aa51-e5e2541d1dad"
      unitRef="usd">110000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTItMy0xLTEtMA_9cb42928-f3db-4764-a439-b4eec60e6fac"
      unitRef="usd">12000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTMtMS0xLTEtMA_6bc63e1c-2d36-4599-81b8-9e2a54a0b23e"
      unitRef="usd">596000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTMtMy0xLTEtMA_0adeffa0-0e72-4455-959c-e93a42dfb452"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTQtMS0xLTEtMA_b40e1d12-c321-48d1-b0e6-ca61e47a694c"
      unitRef="usd">14000000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTQtMy0xLTEtMA_ced72495-8a1b-4116-ace7-3b1a6fc60286"
      unitRef="usd">12000000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTUtMS0xLTEtMA_a63c302f-3d92-41f5-b948-106e52bea283"
      unitRef="usd">44000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTUtMy0xLTEtMA_6935dd24-15e7-4a3a-9b6f-05f7f4a15027"
      unitRef="usd">12000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTYtMS0xLTEtMA_ef4c5fab-ac6e-4410-9775-9f646758c757"
      unitRef="usd">367000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTYtMy0xLTEtMA_26350cd1-2438-4766-a927-e0b03e3e51de"
      unitRef="usd">20000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTctMS0xLTEtMA_a17b1fad-7745-4233-9e0e-65d4de1272f4"
      unitRef="usd">3433000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTctMy0xLTEtMA_e0dd970f-d3ff-4115-883d-19361395f7b3"
      unitRef="usd">51000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mrna:OperatingLeaseLiabilities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTgtMS0xLTEtMA_376e7498-5523-4802-8752-d9ad46275342"
      unitRef="usd">8000000</mrna:OperatingLeaseLiabilities>
    <mrna:OperatingLeaseLiabilities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTgtMy0xLTEtMA_48f0f868-4d73-48ea-ac84-9d9e18d68a8f"
      unitRef="usd">14000000</mrna:OperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTktMS0xLTEtMA_c3313f00-c1d2-455a-8402-597c4cd6dbdf"
      unitRef="usd">440000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMTktMy0xLTEtMA_de297d50-3ba9-402c-aa8c-782609d6217c"
      unitRef="usd">4000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjAtMS0xLTEtMA_fc0f28b9-f870-427e-b93b-03d94d7e5405"
      unitRef="usd">7034000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjAtMy0xLTEtMA_cbcaad8c-3d02-4d03-b712-dc388ee464ab"
      unitRef="usd">-130000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjItMS0xLTEtMA_37d22eca-73c4-4be9-b296-606e1bdb9cc6"
      unitRef="usd">6559000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjItMy0xLTEtMA_bd7363fc-ee52-48f1-b2d4-40e41980159e"
      unitRef="usd">903000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjMtMS0xLTEtMA_3b45d70c-fcd1-4dfd-9963-dc0acbde8729"
      unitRef="usd">860000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjMtMy0xLTEtMA_fdabeb2d-6059-4275-b0a4-140d4558a1c9"
      unitRef="usd">517000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjQtMS0xLTEtMA_19a271b6-2408-4876-b54f-c7e6abd6f2d7"
      unitRef="usd">1706000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjQtMy0xLTEtMA_c887aa3b-1df2-427a-b7cf-1ea9da5bab38"
      unitRef="usd">108000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjUtMS0xLTEtMA_4ac1371a-34f9-4b20-9bb0-81472764eac1"
      unitRef="usd">65000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjUtMy0xLTEtMA_e6936ebe-108b-4009-9672-75f94c322b9f"
      unitRef="usd">25000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjYtMS0xLTEtMA_3a9b63b5-8b17-48b6-a4cb-f408ebc1dc7d"
      unitRef="usd">-4058000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjYtMy0xLTEtMA_3313b765-a586-42de-a953-d039c3f2ab86"
      unitRef="usd">-303000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjgtMS0xLTEtMA_59ba160d-62c0-41a9-936f-032e7dfcb5ab"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjgtMy0xLTEtMA_67ac509f-2418-4b9c-83b1-bb5f2a6c5449"
      unitRef="usd">1853000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjktMS0xLTEtMA_4f764a1f-2aa8-4ab3-9a3f-f0996a3142ce"
      unitRef="usd">64000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMjktMy0xLTEtMA_87d7f341-b925-4e48-b410-53cf6d00e2c5"
      unitRef="usd">106000000</us-gaap:ProceedsFromStockPlans>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzEtMS0xLTEtMA_e4d535c5-de93-4061-b20a-da0b0ff5f856"
      unitRef="usd">-62000000</mrna:ChargesToFinancingLeaseLiabilities>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzEtMy0xLTEtMA_9a936d08-c239-4ff3-b177-ae3439f5c615"
      unitRef="usd">0</mrna:ChargesToFinancingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzItMS0xLTEtMA_4954874d-6dab-4128-bad1-0259b45dabae"
      unitRef="usd">2000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzItMy0xLTEtMA_048b25f5-9799-4564-9a6d-f783dc54bb20"
      unitRef="usd">1959000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzMtMS0xLTEtMA_a0af078b-b3e1-4152-8b90-e44fa023a6c2"
      unitRef="usd">2978000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzMtMy0xLTEtMA_2dda383d-eccd-4bc9-9a13-2d2172194f5f"
      unitRef="usd">1526000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzQtMS0xLTEtMA_779cd44e-2e89-4272-aead-01f07d4cfebd"
      unitRef="usd">2636000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iae5f72aaadd64959816335e7e8bf64f0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzQtMy0xLTEtMA_2461df94-7dc2-49ec-8e66-f62a8a703935"
      unitRef="usd">248000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzUtMS0xLTEtMA_bcde6739-5e8d-4a13-bf99-470c3301a4df"
      unitRef="usd">5614000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifae9686943f64febad60646379a0b1cb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzUtMy0xLTEtMA_479bcc41-0cdd-4056-a423-a180f09a7e7d"
      unitRef="usd">1774000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzctMS0xLTEtMA_5b1a541e-f7b4-4062-8913-528129c15e33"
      unitRef="usd">45000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzctMy0xLTEtMA_c2e6de98-9a0a-4f71-bb21-ec2ef9a0fa15"
      unitRef="usd">9000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzgtMS0xLTEtMA_5f8a777a-734d-480e-a8fe-74acdbc7593d"
      unitRef="usd">363000000</mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzgtMy0xLTEtMA_98b51117-9f4a-4f64-821d-4749bcc0fe8d"
      unitRef="usd">14000000</mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzktMS0xLTEtNzIwNw_8486a060-547a-4b0e-b27a-e5bb9dc66eab"
      unitRef="usd">126000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8yOC9mcmFnOmE3MDhjY2U0ZmZlZTRlZmZiY2NlZTM2YzM0OTk5OTk1L3RhYmxlOmY4ZjJkMDRmZGMzOTQzZTY4ZTlhNjhjNThlMzg1YzQ0L3RhYmxlcmFuZ2U6ZjhmMmQwNGZkYzM5NDNlNjhlOWE2OGM1OGUzODVjNDRfMzktMy0xLTEtNzIyOA_ee08b805-7e3d-443c-ab59-948610efcbef"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8zNC9mcmFnOjRhMGQzMjY3OTJhODQyMTQ4ZGM4YWVhOTFhNDM2MTQyL3RleHRyZWdpb246NGEwZDMyNjc5MmE4NDIxNDhkYzhhZWE5MWE0MzYxNDJfMzcyMw_6696612d-aac9-454a-997e-6e94a4d630ad">Description of the Business&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#x2019;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in more than 50 countries and from the World Health Organization. Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the European Union and Japan and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. On June 1, 2021, we initiated the rolling submission process with the U.S. FDA for a Biologics License Application for our COVID-19 vaccine, and we currently anticipate completing our submission in August 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of June 30, 2021, we had 24 mRNA development programs in our portfolio with 14 having entered the clinic. We have incurred significant expenses in connection with the discovery, development and commercialization of our products, and we expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with the ongoing development and commercialization of our COVID-19 vaccine and ongoing activities to support our platform research, drug discovery and clinical development, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, infrastructure and Research Engine and Early Development Engine (which includes our Moderna Technology Center), digital infrastructure, creation of a portfolio of intellectual property, and administrative support. We may finance our future cash needs that exceed our operating costs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our cash, cash equivalents, and investments as of&#160;June 30, 2021&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of these financial statements. We are subject to numerous risks and uncertainties associated with pharmaceutical development and commercialization, and we are unable to predict the timing or amount of expenses or if we will be able to maintain profitability. If we are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <mrna:NumberOfDevelopmentProgram
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8zNC9mcmFnOjRhMGQzMjY3OTJhODQyMTQ4ZGM4YWVhOTFhNDM2MTQyL3RleHRyZWdpb246NGEwZDMyNjc5MmE4NDIxNDhkYzhhZWE5MWE0MzYxNDJfMTg0NA_ceffccd4-9e16-47ab-83cc-b958bf261890"
      unitRef="program">24</mrna:NumberOfDevelopmentProgram>
    <mrna:NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV8zNC9mcmFnOjRhMGQzMjY3OTJhODQyMTQ4ZGM4YWVhOTFhNDM2MTQyL3RleHRyZWdpb246NGEwZDMyNjc5MmE4NDIxNDhkYzhhZWE5MWE0MzYxNDJfNDM5ODA0NjUxODA4Nw_f61e1dbf-09e3-490c-8efc-1eece58a3a05"
      unitRef="clinic">14</mrna:NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg2Ng_137fa1b7-98f8-402c-befd-b7f37db9606b">Summary of Basis of Presentation and Recent Accounting Standards&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2021 are consistent with those described in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains/losses and gains/losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income for the three and six months ended June 30, 2021 were as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Unrealized Gains on Derivatives Designated As Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;br/&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg3OA_507da3f6-9533-4f97-a80d-ac6924d0073d">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg3Mg_4ab56b16-8d1d-4f24-8f23-5c32e92be0a4">The condensed consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1OQ_931b62f3-fa08-42ae-bd37-f7477609606e">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg3NQ_94ced9cb-6080-4220-b9a4-f0e72e178149">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains/losses and gains/losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg2MQ_5e54bd78-4985-494e-a3f0-90d30ba35dba">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income for the three and six months ended June 30, 2021 were as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Unrealized Gains on Derivatives Designated As Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i60ed33a973974be78cf5fb2ffa1a2b11_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMS0xLTEtMS0w_92593f84-ad25-41fd-9e25-ad58c09fe97a"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecd1d9442a7b4754a406bff7a39e5fd3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMS0zLTEtMS02MTgz_765cca95-af7f-44db-b290-3f3b52907da1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0ef651667664c27bc69872dd1d33b05_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMS01LTEtMS03NzI5_58f1b0cb-408d-4966-95bd-b4bf33cd5e71"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i157887d3dcbd422db9ab258078ee14a9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMi0xLTEtMS0w_3fc3aa7f-4f44-4ec2-817f-21402c5cf9df"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iec75ac0ff6b94c738a5f8719561f6104_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMi0zLTEtMS02MTgz_8c23a697-cbc0-4c00-862a-a663e107850b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia96c0176d8aa4d39a5da077d3b371b0d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMi01LTEtMS03NzI5_c245e6c4-6c69-4eca-8c00-629c2d99c700"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i122512b403f742038c2c1468c00fb915_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMy0xLTEtMS0w_9127360a-9927-443c-96d9-cda7507b031f"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6fdf15d391e54159b27e230febc1be1f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMy0zLTEtMS02MTgz_53ae6a97-b222-4996-bf25-5354d76f1e7c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id896a91ec74c4c49abdf78c300d13ca0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfMy01LTEtMS03NzI5_39860487-c1e5-48f3-b08c-1518f26da064"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if05aff14929149cab57fd79aefeeeb56_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNC0yLTEtMS02MDc_e4f7b211-f10e-486c-8095-f63fb64fe5b5"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i12aafa2a5b1746a4984dfb62d34e42da_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNC0zLTEtMS02MTgz_f0e4102f-c6bd-4666-8f86-47a1adeb5fdd"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNC01LTEtMS03NzI5_2a421e43-9f31-4aad-baa8-2ccada744c83"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ib627f3fa58de490c92d72c00c79d72c4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNS0yLTEtMS02MDc_b27e04e9-a09a-4977-8259-971f5485bac7"
      unitRef="usd">-5000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c6c5bf45d0d43ac9807ba42e62b7367_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNS0zLTEtMS02MTgz_ab6194da-fc83-4103-91e0-544cbdcd71fb"
      unitRef="usd">21000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i058f8b0933d44ff7830cc5ab92c8d5f6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjBlODk3NzUwOGEyNjQwYzZhNWNiODZiMDNiOTg5YTVkL3RhYmxlcmFuZ2U6MGU4OTc3NTA4YTI2NDBjNmE1Y2I4NmIwM2I5ODlhNWRfNS01LTEtMS03NzI5_1506763f-2bf4-491d-a9e1-823fa4a4d926"
      unitRef="usd">16000000</us-gaap:StockholdersEquity>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1Mg_63488fb4-2ab4-4635-9082-2967cf3b7566">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1OA_a1690b51-e64a-4a60-9f47-100655549ba9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;br/&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg2Nw_fea42f0c-6396-4428-a702-4ca8c26804f3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;br/&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMi0yLTEtMS0w_6309d699-b470-4c16-8798-d07ef5372c17"
      unitRef="usd">5603000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifae9686943f64febad60646379a0b1cb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMi00LTEtMS0w_b9268708-890b-4479-a935-480cada72e29"
      unitRef="usd">1762000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMy0yLTEtMS0w_9afd3e36-6104-4559-8bbb-525f9eea245e"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ifae9686943f64febad60646379a0b1cb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfMy00LTEtMS0w_1388ad5f-027e-4c57-8e34-8d75dc54c228"
      unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNC0yLTEtMS0w_73189ae8-c729-43b7-b3c8-1d29d876dcae"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ifae9686943f64febad60646379a0b1cb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNC00LTEtMS0w_e6c9821c-e761-46d0-ac7c-cafe6da7c803"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNS0yLTEtMS0w_d3ea4811-ee6f-4818-a6ef-31070900535f"
      unitRef="usd">5614000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifae9686943f64febad60646379a0b1cb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RhYmxlOjlkNWI4YzM2YWJkZDQyY2Y5YzlhYmFjYzNiMzJhYWIyL3RhYmxlcmFuZ2U6OWQ1YjhjMzZhYmRkNDJjZjljOWFiYWNjM2IzMmFhYjJfNS00LTEtMS0w_8de06991-9ef2-4d87-87f0-fb6aa6f2873a"
      unitRef="usd">1774000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80MC9mcmFnOjU3YmI0MDdhNGZhMzQwYTY5NmI1NmUzNGJjNDBjMWQzL3RleHRyZWdpb246NTdiYjQwN2E0ZmEzNDBhNjk2YjU2ZTM0YmM0MGMxZDNfMzg1NQ_b9b49c76-4af7-4970-b98b-09b7b3c43bbf">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfMTA2NA_cd31e7b1-1d85-45a2-afbd-9d2aef79d3c3">Product Sales&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by customer geographic location was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no product sales for the three and six months ended June 30, 2020. As of June 30, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and December 31, 2020, we had deferred revenue of $7.2 billion and $3.8 billion, respectively, related to customer deposits, classified as current deferred revenue in our condensed consolidated balance sheets. Timing of product manufacturing, delivery, and receipt of marketing approval will determine the period in which revenue is recognized.&lt;/span&gt;&lt;/div&gt;Grant Revenue&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of June 30, 2021, we have earned the committed funding of $5&#160;million. An additional $51&#160;million funding would be available if DARPA exercises additional contract options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. The maximum award from BARDA, inclusive of the March 2021 and April 2021 amendments, was approximately $1.3&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $421&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, we received from BARDA an award of up to $126&#160;million, subsequently adjusted to $117&#160;million in 2021, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $59&#160;million, with an additional $8&#160;million available if the final contract option is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of June 30, 2021, the available funding, net of revenue earned, was $10&#160;million, with up to an additional $80&#160;million available, if additional follow-on projects are approved. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes grant revenue as of and for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfMTA2NQ_cc3e4df9-d303-48ff-87b7-bde2cb7889bc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by customer geographic location was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="ib3e5362a76064a92b61e459fcd0ce315_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMS02LTEtMS03MDI_6247efdf-9532-49cf-a0d6-a765fe9cf1d2"
      unitRef="usd">2093000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98fd324dcb2a418298c8cc16153570f3_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMS0yLTEtMS0w_465d0265-2e3b-4962-8079-e9457d0d32ca"
      unitRef="usd">3451000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1537b27f156c48ffba4b540f307af8f9_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMi02LTEtMS03MDI_1f42919c-3846-4f9b-90a9-29c35392e43f"
      unitRef="usd">2104000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd2776323b3943b9ad57f0cfb5a2e92e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMi0yLTEtMS0w_00d2db8a-2176-416e-9e5a-9cf8b959cf91"
      unitRef="usd">2479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62917e20a8fb457d8e66c38f2ad33f7a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMy02LTEtMS03MDI_add038c8-5d67-4d99-b7a4-537ffe0cea41"
      unitRef="usd">4197000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RhYmxlOmE0OTViNmM1NDZjZjRjYWI5MTk5NDA1NTJiNzAwYjc3L3RhYmxlcmFuZ2U6YTQ5NWI2YzU0NmNmNGNhYjkxOTk0MDU1MmI3MDBiNzdfMy0yLTEtMS0w_7d46e4c3-3f12-4659-8678-af81e3181979"
      unitRef="usd">5930000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id65439feeef443e58684902e2ca1fe70_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjM1NA_75a803d6-7e9d-4518-99a9-157bdba7e0c0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie42b22b2df23458abe04d022388eae80_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjM1NA_c1310ea8-ecae-4336-be1d-340757976dc8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i90e522303a6d4db88a6e75f6bf51b675_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjY0NQ_1e571661-aa20-4d9d-bdf1-a4fc6546da78"
      unitRef="usd">7200000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i925c8f5cb9cd46f6a1ae86a03be5fc3f_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80My9mcmFnOjc1ZWJkMGZmZmZlYjQ4MjFiZmQ1YzI5ZmQ2NTI2MzRmL3RleHRyZWdpb246NzVlYmQwZmZmZmViNDgyMWJmZDVjMjlmZDY1MjYzNGZfNDM5ODA0NjUxMjY3NA_3d07fe83-d60e-433d-8ccc-86fc1b0e790b"
      unitRef="usd">3800000000</us-gaap:ContractWithCustomerLiability>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i197583d029334a8a81529a09b6d9abab_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTUy_502ef6ac-480f-4717-823f-446fef5bffb2"
      unitRef="usd">56000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="id6503cc026fe46aebeebe1584e563292_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMzgz_ac94bf93-f17e-4685-abca-14549533f7ea"
      unitRef="usd">5000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="id6503cc026fe46aebeebe1584e563292_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfNDA2_82db2cc7-4cd5-404c-9b00-3e025ca961af"
      unitRef="usd">51000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i9d8c05f658d243b7a83bfd8f5c1c6f4c_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfNzU5_c3665231-9fec-4f8a-833e-949bff187ca2"
      unitRef="usd">483000000</mrna:RevenueFromGrantsMaximumAward>
    <us-gaap:OtherCommitment
      contextRef="i317ef19f70e3444197530823e5c919f1_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfOTU0_8fb68f57-9387-42b7-96cb-2519cf6a998a"
      unitRef="usd">472000000</us-gaap:OtherCommitment>
    <mrna:NumberOfParticipant
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfNjA0NzMxMzk1OTUzMQ_766e6735-cc47-4f62-a4aa-ba4ec9676bdc"
      unitRef="option">30000</mrna:NumberOfParticipant>
    <us-gaap:OtherCommitment
      contextRef="i1ebdc9e4059d4f3e8af844afeb9fa830_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTE3OA_d74ea212-400c-4d4a-ba19-15a5f8e569b9"
      unitRef="usd">63000000</us-gaap:OtherCommitment>
    <mrna:RevenueFromGrantsPotentialReimbursement
      contextRef="ie51ac7bdfcca483bb11c2dd61678484a_D20210401-20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjc0ODc3OTA3NDM3OA_86855f65-6500-4a02-b5b5-c205fc451cd6"
      unitRef="usd">236000000</mrna:RevenueFromGrantsPotentialReimbursement>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i8dfd3eaf51514a388430a090a9c38bf7_D20210101-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTM3OQ_fb395885-79a5-4941-869b-efec53b20687"
      unitRef="usd">1300000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="ie6e91224fb8d4da7a4999fd677df954b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTU5MA_6996cdfe-9462-4f3e-ad9c-2090c1f734d1"
      unitRef="usd">421000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i3f7b3f76a0254c61a7d0c966cb15f054_D20160901-20160930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTkzMg_013566ef-51df-4d14-bf85-4c3045f8b9d0"
      unitRef="usd">126000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="idc3a7ff346784334ad9e7b0a9a13d895_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTY0OTI2NzQ0NzYzNQ_25cb19a9-e0ae-43cb-9b06-db797e98e4b9"
      unitRef="usd">117000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsNumberOfContractOptions
      contextRef="ia5b1bfb294a14e0a9af5a1f7d2fe3c3d_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTk4Ng_d59b288a-7dde-4610-b1e9-b52ecf488a8a"
      unitRef="option">3</mrna:RevenueFromGrantsNumberOfContractOptions>
    <mrna:RevenueFromGrantsNumberOfContractOptionsExercised
      contextRef="ia5b1bfb294a14e0a9af5a1f7d2fe3c3d_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMTk5Ng_5a3e4c9f-5ec6-4610-a054-541f6130e752"
      unitRef="option">4</mrna:RevenueFromGrantsNumberOfContractOptionsExercised>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="i23d59c82137047499203288390a8fb25_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjEwNQ_575ef3ac-78bb-4a90-9d71-6e11decbaee0"
      unitRef="usd">59000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="i23d59c82137047499203288390a8fb25_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjEyOA_d8631e53-6eb7-4866-a83d-20114e0ceb51"
      unitRef="usd">8000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="i3736c014f39246fab97d6e843cb4749d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjQ5OQ_b6467c9b-5fde-4311-9453-6d9c02dcdb12"
      unitRef="usd">10000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3736c014f39246fab97d6e843cb4749d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjUyOA_7485ef8e-7fcc-402b-af00-9bc52cece349"
      unitRef="usd">80000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RleHRyZWdpb246NzI5NDc4N2QzOTE4NDcyMzg4YTMzOGQzYjBhZjYwM2ZfMjY5Mw_41cab9a4-75c5-4ccc-9419-d3b3a964c901">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes grant revenue as of and for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="ia364f96dfa314c94ab36b5e61edb53d8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi0xLTEtMS0w_50547eeb-f65b-45ad-89f7-8d166399ec91"
      unitRef="usd">134000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2020bda539b4500be4ec167f8f9dd69_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi0zLTEtMS0w_16e43d52-180b-474a-ac69-49ec64edc009"
      unitRef="usd">37000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82c916a0b4ca4f3aaaf4cdcb3d605a58_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi01LTEtMS0w_e041e262-c29a-4a97-a238-1e49555e0c7e"
      unitRef="usd">326000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib842bb3c0b504e23ad5bea99b14f72cf_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMi03LTEtMS0w_49c78e91-68c4-48c4-8b3a-b9f819997355"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i84be31041f544b97a41d04069c6d8bf4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy0xLTEtMS0w_9a235543-f889-473b-aa6d-9413b8fc4178"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ea751eab6f240dba31a0a82fdceab7e_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy0zLTEtMS0w_55240b54-bfb2-4ab3-80c4-885fbd71d512"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2f686c80a94472683e32b196c79f61c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy01LTEtMS0w_ba2feaee-ad20-4e29-9585-426f64cb267d"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i162ebf7a6485464c849cf2578c7dab6b_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfMy03LTEtMS0w_1cbd33ac-210a-4392-9c8b-ecf2402a4546"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97462bb9e06e4d0b8038908806010639_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC0xLTEtMS0w_7e1dd2eb-1ecd-4726-aaef-bf2cb59745a6"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i277a54dbb61f41e99601f903825b48d2_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC0zLTEtMS0w_5e2382b5-f9e7-4324-b038-c49eba9e5822"
      unitRef="usd">38000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC01LTEtMS0w_a627b9e7-ec92-4e91-a2de-edb3e4b4fc4c"
      unitRef="usd">333000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30b0955908be463b8c5776e5549bb45f_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80Ni9mcmFnOjcyOTQ3ODdkMzkxODQ3MjM4OGEzMzhkM2IwYWY2MDNmL3RhYmxlOmRhNDY4MDE3MzgzMTQ0ZmU5NWZkYzdjMTlkNmUwMjNmL3RhYmxlcmFuZ2U6ZGE0NjgwMTczODMxNDRmZTk1ZmRjN2MxOWQ2ZTAyM2ZfNC03LTEtMS0w_1551190b-98e8-4529-a695-40c5606cc711"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RleHRyZWdpb246YjFjOWZhYWM1MzcxNDZlMThkYWMyM2M1N2RhNzQ3NjVfMTE3Mg_47dba873-22eb-43f7-ac07-d979ed2d1217">Collaboration Agreements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of June 30, 2021 and December 31, 2020, we had collaboration agreements with AstraZeneca plc (AstraZeneca), Merck &amp;amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and Chiesi Farmaceutici S.P.A. (Chiesi). Please refer to our 2020 Form 10-K under the heading &#x201c;Third-Party Strategic Alliances&#x201d; and Note 5 to our consolidated financial statements for further description of each of the collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.500%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the six months ended June 30, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of June 30, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $321&#160;million.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50c0e4a432e844f8b79c47cfa66d0c9a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi0xLTEtMS0w_8f06d8b9-b6ac-4c92-be56-5d01573b5359"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a7e7990e9d440e893ed1142076218aa_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi0zLTEtMS0w_03483ef2-07c1-413f-a364-dc992559d355"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7644505741a1400d86377f349317c0fd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi01LTEtMS0w_abe139be-1721-4911-8d4f-239ae5c8f7a2"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaddeea55cf45455cb5d1c9673b0324ce_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMi03LTEtMS0w_22f0940c-72a6-455e-a473-0f4f140e51bd"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e00f59aecfe46eba16e2160aad94c2e_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy0xLTEtMS0w_6d91d054-0ddc-4b30-b51f-ea79cd764edd"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4d9addacdd64f378a73828f0159e567_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy0zLTEtMS0w_c7ad8c3f-87f6-4c0f-bb25-79b2f0aa92fb"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic00107eb57614d2783a2c32384445ff8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy01LTEtMS0w_44712d71-8f1d-45d1-8aac-1e1441b33088"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d9334dd2e954444a97f8e4487361fbd_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfMy03LTEtMS0w_afb232f1-2e51-482a-b178-3c1bb394facf"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75e7c7882cf1442f9e76d9e7fa5fb939_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC0xLTEtMS0w_7a2a2845-54f8-47f8-99e0-26a16394cd2f"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc0ecb7e5c464559a1438e2425eadc54_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC0zLTEtMS0w_d98d91ab-4617-401e-81e9-c1880cde7c32"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b82d07ccaad4e878d47278bb6324ea1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC01LTEtMS0w_a5e52090-519e-4631-82ed-58626bbc8d6d"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie360ccfe76ce4f12acb76df75ae0cd29_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNC03LTEtMS0w_cbae5fe2-01d7-4c2d-b502-95c099cf6e11"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ac3dd43b3bf4cbba83cd10d23c2765d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS0xLTEtMS0w_ea2317f8-aa50-40bd-84b7-3cb174053efb"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8812f9dae82547b18386cb8d2b5e9345_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS0zLTEtMS0w_e61f42c2-81b7-44b7-abca-d445401c0771"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d810941907046baa10069ee651b0e1f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS01LTEtMS0w_225eade6-7142-4085-a633-c9d3e897b6b1"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc4765f3aff24398975e633a19635d2d_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNS03LTEtMS0w_1d6a8d24-248b-4a78-bf88-5db1273d2dc0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d4150668b3b4c44aa607c9d34eb7166_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi0xLTEtMS0w_d2f49e2e-5b66-4497-aa7d-a6b541d171d1"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib52338e34ec645a58c3c88e7c09ae121_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi0zLTEtMS0w_05d82a47-8b9e-4ee6-9849-de77bac02880"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi01LTEtMS0w_88dc0db0-76b0-4946-b3cd-9a1a9432392f"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32e9a9ef8cc640939f59b6dbf739b2f2_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOjIwMjc1N2QxYjJhMzQ4NWJhMWNlZmYzYWJmNzVlMzBiL3RhYmxlcmFuZ2U6MjAyNzU3ZDFiMmEzNDg1YmExY2VmZjNhYmY3NWUzMGJfNi03LTEtMS0w_fe71c615-c73b-496a-af00-4845bead1471"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RleHRyZWdpb246YjFjOWZhYWM1MzcxNDZlMThkYWMyM2M1N2RhNzQ3NjVfMTE3MA_83712127-043c-407f-8dfd-ed456a751933">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the six months ended June 30, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; June 30, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ide4dcbd5648047cc838ad06ddef0f031_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi0yLTEtMS0w_27e2fc2f-096c-45ee-84d7-7cbd810b8904"
      unitRef="usd">6000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetPurchase
      contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi00LTEtMS0w_b63d6520-3d8e-4898-a91c-70e6c31b412f"
      unitRef="usd">17000000</us-gaap:ContractWithCustomerAssetPurchase>
    <mrna:ContractWithCustomerAssetDeductionsDuringPeriod
      contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi02LTEtMS0w_53eb26ed-ec6a-4aaf-b894-8af5e694488f"
      unitRef="usd">16000000</mrna:ContractWithCustomerAssetDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i44b065b0be3c464e8433f98080bb78c2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfMi04LTEtMS0w_65e56954-1fec-4f68-97f8-87f3f071c836"
      unitRef="usd">7000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ide4dcbd5648047cc838ad06ddef0f031_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC0yLTEtMS0w_5c47a400-d812-4ef8-8eed-ef344c881b69"
      unitRef="usd">240000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC00LTEtMS0w_420b7a21-ef12-4a82-9a97-62aff5ab37cf"
      unitRef="usd">18000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="ic759b04977c945af9a1565724750bef0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC02LTEtMS0w_03d70c01-de0a-4005-9be7-c0dd07b018d0"
      unitRef="usd">28000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i44b065b0be3c464e8433f98080bb78c2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RhYmxlOmI5MDczZmU4MjAxMTRkNDRhNmU1OWE5OWYzZjE2NDRmL3RhYmxlcmFuZ2U6YjkwNzNmZTgyMDExNGQ0NGE2ZTU5YTk5ZjNmMTY0NGZfNC04LTEtMS0w_6907cad3-5dec-429b-9fa9-be6d97347c58"
      unitRef="usd">230000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i44b065b0be3c464e8433f98080bb78c2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV80OS9mcmFnOmIxYzlmYWFjNTM3MTQ2ZTE4ZGFjMjNjNTdkYTc0NzY1L3RleHRyZWdpb246YjFjOWZhYWM1MzcxNDZlMThkYWMyM2M1N2RhNzQ3NjVfMTE2Ng_cdac63cc-c243-48b2-ba4a-a753ce946b80"
      unitRef="usd">321000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2Ng_e618b934-2b1e-4bfb-a02d-e70f0dc740c8">Financial Instruments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at June 30, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable securities by contractual maturity at June 30, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive loss, net of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any impairment charges related to available-for-sale securities for the three and six months ended June 30, 2021 and 2020. We did not recognize any credit-related allowance to available-for-sale securities as of June 30, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of June 30, 2021 and December 31, 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis and did not have any Level 3 financial assets or financial liabilities.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2OA_11c2f8e7-23bd-49ea-bf45-2e7c4b1dac3f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at June 30, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0yLTEtMS0w_b8d49254-7c4f-40a8-b7ba-532b77072cb6"
      unitRef="usd">5603000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi00LTEtMS0w_445b3de1-88db-44a9-befa-c1592eb0ecb9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi02LTEtMS0w_7c491774-d1b3-4012-bc47-4c74b9016a8f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7fb2b82ca9d44066a52b12a98ae0d8b0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi04LTEtMS0w_e4d4c56a-efee-429a-b4d0-21e6fc8e8a55"
      unitRef="usd">5603000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01fb537f002a4b8c925b113ba3d2017d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0xMC0xLTEtMA_85e0ecc7-b6c0-4732-8b6b-d047cd15af20"
      unitRef="usd">5603000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81cf2066964f4552b9838011a69044d2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0xMi0xLTEtMA_039000cb-a626-4114-aa7b-34049ca2d3b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia3e40b9256244a589946a1e85bf6cc70_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMi0xNC0xLTEtMA_182510d9-0ab5-486f-9704-8ef471c26771"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0yLTEtMS0w_8442cf19-f64b-448c-b751-1f37860b5eae"
      unitRef="usd">50000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC00LTEtMS0w_a2a1a27a-90b3-42b2-8fed-4aac9096d961"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC02LTEtMS0w_70f00616-ba4d-4671-8d98-686f80f197a8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e02e1f5ba8748bd95d12afcf7465939_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC04LTEtMS0w_4102820c-11e5-4229-b41d-d92134249a6d"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b130a946c83453fb4a2d9207835ffe6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0xMC0xLTEtMA_fac2e90f-3dff-4d12-878f-88e7731e4dc8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i423fce28b3db46918d8d1d5c8d38b86c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0xMi0xLTEtMA_a96244e0-09a7-4e7c-9c98-4a783c357384"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea33fd392c424f96b2db18376181aebb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNC0xNC0xLTEtMA_fa913ad2-3dd2-47ee-ab5e-fde052039428"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0yLTEtMS0w_43e46967-f205-4131-a50b-54d9f16a296b"
      unitRef="usd">87000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS00LTEtMS0w_808b27e2-fcd1-4cfc-989c-5c3c5685f4af"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS02LTEtMS0w_a6c98ea0-51c8-4352-85d4-ac01f417c745"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i027a8da8a838499cac9ccfbdc2f7a524_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS04LTEtMS0w_1472f5d8-f7d7-4dcf-a931-0603a88c2071"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b3dd508a23a494cb5ea06605d67c4ce_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0xMC0xLTEtMA_68d8b6c0-3d57-4b0e-804b-e27009c241e3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd695349782d4fabb5331046948b8614_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0xMi0xLTEtMA_156aea4f-7c00-4530-9f9a-0341ad578204"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i42e44fa9dff64d7aa736f647933beb2f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNS0xNC0xLTEtMA_7d7ba604-ad8e-49d2-8e9c-d8c237064bd2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0yLTEtMS0xMDE2OA_49d78bf4-8fb0-4fa9-ab56-6c3489711146"
      unitRef="usd">4349000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi00LTEtMS0xMDE2OA_ab84965f-f4a3-4881-9357-15f0936ae6bc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi02LTEtMS0xMDE2OA_86965eaa-c311-41d6-91b9-b640159f6720"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i992dfe7000ea4086b948a45ff7846ebe_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi04LTEtMS0xMDE2OA_e69fcb35-afd7-44df-8883-2605ee965857"
      unitRef="usd">4346000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4821d306d1d84e8c92f59601e79d952a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMC0xLTEtMTAxNjg_10eed521-5526-448d-9495-78f1073356bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf6972a4b3a6464fa76fdb392c3e5aeb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMi0xLTEtMTAxNjg_cda564e6-1a5f-4c3f-a422-87ad58b242f2"
      unitRef="usd">1411000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2bd954162504b8b865d6ee4ff792361_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xNC0xLTEtMTAxNjg_49e6047a-772c-4f08-8491-cd3a52254960"
      unitRef="usd">2935000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4dd7c27968a4482bb56525e657054318_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0yLTEtMS0w_b883d02a-5cfe-42d4-9d81-9f71fb9d095c"
      unitRef="usd">2113000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4dd7c27968a4482bb56525e657054318_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi00LTEtMS0w_c8170b58-752e-4d73-8381-e83a8ca72938"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4dd7c27968a4482bb56525e657054318_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi02LTEtMS0w_135a710e-945b-4cc4-b709-8e7aa41bd350"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4dd7c27968a4482bb56525e657054318_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi04LTEtMS0w_8a40fee4-bdfa-4d4d-addc-87e0b135731d"
      unitRef="usd">2111000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32cb4879eecb497aa9402f0d74f44387_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMC0xLTEtMA_4025cb7a-8228-481a-a591-5bfc945be7e5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf2262642e3b47c28ff6867f6509b071_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xMi0xLTEtMA_a0417141-c112-447e-be9a-7bef5629f3b0"
      unitRef="usd">839000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i769d59bacc4a4a21bb4c83f4a46ff03f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNi0xNC0xLTEtMA_90292869-da82-4946-b61b-fe8d20aeb46b"
      unitRef="usd">1272000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0yLTEtMS0w_58803086-a5cb-4a58-8b72-48d3c784d94e"
      unitRef="usd">12202000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy00LTEtMS0w_f7f53a30-780f-490b-9453-367751b71ba3"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy02LTEtMS0w_be052cb4-b5cc-4b38-af39-ab78a2431e27"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib392451a0a484b5dbc71a9445c495423_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy04LTEtMS0w_97685a41-2ea4-4a14-b617-97b5ad059bd9"
      unitRef="usd">12197000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09bbf998b6c041a6901c1dc8996237b7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0xMC0xLTEtMA_14007ed5-95d3-4c2c-b73b-c51d964edafb"
      unitRef="usd">5603000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e0489f9f56e42fe85ab3ecf9d6d2dad_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0xMi0xLTEtMA_c4426832-68a1-452e-973c-36c5ac45b753"
      unitRef="usd">2387000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16c840483704458faf3161e93a3e01e8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfNy0xNC0xLTEtMA_260cdf92-4b8b-4561-818d-35ec5b920423"
      unitRef="usd">4207000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMi0xLTEtMA_68e320c9-a4d7-481f-ab6c-f1060f0c916e"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtNC0xLTEtMA_2787367f-44e8-47e5-ae3a-2f7eb7999553"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtNi0xLTEtMA_7108f792-258c-4a96-8cb4-440e87d8e003"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5adcc5729bae40c6afb7af8e72c59291_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtOC0xLTEtMA_5d71c7be-abd7-4374-b082-10bd84107002"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i774f6d34510445e0ba7f5b0b00875252_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMTAtMS0xLTA_e641cf0c-693f-4768-95f7-7d4a2a1a3372"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0466c7cd491448979678f3b868c44e9d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMTItMS0xLTA_2ea0b6e6-5fef-48d1-94f8-c6e398ccdb9d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if135f26414c04231aa2ea55c9a2c83a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTEtMTQtMS0xLTA_e011dcbd-0857-49fd-98bc-eec79ed4496c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i25503043380a4bc7998a597473d1786d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMi0xLTEtMA_36fc9d89-f09e-4110-80a3-88b899f99ef4"
      unitRef="usd">239000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i25503043380a4bc7998a597473d1786d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtNC0xLTEtMA_48d2c3dc-a976-4288-b517-f7e4500798c3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i25503043380a4bc7998a597473d1786d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtNi0xLTEtMA_c6faa08b-2943-4372-a239-2e24bb72fbde"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25503043380a4bc7998a597473d1786d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtOC0xLTEtMA_00adb9c1-36de-4322-9fdf-ae242663c093"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e114d012176429c97c1208417394403_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMTAtMS0xLTA_eef8e570-652a-44b3-ae26-f38e5f5fe394"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia55f81c1ceb8498fb37e9398c3b61120_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMTItMS0xLTA_010f43ab-c677-4c90-aa91-4e3d3cf96d1f"
      unitRef="usd">215000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12cd6744128743138d2497b1a6aeab5f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTMtMTQtMS0xLTA_4a587319-782a-4088-a5d5-d3c445b2d1db"
      unitRef="usd">24000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMi0xLTEtMA_af81aab3-acb4-4c1a-b081-2949025f06c0"
      unitRef="usd">492000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtNC0xLTEtMA_9f773a47-96de-4a01-90f3-46d6c475864c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtNi0xLTEtMA_404ce486-0d01-41dc-81ff-b6a5c23a7af7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ed771e34dc34a429c0397e23c4ef046_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtOC0xLTEtMA_aa7d936e-30c7-4b07-9ba7-5fc29c332b82"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i519420c4ce3f4e889babc67663290d67_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMTAtMS0xLTA_5f50e76d-1d2e-44e1-92d4-3915d4d25e05"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7fa12a4a1d724b97bb9fb7cdd250ec0e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMTItMS0xLTA_9c73f5a6-d333-4dad-b89d-adeaf9955175"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6954dbaff3c452da6a96be861950389_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTQtMTQtMS0xLTA_365e4af1-e244-4ac6-b78a-89cc5e405200"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMi0xLTEtMTAxNzM_92e03d25-1b72-44de-b037-3b168ed6bd37"
      unitRef="usd">87000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNC0xLTEtMTAxNzM_2ab41dc7-7e94-45af-ba31-80c2e7c26851"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNi0xLTEtMTAxNzM_7aabe5d4-7680-47a5-a909-b1503264c409"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i493f6838a0a64aaea82e5743f2952be8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtOC0xLTEtMTAxNzM_cf4b27c1-3b36-4f55-bd1d-61e1c18e93be"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f3e4a401171474a9007e9abf988d8d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTAtMS0xLTEwMTcz_b98101fb-d6b7-4703-b60e-b2ea33bf0b70"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic540ca4685794ebb951a1f68ef0b6cbe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTItMS0xLTEwMTcz_2b5fc64d-a669-4f7f-9e1d-f9afd395aa10"
      unitRef="usd">38000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a16e85d6b1c4d0b82c2b3e4a95dd15b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTQtMS0xLTEwMTcz_429d1404-ca52-4ba9-b74f-8374b81b31c9"
      unitRef="usd">49000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMi0xLTEtMA_bbca579c-ca0b-42e0-9f8a-9c208e8f9d6c"
      unitRef="usd">1801000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtNC0xLTEtMA_00e34dc2-8536-4252-83f6-5d88f9338c97"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtNi0xLTEtMA_897584e0-2205-4a1e-9a29-69250c02c91d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i846f0646bd6d49ea8fe231170844146e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtOC0xLTEtMA_9a7f8a2d-d528-4768-910d-15262d1bab45"
      unitRef="usd">1805000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i194e3a1c43ff42a5b8386c49d1daa843_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMTAtMS0xLTA_cde5fc96-5785-4191-aa46-ff59a1b96fe8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i230f554c3a46462b96c3244553fa4901_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMTItMS0xLTA_57e57788-a517-456c-a0a6-83e6497350c7"
      unitRef="usd">1239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d36108a148c4a0fbcdf9c7d9b7be3b0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTUtMTQtMS0xLTA_8dfe5f43-923b-45d8-870e-feb43d029257"
      unitRef="usd">566000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMi0xLTEtMA_f31c8362-e3c6-4bca-8969-4f1e6005fadd"
      unitRef="usd">5243000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNC0xLTEtMA_dc7e7298-6e67-4262-81db-4730b1fba635"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtNi0xLTEtMA_0029e74b-e86c-401d-9d51-ac7ab6f70dc1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c96e2e95a944ce8baab70f57149619b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtOC0xLTEtMA_e634abc1-19b0-4214-8630-383bb558b2a9"
      unitRef="usd">5247000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41cbbe97585b49f7816d2b3bc62ef46a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTAtMS0xLTA_d0ccac62-3a5d-4ca4-862c-32ee92f9c945"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a7e6285a6f9420a8a1c73a6d999a977_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTItMS0xLTA_7f4da591-6227-4fec-9a86-91677ce8a8ca"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2db80e5245884f98abb49e31eb422938_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjlhNDE5Njk4Yzc1MjQ3OWZhOWJhOGI2MWFlNDAxNGM5L3RhYmxlcmFuZ2U6OWE0MTk2OThjNzUyNDc5ZmE5YmE4YjYxYWU0MDE0YzlfMTYtMTQtMS0xLTA_1a31fc8c-ce49-4c4e-b1ba-afced10d6acc"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2OQ_ef2d0742-40d0-478f-a969-41300c6440cb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable securities by contractual maturity at June 30, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMi0yLTEtMS0w_341f8325-3752-423b-ab38-521f2558dad3"
      unitRef="usd">2386000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMi00LTEtMS0w_ad143173-089f-4ccd-98aa-998758079138"
      unitRef="usd">2387000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMy0yLTEtMS0w_2124c6d8-d1fb-41c3-b041-56e0e0b29fd0"
      unitRef="usd">4213000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfMy00LTEtMS0w_4965d9db-30a0-45e9-a739-0c1342321ae7"
      unitRef="usd">4207000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfNC0yLTEtMS0w_65d82252-d137-40a1-b6dd-1b9af24c4fcb"
      unitRef="usd">6599000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmEyZDJjMjgyNzQ0MjRiMzk4NTYzYjVlOTE5ZmRhMmQ4L3RhYmxlcmFuZ2U6YTJkMmMyODI3NDQyNGIzOTg1NjNiNWU5MTlmZGEyZDhfNC00LTEtMS0w_f4d40ff9-f4eb-4ff2-a24c-9aba945e5a64"
      unitRef="usd">6594000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMi0yLTEtMS0w_5a44a26b-b4fe-45ec-bcbb-8ce6cd3b0af8"
      unitRef="usd">1981000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMi00LTEtMS0w_863576de-5bb3-48ae-874b-97951c552517"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMy0yLTEtMS0w_d69be412-5403-4e5a-8521-d54fc6a029c8"
      unitRef="usd">638000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfMy00LTEtMS0w_0cf59c0a-0504-485a-819a-b18a8a08e3b6"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfNC0yLTEtMS0w_2dabf71e-e528-4058-826d-34fe73be3e52"
      unitRef="usd">2619000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOmI0MTBkNDk3YjA5NDQxZDBiYjNmM2UwYmFkYWFlZjVlL3RhYmxlcmFuZ2U6YjQxMGQ0OTdiMDk0NDFkMGJiM2YzZTBiYWRhYWVmNWVfNC00LTEtMS0w_4e967201-b89d-40f1-a50f-5adddec55c4f"
      unitRef="usd">2623000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_3be97475-88fd-4f84-bc2a-e50de86ec844"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_4f91f0df-40cf-434d-8b48-35f409deae7f"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_8c8323bb-65ba-4480-bc11-bbc49d0faacd"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMTMxNQ_d985799a-beaf-44a3-b066-b3729be22efa"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfNDM5ODA0NjUxNDkwNw_45ce62e7-ee23-42f8-bb70-17e5ec94a76a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfNDM5ODA0NjUxNDkwNw_c9b42616-6b8f-42e1-ab10-6cdc658a2ce8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RleHRyZWdpb246MTU3MzNkYWZlZWMzNGViYjg1MzMyNDlmNjFkNjRkMzlfMjk2NQ_3e591292-a1f6-4fe2-b493-b6d537a6b82c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0b7d5d68b044d1a9277098a16618625_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMy0yLTEtMS0w_93435466-f201-4801-976b-28a39b53dad4"
      unitRef="usd">3838000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1932c05e81914004be5dc08eaecfac86_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMy00LTEtMS0w_3b68ca40-d905-4f5f-83da-84be4a0afa58"
      unitRef="usd">3838000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0db557e9b08d465ab8c20a75ef2e9031_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMy02LTEtMS0w_c0d4cdac-aad6-4d43-88d0-1f64509b5f86"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i864ecf97b4424e6094f85e6a8a246f8e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNC0yLTEtMS0w_568bebd3-2622-4cde-a199-a6e97332a969"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i516ea12e44884479b0a6bcb19ac9af08_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNC00LTEtMS0w_98806bb8-a192-4c52-b8bf-17ca13ca628a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14ebc7385e514efdadb03d14e93eafbb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNC02LTEtMS0w_80692d8f-d24e-4893-bd95-cd106aaf4ae7"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3181a82c5bb246f2ae1a34c07476b8df_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNS0yLTEtMS0w_a1a0c51c-686a-4281-8a34-ba3da7306f22"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id72d63351ccf43468dfcbe077e57e343_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNS00LTEtMS0w_5f5ce36f-dd99-4401-82fd-6d29de18eb3b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i775e0b2685f849e2bc13548cc7443839_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNS02LTEtMS0w_5e5b19ae-d3cd-40c1-b5ff-47881034f9df"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i353364e17b0948c69aab8712c81c2ae0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNi0yLTEtMS0w_6240292d-69c3-4322-84a5-6bd056c1a0dd"
      unitRef="usd">4346000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bf448fa99154f69805bc0000070e21d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNi00LTEtMS0w_48b91d90-956b-4310-80a9-4214220b5b8d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f00f671da6e4c1f98a8eaee2667cd74_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNi02LTEtMS0w_f0b55daa-57af-42bc-964b-6804b28ac956"
      unitRef="usd">4346000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i70b8d474daa3437dbb2cd804326443ae_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy0yLTEtMS0xMDE4OA_82e9f11a-3269-416f-bb51-ad9cb935f928"
      unitRef="usd">2111000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91999e41635347b4902e1ad73f8105c3_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy00LTEtMS0xMDE4OA_eac1e875-a385-4b58-ad3f-3ff738003c57"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d07569609954f7ba5c83a5cdacc1022_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy02LTEtMS0xMDE4OA_870bcb1b-6060-46bc-9409-2ec8b0edd546"
      unitRef="usd">2111000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i414d3d35d2414d4cbfcac8697786c538_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy0yLTEtMS0w_ca442848-237c-445f-bc53-1cc8f68f9d74"
      unitRef="usd">30000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie25825286c884fff843aea0e9c363a1e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy00LTEtMS0w_2c5795f7-a7fd-439d-b362-5b516f1bdde8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2e8429272a2a4b0998190fc4ddf309c0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfNy02LTEtMS0w_c16f8e96-8b9a-417f-9972-d2bb1b6939af"
      unitRef="usd">30000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i414d3d35d2414d4cbfcac8697786c538_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfOC0yLTEtMS0w_cf8e75e5-9184-4870-ae73-ad27e2cce232"
      unitRef="usd">10462000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie25825286c884fff843aea0e9c363a1e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfOC00LTEtMS0w_ac2f6380-f94c-44a7-9e4d-c3e2800d9f40"
      unitRef="usd">3838000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e8429272a2a4b0998190fc4ddf309c0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfOC02LTEtMS0w_918fc28c-3c64-4e95-9873-3320859bc883"
      unitRef="usd">6624000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i414d3d35d2414d4cbfcac8697786c538_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMTAtMi0xLTEtMA_d5b149cb-5339-47fe-8fc1-971a7cdb4775"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie25825286c884fff843aea0e9c363a1e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMTAtNC0xLTEtMA_67f086c6-4021-4cb0-bcec-8e89507701c5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2e8429272a2a4b0998190fc4ddf309c0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjM4NjFhZTJlNjg4MTQ4MjdiNzRjNTkxYzMxYmUwNTc5L3RhYmxlcmFuZ2U6Mzg2MWFlMmU2ODgxNDgyN2I3NGM1OTFjMzFiZTA1NzlfMTAtNi0xLTEtMA_fa3dd629-630d-4924-b7fb-df426697492d"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37ee58f9c9904729a24edfb35821ac46_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfMy0yLTEtMS0w_a25ff787-8d68-4f5e-8116-282b1d3ae32c"
      unitRef="usd">660000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if206a7fe2c0b4f61b8a9c7db48c74717_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfMy00LTEtMS0w_1958ac97-cd8f-4e1a-a559-9d0209fb9a9c"
      unitRef="usd">660000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b3d345b623d43e5a20fa855453bc2d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfMy02LTEtMS0w_e7f6b304-7132-4b35-80e6-a3092bcff6e5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18a60989d0ea4094b7de163b29974100_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNC0yLTEtMS0w_8124543b-7ff0-4288-8035-cf290c157f97"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73893cab9b854b6b8ba02c2e4b889f2f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNC00LTEtMS0w_9ea06c3b-aa56-475d-aa22-459cda893bd4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a24374f72e7438a9fbdca268f38643b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNC02LTEtMS0w_b4af8097-1ab0-40aa-81e5-c720d9b0f35b"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iabd72a3537a1453a82dc119e321ac20f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNS0yLTEtMS0w_b6bdf68e-a3fe-43f1-a964-e66a88f95604"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i174fd5ae68bf4b5da07bbc030ddd36e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNS00LTEtMS0w_e616486c-80c9-4a43-9ced-7b6897c25376"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i002448bbfd364b528c594c150a64fdfb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNS02LTEtMS0w_989a9da3-9df8-4d8a-87ee-7f01099c3348"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03cae867119545acb97a33eb075f4934_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNi0yLTEtMS0w_9f01860f-c3c2-4b23-b982-1eba9542502d"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8999a018dcb4fc1ae7ae79fda50084a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNi00LTEtMS0w_c966db06-0b65-492f-9bd8-f9b1dfaa4a31"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd279b33ffd34a2398ca36d866add3ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNi02LTEtMS0w_f9c42204-8da3-444d-ace3-d6720b470152"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3b2270f25574b2389448da3126d9486_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy0yLTEtMS0xMDE5Mw_be81706b-2958-4a8d-961b-7e9e1f0cf7db"
      unitRef="usd">1805000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id873b1c04a36458dab4d7141b07cc3e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy00LTEtMS0xMDE5Mw_9f27186a-a796-4ee0-8436-4e3aba1b82a7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9969e6d3b7504aeeb9fcb51894156a6d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy02LTEtMS0xMDE5Mw_91579642-6bcb-4836-9ea5-41a323d37aa3"
      unitRef="usd">1805000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if3f7fd21cde041c28f93122294043d54_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy0yLTEtMS0w_7df29a5f-67d6-4ecc-bf48-9617d1981758"
      unitRef="usd">3283000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia0e4394219d147b9aa8a86441e91f2d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy00LTEtMS0w_e227bc2a-5483-47a2-ba1a-cb8f3ef25096"
      unitRef="usd">660000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1f213588a2543558ea014b5a5ea5e8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81Mi9mcmFnOjE1NzMzZGFmZWVjMzRlYmI4NTMzMjQ5ZjYxZDY0ZDM5L3RhYmxlOjU4MTJiM2Q0NjdmMDRiMGVhMzRkZWI3NzNhYmVhODgzL3RhYmxlcmFuZ2U6NTgxMmIzZDQ2N2YwNGIwZWEzNGRlYjc3M2FiZWE4ODNfNy02LTEtMS0w_3a23dbb1-e281-4f56-94db-98ab79806f17"
      unitRef="usd">2623000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RleHRyZWdpb246NDdlNjM1MjQzNzMyNDQ5OTljOGU4MDg1MDk1NGU0YTBfMjM2OA_93d0f766-23d3-4fab-bc12-b4ab1fe04cfb">Derivative Financial Instruments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge: (1) forecasted product sales that are denominated in foreign currencies and (2) foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate the foreign exchange risk arising from the fluctuations in foreign currency denominated product sales in Euro through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that do not exceed 15 months in duration. We hedge these cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative assets or liabilities associated with our hedging activities are recorded at fair value in other current assets or other current liabilities, respectively, in our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;condensed consolidated balance sheets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The gains or losses resulting from changes in the fair value of these hedges are initially recorded as a component of accumulated other comprehensive income (AOCI) in stockholders&#x2019; equity and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequently reclassified to product sales in the period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;product sales&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We evaluate hedge effectiveness at the inception of the hedge prospectively, and on an on-going basis both retrospectively and prospectively. If we do not elect hedge accounting, or the contract does not qualify for hedge accounting treatment, the changes in fair value from period to period are recorded in the same income statement line item as the hedged item. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, we had net deferred gains of $27&#160;million on our foreign currency forward contracts included in AOCI that are expected to be recognized into product sales within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Balance Sheet Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily accounts receivable in Euro and lease liabilities in Swiss Franc, that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities in our condensed consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our condensed consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross notional amount and fair value of our foreign currency derivatives were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;_________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheets within other current assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheets within other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gains (losses) on our foreign currency derivatives, net of tax, recognized in our condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effect of our foreign currency derivatives in our condensed consolidated statements of operations for the three and six months ended June 30, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We had immaterial gains reclassified from AOCI to product sales during the three and six months ended June 30, 2021. There were no hedging activities for the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RleHRyZWdpb246NDdlNjM1MjQzNzMyNDQ5OTljOGU4MDg1MDk1NGU0YTBfNjA0NzMxMzk3NDgwNQ_a678ba7b-4c0e-4b6f-8daa-92497339ec6d"
      unitRef="usd">27000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RleHRyZWdpb246NDdlNjM1MjQzNzMyNDQ5OTljOGU4MDg1MDk1NGU0YTBfMjM2OQ_b2ab8b17-3aa4-458d-a95f-7ec1fbb3e0a5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross notional amount and fair value of our foreign currency derivatives were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;_________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheets within other current assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheets within other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gains (losses) on our foreign currency derivatives, net of tax, recognized in our condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effect of our foreign currency derivatives in our condensed consolidated statements of operations for the three and six months ended June 30, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC0yLTEtMS01MjY2_7593b828-2ce5-4f9f-b023-73c71413c0da"
      unitRef="usd">981000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC00LTEtMS01MjY5_6b1ebc63-684d-41d7-8f0f-57f5ccd67ccd"
      unitRef="usd">27000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i308f33f6de844de6bd1d4e20b09e4d5c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC02LTEtMS01MjY4_108a7755-6d47-4e92-9459-074e6b6d26f6"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC0yLTEtMS0w_09af1d5f-82d9-4e52-95b4-527836f838ca"
      unitRef="usd">308000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC00LTEtMS0w_8dd7e411-f83b-49d0-9287-62cbb03deb41"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ie5c22ac7c6344bd8940de3f3d859bf90_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNC02LTEtMS0w_fc26762d-ab64-4ace-8b40-6fac4d1508bf"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idceb063e3fb1410babe61be92b0909bb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS0yLTEtMS0w_11916799-fef7-46a0-842f-4d7fc6ae4efc"
      unitRef="usd">1289000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS0yLTEtMS0w_bb737d9f-2821-4aef-97ad-e4e0e8e3422f"
      unitRef="usd">1289000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS00LTEtMS0w_89f69c29-394c-46e0-adf8-0b28aa189070"
      unitRef="usd">30000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idceb063e3fb1410babe61be92b0909bb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS00LTEtMS0w_c0c9eb89-c336-4733-86ec-74f2c99a18f0"
      unitRef="usd">30000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="idceb063e3fb1410babe61be92b0909bb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS02LTEtMS0w_2b4296ac-fdbc-41d5-8603-a064c87404fa"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjNiNjdkNGUzODhiMDQyNGNiMDk3YTM3ZGNjZjY5YzBiL3RhYmxlcmFuZ2U6M2I2N2Q0ZTM4OGIwNDI0Y2IwOTdhMzdkY2NmNjljMGJfNS02LTEtMS0w_8f47bb39-2c2f-4eed-a1e3-a833224fd9bd"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i105c28fecd3545bfb3d35697e79fe0be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNC0yLTEtMS0w_4ab5fde3-b2a0-4852-bb51-3adbd6cee979"
      unitRef="usd">368000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i105c28fecd3545bfb3d35697e79fe0be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNC00LTEtMS0w_e5f83e85-519f-4362-8503-ea0d8a1eecf1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i105c28fecd3545bfb3d35697e79fe0be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNC02LTEtMS0w_a2727ad0-b146-4c3f-b98a-741a61dbd878"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i78b9df3a23274885ab33d029964f7f40_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNS0yLTEtMS0w_1df08bdf-c543-459c-979d-90ac533a4831"
      unitRef="usd">368000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i78b9df3a23274885ab33d029964f7f40_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNS00LTEtMS0w_209f04be-af1d-4f23-b66e-1254376e4775"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i78b9df3a23274885ab33d029964f7f40_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOjhmNDlhYTg1MDUxMTRmYmFhODNjNmRiYTEyNDc0ZWUyL3RhYmxlcmFuZ2U6OGY0OWFhODUwNTExNGZiYWE4M2M2ZGJhMTI0NzRlZTJfNS02LTEtMS0w_ed84f486-af95-4ade-9bc1-479488bb522b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmUyYWFlNWFmYzA2MjQ3MTVhMjlkMDNkODZlYWM4YTc2L3RhYmxlcmFuZ2U6ZTJhYWU1YWZjMDYyNDcxNWEyOWQwM2Q4NmVhYzhhNzZfMi00LTEtMS00NzUw_cbbdf2f4-1a66-4f4d-a9a4-1ecdd06f053a"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmUyYWFlNWFmYzA2MjQ3MTVhMjlkMDNkODZlYWM4YTc2L3RhYmxlcmFuZ2U6ZTJhYWU1YWZjMDYyNDcxNWEyOWQwM2Q4NmVhYzhhNzZfMi02LTEtMS00NzUw_24fb6caf-115d-4398-b072-3962d7fc32a2"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ie5fecea31d594dd0ab5690daae65344a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmRkNWViNGMwNjY0NzQ1NGQ5NzIzNTAyNjgyOThmY2QxL3RhYmxlcmFuZ2U6ZGQ1ZWI0YzA2NjQ3NDU0ZDk3MjM1MDI2ODI5OGZjZDFfNy00LTEtMS01MDA3_640feb45-7262-478c-9a1b-2f3ce4f482af"
      unitRef="usd">-54000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic41d37e05a294447b61d26d700536c4f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81NS9mcmFnOjQ3ZTYzNTI0MzczMjQ0OTk5YzhlODA4NTA5NTRlNGEwL3RhYmxlOmRkNWViNGMwNjY0NzQ1NGQ5NzIzNTAyNjgyOThmY2QxL3RhYmxlcmFuZ2U6ZGQ1ZWI0YzA2NjQ3NDU0ZDk3MjM1MDI2ODI5OGZjZDFfNy02LTEtMS01MDA3_e9180988-bf43-4d8e-b065-1c4dcf94283c"
      unitRef="usd">-19000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RleHRyZWdpb246YzEzMmJmOGI1MzY2NGQ5OTg3NTFhZGUyODM3ODNiOTlfOTA_9bf54ea1-a22c-4345-9136-7f2ee3ba3582">Inventory&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of June 30, 2021 and December 31, 2020 consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RleHRyZWdpb246YzEzMmJmOGI1MzY2NGQ5OTg3NTFhZGUyODM3ODNiOTlfODk_64c78901-4ca0-4745-b204-254ce29405ac">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of June 30, 2021 and December 31, 2020 consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMi0yLTEtMS0w_dfd4b1b4-a8e1-4c2e-9aca-39424750f36a"
      unitRef="usd">378000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMi00LTEtMS0w_235515c7-adea-4868-bd67-cd1ef4aeb70e"
      unitRef="usd">37000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMy0yLTEtMS0w_5d163a74-0aff-434d-b00a-ace4ccdbf100"
      unitRef="usd">224000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfMy00LTEtMS0w_1956e891-79a7-402d-89dd-fc9540f85a34"
      unitRef="usd">9000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNC0yLTEtMS0w_cb1c169a-2f61-4522-ad1c-cca75f80f174"
      unitRef="usd">41000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNC00LTEtMS0w_9fde226b-2969-42ff-8b64-41f34fdd04e9"
      unitRef="usd">1000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNS0yLTEtMS0w_8a107484-195f-4bbb-bb2b-2ae74f8623d8"
      unitRef="usd">643000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV81OC9mcmFnOmMxMzJiZjhiNTM2NjRkOTk4NzUxYWRlMjgzNzgzYjk5L3RhYmxlOjkyYWYxMDAzNzNlNDQ5YTM5OWY1NjMyOWY2NTI1NTM2L3RhYmxlcmFuZ2U6OTJhZjEwMDM3M2U0NDlhMzk5ZjU2MzI5ZjY1MjU1MzZfNS00LTEtMS0w_f5f3c853-1999-49e3-8545-79deb1e9e781"
      unitRef="usd">47000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMjEz_efb8318c-e82d-4060-9e46-0990504d8efd">Property and Equipment, Net&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation and amortization expense for the three months ended June 30, 2021 and 2020 was $69&#160;million and $8&#160;million, respectively. Depreciation and amortization expense for the six months ended June 30, 2021 and 2020 was $84 million and $15 million, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMjE0_7ebe70a5-6264-4308-b603-5ad13ffef4eb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i2e7bc9694442496cb11758c11c2558be_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMi0yLTEtMS0w_a16f1bb3-df38-436a-abcf-9d789f9861b0"
      unitRef="usd">142000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i425177f7064948f1ac420fbb3fef0e74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMi00LTEtMS0w_f6dc309d-5c4d-4b7e-b9cf-2eece2762720"
      unitRef="usd">121000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i782e7b05996e46d48e09abb10bd0b888_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMy0yLTEtMS0w_b5387c1a-8e3e-4cef-b8a8-40c85bbdc038"
      unitRef="usd">199000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i5f885124f6b8428f81517844f40eabfa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMy00LTEtMS0w_fbf966b7-ea50-4c02-9a52-268b64854a9d"
      unitRef="usd">180000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ic255a6d51e9f4cf2a218bc9650ff2949_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNC0yLTEtMS0w_aa4d2777-c094-4979-b1b2-61f5468f9cbe"
      unitRef="usd">6000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i06704fd367eb404db0554bb5e563f35e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNC00LTEtMS0w_67341982-531a-49f6-9bb6-0a129699195a"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i5de8c1fd48ac4d1aa4faaacb3fe97224_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNS0yLTEtMS0w_acc41e68-2cb7-4e41-9b89-5583da6d8176"
      unitRef="usd">14000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ia6a370046fc945508f2069a2bb7980ce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNS00LTEtMS0w_8791bcdf-0418-47da-8598-d4bb75a4f450"
      unitRef="usd">13000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if00cdc03e1254d03b96024e1c1f004e0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNi0yLTEtMS0w_6096f9cc-fdc1-4495-ba81-c6c7f660ead9"
      unitRef="usd">9000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i084d5de85aad4c568986c67f724f5fc6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNi00LTEtMS0w_0a84118e-bee6-42e8-8109-c9b88d8774c3"
      unitRef="usd">7000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i8946ec3ac3654c46b29f79ecd814b660_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNy0yLTEtMS0w_7ef31cff-6eba-4c05-8977-c31c48877e5e"
      unitRef="usd">545000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iade5f7abc6404fd4b696f1bebae23486_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfNy00LTEtMS0w_f2cacc65-547b-44f6-a84d-b30b3e286d19"
      unitRef="usd">56000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i321e4ae9922946c7b2dc52c2fcf14229_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOC0yLTEtMS0w_f0298a9f-4585-4214-a978-c90058fa1c8a"
      unitRef="usd">83000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i1e4bff8b1053446d87c6e24ff337360c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOC00LTEtMS0w_149f4bf5-5357-4e34-a3c6-c788d4b09a1a"
      unitRef="usd">35000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOS0yLTEtMS0w_bac99fdb-0481-4e63-954d-9b9e6a508a1a"
      unitRef="usd">998000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfOS00LTEtMS0w_056394b2-08a2-42d8-ba4d-64123cd79bf0"
      unitRef="usd">417000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTAtMi0xLTEtMA_a14e1997-e16b-41bb-abc9-e8ed302236c4"
      unitRef="usd">204000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTAtNC0xLTEtMA_0ee6f76b-587f-4914-a770-1e01594e35ec"
      unitRef="usd">120000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTEtMi0xLTEtMA_2437ed22-f01b-4c3f-a0e8-37765442f08d"
      unitRef="usd">794000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RhYmxlOjM2OTYzZDA5OTczODQ4NWRiNTI4M2IzNzM3NTc3ZWI3L3RhYmxlcmFuZ2U6MzY5NjNkMDk5NzM4NDg1ZGI1MjgzYjM3Mzc1NzdlYjdfMTEtNC0xLTEtMA_87a2aa59-2600-4cc4-acb9-b49329ade590"
      unitRef="usd">297000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMTY0OTI2NzQ0MjUyMQ_5bb2d088-7696-4824-90a7-b21b6e7c970a"
      unitRef="usd">69000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMTY0OTI2NzQ0MjUwOQ_4c3487ea-9eb0-4154-b72d-3198f3c75d6a"
      unitRef="usd">8000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMzI5ODUzNDg4NDAxNg_d0f8c245-9550-483f-b8a3-52c0eba196bd"
      unitRef="usd">84000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82MS9mcmFnOjZjOGNjNGE4MzA5NzQ3ODg4ZDk4OWNmZWU3YTlkMTRmL3RleHRyZWdpb246NmM4Y2M0YTgzMDk3NDc4ODhkOTg5Y2ZlZTdhOWQxNGZfMzI5ODUzNDg4NDAyMA_28146763-ac55-4485-bdca-777e102540d8"
      unitRef="usd">15000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNDEx_1796a9e9-49b6-4532-9d7a-1258411c21f9">Other Balance Sheet Components&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments to manufacturing vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value added tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - financing (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - operating (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; June 30, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNDEz_41cadde5-27c9-484b-bdb1-63684522f655">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments to manufacturing vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value added tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <mrna:OtherPrepaidExpenseManufacturing
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMi0yLTEtMS0w_a75c937f-d1ab-45d9-ad85-72bc06872a19"
      unitRef="usd">138000000</mrna:OtherPrepaidExpenseManufacturing>
    <mrna:OtherPrepaidExpenseManufacturing
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMi00LTEtMS0w_3983b468-0734-4890-9509-55b024e36900"
      unitRef="usd">217000000</mrna:OtherPrepaidExpenseManufacturing>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMy0yLTEtMS0w_02fc8f27-7cb0-4f22-8c15-d64d4535dfe4"
      unitRef="usd">59000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfMy00LTEtMS0w_fa2802d5-4ea2-40db-951f-b0153510dd41"
      unitRef="usd">7000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNC0yLTEtMS0w_b48813a1-1e92-422a-9c03-c2e8dafec9b9"
      unitRef="usd">51000000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNC00LTEtMS0w_2ad24010-0f9e-42f6-bf03-6246ae2f2a13"
      unitRef="usd">7000000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNS0yLTEtMS0w_0289283b-4a41-4c9b-97f1-0d8f737fa44a"
      unitRef="usd">30000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNS00LTEtMS0w_c22fe90b-a6bd-49a1-8c08-01571775f2f2"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi0yLTEtMS0xMDYxMA_aad2badc-12b4-48ea-96d7-9a8d09a11eb4"
      unitRef="usd">38000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi00LTEtMS0xMDYxMA_46184c2c-934a-4eff-992a-71b755a8f1e8"
      unitRef="usd">21000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi0yLTEtMS0w_beb284cf-95ef-4e1a-a205-4f61ec97d5c4"
      unitRef="usd">316000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjMzMDY1MmMwM2FjNTRkMmZhNWJjYzk1MWU4NTk3ZmZiL3RhYmxlcmFuZ2U6MzMwNjUyYzAzYWM1NGQyZmE1YmNjOTUxZTg1OTdmZmJfNi00LTEtMS0w_91713c94-341a-4d81-ac73-e5f48fa22e98"
      unitRef="usd">252000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNDE2_c21119fa-c917-4d24-be4b-96f3cde1c546">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <mrna:AccruedClinicalTrials
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMi0yLTEtMS0w_59bcfbb8-3511-4b19-ba20-15152c100bda"
      unitRef="usd">108000000</mrna:AccruedClinicalTrials>
    <mrna:AccruedClinicalTrials
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMi00LTEtMS0w_9fbefeee-7257-45ae-99e5-83c4a5826c1c"
      unitRef="usd">98000000</mrna:AccruedClinicalTrials>
    <mrna:RawMaterialsAccountsPayable
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMy0yLTEtMS0w_137059ab-cf63-4e6f-9923-185cf3d8e202"
      unitRef="usd">184000000</mrna:RawMaterialsAccountsPayable>
    <mrna:RawMaterialsAccountsPayable
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMy00LTEtMS0w_5f91375b-c7da-424c-a052-7db9fdc0a38d"
      unitRef="usd">78000000</mrna:RawMaterialsAccountsPayable>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNC0yLTEtMS0w_ad9db5bb-6f16-4d3b-a061-cf036b3b3c84"
      unitRef="usd">146000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNC00LTEtMS0w_760bad18-d1ec-46d7-aa2c-21a1553f92e3"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <mrna:AccruedDevelopmentOperation
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNS0yLTEtMS0w_08ebd2b2-874c-425c-b10f-cb1f9df8010a"
      unitRef="usd">102000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedDevelopmentOperation
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNS00LTEtMS0w_58769059-9772-44f9-bff7-05bd4e341cb9"
      unitRef="usd">29000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedManufacturing
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNi0yLTEtMS0w_4e641d29-7186-4047-af00-9932c8dfd818"
      unitRef="usd">158000000</mrna:AccruedManufacturing>
    <mrna:AccruedManufacturing
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNi00LTEtMS0w_f6b67291-bb43-44a6-8da3-8d5148ade498"
      unitRef="usd">53000000</mrna:AccruedManufacturing>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNy0yLTEtMS0w_a4c55dc3-e6d5-4471-ac2a-d6b126913b96"
      unitRef="usd">49000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfNy00LTEtMS0w_b555b54a-03a4-49d8-9345-853dd565685f"
      unitRef="usd">92000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOC0yLTEtMS0w_27eeba3b-02ff-40e1-9f67-233601b847d9"
      unitRef="usd">62000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOC00LTEtMS0w_2bfa977e-7934-4f80-b9e8-c168030bcf50"
      unitRef="usd">95000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOS0yLTEtMS05NzI0_6e1da8bf-57d4-4948-8c90-ab43573b3a74"
      unitRef="usd">39000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfOS00LTEtMS05NzI0_e9b8efb0-1157-4533-a73c-cd7423f7b659"
      unitRef="usd">25000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMTEtMi0xLTEtMA_1329d4f4-327a-4ecb-8922-da8cf1058166"
      unitRef="usd">848000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjJiODE2ZGI2NTQyZTQ3NGI5YTgyNjg4ZTY0MWEyYjk0L3RhYmxlcmFuZ2U6MmI4MTZkYjY1NDJlNDc0YjlhODI2ODhlNjQxYTJiOTRfMTEtNC0xLTEtMA_69e8cf51-f669-4e5d-b3d3-703d00461499"
      unitRef="usd">470000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RleHRyZWdpb246NDAxMTYwZDM0MTc4NDI5ZjhhYTE0MjFjNDI4MGJmMWFfNjA0NzMxMzk1MzQ2Mw_7d325d8b-ecce-4a23-ab47-c8c9984a60a1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - financing (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - operating (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMi0yLTEtMS04MzQ4_cf5e03b1-3f29-432e-91e9-203104f1fbf6"
      unitRef="usd">159000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMi00LTEtMS04MzQ4_ea2a92c5-4ea0-4ab3-bf75-df5db5cb6b3c"
      unitRef="usd">24000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMy0yLTEtMS04MzQ4_e5513ea6-0ab4-4f23-a8e1-eb9cd25bfb8e"
      unitRef="usd">11000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfMy00LTEtMS04MzQ4_b81c1542-f31f-4167-8248-a737421a502a"
      unitRef="usd">6000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNC0yLTEtMS04MzQ4_65ff28b7-3925-4b06-8439-9de702c649db"
      unitRef="usd">377000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNC00LTEtMS04MzQ4_4d2925a0-19c6-4015-bb51-2f1c96787047"
      unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNS0yLTEtMS04MzQ4_3c198c46-3023-4f4f-ab5e-a233086e5ad6"
      unitRef="usd">66000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNS00LTEtMS04MzQ4_3e60a57d-1d0f-4745-8a61-f5058c3b092e"
      unitRef="usd">4000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNi0yLTEtMS04MzQ4_d0a966c3-8644-4f6d-bd75-d5c3b8121e74"
      unitRef="usd">613000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjkxZTZhYTk1ZGRlZTQzODNhZjdmZjliZGNkNmRkYzY2L3RhYmxlcmFuZ2U6OTFlNmFhOTVkZGVlNDM4M2FmN2ZmOWJkY2Q2ZGRjNjZfNi00LTEtMS04MzQ4_ed8a5b4b-d1c0-4bdd-8caa-de7a638d84a1"
      unitRef="usd">34000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i925c8f5cb9cd46f6a1ae86a03be5fc3f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS0yLTEtMS0w_1b5d22ae-0acf-4b23-b0a6-c85917e8fe62"
      unitRef="usd">3799000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS00LTEtMS0w_544def02-e180-41dc-a422-648ad4e6ba3a"
      unitRef="usd">6145000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="if266088069f84cf6945085f6b87d5db0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS02LTEtMS0w_a3b6dbd1-0539-4be5-b061-15d2c13949de"
      unitRef="usd">2705000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i90e522303a6d4db88a6e75f6bf51b675_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMS04LTEtMS0w_06763770-46ec-4959-942e-d43c5cb4dbcf"
      unitRef="usd">7239000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i323f3434ce0f462a835692c193f97e98_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi0yLTEtMS0w_60868f3a-c6ca-470d-aff0-b6e2c098a95e"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi00LTEtMS0w_e40708a2-1e4c-457b-b562-4c6f7bcaebef"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="id5c114fe9c544d9ab780e9da841683de_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi02LTEtMS0w_b9c25837-cb51-40fd-a17a-70b030c05957"
      unitRef="usd">7000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ieffb4ead51104e6aa5757fa06624c672_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMi04LTEtMS0w_7457de9d-f53f-4650-a062-a97aafbcc6b4"
      unitRef="usd">8000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie0b8c503b84d412cb2d8c21018da6a3a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy0yLTEtMS0w_5b8d94a0-5316-48b4-bd56-4d8329494377"
      unitRef="usd">240000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy00LTEtMS0w_2fcaccdb-5088-4e71-8d91-8af9f826bc89"
      unitRef="usd">18000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="icec7321ec9fc47738508992e3bbe3081_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy02LTEtMS0w_1ea61b1d-dabd-4466-8c42-78ec228fbf44"
      unitRef="usd">28000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6a01b9748ef64174a3c700db54d82b9b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfMy04LTEtMS0w_ace91aac-be65-4733-abbc-35bf6ff2ce22"
      unitRef="usd">230000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC0yLTEtMS0w_eb6103af-cedb-4147-bfa8-5950273c542d"
      unitRef="usd">4044000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC00LTEtMS0w_a6d235eb-1453-4e8c-87c7-b17b0691f931"
      unitRef="usd">6173000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC02LTEtMS0w_8e3a68dd-278c-43d5-a8bc-7e6269361af5"
      unitRef="usd">2740000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82NC9mcmFnOjQwMTE2MGQzNDE3ODQyOWY4YWExNDIxYzQyODBiZjFhL3RhYmxlOjhiODQ0MzlmMjQ1NjQ1NTI4N2NlNTQyZGJhODcxYmRlL3RhYmxlcmFuZ2U6OGI4NDQzOWYyNDU2NDU1Mjg3Y2U1NDJkYmE4NzFiZGVfNC04LTEtMS0w_c967219d-6235-454d-a566-9ab5aedc0401"
      unitRef="usd">7477000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0NA_d69f7f26-e336-4c2f-85b2-6580ad4b65b8">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2035. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, located in Norwood. We also leased other office spaces globally for our business operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cambridge facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2022 to 2029. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an industrial technology center in Norwood, Massachusetts, Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we entered into a lease agreement for a 240,000 square foot building located on the same campus for expansion of our commercial and clinical activities (MTC East). The lease will expire in February 2034. We have the option to extend the term for two extension periods of five years each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of June 30, 2021 and December 31, 2020, we had lease liabilities of $251&#160;million and $24&#160;million, respectively, related to the embedded leases. As of June 30, 2021 and December 31, 2020, we had right-of-use assets of $296&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of June 30, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office, and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC South, MTC North, and MTC East leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0NQ_5a9726c1-3360-4e52-8421-5c4cd0c4973e">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2035. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, located in Norwood. We also leased other office spaces globally for our business operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cambridge facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2022 to 2029. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an industrial technology center in Norwood, Massachusetts, Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we entered into a lease agreement for a 240,000 square foot building located on the same campus for expansion of our commercial and clinical activities (MTC East). The lease will expire in February 2034. We have the option to extend the term for two extension periods of five years each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of June 30, 2021 and December 31, 2020, we had lease liabilities of $251&#160;million and $24&#160;million, respectively, related to the embedded leases. As of June 30, 2021 and December 31, 2020, we had right-of-use assets of $296&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of June 30, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office, and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC South, MTC North, and MTC East leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.</us-gaap:LesseeFinanceLeasesTextBlock>
    <mrna:OperatingLeaseNumberOfProperties
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzY2_0d0b00b4-526e-4d20-9a98-c5d578632f2a"
      unitRef="campus">2</mrna:OperatingLeaseNumberOfProperties>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i6ca4970aeb944ce094587b8e9e52cee5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNjc3_33842325-4450-4583-97cc-9e0f8c70b999"
      unitRef="sqft">261000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ia01e27faf121473685c9340ddfba9ede_I20160831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfOTA5_d227bc21-a219-4873-8746-30e7b843f3b7"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="ia01e27faf121473685c9340ddfba9ede_I20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTA5OQ_e34e112e-3965-4360-b933-3cb66ef9a80e"
      unitRef="extension_period">2</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia01e27faf121473685c9340ddfba9ede_I20160831"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTEyMw_c731c6e4-ab7c-4877-9c60-2ac3651a72d4">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="iad991ea73528435fa5b841a1edd13f95_I20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTM2OA_631ce388-323a-4df1-9f15-b92b8b20ba61"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="i4919b4b841a4432188fe3621950e1631_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTU3Mw_83d10d86-ca76-4154-9daf-d8aa4c9f57a4"
      unitRef="extension_period">4</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i4919b4b841a4432188fe3621950e1631_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0Ng_34164971-5c1f-437b-a634-21e367cc5a8d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrna:AllowanceForTenantImprovements
      contextRef="ic93eda10a84048869aafc24b02582937_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMTc3OQ_bb791269-1612-4fe6-8eeb-f947e97c6455"
      unitRef="usd">22000000</mrna:AllowanceForTenantImprovements>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNjA0NzMxMzk1Nzk1Mw_ffdcb914-10c7-4789-ae25-f391068a353c"
      unitRef="sqft">240000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNDM5ODA0NjUxNjMxNQ_e265b281-877c-43de-b4e5-bb18602594e4"
      unitRef="extension_period">2</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="id8906508ebec47b7aa2e2aee9d10b3e4_I20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNDM5ODA0NjUxNjMyMw_1c5da253-0c04-4de2-af98-1e00d7c539f1">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="if3b49c23c04b441dbe3849a5361236d8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjA5NQ_236a8820-8983-4208-9791-8620acf685cb"
      unitRef="usd">251000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9b90abfb0dbe4272a84180b8ea7942bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjEwMg_eda76c3d-1ccf-43b4-91cd-b033f11aaf32"
      unitRef="usd">24000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if3b49c23c04b441dbe3849a5361236d8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjE5OQ_2dbf5600-b095-464a-b9ad-844c69cc2bb9"
      unitRef="usd">296000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9b90abfb0dbe4272a84180b8ea7942bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMjIwNg_6e09e074-d88f-4a0c-af9c-6534c6c92095"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <mrna:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0Nw_c830d7ad-064f-4314-b6a5-65193abbec2f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of June 30, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office, and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC South, MTC North, and MTC East leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</mrna:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMy0yLTEtMS0w_76d96f5d-b0af-42da-bfca-de2ec1aa6881"
      unitRef="usd">104000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMy00LTEtMS0w_08e44755-c415-4015-aaab-a87164f2740b"
      unitRef="usd">90000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0yLTEtMS0w_fa4475ed-70cc-4f7b-b3fb-3f03d97fdb4c"
      unitRef="usd">475000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC00LTEtMS0w_908afbf8-11a8-4c75-a842-632c955005bb"
      unitRef="usd">55000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNS0yLTEtMS0w_7c2fe523-8069-425b-ab48-5937e8baa031"
      unitRef="usd">579000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNS00LTEtMS0w_545aed19-2f1c-4244-8d94-c6f6443f2396"
      unitRef="usd">145000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0yLTEtMS0w_ed176aa7-3932-4690-a333-bdab493134f9"
      unitRef="usd">11000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS00LTEtMS0w_284f10c2-23fe-49a1-bfdc-2974de08a8f7"
      unitRef="usd">6000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMi0xLTEtMA_042d4dc6-eaba-4407-9c3b-d8ca6c9d9ade"
      unitRef="usd">159000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtNC0xLTEtMA_639ad71d-bb6f-406c-9251-b761d3c10c62"
      unitRef="usd">24000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTEtMi0xLTEtMA_bd60f4e6-7fe2-4087-913e-0c1a79bd4294"
      unitRef="usd">170000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTEtNC0xLTEtMA_89552fb6-c030-4517-98e7-517da7934d1e"
      unitRef="usd">30000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTMtMi0xLTEtMA_b16418bc-3c09-47d3-ae36-f6e69ad55030"
      unitRef="usd">105000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTMtNC0xLTEtMA_3d59bb99-2a44-4170-9824-29b7976b298f"
      unitRef="usd">97000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTQtMi0xLTEtMA_acea8712-3e4e-4cc9-9d8b-3ac86b8fd2ef"
      unitRef="usd">328000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTQtNC0xLTEtMA_970063f4-18b2-4d24-a27e-9135554825f3"
      unitRef="usd">110000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTUtMi0xLTEtMA_bd00bbcc-3df7-4871-82f6-a308934968e8"
      unitRef="usd">433000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTUtNC0xLTEtMA_a0bbfb7d-0eb7-4153-8581-7ef65b1ce6ae"
      unitRef="usd">207000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTYtMi0xLTEtMA_d6904dfd-4ff6-4861-bd87-012df0b414d1"
      unitRef="usd">603000000</mrna:OperatingAndFinanceLeaseLiability>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTYtNC0xLTEtMA_2bbfaebd-a2fc-4921-bdb2-051350fd4b34"
      unitRef="usd">237000000</mrna:OperatingAndFinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0MQ_935fd56c-0976-46b1-8a33-812bbdea3428">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQ0Mg_6673a82a-2959-4d05-8a83-bee0a7555f31">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMS0yLTEtMS0w_9fff3f21-3787-4808-b3cb-f90fd9b12164"
      unitRef="usd">9000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMS00LTEtMS0w_3320057f-1737-464a-98a7-7320216d107c"
      unitRef="usd">100000000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMi0yLTEtMS0w_c1679a06-8127-48c0-9b80-e70ee45bdf48"
      unitRef="usd">23000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMi00LTEtMS0w_9319c298-15f2-47cf-91fd-1df6ee82e3f5"
      unitRef="usd">174000000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMy0yLTEtMS0w_6ef9583b-1942-4636-8184-f33c7f5d7965"
      unitRef="usd">23000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfMy00LTEtMS0w_d07298e2-71f5-49b5-ab7a-c56410bd0e19"
      unitRef="usd">19000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNC0yLTEtMS0w_4606f1e6-dc62-4be5-aa15-6f4a22998daa"
      unitRef="usd">16000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNC00LTEtMS0w_91a9a2c2-537f-483d-a441-f9987c96a58e"
      unitRef="usd">19000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNS0yLTEtMS0w_88d80d76-a1e6-4ec9-92f4-278dcee9b828"
      unitRef="usd">17000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNS00LTEtMS0w_c34305bf-2931-43ef-869c-0580cea1fc07"
      unitRef="usd">19000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <mrna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNi0yLTEtMS0w_d29c1c5e-5332-4cb5-bf20-b70e797bb93d"
      unitRef="usd">94000000</mrna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <mrna:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNi00LTEtMS0w_c1ef7b73-e507-4371-ada4-8aa6a0c490e2"
      unitRef="usd">600000000</mrna:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNy0yLTEtMS0w_3b1940f3-01a8-488c-a890-e986a1181e13"
      unitRef="usd">182000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfNy00LTEtMS0w_eaaaf6b6-d714-48ce-af72-af307cd5b5a7"
      unitRef="usd">931000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOC0yLTEtMS0w_ee5ab2ec-543c-4944-8f7a-4c83f82a4f34"
      unitRef="usd">66000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOC00LTEtMS0w_d17bfaf5-5bdd-4a5b-93f8-54236842a4cf"
      unitRef="usd">444000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOS0yLTEtMS0w_1ff571e7-6f4a-49e8-a4ba-f5d99d9b9089"
      unitRef="usd">116000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVjNmZmMTM2OGRkZTQzNjFhMGVjMjdmZWRlNWViODk5L3RhYmxlcmFuZ2U6NWM2ZmYxMzY4ZGRlNDM2MWEwZWMyN2ZlZGU1ZWI4OTlfOS00LTEtMS0w_b7d19c6a-cdaf-4fa1-a534-ec31a4633d9c"
      unitRef="usd">487000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iebf2947c07b840e4a74467063deb1ae6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzIyMw_2f149b59-c20e-4b27-8aee-089029e5a6fb"
      unitRef="usd">445000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <mrna:LeasesImputedInterestRate
      contextRef="i04fa63042c64408fbd832e6524b4b23f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzMyNg_73eca801-16a1-4b04-a613-7f2913642e98"
      unitRef="number">0.172</mrna:LeasesImputedInterestRate>
    <mrna:LeasesIncrementalBorrowingRate
      contextRef="ie095a587c0d84c63a7d5403131e4b7e3_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQxNw_6bb33004-bc85-4020-9601-7642751232c9"
      unitRef="number">0.082</mrna:LeasesIncrementalBorrowingRate>
    <mrna:LeasesIncrementalBorrowingRate
      contextRef="ied6207c51d5c4d1da7a394ed937340ff_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfNjA0NzMxMzk1Nzk2MQ_edfe51e6-53c9-4ba8-90e7-0108ce73da03"
      unitRef="number">0.037</mrna:LeasesIncrementalBorrowingRate>
    <mrna:LeasesIncrementalBorrowingRate
      contextRef="i61568f63bbbf460192175495b73fb1e2_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RleHRyZWdpb246YjVlOTBkMjRiZjJkNDQwZTkyYTg1NDdmMjZiMjJhMTlfMzQyNA_614f4fc0-71e4-4493-bb7f-f5a8298244c3"
      unitRef="number">0.006</mrna:LeasesIncrementalBorrowingRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfNTgzOA_e0b09b83-6238-4a54-92b7-99bcddb14101">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our Personalized Cancer Vaccine (PCV) Agreement and PCV/SAV Agreement (which also relates to shared neoantigen mRNA cancer vaccine) with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $243&#160;million for both periods as of June 30, 2021 and December 31, 2020. Please refer to our 2020 Form 10-K Note 5 to our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#x2019;s or director&#x2019;s lifetime.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through the three and six months ended June 30, 2021 and the year ended December 31, 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments and Purchase Orders&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of June 30, 2021, we h&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ad&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; $1.5 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2022. As of June 30, 2021, we had $49 million o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;f non-c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2024. These amounts represent our minimum contractual obligations, including termination fees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At June 30, 2021 and December 31, 2020, we had cancelable open purchase orders of $1.3&#160;billion and $897 million, respectively, in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at June 30, 2021 and December 31, 2020, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licenses to Patented Technology&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments, up to $24&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. For the three and six months ended June 30, 2021, we recognized $148&#160;million and $232&#160;million, respectively, of royalty expenses associated with our product sales, which was recorded to cost of sales in our condensed consolidated statements of operations. We did not recognize any such royalties in the first half of 2020 as we did not have product sales during the period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="i453114f3b5a7454382060dc9a3cc7f07_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMTY0OTI2NzQ0NzgyNQ_45dafcff-a8de-4545-817a-6423df79e051"
      unitRef="usd">243000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="if3e4997c888f446e9fe81c8bdd3f1e5d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMTY0OTI2NzQ0NzgyNQ_586ef3a8-4232-4703-a555-d95fbfcf1ade"
      unitRef="usd">243000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i598d0bc0445a41abbc9bdcd1258b0d3c_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjYxNw_5bb72f3d-f857-4c51-bf33-3a55fc0175e7"
      unitRef="usd">1500000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i8caec99e729443a0aee89f8db26aa392_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjgwNg_83f428aa-b0a2-4dfa-8fb3-663bf51b23bc"
      unitRef="usd">49000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i67185c627d644febad389a0c535248b1_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMTY0OTI2NzQ0Nzc5Nw_4910c761-ae38-4fff-8b4d-94fd6b0a3232"
      unitRef="usd">1300000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ic3c3513fce714f9e9e6c45c936e12fe2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMzY5NQ_7251ffa9-d454-4527-a876-3874bc37e4f2"
      unitRef="usd">897000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount
      contextRef="i7c7f1943108a4146a37ed6c8267654a2_I20170626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfNTAwOA_df30d242-c4dc-4ee2-b7e5-bc925b751a32"
      unitRef="usd">24000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjE5OTAyMzI2MTk5NA_8c1009d9-dbad-4e43-8fec-3c166b7c18a2"
      unitRef="usd">148000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83MC9mcmFnOmI0MjZiNjUxN2E0ZjRkMDU5NzQ3NGI2OTc2OTM2MGJlL3RleHRyZWdpb246YjQyNmI2NTE3YTRmNGQwNTk3NDc0YjY5NzY5MzYwYmVfMjE5OTAyMzI2MjAwNw_a1ab59ff-2153-48c3-8c61-d41dba268ea4"
      unitRef="usd">232000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjIwMg_4b8562f0-72d5-4551-bf5e-0e9e3145049f">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, we had a total of&#160;60 million&#160;shares reserved for future issuance under our Equity Plans, of which 33 million shares were reserved for equity awards previously granted, and&#160;27 million&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares were available for future grants under the 2018 Equity Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our option activity during the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $575&#160;million for the six months ended June 30, 2021. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately $59&#160;million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity during the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average Fair Value per Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of restricted stock units vested during the six months ended June 30, 2021 was $9&#160;million. The total intrinsic value of restricted stock units vested during the six months ended June 30, 2021 was $54&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2021, we granted PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan (ESPP)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sold an immaterial number of shares under the ESPP during the six months ended June 30, 2021. As of June 30, 2021, 4&#160;million shares were available for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, there was $336&#160;million of total unrecognized compensation cost related to unvested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 3.0 years at June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfNjM_b4fbd6ef-1b2f-4e39-90a6-b13bddf03f81"
      unitRef="shares">60000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i0e58c0fb75144621874b106da58aa126_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTM1_9fe7c57e-9e59-4b14-b4b0-cd23780b830c"
      unitRef="shares">33000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i806cd5c4c8db4bbb96da09f4192d4f77_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjAx_954cd76c-7967-4976-8f0b-ad312b48a465"
      unitRef="shares">27000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjE5Mw_7d25977f-6c83-4f0f-b3be-150ae0477ce1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our option activity during the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS0yLTEtMS0w_8918e03a-4d27-4f80-912b-76d13b8e2323"
      unitRef="shares">34060000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS00LTEtMS0w_a9a2e50d-923b-4e84-bfb4-0af6a2c6e80a"
      unitRef="usdPerShare">17.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS02LTEtMS0w_654ccb5e-7679-4d8d-86e7-f5055ec367a2"
      unitRef="usdPerShare">9.12</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic32a9001570747069665c11f135527dc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS04LTEtMS0w_1fe136e3-bbb2-49be-8243-2a094a24d2d9">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMS0xMC0xLTEtMA_9f3dae82-1dac-47b9-834d-0f1feb2d515c"
      unitRef="usd">2976000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMi0yLTEtMS0w_01bc452e-4e4f-45c7-8e34-226c6f06aff0"
      unitRef="shares">1130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMi00LTEtMS0w_50cc27c7-2007-4162-97d3-36ad46693d1e"
      unitRef="usdPerShare">173.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMi02LTEtMS0w_d5e19509-d5e2-405d-af2e-86313db368da"
      unitRef="usdPerShare">76.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMy0yLTEtMS0w_5ebbc33b-5472-4e0c-bd5a-5078b3ca8ab2"
      unitRef="shares">3860000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMy00LTEtMS0w_c0f8bc33-7b46-4a28-930e-750f31c80fdd"
      unitRef="usdPerShare">15.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfMy02LTEtMS0w_badac5e6-9af4-40ef-82e3-1c7ded373ca8"
      unitRef="usdPerShare">8.60</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNC0yLTEtMS0w_1963bf15-23ac-433d-8782-2695847259b5"
      unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNC00LTEtMS0w_85c5b3d4-51a6-4b08-92e5-8548e3d32ae8"
      unitRef="usdPerShare">27.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNC02LTEtMS0w_182186ca-cef5-42e6-a77e-35768b1ced4b"
      unitRef="usdPerShare">14.33</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS0yLTEtMS0w_d03be3ac-3294-47fb-a084-fac40cf236dd"
      unitRef="shares">30880000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS00LTEtMS0w_09cfd54d-c342-4e8e-8f09-faea38c21fe8"
      unitRef="usdPerShare">22.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS02LTEtMS0w_3c8a915d-4c9b-4d9e-a21f-62beca67b529"
      unitRef="usdPerShare">11.59</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS04LTEtMS0w_bcdc4ac5-a357-4a82-b0ba-c2d800b3a64d">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNS0xMC0xLTEtMA_219bef9e-6a2a-4e22-95dd-8c7d57560e15"
      unitRef="usd">6547000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi0yLTEtMS0w_ada31f78-c586-4c12-b17b-7d4d67caa6c6"
      unitRef="shares">17220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi00LTEtMS0w_1d586c0b-24d0-4bc8-9e34-de1a8085f313"
      unitRef="usdPerShare">12.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi02LTEtMS0w_50d4c8ca-0512-4abb-94cc-dffdb4ccc31b"
      unitRef="usdPerShare">6.30</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi04LTEtMS0w_d2fbf2d7-a0dc-43bf-b87f-2a88d8aacaff">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNi0xMC0xLTEtMA_1986f618-3703-4f1b-8ff5-deb6c6c32522"
      unitRef="usd">3837000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy0yLTEtMS0w_69a40164-21ed-46b4-bd2e-00fc9e1872ac"
      unitRef="shares">13660000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy00LTEtMS0w_f9985818-9635-4239-b954-5fed99c9eb1d"
      unitRef="usdPerShare">36.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy02LTEtMS0w_9d9b08a8-4406-4c20-8d31-619350b4db10"
      unitRef="usdPerShare">18.26</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy04LTEtMS0w_f9e56572-e76c-42fc-b34f-301e3c7964cf">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjJmMWRhMWU4ODIxNjQ1ZTdhOWI5MDkxYjdiMThlMzFiL3RhYmxlcmFuZ2U6MmYxZGExZTg4MjE2NDVlN2E5YjkwOTFiN2IxOGUzMWJfNy0xMC0xLTEtMA_4b9e5d2c-9321-4a15-a935-231805a47f01"
      unitRef="usd">2710000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTMyMw_8b699010-40b0-4d2b-8c70-499e521db9e3"
      unitRef="usd">575000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTMzNw_1f2711ab-fba9-40f1-82ec-5cd6ac048b82"
      unitRef="usd">59000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjE5OA_4099d58e-47c7-41de-ad17-7c5da5db61b0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity during the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average Fair Value per Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib676efd3333c4e95baf151a431bb5025_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMS0xLTEtMS0w_15e673c0-aa7e-4317-be74-a57092b555d2"
      unitRef="shares">2190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib676efd3333c4e95baf151a431bb5025_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMS0zLTEtMS0w_dc10e821-3a14-468a-b3f8-88413b36b93d"
      unitRef="usdPerShare">30.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMi0xLTEtMS0w_e589d3e6-4811-4a4d-8183-42c9bb9e3e2f"
      unitRef="shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMi0zLTEtMS0w_17caa3c6-a511-49e5-9c83-2bd0dccfc538"
      unitRef="usdPerShare">170.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMy0xLTEtMS0w_1cf2c53b-ed2e-499e-8a2d-4e6a5dba03e7"
      unitRef="shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfMy0zLTEtMS0w_66dc3cb1-5204-4705-be2f-9078c226f3c6"
      unitRef="usdPerShare">25.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNC0xLTEtMS0w_1d6f11d1-b6b7-437a-8af7-2caebf26afaa"
      unitRef="shares">70000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNC0zLTEtMS0w_e2d1b14c-04bd-4499-8f11-ab47f02a6185"
      unitRef="usdPerShare">37.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie402888bb2fc4ea880b40f2a9d7c22f0_I20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNS0xLTEtMS0w_50d413e9-afdc-4f00-afe8-ffb136d0adf7"
      unitRef="shares">2320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie402888bb2fc4ea880b40f2a9d7c22f0_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjA1MDE3NTk1MTM1YTRkMTk4Yzk4Yzc0NjBkNmIyMjcyL3RhYmxlcmFuZ2U6MDUwMTc1OTUxMzVhNGQxOThjOThjNzQ2MGQ2YjIyNzJfNS0zLTEtMS0w_e6cb6fe2-9265-443e-9b60-d44212621c08"
      unitRef="usdPerShare">64.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTEyMw_21c196c0-0bd5-4030-ab08-3c35d4ea369b"
      unitRef="usd">9000000</us-gaap:RestrictedStockExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="id3c693367faa4e6492e2f097d9c118d0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTIwMw_c212bc29-b0bc-4b2d-b479-89c5cd916cdb"
      unitRef="usd">54000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ied36f68f5ff84b10a3d60914c0b61586_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTQxMw_0e320220-dc9c-47c7-8f55-a9c2e90c053a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="ife7005ad8225459bbf949983a16fb039_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTU1NA_d6b17543-6720-4f51-9593-aab3afaf43d6"
      unitRef="number">0</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="i27a9e69e7d27416e8d304a0b72359725_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTU2MA_15accfc6-e828-433c-bd80-373f1173529c"
      unitRef="number">2</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6b1bbe23395c4aa6988514c29e2ee39e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTc0NA_a7e9f0bf-477f-45b3-9e6c-077265c165ea"
      unitRef="shares">4000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMjE5OQ_154d1243-3622-4612-93a4-f74729918d24">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5940ab735af34e5e946ede601d642a53_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi01LTEtMS0w_c35fc61c-d074-496e-972e-c575057b3f82"
      unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a0202da86f1409fafc721c18c4b375b_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi03LTEtMS0w_7c277e21-38a1-4b59-bc0d-e5beecd2abf0"
      unitRef="usd">21000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i940058d521aa4563a84e76e20cd336d6_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi05LTEtMS0w_1dc9e5a7-2073-422c-b3d4-78e4e13704e7"
      unitRef="usd">46000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib67410869f8c478eb669bc8351987988_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMi0xMS0xLTEtMA_754c00ec-e9e2-4204-953e-a5d41da52102"
      unitRef="usd">39000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifdc29bdcf87245dab06fb8bb8f5635ff_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy01LTEtMS0w_2d58f74b-b145-495d-a54c-498491d17183"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0beaf98f2bec4a78acd4d80ffe785bbc_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy03LTEtMS0w_c75f3b1f-5e76-43ed-9e67-ff24b64b7167"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i85a56c15404a4b8eb579be1a6a78e357_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy05LTEtMS0w_bf11ec50-4d20-4c78-a3b8-e5f90f2df957"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8310dab123334253aa6827d712250361_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMy0xMS0xLTEtMA_f933852a-3e96-4df3-8595-106ca8d50f48"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id0463634352040069acfeb178a893295_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC01LTEtMS0w_ee19a741-76e7-4a61-963b-bc0d6b537ea3"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45447fcebe4141ea9d78a8504cdc1c19_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC03LTEtMS0w_c7d2e8d3-6d53-4e63-9a80-ebb87be5632c"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6b9ec1f5cce442791bacd86253cbd96_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC05LTEtMS0w_66b3dace-ad50-44ef-9488-ed5dcb1239d3"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8db1b0e2148b492bb939ebb0463eb2d3_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNC0xMS0xLTEtMA_bce70600-3771-4fbb-8346-6a0503509bfe"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS01LTEtMS0w_d293d99c-28eb-4f48-8cb7-8df5eb37119a"
      unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS03LTEtMS0w_28fd8da0-4a56-4df4-addd-dac1f3b01fe5"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS05LTEtMS0w_8d341b7b-fa50-49ed-b75d-a6f0dd9e41fd"
      unitRef="usd">65000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNS0xMS0xLTEtMA_b13e6eb6-9ae4-4c7a-a752-57c6636b2600"
      unitRef="usd">45000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9f6e9c4e55144bb8df23054a288a2e2_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy0yLTEtMS0xMjYx_a9da8f35-c428-4493-b8c6-232d5d0e04ef"
      unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d0ada455afe4e75bfe9e71f54e33319_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy00LTEtMS0xMjYx_62e6dc68-a007-4bc6-b937-98568faf0771"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1fcb8aedfe9420c8551dec0ade1347b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy05LTEtMS0w_4080b860-3aef-4d8a-a4a6-74e11e25cd54"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3435c602db343908bad969f4cfa4f42_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfNy0xMS0xLTEtMA_1e01653a-7bde-4853-927a-c24bba8d3a9f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7303c622b8134633b87246e130589360_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC01LTEtMS0w_8d22578b-47db-42fd-a232-466229d35f41"
      unitRef="usd">15000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i230bf3fb1f8e419181b3f634ef694994_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC03LTEtMS0w_41e923f1-3558-4101-b992-54f8cfab4583"
      unitRef="usd">15000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i36e5a124b9bb45f6b74b3d193e94adbb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC05LTEtMS0w_f85d32a7-2298-45a2-b1ae-7921a4378113"
      unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80e219eb6c9048bbb915840c4add36fd_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOC0xMS0xLTEtMA_19ee7eb7-73f1-42d2-b631-c336b2f3b5d9"
      unitRef="usd">27000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifea21debe3524bff9d6e588cd4b5716b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS01LTEtMS0w_6465606e-9fcf-47ba-8925-ff27599daff8"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib29b4d951999485cba6731af4351eddc_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS03LTEtMS0w_6d50b0c4-119f-440b-9cc3-d6494ccee0d2"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i283d9247556a4278afc37abb5ac02feb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS05LTEtMS0w_9e31feda-7a8e-4cda-8033-a7d8a6e2acd0"
      unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19460b8e62a442f88dd3c9900970530a_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfOS0xMS0xLTEtMA_48bf75e3-4fb9-430e-a40c-f4f369c0a5d3"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtNS0xLTEtMA_fba372f5-5978-4179-af66-62153478aa19"
      unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtNy0xLTEtMA_40333873-42f6-4964-a186-a0ecf53b0659"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtOS0xLTEtMA_fb33c38c-9959-4c4f-a23b-8eb02abc2789"
      unitRef="usd">65000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RhYmxlOjEyYTVmZTU1YjQ4OTRkNzlhMjVkYjE5ZGYxYzM2Y2ZkL3RhYmxlcmFuZ2U6MTJhNWZlNTViNDg5NGQ3OWEyNWRiMTlkZjFjMzZjZmRfMTAtMTEtMS0xLTA_f56e8606-abed-4306-855f-8aefd0e5aec7"
      unitRef="usd">45000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i23d47f973c914379ad830c261ec3d4eb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTQxMA_2d6334b6-4998-4caf-8368-21cf89377e13"
      unitRef="usd">336000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83My9mcmFnOmE5MmY5YTUwZDY0NDRkNTg5YWVmYmY2YmZjZjNkYjc1L3RleHRyZWdpb246YTkyZjlhNTBkNjQ0NGQ1ODlhZWZiZjZiZmNmM2RiNzVfMTY0OTI2NzQ0NTQzNA_740ae8ad-ac4a-4094-9869-a2048cdae4fc">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMzU1NQ_35e29035-da49-45a2-a3b4-d4a340915e23">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S. federal, state, and foreign income taxes. For the three and six months ended June 30, 2021, we recorded provisions for income taxes of $283 million and $322 million, respectively, compared to an insignificant amount for the same periods in 2020. Our effective tax rate for the three and six months ended June 30, 2021 was 9% and 7%, respectively, and was lower than the U.S. statutory rate primarily due to the benefit related to the release of the valuation allowance on the majority of our tax attributes, the benefit of the foreign derived intangible income deduction and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three and six months ended June 30, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. On a periodic basis, we reassess any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, we determined we should reverse the majority of our valuation allowance through the annual effective tax rate (AETR) with respect to amounts we expect to realize through current year income. In addition, for the three and six months ended June 30, 2021, we have recorded a discrete benefit of $49&#160;million related to the release of the valuation allowance on deferred tax assets that we expect to utilize in future years. We maintain a valuation allowance on certain state tax attributes that we expect will expire prior to the utilization. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. We do not currently expect the CARES Act to have a significant impact on our provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of June 30, 2021 and December 31, 2020, we had an immaterial amount of gross unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially increase within the next twelve months. We accrue interest and penalties related to unrecognized tax benefits as a component of our provision for income taxes. We did not recognize any material interest or penalties related to uncertain tax positions during the three and six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We are not currently subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction since inception.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMzI5ODUzNDg4NzIxNA_0dbd9d5f-6785-4c3c-8947-076d404ba022"
      unitRef="usd">283000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTY0OTI2NzQ0NTkzMQ_b7f8edff-153d-4494-b1db-701a81399f4b"
      unitRef="usd">322000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTY0OTI2NzQ0NzI3OA_cb85caa5-76cb-4b28-8652-300ae0452c99"
      unitRef="number">0.09</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTY0OTI2NzQ0NzI4Mg_87111dde-8704-4176-981e-89b853b5942f"
      unitRef="number">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTkzOA_104e1661-c6ba-4de6-acae-a9d45cef8f80"
      unitRef="usd">-49000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV83Ni9mcmFnOmU5ZDdmYjZlZGQ5NTRkMTg5NTdmMDg2ZGNlYjhmOGVkL3RleHRyZWdpb246ZTlkN2ZiNmVkZDk1NGQxODk1N2YwODZkY2ViOGY4ZWRfMTkzOA_dbe04f34-862f-4ef7-b7ea-ab395c6f0198"
      unitRef="usd">-49000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RleHRyZWdpb246MmNjOGNiMjUwYTMxNGE1Mjk3NTUwODg4YTY2NWMwNmVfNzgz_7813ba1f-c77a-4a49-9112-ef173b627921">Earnings (Loss) per Share &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the three and six months ended June 30, 2021 and 2020 were calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of June 30, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RleHRyZWdpb246MmNjOGNiMjUwYTMxNGE1Mjk3NTUwODg4YTY2NWMwNmVfNzc5_0489572f-fd46-488b-9f5e-9aa81ec17b8e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the three and six months ended June 30, 2021 and 2020 were calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy0yLTEtMS0xMjg4_25f2c9be-3b8b-4871-a310-9f7a3eb61423"
      unitRef="usd">2780000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy00LTEtMS0xMjg4_6e43b98c-9e93-446e-8e58-afd62c187602"
      unitRef="usd">-117000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy05LTEtMS0w_2d369218-5f8f-4e02-8dd2-604b6270da26"
      unitRef="usd">4001000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMy0xMS0xLTEtMA_f1eb1703-34ae-411f-b2eb-c892434cf854"
      unitRef="usd">-241000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS0yLTEtMS0xMjg4_1e6a43c8-40d2-4850-99c3-dafc8b7f627f"
      unitRef="shares">402000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS00LTEtMS0xMjg4_91bbe852-7109-413d-8d3a-97cf5b7f7a38"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS05LTEtMS0w_b9dad254-d2f0-402c-ac4c-4fd2a182e8dd"
      unitRef="shares">401000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNS0xMS0xLTEtMA_2d820cc7-7ef2-45eb-bec5-062c6d78b806"
      unitRef="shares">367000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi0yLTEtMS0xMjg4_4e6affc1-4dd2-40cc-928c-dcb7031fb7ba"
      unitRef="shares">29000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi00LTEtMS0xMjg4_36d67482-e265-4ff6-8194-f87bdb1a53f0"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi05LTEtMS0w_df3711ec-93e1-41da-9cfa-c1de8ee40148"
      unitRef="shares">29000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNi0xMS0xLTEtMA_cde1952c-91ef-485a-bd1e-9d3658f73d77"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy0yLTEtMS0xMjg4_7422777d-e37c-4303-a3d8-baaa32552921"
      unitRef="shares">431000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy00LTEtMS0xMjg4_d6492c7e-f062-486e-ba91-c1a7075586f8"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy05LTEtMS0w_6225f91d-b546-4f82-85f1-cf54f49af199"
      unitRef="shares">430000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfNy0xMS0xLTEtMA_c567ec70-6244-4d6d-934e-a7002b9104e3"
      unitRef="shares">367000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS01LTEtMS0w_9bdb900f-316d-445e-be6c-2133ddc57b95"
      unitRef="usdPerShare">6.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS03LTEtMS0w_126666bc-6fee-47d1-a02c-2e00835f4b52"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS05LTEtMS0w_94453d79-eec3-4ca6-9fe9-73a959621be1"
      unitRef="usdPerShare">9.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfOS0xMS0xLTEtMA_14bee66a-30a8-4632-ba28-9c7099439672"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5c212449977847f097fb6ce69dc98327_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtMi0xLTEtMTI4OA_b73bb955-2bdc-44d1-a25e-5b75135abb2e"
      unitRef="usdPerShare">6.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtNC0xLTEtMTI4OA_9ab1cabf-ff26-43aa-a2a2-e0e6f1cb891e"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtOS0xLTEtMA_e8515786-3517-49ea-bc5b-080462f7e0a6"
      unitRef="usdPerShare">9.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOjNmYzkxNzFmN2E0MTRhMzViYTExNjk5Yjc5YTM0ZDE5L3RhYmxlcmFuZ2U6M2ZjOTE3MWY3YTQxNGEzNWJhMTE2OTliNzlhMzRkMTlfMTAtMTEtMS0xLTA_449b6e69-db71-42d3-90e9-1b16656c1a4f"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RleHRyZWdpb246MmNjOGNiMjUwYTMxNGE1Mjk3NTUwODg4YTY2NWMwNmVfNzc0_ab967b8a-683f-4b41-b21d-0516064e4fa2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of June 30, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff02256a11834a66b8c527254b62d147_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOmQ3Zjg5ZWUzYjA0YjRmMDBiNDY0MmJkMzAwODRkZGJlL3RhYmxlcmFuZ2U6ZDdmODllZTNiMDRiNGYwMGI0NjQyYmQzMDA4NGRkYmVfMi0xLTEtMS0w_ba3c8410-78cf-4eb1-8d9d-919e96d76a4a"
      unitRef="shares">40000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i292b707793574fa196af16232e6fad08_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOmQ3Zjg5ZWUzYjA0YjRmMDBiNDY0MmJkMzAwODRkZGJlL3RhYmxlcmFuZ2U6ZDdmODllZTNiMDRiNGYwMGI0NjQyYmQzMDA4NGRkYmVfMy0xLTEtMS0w_7a6f17b8-d854-48dc-8ce9-4f11387a8265"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idaeb6871e31e46849c7dd99460a52126_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84Mi9mcmFnOjJjYzhjYjI1MGEzMTRhNTI5NzU1MDg4OGE2NjVjMDZlL3RhYmxlOmQ3Zjg5ZWUzYjA0YjRmMDBiNDY0MmJkMzAwODRkZGJlL3RhYmxlcmFuZ2U6ZDdmODllZTNiMDRiNGYwMGI0NjQyYmQzMDA4NGRkYmVfNC0xLTEtMS0w_7993f5ff-bfea-4b3a-803c-1cad8147834e"
      unitRef="shares">42000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i179b2e7c238549528ec055756ce46033_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84NS9mcmFnOmY1YzJkZWNlM2RjYzQ5NmZhNTFkZGE2YTI1YmYwYmE0L3RleHRyZWdpb246ZjVjMmRlY2UzZGNjNDk2ZmE1MWRkYTZhMjViZjBiYTRfMTA5Ng_5645685a-5f99-4ee6-be3a-6487112a89d9">Subsequent Events&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to June 30, 2021, we have entered into additional supply agreements with customers to provide up to 262&#160;million doses of our COVID-19 vaccine and our updated variant booster vaccine candidate based on the initial confirmed volume, subject to modifications.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2021, our Board of Directors authorized a Share Repurchase Program of our common stock, which expires on August 2, 2023. Pursuant to the Share Repurchase Program, we may repurchase up to $1.0&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <mrna:NumberOfDosesOfVaccineCandidate
      contextRef="icbdd283932184bea9f7f771d39f918d6_D20210701-20210805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84NS9mcmFnOmY1YzJkZWNlM2RjYzQ5NmZhNTFkZGE2YTI1YmYwYmE0L3RleHRyZWdpb246ZjVjMmRlY2UzZGNjNDk2ZmE1MWRkYTZhMjViZjBiYTRfMTI4_66892580-564c-4a9c-9257-806959610b47"
      unitRef="dose">262000000</mrna:NumberOfDosesOfVaccineCandidate>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ibdd0a3a2ce304bb5a423153da5ba16fc_I20210802"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV84NS9mcmFnOmY1YzJkZWNlM2RjYzQ5NmZhNTFkZGE2YTI1YmYwYmE0L3RleHRyZWdpb246ZjVjMmRlY2UzZGNjNDk2ZmE1MWRkYTZhMjViZjBiYTRfNjA0NzMxMzk1NjU4Nw_718b1a15-5036-4bac-82b8-d6f4fe2f2f79"
      unitRef="usd">1000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819919036360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Moderna, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3467528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Technology Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">714-6500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,646,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915424344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,603<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">2,387<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,020<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,969<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments, non-current</a></td>
<td class="nump">4,207<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">16,153<span></span>
</td>
<td class="nump">7,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,302<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,840<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,449<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001; 162&#160;shares authorized as of June 30, 2021 and December 31, 2020; no shares issued or outstanding at June 30, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2021 and December 31, 2020; 403 and 399 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,931<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="nump">1,757<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">6,704<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 16,153<span></span>
</td>
<td class="nump">$ 7,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139820008697688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">162,000,000<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">403,000,000<span></span>
</td>
<td class="nump">399,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">403,000,000<span></span>
</td>
<td class="nump">399,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916159240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 4,354,000,000<span></span>
</td>
<td class="nump">$ 67,000,000<span></span>
</td>
<td class="nump">$ 6,291,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">943,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">421,000,000<span></span>
</td>
<td class="nump">152,000,000<span></span>
</td>
<td class="nump">822,000,000<span></span>
</td>
<td class="nump">267,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">121,000,000<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="nump">198,000,000<span></span>
</td>
<td class="nump">61,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,292,000,000<span></span>
</td>
<td class="nump">189,000,000<span></span>
</td>
<td class="nump">1,963,000,000<span></span>
</td>
<td class="nump">328,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">3,062,000,000<span></span>
</td>
<td class="num">(122,000,000)<span></span>
</td>
<td class="nump">4,328,000,000<span></span>
</td>
<td class="num">(253,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="num">(12,000,000)<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">3,063,000,000<span></span>
</td>
<td class="num">(117,000,000)<span></span>
</td>
<td class="nump">4,323,000,000<span></span>
</td>
<td class="num">(241,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">283,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">322,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,780,000,000<span></span>
</td>
<td class="num">$ (117,000,000)<span></span>
</td>
<td class="nump">$ 4,001,000,000<span></span>
</td>
<td class="num">$ (241,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (usd per share)</a></td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="nump">$ 9.98<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (usd per share)</a></td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares used in calculation of earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 4,197,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,930,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">139,000,000<span></span>
</td>
<td class="nump">38,000,000<span></span>
</td>
<td class="nump">333,000,000<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="nump">$ 29,000,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916390488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,780<span></span>
</td>
<td class="num">$ (117)<span></span>
</td>
<td class="nump">$ 4,001<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) gains on available-for-sale debt securities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: net realized (gains) losses on available-for-sale securities reclassified in net income (loss)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net (decrease) increase from available-for-sale debt securities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains on derivative instruments</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 2,795<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="nump">$ 4,014<span></span>
</td>
<td class="num">$ (235)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914628424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,670<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (1,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs of $1</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2020</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(1,738)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2020</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,268<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs of $1</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2020</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(1,738)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">2,561<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="nump">3,860<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,001<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2021</a></td>
<td class="nump">6,704<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,931<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2021</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">2,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,780<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2021</a></td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,931<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910946184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819918926392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,001<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/accretion of investments</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(72)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(629)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(596)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases', window );">Right-of-use assets, operating leases</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,433<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">7,034<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(6,559)<span></span>
</td>
<td class="num">(903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,058)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offerings of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock through equity plans, net</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChargesToFinancingLeaseLiabilities', window );">Changes in financing lease liabilities</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">2,636<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">5,614<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments', window );">Right-of-use assets obtained through finance lease modifications and reassessments</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for financing lease liabilities</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChargesToFinancingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges To Financing Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChargesToFinancingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Right Of Use Asset, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets Obtained Through Finance Lease Modifications And Reassessments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914998456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the Business<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in more than 50 countries and from the World Health Organization. Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the European Union and Japan and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. On June 1, 2021, we initiated the rolling submission process with the U.S. FDA for a Biologics License Application for our COVID-19 vaccine, and we currently anticipate completing our submission in August 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2021, we had 24 mRNA development programs in our portfolio with 14 having entered the clinic. We have incurred significant expenses in connection with the discovery, development and commercialization of our products, and we expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with the ongoing development and commercialization of our COVID-19 vaccine and ongoing activities to support our platform research, drug discovery and clinical development, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, infrastructure and Research Engine and Early Development Engine (which includes our Moderna Technology Center), digital infrastructure, creation of a portfolio of intellectual property, and administrative support. We may finance our future cash needs that exceed our operating costs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of&#160;June 30, 2021&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of these financial statements. We are subject to numerous risks and uncertainties associated with pharmaceutical development and commercialization, and we are unable to predict the timing or amount of expenses or if we will be able to maintain profitability. If we are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912895592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Basis of Presentation and Recent Accounting Standards</a></td>
<td class="text">Summary of Basis of Presentation and Recent Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2021 are consistent with those described in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains/losses and gains/losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income for the three and six months ended June 30, 2021 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:69.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915072984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Sales</a></td>
<td class="text">Product Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.929%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales for the three and six months ended June 30, 2020. As of June 30, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, we had deferred revenue of $7.2 billion and $3.8 billion, respectively, related to customer deposits, classified as current deferred revenue in our condensed consolidated balance sheets. Timing of product manufacturing, delivery, and receipt of marketing approval will determine the period in which revenue is recognized.</span></div>Grant Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of June 30, 2021, we have earned the committed funding of $5&#160;million. An additional $51&#160;million funding would be available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. The maximum award from BARDA, inclusive of the March 2021 and April 2021 amendments, was approximately $1.3&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $421&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received from BARDA an award of up to $126&#160;million, subsequently adjusted to $117&#160;million in 2021, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $59&#160;million, with an additional $8&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of June 30, 2021, the available funding, net of revenue earned, was $10&#160;million, with up to an additional $80&#160;million available, if additional follow-on projects are approved. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue as of and for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912896728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Grant Revenue</a></td>
<td class="text">Product Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.929%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales for the three and six months ended June 30, 2020. As of June 30, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, we had deferred revenue of $7.2 billion and $3.8 billion, respectively, related to customer deposits, classified as current deferred revenue in our condensed consolidated balance sheets. Timing of product manufacturing, delivery, and receipt of marketing approval will determine the period in which revenue is recognized.</span></div>Grant Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of June 30, 2021, we have earned the committed funding of $5&#160;million. An additional $51&#160;million funding would be available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. The maximum award from BARDA, inclusive of the March 2021 and April 2021 amendments, was approximately $1.3&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $421&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received from BARDA an award of up to $126&#160;million, subsequently adjusted to $117&#160;million in 2021, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of June 30, 2021, the remaining available funding, net of revenue earned, was $59&#160;million, with an additional $8&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of June 30, 2021, the available funding, net of revenue earned, was $10&#160;million, with up to an additional $80&#160;million available, if additional follow-on projects are approved. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue as of and for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915030440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration Revenue</a></td>
<td class="text">Collaboration Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of June 30, 2021 and December 31, 2020, we had collaboration agreements with AstraZeneca plc (AstraZeneca), Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and Chiesi Farmaceutici S.P.A. (Chiesi). Please refer to our 2020 Form 10-K under the heading &#8220;Third-Party Strategic Alliances&#8221; and Note 5 to our consolidated financial statements for further description of each of the collaboration agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.500%"><tr><td style="width:1.0%"/><td style="width:44.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the six months ended June 30, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:38.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of June 30, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $321&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912293768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at June 30, 2021 and December 31, 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities by contractual maturity at June 30, 2021 and December 31, 2020 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive loss, net of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any impairment charges related to available-for-sale securities for the three and six months ended June 30, 2021 and 2020. We did not recognize any credit-related allowance to available-for-sale securities as of June 30, 2021 and December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of June 30, 2021 and December 31, 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis and did not have any Level 3 financial assets or financial liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915061016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Derivative Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge: (1) forecasted product sales that are denominated in foreign currencies and (2) foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our condensed consolidated statements of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flow Hedges</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate the foreign exchange risk arising from the fluctuations in foreign currency denominated product sales in Euro through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that do not exceed 15 months in duration. We hedge these cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative assets or liabilities associated with our hedging activities are recorded at fair value in other current assets or other current liabilities, respectively, in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated balance sheets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The gains or losses resulting from changes in the fair value of these hedges are initially recorded as a component of accumulated other comprehensive income (AOCI) in stockholders&#8217; equity and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently reclassified to product sales in the period during which the hedged transaction affects earnings.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We evaluate hedge effectiveness at the inception of the hedge prospectively, and on an on-going basis both retrospectively and prospectively. If we do not elect hedge accounting, or the contract does not qualify for hedge accounting treatment, the changes in fair value from period to period are recorded in the same income statement line item as the hedged item. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had net deferred gains of $27&#160;million on our foreign currency forward contracts included in AOCI that are expected to be recognized into product sales within the next 12 months.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily accounts receivable in Euro and lease liabilities in Swiss Franc, that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities in our condensed consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our condensed consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our condensed consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value of our foreign currency derivatives were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheets within other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheets within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains (losses) on our foreign currency derivatives, net of tax, recognized in our condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of our foreign currency derivatives in our condensed consolidated statements of operations for the three and six months ended June 30, 2021 was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had immaterial gains reclassified from AOCI to product sales during the three and six months ended June 30, 2021. There were no hedging activities for the three and six months ended June 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915565464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of June 30, 2021 and December 31, 2020 consists of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914999704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation and amortization expense for the three months ended June 30, 2021 and 2020 was $69&#160;million and $8&#160;million, respectively. Depreciation and amortization expense for the six months ended June 30, 2021 and 2020 was $84 million and $15 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912261704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Components</a></td>
<td class="text">Other Balance Sheet Components<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 30, 2021 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,740)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915059080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2035. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, located in Norwood. We also leased other office spaces globally for our business operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2022 to 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a lease agreement for a 240,000 square foot building located on the same campus for expansion of our commercial and clinical activities (MTC East). The lease will expire in February 2034. We have the option to extend the term for two extension periods of five years each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of June 30, 2021 and December 31, 2020, we had lease liabilities of $251&#160;million and $24&#160;million, respectively, related to the embedded leases. As of June 30, 2021 and December 31, 2020, we had right-of-use assets of $296&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of June 30, 2021 and December 31, 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC South, MTC North, and MTC East leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2035. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, located in Norwood. We also leased other office spaces globally for our business operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2022 to 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a lease agreement for a 240,000 square foot building located on the same campus for expansion of our commercial and clinical activities (MTC East). The lease will expire in February 2034. We have the option to extend the term for two extension periods of five years each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of June 30, 2021 and December 31, 2020, we had lease liabilities of $251&#160;million and $24&#160;million, respectively, related to the embedded leases. As of June 30, 2021 and December 31, 2020, we had right-of-use assets of $296&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of June 30, 2021 and December 31, 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC South, MTC North, and MTC East leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912277496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Collaborations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our Personalized Cancer Vaccine (PCV) Agreement and PCV/SAV Agreement (which also relates to shared neoantigen mRNA cancer vaccine) with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $243&#160;million for both periods as of June 30, 2021 and December 31, 2020. Please refer to our 2020 Form 10-K Note 5 to our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the three and six months ended June 30, 2021 and the year ended December 31, 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of June 30, 2021, we h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> $1.5 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2022. As of June 30, 2021, we had $49 million o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f non-c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2024. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At June 30, 2021 and December 31, 2020, we had cancelable open purchase orders of $1.3&#160;billion and $897 million, respectively, in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at June 30, 2021 and December 31, 2020, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments, up to $24&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. For the three and six months ended June 30, 2021, we recognized $148&#160;million and $232&#160;million, respectively, of royalty expenses associated with our product sales, which was recorded to cost of sales in our condensed consolidated statements of operations. We did not recognize any such royalties in the first half of 2020 as we did not have product sales during the period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916812824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had a total of&#160;60 million&#160;shares reserved for future issuance under our Equity Plans, of which 33 million shares were reserved for equity awards previously granted, and&#160;27 million&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were available for future grants under the 2018 Equity Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our option activity during the six months ended June 30, 2021:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair<br/>Value per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of June 30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $575&#160;million for the six months ended June 30, 2021. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately $59&#160;million for the six months ended June 30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity during the six months ended June 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average Fair Value per Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock units vested during the six months ended June 30, 2021 was $9&#160;million. The total intrinsic value of restricted stock units vested during the six months ended June 30, 2021 was $54&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we granted PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan (ESPP)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sold an immaterial number of shares under the ESPP during the six months ended June 30, 2021. As of June 30, 2021, 4&#160;million shares were available for future issuance under the ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there was $336&#160;million of total unrecognized compensation cost related to unvested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 3.0 years at June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139820007551544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. For the three and six months ended June 30, 2021, we recorded provisions for income taxes of $283 million and $322 million, respectively, compared to an insignificant amount for the same periods in 2020. Our effective tax rate for the three and six months ended June 30, 2021 was 9% and 7%, respectively, and was lower than the U.S. statutory rate primarily due to the benefit related to the release of the valuation allowance on the majority of our tax attributes, the benefit of the foreign derived intangible income deduction and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three and six months ended June 30, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. On a periodic basis, we reassess any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, we determined we should reverse the majority of our valuation allowance through the annual effective tax rate (AETR) with respect to amounts we expect to realize through current year income. In addition, for the three and six months ended June 30, 2021, we have recorded a discrete benefit of $49&#160;million related to the release of the valuation allowance on deferred tax assets that we expect to utilize in future years. We maintain a valuation allowance on certain state tax attributes that we expect will expire prior to the utilization. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. We do not currently expect the CARES Act to have a significant impact on our provision for income taxes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of June 30, 2021 and December 31, 2020, we had an immaterial amount of gross unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially increase within the next twelve months. We accrue interest and penalties related to unrecognized tax benefits as a component of our provision for income taxes. We did not recognize any material interest or penalties related to uncertain tax positions during the three and six months ended June 30, 2021 and 2020.</span></div>We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We are not currently subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction since inception.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912483768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text">Earnings (Loss) per Share <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the three and six months ended June 30, 2021 and 2020 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of June 30, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.122%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910824888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2021, we have entered into additional supply agreements with customers to provide up to 262&#160;million doses of our COVID-19 vaccine and our updated variant booster vaccine candidate based on the initial confirmed volume, subject to modifications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a Share Repurchase Program of our common stock, which expires on August 2, 2023. Pursuant to the Share Repurchase Program, we may repurchase up to $1.0&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915281304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The condensed consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains/losses and gains/losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914982216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income for the three and six months ended June 30, 2021 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:69.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:69.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910875736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.929%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910824888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue as of and for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.500%"><tr><td style="width:1.0%"/><td style="width:44.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915032248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue as of and for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.500%"><tr><td style="width:1.0%"/><td style="width:44.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Balances of Receivables and Contract Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the six months ended June 30, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:38.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 30, 2021 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,740)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915335976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at June 30, 2021 and December 31, 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities by contractual maturity at June 30, 2021 and December 31, 2020 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910804760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule Of Foreign Currency Derivatives</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value of our foreign currency derivatives were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheets within other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheets within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains (losses) on our foreign currency derivatives, net of tax, recognized in our condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of our foreign currency derivatives in our condensed consolidated statements of operations for the three and six months ended June 30, 2021 was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912126248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of June 30, 2021 and December 31, 2020 consists of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916717256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910621624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of June 30, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Balances of Receivables and Contract Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the six months ended June 30, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:38.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 30, 2021 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,740)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915030440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Assets And Liabilities, Lessee</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of June 30, 2021 and December 31, 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_0df45417-f562-4cb5-b818-06f0b1f96230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfNC0wLTEtMS0w_c39f126f-bef9-413d-adec-7dcd739a3a6b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_56070644-020d-4630-89d9-9eb97d98c943"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfOS0wLTEtMS0w_f6dd721c-9153-4b99-a801-71a67fb857ab"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_d2acc620-2403-40cb-9819-619ca438ec7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZmMTgxYTIwNTQyMzRjYWVhMzhkZjgwYzMzMGZjNzI5L3NlYzo2ZjE4MWEyMDU0MjM0Y2FlYTM4ZGY4MGMzMzBmYzcyOV82Ny9mcmFnOmI1ZTkwZDI0YmYyZDQ0MGU5MmE4NTQ3ZjI2YjIyYTE5L3RhYmxlOjVkZTk3ODM5YTNjMzQ4NjNhOGM4ZjM5NTcwNTAwZDI3L3RhYmxlcmFuZ2U6NWRlOTc4MzlhM2MzNDg2M2E4YzhmMzk1NzA1MDBkMjdfMTAtMC0xLTEtMA_f0ac472d-d198-45b0-99c5-700c28f43323"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC South, MTC North, and MTC East leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Future minimum lease payments under our non-cancelable lease agreements at June 30, 2021, are as follows (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC South, MTC North, and MTC East lease terms which represent a total of $445 million undiscounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North, MTC East, and the embedded lease interest is based upon incremental borrowing rates of 8.2%, 3.7%, and 0.6%, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914926152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Options Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our option activity during the six months ended June 30, 2021:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair<br/>Value per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of June 30, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Common Stock Units Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity during the six months ended June 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average Fair Value per Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914975736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the three and six months ended June 30, 2021 and 2020 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of June 30, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.122%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912288472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>program </div>
<div>clinic</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfDevelopmentProgram', window );">Number of development programs | program</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics', window );">Number of clinics | clinic</a></td>
<td class="nump">14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDevelopmentProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDevelopmentProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs That Have Entered Clinics, Number Of Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819918850424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">$ 3,838<span></span>
</td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 1,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">6,704<span></span>
</td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">6,704<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Loss on Available-for-Sale Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819911011528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,603<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
<td class="nump">$ 1,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 5,614<span></span>
</td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="nump">$ 1,774<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916401560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 4,354,000,000<span></span>
</td>
<td class="nump">$ 67,000,000<span></span>
</td>
<td class="nump">$ 6,291,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,302,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,302,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,867,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">4,197,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,930,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">2,093,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,451,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,104,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,479,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914542120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfParticipant', window );">Number of participant | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">6,291<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember', window );">DARPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember', window );">DARPA | Contract options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Additional commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsPotentialReimbursement', window );">Potential reimbursements</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptions', window );">Number of contract options | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised', window );">Number of contract options exercised | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Contract options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember', window );">The Bill&#160;&amp; Melinda Gates Foundation | Initial project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember', window );">Other grant revenue | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Participant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsCurrentFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Current Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsCurrentFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsPotentialReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Potential Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsPotentialReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsRemainingFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Remaining Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsRemainingFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916402008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - Collaboration Revenue by Strategic Collaborator: - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_OtherCollaborativePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_OtherCollaborativePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139820003185672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 4,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">6,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(2,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">7,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Collaboration Revenue by Strategic Collaborator:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerAssetRollForward', window );"><strong>Contract Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetPurchase', window );">Additions</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerAssetDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">$ 321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerAssetDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerAssetDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819918767576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 6,599<span></span>
</td>
<td class="nump">$ 2,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,202<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">12,197<span></span>
</td>
<td class="nump">5,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">5,603<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember', window );">Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">2,387<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember', window );">Non- Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">4,207<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,603<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">5,603<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Cash and cash equivalents | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">5,603<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Current Marketable Securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Non- Current Marketable Securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Non- Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills | Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills | Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills | Non- Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. treasury notes | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,349<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">4,346<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. treasury notes | Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. treasury notes | Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. treasury notes | Non- Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">2,935<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Non- Current Marketable Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912463416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 2,386<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">4,213<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,599<span></span>
</td>
<td class="nump">2,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">2,387<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">4,207<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915329608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit losses related allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819918728104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Instruments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">12,197<span></span>
</td>
<td class="nump">$ 5,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. treasury notes | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">4,346<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">10,462<span></span>
</td>
<td class="nump">3,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Instruments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">6,624<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Instruments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Certificates of deposit | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Certificates of deposit | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury bills | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury bills | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">4,346<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury notes | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury notes | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">4,346<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate debt securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate debt securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="nump">$ 1,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819912331352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Cash Flow Hedges (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Foreign currency hedges expected to be recognized within the next 12 months</a></td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914470552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Balance Sheet Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Designated as Hedging Instrument | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">981<span></span>
</td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Net realized and unrealized loss</a></td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910658632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819913628424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember', window );">Right-of-use asset, financing (Note 11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916393000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OtherPrepaidExpenseManufacturing', window );">Down payments to manufacturing vendors</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value added tax receivable</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OtherPrepaidExpenseManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Expense, Manufacturing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OtherPrepaidExpenseManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915378872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RawMaterialsAccountsPayable', window );">Raw materials</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedDevelopmentOperation', window );">Development operations</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedManufacturing', window );">Manufacturing</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent', window );">Other external goods and services</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 848<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedDevelopmentOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Development Operation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedDevelopmentOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Other External Goods And Services Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedOtherExternalGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RawMaterialsAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Raw Materials, Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RawMaterialsAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910599016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease liabilities - financing</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities - operating</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819913629864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components - Deferred Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 4,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">6,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(2,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">7,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">3,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">6,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(2,705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">7,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819914341864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extension_period </div>
<div>campus</div>
</th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>ft&#178; </div>
<div>extension_period</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>ft&#178; </div>
<div>extension_period</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseNumberOfProperties', window );">Number of campuses | campus</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">104,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, operating lease</a></td>
<td class="nump">66,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember', window );">Embedded Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">251,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">$ 296,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LeasesIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCEastMember', window );">MTC East</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember', window );">Cambridge leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood leases | MTC South, MTC North and MTC East</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, operating lease</a></td>
<td class="nump">$ 445,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood leases | MTC South</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LeasesImputedInterestRate', window );">Imputed interest rate</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood leases | MTC North</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LeasesIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood leases | MTC East</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LeasesIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Tenant Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LeasesImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases, Imputed Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LeasesImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LeasesIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LeasesIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Extension Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseNumberOfExtensionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseNumberOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Number Of Properties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseNumberOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCNorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCNorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916132584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating, net</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets, financing, net</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liabilities, current</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent', window );">Total current lease liabilities</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization<span></span>
</td>
<td class="text">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819913912456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum Lease Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remainder of the year)</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remainder of the year)</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915931832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Strategic Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV agreement | PCV products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Budgeted amount</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916629336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember', window );">Supply and manufacturing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember', window );">Clinical operations and support commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915354968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Licenses to Patented Technology (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 26, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Consideration paid</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916835048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to non-vested stock-based compensation</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of cost expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share available for future issuance (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member', window );">2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139820022627048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options Activity (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">34,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(3,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares) | shares</a></td>
<td class="num">(450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">30,880<span></span>
</td>
<td class="nump">34,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">$ 17.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">173.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">15.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (usd per share)</a></td>
<td class="nump">27.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">22.98<span></span>
</td>
<td class="nump">$ 17.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">76.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (usd per share)</a></td>
<td class="nump">8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue', window );">Cancelled/forfeited (usd per share)</a></td>
<td class="nump">14.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">$ 11.59<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number&#160;of Options, Exercisable (in shares) | shares</a></td>
<td class="nump">17,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Exercisable (usd per share)</a></td>
<td class="nump">$ 12.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)</a></td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 6,547<span></span>
</td>
<td class="nump">$ 2,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 3,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number&#160;of Options (in shares) | shares</a></td>
<td class="nump">13,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share (usd per share)</a></td>
<td class="nump">$ 36.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value per Share (usd per share)</a></td>
<td class="nump">$ 18.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 2,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819918985016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) - Restricted common stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at beginning of period (in shares) | shares</a></td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares) | shares</a></td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited (in shares) | shares</a></td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at end of period (in shares) | shares</a></td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at beginning of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 30.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (usd per share) | $ / shares</a></td>
<td class="nump">170.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">25.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited (usd per share) | $ / shares</a></td>
<td class="nump">37.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at end of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 64.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819913352056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819910918632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819916307656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,780<span></span>
</td>
<td class="num">$ (117)<span></span>
</td>
<td class="nump">$ 4,001<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (usd per share)</a></td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="nump">$ 9.98<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (usd per share)</a></td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819909738840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139819915026056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>dose</div>
</th>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfDosesOfVaccineCandidate', window );">Number of doses of vaccine candidate | dose</a></td>
<td class="nump">262,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount for share repurchase program | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDosesOfVaccineCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses Of Vaccine Candidate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDosesOfVaccineCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M_GW%N7J^,=\9FN]*T[\!4$L#!!0    ( ,6!!5,$+FI/Y (  ,8)   8
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M965T-"YX;6RE6=MRHS@0_165:Q\R51.#!,8FY;@JP<QNMC:7BC,[SXJ1;6H
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M.SW#X:G2,,O R*SPG+4TZ&#%-L%O#"B;@,]C*<TNL 7JK];P#U!+ P04
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M+HP;D+'7A0O)DJ>ASOT4*$2J( JL2XK+DY6F:,=)<=3QHRTRCMQ>G#0 )UZ
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M>0"-4;?\.J2BGI5!V-)%Z.>+A_W8.^A'FP.F79@.)AGWP&R)(O0SQ8,I-8?
MV10P'EOEQB'D1@=;GH#!P>7?!Y=,+OSU++O0)@'JII%#:ABBGCB%+0G!T,MU
MW\SRX.B5,6RI QZ@CI(G&UW6]")$-:5/1.HJ @1)2M[O"P<KQ%'493N7V"Q
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M[TS0PB-[Y&&MHVD<S&)W;0*8P9LK7^___K>GR\63?X(;D,Y("V"\SH2(HS+
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MTT6#9G3R7Y=(,E<C^3YHU._@$.6Z&\MF3'$2%NI11G>GOR:Q6&),X!OY.!)
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M,RD4DA;@^=KCGM9_H0/&MXJ7_P502P,$%     @ Q8$%4YG\:KA6"   OQ8
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M?L[U4BM7/G-ZN4NNQR#<81.4_."#KC@D?U'1)Y6$JU7WF;3XM<G744.Y6M%
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MU<&8(ABCV!AP@FHY83H62T>Z^P\CSK9,$KH* !8(3(P\Z53)VF?&(AF:!'0
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M:0'>IP8MKKDA!=WWSZM_ U!+ P04    " #%@053=..N;7<$   ?"@  &0
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M0-ZL>5DJ#%26#N#]TD#][H$8]/\5</UO4$L#!!0    ( ,6!!5,[=0%1RP@
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MZ<G?E;-Y#5(C+:&0@;U[E!(&OS?;O_UJ V*R0E9+)0BO6!A8KQN'4<I*6ZF
M$BJD]PK K!-&R[DV4;)/" 6DD%M1V2 4!9;":^\F )2RYED>PJ]45ILX!K=X
MDU.85K6C0/8,SY71"L.8CMUXET!%[U"8181KA"QMC2@A%IE3"&2,'UR@X.]P
MQ+'P0Y  D#6YL9*.":"EC'1+"&UI[)PL@^@U2O]WF5SI((W^/U#THZQ#W2@'
M/F0&U.K%1B#"!?BW:Q^U2$@2GMI\BE+TN\.C4$&1W):4QB$2*^5.3E?>&IUS
MQ'S 1Q0<$=$9'(E+NK["-=<IQ0E=PN22-$)";BG:JH?XZ^42#TOEM"N034]
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M"!=_;XDWP:[X-PZ<E((M^;)0$HJF 7B_L#:T-[1 ]Z/7V5]02P,$%     @
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MUMJ1O,*VH?<,C0^@\TIKMS5\@NF%7+X 4$L#!!0    ( ,6!!5/Z/UV<]P(
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M^]T(,D759ZS'VQ*A4(*JF,LU''%)SU$(JBQS/-Z1_<D1MT0W;*4TLTJ_[M3
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M:_CG1DDT$'H!SU<.._A\00KZ+UR7_P-02P,$%     @ Q8$%4W+H'LA$!P
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MMII..>G9Q1W3DLN=@8M?E#$#:%##NF(:9[$E>"\4%P>H90N5O0$UAL]*VLK
MG2RQ/-6/R:W.M^SHVS(["_BSDT/(DTO(DBP]@Y=WL>8!+_^O6%?'(.'/FXVQ
MFJCQUQG\48<_"OBC;Y'+LU"^%:>F807.(^HU@_H1H[?QX=<*H5!UXRP+7%=;
M3U5> '8JHE,Q0>7B;K4> #>!TR60DB60?6 QEN_9(VIJ2I"NWI . 2JGO8V:
M) ."H1UK+),E&1B^YD+)A2,L($O?S!#0 (VR*"UGHC5!;7U&H73:#]XH1<]5
M"<Q0WUK4U$[DT.89G#E*6+K8C-//0(U7/$"-ME+E$)8AF=YT/R:Z$ENE2B.&
M4\.?H&Z; 'T3 %$8.PH'$9HD%#U5H&"B<()Y-/)HJP1=D%0H+JG/A: <FDO
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MWF"&M^EC4+KQIHT?8);&>]/$RPJC"%G>@/65P6B8;UA!_T7NYO]02P,$%
M  @ Q8$%4VQ"7K@"!   +0P  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL[5=M;R(W$/XKHVU4!8EDV>4E40I()+GV4O5Z4<BU'ZI^,+L#:YW7YFPO
MI/WUG?'"!JY >_?YI !^FWGFY9FQ,UP;^]$5B!Y>2J7=*"J\7][$L<L*+(6[
M-$O4M#,WMA2>IG81NZ5%D0>A4L5IIS.(2R%U-!Z&M4<['IK**ZGQT8*KRE+8
MOVY1F?4H2J+MPI-<%)X7XO%P*18X1?]A^6AI%C=:<EFB=M)HL#@?19/DYG;
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M+J^H)]KZ<5I/O%F&!^',>'I>AF%![WFT?(#VY\;X[80!FO\0QO\ 4$L#!!0
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MGBME(7V0XDVSZC0$C($=ZF03X&<R\&(_Q/&7GT8TH+\>4-6WTWMFSRPU(7-
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M2XV0GQ;4>:)V!^C_7"F[73B MI>=?@902P,$%     @ Q8$%4\#04!5U @
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MG.5]'J_PCD92XR@%-..T+W3:$B603.'##L'B\03&:9=ZO"?]DLPOE:I"CAU
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M03-9AUM$>+&J\2?WN;)T#_"/*[IXH78;Z/M"44OJ7IR!_BHW^P]02P,$%
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M6"$L,'.,(.GU@+=8% Q$:OS=8@XZD<QXN-ZCO_.VDRU+:?%6%U]4[C97@\D
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MX1"*,";:6$PB&*<BC>'M(YI,<5A/Z#0]A3 1<0@3D09P*ZN,>D$^I$:V0L4
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MVAG0]ZU2]K1Q =I_//.O4$L#!!0    ( ,6!!5-@C3:X6 (  #0%   9
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M[HOC_5-#"]!-4Z46X@(_6%U@(2_PVOH"SPM,#<12F&D-Q-[B9^?=S&L@)T3
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MJEMU)03=]J'J@Y<,$&T24]O 5NK'UW9"N)F("BT/Q';FG/$9C\:3SH:R5[X
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ML4G 1>A13^-_:?;'A_SG9G_'X-^72U2N$WI>IS-D!)S&_"/ U@> + 2_/L[
MNS?O-;3.S2B/-"Y1K':467<N!I2+SER@4Z!$<2J-NG29L6ZV89?5N3*CW)$T
M+G@(Y;H[%\/JS%\>4>OJW+P*H\]FE!E=EJMC0+D]Q,4_@%)Y/' I(SB#Q6WD
M6$+6:T[7)-M;HU4I*7_?2E,P%S1(_C%,9)<3V=E$=LM$OV^#!>7I!#'A@BU9
MG.K7+]":FWF.-\CPTI[D:8(M^3?N/VEH#$H: R.-<ZDN7'804J_%IE!JRC\
MGY$%\YGXJ7N&<DAGCXEKNVY))*?;Q>AST\BV;%L?DE.&Y!A#^A()XH-UMA_P
M/'FZ()S&<MIX8%?Y73L-?DX]SB:.@T:P:G33Q'$'^BC=,DK7&.55>WP5O&&)
M-SQNX8_*B4:O7W&CQB(/:VDX:/%YU,A!2PJ@I7H.ZS5*K4#9)P?QJ%9J&B-<
M#U)G@W&MUC1&-FJ)=*^[@L9(9].'^ZDA^Q I)'3<0H-*RR$VDI[N"/< ":)M
M*'0]3N%>*0FG9:64KD.SL&<K)86\K/-<T1-31$JMX>#(BZ=4%)IE=)HM&UA&
M0<"$H!Z0;\I@M0T]%JYUS0QL"N&@7IDFDRI-)8/0K(/3)]GGDX5/C=S<YL1U
MB3;;5-DI485#([NSZ</,^-@HU82CXV8>*55#9E4[\-C,"O?*KCVLJ="%Q@@B
MIVITI3/">RU-T>!JY!.Z^M0@I6C(K&@OK._+ JXJJ[!.U6Q4I:HD$R$S5<]C
M:=;E7I/3#:@V,U<%3J5?J27F5F-CNRW[ U)2B\Q2>Q\)R8E)AIRR8+'E"4U)
M:M^X45-V$6[17:1T%W5MJ)<UY35UU1=(TU:W4%$JC<Q-M8$*_4'YDB6RW(RD
M!LTR:B&E]!R9]3R3(CEKU\81*0E&[I&E2>DI,NMIQX:K0*DV7/7>7F.$Z\V]
MSJ:N8C<:([OEM0PIO4?F-ODY72]H([!2>&P=-V-8R2Q^79G%304=U%KEN=FF
M2E2)+#X@LAT:B<L"P_0B8C2I<MO[4<*LKE\V%)PQWW_[&W2L3V])$'\"=U1:
M>01<$4$3<"E7V<NS^0O,0Y9)<<RC?^E2F/*HY!7;1RX9)9_8+)_=,M&42%AO
M',PV579*1[%91__7^RMN=K[#!ENC396MTF9L;H__$!NY$U4$\P5[ %;"C(_\
M\P%6RHC-RMAQ#\"F]_U\!]"8U!LZC4EMC[C1F-3;J?[>N88LEG5V6I=(4932
MF/]D6(Z6)X+3[%RD-GX&3RZ@9OP2GESKQN?PY"8_!U33YL>2=X2OF6Q(?+J2
M%*R/KJP[GI_TY3<BBK/3ED4D9(5GEQM*/,I3 _G]*I(M7W&33E">MT[^ U!+
M P04    " #%@053^-JE(G<#  !1#@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,RYX;6S-5UUOTS 4_2M6Q -(L,1)FWVHK;2U18 83!L;$H@'-[EMK#EV
ML=UU^_?83I:V21HFV,->5MLYY_C>>SQ_#-9"WJH,0*/[G'$U]#*MER>^KY(,
M<J(.Q!*X^3(7,B?:=.7"5TL))'6DG/EA$,1^3BCW1@,W=B%' ['2C'*XD$BM
M\IS(AS-@8CWTL/<X<$D7F;8#_FBP) NX GV]O)"FYU<J*<V!*RHXDC ?>J?X
M9(IC2W"(&PIKM=5&-I69$+>V\S$=>H&-"!@DVDH0\W,'8V#,*IDX?I>B7C6G
M)6ZW']7?N^1-,C.B8"S8=YKJ;.@=>2B%.5DQ?2G6'Z!,J&_U$L&4^XO6)3;P
M4+)26N0EV4204U[\DONR$%L$H]-."$M"6"?T]A"BDA ]=89>2>@]=89^27"I
M^T7NKG 3HLEH(,4:28LV:K;AJN_8IEZ4VX5RI:7Y2@U/CTR!&9D)29QMEW '
M? 7H';HJ%@X2<_1-:,+06' E&$V)AA1],2NXQ"HTER)'1M-\6= $;12%5.CU
M!#2A3+TQFNUSS1[VD$\,Y?IJ@EZ_>H->(<K1.67,,-7 UR9S&[^?E%F>%5F&
M>[*,T+G@.E-HRE-(6_B3;G[<P?=-Q:NRAX]E/PL[!3^M^ &*@K<H#$+<$L_X
MZ?2@+9W_FWWZS[/O%".JUF#D]*(]>E_,=G*:)&+%->4+="$%-^T$S'ZD%1(2
MC3/"%V"7P Z,\H0N&:"?GXT@^J@A5[\ZPNE5X?1<.+T]X13K/=E9K+)8K&TK
MKQ"+G9C=EN]&^&C@WVV;V82$Q[N020NDIC)M0J*H@NQDVJ\R[7=F>JK,/]X/
MX)"0CKK%E5K\$FP\K,(Y?$X;"['^5G5[-1>;"!S77/RKR+1%Y+#=Q*,JSZ/.
M/,]!)K<=]3JN=(Y?@GTXV)Q,P7,:6*IU.=@"P;AFX=]EIFTR8;N)>.L<QIW9
MWH#4<-]5N' C%;X()S?[.XZ>U<FH4=_CNI--2%@WL@FI;\S3%DQOCY&;TP-W
M'Q]?=0:RJVR;W1GW7X2/FPT>Q\_J8]P\&NL^-B%!W<<F)*S;V*52Y.IO79%S
MD OW-E'(5:VXJ52CU?OGU-WZ:^-G^&2,6\8G]KWDKN0;^>*Q=4[D@G*%&,S-
M5,'!H7%=%N^7HJ/%TEW09T*;Z[YK9N;-!]("S/>Y$/JQ8R>H7I&C/U!+ P04
M    " #%@0534R!%^#$#  ! "P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6RM5EUOVC 4_2M6U(=66ILXI 0J0.)CTS:M4D75[=DD%[#JV,PVT/[[
MV4Y(8"%IM>ZEV(GO.?=>GYS>P5[(9[4&T.@E8UP-O;76FSO?5\D:,J)NQ :X
M>;,4,B/:;.7*5QL))'5!&?/#(.CZ&:'<&PW<LP<Y&HBM9I3#@T1JFV5$ODZ
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M+D9H2-7753TQ<EU]\1?2X/U1#7.\X4'9 -S/I#3O$WN)M/\9IK\ 4$L#!!0
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MG4^X6U6VC')BY-:5N)4T6##=,,,N"\HFX/I:2G.86(&Z;T?_ %!+ P04
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MI#+_B;PGJ7Q\9X!:-MA!G0%E68\'==9DYW[EQ&ORTL=:]=+/UC:56FI<OK@
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MC>\CL)UKNX!,'9RR,<2^"\N2'SI:G\#G6V/H%'CSG?\ZLM]02P,$%     @
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MXA(;2J].-58#J^;Y/O])6:NR_'(&/ 'M /A\HI1=#]P$Y=G2^']02P,$%
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M!F4#<'\NI=E,;'OH_PWR#U!+ P04    " #%@053WG;3=W<$  ##%   &0
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MFW*V!5RC539]4<A51*L")U1WUKWDZM=$Q<G9'5=-RN4SP#0&US_R9*/:1IZ
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MN,'/&B@;@,]74IJWB>V<S8<R_0-02P,$%     @ Q8$%4XB\[,)_ P  Z0T
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M]Z*MU$)LAP ]BE2@77K:5M5V]^[#Z70RQ$"T2<S:IK32_OBSG1!32!Q6%?U
M\^)YYK$]\\PDZ6\8_R:6E$KPDL2IN&HLI5Q=MEIBMJ0)$4VVHJFZ,V<\(5*=
M\D5+K#@EH3%*XA;RO*"5D"AM#/KFVB,?]-E:QE%*'SD0ZR0A_'5(8[:Y:L#&
M]L+G:+&4^D)KT%^1!7VB\NOJD:NS5H$21@E-1<12P.G\JG$-+R>XIPW,B+\B
MNA$[QT!/9<K8-WUR%UXU/,V(QG0F-011_Y[IB,:Q1E(\ON>@C<*G-MP]WJ+?
MFLFKR4R)H",6_QV%<GG5Z#9 2.=D'<O/;#.A^83:&F_&8F%^P28;&W0:8+86
MDB6YL6*01&GVG[SD"[%CX <5!B@W0'L&T*\PP+D!WC/ N,+ SPW\/0,$*PS:
MN4%[W\"K, AR@V!_#E6KU,D-.L?.H9L;=,WN9MMA]G),)!GT.=L KD<K-'U@
M L)8JRV,4AV[3Y*KNY&RDX-/5&V\ !?@@7!.=!R!#V,J212+,S"7O_\".]T_
M0)2"+TNV%B0-1;\EE5]MW9KE/H:9#U3A(P#W+)5+ 6[2D(9O[5N*;T$:;4D/
MD1/PSW7:!-@[!\A#\.O3&'SX]6S+E;[(++/^6U$>L7!&DM6ZC/3H>!]>B?G8
M;7Z]XI9B%;<2V!LW[)C.%"S,6.4S+T&Y=:/<D]<C0#ZZ06[IM E05Z/ WG:&
M)3"3FH5:+[8S@L%Q"_4F9G 1Z-CXP96!+@2EY\ $_#D84S'CT<KHYS^?U%AP
M)VDB_G5X\@M/OO'D5WAZ6"=3R@&;@RSV5'K] )5A.,S V@9,5YKG >JWGDO\
MMPO_;:=_,T,01V0:Q9&,:*G7#"+8\0IAX)F_<N]!X3UP>C?5[X+-+]3$ 5%K
M+L4Y4*56BTNZ +'1FS)&P<$Z0,_?8Y2E2'# O>>YJ'<*ZATG]>N$K5,I5$E6
M;8"@J2$<I9*J,PD8!Y':0TG#XMK!Q,KFU3F85^!<Z&[!MNMD>Z.B+%1ZFD6T
M< 1NKT#LG3A%H&?+CO?^(,TQWN1&&Y;&1-G0_>AY2W6G0L+31'2.NQNHJ+>_
M]SG]PZ%5O)'EC9R\[](9IZK-E"0&4\:5O::K6)>&:0V8UPR\WUP[;W488B?2
M_9<1N"%"NL"LU$+_U"%K916Z=?5:/1MH56?S>32C0*R(^OV@6B/Q?2[/E,8[
MBN XQ]Z+SXHMMEH+W6)K2TU1,4%6,77-.:+=&,-#V:TH/]#**'3KZ$W!1<ED
M4NK5#= &KY1PEZ1!JY+0+9,CDDQY%"YH::*^!;5""4^ME,@J)7(KY7O";HA*
M9#& Y1N,K"(BMR(^,+YA+,Q75%'0.?VDGHR7Y^90W9=+H!X6P!')CJR@(73J
M5;<JA=PJ=9I>('>Z*_.^WW:5*62E$-6TG96;XEH0JWZH?>K%M[*&W++VGI"?
MH!)%JUQ=JVG(+4GO5MH).FP$*Y0667%#-3U@G=).:@"@5RNUR*HBZKD;CKV4
MJ.PU:G!@IXF<S0:VXHG=XEF:%$:>7/!6"#$\<5)@JW[8W8&])RD^YMA')07>
M>:1VB^2[DV*8.]CEY5>PLD*(W4)8FQ3#&H#Z]@-;V<0U36,<LPU)U5;-5=%0
MQ$@J=>W@[-GTYF4/#K?X\.D<(5>5P%9:L5M:?^ZAH :L6Y>G5EYQC;R6Y6E-
MXX"M3.+NJ=/4BB"N$<&?6>!1#1AN=LH7N+7SQC>A?&'>_@LPTTU+]AZUN%I\
M8;@V[]7WK@_AY2C[3F!ALL\6]X0OHE2H+9DK2*_944')LR\!V8ED*_->><JD
M9(DY7%(24JX'J/MSQN3V1#LHOL<,_@=02P,$%     @ Q8$%4RHSLX;! P
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MHXV:O7"MNFH3CJ7V6[G5TKQEIDY/KL"TI- QNF8I2_($N0=H2A_-U&N%#B]
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M*$DIUQ/4_QO&Y,M &VCO^M=_ 5!+ P04    " #%@053IX!3R(H#   ["P
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M@O*5FF\8N7;5T5P:JK7<:T[5+2H[@<:74IJGAEV@KI<G_P-02P,$%     @
MQ8$%4Q@P9?O; P  _A$  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL
MS5C?;ZLV%/Y7+'0?[I7:@@WY5261&I)I=UJUJ%&WAVD/;C@)J("9[32]^^MG
M&P()$%IM><A+8LQW/I]S/IMC>[QG_%6$ !*])W$J)E8H979OVV(=0D+%'<L@
M56\VC"=4JD>^M47&@0;&*(EMXCA].Z%1:DW'IF_)IV.VDW&4PI(CL4L2RG_,
M(&;[B86M0\=3M VE[K"GXXQN807R.5MR]627+$&40"HBEB(.FXGU@.\7A&@#
M@_@]@KTX:B,=R@MCK_KA>S"Q'.T1Q+"6FH*JOS?P(8XUD_+C[X+4*L?4AL?M
M _M/)G@5S L5X+/XCRB0X<0:6BB #=W%\HGM?X8BH)[F6[-8F%^T+[".A=8[
M(5E2&"L/DBC-_^E[D8@C \73;D * U(W\,X8N(6!^]D1O,+ ^^P(O<+ A&[G
ML9O$S:FDTS%G>\0U6K'IALF^L5;YBE(]45:2J[>1LI/3E63KU]N92G6 ?):H
M^2>H4? 6G7VU>-=M0%_G(&D4BV\*_+R:HZ]?OJ$O*$K18Q3'"BC&ME0NZH'L
M=>'.+'>'G'''18\LE:% BS2 H,5^WFW?[["W56K*_)!#?F:DD_"777J'7.<&
M$8?@%G_\SYL[;>'\O]$7_WGTDV2XY61Q#9][;K*$E,/MBYD12_I#?2\D>N"<
MIEO0[9O#S @03=6<H5DD:1S] \$->DC83J'__%51HN\2$O%7AT->Z9!G'/(Z
M9V_NT/IXBD+N2-L$S!G[AE%_1M^F;F]LOQUKVH20&F3>A/1KD$43XE60DW![
M9;B]SG!])B1B&R1H#*(C??V2KW\=>@Y*AP87US-G[!VE>5B3LXEP:FHV$9C4
MU.PB.8EU6,8Z[(SU"010O@Y-;@-X4S4[TUGO2..HI!Y=AZ[8J<J,<W%E"\H3
M6>I+]1.8>0N&C&KRMF$&[0+CH]J*NX-6^Y\HW=Z@+:3 :6S230-5QB,A.=5;
MI*[DDFH<<B5Z5Y4"NY?7V_UP&?IMF/IJ;L$0KZYW"\_PC-Y5-<+=Y>BW3#:W
M/:=<U:<>]ZY$TZI:X/[E->U_J(7?AL%U39L8KU_7M(EQ1V<TK2H2[BY)3ZMG
M85*\5(VN-%;??3R\$F6K>H%'EU=V].%*]%LP;EW8%II!7=@FYLQ.BE0%B707
MI,5JN>PZ'U0?>8*O0TY2U0-"+BYG07F\7:VM0?]CR+P%4M](=;+D =M'Y]D$
M^-9<) @5BLI6?EHI>\O+B@=S1*_US_"]CUOZY_A^D5]%5/3YS<@CY=LH%2B&
MC1K*N1NH2<?SRX;\0;+,G*9?F%1G<],,@0; -4"]WS F#P]Z@/+*9_HO4$L#
M!!0    ( ,6!!5-&.!A>JP(  /4'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8W+GAM;*5576^;,!3]*Q;JI%;: @%"/T20FI!IG50I:M?M8=J# Y?$JK$S
MVR39OY]M"$L:RJKM)?CCGG-\KIU[XRT7SW(%H-"NI$R.G952ZQO7E=D*2BP'
M? U,[Q1<E%CIJ5BZ<BT YQ944M?WO,@M,6%.$MNUN4AB7BE*&,P%DE598O%K
M I1OQ\[0V2\\D.5*F04WB==X"8^@GM9SH6=NRY*3$I@DG"$!Q=BY'=[,(A-O
M [X2V,J#,3).%IP_F\E=/G8\<R"@D"G#@/5G U.@U!#I8_QL.)U6T@ /QWOV
MC]:[]K+ $J:<?B.Y6HV=*P?E4."*J@>^_02-GY'ARSB5]A=MZ]CPTD%9)14O
M&[ ^04E8_<6[)@\' ,W3#? ;@/\2$+X""!I \%:%L &$;U48-0!KW:V]V\2E
M6.$D%GR+A(G6;&9@LV_1.E^$F7?RJ(3>)1JGDCN6\1+0%[P#B<Y34)A0>8$^
MH*?'%)V?7: S1!BZ)Y3J:Y6QJ[2F0;I9PS^I^?U7^ -TSYE:231C.>0=^+0?
M'_7@7>VU->SO#4_\7L+/%1N@P'N/?,\?=IQG^G:XUV7G_]1G_ZQ^E(R@O?W
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M$"9 [Q><J_W$"+2=/OD-4$L#!!0    ( ,6!!5.@3P:"G ,  $P,   9
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MZCL__4HJ0B.-E_!,FF]TJGP]!R6%5#RO@F$%.67E+_Y1"=$( !Q[0% %!.V
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MF!5-3#0^@/;76KN=XQ/T,SC["U!+ P04    " #%@053IA_5\A #   R$0
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M;<=?87MQVK^]F%A,%'1%BVDW5=7,#@,S,%&["QP.D2M[^1',QV%^!# L#J8
M\W%>6)S_:3\C=#\.P[2-O,@(]1FA/L[+ATSM!XOC]\G,Y=]IEB5)FF(9G4Z]
M"J98WM(4OGXV3!MX8'$@TI_E&J\VWB%/]P%6TZ<Z!-LIWHG83O%< ^+/&WAD
MF;_:6!SPP*J ]0[$]\>!GO+[) E4%=.&/<$XDF48 KWH[]$T1;*3PL=?'^PI
M29(L\R. ^14D"8; TX@CF +0@"%)8L_!@_,HVIQ3T?97DLEO4$L#!!0    (
M ,6!!5.7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP
M!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T0
M4FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7
MG:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B
M6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!0
M2P,$%     @ Q8$%4V..1C$G!0  '2X   \   !X;"]W;W)K8F]O:RYX;6S%
MFE]OVCH8A[^*Q=4FG1X@_[I5I5);V Y21ZM2[?;(!%.L)C:S';KVT\\)[>;T
MA)_.S5NN2)P0GMC8S_O:/GW4YF&A]0/[61;*CGIKYS8G_;[-UZ+D]F^]$<I?
M66E3<N=/S7W?;HS@2[L6PI5%/QH,LG[)I>J=G;X^Z\;TPQ/M1.ZD5KZP+O@N
MQ:/]<[T^95MIY4(6TCV->LUQ(7JLE$J6\EDL1[U!C]FU?OQ'&_FLE>/%/#>Z
M*$:]X>["=V&<S/]3/*\A[_C"-B6.+VZY!QGULH%_X$H:ZYH[FN=SS[@5_N;=
M6>7T%UDX8<;<B:]&5QNI[NO'^+?H!Z_1U,/KYZX23\S_J4:]6LE<C'5>E4*Y
M73T:4=2 RJ[EQO:8XJ48]2[U5AAVP^]%_5+^5Z;+W0LZ3Q94ESF1_H*9+AM&
M0I[KV7@RFT_&S!_-KZ^FX_,[?W)Q?G4^NYRP #("D-$!(?^- L@80,8'@9S?
M^8]ODUD F0#(Y("0K9I, 61Z2,@X@,P 9'9(R"2 / :0QX>$3 /(3P#R$RWD
M6-C<R$U=SO2*N;5@%Y652E@; 'X&@)]I >=567+S5,-=<"MM?7!CA/7?JF\.
M!_(!&LD'M)C>S<LJ=VS."Q'6W!#JA=@O7PU7CMV*K5!52WE()T-JG_BP@B^T
M::YTP2&-#(D]\D4JKG+)"S95UIGF]E9S(GT,B?TQ%D9N>1U;L2[.$!,)9$AL
MD*GR3>JT>0J!D"R&Q+;P?7/CH]HGQM6237Y4<E-_X2\V$ZTZ0ZH8$KOBV@^\
MQ@]PA6]5P9I0FEWJ<J/5VS\@<L606!97@MOVZ(;$,"0V@Z^?4KJFAS8M>^G3
M&9]9"-\O6I 1\D)$[(6YT_G#D3>76#8-*I1M;@KYD"(B8D5,5:Y+P>[XSW:=
MP82#V! 3;I1O2,L^7&EK/S+?>7V7X":T1(0L$1%;8EXMK/A1^9O89/NF@T;(
M$!&Q(6"PU,HP(F2(B-@0&#/,,2+DC8C>&W]B.O;ACON?MQ]#.J2,B%@9K>"N
MDPZI(B)616>4UTF)%!(1*Z0SW.NBC)%#8F*'P+BO/0.#5!*3J^0E[NNL0"24
MF%@H( "L64-,.(=%K!4<!(;3@3&23$PLF5T4V-G(2"HQM53V1%HOH"$FDDI,
M+)6]P<V.,\1$=HF)[0+FA=@1.P\QD69B8LW@2"*<"(R19^)#3F*UI@(3))KD
M/2>QV(>Q<%P6K1Z>(,$D[SF=U8V'+),<8F++=Y:7Q@\QD642ZJ62/9B7:^Z3
MYS"52>!:";%END.SSMI$UDF(K;,/\[S4QLGG$!-9)R&VSC[,&3?U'R'$1-9)
MB*VS#_.E/,1$UDG(%TU00![FKPFR3D)L'8P9RC%%UDF)K1/D#1U#>HJ,DQ(;
M!R8.XS"F3)%Y4F+SP,2AO;",S),>,K]I=9L4F2<E-@_&;'4;N$Y/;!Z,&<:4
M*3)/2FR>EVSQMVJVW9%;BK23$FOG-V.[-J=J][00$VDG?9?E%X_YK=[.596L
M*6 W_.GM,F6*M),><EV&'84[2)!V,F+M0,S6H)DA!674>\0@9FL_#E)01JR@
MO;,ONXX?8B(%9=0K-_LQKS>M.#A#"LJHUW'V8]X*&PY(&5)0=J@I-Y^F^4LA
M)MPL1JR@<(VS4SX9DD]&+)_]$X*UC\)1/4/RR8CE@S!]VX>82#X9^4S;FZ79
MS@8_1N(Y;L33;VZV9Z=+L9)*+&?^\=:7Y[S(;PRK/W9;J9*TW@6QJHKBTI==
MJRO-EZ^[FU]W9I_] E!+ P04    " #%@053VW:P<3$"  ")*0  &@   'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(+CNBZ059]23
M3*-L #GEAV(;1-%*LONVG(%]4 ]Z$G%&J$!<_M$' AY?\J$=]]VI[/9]67P>
M#Z>RJG;CV/^JZ[+>Y6-;[KH^G\Y'-MUP;,?S<MC6?;M^;[>YEN4RZN%V1O7T
M>#MS\?K5Y_^9V&TV^W7^W:W_'/-I_,?@^J,;WLLNY[%:O+;#-H^KJOX\7'>7
M^K))=^?)U>+Y;54-SV^IJN<.$@B2^8,4@G3^((,@FS_((<CG#PH(BOF#&@AJ
MY@^ZAZ#[^8,>(.AA_J"T1!F7!$D3K FT3LAU(O Z(=B)0.R$9"<"LQ.BG0C4
M3LAV(G [(=R)0.Z$="<"NQ/BG0CT%M1;"/06U%L(]);)PS:!WH)Z"X'>@GH+
M@=Z">@N!WH)Z"X'>@GH+@=Z">@N!WH)Z"X'>BGHK@=Z*>BN!WHIZ*X'>.GE9
M0J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WH=Y&H+>AWD:@MZ'>
M1J"WH=Y&H+=-7G83Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>CMJ+<3Z.VH
MMQ/H[:BW$^CMJ+<3Z.VHMQ/H[9./E01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H'
MZAT$>@?J'01Z!^H=!'H'ZAT$>@?J'01Z!^H=!'K'Y&<3 KT#]0X"O0/U#@*]
M _4. KT;U+OY2;W+^'7(Y=KSO<;K_R35X_G<?+W\9?F]$^\7S07G^K:B//T%
M4$L#!!0    ( ,6!!5.DR,-W^@$  +0H   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0
MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M.'Y\EIUM^K=\-OY9<?$"4$L! A0#%     @ Q8$%4P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #%
M@053%PQQ=.\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #%@053F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,6!!5/&ZM!U
M- 4  &,5   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #%@053-2(5%CX&  !C&@  &
M@(%X#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ Q8$%
M4P0N:D_D @  Q@D  !@              ("![!,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( ,6!!5-[HJTBPP4  )D:   8
M      " @087  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #%@0533WV4'?0#  "L#0  &               @('_'   >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ Q8$%4T E!"?#!P  _2T  !@
M             ("!*2$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( ,6!!5.NLYOAOP(  ,$&   8              " @2(I  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #%@053Q#BQW*X&  #R
M&P  &               @($7+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ Q8$%4_@$M/ !"0  810  !@              ("!^S(
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,6!!5.9_&JX
M5@@  +\6   9              " @3(\  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ Q8$%4P^7Q.:N"   !A4  !D
M ("!OT0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #%
M@053HZFGR;$(   +%0  &0              @(&D30  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,6!!5-TXZYM=P0  !\*   9
M          " @8Q6  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ Q8$%4UE7JL>L"   %A@  !D              ("!.EL  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #%@053.W4!4<L(
M&P  &0              @($=9   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( ,6!!5,"2FM=80(  "T%   9              " @1]M
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ Q8$%4_H_
M79SW @  <P8  !D              ("!MV\  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    " #%@053RM<M<5$$  "H"@  &0
M    @('E<@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M ,6!!5/VNLQKN @  #\H   9              " @6UW  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ Q8$%4\0%IS4U"@  [1H  !D
M             ("!7(   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #%@053<N@>R$0'  !0$@  &0              @('(B@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,6!!5-?4XOO]@8
M "\2   9              " @4.2  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ Q8$%4W%G343] P  >PD  !D              ("!
M<)D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #%@053
M*!<S6XP#  "=!P  &0              @(&DG0  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,6!!5-!H((&2 <  )T3   9
M      " @6>A  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ Q8$%4VQ"7K@"!   +0P  !D              ("!YJ@  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #%@053#^P""'X"  !+!0
M&0              @($?K0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( ,6!!5.+K!EP" ,   \'   9              " @=2O  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ Q8$%4_0E%D<5
M!   F@H  !D              ("!$[,  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #%@053A%&)X50%  !-$   &0
M@(%?MP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,6!
M!5,#T82W^ ,  -<*   9              " @>J\  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ Q8$%4\#04!5U @  004  !D
M         ("!&<$  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #%@053-&J*C@8#  !L!@  &0              @('%PP  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,6!!5.\34E! @4  -8-
M   9              " @0+'  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ Q8$%4T6RP[S.!   ?@X  !D              ("!.\P
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #%@053Y.\O
M; (%  #M"P  &0              @(% T0  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( ,6!!5.M&EWFW@,  /T(   9
M  " @7G6  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MQ8$%4V"--KA8 @  - 4  !D              ("!CMH  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #%@053]K>F(9D$   F%   &0
M            @($=W0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( ,6!!5,95=IY] (  'L(   9              " @>WA  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ Q8$%4P%@VZ<W P
M7PP  !D              ("!&.4  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #%@053FNL?H<H%  !['0  &0              @(&&
MZ   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ,6!!5/X
MVJ4B=P,  %$.   9              " @8?N  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ Q8$%4U,@1?@Q P  0 L  !D
M     ("!-?(  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,6!!5/=)Y9X, (  $8$   9              "
M@: ) 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ Q8$%
M4]P ";0$!   9Q(  !D              ("!!PP! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #%@053WI )KU8"   9!@  &0
M        @(%"$ $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( ,6!!5/>=M-W=P0  ,,4   9              " @<\2 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ Q8$%4XR(.8/H @  !@@
M !D              ("!?1<! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #%@0532VG+VRD#  "*"0  &0              @(&<&@$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ,6!!5,Z X .
ML (  #0'   9              " @?P= 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ Q8$%4XB\[,)_ P  Z0T  !D
M ("!XR ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #%
M@053&XXYZ&<%  ";&0  &0              @(&9) $ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( ,6!!5,J,[.&P0,  )D.   9
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M970V,BYX;6Q02P$"% ,4    " #%@053NC"3A  %   N%@  &0
M    @(&Q.0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M ,6!!5,&)<QD104  /<7   9              " @>@^ 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ Q8$%4Z> 4\B* P  .PL  !D
M             ("!9$0! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " #%@053&#!E^]L#  #^$0  &0              @($E2 $ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( ,6!!5-&.!A>JP(
M /4'   9              " @3=, 0!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ Q8$%4Z!/!H*< P  3 P  !D              ("!
M&4\! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #%@053
MHPXTOZL"  #N!P  &0              @('L4@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( ,6!!5,.1$!%:0(  (\%   9
M      " @<Y5 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ Q8$%4Z8?U?(0 P  ,A$   T              ( !;E@! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #%@053EXJ[',     3 @  "P
M@ &I6P$ 7W)E;',O+G)E;'-02P$"% ,4    " #%@0538XY&,2<%   =+@
M#P              @ &27 $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MQ8$%4]MVL'$Q @  B2D  !H              ( !YF$! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Q8$%4Z3(PW?Z 0  M"@  !,
M             ( !3V0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $X
,3@!9%0  >F8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>290</ContextCount>
  <ElementCount>380</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSales</Role>
      <ShortName>Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Grant Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenue</Role>
      <ShortName>Grant Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenue</Role>
      <ShortName>Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Other Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponents</Role>
      <ShortName>Other Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2157115 - Disclosure - Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShare</Role>
      <ShortName>Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2161116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSalesTables</Role>
      <ShortName>Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/ProductSales</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Grant Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenueTables</Role>
      <ShortName>Grant Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GrantRevenue</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Collaboration Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenueTables</Role>
      <ShortName>Collaboration Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/CollaborationRevenue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/FinancialInstruments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2329307 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Inventory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2332308 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2335309 - Disclosure - Other Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsTables</Role>
      <ShortName>Other Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/OtherBalanceSheetComponents</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2341310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2350311 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2358312 - Disclosure - Earnings (Loss) per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShareTables</Role>
      <ShortName>Earnings (Loss) per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EarningsLossperShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSalesDetails</Role>
      <ShortName>Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/ProductSalesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Grant Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenueDetails</Role>
      <ShortName>Grant Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GrantRevenueTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails</Role>
      <ShortName>Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails</Role>
      <ShortName>Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Derivative Financial Instruments - Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashFlowHedgesDetails</Role>
      <ShortName>Derivative Financial Instruments - Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails</Role>
      <ShortName>Derivative Financial Instruments - Balance Sheet Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/InventoryTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2436416 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437417 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails</Role>
      <ShortName>Other Balance Sheet Components - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442420 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2443421 - Disclosure - Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Leases - Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446423 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails</Role>
      <ShortName>Commitments and Contingencies - Strategic Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2447424 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2448425 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails</Role>
      <ShortName>Commitments and Contingencies - Licenses to Patented Technology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2451426 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2452427 - Disclosure - Stock-Based Compensation - Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2453428 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456430 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/IncomeTaxes</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2459431 - Disclosure - Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EarningsLossperShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460432 - Disclosure - Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EarningsLossperShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="mrna-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2462433 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SubsequentEvents</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mrna-20210630.htm">mrna-20210630.htm</File>
    <File>a4exhibit3116302021.htm</File>
    <File>a5exhibit3126302021.htm</File>
    <File>a6exhibit3216302021.htm</File>
    <File>exhibit101amendmentsnos4to.htm</File>
    <File>exhibit102amendmentnos8and.htm</File>
    <File>mrna-20210630.xsd</File>
    <File>mrna-20210630_cal.xml</File>
    <File>mrna-20210630_def.xml</File>
    <File>mrna-20210630_lab.xml</File>
    <File>mrna-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrna-20210630_g1.jpg</File>
    <File>mrna-20210630_g2.jpg</File>
    <File>mrna-20210630_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrna-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 290,
   "dts": {
    "calculationLink": {
     "local": [
      "mrna-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrna-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrna-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrna-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrna-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrna-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 517,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 11
   },
   "keyCustom": 42,
   "keyStandard": 338,
   "memberCustom": 30,
   "memberStandard": 39,
   "nsprefix": "mrna",
   "nsuri": "http://www.modernatx.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.modernatx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Product Sales",
     "role": "http://www.modernatx.com/role/ProductSales",
     "shortName": "Product Sales",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Grant Revenue",
     "role": "http://www.modernatx.com/role/GrantRevenue",
     "shortName": "Grant Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Collaboration Revenue",
     "role": "http://www.modernatx.com/role/CollaborationRevenue",
     "shortName": "Collaboration Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Financial Instruments",
     "role": "http://www.modernatx.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Derivative Financial Instruments",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Inventory",
     "role": "http://www.modernatx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Property and Equipment, Net",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Other Balance Sheet Components",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponents",
     "shortName": "Other Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Leases",
     "role": "http://www.modernatx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.modernatx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Stock-Based Compensation",
     "role": "http://www.modernatx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Income Taxes",
     "role": "http://www.modernatx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157115 - Disclosure - Earnings (Loss) per Share",
     "role": "http://www.modernatx.com/role/EarningsLossperShare",
     "shortName": "Earnings (Loss) per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161116 - Disclosure - Subsequent Events",
     "role": "http://www.modernatx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Product Sales (Tables)",
     "role": "http://www.modernatx.com/role/ProductSalesTables",
     "shortName": "Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Grant Revenue (Tables)",
     "role": "http://www.modernatx.com/role/GrantRevenueTables",
     "shortName": "Grant Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Collaboration Revenue (Tables)",
     "role": "http://www.modernatx.com/role/CollaborationRevenueTables",
     "shortName": "Collaboration Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Derivative Financial Instruments (Tables)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329307 - Disclosure - Inventory (Tables)",
     "role": "http://www.modernatx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332308 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335309 - Disclosure - Other Balance Sheet Components (Tables)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables",
     "shortName": "Other Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341310 - Disclosure - Leases (Tables)",
     "role": "http://www.modernatx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350311 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358312 - Disclosure - Earnings (Loss) per Share (Tables)",
     "role": "http://www.modernatx.com/role/EarningsLossperShareTables",
     "shortName": "Earnings (Loss) per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfDevelopmentProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of the Business - Additional Information (Details)",
     "role": "http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails",
     "shortName": "Description of the Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfDevelopmentProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i467f5e1c5b0a40dfb2090010d28b95ad_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "if05aff14929149cab57fd79aefeeeb56_D20210401-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ifae9686943f64febad60646379a0b1cb_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Product Sales (Details)",
     "role": "http://www.modernatx.com/role/ProductSalesDetails",
     "shortName": "Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ib3e5362a76064a92b61e459fcd0ce315_D20210401-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "option",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Grant Revenue (Details)",
     "role": "http://www.modernatx.com/role/GrantRevenueDetails",
     "shortName": "Grant Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "option",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i3d4150668b3b4c44aa607c9d34eb7166_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "role": "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
     "shortName": "Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i3d4150668b3b4c44aa607c9d34eb7166_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "role": "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
     "shortName": "Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ide4dcbd5648047cc838ad06ddef0f031_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
     "shortName": "Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ib392451a0a484b5dbc71a9445c495423_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
     "shortName": "Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i414d3d35d2414d4cbfcac8697786c538_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Derivative Financial Instruments - Cash Flow Hedges (Details)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashFlowHedgesDetails",
     "shortName": "Derivative Financial Instruments - Cash Flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativeNotionalAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
     "shortName": "Derivative Financial Instruments - Balance Sheet Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i78b9df3a23274885ab33d029964f7f40_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Inventory (Details)",
     "role": "http://www.modernatx.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OtherPrepaidExpenseManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436416 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OtherPrepaidExpenseManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:AccruedClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437417 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Other Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:AccruedClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails",
     "shortName": "Other Balance Sheet Components - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TaxesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
     "shortName": "Other Balance Sheet Components - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i925c8f5cb9cd46f6a1ae86a03be5fc3f_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "campus",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442420 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.modernatx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "campus",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443421 - Disclosure - Leases - Balance Sheet Information (Details)",
     "role": "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
     "shortName": "Leases - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Leases - Minimum Lease Payments (Details)",
     "role": "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
     "shortName": "Leases - Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ica994bb2d53148f7a5bb0d0abab6b5fe_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "if3e4997c888f446e9fe81c8bdd3f1e5d_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446423 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails",
     "shortName": "Commitments and Contingencies - Strategic Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "if3e4997c888f446e9fe81c8bdd3f1e5d_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i598d0bc0445a41abbc9bdcd1258b0d3c_I20210630",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447424 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails",
     "shortName": "Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i598d0bc0445a41abbc9bdcd1258b0d3c_I20210630",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i7c7f1943108a4146a37ed6c8267654a2_I20170626",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448425 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
     "shortName": "Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i7c7f1943108a4146a37ed6c8267654a2_I20170626",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i23d47f973c914379ad830c261ec3d4eb_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451426 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ied95a1bb44664caaa76a6b4cd9a0b29c_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452427 - Disclosure - Stock-Based Compensation - Options Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "-4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ib676efd3333c4e95baf151a431bb5025_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453428 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ib676efd3333c4e95baf151a431bb5025_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456430 - Disclosure - Income Taxes (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459431 - Disclosure - Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
     "shortName": "Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i5c212449977847f097fb6ce69dc98327_D20210401-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "idaeb6871e31e46849c7dd99460a52126_D20200101-20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460432 - Disclosure - Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "shortName": "Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "idaeb6871e31e46849c7dd99460a52126_D20200101-20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "ibce2c27f4e1040e687c39c191e8498b0_D20200401-20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "icbdd283932184bea9f7f771d39f918d6_D20210701-20210805",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfDosesOfVaccineCandidate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462433 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.modernatx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "icbdd283932184bea9f7f771d39f918d6_D20210701-20210805",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfDosesOfVaccineCandidate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of the Business",
     "role": "http://www.modernatx.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210630.htm",
      "contextRef": "i179b2e7c238549528ec055756ce46033_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrna_AccruedClinicalTrials": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trials",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrials",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedDevelopmentOperation": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Development Operation",
        "label": "Accrued Development Operation",
        "terseLabel": "Development operations"
       }
      }
     },
     "localname": "AccruedDevelopmentOperation",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Manufacturing",
        "label": "Accrued Manufacturing",
        "terseLabel": "Manufacturing"
       }
      }
     },
     "localname": "AccruedManufacturing",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedOtherExternalGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Other External Goods And Services Current",
        "label": "Accrued Other External Goods And Services Current",
        "terseLabel": "Other external goods and services"
       }
      }
     },
     "localname": "AccruedOtherExternalGoodsAndServicesCurrent",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AllowanceForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Tenant Improvements",
        "label": "Allowance For Tenant Improvements",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "AllowanceForTenantImprovements",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Assets And Liabilities, Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrna_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biomedical Advanced Research And Development Authority [Member]",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge, Massachusetts [Member]",
        "label": "Cambridge, Massachusetts [Member]",
        "terseLabel": "Cambridge leases"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract With Customer Liability",
        "label": "Change in Contract With Customer Liability [Line Items]",
        "terseLabel": "Change in Contract With Customer Liability [Line Items]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityLineItems",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability",
        "label": "Change In Contract With Customer, Liability [Table]",
        "terseLabel": "Change In Contract With Customer, Liability [Table]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityTable",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractwithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer Asset [Roll Forward]",
        "label": "Change In Contract with Customer Asset [Roll Forward]",
        "terseLabel": "Contract Assets:"
       }
      }
     },
     "localname": "ChangeInContractwithCustomerAssetRollForward",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractwithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer Liability [Roll Forward]",
        "label": "Change In Contract with Customer Liability [Roll Forward]",
        "terseLabel": "Contract Liabilities:",
        "verboseLabel": "Change In Contract with Customer Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractwithCustomerLiabilityRollForward",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChargesToFinancingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges To Financing Lease Liabilities",
        "label": "Charges To Financing Lease Liabilities",
        "terseLabel": "Changes in financing lease liabilities"
       }
      }
     },
     "localname": "ChargesToFinancingLeaseLiabilities",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ClinicalOperationsAndSupportCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Operations And Support Commitment [Member]",
        "label": "Clinical Operations And Support Commitment [Member]",
        "terseLabel": "Clinical operations and support commitment"
       }
      }
     },
     "localname": "ClinicalOperationsAndSupportCommitmentMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Services",
        "label": "Clinical Services [Member]",
        "terseLabel": "Clinical Services"
       }
      }
     },
     "localname": "ClinicalServicesMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]",
        "label": "Collaboration Arrangement, Including Arrangements With Affiliate [Member]",
        "terseLabel": "Collaboration Revenue by Strategic Collaborator:"
       }
      }
     },
     "localname": "CollaborationArrangementIncludingArrangementsWithAffiliateMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement [Member]",
        "label": "Collaboration Arrangement [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationArrangementMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ContractOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Options",
        "label": "Contract Options [Member]",
        "terseLabel": "Contract options"
       }
      }
     },
     "localname": "ContractOptionsMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ContractWithCustomerAssetDeductionsDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Deductions During Period",
        "label": "Contract With Customer, Asset, Deductions During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeductionsDuringPeriod",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Deductions During Period",
        "label": "Contract With Customer, Liability, Deductions During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductionsDuringPeriod",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_CurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Marketable Securities [Member]",
        "label": "Current Marketable Securities [Member]",
        "terseLabel": "Current Marketable Securities"
       }
      }
     },
     "localname": "CurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DefenseAdvancedResearchProjectsAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defense Advanced Research Projects Agency [Member]",
        "label": "Defense Advanced Research Projects Agency [Member]",
        "terseLabel": "DARPA"
       }
      }
     },
     "localname": "DefenseAdvancedResearchProjectsAgencyMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_EmbeddedLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Embedded Leases",
        "label": "Embedded Leases [Member]",
        "terseLabel": "Embedded Leases"
       }
      }
     },
     "localname": "EmbeddedLeasesMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_FinancingRightOfUseAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing, Right-Of-Use Asset [Member]",
        "label": "Financing, Right-Of-Use Asset [Member]",
        "terseLabel": "Right-of-use asset, financing (Note 11)"
       }
      }
     },
     "localname": "FinancingRightOfUseAssetMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Right Of Use Asset, Operating Leases",
        "label": "Increase (Decrease) In Right Of Use Asset, Operating Leases",
        "negatedTerseLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssetOperatingLeases",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_InitialProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Project [Member]",
        "label": "Initial Project [Member]",
        "terseLabel": "Initial project"
       }
      }
     },
     "localname": "InitialProjectMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_LeasesImputedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Imputed Interest Rate",
        "label": "Leases, Imputed Interest Rate",
        "terseLabel": "Imputed interest rate"
       }
      }
     },
     "localname": "LeasesImputedInterestRate",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_LeasesIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Incremental Borrowing Rate",
        "label": "Leases, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LeasesIncrementalBorrowingRate",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_LesseeOperatingLeaseNumberOfExtensionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Extension Periods",
        "label": "Lessee, Operating Lease, Number Of Extension Periods",
        "terseLabel": "Number of extension periods"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensionPeriods",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_MTCEastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC East",
        "label": "MTC East [Member]",
        "terseLabel": "MTC East"
       }
      }
     },
     "localname": "MTCEastMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MTCNorthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC North",
        "label": "MTC North [Member]",
        "terseLabel": "MTC North"
       }
      }
     },
     "localname": "MTCNorthMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MTCSouthMTCNorthAndMTCEastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC South, MTC North and MTC East",
        "label": "MTC South, MTC North and MTC East [Member]",
        "terseLabel": "MTC South, MTC North and MTC East"
       }
      }
     },
     "localname": "MTCSouthMTCNorthAndMTCEastMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MTCSouthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC South",
        "label": "MTC South [Member]",
        "terseLabel": "MTC South"
       }
      }
     },
     "localname": "MTCSouthMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck [Member]",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NoncurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Marketable Securities [Member]",
        "label": "Noncurrent Marketable Securities [Member]",
        "terseLabel": "Non- Current Marketable Securities"
       }
      }
     },
     "localname": "NoncurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NorwoodMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwood, Massachusetts",
        "label": "Norwood, Massachusetts [Member]",
        "terseLabel": "Norwood leases"
       }
      }
     },
     "localname": "NorwoodMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NumberOfDevelopmentProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Program",
        "label": "Number Of Development Program",
        "terseLabel": "Number of development programs"
       }
      }
     },
     "localname": "NumberOfDevelopmentProgram",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Programs That Have Entered Clinics, Number Of Clinics",
        "label": "Number Of Development Programs That Have Entered Clinics, Number Of Clinics",
        "terseLabel": "Number of clinics"
       }
      }
     },
     "localname": "NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_NumberOfDosesOfVaccineCandidate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Doses Of Vaccine Candidate",
        "label": "Number Of Doses Of Vaccine Candidate",
        "terseLabel": "Number of doses of vaccine candidate"
       }
      }
     },
     "localname": "NumberOfDosesOfVaccineCandidate",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_NumberOfParticipant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Participant",
        "label": "Number Of Participant",
        "terseLabel": "Number of participant"
       }
      }
     },
     "localname": "NumberOfParticipant",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability",
        "label": "Operating And Finance Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability, Current",
        "label": "Operating And Finance Lease, Liability, Current",
        "totalLabel": "Total current lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability, Noncurrent",
        "label": "Operating And Finance Lease, Liability, Noncurrent",
        "totalLabel": "Total non-current lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Right-Of-Use Asset",
        "label": "Operating And Finance Lease, Right-Of-Use Asset",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liabilities",
        "label": "Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilities",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingLeaseNumberOfProperties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Number Of Properties",
        "label": "Operating Lease, Number Of Properties",
        "terseLabel": "Number of campuses"
       }
      }
     },
     "localname": "OperatingLeaseNumberOfProperties",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_OtherCollaborativePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaborative Parties",
        "label": "Other Collaborative Parties [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborativePartiesMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OtherGrantRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other grant revenue",
        "label": "Other grant revenue [Member]",
        "terseLabel": "Other grant revenue"
       }
      }
     },
     "localname": "OtherGrantRevenueMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OtherPrepaidExpenseManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Prepaid Expense, Manufacturing",
        "label": "Other Prepaid Expense, Manufacturing",
        "terseLabel": "Down payments to manufacturing vendors"
       }
      }
     },
     "localname": "OtherPrepaidExpenseManufacturing",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]",
        "label": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]",
        "terseLabel": "PCV agreement"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines Products [Member]",
        "label": "Personalized MRNA Cancer Vaccines Products [Member]",
        "terseLabel": "PCV products"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesProductsMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales",
        "label": "Product Sales [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductSalesMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RawMaterialsAccountsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raw Materials, Accounts Payable",
        "label": "Raw Materials, Accounts Payable",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "RawMaterialsAccountsPayable",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "verboseLabel": "Budgeted amount"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RestrictedStockAndRestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock And Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock And Restricted Stock Units (RSU) [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsRSUMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RevenueFromGrantsCurrentFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Current Funding Capacity",
        "label": "Revenue From Grants, Current Funding Capacity",
        "terseLabel": "Amount committed for funding"
       }
      }
     },
     "localname": "RevenueFromGrantsCurrentFundingCapacity",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsMaximumAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Maximum Award",
        "label": "Revenue From Grants, Maximum Award",
        "terseLabel": "Award amount"
       }
      }
     },
     "localname": "RevenueFromGrantsMaximumAward",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options",
        "label": "Revenue From Grants, Number Of Contract Options",
        "verboseLabel": "Number of contract options"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptions",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options Exercised",
        "label": "Revenue From Grants, Number Of Contract Options Exercised",
        "terseLabel": "Number of contract options exercised"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptionsExercised",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsPotentialReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Potential Reimbursement",
        "label": "Revenue From Grants, Potential Reimbursement",
        "terseLabel": "Potential reimbursements"
       }
      }
     },
     "localname": "RevenueFromGrantsPotentialReimbursement",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsRemainingFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Remaining Funding Capacity",
        "label": "Revenue From Grants, Remaining Funding Capacity",
        "terseLabel": "Available funding"
       }
      }
     },
     "localname": "RevenueFromGrantsRemainingFundingCapacity",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Assets Obtained Through Finance Lease Modifications And Reassessments",
        "label": "Right-Of-Use Assets Obtained Through Finance Lease Modifications And Reassessments",
        "terseLabel": "Right-of-use assets obtained through finance lease modifications and reassessments"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage",
        "terseLabel": "Payout percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_StockOptionAndIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option And Incentive Plan 2018 [Member]",
        "label": "Stock Option And Incentive Plan 2018 [Member]",
        "terseLabel": "2018 Equity Plan"
       }
      }
     },
     "localname": "StockOptionAndIncentivePlan2018Member",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_SupplyAndManufacturingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply And Manufacturing Agreements",
        "label": "Supply And Manufacturing Agreements [Member]",
        "terseLabel": "Supply and manufacturing agreements"
       }
      }
     },
     "localname": "SupplyAndManufacturingAgreementsMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TheBillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Bill\u00a0And Melinda Gates Foundation [Member]",
        "label": "The Bill\u00a0And Melinda Gates Foundation [Member]",
        "terseLabel": "The Bill\u00a0&amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "TheBillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_VertexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex [Member]",
        "label": "Vertex [Member]",
        "terseLabel": "Vertex"
       }
      }
     },
     "localname": "VertexMember",
     "nsuri": "http://www.modernatx.com/20210630",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r59",
      "r61",
      "r118",
      "r119",
      "r254",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r180",
      "r279",
      "r284",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r253",
      "r260",
      "r299",
      "r300",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r520",
      "r524",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r253",
      "r260",
      "r299",
      "r300",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r520",
      "r524",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r180",
      "r279",
      "r284",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r176",
      "r279",
      "r282",
      "r481",
      "r519",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r176",
      "r279",
      "r282",
      "r481",
      "r519",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r253",
      "r260",
      "r290",
      "r299",
      "r300",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r520",
      "r524",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r253",
      "r260",
      "r290",
      "r299",
      "r300",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r520",
      "r524",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r118",
      "r119",
      "r254",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r279",
      "r283",
      "r522",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r279",
      "r283",
      "r522",
      "r539",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r26",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r495",
      "r514"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r63",
      "r70",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Net Unrealized Gains on Derivatives Designated As Hedging Instruments"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r70",
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Loss on Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r68",
      "r69",
      "r70",
      "r510",
      "r532",
      "r536"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r67",
      "r70",
      "r79",
      "r80",
      "r81",
      "r121",
      "r122",
      "r123",
      "r373",
      "r527",
      "r528",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r334",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r331",
      "r332",
      "r333",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r301",
      "r303",
      "r336",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r303",
      "r324",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r165",
      "r168",
      "r174",
      "r206",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r369",
      "r374",
      "r412",
      "r442",
      "r444",
      "r491",
      "r507"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r13",
      "r55",
      "r113",
      "r206",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r369",
      "r374",
      "r412",
      "r442",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r190",
      "r219"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r195",
      "r197",
      "r503"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r195",
      "r198",
      "r504"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r195",
      "r196",
      "r502"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r186",
      "r191",
      "r219",
      "r494"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair\u00a0Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r188",
      "r219"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r188",
      "r219"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Investments, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r304",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r41",
      "r105"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r20",
      "r106",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r100",
      "r105",
      "r110"
     ],
     "calculation": {
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r100",
      "r421"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r238",
      "r496",
      "r513"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r239",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Share available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2021 and December 31, 2020; 403 and 399 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r75",
      "r77",
      "r78",
      "r84",
      "r498",
      "r516"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Balances of Receivables and Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueTables",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r265",
      "r267",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetPurchase": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time.",
        "label": "Contract with Customer, Asset, Purchase",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetPurchase",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r265",
      "r266",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "terseLabel": "Additions",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r280"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r280"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r291",
      "r298",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r88",
      "r481"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r192",
      "r219",
      "r222",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Credit losses related allowance"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r114",
      "r350",
      "r357",
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r103",
      "r163"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r57",
      "r58",
      "r61",
      "r411"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative assets",
        "verboseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r61",
      "r382",
      "r383",
      "r386",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r392",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r380",
      "r382",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r385",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Net realized and unrealized loss"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r57",
      "r58",
      "r61",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative Instruments",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueTables",
      "http://www.modernatx.com/role/GrantRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r85",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r139",
      "r141",
      "r143",
      "r144",
      "r145",
      "r149",
      "r150",
      "r402",
      "r403",
      "r499",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic EPS (usd per share)",
        "verboseLabel": "Basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r85",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r141",
      "r143",
      "r144",
      "r145",
      "r149",
      "r150",
      "r402",
      "r403",
      "r499",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted EPS (usd per share)",
        "verboseLabel": "Diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r115",
      "r345",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation-related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to non-vested stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of cost expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "netLabel": "Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r79",
      "r80",
      "r81",
      "r121",
      "r122",
      "r123",
      "r126",
      "r135",
      "r137",
      "r152",
      "r210",
      "r263",
      "r264",
      "r331",
      "r332",
      "r333",
      "r353",
      "r354",
      "r401",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r527",
      "r528",
      "r529",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r255",
      "r257",
      "r258",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r406",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r255",
      "r291",
      "r292",
      "r297",
      "r298",
      "r406",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r255",
      "r257",
      "r258",
      "r291",
      "r292",
      "r297",
      "r298",
      "r406",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r255",
      "r257",
      "r258",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Financing Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r431",
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Financing lease liabilities, current",
        "verboseLabel": "Lease liabilities - financing"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance Lease Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Financing lease liabilities, non-current",
        "verboseLabel": "Financing lease liabilities, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remainder of the year)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest or imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Right-of-use assets, financing, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r203",
      "r204",
      "r205",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r224",
      "r225",
      "r256",
      "r262",
      "r392",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Foreign currency hedges expected to be recognized within the next 12 months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashFlowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r61",
      "r291",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency forward contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r380",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r232",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r346",
      "r347",
      "r349",
      "r355",
      "r361",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r136",
      "r137",
      "r164",
      "r344",
      "r356",
      "r362",
      "r518"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r102",
      "r479"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r226"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r53",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r226"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r34",
      "r226"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r90",
      "r162"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization/accretion of investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r202",
      "r489",
      "r505",
      "r538",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remainder of the year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest or imputed interest",
        "verboseLabel": "Amounts representing interest or imputed interest, operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r46",
      "r113",
      "r169",
      "r206",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r370",
      "r374",
      "r375",
      "r412",
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r113",
      "r206",
      "r412",
      "r444",
      "r493",
      "r512"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r113",
      "r206",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r370",
      "r374",
      "r375",
      "r412",
      "r442",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r100",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r73",
      "r76",
      "r81",
      "r83",
      "r104",
      "r113",
      "r125",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r142",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r206",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r403",
      "r412",
      "r497",
      "r515"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r132",
      "r138",
      "r149",
      "r184",
      "r185",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r241",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r351",
      "r352",
      "r353",
      "r354",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r441",
      "r482",
      "r483",
      "r484",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "netLabel": "Lease liabilities - operating",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases",
        "verboseLabel": "Right-of-use assets, operating, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r47"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r54",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Additional commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r367",
      "r368",
      "r372"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Net (decrease) increase from available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r63",
      "r68"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains on derivative instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r74",
      "r77",
      "r367",
      "r368",
      "r372"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive loss",
        "verboseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r201"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Less: net realized (gains) losses on available-for-sale securities reclassified in net income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r64",
      "r68"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (losses) gains on available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r47",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r228"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r240"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r93",
      "r95",
      "r187"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r304",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r24",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.0001; 162\u00a0shares authorized as of June 30, 2021 and December 31, 2020; no shares issued or outstanding at June 30, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r11",
      "r39",
      "r40"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offerings of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r93",
      "r94",
      "r187"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r93",
      "r94",
      "r187"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock through equity plans, net"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r230",
      "r433",
      "r436"
     ],
     "calculation": {
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r56",
      "r231",
      "r436"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r21",
      "r229",
      "r430"
     ],
     "calculation": {
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Furniture, fixtures and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r21",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r21",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r23",
      "r492",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r23",
      "r492",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
     "auth_ref": [
      "r23",
      "r492",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Table]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r23",
      "r492",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r339",
      "r480",
      "r557"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Collaboration Revenue"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r20",
      "r110"
     ],
     "calculation": {
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r14",
      "r22",
      "r110",
      "r540"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted common stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r264",
      "r334",
      "r444",
      "r511",
      "r531",
      "r536"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r121",
      "r122",
      "r123",
      "r126",
      "r135",
      "r137",
      "r210",
      "r331",
      "r332",
      "r333",
      "r353",
      "r354",
      "r401",
      "r527",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r166",
      "r171",
      "r172",
      "r176",
      "r177",
      "r180",
      "r278",
      "r279",
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r281",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Grant Revenue",
        "verboseLabel": "Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenue",
      "http://www.modernatx.com/role/ProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r82",
      "r113",
      "r160",
      "r161",
      "r166",
      "r171",
      "r172",
      "r176",
      "r177",
      "r180",
      "r206",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r412",
      "r500"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Total grant revenue",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r437",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for financing lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r70",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash and Available-for-Sale Securities by Significant Investment Category"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r303",
      "r323",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r303",
      "r323",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r19",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Restricted Common Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r385",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule Of Foreign Currency Derivatives"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r20",
      "r110",
      "r490",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r304",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled, forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Issued (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, non-vested at end of period (in shares)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, non-vested at end of period (usd per share)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value per Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Aggregate number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number\u00a0of Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r309",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Options (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Options Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number\u00a0of Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r302",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Intrinsic value of restricted stock units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Basis of Presentation and Recent Accounting Standards"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internally developed software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r52",
      "r79",
      "r80",
      "r81",
      "r121",
      "r122",
      "r123",
      "r126",
      "r135",
      "r137",
      "r152",
      "r210",
      "r263",
      "r264",
      "r331",
      "r332",
      "r333",
      "r353",
      "r354",
      "r401",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r527",
      "r528",
      "r529",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r152",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r263",
      "r264",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of options to purchase common stock, net (in shares)",
        "verboseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r24",
      "r25",
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs of $1"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options to purchase common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount for share repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r30",
      "r31",
      "r113",
      "r183",
      "r206",
      "r412",
      "r444"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r429",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r429",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r429",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r429",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Other Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r203",
      "r204",
      "r205",
      "r256",
      "r262",
      "r392",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r117",
      "r291",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. treasury notes"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r117",
      "r291",
      "r298",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury bills"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "Value added tax receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r140",
      "r145"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r139",
      "r145"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted average common shares used in calculation of earnings (loss) per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r561": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r562": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r563": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r571": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r572": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001682852-21-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001682852-21-000022-xbrl.zip
M4$L#!!0    ( ,6!!5-YC;>=/0@  *LC   7    831E>&AI8FET,S$Q-C,P
M,C R,2YH=&W=6FMS&KD2_;Z_0DMJLW85KV'P"SNN(D V5&7M+,:5W4^WQ$B
MRL-H(FG W%]_CZ09@PU.\"8W#Z<J&$:M5JM/]^G6S)S]VKWL#/]YWR-3,XO)
M^^O7[_H=4JK4:A_"3JW6'7;)V^&?[TBS6@_(4-%$"R-D0N-:K7=1(J6I,6FK
M5ELL%M5%6)5J4AL.:E95LQ9+J7F5&58Z/[-7\,DI.__E[-=*A71EE,UX8DBD
M.#6<D4R+9$(^,*YO2*622W5DNE1B,C6D46\$Y(-4-V)._;@1)N;GA9ZSFO]]
M5G.+G(TD6YZ?,3$G@KTJ"18<';##8\H:QV'SZ.!D-#H>'X8G37I8;]+Z<>,_
M 8RL0=S/T689\U>EF4@J4V[7;S4;U:.#U)PN!#/35E"O_U9RHN=G8YD8K*<P
MWW_U:C:5436!OI$T1LY:)]!E^*VIT%A,DI;;9,DK*R9$,I:J]:+N_IW:D<J8
MSD2\;/T^%#.NR05?D(&<T>3WL@8P%<V5&'M!+?[+8246<3\7?A-'T!.+A!>;
M"AIV&[W;J1@)0\*@&I#[F]C5_ @(<%5ZU!G_2L^W]D.G-QCVW_0[[6'_\@*9
M,+BZ;E\,R?"2#*[?]:Y($-)*T-RC^R]?!(?UT_9%EP0';/W2]46W-R##MSUR
MU>M<#_K#/J;U_NZ\;5_\T2/MSI!<OB'!2=@LD_85:7<OWP][W7LK89Y=W:L+
MZPT[P>EK#UZW+WI7E<N_W_7^*50UZO7&S^[HJ]TW\'\WM[G5W'Z97)F7+QIA
M>)I.:<+):YI$/"Z3B"LCQDMBIA3C!\>G3\ BI8R!\"HQ'YM6>%B@(Q(&9%J5
M(*P>?+<-!U72)U,ZYT3QN> +L+.9"DW^RJA"U,1+,N"I5(;(A+R1:N:C-:A7
M_B)R3/Z4C*N$EOW5?A)5X9N3Y^*;1A7P:W@$>Y\MR4TB%S%G$U[V+E+>,4QB
MQ42BND$A%0FAR9)DB5$9A\&H=Z[TP5F4S/!+"1J3,8UP21$Y Q<;Z>4V!!(>
M<:VI6EJ1&;WA6'=-I\8U!F.P9.SJ)M:P I%0J),00^1J6 *(R&(JHBG1F?U8
MS5]PQ7,E=@,SH6,45%N;%\),L4&=\L@9:/6F,$TR;'..:8R,ENMN>$ZXAY_
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MO0,>PEL>T#0F53B/?1T.Y9R7!\>V;;9[?):0>*&>K/81A#Q5*A-TD = ,>@
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M6:E<,R>(THXKP^9@>-P*/AY7V6QPTSPVJZ<U]M&R;7@)&[N>AQ *%Q/Y.%"
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M>'WIPX?AD4I08QZ</&<1" J<K. OQF#)+D+1 HO=2P-;F.(NJ%&+^3P(D[Q
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M^WJR^7%I20/HS>^7'"P>(*VV' 40;;8:?OB*S:H"&?QO1U"#-62AIH!VZ\;
MH*LF:P4.&60*B@,^D6&EB)5:EX,C@UT&@;#YV^%B(J?88SL,N+UBL);T@;W'
MJZXS'+]/SB&;_&^9;PST6J'S0?QNV9_I%^"3'P+/D<)"O>W\'7O/?5R<^ -6
M8JCWFT][?_=UWD_CA$O3.)X+*) ;D/YY>'@H<WL<EB?!O1B.,G$Q;%(Y?S=R
MQ;@4T1J,/G*=+[_^<E)[-^RVX:?YSCIOV-:H6AG7Z[6S\U,+CG$T.N7UNE4]
MM<=UF_H-S6RZ-@X7G/Z.YQY]0 _'=X_"X"'B]">=;M6DWZNF/7;OZ_^N5,MP
MRR^5I[:BJ90U:?N<?*.\\:Q:[J31H///N^Z TC>&.XZ@=T&SG7-2;[VE\%[[
M 8UBP>Y($SU:-7Q/KDQ0VX+02;VZ(K05S(,(N$>T&,W<6+:.N0;6$OH6W&D
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MEW*A3A?J].%)[$*=/H!=%NKT89YKH4X7ZO0A8_$AJ-.%2[G0@0L=>*_W6.C
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M>,QM=.SA@D:NV,YB'HB;W@?W//1Q5V7&FAB>6MA3AD_!N-,,\!V?,0["&5#
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M$M]FPVQGQ%<8:*^/SH4E=GC&R$^]^<(2.UQYM)_*X,]&7S^7 ,T+EA7T]_-
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M8J#Y#FEHI^23=C%"]@C'.C\>+8_QI]";G 48+'(LK3<^%F<O8*P9>Y9L7O;
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MY[5\/UCX5/*V!&RTITPT0T"<RE(R;BY8""/P(<3D:9_(5Q;P;2N&RS8)AZ?
M8H#.E;C ]P#GD_7UV%0]^U8+#4AL=H)U+X3G8^S@( KW)B'G,^W]U*,]@8'>
M(2 E9]'F4IQUPG4R[WR.!#M9]2Y4RM+V^+$)KJ#@E2N5%V6XUG'))Z^>X=HX
M+3<:]5?,</W90M:8ZIK+43%[ K];[.J[RT%->P*G_,\FVGM %HA7(%Z!>'L
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M]%7W*]+7W3RT\CF4B0& DK1DD4CQ ^73,/!)97959C=!F9F5\V.S?F:D":_
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MJ("!=PW7]Y;A/%8WO!N&TP<5\5BOW\1LPT"E*X^I@D<YFV3G@OR3[*7TH5F
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M/BU@^UHC"3&$4#8 OG9<'H3>G$?SBE(+]*PSCUSMSM7NC\I?DHS[)+4\)'.
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M>,[I%U88TS-B .!CMH, 7H:;UA3VM'A0*WH$QV YGCEAR&U:%[</;UVP:/6
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MQL(+1/<XX _>O>G+:32PJ[6- P!!5&&Z,IGJ)G-Q[A,LJRA <XV*S25I0C
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MK:3# EZ)GB.T1@IX<%01?H^95%$C=NF]P.P@D9]*?BRJ&5<9$VJ/!W@L\%2
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M.-[OUB[L<GH-C53"16!QG$RSLEV<FP<[K+,6MSCVRJ:611EH<UF5I9/;LDM
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MV>JC)[[[J(LO/.FB/$QEYK'N<C:&OX7O[K!:/FP>HONN1.]<R6K[@$;JC 0
M^,21E=?2G:,%RM)/ R8P%_T==,<.B<!EH.FS4I\#DX'#,[<X.LFI0GZ@B9A>
MB#X85\6VA EASK6*83(R]##'IL7BM(HQN01@7>4K(!\(P]8L43H*>EANS;GS
M7^%Z3?\YC%?"0ZO-#%8\J2#]B@B(V3+$B+YT4A7CU@/<#;@0G6M=(:29DCPS
M+6 %ZB&_!:["A035+HK=29HSG&)E2G-?[PE!+E\SW- , %L86-)O> MR"AL
MR$>([49("; 9"L>9^Y LZ?]9,"D7WT;\EUP=CIG>"_^UR8>E,B.2L<E$LLZY
MZ;@4RO5$:E%4E1_P,,2$E<72#Y8H&23(I#!J@<:/R1R23S^:MI,'WO+ VW&V
M F\6*"&5H_*7]?]WR.!'UJ \PYC9M9V3B3P)C6!%J AD@$O6]@8%5SBT&*KS
M=(/(&2KB0P/1XD019-]W[DSK@1G*?:/Q%<'S2-D5%@?&WU0*$VALY.6%0]&\
MMD#WJ/J!YBCS-+3U\=+*Z7&]R!KLIC0L-4NLT:B:PBF"QB2IVYI;G'S/]#B9
M<% 42BD\=B%?0<R3I%WXV#G-#M9[<FQ_XPQ(3'LK&NW49S23/O;4HSM/Y9=$
M.DXBF*3"DL\(4.D*CJ:<%#.HG?"ML/ZF+,QU^8X];TA'4[B)&24*UU#=@[NF
M@,0B-C8!80WHB4>F]=W1J=:9R(8]\C)8F'('I2]Q.S(SL9^M8G[E3O*\!''P
M6,>)C>V$9*-C,T($16BZ%K%%:8E<KL(C3U[WHL8WBLD<L&(<+<T*[DQVT>D:
M/%HZZ +!:/6&1#)B3XHI7#DGK<[#3"6IHE) 5DM*D#W%B%N* *(GIR-FP0%Z
MNQ5XHS5,U=B9O<;.-&X6A261(%Q'YN\"3P(R=N%'BNG$*P-F"]^]]'@4T<$<
MDD/$]=!-X9KWZ0+EYO:YQM55HA$DZYVST65GR*)6EJ4&N[X9CMA9F_6-X;#=
M8J,>P]N&-V>'JIED;Y#5".M1ZIPG@SC(/\!K-[1431M!CE:\I7>>>X>Y2TLB
M*N'Q$"Y]H9W*G)& G;<,C*T>PIM\YV$B+ #D":2+=N28@U3BB8B$C!VI%+*D
MB)6I%+1XXLKDLJJ"(5XWN@S$[J!K'%:JQ[4BN_9L9*D,!*<%;T[W#8W!\+#I
M?3VLPK-];V[>.?XR8 7-9AUQ:SH'^-\^2*OU8#W7U1%]'(?HY10)S_BGA@"&
MR+03L0!RY]RA;+^E;]!]!.=G^\M;E9(G+NQT6P?%M6MMC@YXQG_PV4)>UVK#
M=9RR/N:@%6!>61)@A?:- 9=L?DRWA;^-'7Q)](O +WPN$H_BB\ZN\"(XX]4C
M3ES5O\:K  2-2KGP_4#'":IZB!I4.J07%<1E!R)55S!B+3=&7A4[QX"M S(<
M1$<>1F>#E2//.02Q$IQ%(!?RP9J0)QZ(%923 F6K_$6^J\A-I-^H&:#0N44"
M.^G>0!K5"FN>#QB*L^,OXO^U4K5@ 7AJE6JI461'Y7*I5@CABQ/XHEH8BT_8
MC)(<\4T"Y DV_BT?K"EGZ,I7&B@ZX2F*(2D,+\6W(QJE!"LTX!S2 ?D/RUT&
MF%"-]+*<1R4Q6I[;=KBE2A)NG:]'&M/MJC?-BYUHB2H&]%_)EXXZ/F8DQH/^
M;0S#7LN82E\RYS[JW4Z(5-&_8I5*X_"TBL%'[SZ(HNW4"Y-,#&&)$\)X*C);
MU,<W$-HLX!DA5P4-*CZH M.4'NF8MW-*\0]];H;2\0W7(V#@!;TEQ8]=9\(/
MPRE>PLG##38 I>/(QK@B?S%@$Y/2W0Q@:TAS;(:YJ>A CRH?UB.<Z RX!=.3
MR[(P;^[&^06XB/2>Q& 1C ,]I6N9"J2>BQ["OD<9=EPE1:X@$;R\BW:B>2O#
MP: UXI<8H%4M6!=>**VS9Z2^R/Z^(CF+7<&J\C 5ES,2;/Z* YN4+FGEDK6Y
MBVU;8\JV.9: $JUCI4>_U\2(/+X6L)+DK!:4^)A>D &RQQ!#8O-9562/4Z?(
MZI5F9Y34K"9S7#G_P?J?,/)&CF+S-OTHL_6]0 'LG_6!*.+V]%J6$XZS8S,.
M?]-4F#@Q=S-==X1#5+!!_"3UT"A3.5)16;/WM=-B7Z5^2DXF8$Q8J#=9DD<(
M^<G8(4J6;AG0ZVA.'ZK(4B,KKG(G3"9Q: *]J1\0:5$@'&%CU&J;%4;UYL&F
MG( B\^9K[W6#)6<RWY$L [A[2[)7U*5<=QR)4)$H+),5Y$76,;Y1+A(.%JR?
M'B)WWK7C]>*^PKGS@]N'(  M?I!5%G"2/A8@!-" 8TZ\2NMH1P9'(N.CT!^T
M^P?HFMRM1>7!O3RX=Y*MX%YG\TS5YU '>NP+TIQ$0A%T(AP+15RIQ*Y*K.N5
M6*5\>EBIGQ3C9%?@KZJBHBK&J@+/PSRN@J6ZX8/B5Z^J,)LP.UFU?FP?'MFT
MJRT_\@-:[YZ[U#&?[.@HIPO3 "^'D;QJ<1QZ*!CR313,>"X,D)4KLZ7I+='=
M/0,K@&*+QJV)(24A#P\KIR5VTD ';0FM4@!,HW)ZP@K7I@^?CXNL6JZ6BXQ/
M)EQ4"I]S &*]1-\?".-& 0JV;"Q\QX4UQ.\K2U<K9;# "Z%WR]$94=23%_ 5
M:.L: -3)9<1>+#B8R^H@A-7D R>0A0XT88_<%]BUA0(Q/N:?DO<=;3%7[R^"
M517P94A!G%!,S2CJQB&%=D+?&:O.(]IX1_H;3H7J_2<*ODU/F"DKV*!<+1,R
M[] W8\NT*%G;+G!$QHW85"2L1LZPXJ8*=T5%7SM*A5"DF#S<QFDF#A5.=4,%
MW*;V O&Y3T Q"Y351VG EK>(-"IY) -.3E4B'2,J,7OL1!X[D&0)F,B)V'%(
MG<[CIX3HE(F32AP5OKBYBOZBRY2"\298J;1#/=H?8?0N4&7 C!]AR@HZ,7?1
M;< Z7XF!?-V-&JLB+;JFL$U&2C]K,@>^Q2?D#]<[ MTYIO20H=#5IJ/#?V,.
M5L]$;0Q$)PTTPLHSS"./L\R%C%2]N50:(5R?> >+RA_-,:!',<INI)1TM 9=
M<WZ[1%5*^.UH6 VY=<,'$9H/EHZ8R.0ZIJSN=O1Y[+*N-4B\!,#+]3 K/DA4
ML\=5IL0^=.XA'.A4FAI[\%:/1KE?LXN;JV9UU-Y$[PQ%[RADFZCECYRDE+0I
M$CR"N")[8R+74E1740HGK6592S]0Z54W<\**H2C**5#6%R(TGH/OD-=>9)71
ME^B-I!/G<D$3.Q.,$7\QN2IRK.+Y=(U1CQ)ZX(!%9.! )&H%J@\$UD<C9L4(
M)5X ^Y7%:$L.!UO+=E&'+G/4I&,##?I(A&^D82STH\9>V&V&G,:^D%7HN9V+
M8%=<1J-'HU;13XB9**LF<I Z@;4,5/)3%":,<E<HFH:=9YS$D"CJSD7! TJR
M$<<DV(<MTERC)P#I8R#5EOQ,$Y8K>;&L20FQBOD7T U2JQU6,C!S&(G#H9P\
MHO(H, <H+>0:5@0"7L5%'!@[$ZIGW"0)50IXEREPO3O0TG&I&#OCHWU61D::
M/#NGJ?/L)!W^685KI9P6P%:.-@$VLW!-S4C3#P;7U'2\C> ZPE8@F#D>)TA@
M83K(8C3N,Q+2:<45+-B<1O@7%KL[)6Z,EZC.B0'H4JA>2UT"N]EB\RGX+LJ$
M*IRW^@<J]4)&6Q^BC *"H=;O!K,*9;:3B P%*P,XU[9#6@3V:UR$#![%S+C+
MDC0CI7?F@15ZO@,'<; 63A9&\M2[QRAU,6H'1GV:5 \J8<H'#AH%4?\$[8TD
M"%3ZE QOBQ>T8R1!Y5)K'+,A<O0Q*#@U'4TC"OX*D+$CU;?3IY*WEAF:Z:=;
MQ-:^U*N3]>G8#1*^N?6])?4F#<&>!R,$#0*191\^Q!HG>9-%(U-0Z'UAA6HS
MQDU;-#5677JCKG/)P:]*PY>Y05/,90FFU%,- 2_S\%::A,&:4;T;6@SQ!L;H
M18-O[DS'19.[F# C9!)XW#C8=&S][L0 6VG^39;H>,TLZ:2F&U)$.EWO+B,2
MCL+NTD8MLIMA$<2(58I[)?+;R,FNL&5(Q5+$TPW,YF'7YMP430XV"ILB6ZMH
MU=:7*6-1'W'L>7NG&=R.9N)1CIG,R(H,:[5GD4AA"6\_4L,#^1VX:;,\9IS'
MC+?&C$^S%3.&S2K,'_U38KX(PD5TH_Q$BJ;02PKR[A9[18DYY]*CQ7^ 3K:Q
M6:JL%E5Z5["1VG2UD>I@B.B0+U";+17O0P6.:E6G)F8UHT9)_N;HZ3IOR*P0
M2DVWC4@(80X:*,>UDR^L)S+[*V!]2>W;  / E5U4TR^E,%%BCB%Y;"PDV\V[
MH@>"-)LT!VV< "=MB^)*&JH69X@ L\"$8EO$81#98R)9F6V"AM9$*F5QU)KJ
M"EP/N_[15!.590=HK@JL5W=!(1AV3[FU9M131Q"CHC8*Z 0X6,/6=[W =#3<
M,K.QHY,J7[!5>'T- EK6KER"D*,O7AJ?H@ !KW>IS#I0-$5/X21K %:#?7R4
M8:RIL ("VD;/1/M$>Q7.HE#.M[F_]3375 FL=!>U![9L8F+:2/7T8Z(*-HH7
M+4-$)36!0\_2ARU%,,YRQGXE0D?]]8"S^I:#R"#A7F6%[M6(51J@JSUD);L$
MJQ'4(4FKAGK\BU,.*)8:O1\039*\D"AD1T>-&&-46_&ZT%RA&(MT\E@AV_GJ
M-R]_4D05+W9A[.EHJAO1SO9X0"%,A7^91[]$LK7"1>QM P=LH7O-#5;2ES1!
M$#<)PG"XC(W'#5 3TD&DS-!]FH:$XX#\.QG'T@1=4GA5)5,M)ED:U=!8/I;9
MK![4.OX^!<>32$K F<,3D%*$ Q"?,A>MU+"=!Q8&*J3?!""Q-QI'97&I!L:W
M[R"FK>LB:05;J'A%R'5"D1 /EP8A]JTGA3?!;F;F=TZ:["W\#CB&T5RA@A!H
M)[8;'Y Z.HD5\@=9"D?M#B36R":8!:?$2XF$!VR8))60J'6Z5,L3O1R?E86^
MQ^*9E3H%#;@$=T4/<IZ;'!"G U. R!;^9->TOA-2<=B<?2";E@L"I,MCY(]Z
MYNO: KH-EHO$@V0Z#"WBJL$(-$9-M:"X&5XH#QXVJ@D"ZB8NE8J?Z. H[!9G
MCM;5;[6MXR'?W&JIE Y6H"8K*VS/6L[$(+)8 09H1&&+EVI)24OE>'\8ZI0.
MFOK)R\(3^:H)@BNBJ\"!&P@3QF;@Q/,&M24H!55<BM<F5I\@-W;FUM+WG]>C
M-BV84EW#%*F+"1X>Z#@BAU%%_36J6KL@V:"-46$.22E[$P5F&50U -69<XC%
MS]CQU(PR9*.0'[5A$7(YXE6R^:^H]DXZ:=;MSRX/UQ:P\3RB7"KQD(4J/UOO
M$919-TMJ^G)$;I;(I3*TIG (+M4Z4Y-XS &[Q/(!+ VHD&\A<;)]!%=][23V
M ]L=LX*C/3UW)O">F+OB5-3#"O-(Y8C Y*0ZQ:^BLANX%HS*6KE\+3TI6E%"
MY'Y!9G<S/!R;8IXH-3*QIN9JJ7,Q7C8:@$+Z"RT<*7@3ZCSBB$!C$"[M.&@8
MQ<D#B5;2$11LT%2IJ!R5J:5//2^H1ARM"M2NR B9.-1QU#(7)@[E0,T2;T*E
M.=JHK-B/!CN1:G;GN?C0XIKV?X9I=8MM,5;1>4HTX5.]D6B#HJVM16$:JO'
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M=+E%J>W(:Z0=_81>_N4@YY6)7D;4=9 WX\_9R56[?QKF\DV9GN3 ,<-.>L&
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M=.=ZJ"!1Y,>3Z<7Q[\JGK"-.)758Z#E4P+!3*\T26GMQ9!*^$2P (\FA 43
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MWT D3]#V#+Z)<897&\Y"9LNCKR$"&NX.$5P*8%G"!>@?WT@FKCN&$;BBUP:
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MC&<4@T3#DD2QO2>;H\3F4"1G<T MI,OEEC)$LSF4A)X<,2D9+FUK$#>;8==
M-W",[<'UZ>X<NOW+'#JGQG!FVBF$QG <G<@^BJ(Y%J]W54'<_-6 AIG2  9
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M%XX+S.Y!-RVJ@D4FB:U#";B >M\!FDR##]AWQ_UQ93F/[.2[]OWJ-,^0NW9
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MPZB74M%*>&N\H^],'<!-X::8E.!'<]V$FP6V_$@$N6PV=4P+LR4,4?W%IU-
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MND'1+S"UN?U8Z:^.#6DF&YN+5J+BPP,!1.I&G?_M#%K=8:?->C3M[KD92:^
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M37PJM5SJ$$"K.%(D4YWFLM]0'[*UQ:3.\8^R1UG6QT,T#Q%VVI;OS6Y0AO1
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M0FXJ,(S6(.D@B;!SS/(QB>>3N$_C0$]ZY=]_;1X=?^@VFC7[H-8ZJ)T=Z++
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M&4[F/E?I2B%6#(\#I-]1H[%T[@Y(V. L%>@#";=2E5QERU8^[38E6QT_[/%
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MHG7A);M% 6WH_%>Q?F:LI8'@;:8!4D*+9P(.&VVM\R*,'_1XH*PD$!)1WB)
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MV%Y:WY7)JTGC1<MUTM_.S&V39LIDA?[$<J!K;@^4GO=8$DY.,3)IP%38V*P
MN[2UI"L9?XC]M=$)F5180;S+P"@XN[,6EBA#W<I4*VRCIBFUODRUB'N?8L_
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M?@!"ZJA^O.;+RJZ*K4I$IU)7-%Q94 HRQ9"B; )RN*V6MC<G?]G4I:HBD<I
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MC,Y3QLV]3?59']43A1G$&-#$;9Z4W]$XA*@&:_&4W?FS,])3,ZDQ8U5ZZ4O
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MD1UC>DSH/9_/F ' ::-  #C)V_]X2354G1]3]]X-V24&,KU5B"M0G-*>62L
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MM -K3+V53WYE!QW,P9+;[L2%+\'=S.<V=P$3O0GK3R;<9]OV6YJSW@VN"#C
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MNDFA#3.&&')N=_"S--:Q!./BNZN&PK*#P[)+C<[=N.Q_Z;#>^.Z2DM>W,!_
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MX87;W;//O,.=R:Z]<.K:?VWG?__;Q7GC['V<_SN^PFMWOD_HDXM+N$70N14
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M7M$?Y@O!(GHQ7RD7::,!_9^E9>3+Q?>JB?;NN-729&H/:EGMGYQ/_Y.\?L5
M_Q?T"R#R<:^+J5GF" [$E$;X$*SNDHK?I G?1Y%J8?S.I<# '%90!M'R?*7&
M^4D-^[;LK-#\K++PSQ6Q.C+A\5:X\CE;<C_ X)0(3/U?XET^_LD"Z%/DW*4
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M^D,"DQIWJ[^!,.F<=TJZIAO:7IO-O <OU>*X'Y<6MD'P1)469FA-)LDG^)V
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M$[_L$6?N&MSA70""4[UZ].TXC1.44ASW['))%SD2MQV+G#S!_%)Y$O*NQ/D
MK!20X3@^\C ^&TS+?LTAB)7@+ *Y$(YDE"<>B!4B<P_EF;PB]RK2U>@:-4@2
M>J[(5"5]%TBCIK/6U9 A*SC_3?R_KM6.; !/7:]IIQ5V5JUJ]:,0/FC"![6C
M>_$;-N@BEV.+ -G4&UJM>KRA$*'3,M+ZT-U(_EI)87@K[HYHE))MT&AR2>_B
M/^S9*L#,2:27U2+.-T_E/.7#306"5" (!#QE!@/"K;M^O,3CD\D(1V>+Q*NX
MT5A) @;YCEL,K-Y)M_U 2L4!&AENB.QH<,MT_?3DHH91+>][$$?5J3$;V5/"
M[4"4ZD6QU@K5/\FB&:+7)3PCY%'*>!1YBD+-E*/H6@\+2J(. 1E#Z=&%^Q%<
ML&UO11'AF3OA)^$4;^'DN@6#AQ)T9)/&:!3MQ**<,P/D"3([-L<$4?0,Q[GE
M:_4GE+IM>P\X+%D6NWB+69)'@(M(5U$"%L&QT=FWD9% MHCH9^E[E.;&H\S$
M-=2"S<_0*+8>9)P15&3\$"-_43_ I1=*4W1KVLOV**#L-2G2M=@MK"H/,Q(O
M1D:^WG*:[4Q;C[R*LB=YPE(='M"$$O@$<^D'_1;&V&5S[$RA**E:F#!0* WX
MM;[SS)8*M9,\7?X\-XTOY5B^I!S?@?5$&'CK_@=K'<+8"3I*K.HB;?GE:J',
MOD ''EP. #U3@RN2O"(+JS#F'/[&7/)4GNIV"NL*/ZQ@2/B;5,63!MJ1ELY:
M_2_=-OLB573R;0&+P**DR8H<44C9]R[1E/0&@6J+#(RL!*F45M;Y!.8+N$&
MW:G3!T2*) @O>#%JP,J.1HW6\;8 <(5YBXU]C;&\1N8BDG$$W\Y)KXI[UZ;]
M52+N((IH9(5JA76-/RG/YQ1TPL;%2:WR[ MOUC$=7;D_N',"DLCFK^J-_V%4
MUWP^>1944<S*CL+FG=C,R434CP;#SN 8G9 E42RZV^J$.7O-GM'C>B1-$]R^
MV+TP4BNXDL9N-=;S-*97+T[T1K.2Y.D!HD:IVC5RUUN /9C]<&1'W69!EC5J
M49A$F#"LUCAW3L[$7/F<B_R8UOO.9]21EFRR.!,"<V9NS)CPV]R>62)%GXUC
M9_1K88!$$6EB+>PU#P0#B@W%AHP';#H?8K4;<)83_0*,K%/TL&EHX@!D3O6+
M)CNZLWSX_;Q2J]:J8$I/)ER4EUUQ &*CPO#S8Z&O18""5S:6OCN#)<3UM95K
M>A6LN:/0>^!HV%;2(47< KUZ"@#1R94$?X_<XWR/J1NDYDFX@4SRIGEQ9"%C
MU3WYUVG.#3E54>N<I>O#,:,</@S)-Q^*9M65M!I,'OO0=^^CRG$'V"1^$L6@
MX+!68HJ.!'O+$PK9&I)$UOR$%%DT_QV9V2!29@7BR&@ FXJ<K]C=4ME6+!G1
MUI=N/$Y#$FCVR$\O2G'4^6>]I0QG6P%K@@T3$(=!>B1,8'O+6)#)@QIR\N81
MG1EQG<M?/:=L(8H(@#]S=MWNRX>'2%:* ]SE!!$>UCJMB*XM$>BW@3!*,TI'
M?&/\?PZ"A=).<HM@?'*J/4?E >M^(6[SY7F,61>+\3U'>7)6^OVR2:=M/B'_
M;+K]PZ-K2<<!"NZD @REU#T'%702O1B(7YHY@"4ZF,&9Y'<*.1LU8HD2A.#^
MS!YLJLVR[@$]*G'>$B6#HFH>3RD2[@QJ*$]NQO!)A&>#E2N&)LQ<2U:>BI82
M47&RJ+D+,IL >,T\S$<-4JZF(%4!1UPES52$0Y?*YA+'QOK11+ZJ\N+FNHT3
MU]6GVX#0'H4@%'7&L>^(TK%$D#](JD6W)O.L1'$))6?16K:]\H,HQ6:\(*PP
M1?7!$67^($+C.?@N>9%%9A%]B$X:.G$N%[2P:OH>\1<3;&)_$YY/SQCU*:D#
M#EAXJH]%LDX0E:IC[29B5H)08@/8G"9!6[+^G%3&0W3H,D])6IEH7D6:XG8:
MQN(GZN*";0[(E^8+$88.K84(OB1IZ^GHR#KZ">D39U;$?B,WL%=!E  3AZWB
M_ 6*[F#+ S<SR(%:L9"GE1(MQ#$)]N&(!+;X"4#Z&-AS)#]+R="UC#?6HE2W
MB/D?H4U:KY_HQ^4@#I?RLHC*XT 1H+20:U00Y28,A6(Y0D]-NG.@I@%[F0+7
M>P1-'Y=*L#,YVC)$Y6^TB]T<=4S%>#Y5C"=WSE;UK^)+D3:3.S6LC)O);;LX
MPMI^3+E-HMQ8X@H"#,WGDCBEVTE"-W:;$!;\\OF^5EL]OE&?JP 4$-1)I0#&
M?G_85 8^B]-9CJ[:@^,H?BXC-T]QS))@F&I@@>E8,F5%^+:#M<E2&Z]#HA>[
M:RU#!H]B5M(V1=I>TO_QQ([ZO@L'<;P1FA(&Y]3[CA&O2MSFAQJO1$UEA%D<
MN*A)QX78J1U)$$0Y,#)4)C;H)$B"&EFJ%<06WW?Y@CMZ;L^W+R ?G%A'ZPZH
MZJ)MA5:1MI6OYLA!K6N5B]@O"SYY\+T5=6\+P? $;1DU5Y$2'#XEJA&Y3D6K
M-] \?6$NI69$6HYHM1CU#DP&I6:FB$6JJ(SX3S$6'4RI,1'V[I4)3&N==F#-
MN.0"5=OD!>[1"P2?/%KN3(RP2^N[,F,U:6=HN4[ZVYEI:-).F:S0G5@.=,WM
M*=+S'DO"R2E )@V8"AN;%6"7MI;T^N(/L;LV.B&3JBF(=QD8 6=WUL(2M:=;
MF6J%;10RI=:7:19Q1U'LQ/>8LL;2^C_E9<@LAMCJBMZ9B9BG+1S'B()/9)5R
MBR*@T>VC?T:WDP\\?EAD>44O@GX'(,P';$F1F4;,?P##WMHA3=;@1$PYV'Q%
MZ55*NX7$BR(PJ9E'Y&Y'[DX50%-\?1(WY,&)GYX&:#FH);=R%,/:(*WJS=]8
M7^1+ZJ .27%H@$2>R3YE1=IF?LAP@<$IK$>7W3IGHD9/ZC$I-T,24Y?"OK*6
M8Y+REL6 P4FDGB.\B8A@"6*NM6..YX0&Z4 -96O.O%!,CDP"]X!:4:G8^EN0
M(Y%]I\09*Z[)%@0083BY)0/L!9R=)>_3G$]0!1WL Q#/@8TB2AL02*7DR"4(
M.09BT_B4"!"PO9M(SP(I)+KV9<D1R!OKP"---27?! 12+WHINB4YZW 6*?^^
MP_W<T]S@>5BS)S(Z'5EZ:SDX#Y<N9NIY8J_G*D14BIH&IQ/SX)5B&)<Y24]_
MKM!Q#8# XWS;1121IU%C1[W;$=-/0=0\E27ZFI^6&!VH5(^HG:K B("B!_&N
M@<"RI(@$)/LZI0@W04M'Y(Y')A.U34\P+DU*F76/90;U?AX5DU!Q#9#M)U9[
M!8XZ'@_(EQ\AZX'B:B8Q+$)<+.H&9+#1D)X%:ZD *0F35,=CM$B&CI*6:1FQ
M(P+-]+V4NH.MT?U'Z>9-2="L5*Q);EW)\DK*O,59W6ZX?GR;N+XF\[;2PYHC
M"CT+"W@"DI4P]?$I"]'C RN>TP2R#4#BW:@U?SP\//GZ;H2771?),,@A^37I
MV0U%\A[<&H38<I:TUPQOFEO?.*FE#W =, ^#'4*W">*I#/$)16<GT4)>D*4+
M5!(JT49VPSIR-0S(I"."V"M ZC=QWU.I96>:"Q4K:>ZU2;=KN98IH--Y1'0B
M9U[((1II&$O(.<*E-+/L;X1M'-[9.9:-2 5ETOT)5<1]<-/Z"5I4JV7F23*,
M3(O,HF;'-&LB*M\=F]>10P&+_(. 6H1*->8O]!P28X+<!=I0O];//E!=R4W&
MR )39HTZGKV:BR$.B28.0(H=FF]5UZ*12F)LT_DZB$[TYH?!R,V'42N-.C+]
M5@(E0\@5%<@J4B"KR,CV#+8A&[JW C>9")1"O\HK\[\*#8-=26Z"RH^[L%>^
M_[J.J47AO[5=^:\TGX0F%:0YKQS5$3<"J*7ZFD2]#C&3GU1%9YNT*S, Z_D
MO'1/L(X4V^19<<YG''BC+A)"9X[5!=DG4A3.9KVAFTZG'@\W%G#PE.(T(/&0
M953&LMGBI%#J7:X_,[>M0.R[-.TI;'Q&%8/49QE3AJ*]?8A:HV.Z/*;"ZS_G
M-;8#C[R7&30:X!,;13KVUPR++,#KYF)I?L$<\+B3=.$2II1Y44[JA(H](E^L
M+)XMTH:WG\^5]#!;CYX8;T26D;>Z#^-D/)0-'..L0EI( '"9-"V<.0YKW79[
M0:HC$>4%T()H7\7!>G=!7HR(?<96ZW^P29W(>]W>XB(*-TVD3]>!KU&^*^9&
MBJ=QX3U9I<Z!VGRL+TI>CA78\'.PY--3EN1N*?XFQW9AD0\I15'GKLG*IR]X
M]S/9OX+2)\5$'1&;6NM8)1(77_F.:YD2\?;O72F*T"\0534A.'AJ+$X*F-(;
M(&4V#<]Z!/U^7I* <6X=7=;75*2]Y,:YXJA(7!;$H]A0W)(/^].X-E4%K3G@
MXMD%-,L,FYA* F#).)<G=L2U!PV(QOX')OXNCE-5^/AK1$Q'^C%FFF/B1);P
MHALVPVJLJ57GMRB(9D&Z/Z68EB'G7;B>(S)ZCFKO_  $UE']>,T#F%T5&[N(
MAJZN:$^SH*QM"KU%^1?DIEPM;6].7L:I2V58013MSK0EE228C"!* $KS7R84
MG,=R/JR<#1GV8PM9^!V-^3E@R'16ALEK5U$<0YP'>=4$RP"T.:M6Y_;#,9T2
M[C**0B+@EE%Z=]G"&)>8#;W,RS@2;0ZD^ JD@DH%@&(PUGJ?@Q?!%G-^X1#?
M5C$KV375?N-13*AJ6[(&60*R$DT]16@X]$1BR5H1>OS>J9EXE0VOO)FN>%FO
M8;0<$&RI=/H( BF9[E"%Q%J/TG37K2B,G7*N5Y*H5\K-7JLD$$[90GPNJ"V5
MO<6Q'X<=1<8Q-!^/*EN/LOM\C=R)$1<*+W/E7VY^>]2=)8M[V/O)<I WH<%
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MW8<X!,3T:@UP_:2FUYOO((?W(&:K2 >OC@4C6<9!Q\($<0Z A)L:ZQEW'68
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M?K8W&77B+H65+FST\-'Y]%!2I !\X-,#'TJ*DJ*DBH:5+FQ04I04*0 ?^'3
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MI$@!^,"G SZ4%"5%214-*UW8H*0H*5( /O#I@ \E14E14D7#2A<V*"E*BA2
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MC1?D*+#/<CT1@-2*@ I<S&V'VNW,9W#(N>4[B[AMR"@!/\M!K_9"(!9PHZS
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MR+KSZ8"3SR7RJ*-VBK)\Y(!9.>L%ZN,6O[%RT"/#.6*ROE:#.5OC6\IL\>K
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M6,=-8%R$@=8(9!<X2M1!W I@=VWTL$[GP1"HI,_.FC<9N/0O42,\D'V7OH$
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MLB1R,R Y"< E2:2$Y!^DF(QT7I((>5 HW**WH,?U]JO1OFG[T.X4JV>L %=
MG"$0M]Y> :+2S# -T"0=E9I E&E:EUS387 F.1L=R%L!<6MT@(,IW=HXG%#N
M?C3I"CWS04_6*1G!8]-Q)<D?=J[I+>'!D%5E<K#*^-N)L;FBYZJ<7&'G#K'3
MVED;M5ZP<31E[>\D?(Q:L*8 1NAA,32=Y:ZIN8L>)/E1!N\+/;.QGU;HN3_T
M9.8C&)&:B3M++GU@3>>B:AI&=+,9I!2SU5Q/KT?=!YB1VD4<WK!84%9YG@VK
M]1O"5Z-:]7DV.CLBW S;W:-.64"I?CL8%/A=6Q=X<CI,U,73ZWV,GW_YT,D8
MAOWC0?6M6KEY-L'T&$P_$IB8=H15T&GZK9W*]]PFY[@:$-ZX,O?B]?]<CZ%\
M>O/SZ4_7>S^JHI73;\.1'XQ*D./YE$:,3^^[O'8QS'2EJ6Z6597K5Z;?IP]Y
M>FVBIOT<]]KC21L>>)K4BVGH$E<?#_#YY/'5Q6D7TVO3[Z6/&^F D8 IE%3>
M!A I^*C1)H(G!YZ"BA/98A9B^L<K?*/)C)HK,SJ]\ITS>ERA^?J439;9GKU[
MN_[=L_D=DGK19E/_\&Q>Q]/M+9V%F@'6Y*(I^<_CZ0\<O"VL>/%ZJ?V1AG6U
M:26U_:@_^$'H?79_^7$=>_TNZ?$;NKVM@+C6Q=/KH_\6\K5PW*!@WN8 RB2+
M6D=IL_!)RFS\1)[#/<KSR6OC?C%RQE\3/>STJ-..[5%K'$]-[6ZQ=$KBS' P
M>O;'H)^.XVAK\!8'']L1UT[;)'"+"IQ>>NL[.!S?_-O3&_N\F*R+1_^ 9H'[
MT"S7*)BT NDR(F8 B<IJ"XX)%-'SC(95%&13"K(5!;]&079["K*943 +K9FU
M3+ML(6;M0#&KL@[6))4"FX--55\*WI=U=UU[@@B"_BL+NJ"L#\@@,4%&LD6/
M=LJ#?,6#M^/!VU)P=CSH#&@1@D.FD4@7+)/654S)"L.Y6NO!:5CAU8!LHV74
M@<(8KR"%H'D&CLX1U;(C$@H5P"91:QUXG]2;B_Y+*G(.&5U4 .1P!&,9NN0M
MT/S*A+76?_?,>_>O^R0+S"E%PC(@:!EL5,9H5 H<N9,JUUKWW3/OS4'O1<3(
M,>L4$3@Y$F@4<TD%R2V+%[Q73[U762XO^IV.#_W!>!UZ0(3<K\+GRZ@'(7LM
MD07'R "5QI7U5B^,TB1?(T1>:STX3VK.12]&C$8*CM'E",:4_3O6.8$R!)3,
M\EKKQ3GSYOWK21.4BR)ZG3P#)[DGN9LL*@G&B0"FUGIRSKQY_WI31<$%@'/&
M6#"9.9.#CJA=BLY*8>:@-VNAH4)$$87)@&5R4%L3I8O<<;3@;)A'M+(6NB!Y
M##19'"4G*YOF*IJ4G /-O"(DZCE(CUKP*2:0B:F(5D:PW@4FC9<6&?=)D0R>
MK.S)NU_7^EYA.W4]+O(]2AKFZ.Q%OWO4[]'7X74/A7[O]GMO1_WX8?;R]OJ2
MH_SA!;=KI&$FD[_OC H9(!-!?-8Q::Y$HN_6+PUIUE*JLG-\YP_?3J][+_Q1
M>^0[-2%3LDY[DL_1%!<"G \I&QLE8XG+Z-GRD.DR=;E*WRGM!GA0>ON(KWNQ
MW\6:D"QC<$0JX9 )R($Y299)@N0 F%*8EX9DVSCR[1ZF#3_HM7O[=[ R<2?T
M 4VB#WE4@7E@*0?!7-'=2=C@E$_W1Y]YS8!*WDK'K!&$28MH/7!KF%6.@_%.
MUB#LM$CZ>?YVO>*F #@P*S09I2S0/)ORD[!D;:6T? 2]-ZT^?^(R@2;Q$+W2
M'+*W+B'SW*L@90QHXQ(2=QZVP/P)#>0F"9:B<TR#0A, C9 Q"9W+TBI?/D+?
MO04Q?ZJ:')(M-GMB",*B%YR^D%!&ST%H?W_9K776L7>2=NND%-XP22QE@3/N
M6"C%N"()7"XQX-*09DX^\(S(Q)3-MOA1LH0FB)4DBU'YX$2T266]/&2:OP\\
M(Y*!2CP:)X1G&42Q5I1VGBP939Z78<LC].[;!YX1?;SEZ+R-/&< G[SCW!NT
M*4@O0$88;SA8@AC%?2DE-KOPD;.::<X< [(75'8AL>!!*XB(+HNE(<T\E-+L
MR.1X2,HBCV@92 B>Z".#YSPG0 9\><@T9Z4T.Y*QP(Q7D0=F(YC(+=G@3LD,
M*1OP5BT-R>Y5*<V./B$85K;Y)@4:,J C-PF5EYE,=$[_WA]]YC4#"@(WBI1P
MB>,Q'D@GDQK(R8'5V8.L00;9(NGG!4@<  522)^8X1!#=JBR(B6>1 X"HU\^
M@LXG,#L7XDIA99!.8,Z"[+/L?9(Y!;3")=32+B%QYQZ8G0NAM9+16D<NDRXQ
M66>#<2IEE8PS.:<EY.)[#LS.:>,G]]E!D$(8B%Z$J+*P/-G@N-.0)N9&_8EY
MCS[PC,(3)FB;&'@AI07+3' B)\DLBP@^V>4AS9Q\X!F123O%G8\I)K"03?"9
M>2S)?;:$:I5:'C+-WP>>$<EB9*2Q>-FW4 )*WLN$(LJ<0\3,$9:&9/?M \^(
M/MF3D6&U YG)!\;@DV8:=*F*PP*/X?[H,Z\9 &N#E. ET@RD4@U'ZX0!50K<
MD7*^OUHX2Z.6?Z)(SW6U')D5 ($)&8%%[W)TP(E2FD41E5X:TLQ'+<^*3)$1
MZRBNM2G5I(0)43MK1$H\21F86AXRS5TMSXIDW"=T,8;D#(.03+#H55":^>B"
M3&QI2';/:GE6]$&;7&(^(R?#5F,.UB>0L51-B,IP58/-H(NDG>:_'Y1D84K*
MH1!9@>0Y<*LB)XK&6 +M=OD(.K>,V?LG+IF-A@LCA/1D0HH<7$Q21Z<<E/HT
ML(3$G7M@=BZ$SB6C4I74E>0A0"[6:-G-QJ0!8W(=:K<MG/Z</U7)L7 0@DA*
M<K#9D"44&&G?X(,.*E=IF=PM@3%T3QX@=S.S@X(* ,HE+/OO)>>6'$(D(Q4E
M:"]%7AK2S,$#G"&9<CF-QI%IHS  T<<RC5IH"$)H@VB6ATSS]0!G2#)DP9 .
M$]E(!T0CYQQ7.4@6T*+F;FE(=I\>X SIXU%E([SW*6D@2])R+:5"@S:42"V[
M/_K,3:@DQ3RS.K!JORBW+F-@DL4 (04>:E!"9Y'T\P)4YU"DRD50)9457 2+
MBMPEI24XSJ 6=7,75:LO '&=(?TA I<IEK*>SAJ= ^,JD$W +HJR+A-QY^X#
MSX70)@6,7O/@R%L21&B,$8&14ZR"$\(N'Z'O/SGI7JAZ<1[&T:"_/_#=S\Y8
MJ<J\32Y.^_C:(2L7'<9.N]>.-_<WOG:;[JZG?C!,4GI'UJJ!@,;&3-:JR-ES
M3T*'+\V"Q16ILHFC=[T!^D[['$EY?,3AJ-S_BL#XIC^LS5)&3+S4HA'>!# *
M/# =<C9>EN3D))>4<E,JO1STN^LX;._W*D4Q^/.8Z)G/2(Z\\,.#EYW^R7]C
MVK^+,OMWLW"HC+4FD9(G&TZ(%)P/0EEF+"('[SZ-@-9_<\L\&?(G8J-7=XC\
MC%D7C?(EATN7(E-&6J^R-=PIS;,FJWW9Z3U_-IX_!KS3D7&CD_4>DG1>)<\,
M"8$@#2?;?@X8J,6\<2$4%P&8S 8$DS:*R$';R%@.CJNE*<RV(#;+[ J6Z9PR
M5P1UC@JX<D$8%))E#)$'Y,M34F_1A-W=%$ADRN?,P0E'?T4?E,G).(_E&+6@
M]/+5.5HDF^7^*R!QX7WVPJO #6@/SD+*08LD2X6#5(=3#FO.QO/' )';9)F]
ML@G!L>A$,H(4;S2N?("E*0BS.+IW1OGX*NI8BD2KQ!)('UW9C^5!H!;!2&V6
ME'+S9]H[H6:0J*06WI1M)=Z)H#F"<CDF%E%>)+(NLBPNYV!<D/05EG#HT4$[
M^LZ8G+%_W!L-SIZ]>_M%8MSJ$8MQ'.-<A+6S.4D!*0915GJ%L]'&R#574AF6
MYW',_ HDBY:E1V PY(>17Z8CV)Q))P0%A YF?+:Y+F=V?@4D4\6PV>^]^Q8)
MZX66^Q<I.0ECM!2E8 ;(X'PBIX_%')07Z$1=3IE\D&BY?]GB&"HA)).^')P0
MK/4:33F3.RL>M%&+:W/.E7!W4R17J&BSBF43!>BL/?=HM6<RH,I1YL5=+UP4
M6LQPM<\9965BPI4=TM9;KH3SS 5=#N[UTQ0\-\WU<(O)("U_V!^\.!Z.^ET<
M#*^09!TSM<.U]-'W(J9M'*(?Q .BU"%&\M?VL1?/[C[=P]T^W</-:#N:5DS&
MR(3."-IC0/J/*PNH2&DZL;AE&>Z<GM\<P46VYCB9KP1;7O2'H^%6?M<[&O0_
M8J+G$2U&;1QNG,;.<<)4O/JU;I]^.Z_.2_S];-+F;&LP&=VUHQ7)6? D18Y*
MV[J4DG#)1D9*4]DDR.0RWLJ04Q'E/.H,\=.J55 S</W>IE]298!]@J\U8D3\
MB)W^47G.VO'HH#^@U[E[P?$=1:Q@1C7HN,',738,)0 4!2&9%1)5=/3SM RM
M64SMO,BTO<Z3YH<5^$467K^2'C=GX8VO37NX=18>QY"B0V#*)<@2+7G> +Z<
M0):)W1?X=+@:47]V"Y^HN(\FI!RC!Y+&@?,H4M)<&PL6/EL(6TGDG_9=OR/2
M,2.);%-.$CUYJHJ#E]82%<E$9]Y%:4,V-<C0JAN1YY"&I]%Q48YWM F2-QZ<
M<SEI8U)V"L)B!R@6F;9W$L.0V03ZHST3"J+FWB06G=8Q<)69JK(FN9[XS>7#
MBFX_PY-<W]J''C>=C0\=I3<Y2RC:M,1'DD,32.YZ+I-U=:C14R<BSR<R7)*(
M0@["@>=E9[LC1>MY-DEDE%%6E6%7#/QS@O=3GOP)P2MD4BY:P:5A8$A)"B:%
M+8?/>DM47.! _J)%E98(7[-4[$:67'CR?9T G7UP)FDD\1]#@5MZR/AZW6N/
MVKXSN7"G\-HYP-_;G0YAJ86==B_Y5R3>AR_[Q_2Q#+0F:/)20W8Z92\Y1%(Q
M0>J@4'-,09$-49.4AIO7O*: >S6@V5EV83/_A(=4XH8A>25= ,580,#(M2FI
M,2EI5X,S(U98^AQ+<SFIPHKH.#FO :(G5>>]SQ!3##)IIKRJ0['*%986Q($*
M%D0(,K*@&& YFDH%],X%,J*,B+D&Y2)66+I1+MU_Z1$+ 2790SPK #*]/?!$
M&DV[J),-&6IB+WV1R%49F0I+VT31WO&WZL?<$W)K:0\!>J,X^J"S )8"F=B>
M>2MRBO2CP9K80P\-*W.Q=Z+(VNIHF7< 1F@K48K G8[&9<UC3>R=AX:5^6Q#
MT )#-EZ#+<?&1@LN9J&,C2:5>L$UL6<>&E;F8J\H%AF"!RG0 N1RC&,Y"#J7
M$X98='78B/R-G.87_4['A_Z@BKJM#8B0^]5VA=>]$D%L]_:O_#9\WQX=K.7<
M[K1I/F<!JQ=E5Q4.CHB69YN^>W5@:\/1P.]A#Z-?1NNFE* WSC%T"8"A=1(3
MYR"8T8);7X<30E?(6DA;R&@ Q90![CDPEJR6QF0)3G(36?ZLV,\*635$UGR6
MTE-"]$K%# KH?T$E'ITV,C I(&)-+*<5LA;.SA+(6%;.8RR[63!XKE%PS;Q/
M#N+%9L]%M[.^0L 6#KY9$WQAT5M+"PM+$>N4?"SU][,TUAM)U,Z,*X=*FYI8
M6"M,+9!M%8MV,QB4T1R2,%9Z$:60Y!R"RKDNZVHK3"V05:53V9N;DD"G"$;@
MG<D6 :R1FN>0:F)5K3"U0/:446BBL5;$S %$=FAT26[.7N7@9%U*K7P%4W_A
M@%[WH8)J+@95C QC,*@B:'+_G.<@+0H0"GV*XST1]3:H'C:HYA.M"E8D9F(D
M5P_0&IO D%T5@I8"T//Z6U0/&U1S,:E0:A9C)J47$3(7GL263MDHCRPFX>IO
M4CUL4,W%IF(^RI1 !ADRQ!"\E3%QEH2,PFB5ZF]330[!NB#Z1_S#5]L)'BK.
MYF)F6<O)8$\>K5!@ K?2ZAAL$D&ADZ#J;V:M<+8(EI=,EC,'W#'#0 ?O.6')
M(6K% RM')-3>\EKA;!&,L1"!U&.6/F<!TEEG%&HI/7=:JB26(+ZUPMDBV&<R
M 5=,:TL&&D0 [S7YE:Z<&1$,UW4X)*2N])[/ 1%*2&F1R!LUE$U-449KT43F
M/'+!:V(GU9'>\UE[,\H%!LX04Q.]L_-<:64$&,4"9E83>Z6.])Z+W2 %EK.)
MLXW$W\Q)EU4I6QNRD2Z(7(?SJ.M*[[GH[X3E_(BD-%@&)D;R>WUB.B7B[<SD
M A\07",RWTF1:8# M HDA659&BK5-&1VEED6@K%1+&Y-C7I2;G;U*TP.(E@1
M?96%KK57(G#AG?7(D@UL<2DWW7KRTK<'?_G.,?Y^=O'QOZG'LK'V[$W95GM]
MJ\I%H]>]H^/1L&K!?]9/N^B\W?.]V/:=UT22P7%YE>M/+R= K?52^5\Y6NJC
M[Q3DU 0LC.>@I,F,"0_!1B=4X%P&+Q/)95.#TCD+!9;??:=L W][@#AZTX]C
M&?/S:%F!=1Q%YS$+DFA.0P9%8LV1/<$X]]HQ@+3 .FDAP7HW8)D!KXSU]/%@
M0(]K^<$''/G0P;<8CP?M6X3@%@6N7B*P0!)5"P"OK'.@/4>K0M8QFI4B7B:X
M;O9[L?:(5<@$\JR"MP9L2$XELAQSS :T*BF&BX_8;X*D%-/+;:(?#K?R.A[U
MA]/^9@#1&?"+J E6>."RE&;0Y-2#DCF %\D)9JQ4.:->?*PLOK&VPNILL I"
MYHC"!ID":,=MLHDG%6V2-E@=%Q^K\\7*G9EJ*[3>@%;T4N8DG8@@2B72(%+)
M&#*:6^XQ+/"Q K5 ZT]9:BO WA1$$L;;5$XBE!:<BSZZ&'-(463CE8 E .R[
MMSN#ZCRFLQ54?LYJE"DI9KV0'AS$H- SK9E*VL12;F#AH;+P5N,*JK.!:DC:
M*0G.6)$@^Q"4+&4NM8-B,_*55%O9C(L#5A (!%*7<M:0C/=&:OIDG)0!@\@K
ML*Y,QD7"JW,B930$)?3 K XD57TIMV!LJ153 SO@%GA]U?^(@UYUI9QQ3%!9
MQS!: >>G!)T5/$FF$T\6L"Q89^4TXVA<<DKXQ0=.#0S(%7!G#]R4M3,ER4)Z
M#9ITM=$YA1+ED:@\+D-4Y_Z LS(N[W4A6Y2E0.!:* :A>#_DKB,":6LGI.8K
MZ*Y,S<5%+Z1DHC!.DX%)U@/Y\5H)A5H9ID!RNP3H?=$?')6,5ERIZ9]%BQ0Q
M@#4.D?[OR)%VP$1FR4 &D-8L/EH6WKY<H75F:(U9""TT")0!2,K97,[,,%DK
MY@(SRZ"9[Q@M*TOR7O<F:)>4"SY&\. %#P&BE9F^Z)R97(8PY7SQNC(?9[X,
M5 X55N68*K 05 K1\'(BD8I /I&0-8#L Z(6J;V0G;-!1P;5Q@ >>8K6.2VD
M"2OS;866:\?1,; NNZPT@LAHE0\28W9))Y%\#78_K<R7>\U>T=$"048:1@K
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M_L95S&^F:.4B)FT N+ &))<V"7 F<*\]^J#R"JVKB.-B 1:3,1PEI"C!%V.
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M\4^PPPUX+6&-I8;K=WNC$SQ7YE1U!OG'=B^NW-#;@/HRBXP;+X(%W40498'
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MI9Q3J^,JYIH;:IW2T&!E"UZ""!.4>:E.O/3S@I<0<4A1CB,O.09H\ YH% 2
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M79?P@V&_;:,2791RJ^H YEE8054I$A,9I&)"V1W[0'9J3NL03#MA6:" (LX
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ME*8(&&P%-AX2C\/:!L$YCV2%<5J5EI!Q6C%.IT(Q*/186P$(1 Y0H7PZO Q
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MF[6V=E#\_GGK4_-L=__#X>=/'^G__FR>[^Y_1<V?[^GN5A/N[A]\4<8%XK@
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M=K<]&/:+9M+Y"'^I[/FWI2 CCVU>$F.FL@?4T]W?'#;;\$=!9YM?A":1KFP
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M3*J7O YY5?V):J/E9.S?BOW?%NN[&,0;CH\RU*N'^I0?PSF+*;08<.,MH#Y
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MVJ+E;0C2@!"86CKC:($743H0SMUL,C-<9K@:,EP]XI(RH<U#:-.M:8)PQH@
M-.(H%6J&P$0J Q[C@#55+E#QV)%#%0</C0<R7K:LX*FJ3PX6=(VI22-Q6ESO
MU'3\M5G+HWS6HWP.+O5MW>_&L0[&&94G/@+]4/?]RT=-I,S76*UK5!1@6NQ/
MK/9MU__4@[9]C*C2N0_-;YJJ)RV0,+M"?],MUKOXPUTJ^SO?WTLT6NU)$KZJ
ML(_I>_QSQ<J\4-QA5MQ_K;@?;4Y.C8Z^T2]!6"$T9L &A0'%ED;5W2C -.<(
M!LZUYFL;_(5ZVF#91ZG6DOEGF?CG3I_!+00TYSD/OM5UD)FH"B:Z..Y)3&09
M$BG,"& A+:#062"1I !:"3%5ACA"UC;@"S*/%R&34":A!2M!<Q[19"7H<:AG
M<AQCI?=:F0 $2=Y+)QG0B"A < A6.Z^M,6L;ZH6JJM]<9I_,/@M3@>8\/LDJ
MT./RT-0IBH/>8L,-\-1P0(G 0'F/ 2%"$,>COFIY4H XKX<"5)'#>$F\8%OM
MSNG0N\93!&&O,@O?=(OU9N$:.L)&BS.S[[W8=_NR*PP9P0*4!%!F/*"2"Z"X
MBR1,$)$POF6)3:XP>IU_E[[]4&:@96*@6KO",A<]C(LN.<,,Y43)HK^28(!2
MZX$47 *&.!4T6JO.L+F=89F&,@VMF#,LD\\#R6?B#B/66XXL PB92#U8!J""
M0X!SB8.7 O& DSN,5)5(EODG\\_JN<,R$SV,B:8<8IQBKS2C0 2L (7: R64
M T92QHQ 1FHQMT.L0A):Q=#A?(TENL9S".']5#SQKJ'CJ/17'V_T^#AR?Q'&
M.VB<#N);[6XCCM:>=HKJLHU>:/@<^)NOD0-_:Q+X>W&-U6R3=JM:6G+48U>4
M'3/D9DF0K=-CX_N[H=!*![NGP\%0=].47CZPS6EOL^BGEQH)*^58-""B?HJ%
M )0I"*1"'G#I8-1.+2;>KFU0^+2U[W*CP\=&< 751#*"%X?@Z5*SG)G * ?8
M$@FHCW\,UPP(1D1P& 6M(H*)G#L//R.XU@BNO-)L1O"C(GBR!S-& P_* TL,
M3<6B-="I=C2*:I267D#.8=J#,X)7&\$55(G("%X<@J>\O-#J:/$(!!Q%<0\V
MR )%" 24,".-M9+SU'287R_T]70(?I:ACT_=:WCE.6Q1GH"1/*]166:Q>['8
MI>Z_D5R@PI !'+@"-"HBP$3S'V@G';826Z]PU$-NB-=9^D/SC.$G\ 5D#%>$
MX2EO0%"4N92 H4E@@#H*@5*I JFQ4&(JB9"D$F] QG"M,;PH;T#&<%48GNS#
M3@3EN.% 4QVM"0(=T%%PP#'G+#0.(9+\ :L8O)8Q_ 3^@(SABC \Y1$@V! 2
M!0>(1@)032.&B3+Q:7P1&<-Y4)5X!*J._?ICJ$W'QW]=^_O&O^.?\4\?Z_[7
M=A>47WFI"M@N&$.XP)#I_[%Q,3V_'.7T'%B?6C$_T;CW#WU#6]L[CK]]'D75
MZ/:&\>H1<XTXF'8<V=>^[C1.='^8HGV&AW[@(T'H4]=.H4*1&5QJ&%4\*DJ&
MZO1R:'=UU[;C%R-JA[YH(/WBUMD9#8CB%R(Y;$YZ@W9:<R_[/H49??>OSMIN
M>#@FJZDOCN833KZB31Q$I(U;OU*7>1>79V/Z;QIM06P\((ET-'TI)M1JKXET
M04)+" Q68/4%X[7QEPXO@B-/(H<"T_?Z&] AWN!+W3G3YX.U/RZOR+@<1P,B
M/([XZGS=.BLA/-JLE*"(6T6O;%[^,A**[Z=/Q3'IVHRE<=A/&^&_?BT?%!6B
M_41<"3JI.WO"P;__T!LW"?])%ZFX<9$V=[>V/[0VUQL[K=>WP[<NHWV]V]K:
M;NUM;S7BH[W=OW>V-O?CD[W]^$]SN[6_U]A]$]]JOONP_9_XN9U_MM-][3:W
M&[_]O;NW]_N,[$V>A+UOON7?/HZ9>#V%9L9?Z,2U.ICU5DHMM]A:)Y1:E+>-
M-]#1)P/_<OS@E6L/3CKZ_&6[6PRC^-*KRY=+Y'UE*R\FJGQ[0C$O8$DS(S?_
MZ)=';[\HWKJB8)3O,?A"0';KV_ %NO6]NRZ+X LLY8,N>_=[0N#'&"S%XA$&
M2]BCS.SC#)8J^BB#);,)[.9T!'Y'-L(]XF;S1V\/$+YF!I2T>XOVO4341M$+
M0M1C( 4^[*IW#5:]8 ^\ZNJ,5:J'\5J>USLY&+U <+;;_$6@0)7,I*Y]] :W
M7JD'+L:OIWZE',+2M.][WVC&SQT.&MO1?'&-OTZ[OD'@^@P!!ZLZ*WOM']7.
M274+L9*LF]NZN-R5BE8_*:73GUFB8GYYM\]JRF 5N%[%B<EK:7%KJ:),OEK'
M[5730'[."K+5M^Q;DGH:][[_)3U^S0WDKQVZGC?;XT/7?XX^'[VGK4__=%I;
M?W7B;YTU<9,VCS_'Y_$[^ZVCW:UOY.#HSV\7AZ['K>/=_1W\>:OYH[EU0';C
M^%IOWQQ^/DK7L*BY]>>W [P3O[,#KQZZ'N #UCSZ_*WY<_NL=619:VL''GQZ
M<]SZ]!&V?GX\:[Z-]WGDVLVC#Z'9AN?%@>L>_-GZ^?Z+Y%(&Z3T04!E ,0K
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M&HB)L- 0%\VH^0]8:Q0+LN(PKT6P:H9[3> .+\$=$ZLEM :@0#R@Q@B@H$;
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MW##GA%G;0'.7$;@7:)8H*^:YLL#"8C(S"SP*"US)<Q686AL4<!ZJ:,$P%5G
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M4-@:H)QAFAC.#:/15H?7C?6'YCTN X]FILQ,67>'9]9$%T^=D[8(B DDE;*
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MAOZ1SY"S+S9+*4LI2VDUI72?*DO8"X>,U8PC&K14SD.--#.$6..EO;?R5NQ
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MEBB'#868P4?J-I:9,S-G9LXKS*D(P5I $FU@21%$"AJD%;78"T2\\;,Q9RY
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M7@=&W6_\,CU_FS&U?&MPR97V0F=KKPMJUIAV5%3I0>KW1NVPF)FFJV&<DKO
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M\8+KN2] 1YY&:>3[ H/G4CYY$?/S-$'RBB8^/XV0I2O90P#G]VG@#,R[E&)
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M^[<=HK_O''WAS;T=O)OOM;G!]A.3Q"F/D=<*YZ-,%EE*" J1V P=CE7^J4O
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M&)$_V0[G:D/RB=556T9F?<4ASS\NUADO.]H<.]HXT;[:T3RG%#N+1TVXHM;
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M2L+]T:&Q(&H(W;/?MKYE7W'\(W9B:BU/!YRG )B[TR&=P+0-AG'DG.*(ZZ#
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MY?RIQC.:2ZS4F>*-#MSP('9BS;VJ6>W!C6NO1)XMF/J6SRK6<#;;,? A&"B
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M0?XV#[Y5Z]=QM]J!8,($;E1G$_+F5Q^.&<_/QVZO'1K_K;\\S0/78)Y"Y>D
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M9B(T$$'&T^U:GM4N)>&P95!OY:AIX/AKTK_:N.T?K^OD<Z0::'8@.60.UON
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M?FSXE7/O'P34/72TN[^ !YF#\\47;3+(DDE%""K'XI-),F%J@+?$@#=+R8@
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M+MT,7))1I<C06\- .L>"%I85FT%S;KV+"T^P:'S>^+PE4MT$G\\U&S(%D;O
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M[)=6RYMG84&<NW%*3,<"0=I:&1>485"T9B&)Q(S((@J7O0JYJ>/WG&F+RH#
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MKA]\AF>&ZS>^S):!$,;YY)Q&3!""N",&.4LQ(H((ZF&)7;"YH.@2EX%XDBZ
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M\->$<HU,IM);^*KS 4_VO&9@ P',8,FS@B,<.6D%;#YBF'5@J-)T)6ES83;
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M<>\-,D$[Q*S7TND4: 0<8U0OT2E!):=+RC@J.9VOG$[Q#:,PX&3B",P#BG@
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MZ(W/ OS%<TU_?B[Z0XSW<G%][Y30Q!C.\YQ;K761Z]QPZY3&ABI[Q0XKONH
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M^LR5(?B>[UB?&3\X];Z3/O:C4$!V$F,!63>D3T%8?:]U%K?F=RM,R@!XTJ4
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M<> E=EAY13KZ[S&V!4@ [&$4>NN_2(O%)X,97'!ZH']_N4#BTYZ6J3^2]M'
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MB.\UB3SGZ/W7UR\00!^2]!KT7]=Y[V49\&C@^CG"E>H'E.8H:TTI25(*)P=
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M_MV85RPO."FB". 63X$)5%:91DL_42T4?G:.IC^#%O-SHMKNJ'?@VM.?.8,
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M52];.K #RQ!3R_%B(ZDDSTP.DLX#(O<480HF_RR <<F[5=^5$JWQ[5.1S@G
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M(@X258(''. ZG\D&S-QX_V(_&LDC&T2-(, L[(D>B"Q=$R2@>'A=>3PV.8-
MULD, :DW*JY98I,6!ZW3]Y]<$ R&3^JB4V*$E>R QE=+CXWTUF"CJ$ VW2<H
MR*'9>..U-QVJK CI]IJ$TR(E"9-<KW+PVS#IX7HF/:QETH/1?3/I\F+G3UD%
M(>U(%<(NCPU7AB%WVYZC^U".1&$AGKV\C[#I(YZ:Q,_3NAM@"^NCG2NS0Y_,
MST W]7'M2%,]\MX8RMJLQW'U1L%$C,*:)5GM6IT)5>V"04:VW08:O?;X] *T
MW+GGRQFCBCM@]3NL7JY7HZ]7,O4J;WK)<K^:E7G<?^%255_EB]-3;)AR/WJ
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ML"ZL*>9CPU16ZBAV@\5XF!G(M^Q9WZ:(/QJW:*LL&@ZAEH0:#J#^_I=9')K
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M*0E\!FAZJ3^C2[ Y!++K.-L/L@"<=&*/.*B$RKC(D*-E:HKQ'+GE) ')I9X
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MS8!'!M"3]U9OP=3.*#@  #TAHWM6UK06V2$5&X*H+B(OO;N8?MX*Y_Z'GUL
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M0M4DCQ%U>AQ#KN.W76>7BZ_/D+M3,A&>1GP7?H$O@M],PMBC6&\DIJBFS@H
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M3@XHHG1P,8O^Z6F;EU:ZD2U&(3PS0["_LQQLL/IZF" :WM(/W4+HL2!T=LO
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MU$IH[1WI_E'F([C4( RHE0#9'ZILOJ)A&5LEG!* X)&Y"$(,Q_'5>%&6W'A
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M*"H)^J41_^4F:Y)LF(,QS5![RG*CHHE ) :H ,H!*F#4:VXX/C,%()$Y-^I
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ML4 3IE/.-"$5$IZ2I3,4?R7043###S.R;U,Q]5*[TC:P*+CKF!0G0I=I+.>
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MVK",7_(=OQ@ZZU%55>M5!?-/T.RV8:J?6=DJL'L] 6*+9_E/9E.H/8(I8P!
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M$0X$"F8(40Z,RUB2ZC,S=4>-[4'+VKZ$<7[U[0M.*7.9Y@OUCC-)I;!&LZS
M><I?**GAX(ST4%!JLLD\%-NKNGTON"$%U@_GQPTKWIIJ9><3=.>#D'DJ! 82
M]P0R"P9.2 Y<I)BR3M;;QYV=VX!&NYV::T&CGMIJMZ@R+ Z(X?57G8SY2CBG
MR\7>\D68SX\I83A9]$?) 1:; AA5DTA$0P.2#)"/1XH!%!K3*<%?!]Z0PO%V
M]&FOF6:D>3W]2EAF\^-:?RV*D\^GG$ K[\@2>@HK,GI G3(R%V2QL0LW+J(8
M4NC=C@(/'N>6"RUG1T2[CYB0*$C&C*"<B5:PA%S(3'$I,HEF) 2O%$2TY .]
MD 8[K;Z] ]600O"&OJ25'GHD8F2E;ECNYSR15><,B26R3)XC!&4Y>(&A3M19
MM'V*-_<A:UGEMU8%7TH!'X6NTPP,?$$%))XQAO(LK_L\ K=6^0=3W=Z>%7=D
MHAL-?-,=*./EX<H/DV>>36M)%:>I N*&6^;JOHAH537/":)G"EC4UF8*Y)CJ
M4]"^ ]20XNJNS&BEF&9,N4$^,L,<"X7W3I<5#@\.K02RZ))"^X0AY2X$N<\"
M#J9^W9X76ZJA9]62V8+94A"7?+2@HE3@(K-U\S&+*G*3M'B4JN7#@\0/X;A&
M)M_S66M"B!RTT'5A1@C@?5VGD;-5T3!I0A_"WXQGH&[R(7RX+3K<0@$M,X;Y
M$>8;)$S,.!%EW2FVVO]!$OJ<$^1B= I%%M:K9'L;I('ZQT:4:*"&AI'3':L5
MSI!IRW@N4D#*@4PSKPO\G)) DCHG,\?(^DSIK8-NH#ZS!5>:*Z?;_.\9&!^9
M"$H7L";Z&A/4Y7Y<4&9=Z/W$);=]G.<M@(94?FI,CA8JN,*'OSZ_.DQOZ'7;
M=B'[G^CGVU?O/NV__^7]AU<?]SZ]ID\O ]JB;\@ME^_70&0=>1IU$GDQ6ZS2
MJ-/YKP4]^CQ%+C)8IE1MD9,A^*B!V\"DU5ZRTFMYWV4D#?8Y(K&PEM5?XE><
MS%9[3TZO/K)":8/, (^*0UW2 J'N+DA**N=XTKQ3!G\GK"&%K5LQXX:]CXV4
MT3!*62S?EW_,9GF5B^+\ZSCA8I_RQQ%/2;B@$\1H"J6-3@,!4\"DI!?.VNA[
M]1JY#=.0HM>FS&BDAF:T^ =.<1XF=:=9/AQ/QXME74SY%<^X&@N7/F4.F45&
MLBJ$D#Q15WB/PFJA6)_$YAY@0PI9FQ*DI4*:L>0=+K^WL1A%XV6]$P@MD+(L
MY<$52]$SC\P7:9SNE.Q>@K']1._9E7XAC9[458_&T\^GZXEGT\7/6&9S/-^6
M@XNWX^EL3GG#Z^D2Y[BH.SLO7^6D#O<6EP>S7"<X%R=UVY',9/ -)I"A/MJN
M4&X1C  :*JE9T#K*7O/(.Q-R2,[\X7R]/DT]3)8T7.]P"OS4P/Q,]J>L6H[H
MDIQGH&U.%0P%*90C _?&HA$IY$X%BUL ;1@1P)/BUW;#WY@+NR&[=CJY@)Y&
MJ38=5<9"4$) D$;'&#5F[WXLD[C%5J,+9.,405BA&8FGB6S>^+H_.(-+TMM0
M&$_8>?_E;2[X<4W^4+E[ZW:E!^JTZ4*W$X%.D)R-PJCNATHE!L#H2#JF" B*
M1&@<LRI;2D7Z%"!O0S2D9/"IT*R)=MO6NM_-IK/+Y#_+:9PIF),*P+FL+5>-
M(D&9!Z.]X99SSW(GFW8GKB'EF$^%=PTUW7['[@63:[G7(<=,I# .%&IZ#&1]
MZ5ERT2(KND_=]UXW^I#2[U><'N%BA"D):2RO4U@TNL8I>K89HZ<\F1S)R:A.
MZR[.$ PI(-A6Z]=KN@\8Y:;EVTLU)I-U$@4%E,(")1T^@N.>1%&>Z22S$ZE/
M$>;NB8M'3LQ:*WVK87_DJ<$7[]]^^/CJG_2=U_]Z]?H=O7SUYOU^GWG"V^ZU
MFTG#M21M-(.X3H/?#[5G&ST R^5\'(^6==W2I]F'<#*W'")112DP.4504M;M
MJH81.7,B*G)B5Y^EXUL";Q("WG+[N@_HE\GLCW]B_HS_".-I?7/5&.\CIDE8
M+,9EG,XZXM4&RCEY)UU2D+FDA"D&>J0YA2DB>8D\"%%<QS42C:08E+/<(:MO
M#!D?@QEMTYL;)#C?)4F1^>+2+LF]_-]')^'V6J/KB\B* G+%ZA9W[E>;8"04
M[[(*N3"N=FLS&@DVI,1^B$_ 8_#GR3P4KO 2LDQ0LB6A#$GF(KUT-C@FE-&E
M4P%YIP]%6T=[S6B> ZOU@+WW+UZ?[N=^7RYT63X[ML 66[2FV)=X3H&T5!D"
MTK"7D%2TGM>5USOWNEN)M*$+[IR[#.B!V<1'[XY4W6W3K],YALGX?S'_<S:I
MQ_2=A1SOIQ=&?3Y>T$<OZ>7T\P><CV?YNS1H2S&,@7:!@](JU<.C)+#B(YJ<
M50Z=RDJ=)'H*+GK(#\A.&=5R,^A50<X!1>EB])S7%6H6*'P($$,*P&O_?26B
MS]C'"]P!JNWZII(P:9,9",T,*$HH(*1D(&I5)_09%[)/:YD[UC<]]N+8-GRX
M^M0\?-R?3)CJB\Y%2@?1<,H+,J>$U H!,GJ*P;6G7WUVT?\?RMUZT7-(W.A.
M^'437<&UUDPB.%\D**11#4F2?XHRF)KJRKC[+* 187>W8GBWA.VAV\>>W=C;
M_^<O;][_UFD^X_SJ.YK!N%F:1G,6M9].6!Q\F,^^CNEJ/Q__NJC'#9Q/ENVE
MY?CK2>^1@-8%)^L*1D1B /,0!&8P7K)Z+J'WO,_3O3[&!JL<Y[43\$L\^?UZ
M>KT#T2C2$Q!R=D "UZE=AA ]TDO.Z8$W$FVG*'<==(,J6W0BUPT+9=MJK=_A
M*5>6\L:DK2U6@XDLU_-\R-];D59_8; ^)];GM(1[@ TI@ML1B5JJJN6JZRO,
M7KGQ[WWM+[2&PE(\=TQ!UIX<M%UM'10%&,:8BT,7\J[,TJT@AQ1H/9IQ:J/"
MK3E60Y];3DBH6%PI/-<^?:X>G:BP]KDNJIXDX[*@T%-Z9>Z+I>Z^Q9"Z!W0F
M0\.Q[FA;[FR(,?(V,ADM B827AEN*3=5A6@:2.ZH)>=]5N)N"'1(G3 ?S<:T
M4V4;.W,=X963JRX_'(L1BT6GK",89RG5S<: 9P'!*"UD5,RP9-<R/YO>><,3
MY)YT -U?-=VVI-#(7#S_]'UY.5ZL8OZ]:?XPQ\/QT>$(N=$B,F*%<0%4R0F\
M=@QRYC(9PW3!/L7Z!X#=\)2Z)TV[7>FTHZN\WF=LY'1*JC -N5I657R$4!,$
M[Z*1%I7)I<]Y+.N@6X=>[D=WBELJK2.=SCJ>5TB$*'A$!5:@ 26,(#3*@ N,
M.!Z3M;[/.H$[8:U#(/_#V:=6>NIKB2XVP1P5G:T5SD"2&(G16/?O43:90B'_
M[)B+JD_[T7NAK56:9/\'C-"#]=611J>'_YQ5P6X\!&BD:""LH135UHU_"C5"
MU&0R$R_1:\-XB'W.9'H8WK4(]^,7PYNKMF%Y_,L<TW@U>O3W!$]7ZU^, FLC
M[*Q2-:PH?&UW40_KU Y<1BM9/;PS]-G0L0ZZM2CVPU7*&VNM4R\JIW(R,:P<
M=)TRMPR"= 62ED(H)HIC0UFK]8/5O!^NAW8G$1R$.?Y,]B_7-0]D\$YHZ44]
MJ$X)D,;ZNMVA4-#F$'CF@C*!Z&3IPXF;\:Q%CA^D!MY0,RT-QDTBGQP*?%ED
MI;CDB14P,2E004OP,M,("$0"Z%0L?6*?]3%N?RSG+"'F50.(UXO%43T8^7VI
MAXS,IJLC)4;:1)GKZ5M!UH[*RM&CS)T&%A*W4@<?>)_=9O="&]*2V$ZLNGY>
M9TMU-7NF+L):P?@P"5,R&4IX"@48,.\HS_$Y@K.%_DI:!ZE$MV,0;L;S!%8X
M].3+ Q739C+H!7F S[CX-#N7\-J,* ]*^AP2&%E/OU$Z04#-(5F;4N)&F:O[
MR6Z9_KG_7D]@34(K)O08_:9'LEXY]?,C+I;S<5IB/CT5]/(;%[YYLC/F>NZ;
M)D=U9\VK;^D@3#_CQ[#$5Z5@6HZ<5E%'-(#5;"AI.026&/#B1*;LQ9K<9X_H
M;N7<88240I9D*RBP)R-2(SA.C-0&%#-H6& E]=L;\Z (Z9$WS@R7[S?D<SU(
MT#N,/YE?O(Q/JJPL>D]<HCQ4V7I GF46"HM&2Z\"8WUFZ=;'.*30Y.F3=%L2
M]";I3>FUS:$8HS10F%Z+L:% I+0:;$R,%6.93SO-->]=:?_(6V:>/$FW)<%C
M6%+AHW*:0D/F3=T2'2@ Q4"LHA&PVK 2.ZU=?Z@EW3*5774I.-_>=]JWX/OV
MOI<8ER.#V7AF!$B+@L8D.HA9.-"!<6W)__'4OSZR#M(A!4*=.'=G^MM:F>VJ
M)^%XU6GUTVPOD9&:XST@H[8E6TZI6BJ%C)$HX+0W4(+T6)@TE,;W8=QF0 ?5
M"G)7C.NHRWZ$HU$A;[0\KM6ANO*N^LK5&56U0V^TG&M@J2Z6JK[)U8;DOOAB
M@RNNI#[[U=?'N&%8\F/2K(T&NQ2$WX;E*>-7JQ*.S\\N#Y/)XBZ+/(JI!.Z,
M!E&BJ2>C:8@B)1 HG8Y"%IGZ'%/7!/X3V.O2T]_N1NU]MYWOU^&='\_*SV$Q
M7LP*2;(@,587#C7!2/3J='47C>+^DMX,\USWH,ZF:3PY63 Q*S=D*^%J?O(2
MES0BB\N"K;=__3%@-MD(_^CCV^H<T6VRT9'V7J;((F#2#%3MA^^2B&"34TYJ
MP7SH$\]M!;M%[7]E#BY==8_LU'Q^3,K^5Y@<X8B"<45C4R@%CIFL4>+@M4^@
MM63:"E^8Z'0@ZSKPAI12[8Z#U[JB-]=DLSCDLL!G!SK7[968/4DG=&W93W)&
M'ST(35E?UDR(W.M@A!O@_#"UWZU(M+VF.I'F'7F:4S0H,1H9!5&8UP6.$2$F
MZT"(&+W2*)3N,W]X&Z(?IB+;D#H/U%??0/)TVBQ,7D\)Z]$J%CX/?BIJ"E<N
MMA&['!''X_WQY^FJHVK=-W>V@^Y%6.+GV?QXB\AQ)[B:A(J['\%&L>'51*>6
M?2YTB#M90%T71BZ6JRAXQ-!1BJ,R8,;:\4L9B%Q(0&U01XS1IC[>:5.DV]K9
M>^Z7TM%AY0KF?\QGB\7WUJEUA?')\5:U01IJ;Y2P=9($\\G4C(^,0=3<*F>5
M$KS/YJ<F\(<4079EZE6CO7OE-XL/'@J]]OK]#EUDF4S1$5*N"S4+&O!9$/0@
M5.#<Y3PPWEZ"/ZC:_I,@[L.UWXVXE^<B+E3@G'8AU D)I@,]5J+NN&?> SU0
M+B?,-IL^*V;613BDP/=1V==$A;N/?2^-"D5NKQ;+\6%]:'X)X_FJ7C K;\/\
M=UPU)+T8QYUUN3D*D],*<^OXMPNV;C%P_Y'L% =?9N[WV8+]\?3S!,\1D2@C
M%,9JSPI(FR2H6@_PMK;C=R)YPQ+ZT"?O?CCFOJ;Z^YUKLZ?Q]/T4_Q^&^;G*
M1S9C42P(2#YS<B].0'!60"'C$DIDRNXHN-@,]Y"CX4Y\W<S -U7\CN**[YA7
M)[41Y$\'\]G1YX-?QE]7Z!??X:/WHL3L(0>C*9Z/')RO)U5%);E2EL7<9\:W
MF0A#JN8.G,)MZ;"K].YZ/%=R+H9'!=S65HY&TC#IC#4=1>>D#M+U62/SV 6;
MM6S3)1@C:44P0E/$FW,$Y5*DE$<C! Q6L^""4GU6D&Z/?<C.J2E'F[BDAZM]
M,&[IL@@Z.8<))6@LB2R0K6W#/(D0=(R4LENGV"!=T\8D?BSW- @2MR?#[K/K
M\_=.&OV\Q; XFF/>6YY[UO?3\+$.0#UA;#6VC7/H+1!TRY1;C4JK?'B%XOS>
MM>_E9%81C71!&:1V(&4PH&KHXY/BD+7AN9Z&:'(G'WD;I)T5'DGNJ*RT8$(]
M<<8;#E&I ERS&- (:5R?I5 M"X\["P*:,.C!%<9-=-6P?=A\_)4&YRN>-C&+
M%D7A.M%MA05*"4A4Q@F**X$CY0[(^RP0NXID4)ZU"S.V&ON^7O"L2><VM>!K
MUVCBB>Y&ULB7G-_D'2Y'63DC519@>:+8**$%KTLD"HO,$F/)IC[5THLH6O3^
M7EWK8_B#@C-B7IB<G%GV$1<X_TKV)UM6(I<1.)/U=)]2[4\]*3(*+WG26OE>
MG2GOPS8D+_%@;MS4NKNA2IJVB5_AH@!OO#C _(_9+%\!YH2/)H9 JJPM"A+'
MZJLBH"TB%,\5>:R^7+D=W) <1WNR-%)*>[;\-IO_7ANESA(NK@ +QF>FDZGG
MAM5BH_= SDR#3$F@%+7C?)]4?PUP0YKY;L^61DKI&VR<[;4+%[;9$=8M0H][
MKM@D$-D$=:.PY-9-B?3W23:.JSY45PX?695@+BRDN=A\]FK/65&\2$)FX$&2
MGW&:@4LZ0)+:*L1D47?:G]I=M@9[,!^$<+V!]ZEF"XH2"9-LK<4Q",H7$#EJ
M;<C/,]_G:*BN8@WJ*,V!/3XW;/8<"+]:;EM^B$@GR_K6%(P2[VQ4]8[)!U"2
M/&9 77=$1:DEELAXG_1L!\(-*93],9^>;E3K&S*MCAWX.4RJ6/L'B,O:!WHV
M735C.CFJX/2(@KIO]^38\I,]/">5IBU"JT9W;A*"]1B%9J':Q?M?/BCB;#->
MXD)CSF18<DR@;"*3[&1M,HQ1H.>% O].ENM><-M:_AO$U2S6OG .LJHGLW*M
MP>FZ"U'8&-$%:46?".<^Z1ZWGM2:*5<-XY::Z#;3< [&(-E-Y8%A(*.**H)'
MYB#XVIY-JF1RVLF$PP"W#_?F1@N=-#I$N0IV6=RW87I4ZGKJ.GT\$E*([%@
M;4UMA9H41%5_E&"5H^B6Y+S/=ZUUIR$5A'KIO_V0-S,3-Z ZW[S.ZT$G)9)2
MZXD9UM2CO4T"[DM=5:E#\7T68=^.:4@]B7;B2+;73#.FK*9B]S+%:I_"M]K:
MADQ9G)QCJE8J&?3@,#H*UBGK]=YZP)R<E<*8)/M4LN[&-:2CM7LSIJ&&'BV=
MNG[@:9_DZ?;[]$Z5UI2PU3*M:W<[HT- 'G2Q!;2/I;8I4^"X(,?#(WJ,.<A.
MS7!OA;151'-ZU=7 OZ*QH_<FJTD[>L[V<?YUG+Z++FL_ML@U:,[J7(^I1Z!&
M!5I*ZY &Q@:Y5G"SP4V'E .U(<6EZ*;7\+<)=T_1O<2O.)FMRE2G[:MGTQ%:
MEU)R$;*39!9C)&=J' /!DTX64=F2-R'#33<94I+33_E;#V_;J/9V09FHT[E6
M@,DL$Z9 0;;@G@CH<HXQJM!I@OQN7$-*A=JRI(->VFVS.('S<78<)A? D-VZ
MT(K)Z)PE3PF,"G7V/F<(P0E@RL8HF:(XO-/NB370#2DKZL.;YCIJZE9>T(=C
M&O9/JR5E(Q<5]TQF0&-K_U=O(4A90*C(1:BGV>%&#N7RY8>4T/1S)5L,:3/#
M\(I2C-DQ4F*SFJFZ0<I"DA0;12W9K1801XB%"TB"('*%=6E/%ZMP+[1U6&*>
M)$OZ:*>I/;A<UF,A*V'1@<YUX5=F&EPF%@LK>;;)"61F$W.P<?74/DD]MQG0
M-GJ]N&+XM)WSXD,XKL654396BJ(0+,9ZM(Z3$&TQ%,(DB9*COI9&WZ+>.VZR
MCI;=T]5RJ^%]M*+5Q;GN[I6K>V[6NWRUB:R-:EBK6]Y N"B"-4(S*#(PXH;T
M$*S(H)DR4HC@BN[3:?(60-L&')_"-SPC_OE#%4M,HJ*@K)F<&(]D[$H"=$DK
M;W(NG6;Q;P SI!)6"TY<#2FV'?]FD>?%!51G,AZ?)\F:)U2!_%W=P*V$"^"#
MTJ!1(?TAF6=]&'$7JB$5N'I0HYE&VI:X]H^F>7Y\@ZRH62@I"/"\GLO$LH(0
MDR2W*52EKDB=2'(GK"$5N'JPI)U.VM'D[)C&FZEKB_)614,Q6]WQICU)*Y,"
M&;R72B7A2I]-B'?C&E)%JPM1VFFE;]"[PK>X& F^GI;9_&3@MHAOU[INDU!V
M<PFVC%I/%ON<GXYZYW+HD;<BA:PM9&=KFU-5P!>60 J5#:6WQH9PWUAN<L.V
MYN2J--FG$*6K36$+\58)#\XSA!)+T%(RH66?]G=WPAI"V-J-%'=;EFT4U"6:
MO0HH!5:*3PZ2XHHL'28(.F8HSOJ@DPS9]:F@KOV,/$XLNS.^M%).HV6IMTA\
MS4,&DZ7AF4%D=7$4+PJ\YK:*K -+M4,TV\INWAV1-(_#HE0E<T=YI6 US10.
MHHB<0D6?8XA"%Q,'&H<]JNG<BA@;1F6;Z&@WI8!8;&$8(K"825A!3ZG3M2%!
M")[I@.AEGQ6Z0R\%[(XSS?2S(P-Z8;Y<<&>5UAE0^CJI&@M$+0(XY7D4UAK'
M51L;>MM2A69F]()47$1*E7R$:"*%.(49RIU0@)&97*1RW+%=Q*#WRCYD8_I
MDJQI3Q^HK+XF]:+(SH04ZMDFQ:3:G#,"Q<@62@F,>2:#+')W5G4S_@S#L#;B
M3TM%[<B\UC/[)*84(/ITNO+ <^V@<.L*%]X@;Q28[LQ/H#7(1&UQ9+!0&I T
M>"%JRT3*#Q+6EGG;U2B>M*W<2..7-X1UTL&.4S'EBA/<\Y,VPBIE#2X$#MPG
M*Y.))5Q=!-4T%1NR'>S(C8>,_BY*Q6_'T_'AT>'JQ8=PO.I<O'6=^*Z+-BP2
MKXV]T;J&-[A8(-X2)9T#.,)1UHB\=@KGK&:>%"R!3Y1'!.N2D0%SLGUZKJR+
M<-N0[,[[_#K-X\5J51#F5]]J9[6]P_IJE)EA,08&J(HFHV@0G+$63#:E*$PB
MV3[I[X/@#L&E=67>U?"MOU)[SY*.=&1DBX*'(FW=:(L.8CV=R*,OWD?*4F*?
M9@FW !J"Z]LIAUHHIF_B>%%20<E,7>\!(2ARQH$R62=9!.:5"UX6T6NQUGW(
MNDK^$0_#F-SA_'WYA9[I,*D'3HR"3Q@\/<+289W#IL3/U;/,LQ \!2.M-WT6
MYVV.=4B6N2G'UDJHVZEQ9P]:1?;IC]FH6&&U"YE\A5&@9"W<<HY@0L6FR>CD
M/K,F:P(<DKE^/&(]4&&[91/1 T?.,"ER,F 2#[7_=X&@; 8CK+=%H)+^$6S6
M18A#6D'W^(S:6&D[Y=0OLZ/YJ$B="%@$GDS=ZZYJ V@T(%GBW''A<0<+'.Y"
M.*2E=H_.J(U5UJ;6=B.T3[.?\4,8YU5'SW-PMKICPSWP*'QM_6,@NEP@<86L
MGI MKI8";JFVK7_/(>TX[<*0GCK8F<5YA]^6G_[ R5=\.YLN#Q8C7Y1$%XG!
M,150G,8D)NW .Y9#DC+%3AVN-T4ZI+VJCVJ!ME+A(Q=W1U> -"KOTF5W4^"]
MBG_7)5Z>7/26)Y H!2@A'3BF-7 5K7,JEQ >H9:YJQ+OW3FHR)H7(2FNBY:R
M!F$$!,[JN94\EX(%C>PS(?]PS$,J*73AX$;%WG;J;>9.UQV4L\R5?+X7]4!Q
M8Y4DGQ\U1&4U4$(;$6V(P?6I!&\(=$@EA^$0[X&*?!RVK;):J;&XE"6P3)&E
MDI%B3*LT")-*D;[01WWRQHVA#JDD,3S&;:S,1^'<2=Z;N$GU?/-06*B+\1"B
M40SJQ)LU@7.4??8";HIT2"6+P3%N8U6V*6'<"?'F-)IKYJQ52.- ]E>Y0I:8
M%P-)&^VD4]&K]18.;7[O(94TNC)H%[K9N<6ZEB>[R&CHD6Q+<HR2<F*Z4X+H
M7@0Z6:32_A$3A(&7/ 9EP;92[>XF^@,7K(2D*67AM2N1S1"S3E /<C2JQ"B\
M_W$F^F]?J^-=#!(+D,"F;A#DX#0E<HD9<C#"YUXMI#>".:1<O"FSUJHO-E%>
MWR=KQ#AZZ^H>4T]1L?*Z;@/)"E(J3):8G3)]UC>NL;!^X+/VS?FRD3+Z%IU?
MA?F4G,7BS6RQ(,^Q?Q#F^'-8C%.8YI?CR1$Q^ATN+WZZMUS.Q_%H63LX+6<O
M9H>'L^G^<I9^/YA-Z/+;K$3N!Z9)@7M'8]6H+/[;ZMG!O/>5 H+/^.[H,-:B
MX"G0%;S%^Z/E8DGH:\O'DH,UJ9[$SNLJI,B(Y<HY\!)SX%)8H?MLZML0Z+;F
M\9;;7;O/2K.C(D4HRG,HJV=?N+K_27(P.A4M75!.Z%V.RLTPA^1^>_+NJG7M
MI\MFWOA&B+<-QE[^[Z/%LCJ>D7.H6 @1I*NK;P5+X+,7X#+S&'5TUN^0>/<#
M'I)'?W0*-M;OFB' Z?OU1Z1PX^]_^O]02P,$%     @ Q8$%4U=%K9,W2P
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MZ='OYGZ(74$*7C2S^;O\2].DV=$D?83IEW&$V<?F-(V,%S8)RHF.(A$)3I/
MN29H5G$?T<I*3%81@_68AI>#GAC75*%Z!7GX #/ !YX@K)=X4)TVG\LF6"Y^
MA$)O!$..X0Z0>.X%!!=H 0?<&=P<@=I*9_\]L)Z*5/1'^]N"P7<5C%]@@FL^
M16Q'Z0P)7-8['W^!%3P6.5Z)+I*8+2X\H]QZB[Q$84Z,1IT<#55$XP%@3T4X
M^J3_;?$0?=PCY2Q;K7DD*%Z7U!EBF445B4$F005'LC8>6' ) 56[/:XB>2H"
ML!.%;W-<]J8_OIF@ 0^_-K/9R.4 05-#7&06(>'ZO VXW"0U!S# $ZNK.5Z"
M>3HZXY8$KG )O)E\@=F\+'&!Z<UD#E/\R2BJ(-$6LH1)0*T%=1@TB/ (DA%-
M&94-0M-5&+\.T:/G?B^DKG#0OYN?P/1M,VFN2^?J&O(*C%*L\*F$:! 1"1$$
ML9)EQKB*$F*=$^!>7(]>''HD>X6[X/*$>HV$>-%,$.$Y@EP>8<UD]C/D9@J+
MSWWR7V'VVWC23,?S;RNYQIOM^E->_>L<?_T;S$^:=+D99J.0A+4* @$MBZ)C
M'7$>)$F0!$,56<?$*QTU@RWRT8OKH0K$;=E7_<@^+F&Y%W]&13V/YR.J'6A4
MT0C'@YE(%?'2SD(2QW$OYARBD[6NQ#L!/1&9VHW0M_FO=^7_6YA?4= \STZ%
M# 2"+VD'>#L'K@21*0.+B85421&Z!N/1\WI[HM[FL-F5PZ_\=()GU^P]3#^>
M^"E<FG-&9I8T(]FPB-IX<@2A)F(2XT(&DUFH$\E;A^C1\[T74M\6 =NW"/SL
M9^,XPDN'!NJ!H$T?B.2<$HO&.,E2>:V]=SS4\7'<"6=XYO?#K0=$8'-25W"+
MWP3U<GQZ/H<TLL%RD1&'S@66DQ%/)L?Q N(JN6B2IG4<'FL /5$9V(;<%=P?
M_X"2EPCIZ MJL<?P]KR0YEUN(<[>G<]+TE[)@US"?3F>Q=-F=CY='(P7E#'2
M2N/06-.02P8C-\3J[$CVP0AG#7(\51&:?O _^DMF#VR\+8QN*&%<G)\T*@&@
M$Z&ZJ% R!MPYM@A) ,X=E4J9O<K<GJZP?<C"EN*X.2,K7(1KP"[)<POSB(?$
MA3"!N%9UEQGO[2AQQWKP2CO!$?N0<K<.Z'?)ZYF9%:[?BVO@DP^G,$H6;WN9
M(_$*@4B#-+ *58T,(7EMO.:R3IK2=1P]2LZ5I/CJE^ .Q+SK6/EAD>+\UR*C
MD/[VXWQZ#I<_;"9S^#I_==J^\&\_SN"X?+&M/,RF\]'[:9/.X_S==)D\<_1U
M/"LQ<"XY$R4@PDIHA!/+DB B.<:-SX;#'1G;MR4"7W!%&O"[FY*P#D&/LG!/
M,<(]LK$%,YL>B=KCA7,%S]4<J9?MX=H)U.A&141?'+\-I\_+8UT]QR73^^'4
M;;;W1.;!9(#RK$!83: U!JT$8D7R1%D>)'/1Z6ZYYH?(^VNU,7MA_2;4[9'E
MI0AEA>JC/X79;ZT:-<I4B> 2VOL4CT1I4,-Q(EL"(7L: 7P6-UQMM\M9UCQ[
M.-6O1XHW_9&K0K' +U,_F2^A","5B( &BY 215,RXD50N+D<Y)22<J).SN@5
M$(^9Q;O2M._-^:(YQ1\UBS#NT111';>JQQ*:"EPGQSTQ"5#R!!4D)&E)I-3A
MCZC,6G7:J/>_YS%SM&\RKC6U_O.G&]1!T^&/>L6&'S^]>_&__OO=KR]???CX
MZG___N;3_[V.L*>BPSM>,TCQX4/+NUF$2"T8+] ^UR4038,7#I24PCMD;J /
M%R'>\<+>BQ$18O:@\/QTN@140RYQ<U0<O#24Z8"7QF,I1GPSB5/P,W@)B[_?
M3#[.F_C'27.*O)XMLD<^X*Y[W4S_]-,T\EYGL,")D0ZM)!'P$(U.$@99X_9*
MAE6*WFT(]"#\[9O(R1V)&]484T%YN>WW*JTDHG"*Y,P2+IY*XEA":#1:[P*5
MRM<I>3P -V55YMWT2>U$^0K>[MM+'=%V"2ZB?5X\GTDG$B!)HGT(1CE(6G7R
M,6UQ8-[$\L2%83?:5_$_(Z(WL]DYI)?G4Q3/]S =-TL_^5OXL_W5;$09BJ;,
MGNCH,Y$R4&(-341IU 4E\\GJ.BG0W? ] ZGIET<5DNC7H/R[/SV'2Y"!&B=H
MU$0%AC: 3(Y8AE9&EE27T\^'6"=/H!.\9RE'.W"H0MK]O<+>_O+=YS;9^M57
MF,;Q#-(HZJ!TU(X$E1!Q<HDXA(R";VU6P5J=ZI1I;H[U60I87[RKD.A^WY:X
M&W"F64J+.\.(X%%G\XQ8BJ>L4$Y39KP3E4HU-H;Z+&6M)\Y5R*F_#_"KL\^G
MS3=8 ']_/HTG2+WWIWXR*H$.+XPA/J5<G-Z!6.\E"0'Q9H5&JJG3L&(KN,]7
MY/KA8(5$_Z/TS_-E5=&GYBBEEA_^]+T?IS>3%_[S>.Y/VP.ZM$1,+YJS4H?2
M.G _ %)O-I[#TCV\6.T'B,WQ@JOMPD<B9VDD"E  4?)72\)&BI$H%9-(V8&7
M=5Q.M5?VM(7YH.2B0G5#6UQ:8$_AI$2@O\!E\<U;F+_+G_S7]\VT9>A\/AV'
M\WG),_G4O,<U3^8CX9Q)#&G+:4GU=DA;-,8I82Y&S[027M:YYW<$_K2E=DBN
M5LAOOEX"%ISD47-.%-6,H(4N\6:(BC@5&55X;0"MD^RWY[JZ(05F>XK?X7JM
MX(9/%I%$/!9!HQ$D0Q0D^*0)XUYX9KWTIL[M^8 ;OA>_LM59Y\3LTK]=:F9"
M@$@B*%#>1#!0)TWB(;_RSGFZ4EO)E(]HK)::32E*QQKG"=YK(@J%2S5//$]W
ME^#9#L3<=Y[NK24LQ*M<2<VD*%-MZAIP4 ZL)]$B"V7"M7F&1F?0FMN@E8F^
MEN#? ^M ,GDW8O<ZR=F9[#4**J]C6F;3= &U25KOYF65=\$:-KVW OMN5E?V
M1OO!!(.C3N-YZ7;%!=Z./@42%)<D,$@LF#;%YK$+Q)J<WWW)PR8DK]*8]NRL
M62B[RY2X%$!):CBA/)>4.(?F,L<E,FU9]E)'IE05&;@%90]5UKNSZ%8[P5WH
M6R'M9HU?997Q&F-@$7&5?E9$JM+D)QD@)EN;!-B4=)V^*O?">@J"T!_=*YP"
M1S&>GYV?EKE!Z]P92Z TIA@HI\1IT"B]V1!O!$=-R7-KN;*"U[$R.D-\$L)2
MA1\5<G4^P!S7"FG526*)*G"KDN1 G/,E79OJ$K W1'L9I3,T:ETGI>)N/$]!
M)'J@]-H,FWX3V#^>GYWYZ;<FETKZ69/?3V&&-&@=]7Y2O/+X'4IX<U[:U1U_
M+,X>/TVS2U6KR?=N +2I9XM-\+(0Y72V3?[['E#VD3Z_;^+>R+[WB8L<$FHN
M*4MKO*/"&YL=90H@ACS: ][J5V'QVUYZG7#_63":DV#*IF8QDN"2Q3VN@J&9
M)0][NQ&O(=U927CWXLU=$8Q5D..J?SPJ*;Q@BB@K/9$02BOEY(FW0FAI5#25
M?,@;@!S^5J@J6[=TB$KLJE$*<-M/S[G63N"5IMH "U69A&0\R4EGZCCCEM9I
MI',(^=_56/=P[O<F=*\Q+6G'8"JU5,:2MN==":8*5PAA(XD1M*$V4)_J."\>
M78A\*!D;DJ.UBA&N;Q&7@]?*!L*M*5/)%*K<CAD2+&-"91<SJQ0?[3V$V/%"
M6@1)N$]>&*M(DLSA990I\=19(H.("KR(7-8IS]H$Y5#AQV&O\EIL>ARARZ"L
MTA 2R4'818J$TSF0[,!&:3484:>YV4&&+NL)PT:!S4V8,EC\J@NH[X'-C=G7
M*9"U#>T'$XQR^O*@)5$!=0>)VBRQH60!64B9Y6!-I;RVQQ+8[%\>-B%YW9 &
MJIF_3Z;@3\?_ABLC+7Y!E.6D7'I2@9GHK$& %,D@!<^HY+I :% I:Z<MN#K9
MM9LB/11O]D8,7J_1],^=&E'3:WA7V,JXE)<P&Q]/VMMX^K_/<17YVWAR_,+/
M3EZ?-G_^-Z3CBVY1U"8T9((K9I3$*]@CP=">)C(IG4+"1?GJGL*MT3\]J1N
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M>V;26CC#9R;UQ*ZF%JT'$P060*6@!#%&E71.B;JJ#@&_E=)9[APWG:IC#E$
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MRI6#.Y 0@R;4)VJRY(J;.B-7'H_T/J!"';KP;L#@"D)[X5J[5"-6U79&.\G
M$94HJ@PN"^*RTZ6ZCP9NJ#6Y3O'.6D@'Z/>LSO%UGM"=V%5!P[L&; G)6Y$4
M<$^8M;0TZ>/$22=+DUIK+/<Q^#H!U#O ?)>=G5E49VK U:3'WY$GLP\??U^"
ML\9SRU&_#4K@8L%P8DL<RTAO9) 0;*C3@?5>6-\EJ4>VU6C^O.B07:+^BZ2
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M4;U3=FX>(\,Q;-/C9OGC\D=  /_U'_\_4$L#!!0    ( ,6!!5,"8\ G$(P
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M45$11P8*%<=BB/L%(S%.0>)(/[YM(CMTM!!^,+0[?J<:&-=V<D;Y8U1X>2G
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M+2^EHZ4IIPB1@V@HRLOMD/UAZ"]DM_>-.7G]@./OCZ4MJP654L#1E];0T=*
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MI;3Q4$V!4#JG#8^UY'#MG>/!P&M13Q:],1$?K3,GW!XSUU)T2C)/)^;G)YY
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M@1T]$!,R&9TZ!7?+84UOW BNJMF,U97,]\X_)*8>&PD#L#]PK=Q7EOX];.@
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MD,(H(?MC51+0<:;<Q(SL^RW_ZA3($'/K_D0*^BM,OE4>*%7:Z^@10TO0SSM
M>,JN;>-]2+;9A[K'<]JV,YV#I9T=GY<F$RNNH<L4DXC;!6$(Q03WFR+45G&V
MTL#32<-L)13O#I",[AM0/?5$%!PQVI^#)A$<3$:R SA!![RMV2*\J6+S/6D\
M! 1N^]5Y+XGW&O?N^STK(AX1LIJ24BQ/;0V<WM"V[;VXT^C#7\1=?=S=U*%W
M150R>MHH1!>,%?_!TB(<X0'3TCP AD28U_/5.9O;,4C7L$T&,-Y^C*M5/@B%
M56?;S*.,-*GJ]K.2Q:#QRQWD)U*;@F=$<)4+;D3Y/P%[M_ TM_\\_OSU8ME_
MLT#EBY^<X83M90O:>!JI_2:*/N-FN,Y,P[QSI>=_M(DD%70\7&/VOYW07"29
MGI2#YGE"A=YUG5)W6.$VH\YL2NM$52U)IBK#Z3:^WCA5&5D:]F0R:%Z;JI%I
MDEKD_9+(,[)5FAA+]W)L#5:'$XJFQO[$E,%6*@L)D6Y1^B["R+=+,XX*3;Y6
M_C..!2[*8X;O_DFM%WJUP-3LYN?<S9@I65UUX4HFU\0;<W$^+6DU"$'UQJJR
M>Z+3DFXAVR<@8-,Y]Z)L9B9CTP/872+AR(9V<#T#?S3)9]V4%%:S=ZEE-)*7
MFZGU8DWN9G2>5!.]LIK9>O&P^AH<N,3J6_PE,_\EGH=!=;]O8\=>-@&:0!IA
MU+N>UT3P-,;YX,/^GH9D6,DTZ815DZMH<][2$*2;.40I.+R:+>02EA02\8\;
M9E&GFSY5NXR2V;KR01^+:9]1HT^W)X5)A=H=3.0"XT5%8C*"1X*?;*B-JMJ0
M[(]E:_3F9^GYL+'RBNAU1KS:P7T.QY'AW)'U,&U)'BOG=/A/S!93" )9"56
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M%(I:WHP_7[N_OJJT'DK/XZID']VA;^HN[5#H[]M%[J RVQQL:9+=L$:A77O
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M)-C,_..4Z^R#'=:#7HXCHJ+61<>6MG.5T=_::CJ:-E7%D\O48BYK&6Y@*#O
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MV$B$P]:D8*I[*H C88D3_(?K,6?9XN E7K?L7SDYR0C^"H=5<9MLF\*M6K>
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MO>3S*1XQ70SK$^=^&C9>\5D^[ ]H?T/V>\ "_EO(_@[L'[A0 !TE!7GS*)D
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M#".<\A?(RK&5$RHV>^HDH(XB:BX$E'=^;@2Q_Y<*N@@>RR6JLJ_+D( G7TG
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MA,N'^]33ORP\G^%'4K@J_5&$2 ;.6ZUA:%?(12G<6+7X^&F!T.WMX#.B:SV
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MT=%A(#J$TZPO>ZL>C@2T$+FPW(FS%GWOFVKE=6_O,V>P<E0O2 1V<+Z->*,
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M?NZLX534/VX16YU/E,:]0Z_3MD_Q!J_U3^#\FC]O%H3H+BL-N1R;ODYUV>S
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MV18SJ-R_N<LI[5@DKK%<-&\[)*K>=M?&)(56\ HEO!-RO=_<"DQ!Y\-SJJ-
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M6M$<U)5WMQ</P@Z>J>"CKY. F9C]:O !7PEL=P\4,T/>15\US"WS5YA,O;*
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M1@--\D[F;,FS3H>8*GE_-)+PC[6U4DV09/H*8<H,Z?LTUK[Y. BZD_]/_\G
M*4*E_"G^**0UC,DWY8;$0GB9<8 D9SPBP/BFBM/WL]!#PW#<_^#NO<.:VKI]
MX86(J#0%D4Y4JE21*BTB(@(" M)+5$ I @+22U04D"H@H%1I(E(B-=2$CHCT
MWDGH/:$&2+GQ/>>>HWO?_>[O?/<^Y]QS_UC/L]9*UAQSCOH;:XXY%XO)UT$I
M4?&[K]$OQS:FKCW4;[BN_W$6TR6\'EYCXE+XJ*(R\A'\ _LU'M=X6Y[C9Y=4
M8%W1(22 ;L=1R;P9<0I+GTR?Y8?BTG=2/B5&(3(4L7";8ZGA#?..C\REG&LZ
MD5+)L2OK\/:=JBU%E:#&H7O%K%6:5X+L*ULT5BNB],QSAO-6B3S86WDHH]*A
MLNY21W:EZIC/RS',1WHZ8+]3W3\ZN@PJESMM _NX>?OQ#S!Q#<;LHA-CGT**
MO*.&AA:XE*&7BU!7+!1NM+G-+JA]+V85[I*P( %O$,Q+5Z4_1:*0QT<J<ORS
M$84>-!SF)ULIW+N[\/B\B2WO<].1TW0[Z<?\+^("4):7>L51+N?':_/])%0\
MA,TM@A_;&HVGT(<]!=!56+?FZOASPS7#1KM;U1#ED/[>K%A5D29=!IE5^,:4
M1/C38=//79X.9FHU&OF34IG?$"S^"CU$;KP5AC>-LS3]%G&@JKJB[H7SO$>2
MQ -7077]M5P&=M"7X3ZSW2]%*YA4.D035A7EQMK'(':X[%\Y4E(DU9'Q_#8;
MY?"QNB8+!%U-4K^H?D7(C\=N+WTWK;OQ*B</\LE)'UZ4)0+I:)YJ>U&/.NB9
M^X+%)53D8(_-3>L)'_X;DCUA*_YZ>6J/792:NWB">>VYNJ]_M$G_7AT]8MS$
M:.XO@,1&SJE)@UA7XE9"GA[$3DA$'3\$"II&5T>ZA/T4>>UVX_ L> Z0;).W
MH?&5-)YL%C0YM[,XI#$B =$>) !ZR(X!A4%*==)GUSV='C49.'$?SIY T2H_
MT?_*.G%"Q6!U6#E5VV^OD 1PKQ+)6:/T%K15=TS7O%?1W"?3VZ6]/+A1E798
MOYG7AQ?D#7@#G%$?Y&#B%W/>WVL!KRV[M8N:CTWY@K_M>Y<@=%4!9,6#[A,[
MFOO(^*2*Q)4:CXLD(%BFE@1D?&+ 'W/Y.8%G[=A]R'Z?'++Y?T[@D?4S. 7W
M@@2HF( Q].)$_FB<?7<H:(<YB 0 Y)&@'7=T\UW!>!(0,H$\H,0B84_%"<<,
MCZ9)@(C"'QI;^@.M2N@?VK+[$[%_;QHXW#]& GKX('4D8*NI\G^WVW:'<"82
MT(T+Z" !;QG^NW=:.1ZG@;'6QNDZN?5,(++R+(%2J]LOE/6^&5JD9BFFZ4 I
M+&2CD#9'H+..B?()T05<O!;?;&.'M* 2E$RQ=X-9V=:#AC&%D-']68_-YEQ$
M7WEHIJ7^$%B)_X5G0?'&:;>Z4#[?I^[KW:7#]0\EJHH,H_.$XD4--W;LBU)%
MG<?L FM>=EREO_#=KO'UN27AK4*#\-4O7G7[@],!NHDD !4) R_9_QQ#\C]*
MH%C'MHG![\&84TA<]>'+L'Z"?2=R<9.H!=JZ2@+N5OH1_<%X>B@^9HL$X"7*
M%PET5Z S3-"?]8<<5M">?FHBA>S/^L.[>NJ'_<G0[FE\ G@.M,+" .TF,_!%
M-PF(58;\#:=73@N2 #-WEX,C\K_;\$&$&ZC- W*F@;E&EI,ZF;N8UN'T'2DR
M7'BN_2_3OK1./B1 ]0X(=WP:;QF@H@9:U7$B 6#HE@E9%-#/%DHD0!E$I 83
M;Q] ?QNA(2'2>9]N2NB5F,^EYK@#%UCN4M:_CYAAER8$N<1%]@CN)& N"HR*
M;N*213F_' L(JOM1"O[@ZB%(D?/D_E-YBA&_=+,U?P$2<)&!$3J,AQZJ.VE8
M&$<&\K9A8(U$T:$Q"@]70@[M^1Z)QMI"6Y>(].N43#LP2D*61//*P1=MPCH)
M@/"L0D>O6C"5W,W2"&@/%-]V^;$;)HQB0SJ*A_9][ZI.+1!JNR15$O%ZC^TX
M\5$6F8=%N!BR-OI!\<?(K'T#*R(!!NZ@A9 I$G# M U'&VGCX\$8UI\\F[IG
MW(#$#$XS@I?$7<ALNTL"L%+0)F/_VR3@8QV22*%* II[B9\6P)T,/XV!['?.
MBO,3-=-QM- #GDTAX9EIG,/F&] ."YPL)$$H+@F,RD?P0GNLR/H-9/R+G?T;
M\3,D(#0Q#LJGBS\!QL?LQS-C7/#27LW1AS3C9%:> ^.U07_J2UY5]+;J)A0?
M"FW6:D?&YA(I0<3;1]_#<+)$]AJT.H&*S"',:=!/J_M#1P8FV@XR]I'$FV T
MW]QTNP$)H(@F ;P!\U8NV+B9P'AL<.OP.LM5^^K43RBJM=N@TZ[Q'M\FY+KU
M@J;CTC_L,(QMM\D'YAT?>U>15/CVP<)X>?5-4[]U6TKJU9AUB(J_'6X=U$0>
MY#([(N;TI-5J*'=3-^A2QO6%6\#V\XY6WW(WQ42I[\7/#/FKY@A#:6E>U>MU
M0VV9E<D7N[?6M)H%UC[&I=@4K$TEE 8\,_+2&><V_KGRRV^\90A' F#G?Q;H
MI&.:]J=W9'XRAP:*]:B'KT.P7.]C\LT%!3Z6A%.2 *[L/TL;_JNW 8O^YLJ0
M/U>_(<@&5O%3/.;_8M>!1\3@<2B>XJ>79/@[:?ZE_R4!N ='FX<<9//"4"%_
MUJ"&;"*7G'XV=/ZG[3[_4T^S_BC OW+ _SU[/45D(GY/\FJ:/FN^FI10,#:X
M6SSIQ%A_*8Q_N7+^?3%7]?U#K#F8'?Q821(]N".?[;69M7JV]9+]T$41MX]=
ME&+J/'(3##IMQVK!]>#RZ3 G?S6[-#X_)W6-)!7.^?LFV6\T*'WCZ^567U[;
M6[4*.E(+[!V#/?>_J2B+*@M6&,DR=88)J/ W-@F%Y4:]8M3Q#3L8JU0D/'KJ
MG+-2ML[G;"YZZ%,H.@AZ'/*C\I8IETEKW#T>/N^R@Y2T+GSG9/;:09G&FCOX
M-_TC>W*&:6C/^$_;%/U964M!!L&66![BRSTR&ZD82 "3^A_,.8!EL#*="&W:
M@.!?8-.M9B"'Q_/)%FGB16;>_V;3(",T]( $,%1!MRAV-ZC([DH3Z4<"YD.@
M/\TH@.SUG9#$G_.++.KX*X1] ATYS\<=(T>!IW_V,7_T=[O.9(>=CCDB1\$+
MH/_NO?9+?XU\3">) K^NU<W7_JQ<6B 3Y\%XIR<TZ_4=[1J'N92TY#?+(S;#
M_Q^<(BO.\>BV U&A7U$-!6/D9;*TL)>--9M288U(,&'[P*8.>B9QW#H7"3(>
M7CR(O],M_D.IB!]:I[E<6#B?4XA( -]O%YPS;=7!X(0@:^MEZ$V_I5TOYR.%
MZ?(/6R[DX6ZZL)C/$FO)!AZE_T?6#CTS0OX2NV.ZB1E/]_$X*(Z3'%=XYKK_
MN1FORO\SX-">_L_%.O1,CUBV,+W]<\5M] 'UX>NFZ6W4O\;^Z+@_T%KZD[."
M%?P).BR2 T?](@EH!_'_@5CO'_4 8MK[EX!)D0<%7LO+]5?",B.J\APZ"R'F
M7$.](L<$,YV3HTS#SXY_8H Q#^-M<* <_P?%Y4=J/Y*<<^TK5?P8J1M3;"W=
M9.DE!^[OSRWV"7= [1@B=#'13>?[1L?;W/,=&*6,\F7\RTY3/+XO/RO<EE=D
M)K?6(='6GZ?C-#2JQ(S4<@F@Q^L8Q]J,JCE(Y_&%3&D9>^64UVWZF5L-%<_^
MPU#J:BU=H@^Q+L1K&G\<E 5-X" 928R^82\O>>E+(_@5C!W3_8,3)["L3.B2
MY8W:%R=>QUNO3M"0@.OQ@60A=-"3@-\"0/3OTI_Y7V"0/WKQ7]I6KJM'[IPR
M)F.,KYMDV/LWTBRB_!O<H5S83 *VB2 WLG90_O?O-8,?3O=(R'Z:P5_-I<C!
MK-31>*C-HTP+"!-,_C2;\+#9<SEHM<6WP!,[Z=UA$6PX>2[),DE^D>V$UE<U
M_]P9T-AFBPSB4IDN8UU%5G;GA2BWKR+Z-[-?U&G.<'HT<!YYP/*<RRER<%F0
MZJTI:^Y$FYMV!2W1R<^  Y4+C]GD9FS2J/SI T)^Y#WD$6FTZ(OM+2Q;*C.:
M+CY</&5]]<XM^NRKWG(WQ*=T XPVC?W&D3=8GVF[:!A6O'#R$+XI5-PA-76G
M05DEV##:OFV3_M;4,5K.A)PHAC,RG8>&F8O.:Q"FZ*KT@\==Y 3&,NAH0KT&
M4FL4:VGY)!7^D,/<1IA582\"@6X^<2>-0F(.8"V4OUV>, V'5-[9:!7-.'!'
M@AK&R>R:+EYQWY[:- \4&"EZ5K8 )]0<1OTUC;,-Z!.C2,TRB_7)<+3KOB09
MA!RT0E:_0OV"-;A+QK&PK@^3$>:J6XN!X*"*>1* M!Z8SSTR<I'LP)YKV@P8
MN:#P"UTW/P3DX HY?I#!=;N&=5 S76E@O%W5> U+\^S&8Z+I=@1R^#YQ__A3
M[Q<5+GV%+ I>#W$I 3_(4E5V33Q< TVAK[$8VWIR7_AP;N,"(8U3S&OVB^<$
M<G_--R5?O> V:VZHP-WQBGCXJUD%;'3<OW9G;M\?N76?L+B/W-+#_N5H7LHI
M7A^7738*3ZTI]M=17H#.I\MU$#P9-I^.7AHR#YP,1$G6L%:$S'?AH=1.9%@6
MV);7SFO6X3(.F^#WLC[?@Z^:CIY9KX)NCNQ>4^H6Q[^'UA+WB9KR?]FL.G4H
MQR."4*\[W%/\3=M$-[YTD0U:U$#8X/BK9GG#39V./(Y>=:T]' ,E*F#Q7'!Q
MPA%WKD 5>:!QU)M@,HR+C3*'GJGH>58CV#X>Z_*&YE^':'.XQB7KFI/I'6CN
MIX!<OZS6V;F"?A8Y_5VM@>,,4ST;S]/3YB]O.8HFFE%]D!Z5=3.T*7_S]G$@
M!7#L^D1=VV%QMX!"(-=0LEGINPY&%2^7RR_1@M.^!2\,*^6HCU^->4M_$ATW
M/@G_3@(^SQ8D*N%A+CTM(3>'=N+-[<X/ZY?=R.<LU9[[P33':FNREQ*(F7.:
MN=#0[F R@Z5\,IUC)N:YT8*5._I  A+\9\5W1\!U;99JZO)^V?9K8[T:1-"<
MF\1_7&RNPWKJ5XF&/U=WNFD=3*.(ZCR<W!><DG?RU;HF1Q "('?P5G>*+;&&
M>K^2YZ\4D<OCG+OX_,_%=+S(U/^K.B+L@CX_1I]HRZ;@IHV]&/@/<C_2+8,^
M;0BO^BJU)L^ SG7ZR24=+NJDYIRM>9_5K/WJ>ALK6<XT-60Y5Q2 0-!OX6CP
MT8D)$K#T*7L^)_;KH)+SY ]86#J-%"Q<F9/=*GO+O)WIH&+_[G,KEE9Y[H]!
MWS;7KDO/7 ULVG_0U<W2V)%&8W(&*GX549Q9EW+>*[IC^4A$24N]/ [?K^PH
MB?+/E2O<C;#EME]_-H<XDG;_>\@CW/,KYHGF^7\$]"C?^7-T2ZR'%+>FHR9]
MA_6'=DL+U)TNQ(N@*[9B1C@CYTIM'N.N@ZP&=SR8XW7X.AT:&@V?!;PSGK7V
MY61X^V#E5L&5PT+#>7[$PAKQ@=HYXQ^@9S]+KWX]F!=( *NR@#:F5V3#"LHP
MOASIY"7:X2@?,CHGRND3^? .X\%#RON,%#/L.V%;T5&!YTJQCO:>28FO%<71
MVDH?:XSCFID*].L7).9#6?.$J^IIOZL E->Y;8_ N&3M&FQA_%0D2C?85\A1
MHK3# [5NR4WHR?,_Z5_N?)O-2J*=)^PP%O$$)SLS1)9=A-33=!HBEW<@QS,;
M2UWU 48T46+^[>ET04FFGMC1!NF=5(#Y&UX'!\G$FV'6?&4J^<\73[2YP9Z@
M>&E#WG)0!^M_:ZHNYEHMRGPNQ\#D#RK#4H>*E9M(3T)NR@ZYCD#&ETMNOO$Z
M=GXL)TG&&^?%D64CI^1&43"IL ?MVY&3\BZ+A%KVJ46^8K?8M'=EKR.4B=S1
M^]YRBLKKRB3;K::S:?$K4G>ISY* TU^&0&RZL%%'LXIDYLEFK\1JP^QO"7#W
MS..FO >*W=5Y\<:GQT^H+(KT!C(L';*$KDE_%G.Q6OGN=,.[3UW_-8R74>LM
MRT<AF>WZU:2-SQ\9KNH^'S.,3$N32GULW.NA0)/<$2IMKG%)\G55?$[2>08.
MGE:3EY276P<OS#V"6?D+I%G*ZL++L/ P$3$G_7M)6.?9#QO-KR0_,)I,*<[Y
MUQAZOKPQXVI).$<1AX+0FGB+-U4'OLEI?O"U.%25L?3\$_JY?=ZYN!5'LS]N
M&A%! NSI6''4>Q]Z\->#.OKQCW/*WRW"QT6?&KX_?/_A7@!=P <(F#@^Q9#<
M#*)T+N]@W7= ,-6$6%74+SY19WP9H%CA"=X(6VD<.JSS-EPC ?2Y)\!TNS]$
M-4$_4NM\ P5XLE8:;FQKS;K0CY,]G%;_QX!;JUJU_2[6 P4N3_98@M%7&DSR
M\X5I%8YEWP^R\D-MGE/[O+P'?ZJ\Y'S)5*_.\#G/CK1?LWP1W".K+! T(/J,
MH.H;(SUWPF8\[18E+2C0#SL1F!S6D-=28PD*ON\NH.,@9E'HM;SB!BFUJH/Y
M6Y7#L? (?PVO+Q []OC.HO1';\T;CK' U>Q9U=D3G$J^LLF!(OW2\@I.T&T;
M=X-/^%.A=5]AVW,KZG*G[-QU^7X,+3LT&L7$W&,.F&"(\>,F5G%'!Q0Y&VP;
MTT->I-C#[,_G#"WFISP:R#&S:K5ORZGQ'.7,;>/2W-;'_ CD[NM:-V_V>KM4
M$;ZR+6?07S$YG1J 0D'HS;S!C8>W@G*+.KBN]@G+L1!">RX1Y9BQN@U*G'@-
M0IX45,)_4K9AS+^ZH&I>>P!9_5JW\G@E"?!$K,+BNU:VT9/295(D0'(39Q64
MDWBK /[Y &$NW@!9T!]$SDY"IXG!2+E  6B[)O8QX?4&"=AQ'U[Z9>+FH FK
M0-0T#@>OB7N1@*PT1.[_+*QO\,X@+@:3TWQ\E$.8(&Q8=_%NKBJ3[M6;0>XU
M5'HKNL>2C:0.C+ANC*DKZ/$962]1L&7O]7S.'KNS_!!G@'Y33I/,VR]K,6ZE
M_D#(IQ=?6LEGH%#\C3HMWFP5-1SJ)&TIH!.GZU*^4FN:^2V"[^"[]869!R^H
M>1_6U2E+>WO.-@]O6SB<X7N+I<N9KWT[PCJZWFNB4'6/MIE1>4_;VML:#0]>
M\Y?.FYCJ,F\V4QI<2P,1^L]TN*;AZL>:X7*K$&'.)HGR2>Y)[O5 32.D;6#;
M5(=@NW,6IZZIPSQ7EMCDA$M'4='DFK?M[KMJI_66[)7SWKQVV8;WZZ_(\? $
M?5N_JU_*QEK*6<H9Z]=G/"@\;C!CZXBP?!DF^(EG OK[_CS#\5N@M=?D2"*L
M3P*^WD0>RK,?;B'IT9L'[&!,UF%6$_+@K#I>_[1@)D*$\(]2\U\/X7JD _1
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M\>8@:DH,QM98*, GNDEVY!!QU06AO_56/;_(CH>@C@8=4D%QY\ '/ M\^C\
M-H'G5(&AN.J+,O O>>&=%%)&X_,'[UO^D, O<%,0HIXH*J!I+'7-ATA !4_Y
M6RVN%*,I?85C)Z>T."-( /T)U^%R/[Z%^!-5:)<S)A,,D[HYHY<5#,/299:"
M*5[HJS2P';=Y)GVPS_1HQ**UD#DX\>KKC;6AO<VEP*;Z6J7H]J^X/&OK#J&4
M/.%/A"DGRV2S;:\E736#(^K00HV(<9/ISP)/5MUZ2FE3G+5?448\>WCJ^,RS
MG"U_,BZ\G@_&TX/QS@B64<3JIOH*8M!#=\.V6B@W#LUP2&5*5E17$C#[S$>9
M#"H_&J83J4%$6?720(@O@R-W]P9TSF<X"L%HY;W:FBA?<)@R%E#+KFIJ'SMB
MV4&+F5!@W)*9.%9Y4B(NA3-L$:^%<33#,KS:L62W%&Y".*4F%7@-]6L[*;V>
MQG8S":5?80H>\YR+TH#9_M:Q:(%FT,YI<KRJGR4!K:L(UB\[ _J.D^.&N6@?
MZ2NLFD7.&E/F2[MXY4W<R:W-,_XL ]+=H6;T>6*?2^V*355.P&BKMEVR7W0T
MWJ9D%7.;V&N]!K/XDJ8;"EYB?DP"7K21@,C>.5P0\841%,<)Q4VZ#Z1J?A=R
MLE_RZ,E1I5\4LI_2V50G0L!&T_J3S ;M6&K"L0*RMLB1 &RU8OH9:(]0-PF@
MC"8!' 5*R5M'O</KUJ.$;GSXLS2&A\-6%ZE*3GS\2#?:=BC%24Z(^_^1#P^J
M(4--G[/;ALUM=0:.<./5S -!O5WAN0?ZVGO)'U@[%&>NON&5:S_]HT6=DB;N
M.9#K?&]SP'@OULC<O]H\+U?MG-$MU!^S1!-E91(0P](,W:.K(@&]VN:#0;.;
M!V?]U4G _?%TPKD!BKJ_2S1_:\Y*WI);E\JQ \V%'.%O?0"M?*L8&?)CSGW?
MW;R\&W\C60.. 87F#']T+#PK=3!V>%R_D_>8S-1'^NPB.\JYZ-&VH_/@,.Y3
MQ DX-L*SSWX8C'D.#RVZGS QMLZQ5W#_*C(^PD5@OJT\  9A)W8J,R'JL-%!
M'J/^EV<5D+2FIIIIG(CA76'CBG[1G!NJ(O8A?(DG91\#T9I'0G^QD^/OQZ5*
M.(O@N=I0BBYKM]QM9LC19?!BW<_4$XK-+[M+);Z630+2]B'[Y#NMT;]>%/5>
M/X<LB2/Z34*G]TD ._B7\QHUP-HAR4RTFDB<PT\NNJANFB3JC9FT<B\<K/=_
M6G;6C/Z1M+S[;]_/>1?(X\C"#H^0!BO?LH&GKJ-O>!L:"=?OMT+9&:Q%.J8>
M&#8EM0NG'1#R,LDIL[,XG@&$-P2-)8D33J#)VHXE8V#CCH&[ >##4EUB(++R
M,.3(0(ULA!,0'#<8]P5<+@4YI&LAJS#9+L)@B9\_@@>3H-N[A+8!\&^-Z/U&
MP+].C8)8T$\"TF$;RAG$@5[HDBP+D3J:*!2]KLU"#'*%SGB3/5_^_(H@P^ZC
M=#P!ZKK+L/<IG 2H5"(QBE#L/:B#'7*'@WR#DFP[S!!QO>O0?"D2L+AZ%%W
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M)@&&,F-9XX7U06OSF1S!AC1!J<W0TBC?GH"U$D4JF7=5141HK%(0D27D%0E
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M_!5\4'[AQ2QOJ)O?%YEK\1(R[@=H7F/43[UIRW8;6O.-[2-#CK238],TG;^
MZ&#'^-(A=R) F#B+>ACI?3KF8_?'TUDC1M!@1869\7P<WCQGZ;R,?%%FL&H
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M)!\3+5?EU862-3KVQKB^PA$?I7"6J]0^^<DV'*T'W.X]2WI+]0XY15E@;KW
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M)FDX6PDI'+\]R#U7*1_S.$@NL_%9;?5)%0>+STCER'NT) I_!B< )%J.V^+
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M0^<?,(0RC&7GLMS2U:XUTZCNMM$K5DPPWLFV<OS"6[SU] AZ0(<RF"F^[/L
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MW=Q?A7ZYVZD22\YP/@QFR(J_'00/\&7*\/3N!_/R[*VY/;^>O"4B.?-,)C!
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MG/>5ZO*9W5K==;L0#-69RVX&L^_-10E(:(Q$J8\RIHJTAWC#OG"D;;F/]_%
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MNO/TJ35>P'SWD\7'>4M(&GR?,OX)>M_2HZDZIQZ>8TG?XO5HY,[2L:7W<@6
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MDJD6TP>&FDT- SWRC$++JNUK.'=%[FD=R[L-VQJJFC,PSH0TUO0B%J[LY?V
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M'!/L02J<WF];A<P$P?<^/\.*UI".H\N,JR"-V;@=PL;!L78K%&\0S$T&I/L
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ME(Y,^["Y=;0:=8O1%W.#F0RH$"(#YBM)LA,'4&V_B(' @5O(_GTD*0 R#3M
M=_M5= Y<0!#_IODGH.GTQ1B5)WSF/J^2+(3R:J"RI\Q;;:QYQB@K9&.4#.!R
MP14].TI],D[KGX'9?PT:EBC'_!OUX@-\0HUG/I2I)%C?+>UP-Z&*?2M.NE_M
M_U\IRO\C[?K_.M$'@E>16<<D]$169Y*3[.2A,LJ#2]O%N2\>-SP5YS^<\4_&
M[O_/1)=[E@9+92E-MWY\-0/WDR,<#7GD_P-02P,$%     @ Q8$%4PW_7B7G
MP@$ F^(! !0   !M<FYA+3(P,C$P-C,P7V<S+FIP9^R\=U143[<H>,@H29$<
M5:)$17(4E202)3=1,DV#Y$PC"$A. @H"(DEB2\XY*DE2DW/.W<0&FN['[]YY
M,]_WN^_.G9FUWIN9M;[JL_\XU56[:N>]ZYQN[!1V";CS2E%%$<#!P0',;SX
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M1Z^=Z^K+(U48 9P4:_8E0#:X&-I1AK"]OBU)BR&QP (KX),!+FJ+GR?VSW5
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MJX43&BL^&?2XJ(AH#:!.MXDP..;G6G+Z^O/ASF7,01$1NO'E38U3Q=+!79Z
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MMGP\\Y!NRN/2%I"55M3+WZB0JU>S6@UU$)4!JYX70B_HY-?#[UO5)S&7:Z/
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M]OW'-XHX=PHZ?XDFA%<7B(($;8A,C1-1C2/9(=IC8:^K3^,>><O>EVE%G-U
M7M\NK>=UDY#B@5 4W5F59[#EB[(Q$%(TQ+/A0ZU8XN__QMI;1L751&VB32 !
M@@5W27 /[I"$8"'0N$/CUKA+0^/N! B0A 1W=W<"! @.C;M#-]KX\'XS:];,
M]\Z],W/7_;O7/N=4U=GR/+5V[4H3XR"15TWY&OK1$L"V"LB)8S\2W:C#BUG!
M.\\\B&9?H4(ZC%XNRT:!?6.-EAABN[JTU*[1:##X2_FVN.?O6UEIH]Q>#,3H
M;T!A7+,@G9!07L68%>^5EE/ ?&R6I,=5GRO-JUNL?1IB"D6O"/^_.Z#W%0)C
M,$\LJ$#KBICG<6MLIJCK9)W?FOMZ&4G_P>?ZIAD.SF.!#S(AO$MOVI8!S$-H
M6TBZNZ9]-D>D/'_'T=@AZ(@=>!1/?P2:?_"YSQE<:OAS>M9B>2QD1KX>_7QL
M#!A+"X^#6D&>@F)(R:WK \G8Y>1]LB<,4G%842NSY78_F]B0?^QI/V [?I\7
M5B(T0&U+BV]DH^?&A 5"RIX(=!S9=6.#TVIN7UF<H04D;[->U\/!)RW4KLK3
M7!7V=G58^BV9Y&C:*EV\+0M-Y%ATZ&S.H[C"!7/[EZ+?9A/FEQ>61JRX$UVI
M"$IJ"8P%!P!W94&X>,)O4H)V!J1>$0Q)47LQ2O(;' @U?T!JH>0;[)7X%'%5
MTVZ[8T32?2N?0&5+D%]\[HM^^,0:F);6'-NN3J1F_$Z0MYD5;;X"EU4F>8,V
MU$=';;EIR5B^%C\TI?E#"/!1I/B,"0-'4?+!,VG-8>&%L+V&1\"\7LSEJ8P]
M=+-TQ3+E2TC:L ,M^-4"$)V,_Y"46]6(\A'P,FT#>$_:<5=3VH%L'FN'<_?Y
M<>UQ'C\"K"/L\RP6T7Z\JE9!%T_N0/W5[[,Z^0JB 4+*2W*\+Q#YPRF964#\
ME!+_^*9+"6C2AOK&=OQ9B'=-SD#NJ,"!O8KQ496RDMQRWEXWN1@9I?XT=>S;
ME(+L3)T+7BKJCLKWX Z$9U=';'-\Z 66KU0L9Z%!,PIU,=(?UMNTR/.02.D0
M3^W)+:[EZ/K1C^_E(R#YP6<:1.B5,=#53CDE,*+TQT.0ASR7C7> F@CW4 &
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M/3Z2*0ZEIVSWV:/:GMP12-GG[XPQ#TX1H]SQK5CK%>C(9FX:J+E,Z>+@NI<
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MKAS*90FD2IT N1[+K+_XIEXCP7DZ*X.N)MLZ9=W\VCS]GMZ%?0J ^D^G;6U
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M.SGJAK(;BL\/H@"!YFT*5*).^X4M&^NGSDO*)#7CU.EBNQ<_AJ;$J&$7TK.
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M S#.;=-$0V, 6760VCL 9:<(*ACU-.6ZHE\*-6]"3R$;?G$?5D')\5>@+=D
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M::M;'9$"6:_VSQ2H+[.X,@OWV:I!6.H<O8Q?)O1?GUJX:#KUD:=9,Y,1H6S
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M7-)F+#$J[AMBR%\50^:U_5KIQW;P$!UI*6W7TW9%KJP=2-';Q".!/J$7%O*
MOO4J-X\]ZN.OW5MBNSD!OVP0"B8JFNV:- EROZG6T-W:EF?WJXJ=BL7>:_6/
M@#B>5,1UFJ.=/T7!6GV_^ZX%F0)QT\1-W4]>%W47)1G-Z.[ITM!<40\XL!W=
M[J3W*<) *UXZ[[PKO2OY>HQ<$X@=I$8QBE%"$D#Z$G%'"Y>71RV8LFC;C(8
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M],&,]0?NX9*>N,8A7T;T^/H#Q% M&ZJ<,-4G,WEV0=/,+XZK=I,37.=9;4%
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MSTI^;%T92&Y%J1+ 6+P%%!VY:@&O4XP\7<D3@@FJ]CX=4S,_K0;W0I#-J*@
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MZ>/.XX8H-5X,P!?:0M7F<$I<;X3<.D51%AMK49,+BA #98\F?TP(?=_OXU6
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M=4 ? 8DKA.>\QD;0J]<=ZE;,E4LPR):WF]+O@?%!W)^I SX4?2B< 2B#(#Q
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M.X6<XC]PTVTY'C[EMKAS#3<2V6OJ&IL!\>]>T92Y5L[T<_6^YSUD;L3>R1V
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M?R?\AL^Y$=UTS+UAYX\G-#Y/E#DLAFDT, ==_GA\N3[QGT(U28HX31>1WV2
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M<9MIG547<A*@?3']L2?5[Z>@*HZ.3.U7-) T*H#>[NX2\N/#$+%P[J[Q%XR
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MIP]_NH9<#NLV+-)<$- :K&_^J$3[RL?JXN?2O]=SXJ+2S=/@_VU7*:&PI*O
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MXQS [;I_F8+WKK9E@5KNH'/^,;??E0$A<8DF<_!K:4X=%YFM68.?5(#]C1)
M)W[NFQ[8O"%%0N3 9C<G)@I?"*DPRMXI!(@\1\]E!+<Q7''9S5S$0$I*UDB]
MWTRLM_%G@_)OLUQ?@?VYP7@Z>^@&OOO:34<)=?!QUYSH)]*5%L1$_4&&[ZT
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MG>\LD%E1E;+V=OH6]XB,+_=]L8YXI]_'LSI&?BS!;6E^2PGU,2EH1:0=\^C
MMW] Y^LIN[!O. ];KA.#@1+7VOKQ/%CUH(%BF^#0;3C3UG8-XTA^ ?_/$A(\
MPC8Y2:E>J[$F?ZY96Y4,K!1<=8'ZQM#XJS8U0<1*(T#35G*-ZZN_3RE6Q8:\
MLTPM0>^,C&KGV06FXL]'V&@#X1,_#]Y^7@ //0C2J]][;EOG-I[C9 K10@33
MPCV4/7Q[YRW+%O/ZC(.QD9K2K!S[O:L'92C+<_>YS' MMW^MI&NS]'BI(7/
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M.TF_A8P/1.3^%IK<D=;D)JUGGN)MY=-<LJ?GX:75T5K"1]R0@1+>X%>%0I0
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ML-6"E>42X9M*P%HXP)T]1ZFG,^A!7>RWEO#PY;)[)&U@U25^6HIT%?8@EWZ
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M"6Q,UUX(9YU)!B#I:XS0IWD,T@B6-/1&LX9V=[Z^%P/-3"OGJ'0WK;U)6C1
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M\%_4JN:%YRNNN&E$UH8X$XO-DY(X]L CK">^8F4BBBZI$)>J.1S=FYIPU*
M'GPH%S),A&4>EQ]L,I;%"<X'[42I%Q383_C*U:6<K,EXGS/((GYNP:G:)!8>
M3.(J:YCX,RYR,R*C_K5<?,VR817ZVI2)]DE1C(AN\Y:3,[-?(,7/4KBS;NDW
MCCROS#-^]-_&WVNN.!TE9+]UA^7C&-C)S7]S^WQ\)49?BPSH=8^4;,K?KAS=
M"YQ^?V@O':/GX>YU!S[-2E_/I%FU'!SS-,UV\!':9J/:$O%]7,ROUY"?MB<W
M>D$\SH2>>\PF[3<0H%;JY,P4T0-%*_Y*,OK^WL8R[HK\'CS'T8A&*Z8+&R"-
M4FK@U8OTDG[[S\^X]Y2<*6MEC<XW:F%R[ N:;X\]3-W.J\B #YXJAD1C2G0/
MG<12<$H-3CTYC U@Q-IO%#OP5\UZ!$U<WUVT"&/Z:R0ASHYJJ^.8WQ9LL#E"
M9; 1JH<#N23 P<X>F_1PFOD;7UE*TQS46U#[;,6P_)J:\ G:<,8)[J]6.K0
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M/'7I2H?"62=,_>RL(!V1_@S(<+%LTGJHEO)H;B24EB&2)=+T?+V0TYR%WZF
M.]S6SU0FN=@.>\?\#(37(L.]VQXU=#MP:4_]2=]P):Q.5NKJO%G$Y6G_>/RZ
M-0Y&3"+M'/\L]GY['$+(.DU!K-_Z$5]Y("U8 :5<YR+N2I%Y7\'SIUX_0UCZ
M2,&F9WORJ #@;.5,GJ+M#RL$#K]>BE% =L2D+[6?0CI0_R0>%Z1S6J:S>W-3
M_)FIC9>7"8S8^&#+J1DK/MW&<29E229A">+F1 OH,MI7;_V*<:9[H?:'UZ]"
M LH]>L^]UTYG-@P0K!2S63PF77!J6XCW(DI834!1IP;:E_1(554V612B0MAQ
M:28DW'M0C#2]T]5PLS_'J^U_-+ V%0\_AGQ[S34-.V WWP5@!OR6M&![@/.4
M:>5&0]\CWKK7XZ8@V3BQNXG=\$Z/DN>/+=2T$DIYA!7;[TZT'UEL_L@9(**A
M'2G=AH&&K;!T_ XNLM;&P3"0%K."L0TLZN?M</DO\[!E0@KVZ;IVHZ(5TN9T
M7".^SYA:,I.G?OE>N9]S4# A#MHH0.V=VVQ[8%'54W7[V8M/K1?TWPE9L!CZ
M?FL_I6COVNX-]&V JK!M+I2G\N_&EA3=:BD<"7Z@L>BQ4=)CN&/K+#A7<]$$
M_Y5L=@0VUGXQ6>:=NN#GP\I]\C^JH',X)Z@UI]P'0CK!FSVR P90[LV*9-(8
M?S/J!=X[1'AEGR=ED%C4_BVG%C8-'JH<@I>$I/%-SNEQ0<]N9-J #2E7+1$7
M_NF.D;6TXW+:RKD[YFT9T]*(2JG5\GM$!;R+=Q'%@!?K4D>/]W[\A*[MO5@B
M&].!8&S%!3B'YR,_W-SX-$$;I<'#5$ (CXMN>DVE*2YYS2J/ CG6L*Q)VUV$
MK7N]P/&+%-\(L3]T>_76\X9A_3VE/KF*: Z[ABB[:.EH:0ZC)P#@$Z%CD^,B
MP[Q],1OKRHG=@5@[[D1]XSWI*R%*+&)_#BRZ0/&F]"!)RXG>+A>A_/N.)PW@
MM9^H&U5)G+"3K_MT".DY>L/B_;R*-)YR-Z<>#$(O:X;;S6#"IX6!D4F>LBMB
M1@R(^Q :5DP2R2(RQ?A0 3A":UCG22_%;)9))CB07>'<KO!).JT^JXW9LS.=
M<V;/UIDXRO@*L_:GVQ2Q<= %WJI<10Q#_FR>2 E!.0N0CAC<SJEE;K!3$08F
M$2D5(,ZG*%%9<Q7X0NF(J8 7=QT#MA6(\G'R8<.<< 5WNBM]\T0:1F\7Y<T=
M4@&7/2D2>U2 "-V48LX7_Z* /8FVG<,JZTZ]NM&=M,6AQ<>.[/D>@OH$XVC!
M"OLY/X=S*2DM@>'_K@/-JD;$XGJ^!USX?(X"UKNM?+Q1G"_78^C\P-2U2?4M
M2[!U_?A:$/0*6G;Q7A,=)..JO8@/:$<+E? [@PJXU!M+,AUJJB@,>[W@ZJT<
M=>G8*2LQ]*L1LFH+ZF $KQ#6RCS"(?;9 D+0$I*Y![()WL!+ J3G6([<+^2Y
MU_AUK^GSMRB*_SE76$^.%.K9Z%0GIQ?TCXJIU=3YP'P^6K8)"K-BCZ!PXZ =
M;NMH@O<K3*G58 ;_J\#LG63)G?=6W)P)<\LTUOL3/BQ^-+?&!J><7]M\2P!U
M*/)/8GVX7[DD7-_JA-4YN[4940%5P 5]]!3;/( 5</$"JZ&<RTKIJ_P"L,Z<
M^\"(:_JWV+>UW78MY7(-<MV" .]"KRNJ;,/^62L7PY:OL1N,\\4O5U5/@A:?
MX]$?+7-"]%CCG/2+K9VS!9MD1T2R&>PQB_=&21*OW+$6FZYNO6JI/RQFU$V4
M?K)8FD^UNJ!LTE7'3#MF76BVF>C\LTTQ@3@?-!D1N9^G/KIWL:!8BL([*9^U
MH-,Z"B=_! F_GVO$%H3V%F#EY4(\?*0I9C.(+)SIXNSVFX8X!3W4\(*_MHZ\
M=>8\MY>)3A-/E>I$6Q1JBJUJ.2%\UCXLA%P<)#I[THP,,AAG/*4CAV^&C=TB
M3KU1O;&K\[Q#BS&-4VF(*<B="N@60Q;&_"/P>;__&YDK\MCFX$;6<HB,-MGD
M4$3$:.N0!_Z7,9_(Z#+<OK"2$(V\]ZYQOS(<MF>C(;.X4)GO0@6(CM/."#V5
MI+7Q/?*7;FM(&>R>=&O.8DQIJ+9-6F%#M-(]^:VX91JLG*UH6N'K# =MGMA]
M=_KJW7NJKMB,D@EFV]]1  7(U)1:<;MT3:F<$CZ6O@NC!'0A?N;-56[*D"26
M%45^-8/-G&2B7 !K7SP/94^SFZL(D[\V@T;<UR>J$N%TD;]*57>1W1+6 \32
M]6G]YW$#/JS5#XQ7,E;C"V\"Y KSLCN_3BFB(#Q.UG1U<7LW*R0<'KMY$WV0
MBIW>9XR"3M&X [6Y+/T\0V9IK<\0@1&NYK0"E[SIP: 0#^[R?)%VS8*7)7GS
M4VGSSIR]/6B&BHR3.):?>-X0Y8B!N&>,Q=<42GBV RDN)L=[9[:0UR#?)Q5\
M/NWP01Z.=7K(V,:,%((.1\C-H:]-X>J<W9RY@L_TPXUI(/8=??:P74Z\.4D&
M;M%^$ D_TAY>MI)HTE,=$0U^7#"'GG6K]4U[*SZ]$ON2">H9E-)?VG5N,EHX
M@='@\^J:@&^7\96_!B.JY\-9)U,@W%O\KWKYW_$O1Q9]-Y+0BE;8Y2@N.BM4
M;MMH4*U6 2^R372Y<?0+_&8,HA'7FC&TJ3NJE!VY9G%L:. Q':7V<.%6+8&G
M!L+3MX<:?PD\['P1JZ7T+E%O+;J[L4;;#^F3.S^M\8BHEOY 6/&DW@,??2RO
M]J+SZAD>;&[1R.<B>(U<MJQ56YTM.6OEDOBCX:0BH??#]:A?-%Q1FE]W<%(*
MK[4S'K4W&R:UJIW+"[2-Y"#I:(9\-]MZ=+23YPOJ3L@ZPI@G^H.(2DN:A3;S
MTU4*)8]F0ZHH=\=:[S7?4\M78B<'#T5'O\ZJZ?'8T;O9J^C"4O3OP9)0'#\7
M!WS4C=MC$"#V?Q4.!OLKDU\9U9QNJO@4W'HK",AM&HZ2KUM\O[_7S9G]L5T5
MFY;NY7&^1<4UB=?>Y-?Y6]?D^-B.!#I@<9P),=*5]+\"#C [G*G']52 (RUO
MD^[\;IE/M)[;.0/@GOK#@643FR[@V@H)4?5O+R>:^FNKCDMK!V6+=%FKI9;(
MI$*A/-GMDQ.=%Q@/(WZJW7VG=/ +KWYS[*!AY\XR]"PN&:/>5#U9Q_<RJ;\8
MZ91V,<A-^O7:U;VDAML;[Z!*0@M74G-*50/T8A%.P"LXD$66C@4M()B<SEK9
MS#OZ\J\S*+&?2=-$OITMT-V5[-99@<P*=,Q>Z(F#.#&6KFC6:3\HZFEFB+'B
M<+O<.WL7\.':K8V;?-R"S8PF@>%T2='[3!%40*WZ-(4!9P@^D#U)CVK5+-?Q
M3CN1E_XPX.?-ESV>&G6VB/Z]IS])Q^<H="24I6&?$Y>=8G"G$EH#JNK.H/QE
M1QQMVPY?#W+@.:X(2\V>WQ]XM>Z8[_><-!</!4'6#*VMHJ2:^'7IWVD<WXX7
M^1UZE60RKL0?K($+<WF(!&_.!@="9Z3:=/O=*L1X-+[^21:7=? \O1MXR[30
MVFQ>U*";?L_\HN3.9LCF%;/DH^=U!S+A'@[>.6_J1JM_$%+Z3BM!.+MRRTWY
M\+WWTE&76\:F%3\/4@%BY3&OF8^I (RO-'I29GUR2##!^-9**Q6 DHV\.FN%
MB"H3YZV:\E;9L- 1.O/&9B6\9EQ6CF?53XK!5_$B<S/W]-J7AG7-D@9.+2O)
MUY]-'KVD@^J;40&,P2%PDMK^'\[R&.'VX):LX+5OGT-607\"/XA\:VLB*EA"
MR]Q9H>#7479WU8#BMXV>^;HI^I>U&7:,(+> +B:1=Z^/S'>]T>D2G,_S7$HL
M8?1D'.D)D-E9C=0>6V]I217[9OQ04_0/F_Z3K:YC;@QLJOV!OTBGKXM'P(J5
M5"E#7]KI%<E&19F2ZSH\>5/?Z_C37>S<W??67*I<LWJ_ #1^WMJ.O<HT(&WZ
MO"%H8(G_!:< NRG?A_/=4)]+)W&,>D0=&'@?R$69&,7HD3.6%9G7['UX7?HR
MU4/*+LV=)2U$@H?VX312$BV3F6+I+%G\P]$>D3GI7S[R.V*#*]1_NN8E!%4O
M_"@)+E*%=9VZ/R<HJ95T[J?X3ZA\<CMTLIUK2[XNX009A2W^>!H>.F#'&M[:
M-K\<]7/)\^UCTTK_<T.T8F[]]_>?_J, ?I6TPYI#A_V2INQ:>6'!W"+E__=J
M]=]GEBF/ZI)?QCI"C\]9^*3D5?B(@?7VM$KQ8A"])1A\*U[K-U8H$$&^EUGV
MRRCEYZW,GOVO;VIGW#7P%?!D.YA7 MJD#A,&R9]G(^ZV@U$5%M$U=LZB94OO
M ]7>0[786S3QB '*+<[U+HG=RF'*S91),1I.<L:DG;2]K.TZ)-R@,)-== EH
M5[?7&4WT<CSP'R4$Z2SPG%3RD<?C@&2@U]Q^+JSQ*T5#N-+IGG;AWAA\D0JX
MDDXP52H)UBPNB\Q^.$)1GG6B@WXKY?Q\Z&S(+3]1GX#W_P(]2P5X!V6.17"4
MN:5)G97+LV1Z(M1[JH^8A;Y_2,LKZ1+3%OCVQ9C*A?ET.'\3,0/8-75Q]L:;
M,3M0>X;_D=ZIZ=QB?J9YL/*=B.LC3DLKFH$WH3,\$U6W/,Q_,I_MOLY(]^2"
M-#$[=.K?H%$#&G\>V_8YH@+>(QLW<S7LS% O/N71E]P'E(!SRF_ ZN]SNJ03
M$]4'@/MLYYO#>W('&;_>?[>\^S4XCSPR/Y$-THS4FQ_(X(<BI+[6A$HKE,B/
M(QOPZ</".3O<[-##/3SK]G& >\6-(R->\_0O2\"M?Z]1]BRD_\WJJ$I/4XT+
M,9MT<38U18I]Y-##XV#A)#I#E8W2TKG])VTYP 5PPQ&$0(SCRFIT13W4X>T*
M:^'\[:9&-,%[X]J'Z8**>VU.3=N$T28G.R?93Z&U@S/KMX7)[ 4ZY(K36^86
M"E3 \4C[,]*@Y:OTCLKU$TI;*$IHR& 4DNH+[J<"T@?VN.&;;\WZ'#RG9-U.
M*_C7$$Q:XG5S+@$*1:=6>K."%U$X@A%T1I9]'KD@*4#:#UO3^ZZHHU@IM<"F
M4.>X CH:>I &2@=E V_5M<(21<;B<C_S+>R1 Q%)5M_&L7K8T3CY<S2 L_PH
MD6S1L&SJZIVE(Z89<<^$(L25!C)P_C[N<V4/=U1]^.*?VI370"/^MT9E(D_>
M(PS;DI?5^>\'-_8N"1<$>?;/^-I,K?<EB.&_LPLLH,G!26)3G[:74WY_JELE
MYS98;1RAC7]CP'"3!*UW5(#?:3)L4UAU4JI-.CCK1;4LZ:A.IXMB&5H+<YNH
MA*(6!\6NT?Y/N[#_'V_'%N;]KN28&[*A.0/C<_C0SB/D;U I\N!9O1)7557*
MT(.LF/C"H+ V2NLQ2;#]X%YXC*M35_4Q<^=1PUCT^U:E4^T6@W'^)NN#XD,4
MZ<EW'P865:O$6N$%F0[9JI.[#MC<WWDM[I ! IGN#UIM1+^P]928CD^".CH3
MTF^D:;_Y-[-X*G+]WTJ@Y8K!P@VN0*/6K!?N[>:/^8#[S+J4V=9F*B!!3-B>
MC@*V9.8@H-JDM[$QJ6(^19UV[#[USVF)>G"TXC!B4.6(;+/JX&B$^UP2>N6@
MFC3X+'Y,JZ'CD]L=X#/P8%;WY)4[\<A!1!8QK2J='&BBV+5X8^SU0D (.<]C
M;"-QJ(M@ZT_:^F/-WYQY/Q,4*9ZC-"AGX4_)4U1U&&!86,-)3!W+KI=-"=>:
MIM.*PS/$=>0LEJQ.5LWG='7 [5H$D9_&P^(>D(3%6=LKBRVMB]82&U+9R8>@
MGF\R2B(TA#OE?"/PN0/.[=7#=L7+[I+'WT-YS"SOA^BN'YEZ#!.,-AP)@KVL
MY$J)3D<"Y!1QQ#[QF0J("@AL4UJ#+\GHL?E;=-K];LA!#J+79N!?MD,>-FUL
M.<L<V+>4>.3[>SK^/6X<GW^:AW0P4(JHA#KY.W1L&=_[4<U7TMD 76'/K*31
MNV-92Z=,Z^_%&_E)/PU 1'1SJ'%.]6DY5,8[_UN3H::OJN_^<)1T I[>_]-,
M5^ <^@$>^CERO300T@EE0E?C>[HAXH$9>V9_N@BD>8=-83Z?%;(VV3@[(N'F
MGL>=3.7C*[T;^CK+7"VI"^7^.8?/%.T:1-QNGLAM"5MF@OOOT;P+X&MQB)RB
M7/YKXR)O'\G!;IHVJ97W,5E55S$29W(>QB(U,UV8[@0MUY"C E3J7WTC5O4H
MU;$5QBR1>9YW.C",XX?63;*CL /V]5,FS4E/9]"2KK?./6 ^@S/EZ[*=',[
M0W\VXK,PA"]P@X/"RNZ*5+O<+NA:P7&/:6^1T69(G #I-F=$\5##BMO3 STS
MT0,WYI,[@='SASXME6T>;J\1Q_U7&C#= B0^31 IU-K*BE"J60>ZHS[I#%H>
M:ZB T7STC.<1Q&_KS33.KH.'_>4(V%S]X5&[S6(_S+)>@R2B1[G^^LNKW[^W
MCD;2%(OQF2TNN=,SJ/[:* V*6!,H8[UBTI/0K?/F+@+8304D.8LYUCX('O0]
MVNUV>0G;J4KJ7>N6I3#W5R!01,.F1N[1A[QZ?29=4\P6%>@W&ND3TV<(D]Z+
M@F-Y;L6/LJF %OIT@<.5'U\%>W%CB%*RE,V[S&A<AA@L\AASB\,5=144%;%.
M&G0TD3V9V.DE!:(ED\B8"&;*YQRU%K_37;<R4\J7[TD(:^$\@Z_&Q<JD5,3C
M.\7W\O7KC-SK%I1ZE7Q6M=3W(P9"53(+:!R]UO36XJ*5-:&TSQATQ[3<V^+*
M+0ZQ.T_E9?Y:'"E,')FFC6A/(/=MUA\/'@M".UZX0U&=>LVMQR'M8""..;_W
MDT3+++IX6V$*.-K@6+#M(!$/68.3@%V/+!:^@/:C"D:&\H)\H%NQ1!8*G@W^
M)G\&W7ECLNHIM+5$$H\MJFA5AIMM#+6&:U"NS26L/BJQV?\<DA?#H+1U.G+B
MJD(%G 4MFPN$YXF)#9XB)E*(C0A)W^B.X4^0P"LZTDS%#QLIGV'[T5D5/MQ:
M6Z<3YP(\8+A+5 #GU)RN36<8'DT%T.V+9+0E^1*[P.Y9L%KK9['R)=F#>$;G
M2-(]ED6/0K2LJ76RUGE-;#\&+!/('9$=YN;$Z@KZ)/[/]K6"?FLHZW@(&Q7
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M2K3\3$+!B'J7+<D*-7V<:+$]B1KPA.?N,(F$:+Q6WNUIXQHPT^=3O?S?>T:
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M< L(D#?@"UQ0]/.EA B22^51B7\\ ^<-C%N>RA$4.;4*+ "/M3/CW(>6+!?
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MA5BC=::YO4Z1^5<NTSZ#F?<*Q76A O[!*IUB.8V)Q(")>]OP9,%Z_CM6.K"
M^WJ+O:61BZBYNPUG<YF!-"Y#.-E6Z'G$5W(P&K;[(=:]=4"Z9'_^JA0#[;P
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MLKBV!)G2 N&TP&X@]?)!0X>8I*:TPU8&83B/R5H%MU!JFR+GM0_9.P*^VF3
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M!R=U.!G$3>-?YN-U/"WRVE#4:_L!#.O:<(_/EUP9\IYA*-5 %I$SLR1 1..
M7*:X[*]X,IU7*Z9\()I3')96Z@YLRO@W%G&(! F2A1+L6@:!4E3=E5)Y,I>H
M#SGUPC.TD%OC,-_D%4/_,\Z18<VGI&OQQ=&[4#LL>R"6I76<[-Q6$J ->;5U
MRDW&GGE=N;'E@.&(:6:+^T.5&1R"@6\?+M K>H&:39'='4*9>-'=YC?S9MX?
M'>MZ==J6'=\CK)J?AWXL+;CW&,!*$48IRMC+_B?RSSLODT^)!WY7!#-3P\YN
MQYZ9$02DT*,-!I@69/4.I"E5'^89 C(CA0#_^OY?9FC_-"O2AQ$0.9$B4W4&
M7^AXTX*VNV%7C/[CL18[];K*M) ST))%P-!IMY3; )K_R6#Z&BJNPU6/+PA>
M=A?:*Z+HTPIAW#X'EJFE8LNC2/\0]J]W9N\30+.Z*9DNZ/KI% RU.,.MK<5C
MB[2UKF4;R\G.[=VN-Q?>LYWO:KC1,025^DP"T. O-_;;<&@V:J0$7JVM:4S[
M[4RT&M2AS?;M>A<\R$3_H=345@%PD4(!<T7(G&YSWXQX:6K*Z?H:+AF9MU["
ME52:ZI22)JP-Q3AQ5HBVBO,&E+;&_(YAF3+X2J<9VS'[+"]GE=F$.?WVA)3Y
MU%K*-2L+;0_6RB_O/Y:T(FGV6%M=KC8FO$A,L@U3]J?QSJUTPPW8<_Z>$R4R
MJ3L6JOLP9S[47W?+Y].ATZ4-JV38GIK@.+:;X-I(WIW9',M=O;N4--R3Z9)<
MWG&I3KX9^-)R+%4T>;)PLD%2PTRX7">GLI8*,-\4%5 @6$%=^98\6+#MSA#?
M'8?#=[7=R+%B*C]//P:9*ZWJD46%'TX);U0E)WNXXNT<1.(RF#:\C<&U#5^!
M_%CR023.FI@,!PME6*\-RK4.EQQV&HEP1]W<.M$\XC2]T\RPNYSBP]66%W'8
MH/VQU\#,-4O]P?HEJU>09RX6;J7E=LI)6XU^)HE"FCQ)?B)"F^  WY+3NVLL
M-):/1F"';5O4\1[LI[0S\D1EFVD@EXZ(26S3IJW@KRPEX?E==UXEG(E;VVA3
M("0*Y(A@</:5MEG#A=<4N_U([-R/]JQ_D<"2<)D76>)_F'+?Z9C708^,4:-E
M+DDN/DFSVT_F%^J^YJP>-XN-W!RL:K +"N'ISI]5CUMX1KRJ#-VBIU^3EVMF
MJ1BJAB*V1')JS-P=;8FU6RW ]F9/PL?BG6=[(U-+C?;._18R?E(+2[=;&:V.
ME:YC38=5; _+**0*EPS'#M7!L@Y>*@'L"S^;Z5"^_/XYS+_'%M^H&>(RB<9Y
MYI(BOV:M=:=8>FH'Q&.^1W.;G[L.4"E<# %;U8V(WMYLFQR55'?]SI3TT<WU
ML*,TR*[$OWS31^^KPT=1@8_"(D'Y/M1.*S5) N$GYKQ/NH.>.T]H+C!]3>45
M=+_4HV:\<!KQG+AA5'W=T4_91<&0W9>)GV9"KWMF2J;LBN9QO-[<@U:^QYSV
MN./\*$W8<24??'I;1&YKKR@3C:*;=7T<TDX66U,R[<C40,8/\"H)N%9%PNU(
M-EWPW92*5R.A%)@$RP_FW?#B6(V.?,7P*P7RDT[9&-Z+9:9 @=:XRSK'U0"]
MLK$E*C(JE"DRO6UY4G*4-A".67:1K\&@3KAJ V7W3#&,2R*P[D_(HW7O9UQ?
M;!V.8RH?P00_LWVASXY*6T;-V?O[ H_N=G4<VR,_Q!$N(H!M$#KD+]$5X+29
M/>_^A T,TVOTI;E:!SZQ1V";(:1\A&WRDP!;8Z'YJ\WM]J<E-(A= "A)YD_]
MP:(0Z+#W/NB+UW[PP]W$ \+7*ESQM3A"<BHYL?&VE)-UZ"C'VJW&$K*"'R$!
MW!S(6S[F!Q>J'STU=[<E 50$R")3^U#]OIW/.E)+F:GEBIV4^'0M63&7OG]E
M!MJMKKK3RWYTB[N ,>ND1!?%I"1]8^6Q/<:)CQBEJ[!M*<HL!510Q_=/6WY4
M-WV#Z!;'IQ;G5X2,E0 )B]3:&!;8B6_->_BW11/I8,W=3RL^.'GTN![Q9B8,
MZ*]<=QHZM/[M-PAC@=KZW40&4G)38&VAQ<R0.!(@(S"*. G?I:VI% 8M_(@@
M>"%D^D1-B^6[-KXME\/GGF!MX2,;B0+()"$@CA*X6U$E<UH_CZH<UR8PQQV]
M$K6<Y]DOH"=JLA ^Q<'WE^%8FC/E&FHO<EPF_O3H0)K(F.D_\:)('C2C3X!2
M$YEK8H"6JPXD@*=0Q($6:,[%WQ-V5($XW2?C;L4 ]\UN[C@F2G+KQ _H-XM;
MX$5]VR2 C/>5TADOHQ>$:&>BS%)5/:Q!-AN!Z?0Z,0%@PV?7+EHLRZI@*AP/
M+6(:W6;S-GQ1KZ7I"<E(XF0W:E4,0:0"'O">*G*1 /?(R/,#AH\?D(TY-F1&
M\)#)4EH38]FVX?!DYIX:7&L%-">[ZW^:5CQ  M0GPO=DH=I[8N'%,V"'O(T4
M3ZNN+_'S]^C."20_ODLQ79KND3R2EJ=W7:=K->&SI=NAUGPR!9NNF%<67W))
MK29?#)Q_+7#-I(2X<8X@E&[5='B)OH >B#6NS)T6GQS.!NZHE6ABK'5!#4&,
MB)VVN"6;'RM>I1LD +_0%O4OI\MQF/O -34LRXX3+0EP+IS6BBQPR=JH[_,K
MX@5:@?%JHPT[&L2V3MRR(%!Z#8:_3"S.PT3=FJNZ7$GLR8S7Q)1(^ PL0JS&
M8H57,.D9*+@F^;QT#\/='J'@CQJ V_FP#56;8QC^8W[]F]BZB;R%-6<2 )UU
M:OEPQ[4PA+: #.+59-BZ)CY3WAQ'6 7A#B/:F$6.?Y,=TW0='G[NE_ABR@P)
M "BN7W[%MF3W]G2"@7SZAE(@_98QNT2)LP\CX7LF'Z;$ON.RZ-?("@?FG!#-
MT4F&>6=4^XL[S55+QR0 )L=X[^*;B)M.1J=J\)\Y<:UI(..&\"#O&V1<_%;_
M)FW&=WF8P.7RR/R1UUM.LD35N:@W=A3=3 )@*2%8+9FR$V+4@4S1O)MH9=2J
M^D@Y?GWECQMJ95K\=-;04J<JV+TZO+G\%4'PYJ$BJ D>#R%>$Q4GPK=(@)W9
M,SF<J$6._7 4 <]D=\K?00P^^V*0G+\$,#IQ^!-+$F FA^P&BF,NQ.P9)HN1
M 4*5&GZ*)5.RP"!\E1=& L IS8B=Y&Z.$(&?'J+FU#'*$?];DHK8-T8$+IJ2
MJT*0$24CAEP5(V+W@S/HD %) J!>%L/M_L#[R)MQD-VL4^X68K ;ZJ\6G"/V
MC4,B3AA)@#GQ =0J+_VR,VA.8@!^]A]4_51EE!CRE;P#.[P@L;>*7+L9?.</
MN4)9ZKE3[1W(H@,RACR4T&4!9UE) "T[_P-5XZYAEMV8OL.2G,J7DN%O9+E?
M /)N2Q:=YWT<<C]2%BC'<>)P7$9\^)U<=WB&+ZKK\&H7.74/PG]^'T"M%,]@
MZ<@ML>9B=.'$PA;AV&LDP*(NC'A]2[%*/CLPZMF9,]?'FI=3"S77:OKQ,[K0
MG,P8]2VRICX@^W06LDL')5Y7=^?=)5;HG?HVJ*^DZ6&U88B/>(7\>.(?8U R
M-#<S##,,7QF=[[7'IEC"ZN;>]89N;WR ] TFGD);]T-FZ, LL&D(;ZC2E;75
M#+A9;DT6$$^FXP0%>#6V7J_!-A=, ECS>^'S]_&. N;>9JA)<UWXW77!#)6J
MY.&%8_@G!=@FBEGSN+KA#GSC2^[.\MDU "@DA> 7N<P[R'%G8;X^3? ;L<XP
M^REJB^S+^&ZR"J;WD,>1 -<V1$D *T=R2/.H8GWRNHC-QX;UP,/QO;BY=I'"
MS*@;. QO=LF:PPEG(YP&+Q=35[4C>UI5J3&&'R^;P(JK5G>D9(W9>XN>+\=W
MEJ2I/2G4O$-1(&/.<-N&/U K&]'SWG(-4U.[+_HU@DNI]@Q_3(2+QZMCFH,G
M?OGO=<T(QVT8Y>[Y1ESTVV 65M?'?!#8[[D8VEM"UFW$ YO(Y6T57JS+J.*1
M/QUHY:,C\=X(#&N.XT/L;6%^S>A5CFMXK0U?$8M)IF*ZY:-E<NAHJ>,V-E\'
MPIK1RS-/<XSR'SZK^I.WQQ^'U6H$RZGTS%WN#9JT46<&71$S'88>:09VBQPX
M6H,]@:Y[3:.X$D7U"A*@+'7Z$7SF?.(I;WL*9$/VE!J(PU0<2)( (6EBH(*<
MO9'($_+0H/EHH^^WI [#08\G:#?<!2E*3)TG:!)"NPNHEL(\U/'"33<7B*!M
M'U'3T:V4TC%\.?A/$*=,J/#H810<(=0_[1^E-52)*='M_1.;:3ZBMPZEVYC/
M"R^!.&(*]03($;XH0#RY8%P$B@AE+^](RC1/N,MF=PV(#Y*M@]K!GC:X;<V_
M@#=<HP3FL,=B!0\_-+N LF.UB<R/ZQ=T=[>1P7KJI^(I0,)A^R<"<L'M 5&Y
M4<$NEV+@B+I/>N\G3>264X9*Y7T0)>6!&[$@E(J)\&I!Y\&GLNL6:]V!'7EC
M5'@*A<Y<Y,].&)V/LI_%\ %:P;U;'2O\(JZW(5#P&PE0)=*!]8W#/DV9)X\:
MUS\-$CG]'=5_U RXR9>I)RFA@5&+HV!.Z+4+X$M1WXU9SW\!4W%9'$$51Q+_
M"4%O_Q-RT&Y5LY[29Q-5S]/K.G->RV-B%YJ\TP;0^>^;2'^_D<1J;]#_UZ8T
MH7?<Z%[G0T![M&2OA][:V9[R9B#YV3EZS2C]>Y?_693"6C[$.8JM3^E*\C]
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MM57^DZ9M9C*2+I6_=.\9C;D?0P?M!'_>J K;%Y:?<N,3$$V)M$MY$+'^*JJ
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MO;!S?RSY]AR(.5,A2/ZN%4/-#'3'Y>:>9[O8BKE&^T3)D^W)<JEK@P#\S^X
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MY]TW[E1!OEL:;%%*==W[PG\FXOK$OV/.38PTQ&#?Y_@*6$2L$V TM6$X7OE
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M=9N75%=#"#M?A7C,Q2VDG+YW(F9QIS!!L"0#%11X*  O1*3NHP!]Z+(+ARB
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MAW!S[LY$YIJM3S\N^C6A,I4!0A_>'26W,DS9Z_;^VCDKXM;^XKAR_OWA$(R
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M3YQ ?]/XM'1];_75WY(C$?2\$-?[?WM+GO\O_U_^+P4=-?U_ %!+ P04
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M-5+S/"2GZ#PO#XY(&ED6!O!CE93D @.#$I.<>N9DR4DN&-5/4'+IT@$;B;N
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MX_# *9'/31D[P/!\G9/:::[U"^N9^XP%F*Q>E_.2/.N78)(M5C?U<WH4S+
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MSC8WM^G*!_LP]@M\&JZBG+$TLFXT!T\M4M"#NNC2*SE<'AF1XG9!=+[):9=
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MTD4W3W:!+G^R9PNXQ?/SHFE<7V\?51^KRJP>)J7,<H)3 5!JWE>P3"$@4!9
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M=!_T[Y6ZKRJUFC"EA%!8@C+E!8 0IH#8$LVR5$KFJ6'DU*GSG,^@7C0[E,B
MQU:A*[8.VZ\1$(O,@#OU$WLTU-J\44*IS08/&AC#D]KR"+!Z[,!&@'>@'=A0
M,/MMPGKBU;D)ZWJOX39A/;T[V(3UO;9?/-W*1GQ]4FKUJYTJ6_E0-]5)"ZE%
MF8*\[J-!<P:(W5=EA2X$SE0)B5=9P:6!QA8!;W0T:D.3C:6]MCTO8NL6PX9
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M$5BLZ_)X PMT777\5)3K^B7^$C5?U:/=3/B;6CPNV?>GJ6"S]DVF4\$IQ@7
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MK>R_E&?9L4,"%C"T:M[]@,;=?#5=O6CI'A?SJ@1[)<]NPY.LB N9%Q3DDBJ
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M:T>XFS;JS1\;G5?=*\6<:&90WCBOYB$9=%S9;X3OG:UH-G(Q)[#($@[BF!4
M*28 E3 #,<,*D3Q)LL*I+NZ)-L9F)MU]__K5;3B? HXKJ6W0& .<40%0FF0
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MV#DU=M=?9Z_IL>JZY7RYEN*M_GZJ1_O]<DIGY41*FBA,.8 9Q !)(O2*BT-
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M&,H$<BO;XQ'V84KXO [P=M:11S #,^SY)$U;<0.G8CK&)7S>I9TV7S_)TC$
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MH]ZPH0KCT?M<=,3X)#QG0>R.-KV<^<>__;?V$_W#R/=O_^W_ U!+ P04
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MS1M!0K8/B;TD.C JWDR7X^7EV_$$/ER<!YB/:&*24:F)=)02F:DG/BE*-*7
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MON=]0VL+SG<_9PEUU=2 I?HXGWV%^?+RX\3CNIRF$ME^+2=Y^/7J* _>@U_
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ME#85HV0U93)'XE4N5V"L])MDD61  ZR-+QFS=8^3.SJ&/3+M0_</KQMWEO.
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M1*2+0*R-EM"DO/#"4&;K)'7^D+36V@<<V"'<14&M!B+S"Z1C[,-XTL5R(Z.
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M\'2K.N#J30T-0.JW!9SD-XOE^!P#L<4H:)L-I91(SQP&7\J0(%@DB3H-QO+
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M!T??QXM14%9I"(GD() %YB5Q.@>2'=@HK08C*F7N/$?6X""KA(;[KD)OJFD
M9_=X>#T[]^/IR*ID>="2H'>#'G=.FMC +'$64F8Y6$/KE"8^2LZPN.I1W;.^
M9=\ @&XMNP^P_&TZ!S\9_Z-41I;RS"*W7Y"KLO)^A9+0.P)FHK,&&:(H-BEX
M)BZZ0&A0*6NG+3A>>[_<B-)A8=<#.)[>+OO75'-(O.*E] A]#8OQZ;3;&>;_
M?H%<Y\MN2MVJGO@OD$[ABF=JDTH0'%%62MP.NIPC6P92*YU"0B'X.I:O#^J'
M/2RJC=@#:+0M%#_EQEPQ)KWB442B?-8H68?+L_S#.!?X(RISI1%7&Y,X[$E1
M53SVJ)N7 ;JR\MZ/I_ .G:%%)\72N*N,V<"EQ&(D&*M9XKD**$"6/%0WDQM1
M.OCY^6%BDJH*; &@)\?OCI;+^3A<++O+@=G'3@&X+9SD+_[[I]ED\G8V_]W/
MTR@J*;Q@JAC\<BP;#+HMR1-OA="RS(,QE7+9-R?R183*.Z+E/C0KJ:X!5':]
MY\]F$]368K7;C#C7V@D?B)+E%*LT%PC)>(+[3*:.,_0\ZG12>TC+P!BKI?8'
MIS%[Z:"91JG/+<0KF7V<S3OU/2)6='.IC.CH$N\8^C6B]-DH_35C!&VH#=0G
M505X>Q(^\ 9]()0>4KMM&D:7,?)2-A!N3<EL5NAW.V9(L(P)E5W,K,ZNO*-A
MK'>!/9QAW$8'O?;@;>72&G\QF\;Q9.Q7K64>:6GL[S<Q'N#6>A\RA[VV[DW
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M)HG**#Z9/7(K30D(<A8V,9GU#WWH?0@8+O&G K@.H82A@?;E#%Z-)Q-DZ%?
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M!T>\"XE8+S2X8%78;$;!#F#<C,)ADO :A&8%A38 U./9_&O)(X-'F8&8+67
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MQN@Z)$H49X!15&"XW"@E.J,HI9!:LCJW[MM2VLH,EMY!,SN@!G='Z&SI)X=
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M$?U3)QQN!E":$QM*DN,\& I!5RJ'^8/U[]W'OZNGL0;@N'&+-GRWPO5$B0)
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M2%)(*T1 &QLU36PCJQ=8':O]IZ.9 531 :Y^G9+#CK=9M)O4V/4X!A>,$5J
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MV\\"Z #1=P"AK8_F:ZO+7>0LHP"=K*W[?!,=.8I4C)-TQ#234;=*U3Y+7&_
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MB2E00.<S R33';.(C,73+)/:!W6=AS7'H&X(/74 MWO)V!L.:L^H]#J!#+Z
M8A3Q.8J^(-?-1CJ28&*CEXL?:!FW)VE\D!VIG0[P]= O>)C]O[/0/OF(&823
M"+6($#R7@4Z04"Q+F9UNX]/M0-RXO4[C(W!H_74[Z75+FN+'IX VN9G-W],\
M$[,CBUWE75A1T0NM( 9&0:W$"([) I%Q:2U&DU*; O3Q\RYK=;VF/YRD</EQ
MM73@0F<7F%8(R.H:=,<#"438.L64!R>""LP_!\_-'_\2,BS[0.9!AN5X@8_=
M.GQ_/05Q4Q?L+MZ%[]?+I%D(6'@$&2T9\%4[H^!U")Q$QV6B$U]V LZ6+WD)
M69*#X3.4\#MPZ-8GX?WL>[BL]\1-LGZ:_YA-T]HCD )1:RE LD2",F;5"J+
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M^-BPP4^/65@7E/&(.D<MP5I="S.4IXLZ1OI1*>^$]\+N5%^P&VPVD3%>7>Y
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MI;\.S-\&5M8GM7CC4BX<[&H$$T99MUX'",&GG%@@[Z#-D*"M9(WK& ZF_-U
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MXV#64C7MTSSK/ZC_J&O6_[__Y_\'4$L! A0#%     @ Q8$%4WF-MYT]"
MJR,  !<              ( !     &$T97AH:6)I=#,Q,38S,#(P,C$N:'1M
M4$L! A0#%     @ Q8$%4XB<I(0Z"   >B,  !<              ( !<@@
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M,#(Q,#8S,"YX<V102P$"% ,4    " #%@053[%F(M_DC  !/; $ %0
M        @ &]UP0 ;7)N82TR,#(Q,#8S,%]C86PN>&UL4$L! A0#%     @
MQ8$%4U=%K9,W2P  YC\# !4              ( !Z?L$ &UR;F$M,C R,3 V
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( ,6!!5,"8\ G$(P  +7Y   4
M      "  5-'!0!M<FYA+3(P,C$P-C,P7V<Q+FIP9U!+ 0(4 Q0    ( ,6!
M!5-5 [DSL 0! ,1I 0 4              "  973!0!M<FYA+3(P,C$P-C,P
M7V<R+FIP9U!+ 0(4 Q0    ( ,6!!5,-_UXEY\(! )OB 0 4
M  "  7?8!@!M<FYA+3(P,C$P-C,P7V<S+FIP9U!+ 0(4 Q0    ( ,6!!5._
M=:A%;_,  ,%U"@ 5              "  9";" !M<FYA+3(P,C$P-C,P7VQA
M8BYX;6Q02P$"% ,4    " #%@053,-1Q2!R1  "JOP8 %0
M@ $RCPD ;7)N82TR,#(Q,#8S,%]P<F4N>&UL4$L%!@     .  X MP,  ($@
$"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
